meta_review,paper,first_author_meta,year_meta,doi,available_age,available_IQ,available_control,available_rob,amstar_rank,intervention_general,intervention_precise,intervention_augmentation,mono_aug,outcome_general,outcome_raters,outcome_followup,outcome_type,outcome_measure,duration_month,dose,dose_unit,author,year,trial_id_supp,design,measure,n_cases,n_controls,n_tot,multiple_es,reverse_es,value,ci_lo,ci_up,sd_cases,sd_controls,mean_pre_cases,sd_pre_cases,mean_pre_controls,sd_pre_controls,sd_change_cases,sd_change_controls,rob_num,low_RoB_num,RoB_Rand_num,RoB_Deviation_num,RoB_Missing_num,RoB_Report_num,RoB_Outcome_num,RoB_Rand,RoB_Deviation,RoB_Missing,RoB_Outcome,RoB_Report,control_group,active_controls,perc_female,mean_age,mean_iq,diagnostic_criteria,amstar_rank_crit,ams_2,ams_4,ams_7,ams_9,ams_11,ams_13,ams_15,amstar_rank_non_crit,ams_1,ams_3,ams_5,ams_6,ams_8,ams_10,ams_12,ams_14,ams_16,id_row,trial_id,Duration_cct,IQ_cct,Age_cct,min_age_meta,max_age_meta,min_IQ_meta,max_IQ_meta,n_cct_intervention,n_outcome_intervention,outcome_intervention,n_meta_intervention,meta_intervention,min_age_intervention,max_age_intervention,min_IQ_intervention,max_IQ_intervention,factor,n_papers_pico,Age_precise,PICO_amstar_ID,available_control_agg,indirectness,rob1_report,rob
  93 Ang (2023) Ang 2023,10.3390/medicina59020392,100   0 100,100,Critically low Acupuncture,Acupuncture,100,Acupuncture plus conventional medicine vs. conventional medicine Generalized anxiety,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners parents symptom questionnaire (PSQ), 2.76179517    3.0000000 sessions/week,Meng 2012 NA,RCT (parallel, crossover, open-label),MD, 36, 32   68,NA reverse -0.0700000000 -0.880000000  7.400000e-01,  1.4500000,  1.8800000,NA NA NA NA,NA,NA 100 100,100 100,100 100 100 some,some low some,some,Active (any credible active intervention),100, 23.529412  9.000000,NA,DSM-IV/5 2,1 1.0,1.0,1.0,0.0,1,0 3,1,1 1 1 0.5 0 0,0 1,   1,Meng_2012,2-6 months NA 6-12 yo,9 9.5,NA,NA,  2  4 Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 1,Ang (2023),9 9.5,NA,NA Ang (2023)_Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ang (2023) - Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
  93,Ang (2023) Ang 2023 10.3390/medicina59020392,100   0 100 100,Critically low Acupuncture Acupuncture,100 Acupuncture plus conventional medicine vs. conventional medicine,Generalized anxiety,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire Conners parents symptom questionnaire (PSQ)  0.92059839    3.0000000,sessions/week,Yu 2021,NA,RCT (parallel, crossover, open-label),MD, 52  51  103 NA,reverse,-0.0600000000 -0.680000000, 5.600000e-01   1.4100000,  1.7900000 NA,NA,NA NA,NA NA,100 100,100 100,100,100,100 some,low low some some Active (any credible active intervention),100, 10.679612  9.500000 NA DSM-IV/5 2,1 1.0 1.0,1.0 0.0 1,0 3,1 1 1,1,0.5,0,0 0,1,   2 Yu_2021 < 2 months,NA,6-12 yo 9,9.5 NA NA,  2, 4 Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1,Ang (2023) 9,9.5 NA NA,Ang (2023)_Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ang (2023) - Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
  93 Ang (2023) Ang 2023,10.3390/medicina59020392 100   0 100,100 Critically low,Acupuncture Acupuncture,100,Acupuncture plus conventional medicine vs. conventional medicine Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,Conners parents symptom questionnaire (PSQ), 2.76179517,   3.0000000 sessions/week,Meng,2012,NA RCT (parallel, crossover, open-label),MD, 36  32   68,NA,reverse -1.1600000000 -2.130000000 -1.900000e-01,  2.0100000   2.0500000,NA NA NA NA NA,NA,100,100 100 100 100,100,100 some,some low some,some,Active (any credible active intervention) 100  23.529412, 9.000000 NA,DSM-IV/5 2 1 1.0,1.0 1.0,0.0,1,0,3,1 1 1,1,0.5,0,0 0 1,   3,Meng_2012 2-6 months,NA,6-12 yo 9,9.5,NA,NA   2  4 Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 1,Ang (2023),9,9.5,NA NA,Ang (2023)_Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ang (2023) - Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
  93 Ang (2023),Ang 2023,10.3390/medicina59020392,100   0 100,100,Critically low,Acupuncture Acupuncture 100,Acupuncture plus conventional medicine vs. conventional medicine Conduct Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners parents symptom questionnaire (PSQ), 0.92059839    3.0000000 sessions/week Yu 2021 NA,RCT (parallel, crossover, open-label),MD  52, 51  103 NA reverse -1.4700000000,-2.260000000 -6.800000e-01,  2.0300000,  2.0400000 NA,NA,NA NA NA,NA,100 100 100,100 100,100,100 some,low low,some,some Active (any credible active intervention),100, 10.679612  9.500000 NA DSM-IV/5,2 1,1.0 1.0 1.0 0.0,1 0 3 1 1 1 1,0.5 0,0 0 1,   4,Yu_2021 < 2 months NA,6-12 yo 9 9.5,NA NA,  2  4 Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1 Ang (2023),9,9.5,NA,NA Ang (2023)_Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ang (2023) - Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
  93,Ang (2023),Ang,2023,10.3390/medicina59020392,100,  0,100 100,Critically low,Acupuncture,Acupuncture 100 Acupuncture plus conventional medicine vs. conventional medicine Learning disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners parents symptom questionnaire (PSQ)  2.76179517    3.0000000,sessions/week,Meng,2012 NA,RCT (parallel, crossover, open-label) MD  36  32,  68,NA reverse -1.0300000000 -1.830000000 -2.300000e-01   1.5300000,  1.8200000 NA,NA,NA NA NA,NA,100 100 100,100 100,100,100,some some low,some some Active (any credible active intervention) 100, 23.529412  9.000000,NA DSM-IV/5,2,1 1.0,1.0 1.0 0.0 1,0 3 1 1,1 1 0.5,0 0 0 1,   5,Meng_2012,2-6 months NA 6-12 yo 9 9.5 NA,NA,  2, 4 Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1 Ang (2023) 9 9.5,NA,NA Ang (2023)_Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ang (2023) - Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
  93 Ang (2023) Ang 2023 10.3390/medicina59020392,100   0 100 100,Critically low Acupuncture,Acupuncture,100,Acupuncture plus conventional medicine vs. conventional medicine Learning disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners parents symptom questionnaire (PSQ), 0.92059839    3.0000000 sessions/week,Yu,2021 NA,RCT (parallel, crossover, open-label) MD  52, 51  103,NA reverse,-1.0400000000 -1.680000000 -4.000000e-01,  1.5100000,  1.7900000,NA NA NA NA NA NA 100 100,100,100,100,100,100,some,low low,some some Active (any credible active intervention),100, 10.679612, 9.500000,NA DSM-IV/5,2 1 1.0,1.0 1.0,0.0,1 0 3 1 1 1 1,0.5 0,0,0 1,   6 Yu_2021,< 2 months,NA 6-12 yo 9 9.5,NA NA,  2, 4,Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1 Ang (2023),9 9.5 NA NA Ang (2023)_Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ang (2023) - Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
  93 Ang (2023) Ang 2023,10.3390/medicina59020392,100,  0 100 100 Critically low Acupuncture,Acupuncture,100,Acupuncture plus conventional medicine vs. conventional medicine Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Conners parents symptom questionnaire (PSQ)  2.76179517,   3.0000000 sessions/week Meng 2012,NA RCT (parallel, crossover, open-label),MD, 36, 32   68,NA,reverse,-1.0900000000 -1.800000000 -3.800000e-01,  1.1600000,  1.7300000 NA,NA,NA NA,NA,NA,100,100 100 100,100 100 100,some some,low,some,some,Active (any credible active intervention) 100, 23.529412  9.000000 NA DSM-IV/5 2,1 1.0,1.0,1.0,0.0,1 0,3 1,1 1 1 0.5,0,0 0,1,   7,Meng_2012 2-6 months NA 6-12 yo,9,9.5 NA NA   2  4,Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1,Ang (2023),9 9.5,NA,NA Ang (2023)_Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ang (2023) - Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
  93 Ang (2023) Ang,2023,10.3390/medicina59020392 100,  0 100,100 Critically low Acupuncture Acupuncture,100,Acupuncture plus conventional medicine vs. conventional medicine,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners parents symptom questionnaire (PSQ), 0.92059839,   3.0000000,sessions/week Yu,2021,NA,RCT (parallel, crossover, open-label) MD  52  51  103,NA,reverse -1.2200000000,-1.790000000,-6.500000e-01   1.1700000,  1.7400000,NA,NA,NA NA NA,NA,100 100,100,100 100 100 100 some low low some some Active (any credible active intervention),100, 10.679612, 9.500000 NA,DSM-IV/5,2 1 1.0,1.0,1.0,0.0 1 0 3 1 1,1,1 0.5,0,0 0,1,   8 Yu_2021 < 2 months,NA,6-12 yo,9 9.5,NA,NA   2, 4 Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1,Ang (2023),9 9.5,NA,NA,Ang (2023)_Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ang (2023) - Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
2157,Lopez-Pinar (2019),Lopez-Pinar,2019,10.1177/1087054719855685 100   0,100,100 Critically low Mindfulness,NA,  0,NA,Generalized anxiety Self-rated,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 1.38089758,   1.0000000 h/wk Gu 2017,NA RCT SMD, 28, 26,  54 NA NA  1.2800000000  0.790000000, 1.770000e+00 NA,NA NA,NA,NA,NA,NA NA,  0   0,100   0 100 100,  0 some high low high,low,WLC (wait-list control)   0  44.432143 21.500000 NA DSM-IV,2,0 0.0 1.0 1.0,1.0 1,1 2 1,1,0 1,1.0 0 1,1 1,   9 Gu_2017 < 2 months,NA >= 20 yo 21.5 35.8421686746988 NA,NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35,NA,NA,Lopez-Pinar (2019)_Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Lopez-Pinar (2019) - Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,high
2157 Lopez-Pinar (2019) Lopez-Pinar 2019 10.1177/1087054719855685,100   0,100,100 Critically low Mindfulness,NA   0,NA,Generalized anxiety,Self-rated At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  2.76179517 NA,NA,Hepark,2015 NA,RCT,SMD  41  42   83 NA NA, 0.2200000000,-0.110000000, 5.500000e-01,NA,NA NA NA,NA,NA,NA,NA,  0,  0 100   0,100,100,  0,some,high,low,high low,WLC (wait-list control)   0  45.456311,35.842169,NA,DSM-IV,2,0,0.0 1.0,1.0 1.0 1,1 2,1,1,0,1 1.0,0 1 1,1,  10 Hepark_2015,2-6 months,NA,>= 20 yo,21.5 35.8421686746988,NA NA  13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35 NA,NA,Lopez-Pinar (2019)_Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Lopez-Pinar (2019) - Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,high
 343 Bikic (2017) Bikic,2017,10.1016/j.cpr.2016.12.004 100   0,100 100 Critically low,Organizational skills interventions,Organizational skills training,100,0.36 on medication Academic/job performance,Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale, 2.53164557,NA NA Abikoff,2013,NA,RCT (parallel, crossover, open-label) G  64, 33,  97,NA NA, 0.7370000000  0.308000000, 1.167000e+00 NA NA,NA,NA,NA,NA,NA,NA,  0,  0 100,  0,100 100,  0,some,high some,high,low WLC (wait-list control)   0  36.000000  9.500000 NA,DSM 2,1,0.0 0.0,1.0 1.0,1 1 2,1,1,1 1 0.5 0 0 1 1,  11,Abikoff_2013 2-6 months NA 6-12 yo,4,15 NA NA, 11  1,Academic/job performance, 1 Bikic (2017),4 15,NA,NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Mixed,Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 serious,low high
 343 Bikic (2017) Bikic,2017,10.1016/j.cpr.2016.12.004 100,  0,100 100,Critically low,Organizational skills interventions,Organizational skills training 100,0.67 on medication,Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks),Questionnaire Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale  4.60299194 NA,NA Evans,2011,NA,RCT (parallel, crossover, open-label) G  31  18   49 outcomes NA  0.0890000000 -0.483000000  6.600000e-01,NA NA,NA NA NA NA NA NA,  0   0 100   0 100 100,  0,some high low high,low Community control   0, 29.000000,11.000000 NA,DSM 2,1 0.0,0.0,1.0 1.0 1,1,2 1,1,1,1 0.5,0,0 1 1   12,Evans_2011 2-6 months NA,6-12 yo 4 15,NA NA  11  1 Academic/job performance, 1 Bikic (2017),4,15 NA NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious low high
 343,Bikic (2017) Bikic,2017,10.1016/j.cpr.2016.12.004 100   0,100 100 Critically low,Organizational skills interventions,Organizational skills training 100,0.5 on medication Academic/job performance,Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire,Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale, 5.98388953 NA,NA,Evans 2014,NA RCT (parallel, crossover, open-label) G, 24, 12,  36 outcomes NA  0.6980000000, 0.002000000, 1.395000e+00 NA,NA NA NA NA NA NA NA   0,  0,100,  0,100,100   0,some,high,some,high low,Community control,  0, 17.000000 15.000000 NA DSM 2,1,0.0 0.0,1.0,1.0,1,1,2,1,1 1 1,0.5,0,0,1,1   13 Evans_2014,2-6 months,NA 13-19 yo,4 15 NA,NA, 11, 1,Academic/job performance  1 Bikic (2017),4,15 NA NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,low high
 343,Bikic (2017),Bikic 2017,10.1016/j.cpr.2016.12.004 100,  0,100,100 Critically low Organizational skills interventions,Organizational skills training 100,0.446 on medication Academic/job performance,Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire,Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale  7.36478711 NA NA Evans 2016,NA,RCT (parallel, crossover, open-label),G,112 104  216 NA,NA  0.1990000000 -0.067000000  4.660000e-01 NA,NA NA NA NA,NA NA,NA   0,  0 100,  0 100,100,  0 some,high low,high low,Community control,  0, 26.000000 12.100000 NA DSM 2 1,0.0,0.0,1.0 1.0 1 1,2 1 1,1,1 0.5 0 0 1 1,  14 Evans_2016 7-12 months NA 6-12 yo 4 15 NA NA  11, 1,Academic/job performance, 1 Bikic (2017) 4,15 NA,NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1 Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious,low,high
 343 Bikic (2017) Bikic,2017,10.1016/j.cpr.2016.12.004,100   0 100,100 Critically low Organizational skills interventions,Organizational skills training,100 0.43 on medication,Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire,Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale, 1.84119678 NA,NA,Langberg,2008,NA RCT (parallel, crossover, open-label),G  24, 13,  37,outcomes NA, 0.2700000000,-0.393000000, 9.330000e-01,NA,NA,NA NA NA,NA,NA NA,  0,  0 100,  0 100,100   0 some,high,low high,low WLC (wait-list control)   0  17.000000,11.500000,NA DSM,2,1,0.0 0.0,1.0 1.0,1 1,2,1,1 1 1,0.5,0 0,1,1   15,Langberg_2008,< 2 months NA,6-12 yo,4 15 NA,NA, 11, 1 Academic/job performance  1 Bikic (2017),4,15,NA NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1,Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious low,high
 343,Bikic (2017),Bikic,2017,10.1016/j.cpr.2016.12.004,100,  0 100 100 Critically low,Organizational skills interventions Organizational skills training 100,mono Academic/job performance Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale, 2.76179517,NA NA,Mautone,2012,NA,RCT (parallel, crossover, open-label) G  29  32   61 NA,NA  0.5000000000 -0.070000000, 1.069000e+00 NA NA,NA NA,NA,NA NA,NA   0,  0 100   0,100,100   0 some high,low,high low Not a therapeutic intervention,  0, 43.000000, 5.500000 NA DSM 2,1,0.0 0.0 1.0,1.0 1 1,2,1,1 1 1 0.5 0 0,1 1,  16,Mautone_2012,2-6 months,NA < 6 yo 4 15 NA NA  11, 1 Academic/job performance, 1 Bikic (2017) 4 15,NA,NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious low,high
 343 Bikic (2017),Bikic 2017,10.1016/j.cpr.2016.12.004 100   0,100 100 Critically low,Organizational skills interventions,Organizational skills training 100,0.42 on medication Academic/job performance,Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire,Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale  2.76179517,NA,NA,Power 2012 NA,RCT (parallel, crossover, open-label) G 100, 99, 199,NA NA  0.1800000000 -0.112000000  4.710000e-01,NA,NA,NA,NA NA,NA NA,NA,  0,  0,100   0 100,100   0 some high,some,high low,Not a therapeutic intervention,  0  32.000000  4.000000 NA DSM 2 1 0.0 0.0,1.0,1.0,1 1 2,1 1 1,1,0.5 0 0,1 1,  17 Power_2012 2-6 months NA,< 6 yo,4 15 NA,NA, 11, 1 Academic/job performance, 1 Bikic (2017),4 15 NA NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1,Mixed,Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious low,high
 343 Bikic (2017) Bikic,2017,10.1016/j.cpr.2016.12.004 100   0,100,100 Critically low,Organizational skills interventions Organizational skills training,100,0.67 on medication Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks) Observational tool,Grade Point Avarage  4.60299194 NA NA,Evans,2011,NA,RCT (parallel, crossover, open-label) G, 31, 18   49,outcomes,NA  0.2750000000,-0.299000000, 8.490000e-01 NA,NA NA NA NA,NA NA,NA,  0,  0 100   0 100,100   0,some,high,low,high low Community control   0, 29.000000,11.000000 NA DSM 2,1,0.0 0.0,1.0,1.0 1 1,2 1,1,1 1 0.5,0 0 1 1   18 Evans_2011 2-6 months NA,6-12 yo 4 15 NA,NA, 11, 1,Academic/job performance, 1 Bikic (2017),4,15,NA NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Mixed,Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious low high
 343 Bikic (2017) Bikic,2017,10.1016/j.cpr.2016.12.004 100   0 100 100,Critically low Organizational skills interventions,Organizational skills training 100,0.5 on medication,Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks) Observational tool Grade Point Avarage  5.98388953 NA,NA Evans 2014,NA,RCT (parallel, crossover, open-label),G, 24  12   36 outcomes NA  0.2170000000 -0.462000000, 8.970000e-01,NA,NA NA NA,NA,NA NA NA,  0   0,100,  0 100 100,  0 some high some,high low Community control,  0, 17.000000,15.000000 NA,DSM,2,1,0.0 0.0,1.0,1.0 1 1 2,1,1,1,1 0.5 0,0 1 1,  19,Evans_2014,2-6 months,NA 13-19 yo 4 15,NA,NA, 11  1,Academic/job performance, 1,Bikic (2017) 4 15 NA,NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious low high
 343,Bikic (2017) Bikic 2017,10.1016/j.cpr.2016.12.004 100,  0 100 100 Critically low,Organizational skills interventions Organizational skills training,100,0.69 on medication,Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks) Observational tool,Grade Point Avarage, 2.53164557,NA NA Langberg,2012,NA,RCT (parallel, crossover, open-label) G, 23, 24,  47 outcomes NA  0.6430000000, 0.066000000, 1.220000e+00 NA,NA,NA,NA NA,NA NA,NA,  0   0,100,  0 100,100,  0,some high,low high low,WLC (wait-list control),  0, 24.000000,12.500000 NA DSM,2 1 0.0,0.0 1.0 1.0 1,1 2 1,1 1 1 0.5 0 0 1,1   20,Langberg_2012,2-6 months,NA,6-12 yo,4,15,NA,NA  11, 1,Academic/job performance  1 Bikic (2017),4,15 NA,NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Mixed,Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious low high
 343,Bikic (2017),Bikic,2017,10.1016/j.cpr.2016.12.004 100   0,100 100 Critically low,Organizational skills interventions,Organizational skills training,100 0.389 on medication,Academic/job performance Teacher-rated At study endpoint (closest to 12 weeks),Observational tool,Grade Point Avarage, 1.38089758 NA NA,Sibley,2013 NA RCT (parallel, crossover, open-label) G  18, 18   36,NA NA,-0.2610000000,-1.030000000  5.070000e-01,NA,NA NA NA,NA NA NA,NA,  0   0 100,  0,100 100,  0,some high,low,high,low TAU,  0  28.000000,13.000000,NA DSM,2 1,0.0 0.0 1.0 1.0 1 1,2,1,1 1,1 0.5,0,0,1 1,  21,Sibley_2013,< 2 months NA,13-19 yo,4 15,NA,NA, 11, 1 Academic/job performance, 1 Bikic (2017) 4,15 NA NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,low high
 343 Bikic (2017) Bikic 2017,10.1016/j.cpr.2016.12.004 100   0,100 100,Critically low Organizational skills interventions,Organizational skills training 100,0.609 on medication,Academic/job performance,Teacher-rated At study endpoint (closest to 12 weeks),Observational tool,Grade Point Avarage  1.84119678,NA NA Sibley 2014,NA RCT (parallel, crossover, open-label),G, 10, 13   23 NA,NA  0.6000000000,-0.054000000  1.253000e+00 NA,NA NA,NA NA,NA NA NA,100 100,100 100 100,100,100,some some,some,some,some,TAU,  0  30.000000,10.500000 NA,DSM 2 1,0.0,0.0 1.0,1.0 1 1 2 1,1 1,1 0.5,0 0 1 1   22 Sibley_2014 < 2 months,NA 6-12 yo,4,15 NA NA, 11, 1,Academic/job performance, 1 Bikic (2017) 4 15,NA NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1,Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,low,low
 343,Bikic (2017),Bikic 2017,10.1016/j.cpr.2016.12.004 100   0 100,100,Critically low,Organizational skills interventions,Organizational skills training,100 0.344 on medication,Academic/job performance,Teacher-rated,At study endpoint (closest to 12 weeks),Observational tool,Grade Point Avarage  2.30149597 NA,NA Sibley,2016 NA RCT (parallel, crossover, open-label),G, 67  61, 128,NA NA, 0.2200000000,-0.126000000, 5.650000e-01 NA NA,NA NA NA NA NA,NA,  0,  0,100   0 100,100,  0,some,high,low high low TAU   0  35.000000 12.700000,NA DSM 2,1,0.0 0.0 1.0,1.0,1 1 2,1 1,1 1,0.5,0 0,1,1,  23 Sibley_2016 2-6 months,NA 6-12 yo,4,15 NA NA, 11  1 Academic/job performance, 1,Bikic (2017),4,15 NA,NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1 Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious low,high
 962 Ding (2018),Ding 2018,10.1142/S2575900018400013 100,  0,100,100 Critically low Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT) 100,medication,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire,ADHD Severity Ratings + Symptom Inventory Scale of ADHD + Conners parents symptom questionnaire, 3.98388953,NA NA Sprich 2016 NA,RCT (parallel, crossover, open-label),SMD  24, 22,  46 NA,reverse,-0.7700000000 -1.380000000,-1.700000e-01, 10.4000000   8.2300000 NA,NA NA NA,NA,NA 100,100,100,  0 100 100,100,low high,low,low,some,Active (any credible active intervention),100 NA 16.000000 NA DSM-5/ICD-10,3,0 1.0 0.5,1.0,0.0,1 0,5 1,1,0 1 0.5 0 0,0,0,  24,Sprich_2016 2-6 months NA,13-19 yo 10.3 16 NA NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA,NA Ding (2018)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ding (2018) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 962 Ding (2018) Ding 2018 10.1142/S2575900018400013,  0   0 100,100 Critically low Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),100 methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire ADHD Severity Ratings + Symptom Inventory Scale of ADHD + Conners parents symptom questionnaire  2.76179517,   1.0000000 h/wk Yang 2012,NA,RCT (parallel, crossover, open-label),SMD  29, 31   60 NA reverse -0.7600000000,-1.290000000,-2.400000e-01,  0.1000000,  0.3100000,NA NA NA,NA,NA NA 100,100 100   0 100 100,100 some,high,low,some,some,Active (any credible active intervention),100 NA,NA NA,DSM-5/ICD-10,3,0 1.0 0.5 1.0 0.0 1,0 5,1,1 0,1 0.5,0,0 0 0   25 Yang_2012 2-6 months,NA NA,10.3,16,NA,NA  20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA NA Ding (2018)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Ding (2018) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 962 Ding (2018) Ding,2018 10.1142/S2575900018400013 100,  0,100 100,Critically low,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT) 100 atomoxetine,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire ADHD Severity Ratings + Symptom Inventory Scale of ADHD + Conners parents symptom questionnaire, 1.84119678,   0.8333333 h/wk Xu 2015,NA RCT (parallel, crossover, open-label) SMD  31, 30   61 NA reverse -0.6100000000 -1.130000000,-1.000000e-01,  4.5800000,  5.7800000 NA NA NA,NA NA NA 100,100 100   0,100,100 100,some high some some some Active (any credible active intervention) 100,NA 10.300000 NA DSM-5/ICD-10 3 0,1.0,0.5 1.0,0.0 1,0 5,1 1,0,1,0.5 0,0 0 0,  26,Xu_2015,< 2 months,NA,6-12 yo,10.3,16 NA NA, 20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA NA,Ding (2018)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Ding (2018) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3419,Storebo (2019) Storebo,2019 10.1002/14651858.CD008223.pub3,100,  0 100,100 High,Social skill training Social skill training,  0,NA,Social-communication skills,Mixed At study endpoint (closest to 12 weeks) Mixed (different types of tool are used),Conners Behavior Rating Scale: Social Problems Index + Strength and Difficulties Questionnaire: Prosocial Behaviour Subscale (teacher-rated) + Social Skills Improvement System + Social Skills Rating Scale: Coorperation Subscale NA NA NA Pfiffner,1997,NA RCT SMD   9,  9   18 outcomes,NA  0.4000000000 -0.540000000  1.330000e+00, 13.5000000, 13.3000000 NA NA NA,NA,NA NA,  0   0,100,  0 100,  0   0,some,high,low,high,high,WLC (wait-list control),  0  30.000000, 9.000000 NA DSM-III-R 0 1 1.0 1.0,1.0 1.0 1,1,0 1 1 1,1,1.0 1,1 1 1   27,Pfiffner_1997 NA,NA,6-12 yo,9 11.2,94.35 100,  5  3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1 Storebo (2019) 9 11.2 94.3418181818182 100 Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
3419 Storebo (2019),Storebo,2019 10.1002/14651858.CD008223.pub3 100,100 100 100 High Social skill training,Social skill training   0 NA Social-communication skills Mixed At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) Conners Behavior Rating Scale: Social Problems Index + Strength and Difficulties Questionnaire: Prosocial Behaviour Subscale (teacher-rated) + Social Skills Improvement System + Social Skills Rating Scale: Coorperation Subscale  1.84119678,NA NA Storebo 2012,NA RCT,SMD  27, 27   54,NA NA  0.1600000000,-0.370000000  7.000000e-01,  5.7000000   5.9000000 NA NA,NA,NA NA,NA 100,100,100,  0,100,100 100,low high low,low low,TAU,  0  29.000000,10.400000, 94.35000 DSM-IV 0 1 1.0,1.0 1.0 1.0 1 1,0 1,1,1,1 1.0 1,1 1 1   28 Storebo_2012,< 2 months,Average (80-119),6-12 yo 9 11.2,94.35,100,  5  3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1,Storebo (2019),9,11.2 94.3418181818182 100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3419,Storebo (2019) Storebo,2019 10.1002/14651858.CD008223.pub3 100,  0 100 100 High,Social skill training Social skill training   0 NA Social-communication skills,Mixed At follow-up (closest to 26 weeks),Mixed (different types of tool are used),Conners Behavior Rating Scale: Social Problems Index + Strength and Difficulties Questionnaire: Prosocial Behaviour Subscale (teacher-rated) + Social Skills Improvement System + Social Skills Rating Scale: Coorperation Subscale NA NA,NA Pfiffner 1997 NA,RCT,SMD,  9,  9,  18,outcomes,NA  0.0600000000,-0.860000000  9.800000e-01  14.2000000,  1.1000000 NA NA,NA,NA NA,NA,  0,  0 100   0,100   0   0 some,high low,high high,WLC (wait-list control),  0, 30.000000, 9.000000,NA DSM-III-R,0,1,1.0 1.0,1.0 1.0 1,1,0,1,1,1,1,1.0,1 1,1 1,  29 Pfiffner_1997,NA,NA 6-12 yo 9,10.4036363636364,94.3418181818182,94.3418181818182   5, 3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1,Storebo (2019),9,11.2 94.3418181818182 100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks) 1 Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no high high
3419 Storebo (2019),Storebo,2019 10.1002/14651858.CD008223.pub3,100 100 100 100 High Social skill training,Social skill training,  0,NA,Social-communication skills Mixed At follow-up (closest to 26 weeks) Mixed (different types of tool are used) Conners Behavior Rating Scale: Social Problems Index + Strength and Difficulties Questionnaire: Prosocial Behaviour Subscale (teacher-rated) + Social Skills Improvement System + Social Skills Rating Scale: Coorperation Subscale  1.84119678,NA NA Storebo 2012,NA RCT,SMD, 28  27,  55 NA NA, 0.1500000000,-0.380000000, 6.800000e-01   6.0000000   6.8000000 NA,NA NA NA NA,NA 100 100 100   0 100 100 100 low,high,low,low,low,TAU,  0  29.000000,10.403636, 94.34182 DSM-IV 0,1 1.0,1.0 1.0,1.0,1 1 0 1,1 1 1 1.0 1,1 1 1,  30 Storebo_2012,< 2 months Average (80-119) 6-12 yo 9,10.4036363636364 94.3418181818182,94.3418181818182,  5  3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1,Storebo (2019),9,11.2,94.3418181818182,100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low low
3419,Storebo (2019),Storebo 2019 10.1002/14651858.CD008223.pub3 100,100,100,100,High Social skill training,Social skill training   0,NA Social-communication skills,Mixed,At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),Social Skills Rating Scale + Weiss Functional Impairment Scale: Social Acitivities Domain (parent-rated) + Strength and Difficulties Questionnaire: Prosocial Behavior Subscale + Social Skills Improvement System, 1.84119678,NA,NA,Antshel,2003,NA RCT,SMD  80  40  120,outcomes,NA, 0.2300000000 -0.150000000, 6.100000e-01, 11.8000000  10.6000000,NA NA NA NA,NA NA,  0   0,100,  0 100 100,  0,low high,low high low,WLC (wait-list control)   0  25.000000,10.000000,100.00000 DSM-IV (DICA-R-P) 0,1,1.0 1.0,1.0 1.0 1,1,0 1,1,1 1 1.0,1 1,1,1,  31 Antshel_2003,< 2 months Average (80-119),6-12 yo 9 11.2 94.35 100,  5, 3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1,Storebo (2019),9 11.2,94.3418181818182 100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
3419 Storebo (2019),Storebo 2019,10.1002/14651858.CD008223.pub3 100,100 100,100 High,Social skill training Social skill training   0 NA,Social-communication skills Mixed At study endpoint (closest to 12 weeks),Mixed (different types of tool are used) Social Skills Rating Scale + Weiss Functional Impairment Scale: Social Acitivities Domain (parent-rated) + Strength and Difficulties Questionnaire: Prosocial Behavior Subscale + Social Skills Improvement System, 1.15074799 NA NA Hannesdottir 2017 NA RCT,SMD, 15, 14,  29 NA NA  0.1400000000,-0.590000000  8.700000e-01, 12.1000000,  8.1000000,NA NA,NA,NA NA,NA   0,  0,100   0,100 100,  0 some,high,low high,low,WLC (wait-list control),  0, 29.000000, 9.200000 100.00000,diagnosed by a licensed clinical psychologist or medical doctor,0 1 1.0,1.0 1.0 1.0 1,1,0,1 1 1 1,1.0,1 1,1 1   32 Hannesdottir_2017 < 2 months Average (80-119) 6-12 yo,9 11.2 94.35 100,  5, 3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1,Storebo (2019),9 11.2,94.3418181818182 100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
3419,Storebo (2019),Storebo,2019 10.1002/14651858.CD008223.pub3 100   0 100 100,High,Social skill training Social skill training   0 NA,Social-communication skills,Mixed,At study endpoint (closest to 12 weeks),Mixed (different types of tool are used) Social Skills Rating Scale + Weiss Functional Impairment Scale: Social Acitivities Domain (parent-rated) + Strength and Difficulties Questionnaire: Prosocial Behavior Subscale + Social Skills Improvement System,NA,NA NA,Pfiffner,1997 NA,RCT,SMD,  9,  9   18 outcomes,NA, 1.3200000000, 0.270000000, 2.360000e+00  12.8000000,  6.4000000 NA,NA NA NA NA NA   0   0 100   0,100,  0,  0,some,high,low,high high WLC (wait-list control)   0  30.000000, 9.000000,NA DSM-III-R 0,1,1.0 1.0 1.0 1.0 1,1,0 1 1 1,1,1.0,1 1 1 1   33 Pfiffner_1997,NA NA 6-12 yo,9,11.2,94.35,100   5  3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1 Storebo (2019),9,11.2,94.3418181818182 100 Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high,high
3419,Storebo (2019) Storebo 2019,10.1002/14651858.CD008223.pub3,100 100,100,100 High Social skill training,Social skill training,  0 NA,Social-communication skills Mixed At study endpoint (closest to 12 weeks),Questionnaire Social Skills Rating Scale (SSRS) + Strengths and Difficulties Questionnaire (SDQ): Prosocial Behavior Subscale, 1.84119678,NA NA,Antshel 2003 NA,RCT,SMD, 80  40  120,outcomes NA  0.1600000000 -0.220000000, 5.400000e-01   9.1000000, 10.2000000 NA NA NA,NA NA,NA,  0,  0,100   0,100,100   0,low high,low high,low,WLC (wait-list control)   0, 25.000000,10.000000,100.00000,DSM-IV (DICA-R-P),0,1 1.0,1.0 1.0 1.0,1,1,0,1 1 1,1 1.0,1 1,1,1,  34 Antshel_2003 < 2 months Average (80-119) 6-12 yo 9 11.2 94.35,100   5  3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1,Storebo (2019),9,11.2,94.3418181818182 100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
3419,Storebo (2019) Storebo 2019 10.1002/14651858.CD008223.pub3,100 100,100,100,High Social skill training,Social skill training,  0,NA,Social-communication skills Mixed At study endpoint (closest to 12 weeks) Questionnaire Social Skills Rating Scale (SSRS) + Strengths and Difficulties Questionnaire (SDQ): Prosocial Behavior Subscale  3.68239356 NA,NA,Choib 2015,NA RCT,SMD  25, 24   49 NA NA  0.3300000000 -0.230000000  8.900000e-01   5.0000000,  8.2000000 NA,NA,NA,NA,NA NA,  0,  0,100   0 100,100   0 some high some high,some WLC (wait-list control),  0  56.000000,11.200000 100.00000,DSM-IV,0 1,1.0,1.0,1.0 1.0,1 1 0,1,1,1 1 1.0 1,1 1 1,  35 Choib_2015,2-6 months Average (80-119) 6-12 yo,9 11.2,94.35 100,  5  3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1 Storebo (2019) 9,11.2,94.3418181818182 100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
3419,Storebo (2019) Storebo 2019 10.1002/14651858.CD008223.pub3 100 100,100,100,High,Social skill training,Social skill training,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) Disruptive Behavior Disorders Rating Scale + ADHD Rating Scales: Hyperactivity and Impulsivity Subscales (total scores) + Conner Teacher Rating Scale: Hyperactivity Index + Strengths and Weaknesses of ADHD Symptoms and Normal Behaviors + ADHD Symptom Checklist + Child Symptom Inventory (ADHD (inattention) scale score) + SNAP-IV (teacher rating scale)  1.15074799,NA NA Hannesdottir 2017,NA RCT,SMD, 15  14   29,NA,reverse,-1.3500000000 -2.170000000 -5.400000e-01,  7.4000000   6.6000000 NA NA NA NA,NA NA   0,  0,100,  0 100,100,  0,some,high,low,high low WLC (wait-list control),  0, 29.000000  9.200000 100.00000,diagnosed by a licensed clinical psychologist or medical doctor,0,1 1.0,1.0 1.0,1.0 1 1 0 1 1,1 1,1.0,1 1,1 1   36 Hannesdottir_2017,< 2 months Average (80-119),6-12 yo,9.2 10.4,94.35,100   5, 3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1 Storebo (2019),9 11.2 94.3418181818182,100 Storebo (2019)_Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2019) - Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
3419,Storebo (2019),Storebo,2019,10.1002/14651858.CD008223.pub3 100,100,100,100,High,Social skill training,Social skill training   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),Disruptive Behavior Disorders Rating Scale + ADHD Rating Scales: Hyperactivity and Impulsivity Subscales (total scores) + Conner Teacher Rating Scale: Hyperactivity Index + Strengths and Weaknesses of ADHD Symptoms and Normal Behaviors + ADHD Symptom Checklist + Child Symptom Inventory (ADHD (inattention) scale score) + SNAP-IV (teacher rating scale), 1.84119678,NA NA Storebo,2012,NA,RCT SMD  27, 27   54,NA,reverse  0.1800000000,-0.360000000, 7.100000e-01  11.5000000  13.2000000 NA NA,NA,NA,NA NA,100,100,100,  0,100,100,100,low,high,low low,low TAU,  0  29.000000,10.400000  94.35000,DSM-IV 0 1 1.0 1.0 1.0,1.0,1,1,0 1 1 1,1 1.0,1,1,1,1,  37,Storebo_2012,< 2 months,Average (80-119) 6-12 yo,9.2 10.4 94.35,100,  5, 3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1 Storebo (2019) 9,11.2,94.3418181818182 100 Storebo (2019)_Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2019) - Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3419,Storebo (2019),Storebo 2019 10.1002/14651858.CD008223.pub3,100 100,100 100,High Social skill training,Social skill training,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At follow-up (closest to 26 weeks),Mixed (different types of tool are used),Disruptive Behavior Disorders Rating Scale + ADHD Rating Scales: Hyperactivity and Impulsivity Subscales (total scores) + Conner Teacher Rating Scale: Hyperactivity Index + Strengths and Weaknesses of ADHD Symptoms and Normal Behaviors + ADHD Symptom Checklist + Child Symptom Inventory (ADHD (inattention) scale score) + SNAP-IV (teacher rating scale), 1.84119678 NA,NA Storebo,2012 NA RCT,SMD  28, 27,  55,NA reverse, 0.1700000000,-0.360000000  7.000000e-01,  9.6000000  11.9000000,NA NA,NA,NA,NA,NA,100,100,100,  0,100,100,100 low high,low,low low TAU,  0, 29.000000 10.403636, 94.34182 DSM-IV 0 1 1.0 1.0 1.0 1.0 1,1 0 1 1 1 1 1.0 1 1 1,1   38,Storebo_2012,< 2 months Average (80-119) 6-12 yo 10.4036363636364 10.4036363636364,94.3418181818182,94.3418181818182   5, 3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1,Storebo (2019) 9 11.2 94.3418181818182,100 Storebo (2019)_Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Storebo (2019) - Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low,low
3419 Storebo (2019),Storebo 2019 10.1002/14651858.CD008223.pub3 100 100,100 100,High Social skill training,Social skill training   0,NA,Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks) Mixed (different types of tool are used),Classroom Performance Survey (CPS) + Conners Behavior Rating Scale (CBRS): Academic Performance Index + Social Skills Improvement System (SSIS): Academic Competence Scale + Academic Performance Rating Scale (APRS) + Wechsler Individual Achievement Test (WIAT) + German teacher-rated questionnaire for learning and working behavior (Arbeitsverhalten Lehrer)  1.84119678,NA,NA Storebo,2012,NA,RCT,SMD, 24  26   50 NA NA  0.1700000000,-0.380000000  7.300000e-01, 15.2000000, 10.1000000 NA,NA,NA NA NA NA,100 100 100,  0,100 100,100,low high low low low,TAU,  0, 29.000000 10.392000, 94.36800 DSM-IV,0,1 1.0 1.0 1.0,1.0 1 1,0 1 1 1,1,1.0 1 1 1,1   39,Storebo_2012 < 2 months Average (80-119),6-12 yo 10.392,10.392 94.368,94.368,  5  3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1 Storebo (2019) 9,11.2 94.3418181818182,100,Storebo (2019)_Social skill training_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2019) - Social skill training_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3419,Storebo (2019) Storebo 2019 10.1002/14651858.CD008223.pub3,100 100 100 100 High,Social skill training Social skill training,  0,NA,Academic/job performance Teacher-rated,At follow-up (closest to 26 weeks) Mixed (different types of tool are used) Classroom Performance Survey (CPS) + Conners Behavior Rating Scale (CBRS): Academic Performance Index + Social Skills Improvement System (SSIS): Academic Competence Scale + Academic Performance Rating Scale (APRS) + Wechsler Individual Achievement Test (WIAT) + German teacher-rated questionnaire for learning and working behavior (Arbeitsverhalten Lehrer), 1.84119678 NA,NA,Storebo 2012 NA,RCT SMD, 26  27   53,NA NA -0.0400000000 -0.580000000, 5.000000e-01  12.0000000  12.6000000 NA NA,NA,NA NA,NA 100,100,100   0,100 100,100 low,high low low low,TAU   0  29.000000 10.396226  94.35849,DSM-IV 0 1 1.0 1.0 1.0,1.0,1,1 0,1 1 1 1 1.0,1,1,1,1   40 Storebo_2012 < 2 months,Average (80-119) 6-12 yo,10.3962264150943,10.3962264150943,94.3584905660377 94.3584905660377   5, 3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1 Storebo (2019),9,11.2 94.3418181818182 100 Storebo (2019)_Social skill training_Academic/job performance_Teacher-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Storebo (2019) - Social skill training_Academic/job performance_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,low
2646,Otasowie (2014),Otasowie,2014,10.1002/14651858.CD006997.pub2,100   0,100,100,High,Desipramine,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners ADHD Rating Scale, 1.38089758    9.2000000,mg/kg/d,Biederman 1989 NA RCT (parallel, crossover, open-label) G  31, 27,  58,NA reverse,-1.1800000000 -1.740000000,-6.100000e-01  25.1000000, 26.5000000 NA,NA,NA,NA NA NA,100,100,100,100,100 100 100,some,low,low,low,low,Placebo   0,  6.450000 11.500000,NA DSM-III 0,1,1.0,1.0,1.0 1.0 1 1,0,1 1,1,1 1.0 1 1 1,1,  41,Biederman_1989 < 2 months NA 6-12 yo,11 11.5 NA,NA,  4, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Otasowie (2014) | Catala-Lopez (2017),11,11.5,NA NA Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Otasowie (2014) - Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
2646,Otasowie (2014),Otasowie 2014 10.1002/14651858.CD006997.pub2 100   0,100,100,High,Desipramine NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners ADHD Rating Scale  1.38089758    3.5000000 mg/kg/d,Spencer 2002 NA RCT (parallel, crossover, open-label),G  21  20,  41,NA reverse,-1.7700000000,-2.500000000 -1.030000e+00, 12.0000000,  7.3000000 NA,NA,NA,NA,NA NA 100 100 100,100,100,100,100 low low,low,low,low,Placebo,  0, 17.070000 11.000000 NA DSM-IV,0 1,1.0,1.0 1.0 1.0,1 1 0,1 1 1,1,1.0 1 1,1 1,  42,Spencer_2002 < 2 months NA,6-12 yo 11 11.5 NA NA,  4  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Otasowie (2014) | Catala-Lopez (2017),11 11.5,NA NA,Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Otasowie (2014) - Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
2646,Otasowie (2014),Otasowie 2014,10.1002/14651858.CD006997.pub2,100,  0 100,100,High Desipramine NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire,Conners ADHD Rating Scale  1.38089758    9.2000000 mg/kg/d,Biederman 1989 NA,RCT (parallel, crossover, open-label),G, 31, 27   58 NA reverse -0.6800000000 -1.210000000,-1.500000e-01  27.3000000, 41.6000000 NA,NA NA,NA,NA NA,100,100 100 100,100,100 100,some low,low low low Placebo   0   6.450000 11.500000 NA DSM-III,0 1,1.0 1.0,1.0,1.0,1,1,0,1,1,1,1 1.0,1,1 1,1,  43,Biederman_1989 < 2 months,NA,6-12 yo,11.5 11.5,NA NA   4  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Otasowie (2014) | Catala-Lopez (2017),11,11.5,NA NA,Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Otasowie (2014) - Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
2646,Otasowie (2014) Otasowie,2014,10.1002/14651858.CD006997.pub2,  0,  0,100 100,High Desipramine NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire,Conners ADHD Rating Scale  0.46029919,   3.4000000,mg/kg/d,Donnelly,1986 NA,RCT (parallel, crossover, open-label) G, 19, 12   31,NA reverse -1.4000000000,-2.210000000,-5.800000e-01   2.6000000,  3.8000000 NA NA,NA NA NA,NA,100 100 100 100,100 100,100 some low,low low,low,Placebo   0   0.000000,NA,NA DSM-III,0,1 1.0,1.0 1.0,1.0,1,1,0,1 1,1,1,1.0 1,1,1 1   44,Donnelly_1986 < 2 months,NA NA,11.5 11.5 NA,NA   4  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Otasowie (2014) | Catala-Lopez (2017) 11,11.5,NA NA Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Otasowie (2014) - Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3090,Ruggiero (2014) Ruggiero 2014,10.1016/j.euroneuro.2014.08.001 100,  0,100 100 Critically low,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Mixed (different types of tool are used) NA  1.84119678,   3.0000000 mg/d Biederman 2008 NA RCT (parallel, crossover, open-label),RR 259, 86, 345 NA reverse, 9.1866151866  2.980279744  2.831744e+01,NA,NA,NA,NA NA NA NA,NA 100 100 100 100,100,100 100,some,low,low low,low Placebo,  0 NA,10.500000,NA,DSM-IV-TR,4,0 0.5 0.5 1.0 0.0,0 0 3 1 1 1,0,0.5,1,0 0,1,  45,Biederman_2008 < 2 months NA,6-12 yo 9.1 14.5,NA NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3090 Ruggiero (2014),Ruggiero 2014,10.1016/j.euroneuro.2014.08.001,100,  0,100,100,Critically low,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Mixed (different types of tool are used),NA  2.07134638,   2.5000000 mg/d Sallee,2009 NA,RCT (parallel, crossover, open-label) RR 256  66  322,NA,reverse  2.2236328125, 1.126326403  4.389973e+00,NA NA,NA,NA,NA,NA,NA NA,100 100 100 100,100 100,100,some low low,low low,Placebo,  0 NA,11.000000,NA DSM-IV-TR,4,0 0.5 0.5 1.0,0.0 0,0 3,1 1,1 0 0.5,1,0,0 1,  46 Sallee_2009,2-6 months,NA 6-12 yo 9.1,14.5,NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3090 Ruggiero (2014),Ruggiero,2014,10.1016/j.euroneuro.2014.08.001,100   0,100 100 Critically low Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) NA, 2.07134638,   3.0000000,mg/d,Connor,2010,NA RCT (parallel, crossover, open-label) RR,136, 78  214,NA,reverse, 9.8933823529, 3.754976542  2.606648e+01 NA,NA,NA,NA,NA,NA,NA,NA 100 100,100 100 100 100 100 some low,some,low,some Placebo,  0,NA  9.400000,NA DSM-IV-TR 4,0 0.5 0.5 1.0 0.0 0 0,3 1,1 1,0,0.5 1 0,0 1,  47 Connor_2010,2-6 months NA 6-12 yo 9.1,14.5,NA,NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA NA Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3090 Ruggiero (2014),Ruggiero 2014,10.1016/j.euroneuro.2014.08.001,100,  0 100 100 Critically low,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Mixed (different types of tool are used) NA, 1.38089758    2.5000000,mg/d,Kollins,2011,NA,RCT (parallel, crossover, open-label),RR,121, 57  178,NA reverse, 1.8118245391, 1.074294233  3.055688e+00,NA,NA NA,NA,NA NA,NA,NA,100 100,100 100 100,100 100 some low,low,low some Placebo   0 NA 12.600000 NA DSM-IV-TR,4 0,0.5,0.5 1.0 0.0,0,0 3,1 1 1,0 0.5 1,0 0 1   48,Kollins_2011,< 2 months,NA,6-12 yo,9.1 14.5,NA,NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA,Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3090 Ruggiero (2014) Ruggiero 2014,10.1016/j.euroneuro.2014.08.001,100,  0 100,100 Critically low Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),NA, 1.84119678    2.5000000 mg/d,Newcorn,2013,NA,RCT (parallel, crossover, open-label),RR,221,112, 333 NA,reverse  3.5475113122  2.126499627, 5.918100e+00 NA,NA NA NA,NA NA,NA,NA,100 100,100,100 100,100,100 some,low low low low Placebo,  0,NA  9.100000,NA DSM-IV-TR 4,0 0.5 0.5,1.0,0.0 0,0 3,1,1,1 0 0.5,1,0 0 1,  49 Newcorn_2013 < 2 months,NA 6-12 yo 9.1,14.5,NA NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA,Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3090 Ruggiero (2014),Ruggiero,2014,10.1016/j.euroneuro.2014.08.001,100,  0 100,100,Critically low Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Mixed (different types of tool are used),NA  2.99194476    4.0000000 mg/d,NCT01081132,2014 NA,RCT (parallel, crossover, open-label),RR 157 155  312 NA reverse, 2.0642733063  1.453984361, 2.930722e+00 NA,NA,NA NA NA NA,NA NA   0,  0   0   0   0,  0,  0,high,high,high,high high,Placebo   0,NA,14.500000 NA,DSM-IV-TR 4,0 0.5,0.5 1.0 0.0 0,0,3 1,1,1,0 0.5 1 0,0,1,  50 NCT01081132_2014,2-6 months,NA,13-19 yo,9.1,14.5,NA,NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA,Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
8992 Fahrat (2024),Fahrat,2024 10.1089/cap.2024.0049,100,  0,100 100 High,Alpha-2 agonists (guanfacine / clonidine),NA,  0 NA,Tics/Tourette disorder symptoms Mixed At study endpoint (closest to 12 weeks) Questionnaire,The Yale Global Tic Severity Scale, 1.84119678,   1.5000000,mg/d,Scahill 2001,NA,RCT (parallel, crossover, open-label) SMD, 17  17,  34 NA,reverse -0.7500000000 -1.470000000 -3.000000e-02,NA,NA NA NA NA NA NA,NA,100,100 100,100,100,100,100 low,low some low,low Placebo,  0,  8.800000 10.400000 NA,DSM-IV,0 1,1.0,1.0,1.0 1.0,1,1,1 1,1,1,1 1.0,1 1,0 1   51 Scahill_2001 < 2 months NA,6-12 yo,9.07,10.6,NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA,Fahrat (2024)_Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Fahrat (2024) - Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
8992,Fahrat (2024),Fahrat 2024 10.1089/cap.2024.0049 100   0,100 100 High Alpha-2 agonists (guanfacine / clonidine) NA,  0 NA,Tics/Tourette disorder symptoms Mixed,At study endpoint (closest to 12 weeks),Questionnaire,The Yale Global Tic Severity Scale, 1.38089758    0.1900000 mg/d Singer 1995 NA,RCT (parallel, crossover, open-label) SMD  34  34   68 NA,reverse,-0.6900000000,-1.180000000 -2.000000e-01,NA NA NA,NA,NA NA,NA,NA 100 100 100,100 100 100,100 some low low,low some,Placebo   0   8.800000 10.600000 NA,DSM-III-R 0 1,1.0,1.0 1.0 1.0,1,1,1 1,1 1,1,1.0,1,1 0 1   52 Singer_1995 < 2 months NA 6-12 yo 9.07,10.6,NA NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA NA,Fahrat (2024)_Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Fahrat (2024) - Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
8992 Fahrat (2024) Fahrat 2024,10.1089/cap.2024.0049 100,  0 100 100,High,Alpha-2 agonists (guanfacine / clonidine),NA   0 NA Tics/Tourette disorder symptoms,Mixed,At study endpoint (closest to 12 weeks) Questionnaire The Yale Global Tic Severity Scale  3.68239356    0.2500000 mg/d,TSSG,2002,NA,RCT (parallel, crossover, open-label) SMD,NA, 32,NA NA reverse -0.6900000000 -1.180000000,-2.000000e-01,NA,NA NA NA NA,NA NA,NA,100,100 100 100 100,100,100 low,low some low,low Placebo,  0, 14.600000 10.200000,NA DSM-IV,0,1,1.0 1.0,1.0 1.0,1,1 1,1,1 1 1,1.0 1,1 0 1,  53,TSSG_2002,2-6 months NA 6-12 yo 9.07 10.6,NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA NA,Fahrat (2024)_Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Fahrat (2024) - Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8992,Fahrat (2024) Fahrat,2024 10.1089/cap.2024.0049 100   0 100 100 High Alpha-2 agonists (guanfacine / clonidine),NA,  0 NA,Tics/Tourette disorder symptoms Mixed At study endpoint (closest to 12 weeks),Questionnaire,VAS (ADHD symptoms and TICS)  1.84119678,   1.5000000,mg/d Chen 2024 NA,RCT (parallel, crossover, open-label) SMD  98  29, 127,NA reverse -0.9300000000 -1.360000000 -5.000000e-01 NA NA,NA,NA,NA NA NA NA 100 100 100 100 100 100 100 low low,some low low,Placebo   0,  9.400000  9.070000 NA DSM-IV 0 1,1.0,1.0,1.0 1.0 1 1 1,1 1 1 1 1.0,1,1,0,1   54 Chen_2024,< 2 months NA,6-12 yo 9.07 10.6,NA NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA Fahrat (2024)_Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Fahrat (2024) - Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
1110,Faraone (2002),Faraone,2002 10.1177/108705470200600203 100,  0 100 100 Critically low,Amphetamine,Adderall   0,NA,Disruptive behaviors,Mixed At study endpoint (closest to 12 weeks),Questionnaire,Iowa Conners Rating Scale,NA,NA mg,Pelham, Aronoff,1999 NA,RCT (crossover),G  25  25   50 outcomes,NA, 1.1300000000  0.530000000, 1.730000e+00 NA,NA NA NA NA NA NA NA,  0,  0,  0   0,  0   0,  0,high,high high high,high,Placebo   0 NA  9.500000 NA NA 6 0 0.0,0.0,0.0,0.0,0,1,6,1,1,0,0 0.5 0 0 0,0   55 Pelham, Aronoff_1999,NA NA,6-12 yo,8,9.5,NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
1110 Faraone (2002),Faraone 2002,10.1177/108705470200600203 100,  0,100 100,Critically low Amphetamine Adderall,  0,NA Disruptive behaviors,Mixed At study endpoint (closest to 12 weeks) Questionnaire,Iowa Conners Rating Scale,NA NA mg,Pelham, Aronoff,1999,NA,RCT (crossover) G  25, 25,  50 outcomes,NA  1.5100000000  0.880000000  2.140000e+00 NA,NA NA,NA,NA NA,NA NA,  0   0   0   0,  0   0   0 high,high high high high,Placebo   0,NA  9.500000 NA NA 6 0 0.0,0.0 0.0,0.0,0 1 6 1,1 0,0,0.5,0,0 0 0   56 Pelham, Aronoff_1999,NA NA,6-12 yo 8 9.5,NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
1110,Faraone (2002),Faraone 2002,10.1177/108705470200600203 100,  0 100,100,Critically low Amphetamine,Adderall,  0 NA Disruptive behaviors,Mixed,At study endpoint (closest to 12 weeks) Questionnaire,Iowa Conners Rating Scale NA,NA,mg,Pelham, Aronoff,1999,NA,RCT (crossover),G, 25  25   50,outcomes NA, 1.1800000000, 0.570000000  1.780000e+00,NA,NA NA NA NA,NA,NA,NA   0,  0,  0   0   0   0,  0,high,high high high high,Placebo,  0,NA  9.500000 NA,NA 6 0,0.0 0.0,0.0,0.0 0,1 6,1,1,0 0 0.5 0,0 0,0,  57 Pelham, Aronoff_1999 NA,NA,6-12 yo 8,9.5 NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
1110 Faraone (2002) Faraone 2002,10.1177/108705470200600203,100,  0 100 100 Critically low,Amphetamine,Adderall   0 NA Disruptive behaviors,Mixed,At study endpoint (closest to 12 weeks) Questionnaire Iowa Conners Rating Scale,NA    0.6000000,mg/kg/d,Pelham, Gnagy,1999,NA RCT (crossover) G  21  21   42,outcomes,NA  1.0200000000  0.380000000, 1.670000e+00,NA,NA NA NA,NA NA,NA,NA,  0   0,  0,  0,  0,  0   0,high high,high high,high,Placebo,  0,NA  9.500000 NA NA 6,0,0.0 0.0 0.0 0.0,0 1,6 1 1,0 0,0.5 0 0,0 0   58 Pelham, Gnagy_1999,NA NA 6-12 yo,8,9.5,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
1110,Faraone (2002) Faraone 2002 10.1177/108705470200600203 100,  0,100 100 Critically low,Amphetamine Adderall,  0,NA,Disruptive behaviors,Mixed,At study endpoint (closest to 12 weeks) Questionnaire Iowa Conners Rating Scale,NA,   0.6000000,mg/kg/d Pelham, Gnagy,1999 NA RCT (crossover) G, 21  21   42 outcomes NA  1.5200000000  0.830000000, 2.210000e+00 NA,NA NA,NA,NA,NA,NA,NA,  0   0,  0,  0,  0   0   0,high,high high,high high,Placebo   0 NA, 9.500000 NA,NA,6,0,0.0,0.0,0.0,0.0 0,1,6 1,1,0 0,0.5 0,0,0 0   59 Pelham, Gnagy_1999 NA NA,6-12 yo,8 9.5,NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
1110 Faraone (2002),Faraone,2002,10.1177/108705470200600203 100,  0,100,100 Critically low,Amphetamine,Adderall,  0,NA,Disruptive behaviors Mixed At study endpoint (closest to 12 weeks),Questionnaire,Iowa Conners Rating Scale NA    0.6000000 mg/kg/d Pelham, Gnagy,1999,NA,RCT (crossover) G  21, 21   42 outcomes,NA, 1.1000000000  0.450000000  1.760000e+00 NA,NA,NA NA NA,NA NA NA   0   0,  0   0   0   0   0 high,high high,high high,Placebo   0,NA  9.500000 NA,NA 6 0 0.0 0.0 0.0 0.0 0 1,6 1,1 0 0 0.5 0,0,0,0,  60,Pelham, Gnagy_1999,NA NA 6-12 yo,8,9.5,NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
1110,Faraone (2002),Faraone,2002 10.1177/108705470200600203 100   0,100 100 Critically low Amphetamine,Adderall   0,NA Disruptive behaviors,Mixed At study endpoint (closest to 12 weeks) Questionnaire Iowa Conners Rating Scale  0.69044879 NA,NA Pliszka 2000,NA RCT (parallel),G, 20  18,  38,NA,NA  0.6000000000 -0.050000000, 1.260000e+00 NA,NA,NA,NA NA NA NA,NA,  0,  0,  0   0   0   0   0 high,high,high,high high Placebo   0,NA, 8.000000 NA NA 6,0,0.0,0.0 0.0,0.0,0,1 6,1,1,0 0 0.5,0 0,0 0,  61,Pliszka_2000 < 2 months NA 6-12 yo 8 9.5 NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
2877 Punja (2016),Punja,2016,10.1002/14651858.CD009996.pub2,100   0 100 100,High,Amphetamine,Mixed amphetamine salts (short acting),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,ADHD Rating Scale, Fourth Version  1.00000000,  15.0000000,mg/d Barkley,2000 NA RCT (parallel, crossover, open-label),G  31, 31,  62,NA,reverse,-0.1600000000 -0.660000000, 3.400000e-01,  9.0000000  12.5000000 NA NA NA NA NA NA 100,100,100,100,  0 100,100 some some high,some,some Placebo   0, 14.000000,14.000000,NA DSM-IV,0 1,1.0 1.0,1.0,1.0 1,1 0,1,1 1,1,1.0,1 1,1 1,  62 Barkley_2000 < 2 months NA 13-19 yo,8.2 14 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
2877 Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2 100   0 100,100 High,Amphetamine,Mixed amphetamine salts (long acting)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners Global Index, 0.69044879,  20.0000000,mg/d,Biederman,2002 NA RCT (parallel, crossover, open-label) G,360 203, 563,NA reverse -0.3971889218 -0.570922486 -2.234554e-01, 10.7000000   8.8000000 NA NA NA NA NA NA,100 100,100,100 100,100 100 some,some low some,some Placebo,  0, 23.000000, 8.600000,NA,DSM-IV,0,1,1.0 1.0,1.0 1.0 1 1,0,1,1 1 1 1.0,1,1 1 1   63,Biederman_2002,< 2 months NA,6-12 yo 8.2,14,NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
2877,Punja (2016) Punja,2016 10.1002/14651858.CD009996.pub2,100,  0 100,100,High,Amphetamine,Lisdexamphetamine (long acting),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire ADHD Rating Scale, Fourth Version, and the Conners' Parent Rating Scale-Revised: Short Form, 1.00000000   50.0000000 mg/d Biederman 2007b,NA RCT (parallel, crossover, open-label),G 213  72, 285,NA reverse -0.2900000000,-0.550000000,-2.000000e-02, 59.8000000, 34.8000000 NA,NA,NA NA,NA NA,100,100,100,100,100,100,100,some,low low some,some Placebo   0  31.000000  9.000000 NA DSM-IV-TR,0 1,1.0,1.0 1.0 1.0 1 1,0,1 1,1 1 1.0,1,1,1 1   64 Biederman_2007b,< 2 months,NA,6-12 yo,8.2,14,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
2877,Punja (2016),Punja,2016,10.1002/14651858.CD009996.pub2,100,  0 100,100 High,Amphetamine,Lisdexampehtamine (long acting)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners' Parent Rating Scale - Revised, 1.61104718   50.0000000,mg/d Coghill 2013,NA,RCT (parallel, crossover, open-label) G, 98,103  201 NA reverse -1.1700000000,-1.470000000 -8.700000e-01, 17.6000000, 18.0000000,NA,NA,NA NA NA NA,  0,  0 100 100   0,  0,100,some low high,some,high Placebo   0  19.000000,10.900000 NA DSM-IV-TR 0,1 1.0 1.0,1.0 1.0 1,1 0,1 1,1,1,1.0,1 1 1,1,  65,Coghill_2013,< 2 months NA 6-12 yo,8.2 14,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
2877,Punja (2016) Punja 2016,10.1002/14651858.CD009996.pub2 100   0 100 100,High,Amphetamine Mixed amphetamine salts (short acting)   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners' Abbreviated Symptoms Questionnaire, 0.92059839   10.0000000,mg/d,Manos,1999,NA RCT (parallel, crossover, open-label) G  42, 42,  84,NA,reverse,-0.7500000000,-1.200000000,-3.100000e-01,  9.9000000  11.7000000 NA NA NA,NA,NA NA,100 100 100,100 100,100,100 some,low some low some,Placebo,  0, 21.000000,10.100000 NA,DSM-IV 0 1,1.0,1.0 1.0,1.0,1,1 0 1,1,1 1,1.0 1,1,1,1   66 Manos_1999,< 2 months NA 6-12 yo,8.2 14,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
2877,Punja (2016),Punja,2016,10.1002/14651858.CD009996.pub2,100   0 100 100 High Amphetamine,Dextroamphetamine (short acting),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,Conners' Parent Rating Scale  0.46029919,  15.0000000,mg/d Nemzer,1986 NA RCT (parallel, crossover, open-label) G, 14, 14   28 NA,reverse,-0.6000000000,-1.360000000, 1.600000e-01   6.4000000,  6.2000000,NA,NA,NA,NA NA NA 100 100,100 100,100 100 100,some low,some some some Placebo,  0  21.000000, 9.360000,NA,DSM-III,0 1,1.0,1.0 1.0,1.0 1,1 0,1 1,1,1 1.0,1 1 1 1,  67,Nemzer_1986,< 2 months NA 6-12 yo 8.2 14,NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
2877,Punja (2016) Punja 2016 10.1002/14651858.CD009996.pub2 100   0,100,100 High,Amphetamine Mixed amphetamine salts (short acting),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Conners' Parent Global Index  0.69044879   22.5000000 mg Pliszka,2000 NA,RCT (parallel, crossover, open-label),G  12, 12,  24,NA,reverse -0.6200000000 -1.450000000  2.000000e-01   0.7000000,  0.9000000,NA NA NA,NA,NA,NA 100,100 100 100,100,100 100 some,low low some some,Placebo   0 NA  8.200000 NA,Diagnostic Interview Schedule for Children,0 1 1.0,1.0 1.0 1.0,1 1,0 1 1,1,1,1.0 1 1,1 1   68 Pliszka_2000 < 2 months NA 6-12 yo,8.2,14,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
2877 Punja (2016),Punja 2016,10.1002/14651858.CD009996.pub2,100   0,100,100 High Amphetamine,Mixed amphetamine salts (short acting),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire ADHD Rating Scale, Fourth Version  1.00000000   15.0000000 mg/d,Barkley,2000 NA RCT (parallel, crossover, open-label),G  15  15   30,NA reverse,-0.0500000000,-0.770000000, 6.600000e-01, 14.7000000, 13.8000000 NA NA NA NA NA,NA 100 100 100,100,  0,100,100 some some,high some,some Placebo,  0, 14.000000,14.000000,NA,DSM-IV,0 1,1.0,1.0,1.0 1.0 1 1,0 1,1 1 1,1.0 1 1 1 1,  69,Barkley_2000 < 2 months NA,13-19 yo,8,14 NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
2877,Punja (2016) Punja,2016 10.1002/14651858.CD009996.pub2,100   0 100,100 High Amphetamine Mixed amphetamine salts (long acting)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire Conners Global Index  0.69044879,  20.0000000 mg/d,Biederman,2002 NA RCT (parallel, crossover, open-label),G,360 203, 563 NA reverse,-0.3917394022,-0.565430566,-2.180482e-01  11.0000000   9.4000000,NA,NA,NA NA NA,NA,100,100 100,100 100,100 100 some,some low some some,Placebo,  0  23.000000, 8.600000 NA,DSM-IV 0,1 1.0,1.0,1.0,1.0 1 1,0,1 1,1 1 1.0 1,1 1 1   70 Biederman_2002,< 2 months,NA 6-12 yo 8 14 NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
2877 Punja (2016) Punja 2016 10.1002/14651858.CD009996.pub2 100   0 100,100 High,Amphetamine,Dextroamphetamine (short acting),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire Conners' Teacher Rating Scale, 2.00000000 NA,NA,Donnelly,1989,NA,RCT (parallel, crossover, open-label) G  20, 20   40,NA reverse,-0.8800000000 -1.530000000 -2.200000e-01,  3.1000000,  3.8000000 NA,NA,NA,NA,NA,NA,100,100,100 100 100 100,100,some,some,low,some some Placebo,  0   0.000000  8.000000 NA DSM-III 0 1 1.0 1.0 1.0,1.0,1,1 0 1,1 1,1 1.0,1 1 1 1   71 Donnelly_1989,2-6 months NA 6-12 yo,8,14 NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
2877 Punja (2016) Punja,2016 10.1002/14651858.CD009996.pub2,100   0 100,100 High Amphetamine,Mixed amphetamine salts (short acting)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire Conners' Abbreviated Symptoms Questionnaire - Teacher Version  0.92059839,  10.0000000,mg/d,Manos 1999,NA,RCT (parallel, crossover, open-label),G, 42  42   84,NA,reverse,-0.8600000000 -1.310000000 -4.200000e-01, 10.4000000, 13.6000000 NA NA,NA NA,NA NA 100 100 100,100,100,100 100 some,low some low,some,Placebo,  0, 21.000000,10.100000 NA,DSM-IV 0,1 1.0,1.0,1.0,1.0 1 1,0,1 1 1 1,1.0,1 1,1,1,  72 Manos_1999 < 2 months,NA 6-12 yo 8 14,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
2877,Punja (2016),Punja,2016 10.1002/14651858.CD009996.pub2 100   0,100 100,High Amphetamine,Dextroamphetamine (short acting),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire,Conners' Teacher Rating Scale, 0.46029919   15.0000000,mg/d,Nemzer 1986 NA,RCT (parallel, crossover, open-label) G  14  14,  28 NA reverse -0.6900000000 -1.460000000  8.000000e-02, 18.9000000, 18.6000000,NA,NA,NA NA,NA NA,100,100 100 100,100,100,100,some,low,some,some,some,Placebo,  0, 21.000000, 9.360000,NA DSM-III 0,1 1.0 1.0 1.0 1.0 1 1 0,1 1,1,1,1.0,1 1 1,1,  73 Nemzer_1986,< 2 months,NA,6-12 yo 8,14,NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
2877,Punja (2016),Punja,2016 10.1002/14651858.CD009996.pub2 100,  0 100 100,High Amphetamine,Dextroamphetamine (short acting),  0,NA CGI Mixed At study endpoint (closest to 12 weeks),Observational tool CGI  2.00000000   55.0000000,mg/d Borcherding 1990,NA,RCT (parallel, crossover, open-label) G  31  31,  62,NA,reverse -0.5000000000,-1.010000000, 0.000000e+00,  3.9000000   3.9000000 NA,NA NA,NA NA NA,100,100 100,100   0 100 100 some some,high,some,some,Placebo   0,  0.000000, 8.600000 NA DSM-III 0 1 1.0,1.0,1.0,1.0,1,1,0 1,1 1 1 1.0 1,1,1,1   74,Borcherding_1990 2-6 months,NA 6-12 yo 8.2 8.6,NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Punja (2016)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
2877,Punja (2016),Punja 2016,10.1002/14651858.CD009996.pub2,100,  0,100 100 High Amphetamine,Mixed amphetamine salts (short acting),  0 NA,CGI,Mixed,At study endpoint (closest to 12 weeks) Observational tool CGI, 0.69044879   22.5000000 mg,Pliszka,2000 NA RCT (parallel, crossover, open-label),G  12, 12,  24 NA,reverse -1.3900000000,-2.300000000,-4.800000e-01   0.7000000   1.4000000,NA NA,NA NA,NA NA 100,100,100,100 100,100 100 some,low low some some Placebo,  0 NA, 8.200000 NA,Diagnostic Interview Schedule for Children 0 1,1.0 1.0 1.0,1.0,1,1 0,1 1 1 1,1.0,1,1,1 1   75 Pliszka_2000,< 2 months,NA,6-12 yo 8.2,8.6 NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA Punja (2016)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
2877,Punja (2016),Punja 2016,10.1002/14651858.CD009996.pub2 100   0,100 100,High,Amphetamine Mixed amphetamine salts (long acting) or Lisdexamphetamine (long acting)   0 NA Academic/job performance NA,At study endpoint (closest to 12 weeks),Test Permanent Product Measure of Performance scale, 0.69044879   30.0000000 mg/d Biederman,2007a,NA RCT (parallel, crossover, open-label) G, 50, 50, 100,NA NA  0.5900000000  0.190000000, 9.900000e-01  76.0000000  76.0000000,NA,NA,NA NA NA NA,100 100,100,100 100 100 100,some,some low some,low,Placebo   0  36.000000, 9.100000 NA DSM-IV-TR 0 1,1.0,1.0,1.0,1.0 1 1 0 1,1,1 1 1.0,1 1,1,1,  76,Biederman_2007a < 2 months NA,6-12 yo,8.6,10.58,NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
2877,Punja (2016),Punja,2016 10.1002/14651858.CD009996.pub2,100,  0,100 100 High Amphetamine Dextroamphetamine (short acting),  0,NA,Academic/job performance NA At study endpoint (closest to 12 weeks) Test,Barnell LoT, Ltd, Developing Key Concepts in Math test  2.00000000,  55.0000000,mg/d,Borcherding 1990,NA RCT (parallel, crossover, open-label) G, 33, 33,  66 NA NA, 0.4700000000 -0.020000000  9.600000e-01   4.6000000   7.9000000,NA NA NA,NA,NA NA,100,100,100,100   0,100 100 some some high some,some Placebo   0,  0.000000, 8.600000,NA DSM-III 0 1 1.0,1.0,1.0 1.0,1 1,0 1 1 1 1,1.0,1,1,1,1   77,Borcherding_1990,2-6 months NA 6-12 yo 8.6 10.58,NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
2877,Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2 100,  0 100 100,High Amphetamine,Mixed amphetamine salts (short acting)   0 NA,Academic/job performance NA At study endpoint (closest to 12 weeks) Test Permanent Product Measure of Performance, 0.46029919   46.8000000,mg/d Childress,2015 NA RCT (parallel, crossover, open-label) G, 97, 97  194,NA,NA, 0.7500000000  0.460000000  1.040000e+00, 37.4000000  35.8000000 NA NA NA,NA,NA NA 100,100,100,100,100,100 100,some,some low some,low,Placebo,  0  39.200000  9.600000,NA,DSM-IV-TR,0 1 1.0 1.0,1.0 1.0 1,1,0,1 1 1 1,1.0 1 1,1,1   78 Childress_2015 < 2 months,NA 6-12 yo,8.6 10.58,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
2877 Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2 100   0 100 100,High Amphetamine Dextroamphetamine (short acting) or Dextroamphetamine spansules (long acting) or Mixed amphetamine salts (long acting)*   0 NA,Academic/job performance,NA,At study endpoint (closest to 12 weeks) Test,5-minute timed math task  1.84119678 NA NA,James 2001 NA,RCT (parallel, crossover, open-label) G  35, 35,  70 NA,NA, 0.5600000000, 0.090000000, 1.040000e+00  52.7000000  51.3000000 NA NA NA NA,NA,NA,100,100 100 100 100,100,100,some,low,low,some,some,Placebo,  0  40.000000  9.100000,NA DSM-IV,0,1 1.0,1.0,1.0 1.0,1,1,0,1 1,1 1,1.0 1 1 1,1,  79,James_2001 < 2 months NA 6-12 yo 8.6 10.58,NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA,Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
2877 Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2 100   0,100 100,High,Amphetamine Mixed amphetamine salts (short acting and long acting)   0 NA,Academic/job performance NA At study endpoint (closest to 12 weeks),Test,Permanent Product Measure of Performance  1.15074799,  20.0000000 mg/d,McCracken 2003 NA RCT (parallel, crossover, open-label) G  49, 49   98 NA,NA, 0.2800000000 -0.120000000  6.700000e-01, 52.0000000, 50.3000000 NA,NA,NA,NA,NA NA 100 100 100,100 100,100 100 some some low,some,some Placebo,  0  14.000000, 9.500000 NA,DSM-IV 0,1 1.0 1.0,1.0,1.0,1,1,0 1 1,1 1,1.0,1,1,1 1,  80 McCracken_2003 < 2 months NA 6-12 yo 8.6 10.58,NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
2877 Punja (2016),Punja,2016,10.1002/14651858.CD009996.pub2 100   0 100 100,High Amphetamine Dextroamphetamine (short acting)   0,NA,Academic/job performance,NA,At study endpoint (closest to 12 weeks),Test,Wechsler Intelligence Scale for Children - Revised  0.46029919   15.0000000 mg/d Nemzer,1986,NA RCT (parallel, crossover, open-label),G  14, 14,  28,NA NA  0.4600000000,-0.300000000, 1.210000e+00, 16.7000000  17.4000000 NA NA,NA,NA NA NA,100 100,100 100 100 100 100,some,low,some,some,some Placebo,  0  21.000000, 9.360000,NA,DSM-III,0,1 1.0 1.0 1.0 1.0 1 1,0,1,1 1,1 1.0 1 1,1 1   81,Nemzer_1986,< 2 months,NA,6-12 yo,8.6 10.58,NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
2877 Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2,100,  0,100,100 High,Amphetamine Dextroamphetamine (short acting),  0 NA,Academic/job performance NA,At study endpoint (closest to 12 weeks),Test,Wide Range Achievement Test - math subset, 0.92059839,NA,NA,Shekim,1986 NA RCT (parallel, crossover, open-label) G  22  22   44,NA,NA -0.0100000000,-0.600000000, 5.900000e-01,  9.5000000, 11.7000000 NA NA NA NA,NA NA,100 100 100 100,  0,100,100 some some high,some some Placebo   0   0.000000  9.750000 NA,DSM-III,0,1 1.0 1.0 1.0 1.0 1,1 0,1,1,1,1,1.0 1 1 1 1,  82 Shekim_1986 < 2 months,NA 6-12 yo,8.6,10.58,NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
2877,Punja (2016) Punja 2016 10.1002/14651858.CD009996.pub2,100,  0,100,100,High Amphetamine,Lisdexamphetamine (long acting)   0 NA,Academic/job performance NA,At study endpoint (closest to 12 weeks),Test,Permanent Product Measure of Performance  0.46029919,  50.0000000,mg/d Wigal,2009 NA RCT (parallel, crossover, open-label),G,113 113, 226 NA NA  0.7800000000  0.510000000, 1.050000e+00, 36.3000000, 36.3000000,NA NA,NA,NA NA,NA,100,100,100,100 100 100,100 some low,low some,some Placebo   0  24.000000 10.580000 NA,DSM-IV-TR,0,1,1.0 1.0,1.0 1.0,1 1 0,1 1 1 1 1.0,1 1,1,1   83 Wigal_2009,< 2 months,NA,6-12 yo 8.6,10.58 NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA,Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
2877,Punja (2016) Punja 2016 10.1002/14651858.CD009996.pub2,100   0 100,100 High Amphetamine,Mixed amphetamine salts (long acting)   0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview Adverse events  0.69044879   20.0000000,mg/d Biederman,2002,NA RCT (parallel, crossover, open-label),RR,374,210, 584 NA reverse,11.5106951872, 4.280245271, 3.095526e+01,NA NA,NA NA,NA,NA NA,NA 100 100 100 100,100 100,100,some some,low some,some,Placebo   0  23.000000  8.600000 NA,DSM-IV 0 1 1.0 1.0,1.0 1.0 1,1 0 1 1 1 1 1.0 1 1 1,1   84,Biederman_2002 < 2 months,NA,6-12 yo,8.2 14.6,NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
2877,Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2,100,  0 100,100,High Amphetamine,Mixed amphetamine salts (long acting) or Lisdexamphetamine (long acting)   0,NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Interview,Adverse events, 0.69044879   30.0000000,mg/d,Biederman,2007a NA,RCT (parallel, crossover, open-label),RR, 52, 52  104 NA reverse, 5.0000000000, 0.245868146, 1.016805e+02 NA NA,NA NA NA NA,NA NA,100,100 100,100 100,100,100 some some,low some low,Placebo,  0, 36.000000  9.100000 NA DSM-IV-TR,0 1 1.0 1.0,1.0 1.0 1 1,0,1,1,1 1 1.0,1 1,1 1,  85 Biederman_2007a,< 2 months NA 6-12 yo 8.2 14.6 NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
2877 Punja (2016),Punja,2016 10.1002/14651858.CD009996.pub2 100,  0 100,100 High Amphetamine Lisdexamphetamine (long acting)   0 NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview,Adverse events  1.00000000   50.0000000,mg/d Biederman,2007b,NA,RCT (parallel, crossover, open-label) RR,218  72, 290 NA reverse  9.3577981651  3.052844863, 2.868419e+01 NA NA,NA,NA NA NA NA NA,100,100,100,100,100,100 100,some low,low,some some Placebo,  0  31.000000, 9.000000,NA,DSM-IV-TR 0 1 1.0,1.0,1.0,1.0 1,1 0 1 1,1 1 1.0 1 1 1 1,  86 Biederman_2007b < 2 months NA,6-12 yo,8.2 14.6,NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
2877 Punja (2016),Punja,2016 10.1002/14651858.CD009996.pub2 100   0 100 100 High Amphetamine,Mixed amphetamine salts (short acting),  0,NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview,Adverse events, 0.46029919,  46.8000000,mg/d,Childress 2015 NA,RCT (parallel, crossover, open-label),RR  97  97  194,NA reverse  9.0000000000  0.491118361  1.649297e+02,NA,NA NA NA NA NA,NA NA,100 100,100,100 100,100 100,some some,low some low,Placebo   0  39.200000  9.600000 NA DSM-IV-TR 0 1 1.0 1.0,1.0,1.0 1 1,0,1 1,1 1 1.0,1 1,1,1   87,Childress_2015 < 2 months,NA,6-12 yo,8.2 14.6 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
2877 Punja (2016),Punja 2016,10.1002/14651858.CD009996.pub2,100,  0 100,100,High Amphetamine,Lisdexampehtamine (long acting)   0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Interview Adverse events, 1.61104718,  50.0000000 mg/d Coghill 2013,NA RCT (parallel, crossover, open-label),RR,111 110  221 NA,reverse  9.2492492492  2.896326694, 2.953693e+01 NA NA NA NA,NA NA,NA,NA   0   0 100,100   0,  0,100,some low,high some high Placebo   0  19.000000 10.900000,NA,DSM-IV-TR 0,1 1.0,1.0,1.0,1.0 1,1,0 1 1 1,1,1.0,1,1 1 1,  88 Coghill_2013,< 2 months NA,6-12 yo,8.2,14.6,NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high,high
2877 Punja (2016) Punja 2016,10.1002/14651858.CD009996.pub2,100,  0,100,100 High,Amphetamine,Lisdexamphetamine (long acting),  0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Interview Adverse events, 0.92059839   50.0000000 mg/d,Findling,2011,NA RCT (parallel, crossover, open-label),RR 233  79, 312,NA reverse 13.3927038627  3.369509385  5.323164e+01 NA,NA NA,NA,NA NA NA NA 100 100,100 100 100 100 100 low,some,low some low,Placebo   0, 21.000000 14.600000,NA,DSM-IV-TR,0,1 1.0,1.0 1.0 1.0 1 1 0,1,1,1 1 1.0,1,1,1,1,  89,Findling_2011 < 2 months,NA,13-19 yo,8.2 14.6,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
2877 Punja (2016) Punja 2016,10.1002/14651858.CD009996.pub2 100   0,100 100 High Amphetamine Mixed amphetamine salts (short acting and long acting)   0 NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Interview Adverse events  1.15074799,  20.0000000 mg/d,McCracken 2003 NA,RCT (parallel, crossover, open-label) RR  51  51, 102,NA,reverse  1.8181818182  0.973182335  3.396882e+00 NA NA NA,NA NA NA NA,NA 100,100,100 100,100 100 100 some some low,some,some,Placebo   0, 14.000000  9.500000 NA,DSM-IV,0,1,1.0 1.0 1.0,1.0 1 1 0,1 1,1 1,1.0 1,1,1 1   90,McCracken_2003,< 2 months NA 6-12 yo,8.2,14.6,NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
2877,Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2,100,  0,100,100 High Amphetamine,Mixed amphetamine salts (short acting),  0,NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview,Adverse events, 0.69044879   22.5000000,mg Pliszka 2000,NA,RCT (parallel, crossover, open-label),RR  20, 18,  38 NA reverse  6.3333333333  0.349360980  1.148128e+02 NA,NA,NA,NA NA NA NA,NA 100,100,100,100,100 100 100 some,low,low,some some,Placebo,  0 NA  8.200000 NA,Diagnostic Interview Schedule for Children 0 1 1.0 1.0 1.0,1.0,1 1,0,1,1 1 1 1.0,1 1,1 1   91,Pliszka_2000 < 2 months NA,6-12 yo 8.2 14.6 NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
2877 Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2,100,  0 100 100,High,Amphetamine,Dextroamphetamine (short acting)   0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Interview,Adverse events  1.61104718,  15.0000000,mg/d Ramtvedt,2013,NA,RCT (parallel, crossover, open-label),RR  34, 34,  68,NA,reverse  1.4117647059  0.946262289  2.106265e+00 NA NA NA,NA NA NA,NA NA   0   0,100,  0,  0   0,100 some,high,high,some high Placebo,  0  19.000000 11.400000,NA,DSM-IV-TR,0 1,1.0,1.0,1.0 1.0 1 1,0,1,1,1,1,1.0,1 1 1,1,  92,Ramtvedt_2013 < 2 months,NA,6-12 yo 8.2,14.6 NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
2877,Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2,100,  0 100,100,High Amphetamine Mixed amphetamine salts (long acting)   0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Interview,Adverse events, 0.92059839,  25.0000000 mg/d,Spencer 2006 NA,RCT (parallel, crossover, open-label),RR,233, 63  296,NA reverse 22.4420600858  3.186564226  1.580530e+02 NA NA,NA NA NA NA,NA,NA 100 100,100,100 100 100 100 some some,low some low Placebo   0  34.000000 14.200000,NA DSM-IV-TR 0 1,1.0 1.0 1.0 1.0,1,1 0,1 1,1 1,1.0 1 1,1 1   93,Spencer_2006,< 2 months,NA 13-19 yo,8.2,14.6,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
2877 Punja (2016) Punja,2016 10.1002/14651858.CD009996.pub2 100   0 100 100,High,Amphetamine Lisdexamphetamine (long acting)   0,NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Interview Adverse events  0.46029919   50.0000000,mg/d Wigal,2009,NA RCT (parallel, crossover, open-label),RR 129,129  258,NA reverse, 7.0000000000, 0.873612191  5.608896e+01,NA NA,NA NA NA NA NA NA 100 100 100 100,100 100,100,some low low some,some Placebo   0  24.000000,10.580000 NA,DSM-IV-TR 0,1,1.0 1.0 1.0,1.0,1 1,0,1 1,1,1,1.0 1 1 1,1   94 Wigal_2009,< 2 months NA 6-12 yo 8.2 14.6,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
2877,Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2,100,  0 100 100,High,Amphetamine,Mixed amphetamine salts (long acting),  0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Interview,Adverse events  0.69044879,  20.0000000 mg/d Biederman 2002,NA,RCT (parallel, crossover, open-label) RR 374 210, 584,NA reverse, 8.7032085561, 3.211752542, 2.358396e+01 NA,NA,NA NA,NA,NA,NA NA,100 100,100 100 100 100,100,some,some,low,some some,Placebo,  0  23.000000, 8.600000,NA,DSM-IV,0,1,1.0,1.0,1.0 1.0,1 1 0 1 1,1,1,1.0 1,1,1 1,  95 Biederman_2002,< 2 months,NA 6-12 yo 8.6,14.6,NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
2877 Punja (2016) Punja,2016 10.1002/14651858.CD009996.pub2 100   0 100,100 High,Amphetamine Mixed amphetamine salts (long acting) or Lisdexamphetamine (long acting)   0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Interview Adverse events, 0.69044879   30.0000000,mg/d Biederman 2007a NA,RCT (parallel, crossover, open-label) RR  52, 52  104 NA reverse  1.0000000000  0.064246613  1.556502e+01 NA,NA,NA NA NA,NA NA,NA 100,100 100,100 100 100 100,some some low some low,Placebo,  0, 36.000000, 9.100000 NA DSM-IV-TR,0,1,1.0 1.0,1.0,1.0 1,1 0,1,1,1,1,1.0 1,1,1 1   96,Biederman_2007a < 2 months,NA,6-12 yo 8.6 14.6,NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
2877 Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2,100,  0,100,100 High,Amphetamine Lisdexamphetamine (long acting),  0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Interview,Adverse events  1.00000000   50.0000000 mg/d,Biederman,2007b,NA RCT (parallel, crossover, open-label),RR,218, 72, 290,NA reverse, 6.7706422018  1.679539590, 2.729414e+01 NA NA,NA,NA NA NA,NA NA 100,100,100 100,100 100 100 some low low some,some,Placebo,  0, 31.000000  9.000000,NA,DSM-IV-TR,0,1 1.0 1.0,1.0 1.0,1,1,0 1,1 1,1 1.0,1,1 1,1,  97 Biederman_2007b,< 2 months,NA 6-12 yo,8.6 14.6,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA,Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
2877 Punja (2016) Punja,2016 10.1002/14651858.CD009996.pub2,100,  0 100,100 High,Amphetamine Mixed amphetamine salts (short acting),  0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview Adverse events, 0.46029919   46.8000000,mg/d Childress,2015 NA RCT (parallel, crossover, open-label),RR, 97, 97  194 NA reverse, 7.0000000000  0.366404012, 1.337322e+02,NA NA,NA,NA,NA,NA NA NA 100,100,100 100,100,100 100 some,some,low some,low Placebo   0, 39.200000  9.600000 NA,DSM-IV-TR,0,1 1.0,1.0,1.0 1.0 1 1,0 1 1 1,1 1.0,1,1 1,1,  98 Childress_2015 < 2 months,NA 6-12 yo,8.6,14.6 NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA,Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
2877 Punja (2016) Punja,2016 10.1002/14651858.CD009996.pub2,100,  0,100 100 High,Amphetamine,Lisdexampehtamine (long acting)   0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Interview,Adverse events  1.61104718   50.0000000,mg/d,Coghill 2013,NA RCT (parallel, crossover, open-label) RR 111 110  221 NA reverse,12.3873873874  3.006416510  5.103996e+01,NA,NA,NA,NA,NA NA,NA,NA,  0,  0 100,100,  0   0,100 some,low,high,some high,Placebo,  0, 19.000000 10.900000,NA,DSM-IV-TR 0,1 1.0 1.0,1.0,1.0 1,1,0,1 1,1 1,1.0 1,1,1,1   99 Coghill_2013 < 2 months NA 6-12 yo 8.6 14.6 NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
2877 Punja (2016) Punja 2016,10.1002/14651858.CD009996.pub2 100,  0,100 100,High Amphetamine Lisdexamphetamine (long acting),  0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Interview Adverse events, 0.92059839,  50.0000000 mg/d,Findling 2011,NA RCT (parallel, crossover, open-label),RR 233, 79  312,NA,reverse, 2.9384835479  0.914265404  9.444397e+00 NA,NA,NA,NA NA NA,NA,NA,100,100,100 100 100 100 100,low,some low some low Placebo,  0  21.000000 14.600000 NA DSM-IV-TR 0 1 1.0 1.0 1.0,1.0,1,1 0 1,1,1,1,1.0 1 1,1 1  100 Findling_2011 < 2 months,NA 13-19 yo 8.6,14.6 NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
2877 Punja (2016),Punja,2016 10.1002/14651858.CD009996.pub2,100,  0 100,100 High,Amphetamine,Mixed amphetamine salts (short acting and long acting)   0 NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview Adverse events  1.15074799,  20.0000000 mg/d McCracken,2003,NA RCT (parallel, crossover, open-label),RR  51  51  102,NA reverse  1.6000000000  0.803983687  3.184144e+00,NA,NA NA NA,NA NA,NA,NA,100,100,100 100 100,100 100 some some low,some,some,Placebo   0, 14.000000, 9.500000 NA DSM-IV 0 1,1.0,1.0 1.0,1.0,1,1,0,1,1 1 1 1.0 1,1 1,1, 101 McCracken_2003 < 2 months,NA,6-12 yo 8.6,14.6,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
2877 Punja (2016) Punja 2016,10.1002/14651858.CD009996.pub2,100,  0,100 100 High Amphetamine Dextroamphetamine (short acting)   0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Interview,Adverse events  1.61104718,  15.0000000,mg/d Ramtvedt 2013,NA RCT (parallel, crossover, open-label) RR, 34, 34,  68 NA,reverse  2.1428571429, 1.407839526, 3.261619e+00,NA NA NA NA,NA NA,NA NA   0,  0,100,  0   0   0,100,some,high,high some high,Placebo,  0, 19.000000 11.400000,NA DSM-IV-TR 0 1 1.0 1.0 1.0,1.0,1,1 0,1,1 1 1,1.0,1,1,1 1, 102 Ramtvedt_2013,< 2 months,NA 6-12 yo,8.6 14.6,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
2877 Punja (2016) Punja 2016 10.1002/14651858.CD009996.pub2,100   0,100,100 High,Amphetamine,Mixed amphetamine salts (long acting),  0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview,Adverse events, 0.92059839   25.0000000 mg/d Spencer 2006,NA,RCT (parallel, crossover, open-label),RR 233, 63, 296,NA reverse, 3.7854077253  0.926690873, 1.546288e+01 NA NA NA NA NA,NA,NA NA,100 100 100,100 100,100,100,some some,low,some low Placebo,  0  34.000000,14.200000 NA,DSM-IV-TR,0 1 1.0 1.0,1.0 1.0 1 1 0 1,1 1,1,1.0 1,1,1,1, 103,Spencer_2006 < 2 months,NA 13-19 yo,8.6,14.6,NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
2877 Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2 100   0 100 100,High,Amphetamine Lisdexamphetamine (long acting),  0,NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview Adverse events, 0.46029919,  50.0000000,mg/d,Wigal 2009,NA,RCT (parallel, crossover, open-label),RR 129,129  258,NA reverse 11.0000000000  0.614504884  1.969065e+02,NA,NA,NA,NA NA,NA NA NA,100 100,100 100,100 100 100 some low low some,some,Placebo   0  24.000000 10.580000 NA DSM-IV-TR 0 1 1.0 1.0 1.0,1.0,1 1,0,1 1,1 1 1.0 1 1,1 1  104,Wigal_2009,< 2 months NA 6-12 yo 8.6 14.6,NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
1598 Huang (2022),Huang,2022 10.1542/peds.2022-057745,100   0 100 100,Low,Physical training Physical training 100 augumentation,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Digit Symbol Scores, 1.38089758,NA,NA,Kang 2011,NA,RCT SMD   7,  6,  13,outcomes reverse,-0.6300000000,-1.750000000, 4.900000e-01 NA,NA NA,NA,NA,NA,NA,NA   0,  0,  0   0 100,100 100,high high,some,some some,Not a therapeutic intervention   0   0.000000, 8.400000,NA DSM-IV, DSM-V 1 1,1.0 0.0 0.5,1.0,1 1,2 1,1,0,1,1.0 0 1,1 1  105 Kang_2011,< 2 months NA 6-12 yo,7.7,15.8 NA,NA, 22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
1598,Huang (2022) Huang,2022,10.1542/peds.2022-057745 100,  0 100,100 Low Physical training,Physical training,100 augumentation,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test TMT-B, 1.38089758 NA,NA,Kang 2011,NA RCT SMD,  8   7   15,outcomes,reverse,-0.5700000000 -1.610000000  4.700000e-01,NA,NA NA,NA NA NA NA NA   0,  0,  0   0,100 100,100 high high,some some some Not a therapeutic intervention   0,  0.000000, 8.400000,NA,DSM-IV, DSM-V,1,1 1.0,0.0,0.5 1.0,1 1 2 1,1,0,1,1.0 0 1,1,1, 106,Kang_2011 < 2 months NA 6-12 yo 7.7,15.8 NA,NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
1598 Huang (2022) Huang,2022 10.1542/peds.2022-057745 100,  0 100,100 Low Physical training Physical training,  0 NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test Digit span task  2.76179517 NA NA,Ziereis 2014 NA,RCT SMD  13,  8   21,outcomes reverse -1.2100000000 -2.170000000 -2.500000e-01 NA,NA,NA NA NA NA NA,NA   0   0   0   0 100 100 100,high high some some some,No intervention   0  25.600000, 9.200000 NA,DSM-IV, DSM-V,1 1,1.0,0.0 0.5 1.0 1 1 2,1,1,0,1 1.0,0,1 1,1, 107 Ziereis_2014,2-6 months NA,6-12 yo,7.7 15.8 NA NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
1598 Huang (2022) Huang,2022,10.1542/peds.2022-057745,100,  0,100,100 Low Physical training,Physical training,  0 NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test Digit span task, 2.76179517 NA,NA Ziereis,2014 NA RCT,SMD, 14   8,  22 outcomes,reverse -0.9900000000,-1.910000000,-6.000000e-02,NA NA NA NA NA,NA NA NA,  0   0   0   0 100,100 100,high,high,some,some some No intervention   0, 25.600000  9.200000 NA,DSM-IV, DSM-V 1 1 1.0,0.0 0.5,1.0,1,1,2 1 1,0,1,1.0,0 1 1,1  108 Ziereis_2014,2-6 months,NA,6-12 yo,7.7,15.8,NA,NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
1598,Huang (2022),Huang 2022,10.1542/peds.2022-057745 100,  0 100 100 Low,Physical training Physical training   0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test WCST, 1.38089758 NA,NA,Choi 2015 NA RCT SMD  13, 17,  30,NA reverse -0.8000000000,-1.550000000 -5.000000e-02,NA,NA,NA NA,NA,NA NA NA,  0   0,  0   0   0,  0   0,high high high,high,high,Not a therapeutic intervention,  0,  0.000000 15.800000 NA DSM-IV, DSM-V,1,1 1.0 0.0,0.5 1.0,1,1 2 1 1,0 1,1.0,0,1,1,1  109 Choi_2015,< 2 months,NA,13-19 yo,7.7,15.8,NA NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high,high
1598,Huang (2022) Huang,2022,10.1542/peds.2022-057745 100,  0 100,100 Low,Physical training Physical training   0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test,Stroop test, 1.84119678,NA,NA Memarmoghaddam 2016 NA RCT SMD, 19  17   36,NA reverse -1.5400000000 -2.280000000 -7.900000e-01,NA,NA NA NA,NA,NA NA NA,  0,  0   0,  0 100,  0 100 high high,some,some high Not a therapeutic intervention,  0,  0.000000  8.300000 NA,DSM-IV, DSM-V,1,1,1.0,0.0 0.5 1.0 1,1,2 1,1 0,1,1.0,0,1,1 1, 110 Memarmoghaddam_2016,< 2 months NA 6-12 yo,7.7 15.8,NA,NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769 NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
1598 Huang (2022),Huang,2022 10.1542/peds.2022-057745 100,  0 100 100 Low Physical training,Physical training,100,augumentation Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,Stroop color-word test, 2.76179517 NA,NA,Pan,2016,NA,RCT SMD  16, 16   32,NA reverse,-2.2000000000 -3.090000000,-1.310000e+00 NA,NA NA,NA,NA,NA,NA,NA,  0   0   0,  0 100,100,100 high,high low some,some,Not a therapeutic intervention,  0,  0.000000, 8.900000,NA,DSM-IV, DSM-V,1,1 1.0,0.0,0.5,1.0,1,1,2,1,1,0,1 1.0 0 1 1,1  111,Pan_2016 2-6 months NA 6-12 yo 7.7,15.8 NA,NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769 NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
1598,Huang (2022),Huang,2022,10.1542/peds.2022-057745 100,  0,100 100 Low Physical training Physical training,  0,NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,STOPIT  2.30149597 NA NA Bustamante,2017 NA RCT SMD   6,  5,  11,outcomes,reverse,-0.0900000000,-1.280000000  1.100000e+00 NA NA,NA,NA NA,NA,NA NA   0   0,  0,  0,  0   0,  0 high,high,high high high,Not a therapeutic intervention   0, 31.000000  9.400000 NA,DSM-IV, DSM-V 1,1 1.0,0.0,0.5,1.0,1,1 2 1,1 0 1 1.0,0,1 1 1  112,Bustamante_2017 2-6 months,NA 6-12 yo,7.7,15.8 NA NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
1598 Huang (2022) Huang 2022,10.1542/peds.2022-057745,100,  0,100,100,Low,Physical training Physical training,  0,NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test,AWMA Verbal  2.30149597,NA NA,Bustamante,2017 NA RCT,SMD  13  11,  24,outcomes,reverse -0.2200000000,-1.350000000  9.200000e-01 NA NA,NA,NA,NA,NA,NA NA,  0,  0   0,  0,  0,  0,  0,high,high,high high high Not a therapeutic intervention,  0  31.000000, 9.400000,NA DSM-IV, DSM-V,1,1 1.0 0.0 0.5 1.0 1 1,2,1 1,0 1,1.0,0 1,1,1, 113 Bustamante_2017 2-6 months,NA,6-12 yo 7.7 15.8 NA,NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
1598,Huang (2022) Huang,2022 10.1542/peds.2022-057745,100   0 100,100 Low Physical training Physical training   0 NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,AWMA Visuospatial, 2.30149597 NA,NA Bustamante,2017 NA,RCT SMD, 13, 11   24,outcomes,reverse  0.1900000000 -0.960000000  1.340000e+00,NA NA NA,NA,NA NA,NA NA   0   0   0,  0   0   0   0 high,high,high high high Not a therapeutic intervention   0, 31.000000  9.400000 NA DSM-IV, DSM-V,1 1 1.0 0.0,0.5 1.0,1,1 2 1 1 0 1 1.0 0 1,1,1, 114 Bustamante_2017,2-6 months,NA,6-12 yo 7.7,15.8 NA NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
1598,Huang (2022),Huang,2022,10.1542/peds.2022-057745,100   0,100 100,Low,Physical training,Physical training   0 NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test Stroop color-word test  2.76179517 NA,NA,Lee,2017 NA RCT SMD,  6   6,  12,NA,reverse -1.2000000000,-2.450000000, 5.000000e-02,NA NA,NA NA,NA,NA NA NA,  0,  0,  0,  0,100,  0 100,high,high,low some high Not a therapeutic intervention,  0   0.000000, 8.800000,NA,DSM-IV, DSM-V,1 1,1.0,0.0 0.5 1.0,1 1,2,1,1,0,1 1.0 0 1 1,1  115 Lee_2017,2-6 months,NA,6-12 yo,7.7 15.8 NA NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
1598 Huang (2022) Huang 2022 10.1542/peds.2022-057745   0,  0,100 100 Low,Physical training Physical training   0 NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,Coris Test, 3.22209436,NA,NA Liu 2018,NA RCT,SMD, 32  32,  64,NA,reverse -0.7200000000 -1.230000000 -2.100000e-01 NA,NA NA,NA,NA NA NA NA,  0   0   0,  0   0,100 100 high high high,some some,Not a therapeutic intervention,  0  50.000000,NA,NA,DSM-IV, DSM-V 1 1 1.0,0.0 0.5,1.0 1,1 2 1 1,0,1,1.0,0 1 1 1  116 Liu_2018 2-6 months,NA,NA 7.7 15.8 NA NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
1598 Huang (2022) Huang 2022 10.1542/peds.2022-057745,100,  0 100,100,Low,Physical training,Physical training   0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Simon Task  1.84119678 NA,NA,Benzing,2019 NA RCT,SMD,  9   7,  16 outcomes reverse -0.3300000000,-1.330000000  6.600000e-01,NA NA,NA,NA NA NA NA NA   0   0   0   0,100,100,100,high high,low low low,Not a therapeutic intervention,  0, 17.600000 10.500000 NA,DSM-IV, DSM-V 1 1,1.0,0.0,0.5 1.0,1 1 2,1 1 0 1 1.0,0 1,1 1  117,Benzing_2019,< 2 months,NA,6-12 yo,7.7,15.8 NA,NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
1598,Huang (2022),Huang,2022 10.1542/peds.2022-057745 100   0 100 100 Low Physical training,Physical training,  0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Flanker Task, 1.84119678,NA NA Benzing,2019 NA,RCT SMD,  9,  8   17 outcomes reverse -0.3900000000,-1.350000000  5.700000e-01,NA NA NA NA,NA NA NA,NA,  0   0,  0   0,100,100 100 high high,low,low low Not a therapeutic intervention   0, 17.600000 10.500000 NA DSM-IV, DSM-V,1 1,1.0 0.0,0.5,1.0 1,1 2 1,1 0 1,1.0,0 1,1,1  118,Benzing_2019 < 2 months,NA,6-12 yo,7.7,15.8 NA NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
1598,Huang (2022),Huang,2022,10.1542/peds.2022-057745,100   0,100,100 Low Physical training Physical training,  0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test,Color span backward, 1.84119678 NA,NA Benzing 2019 NA RCT,SMD, 10,  8,  18 outcomes reverse,-0.1900000000,-1.120000000, 7.400000e-01 NA NA NA NA,NA NA,NA,NA,  0,  0,  0   0 100,100 100 high,high,low low,low Not a therapeutic intervention   0  17.600000,10.500000,NA DSM-IV, DSM-V,1,1,1.0,0.0,0.5 1.0,1,1 2,1,1 0,1,1.0,0 1,1,1, 119 Benzing_2019,< 2 months,NA,6-12 yo 7.7 15.8,NA NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
1598,Huang (2022),Huang,2022,10.1542/peds.2022-057745 100   0 100,100 Low,Physical training,Physical training,100,augumentation Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test,Cognitive Flexibility Test, 1.84119678 NA,NA Da Silva 2019 NA RCT,SMD  36  30,  66 NA reverse -1.0000000000,-1.510000000 -4.800000e-01 NA NA NA NA,NA NA,NA NA   0   0   0   0 100   0,100 high high,some,some,high Not a therapeutic intervention,  0, 30.000000,12.000000,NA DSM-IV, DSM-V,1,1 1.0 0.0,0.5,1.0,1 1,2 1 1 0,1 1.0,0 1 1,1, 120 Da Silva_2019,< 2 months NA,6-12 yo 7.7 15.8,NA NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high high
1598 Huang (2022) Huang,2022 10.1542/peds.2022-057745 100   0,100 100 Low,Physical training Physical training,  0 NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test Stroop test, 2.76179517 NA NA,Hattabi,2019,NA,RCT,SMD, 10  10   20 outcomes reverse,-0.8200000000,-1.740000000, 9.000000e-02,NA,NA,NA NA,NA NA NA,NA   0   0,  0   0 100,100,100,high,high some some,some,Not a therapeutic intervention,  0 NA,10.000000 NA DSM-IV, DSM-V 1,1,1.0 0.0 0.5,1.0 1 1 2 1,1 0,1 1.0 0,1,1 1  121,Hattabi_2019,2-6 months NA 6-12 yo,7.7,15.8 NA,NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
1598 Huang (2022) Huang 2022,10.1542/peds.2022-057745,100   0 100,100 Low Physical training,Physical training   0 NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,ROCF Test, 2.76179517,NA,NA,Hattabi,2019 NA RCT,SMD  10  10   20,outcomes reverse,-0.5700000000,-1.470000000  3.200000e-01 NA,NA,NA,NA NA,NA,NA NA,  0   0   0   0 100,100,100 high,high some some,some,Not a therapeutic intervention,  0 NA 10.000000 NA DSM-IV, DSM-V,1 1,1.0 0.0 0.5,1.0 1 1 2,1,1 0 1 1.0 0 1 1,1, 122 Hattabi_2019 2-6 months,NA 6-12 yo 7.7 15.8,NA NA  22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769 NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
1598 Huang (2022) Huang 2022,10.1542/peds.2022-057745,100   0 100,100 Low Physical training,Physical training   0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Stroop color-word test,16.57077100 NA NA,Kadri 2019 NA,RCT,SMD  20, 20   40 NA reverse,-2.7800000000 -3.660000000 -1.900000e+00 NA,NA,NA,NA,NA NA NA,NA   0   0   0   0,100 100 100 high,high some,some some Not a therapeutic intervention   0  10.000000 14.500000,NA DSM-IV, DSM-V,1,1 1.0 0.0 0.5,1.0,1 1,2 1,1 0 1,1.0 0,1 1,1  123 Kadri_2019,> 12 months NA 13-19 yo,7.7 15.8 NA NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
1598 Huang (2022),Huang 2022,10.1542/peds.2022-057745,100   0,100,100 Low Physical training Physical training   0,NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,Stroop color-word test  2.76179517 NA,NA,Chen,2022,NA,RCT,SMD  11, 11   22 outcomes reverse,-1.4800000000 -2.440000000,-5.300000e-01 NA NA,NA NA,NA NA,NA,NA   0,  0,  0,  0   0   0,  0 high high,high high,high,Not a therapeutic intervention,  0  17.200000, 8.400000,NA DSM-IV, DSM-V,1 1,1.0 0.0 0.5,1.0,1 1,2 1,1,0,1 1.0,0 1 1 1, 124 Chen_2022 2-6 months,NA 6-12 yo 7.7,15.8 NA,NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
1598 Huang (2022),Huang,2022 10.1542/peds.2022-057745 100   0,100 100 Low,Physical training Physical training,  0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test,Cognitive Flexibility Test  2.76179517 NA NA,Chen,2022,NA RCT,SMD, 11  11,  22,outcomes,reverse,-0.6900000000,-1.550000000, 1.700000e-01 NA,NA NA NA NA NA,NA,NA,  0,  0   0   0,  0   0   0,high high high,high high,Not a therapeutic intervention   0  17.200000  8.400000 NA DSM-IV, DSM-V 1,1 1.0,0.0 0.5 1.0 1 1,2 1,1 0 1,1.0 0,1 1,1  125,Chen_2022 2-6 months NA 6-12 yo 7.7 15.8 NA NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
1598,Huang (2022) Huang 2022,10.1542/peds.2022-057745 100,  0,100,100 Low Physical training,Physical training   0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test,N-Back, 2.76179517 NA,NA,Chen 2022,NA,RCT,SMD  10  10,  20,outcomes reverse -0.8500000000,-1.770000000, 7.000000e-02 NA,NA,NA,NA NA,NA NA,NA   0,  0,  0,  0,  0   0,  0,high high high,high,high,Not a therapeutic intervention,  0  17.200000, 8.400000,NA,DSM-IV, DSM-V,1 1,1.0,0.0 0.5,1.0,1 1 2,1 1,0,1,1.0 0,1 1 1  126 Chen_2022 2-6 months NA 6-12 yo 7.7 15.8 NA NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769 NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high,high
1598 Huang (2022),Huang,2022,10.1542/peds.2022-057745,100   0 100,100 Low,Physical training,Physical training   0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test,Stroop color-word test  1.38089758 NA,NA,Song,2022 NA RCT,SMD,  2   2    4 outcomes reverse,-0.7600000000,-2.860000000  1.330000e+00 NA,NA,NA NA,NA NA,NA,NA   0,  0   0,  0,  0   0,  0 high,high,high high,high,Not a therapeutic intervention,  0   0.000000, 7.700000 NA,DSM-IV, DSM-V 1,1,1.0,0.0,0.5 1.0 1 1,2 1,1,0 1 1.0 0,1,1,1  127 Song_2022,< 2 months,NA 6-12 yo,7.7 15.8,NA,NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
1598 Huang (2022),Huang,2022,10.1542/peds.2022-057745 100,  0 100,100,Low,Physical training Physical training,  0,NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test TMT-B  1.38089758 NA NA Song,2022 NA,RCT SMD   3,  3,   6 outcomes,reverse -2.0700000000,-4.220000000  8.000000e-02 NA,NA NA,NA NA,NA NA,NA,  0,  0   0   0   0,  0,  0,high high,high high high Not a therapeutic intervention   0,  0.000000  7.700000,NA,DSM-IV, DSM-V,1,1 1.0,0.0 0.5,1.0,1 1 2 1,1 0,1,1.0 0 1 1 1  128,Song_2022 < 2 months NA,6-12 yo,7.7 15.8 NA,NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high,high
1598,Huang (2022) Huang,2022 10.1542/peds.2022-057745 100   0,100 100,Low,Physical training,Physical training,  0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test ROCF test  1.38089758,NA,NA Song,2022 NA,RCT,SMD,  3,  3,   6,outcomes,reverse -0.7800000000 -2.470000000, 9.100000e-01 NA NA,NA,NA,NA NA,NA,NA,  0   0,  0,  0   0   0,  0 high,high high,high high Not a therapeutic intervention   0   0.000000, 7.700000,NA,DSM-IV, DSM-V 1 1,1.0 0.0 0.5,1.0,1 1 2 1,1,0,1,1.0 0 1 1,1  129,Song_2022 < 2 months,NA,6-12 yo,7.7 15.8,NA,NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
1598 Huang (2022) Huang 2022 10.1542/peds.2022-057745,100,  0,100,100 Low Physical training,Physical training,  0,NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test Flanker Task, 2.76179517 NA NA,Liang 2022 NA,RCT,SMD, 13  13   26,outcomes reverse -0.6000000000,-1.390000000  1.900000e-01,NA,NA NA NA,NA,NA,NA,NA,  0   0,  0,  0 100,  0   0 high high,low,high,high,Not a therapeutic intervention   0, 22.500000  8.400000,NA DSM-IV, DSM-V,1 1 1.0 0.0,0.5 1.0,1,1 2 1,1,0 1 1.0 0 1,1,1, 130,Liang_2022 2-6 months,NA,6-12 yo 7.7,15.8 NA,NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
1598,Huang (2022) Huang 2022 10.1542/peds.2022-057745 100,  0,100 100 Low Physical training,Physical training   0 NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test,Tower of London, 2.76179517,NA,NA Liang,2022,NA,RCT SMD, 13  13   26 outcomes reverse -0.5000000000,-1.290000000, 2.800000e-01 NA NA NA,NA,NA,NA NA NA,  0,  0,  0   0,100,  0   0 high,high low high high,Not a therapeutic intervention,  0, 22.500000  8.400000 NA,DSM-IV, DSM-V,1 1,1.0 0.0,0.5,1.0,1 1 2,1 1,0 1 1.0,0,1 1,1, 131 Liang_2022 2-6 months NA 6-12 yo,7.7,15.8,NA NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
1598,Huang (2022),Huang 2022 10.1542/peds.2022-057745 100,  0,100 100 Low,Physical training,Physical training   0 NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test TMT-B, 2.76179517,NA NA Liang 2022,NA,RCT SMD  13  13,  26 outcomes,reverse,-0.5100000000 -1.300000000  2.700000e-01 NA NA NA NA NA NA NA,NA   0   0,  0,  0 100   0   0,high high low,high high,Not a therapeutic intervention,  0, 22.500000, 8.400000 NA DSM-IV, DSM-V,1,1,1.0 0.0,0.5 1.0,1,1,2 1,1,0 1 1.0 0 1,1,1, 132,Liang_2022,2-6 months NA 6-12 yo 7.7,15.8,NA,NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769 NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
1598,Huang (2022),Huang 2022,10.1542/peds.2022-057745,100   0 100 100 Low,Physical training Physical training 100 augumentation Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test,Stroop color-word test  2.76179517 NA NA,Chang 2022 NA,RCT,SMD   8   4,  12,outcomes reverse -0.7400000000,-1.980000000  5.000000e-01 NA,NA NA,NA,NA,NA NA,NA,  0,  0   0,  0,100   0   0,high high low,high high Not a therapeutic intervention,  0, 18.700000  8.300000 NA,DSM-IV, DSM-V,1 1 1.0 0.0 0.5,1.0 1,1 2,1,1 0,1,1.0,0,1,1,1  133 Chang_2022 2-6 months,NA,6-12 yo,7.7 15.8,NA NA, 22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
1598,Huang (2022),Huang,2022,10.1542/peds.2022-057745,100   0,100 100 Low Physical training Physical training 100,augumentation Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test Stroop color-word test, 2.76179517 NA NA Chang,2022,NA RCT SMD,  8,  4   12 outcomes,reverse -0.5100000000,-1.300000000, 2.700000e-01 NA NA NA NA,NA NA,NA,NA,  0   0   0,  0 100   0   0 high high low,high high,Not a therapeutic intervention   0, 18.700000, 8.300000 NA,DSM-IV, DSM-V 1,1,1.0 0.0,0.5 1.0 1 1 2 1 1 0,1 1.0,0,1,1 1, 134 Chang_2022,2-6 months,NA,6-12 yo,7.7 15.8 NA,NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769 NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
1598 Huang (2022) Huang,2022 10.1542/peds.2022-057745,100,  0 100 100 Low,Physical training Physical training 100,augumentation,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test WCST, 2.76179517 NA NA,Chang 2022,NA,RCT SMD   8   4,  12 outcomes reverse -0.1600000000 -1.360000000, 1.040000e+00,NA NA NA NA NA,NA NA,NA,  0   0   0   0,100,  0,  0 high,high low,high high,Not a therapeutic intervention,  0  18.700000  8.300000 NA,DSM-IV, DSM-V,1,1 1.0,0.0 0.5,1.0,1,1,2,1,1,0 1 1.0 0 1 1 1  135 Chang_2022 2-6 months NA,6-12 yo 7.7 15.8 NA,NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
1598,Huang (2022),Huang 2022 10.1542/peds.2022-057745 100   0 100 100 Low,Physical training,Physical training,100,augumentation,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test,WCST  2.76179517,NA,NA Chang 2022,NA,RCT SMD   8,  4,  12 outcomes,reverse -0.1700000000,-1.370000000, 1.030000e+00,NA,NA,NA NA,NA NA,NA NA   0,  0,  0   0 100,  0,  0,high high,low high high,Not a therapeutic intervention,  0  18.700000, 8.300000,NA,DSM-IV, DSM-V 1 1,1.0,0.0 0.5 1.0,1,1,2,1,1,0 1 1.0 0 1 1,1  136,Chang_2022 2-6 months NA,6-12 yo 7.7,15.8 NA NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
3228 Seiffer (2022),Seiffer,2022,10.1177/10870547211017982,100   0 100 100 High,Physical training,Physical training,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA  1.84119678,  24.0000000,sessions Benzing 2019,NA RCT,RR  26  25,  51,NA,reverse  1.8857142857, 1.210856203  2.936697e+00,NA,NA NA,NA NA,NA NA NA,  0,  0 100,100 100,100   0 low some low high low WLC (wait-list control)   0, 18.000000,10.430000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-10,0 1,1.0,1.0,1.0,1.0 1,1,1 1,1 1,1 1.0,0 1,1,1, 137,Benzing_2019,< 2 months NA,6-12 yo,8.49 15.9 NA NA  22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
3228 Seiffer (2022) Seiffer 2022,10.1177/10870547211017982,100   0 100,100 High,Physical training Physical training   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA  1.38089758   18.0000000,sessions,Choi 2015 NA RCT RR  18  17,  35 NA,reverse  2.8333333333  0.477447713  1.681394e+01,NA,NA NA NA,NA NA,NA,NA 100 100 100 100   0 100,100,low,some,high low,some Not a therapeutic intervention,  0   0.000000,15.900000 NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-11,0,1,1.0,1.0 1.0,1.0,1 1 1,1,1,1,1,1.0 0 1 1 1  138,Choi_2015 < 2 months,NA 13-19 yo,8.49 15.9,NA NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA,Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3228,Seiffer (2022) Seiffer,2022,10.1177/10870547211017982,100,  0 100 100,High Physical training Physical training   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA NA  1.84119678    8.0000000,sessions Felmet,1998,NA,RCT,RR, 20, 20,  40 NA reverse  4.3157894737  0.317557276, 5.865411e+01 NA NA NA NA,NA,NA,NA NA,100,100 100 100,  0,100 100 low some,high,low some WLC (wait-list control)   0   0.000000, 9.700000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-12,0,1,1.0,1.0 1.0 1.0,1,1 1,1 1 1,1 1.0,0 1 1 1  139 Felmet_1998 < 2 months,NA 6-12 yo,8.49,15.9 NA NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769,NA NA,Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3228,Seiffer (2022),Seiffer 2022,10.1177/10870547211017982,100,  0 100,100 High Physical training Physical training   0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,NA  1.84119678   20.0000000,sessions,Garcia,2016,NA RCT,RR,  9,  9,  18,NA,reverse  0.5294117647  0.253494031, 1.105655e+00 NA,NA,NA,NA,NA,NA NA,NA,  0   0 100,100   0,100,  0 low some high,high some,WLC (wait-list control)   0  33.000000,10.490000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-13 0 1,1.0,1.0 1.0,1.0,1,1,1 1 1,1 1,1.0,0,1 1,1, 140 Garcia_2016 < 2 months NA,6-12 yo 8.49 15.9 NA,NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769 NA NA,Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
3228 Seiffer (2022),Seiffer 2022,10.1177/10870547211017982,100   0,100,100 High,Physical training Physical training   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA CBCL, 1.38089758,  12.0000000 sessions Kang,2011 NA RCT RR  16, 16,  32 NA,reverse  0.5555555556  0.302402695, 1.020632e+00 NA,NA,NA NA,NA NA NA,NA   0   0 100 100 100 100   0,low,some low,high,some Not a therapeutic intervention   0,  0.000000  8.490000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-15,0 1 1.0 1.0,1.0,1.0,1 1 1,1 1 1 1,1.0 0 1 1 1  141 Kang_2011,< 2 months NA 6-12 yo,8.49 15.9 NA NA, 22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769 NA,NA Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
3228,Seiffer (2022),Seiffer,2022 10.1177/10870547211017982 100   0,100 100 High Physical training Physical training,  0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,NA, 1.38089758   18.0000000 sessions,Soori,2020,NA RCT,RR, 28, 28   56 NA reverse  0.5160493827, 0.332044802  8.020212e-01 NA NA,NA,NA NA NA NA NA   0   0,100,100   0 100,  0,low,some,high,high some No intervention,  0  53.000000,12.530000,NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-17 0 1 1.0 1.0,1.0,1.0 1 1 1,1,1,1,1,1.0,0 1,1 1, 142,Soori_2020 < 2 months,NA 6-12 yo 8.49,15.9 NA,NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA NA Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
3228,Seiffer (2022),Seiffer,2022,10.1177/10870547211017982,100   0 100,100 High,Physical training Physical training,  0 NA,Social-communication skills Mixed At study endpoint (closest to 12 weeks),Questionnaire,SDQ  0.92059839,   8.0000000 sessions Davis,2017 NA RCT,G,  4,  4    8,NA reverse -2.2000000000 -4.250000000,-1.500000e-01 NA,NA NA,NA NA NA,NA,NA 100 100 100,100 100,100,100 low some low,low,some,WLC (wait-list control)   0  12.000000,10.270000 NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-12 0 1 1.0 1.0,1.0 1.0 1 1,1 1,1 1,1,1.0 0,1,1,1, 143,Davis_2017 < 2 months,NA,6-12 yo,8.49 10.49,NA,NA  22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769 NA NA Seiffer (2022)_Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Seiffer (2022) - Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3228 Seiffer (2022),Seiffer 2022 10.1177/10870547211017982,100   0 100,100 High Physical training Physical training,  0 NA,Social-communication skills,Mixed,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  1.84119678,  20.0000000,sessions Garcia,2016,NA,RCT,G,  9   9,  18,NA,reverse  0.6000000000 -0.520000000  1.720000e+00 NA NA,NA NA NA NA NA,NA   0,  0 100 100,  0,100,  0 low,some,high,high,some,WLC (wait-list control)   0, 33.000000 10.490000 NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-13 0,1 1.0 1.0 1.0,1.0,1 1 1,1,1,1 1,1.0,0 1 1,1, 144 Garcia_2016,< 2 months,NA,6-12 yo,8.49,10.49,NA,NA  22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA Seiffer (2022)_Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Seiffer (2022) - Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
3228 Seiffer (2022) Seiffer 2022,10.1177/10870547211017982,100,  0 100,100 High,Physical training Physical training,  0,NA,Social-communication skills,Mixed,At study endpoint (closest to 12 weeks) Questionnaire,CBCL  1.38089758,  12.0000000 sessions Kang,2011,NA RCT,G  16  16,  32,NA reverse,-0.6700000000 -1.440000000, 1.000000e-01 NA,NA,NA,NA NA,NA NA,NA   0   0,100 100,100 100,  0,low,some,low high some,Not a therapeutic intervention,  0   0.000000, 8.490000 NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-15,0 1 1.0 1.0,1.0,1.0 1,1,1 1,1 1 1,1.0 0 1,1 1  145,Kang_2011 < 2 months,NA,6-12 yo 8.49,10.49,NA NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769 NA,NA Seiffer (2022)_Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Seiffer (2022) - Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
3228,Seiffer (2022),Seiffer 2022,10.1177/10870547211017982,100   0,100 100 High,Physical training,Physical training   0,NA,Social-communication skills,Mixed At study endpoint (closest to 12 weeks) Questionnaire,CBCL, 2.76179517   24.0000000,sessions,Pan,2016,NA RCT G  16  16,  32 NA,reverse -0.2800000000,-0.970000000, 4.200000e-01,NA,NA NA NA,NA NA NA,NA   0,  0 100,100 100,100   0 low some low high,some,WLC (wait-list control)   0,  0.000000, 8.900000 NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-17 0,1 1.0 1.0,1.0 1.0 1,1 1 1 1 1 1 1.0,0,1 1 1  146 Pan_2016,2-6 months,NA 6-12 yo,8.49,10.49 NA,NA, 22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA Seiffer (2022)_Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Seiffer (2022) - Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
3228,Seiffer (2022),Seiffer,2022,10.1177/10870547211017982 100   0,100 100,High Physical training Physical training,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),NA,Passive, 2.76179517,  36.0000000 sessions,Bahram,2014,NA,RCT,G  15  15   30 NA reverse -0.8000000000 -1.550000000 -6.000000e-02,NA NA NA NA NA,NA,NA,NA   0   0,100,100 100,100,  0,low,some low,high,some No intervention,  0,100.000000  9.470000 NA NA 0,1 1.0,1.0 1.0 1.0 1 1,1 1,1 1,1 1.0,0,1 1,1, 147 Bahram_2014 2-6 months NA,6-12 yo,8.49,15.9,NA,NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769 NA NA Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
3228 Seiffer (2022) Seiffer,2022 10.1177/10870547211017982,100,  0 100,100 High,Physical training,Physical training   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) NA,Passive, 1.84119678,  24.0000000,sessions Benzing,2019,NA,RCT,G, 26  25   51 NA,reverse -0.1200000000,-0.670000000, 4.400000e-01,NA NA NA NA NA NA,NA NA,  0,  0 100 100,100 100   0,low,some,low high low,WLC (wait-list control)   0, 18.000000 10.430000 NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-10,0,1,1.0,1.0 1.0,1.0,1,1,1,1 1 1 1 1.0,0,1,1,1, 148,Benzing_2019 < 2 months,NA,6-12 yo 8.49 15.9,NA NA  22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769,NA NA,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
3228,Seiffer (2022),Seiffer,2022,10.1177/10870547211017982,100,  0 100,100,High,Physical training,Physical training   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) NA Passive  1.38089758,  18.0000000,sessions,Choi,2015,NA,RCT G, 18  17,  35 NA reverse,-1.2900000000 -2.090000000 -4.900000e-01,NA,NA NA,NA NA,NA NA,NA,100 100 100,100   0,100,100 low,some,high,low,some,Not a therapeutic intervention   0,  0.000000 15.900000,NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-11,0,1 1.0,1.0,1.0 1.0,1,1,1,1,1 1,1 1.0 0 1,1 1  149,Choi_2015,< 2 months NA,13-19 yo,8.49 15.9 NA,NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769,NA NA,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3228 Seiffer (2022),Seiffer 2022,10.1177/10870547211017982,100   0,100,100,High Physical training,Physical training   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) NA,Passive  0.92059839,   8.0000000,sessions,Davis,2017 NA RCT,G,  4,  4    8,NA,reverse -0.1700000000,-1.560000000  1.210000e+00,NA,NA,NA NA,NA NA NA NA 100 100 100 100,100 100,100 low,some,low low,some,WLC (wait-list control),  0  12.000000,10.270000,NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-12 0 1 1.0 1.0,1.0,1.0 1 1 1,1 1,1,1,1.0 0 1 1,1, 150,Davis_2017,< 2 months NA,6-12 yo,8.49,15.9 NA,NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3228 Seiffer (2022) Seiffer 2022,10.1177/10870547211017982,100   0,100 100,High,Physical training Physical training,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) NA,Passive  1.84119678,   8.0000000,sessions Felmet,1998 NA,RCT,G  20  20   40 NA reverse -0.3400000000,-1.020000000  3.400000e-01,NA,NA,NA NA NA NA NA NA,100 100 100,100   0 100,100 low,some,high low some,WLC (wait-list control),  0,  0.000000, 9.700000,NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-12,0 1 1.0,1.0 1.0,1.0 1,1 1 1 1,1,1,1.0 0,1,1 1, 151,Felmet_1998,< 2 months,NA 6-12 yo 8.49 15.9,NA NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769,NA,NA,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3228,Seiffer (2022),Seiffer 2022 10.1177/10870547211017982,100,  0,100,100,High,Physical training Physical training,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) NA Passive, 1.84119678,  20.0000000 sessions Garcia,2016,NA RCT G,  9,  9,  18 NA reverse  0.2500000000,-0.850000000, 1.350000e+00 NA NA NA,NA,NA,NA,NA,NA   0,  0 100,100,  0,100,  0,low,some high high,some WLC (wait-list control),  0  33.000000 10.490000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-13 0 1 1.0 1.0 1.0,1.0,1 1 1 1 1 1,1 1.0,0,1 1 1, 152,Garcia_2016,< 2 months NA 6-12 yo,8.49,15.9 NA,NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA NA Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
3228 Seiffer (2022),Seiffer,2022 10.1177/10870547211017982,100   0,100 100,High Physical training,Physical training   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),NA Passive  1.38089758   12.0000000,sessions,Kang 2011 NA,RCT,G, 16, 16,  32 NA reverse -0.8300000000 -1.610000000 -5.000000e-02 NA,NA NA,NA NA,NA,NA NA,  0,  0,100,100 100,100   0 low,some low,high some,Not a therapeutic intervention   0   0.000000  8.490000 NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-15 0,1 1.0 1.0 1.0,1.0 1,1 1 1 1 1,1,1.0,0 1,1,1, 153 Kang_2011,< 2 months NA,6-12 yo,8.49 15.9,NA NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA,NA,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
3228 Seiffer (2022),Seiffer 2022,10.1177/10870547211017982 100,  0,100 100,High Physical training,Physical training   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),NA Passive, 2.76179517   24.0000000 sessions,Pan,2016,NA,RCT G, 16, 16   32,NA,reverse -0.5000000000,-1.200000000  2.100000e-01,NA,NA,NA NA,NA NA,NA NA   0,  0,100,100,100 100   0 low,some low high,some WLC (wait-list control),  0,  0.000000, 8.900000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-17,0,1 1.0,1.0 1.0,1.0 1,1 1 1,1,1 1 1.0,0,1,1 1  154 Pan_2016 2-6 months,NA 6-12 yo 8.49,15.9,NA,NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
3228 Seiffer (2022),Seiffer 2022,10.1177/10870547211017982 100,  0 100 100,High Physical training Physical training   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) NA,Passive, 1.38089758,  18.0000000,sessions Soori 2020 NA RCT,G  28  28   56 NA,reverse,-0.4300000000,-1.050000000, 1.900000e-01,NA NA NA NA NA,NA NA NA,  0,  0,100,100   0,100   0,low some high,high,some No intervention   0, 53.000000,12.530000 NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-17 0,1 1.0 1.0 1.0 1.0 1 1 1,1 1 1 1,1.0,0,1 1,1, 155 Soori_2020 < 2 months,NA 6-12 yo,8.49 15.9,NA,NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769,NA,NA,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
 798,Heirs (2007) Heirs 2007,10.1002/14651858.CD005648.pub2,100,  0 100 100 High Homeopathy Homeopathy,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,Conners' Parent Rating ScaleRevised, ADHD Index subscale, 4.14269275 NA,NA Jacobs,2005 NA RCT,SMD  21, 22   43,NA reverse, 0.1700000000 -0.430000000, 7.700000e-01  13.8800000   8.8200000,NA NA,NA NA,NA NA   0   0,100   0,100   0 100,low high some low,high,Placebo,  0,NA, 9.000000 NA Diagnostic Interview Schedule for Children 0,1 1.0 1.0 1.0,1.0,1,1 0,1 1,1,1,1.0,1,1,1,1, 156 Jacobs_2005,2-6 months NA,6-12 yo,8.5,9,NA,NA   3, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 2,Heirs (2007) | Catala-Lopez (2017) 8.5 9.3 NA NA,Heirs (2007)_Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Heirs (2007) - Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high,high
 798 Heirs (2007) Heirs 2007 10.1002/14651858.CD005648.pub2,100,  0,100,100,High Homeopathy Homeopathy,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Conners' Parent Rating ScaleRevised, ADHD Index subscale  2.00000000,NA,NA,Strauss 2000 NA RCT,SMD, 10, 10   20 NA,reverse,-0.1700000000,-1.050000000  7.100000e-01   6.1500000,  5.1900000,NA NA,NA,NA,NA,NA   0,  0 100   0,  0,  0,100 some,high,high,low,high,Placebo   0  10.000000  8.500000,NA,NA,0,1,1.0 1.0,1.0 1.0 1 1,0 1,1,1,1,1.0,1,1,1,1  157,Strauss_2000,2-6 months NA,6-12 yo 8.5,9,NA,NA,  3, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 2,Heirs (2007) | Catala-Lopez (2017),8.5,9.3,NA NA Heirs (2007)_Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Heirs (2007) - Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
 798,Heirs (2007),Heirs,2007 10.1002/14651858.CD005648.pub2,100   0,100,100 High Homeopathy Homeopathy,  0,NA Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,Conners' Parent Rating ScaleRevised, Oppositional subscale  4.14269275,NA NA,Jacobs 2005 NA RCT SMD, 22  21,  43 NA,reverse, 0.1000000000 -0.500000000  7.000000e-01  13.1700000  14.3900000 NA NA NA,NA NA NA,  0,  0,100,  0 100,  0,100,low,high,some low high Placebo   0,NA, 9.000000,NA,Diagnostic Interview Schedule for Children 0 1,1.0,1.0,1.0 1.0,1 1 0,1 1 1 1 1.0,1,1 1,1, 158 Jacobs_2005 2-6 months,NA 6-12 yo 8.5,9 NA NA,  3, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  2,Heirs (2007) | Catala-Lopez (2017),8.5,9.3,NA NA,Heirs (2007)_Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Heirs (2007) - Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
 798 Heirs (2007),Heirs,2007 10.1002/14651858.CD005648.pub2 100   0 100,100,High,Homeopathy,Homeopathy,  0,NA,Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks) Questionnaire Conners' Parent Rating ScaleRevised, Oppositional subscale, 2.00000000 NA NA,Strauss 2000 NA,RCT SMD  10, 10   20 NA,reverse -0.2600000000 -1.140000000, 6.300000e-01   5.4600000   8.4800000,NA,NA NA,NA NA,NA,  0   0 100   0   0,  0 100 some high,high,low,high Placebo,  0, 10.000000  8.500000,NA,NA 0 1 1.0 1.0 1.0,1.0 1 1 0,1,1,1,1,1.0 1 1 1 1  159,Strauss_2000,2-6 months NA,6-12 yo 8.5 9 NA NA   3, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 2,Heirs (2007) | Catala-Lopez (2017) 8.5 9.3 NA NA,Heirs (2007)_Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Heirs (2007) - Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
 563 Castells (2018),Castells,2018,10.1002/14651858.CD007813.pub3,100   0,100,100,High Amphetamine,mixed amphetamine salts,100 monotherapy,CGI Mixed At study endpoint (closest to 12 weeks) Observational tool,CGI, 0.69044879,  60.0000000,mg/d Spencer 2001,NA RCT (parallel, crossover, open-label) G, 27, 27   54,NA,reverse,-1.0400000000,-1.610000000 -4.700000e-01   1.0000000   0.9000000 NA,NA,NA NA NA NA 100 100 100,100 100,100,100,some some some some,some,Placebo   0  44.400000 38.000000,NA,DSM-IV 0 1 1.0,1.0,1.0,1.0,1 1 0 1 1 1,1 1.0 1 1 1,1  160 Spencer_2001 < 2 months NA,>= 20 yo 33.6,41.04,NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Castells (2018)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Castells (2018) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 563,Castells (2018) Castells,2018 10.1002/14651858.CD007813.pub3 100   0 100 100 High,Amphetamine,lisdexamphetamine 100 monotherapy CGI Mixed At study endpoint (closest to 12 weeks),Observational tool CGI, 0.92059839,  54.5000000 mg/d Waxmonsky,2014 NA RCT (parallel, crossover, open-label),G  11, 13   24 NA,reverse,-1.2200000000,-2.100000000,-3.300000e-01   0.8000000   0.8000000,NA,NA,NA,NA,NA,NA 100,100,100,100,100 100,100 some,some,some,some low Placebo   0  74.100000 41.040000,NA DSM-IV,0 1,1.0,1.0 1.0 1.0 1,1 0,1,1,1,1 1.0 1 1 1 1, 161 Waxmonsky_2014,< 2 months,NA,>= 20 yo 33.6,41.04 NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Castells (2018)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Castells (2018) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 563 Castells (2018) Castells,2018,10.1002/14651858.CD007813.pub3 100   0 100,100,High,Amphetamine,triple bead mixed amphetamine salts   0,NA,CGI,Mixed,At study endpoint (closest to 12 weeks) Observational tool CGI  0.92059839,NA mg/d Weisler 2017,NA RCT (parallel, crossover, open-label),G 177  86  263 NA,reverse,-0.7500000000,-1.010000000 -4.800000e-01,  1.3000000   1.1000000,NA,NA NA,NA,NA NA,100 100,100,100,100,100,100,low some,some some some Placebo   0  42.400000,33.600000,NA,DSM-IV,0,1,1.0 1.0,1.0 1.0,1,1 0,1 1,1 1,1.0,1,1 1 1  162,Weisler_2017,< 2 months NA,>= 20 yo 33.6 41.04 NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA,Castells (2018)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Castells (2018) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 563 Castells (2018) Castells,2018 10.1002/14651858.CD007813.pub3 100   0 100,100,High,Amphetamine,lisdexamphetamine 100 monotherapy Depressive disorder symptoms,Clinician-rated,At study endpoint (closest to 12 weeks) Questionnaire HAM-D  1.38089758,  70.0000000,mg/d,Biederman 2012 NA RCT (parallel, crossover, open-label) G  31, 30,  61,outcomes,reverse, 0.0600000000 -0.440000000  5.600000e-01,  1.7000000   1.6000000 NA,NA,NA,NA,NA NA,100,100 100,100 100 100 100 some,some,some some,low,Placebo,  0, 38.000000 21.600000,NA DSM-IV,0 1 1.0 1.0 1.0,1.0,1 1,0,1,1,1 1 1.0 1,1,1 1, 163,Biederman_2012,< 2 months,NA,>= 20 yo,21.6 37.5,NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA Castells (2018)_Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Castells (2018) - Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 563,Castells (2018) Castells,2018,10.1002/14651858.CD007813.pub3 100,  0,100 100 High,Amphetamine dexamphetamine,100 augmentation to psychotherapy Depressive disorder symptoms,Clinician-rated,At study endpoint (closest to 12 weeks),Questionnaire HAM-D, 4.60299194   20.0000000,mg/d,Weiss 2006,NA RCT (parallel, crossover, open-label),G  23, 26,  49 outcomes reverse  0.2800000000 -0.290000000, 8.400000e-01,  7.3000000,  3.3000000,NA,NA,NA,NA NA,NA,100,100 100 100 100,100 100 some,some some,some some Placebo   0  36.000000,37.500000,NA,DSM-IV,0,1,1.0,1.0,1.0 1.0,1 1 0,1 1 1,1 1.0 1,1 1,1, 164,Weiss_2006 2-6 months NA >= 20 yo 21.6,37.5,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA,Castells (2018)_Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Castells (2018) - Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 563 Castells (2018),Castells,2018,10.1002/14651858.CD007813.pub3 100,  0 100 100 High,Amphetamine lisdexamphetamine 100,monotherapy Generalized anxiety,Clinician-rated,At study endpoint (closest to 12 weeks),Questionnaire HAM-A  1.38089758   70.0000000,mg/d,Biederman,2012 NA RCT (parallel, crossover, open-label) G  31, 30,  61 outcomes,reverse  0.0500000000 -0.450000000  5.500000e-01,  1.9000000,  2.1000000,NA,NA NA,NA,NA,NA,100 100 100 100 100,100 100 some,some,some,some low,Placebo   0, 38.000000 21.600000 NA,DSM-IV,0,1 1.0,1.0,1.0 1.0,1,1 0 1,1 1 1,1.0 1,1,1,1  165,Biederman_2012,< 2 months NA,>= 20 yo 21.6,37.5 NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA Castells (2018)_Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Castells (2018) - Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 563 Castells (2018) Castells 2018 10.1002/14651858.CD007813.pub3 100,  0 100,100 High Amphetamine,dexamphetamine 100 augmentation to psychotherapy,Generalized anxiety,Clinician-rated,At study endpoint (closest to 12 weeks),Questionnaire HAM-A  4.60299194   20.0000000,mg/d,Weiss 2006,NA,RCT (parallel, crossover, open-label),G, 23  26   49,outcomes reverse  0.2300000000 -0.330000000, 8.000000e-01,  7.8000000   4.5000000 NA NA NA NA,NA,NA 100,100,100,100,100 100 100,some some,some some,some,Placebo,  0  36.000000,37.500000 NA,DSM-IV 0 1,1.0,1.0 1.0 1.0 1 1 0 1 1 1,1,1.0,1 1,1 1, 166,Weiss_2006,2-6 months,NA,>= 20 yo,21.6,37.5,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Castells (2018)_Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Castells (2018) - Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
1056 Elliott (2020),Elliott 2020 10.1371/journal.pone.0240584 100,  0 100 100 Critically low,Amphetamine mixed amphetamine salts xr,100 monotherapy,Executive functioning (report),Mixed At study endpoint (closest to 12 weeks),Questionnaire BRIEF-A  1.61104718,  43.7500000 mg/d,Spencer,2008 NA,RCT (parallel, crossover, open-label) G,137,137, 274,NA,reverse,-0.6500000000 -0.890000000,-4.100000e-01 NA NA NA,NA,NA NA NA NA   0   0 100   0,  0,  0 100,some high high some high,Placebo   0  50.000000 36.550000 NA DSM-IV-TR,2 1 0.0 0.0 1.0 1.0 1 1 1,1,1,1 0 1.0,1 1,1 1  167,Spencer_2008 < 2 months,NA,>= 20 yo 29.1 36.55 NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA,Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Elliott (2020) - Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high high
1056 Elliott (2020) Elliott 2020,10.1371/journal.pone.0240584,100,  0,100 100,Critically low,Amphetamine mixed amphetamine salts,100 monotherapy Executive functioning (report),Mixed At study endpoint (closest to 12 weeks) Questionnaire BRIEF-A, 0.69044879   50.0000000,mg/d Wigal 2018a,p481 RCT (parallel, crossover, open-label) G  86  43, 129 outcomes reverse -0.4300000000,-0.800000000,-6.000000e-02 NA,NA,NA NA NA,NA,NA NA   0,  0 100,  0,100   0,100,some,high some low high,Placebo   0, 38.400000,33.100000 NA,DSM-IV-TR 2,1 0.0 0.0 1.0,1.0 1 1,1,1,1,1,0 1.0 1 1 1,1  168,Wigal_2018a,< 2 months,NA >= 20 yo,29.1,36.55 NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA,Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Elliott (2020) - Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high high
1056,Elliott (2020),Elliott 2020 10.1371/journal.pone.0240584,100   0,100 100,Critically low,Amphetamine lisdexamphetamine 100,monotherapy,Executive functioning (report),Mixed At study endpoint (closest to 12 weeks) Questionnaire BRIEF-A  2.30149597,  50.0000000 mg/d Adler 2013,NA RCT (parallel, crossover, open-label) G  80, 81, 161,NA,reverse -0.7300000000,-1.050000000,-4.100000e-01,NA NA NA,NA,NA,NA NA NA,  0   0,100,  0,  0,  0 100 low high high low,high,Placebo,  0, 47.790062,34.552174,NA,DSM-IV-TR 2,1 0.0,0.0 1.0 1.0 1,1,1 1,1,1,0 1.0,1,1 1 1  169,Adler_2013 2-6 months,NA >= 20 yo,29.1,36.55 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Elliott (2020) - Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high,high
1056,Elliott (2020),Elliott,2020 10.1371/journal.pone.0240584 100   0 100 100,Critically low Amphetamine triple bead mixed amphetamine salts,100,monotherapy Executive functioning (report) Mixed,At study endpoint (closest to 12 weeks) Questionnaire,BRIEF-A, 0.46029919   25.0000000 mg/d Wigal,2018b p111,RCT (parallel, crossover, open-label) G  79  79, 158,NA,reverse,-0.7200000000,-1.040000000 -3.900000e-01 NA,NA,NA NA,NA NA NA,NA,  0   0 100,  0 100   0,100,some,high low,some high,Placebo   0, 44.900000,29.100000,NA,DSM-IV-TR 2,1 0.0 0.0 1.0,1.0 1 1 1 1,1,1 0 1.0,1 1 1 1  170,Wigal_2018b < 2 months,NA,>= 20 yo,29.1 36.55,NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Elliott (2020) - Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high high
1056,Elliott (2020),Elliott,2020,10.1371/journal.pone.0240584,100,  0,100,100 Critically low Amphetamine,mixed amphetamine salts,100,monotherapy,Executive functioning (report),Mixed,At study endpoint (closest to 12 weeks),Questionnaire,BRIEF-A, 0.69044879   50.0000000 mg/d,Wigal,2018a,p481 RCT (parallel, crossover, open-label),G  86  43  129 outcomes reverse,-0.5700000000 -0.940000000,-1.900000e-01 NA,NA,NA,NA,NA,NA,NA,NA,  0   0,100   0 100   0,100,some high some,low,high,Placebo,  0, 38.400000 33.100000,NA,DSM-IV-TR 2,1 0.0 0.0 1.0 1.0 1 1,1 1,1 1,0 1.0 1 1 1 1, 171,Wigal_2018a,< 2 months NA,>= 20 yo 29.1 36.55 NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Elliott (2020) - Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high high
1255,Gan (2019),Gan,2019,10.1089/cap.2019.0059 100   0,100 100,Low,Vitamin D Vitamin D 100,methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire,Conners Parent Questionnaire + Attention-deficit/hyperactivity disorder  1.84119678,2000.0000000 IU/d Mohammadpour,2018,NA RCT,SMD  29  25   54 NA NA, 0.0900000000 -0.440000000  6.300000e-01   9.6000000, 10.2000000 NA,NA NA,NA NA,NA,100 100,100 100,100,100 100,some low low,low low,Active (any credible active intervention),100, 25.806452  8.500000,NA,DSM-IV,1 1,1.0,1.0 1.0,1.0,1 0 1 1 1 1 1,1.0,1,0 1,1  172,Mohammadpour_2018 < 2 months NA,6-12 yo,8.5,9.5,NA NA,  3  2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Oppositional Defiant Disorder symptoms  1 Gan (2019),8.5,10.5 NA NA,Gan (2019)_Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Gan (2019) - Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
1255,Gan (2019),Gan,2019,10.1089/cap.2019.0059 100,  0,100 100,Low Vitamin D,Vitamin D 100,methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Questionnaire,Conners Parent Questionnaire, 3.00000000,1000.0000000,IU/d,Naeini,2019 NA,RCT,SMD  35, 36   71 NA NA, 0.7400000000, 0.260000000  1.220000e+00, 16.6600000  14.5000000 NA,NA NA,NA,NA NA,100 100 100,100 100,100 100 some,low,low,low,low,Active (any credible active intervention) 100, 19.354839, 9.500000 NA,DSM-IV 1,1 1.0,1.0,1.0 1.0,1 0 1,1 1 1 1 1.0,1 0 1 1, 173 Naeini_2019,2-6 months,NA 6-12 yo 8.5,9.5 NA,NA   3  2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Oppositional Defiant Disorder symptoms, 1 Gan (2019),8.5 10.5 NA NA Gan (2019)_Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Gan (2019) - Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
1255 Gan (2019) Gan,2019,10.1089/cap.2019.0059 100,  0 100,100 Low,Vitamin D,Vitamin D 100 methylphenidate,Oppositional Defiant Disorder symptoms,Mixed At study endpoint (closest to 12 weeks) Questionnaire Conners Parent Questionnaire, ODD subscale  2.76179517 3000.0000000 IU/d,Elshorbagy,2018,NA RCT MD  19, 16   35,NA NA 15.0700000000, 8.650000000  2.149000e+01,  9.1620000, 10.0450000 NA,NA,NA NA,NA NA,100,100 100 100 100 100,100 some low,low low low,Active (any credible active intervention),100  16.666667,10.500000 NA DSM-IV 1,1 1.0 1.0 1.0,1.0,1,0,1,1 1,1,1 1.0,1 0,1 1  174 Elshorbagy_2018,2-6 months,NA,6-12 yo 8.5,10.5 NA NA,  3  2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Oppositional Defiant Disorder symptoms, 1 Gan (2019),8.5 10.5,NA NA Gan (2019)_Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Gan (2019) - Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
1255,Gan (2019) Gan,2019 10.1089/cap.2019.0059 100,  0 100 100,Low Vitamin D Vitamin D,100,methylphenidate Oppositional Defiant Disorder symptoms,Mixed,At study endpoint (closest to 12 weeks) Questionnaire,Conners Parent Questionnaire, ODD subscale, 1.84119678 2000.0000000,IU/d,Mohammadpour 2018 NA RCT MD, 29  25   54,NA NA, 4.4800000000,-1.850000000, 1.081000e+01  12.1000000, 11.6000000 NA NA NA,NA NA,NA 100 100 100,100 100,100 100 some,low,low low,low Active (any credible active intervention),100  25.806452, 8.500000 NA DSM-IV,1 1 1.0,1.0,1.0 1.0,1,0 1 1 1 1 1,1.0 1,0 1 1  175 Mohammadpour_2018 < 2 months,NA,6-12 yo,8.5,10.5,NA NA   3  2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Oppositional Defiant Disorder symptoms, 1 Gan (2019) 8.5 10.5 NA,NA Gan (2019)_Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Gan (2019) - Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3490,Talebi (2021) Talebi 2021 10.1080/10408398.2021.1940833,100,  0 100 100 Low,Zinc NA,100 Methylphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Mixed (different types of tool are used),PTR-ADHDS, 1.38089758   15.0000000 mg/d Akhondzadeh 2004,NA,RCT (parallel, crossover, open-label),G, 22  22   44,NA,reverse -1.2300000000 -1.870000000 -5.800000e-01,NA,NA NA NA NA NA NA,NA,  0,  0,100 100,100   0 100 low low low low,high,Active (any credible active intervention) 100 NA, 7.880000,NA,DSM-IV,1 0,0.5,1.0 1.0,1.0 1 1 2,1,1 0 1 1.0 0,1 1,1, 176 Akhondzadeh_2004,< 2 months,NA,6-12 yo 7.14,9.92 NA,NA   6, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Talebi (2021) | Catala-Lopez (2017),7.14,9.92,NA NA Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
3490 Talebi (2021),Talebi 2021 10.1080/10408398.2021.1940833 100   0 100 100 Low,Zinc NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Mixed (different types of tool are used),ADHDS  2.76179517   40.0000000 mg/d Bilici,2004 NA,RCT (parallel, crossover, open-label),G, 95, 98, 193,NA,reverse,-1.6200000000,-1.940000000 -1.290000e+00,NA,NA NA NA,NA NA,NA,NA,100,100,100 100,  0,100,100,some low high,some low Placebo,  0 NA  9.550000 NA DSM-IV 1 0,0.5 1.0 1.0,1.0 1,1 2,1,1 0,1,1.0 0,1 1,1  177 Bilici_2004 2-6 months,NA,6-12 yo 7.14,9.92,NA,NA   6  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Talebi (2021) | Catala-Lopez (2017),7.14,9.92 NA,NA,Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3490 Talebi (2021) Talebi,2021 10.1080/10408398.2021.1940833 100   0 100 100 Low Zinc,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),CPTRS & SNAP  1.84119678,  15.0000000,mg/d,Arnold,2011 NA RCT (parallel, crossover, open-label) G  28  24   52,NA,reverse  0.0400000000,-0.500000000, 5.900000e-01,NA,NA,NA NA NA,NA,NA,NA,  0,  0,  0,100,100,100,  0 high,low low,high,low,Placebo   0 NA, 9.920000 NA DSM-IV 1,0 0.5,1.0,1.0,1.0,1,1,2 1 1,0,1,1.0 0,1,1 1, 178 Arnold_2011,< 2 months,NA 6-12 yo,7.14,9.92,NA NA   6  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Talebi (2021) | Catala-Lopez (2017),7.14 9.92,NA,NA,Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
3490 Talebi (2021),Talebi 2021,10.1080/10408398.2021.1940833 100   0 100 100 Low,Zinc,NA,100 Methylphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Mixed (different types of tool are used),CGI  1.38089758,  10.0000000 mg/d Zamora,2011 NA,RCT (parallel, crossover, open-label) G  20  20,  40,NA,reverse -0.4300000000 -1.060000000, 1.900000e-01 NA,NA,NA NA,NA NA,NA NA   0   0,100 100,100,  0 100,some,low,low some high,Active (any credible active intervention) 100 NA, 7.140000 NA DSM-IV,1 0,0.5,1.0,1.0 1.0 1,1 2,1,1,0,1 1.0,0 1 1 1  179,Zamora_2011,< 2 months NA 6-12 yo 7.14 9.92,NA,NA,  6, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Talebi (2021) | Catala-Lopez (2017) 7.14 9.92,NA,NA,Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
3490,Talebi (2021) Talebi 2021 10.1080/10408398.2021.1940833,100,  0 100 100 Low Zinc,NA 100 Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Mixed (different types of tool are used),CPTRS  1.84119678   22.0000000,mg/d,Salehi,2016 NA,RCT (parallel, crossover, open-label) G  50  50  100 NA,reverse -0.4800000000 -0.880000000,-8.000000e-02,NA,NA NA,NA NA,NA NA NA   0   0,100,100 100   0 100 low low,low some high,Active (any credible active intervention),100 NA  9.310000,NA DSM-IV,1,0 0.5 1.0 1.0 1.0 1 1 2,1,1 0 1 1.0 0,1,1 1, 180 Salehi_2016 < 2 months NA,6-12 yo,7.14 9.92 NA,NA,  6, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Talebi (2021) | Catala-Lopez (2017),7.14 9.92 NA,NA Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high high
3490 Talebi (2021),Talebi 2021,10.1080/10408398.2021.1940833 100,  0,100,100 Low,Zinc NA 100 Methylphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Mixed (different types of tool are used) CPQ, 1.38089758   10.0000000 mg/d,Noorazar 2019,NA,RCT (parallel, crossover, open-label) G, 30, 30   60,NA reverse  0.0400000000,-0.460000000, 5.500000e-01,NA,NA NA NA NA NA,NA NA,100,100,100 100 100,100,100,low,low low some low Active (any credible active intervention),100,NA  9.500000 NA Psychiatrist & K-SADS 1,0 0.5,1.0,1.0,1.0,1,1,2,1,1,0,1,1.0 0,1 1 1  181 Noorazar_2019 < 2 months NA 6-12 yo 7.14,9.92,NA NA   6  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Talebi (2021) | Catala-Lopez (2017) 7.14 9.92 NA NA,Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8997,Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885,100   0,100 100 Low,Viloxazine Viloxazine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire ADHD-RS  1.38089758  100.0000000 mg,Nasser 2020 NCT3247530 100 mg RCT (parallel, crossover, open-label),MD 147,155, 302 outcomes,NA  5.7000000000, 2.520000000, 8.880000e+00 NA,NA NA NA,NA NA,NA,NA,100,100 100,100 100 100,100 some low low,low,low Placebo,  0, 36.767219, 8.500000,NA,DSM-5,1 1,0.5 1.0 1.0 1.0,0 1,3 1 1 1 1,0.5 0 0 0 1, 182 Nasser_2020,< 2 months NA,6-12 yo 8.45 13.9015384615385,NA,NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA,NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8997 Yu (2024) Yu 2024,10.1001/jamanetworkopen.2024.45885 100,  0,100,100,Low Viloxazine,Viloxazine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire,ADHD-RS, 1.38089758, 200.0000000,mg,Nasser,2020,NCT3247530 200 mg,RCT (parallel, crossover, open-label),MD 158 155, 313,outcomes,NA  6.8000000000, 3.670000000  9.930000e+00,NA NA,NA,NA,NA NA NA NA 100 100 100,100,100,100,100 some,low,low low low Placebo   0  37.498083  8.500000 NA DSM-5,1,1 0.5,1.0 1.0 1.0 0,1,3,1 1 1,1,0.5,0 0,0 1  183 Nasser_2020 < 2 months NA,6-12 yo 8.45,13.9015384615385,NA NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
8997,Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885 100   0,100 100,Low,Viloxazine Viloxazine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire,ADHD-RS, 1.61104718  400.0000000 mg,Nasser 2021a NCT3247556 400 mg RCT (parallel, crossover, open-label) MD  99  96, 195,outcomes,NA  5.1000000000, 1.290000000, 8.910000e+00 NA NA NA,NA NA,NA,NA NA,100,100,100 100 100,100,100 some low low,low low,Placebo,  0  34.875385 13.901538,NA,DSM-5,1,1 0.5 1.0,1.0 1.0,0,1,3,1 1,1,1,0.5,0,0 0,1  184 Nasser_2021a < 2 months NA,13-19 yo 8.45,13.9015384615385,NA,NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA,NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8997,Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885,100,  0,100,100,Low,Viloxazine,Viloxazine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire ADHD-RS  1.61104718, 600.0000000 mg Nasser,2021a NCT3247556 600 mg,RCT (parallel, crossover, open-label) MD  97, 96, 193,outcomes NA, 3.5000000000 -0.330000000  7.330000e+00 NA NA,NA NA NA NA NA,NA 100 100,100 100 100,100 100,some,low low low,low Placebo,  0, 31.624870 13.749741 NA,DSM-5,1 1 0.5 1.0 1.0,1.0 0,1,3,1 1,1,1,0.5 0,0 0 1, 185,Nasser_2021a,< 2 months,NA,13-19 yo,8.45,13.9015384615385,NA NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8997,Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885 100   0,100 100 Low,Viloxazine Viloxazine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire ADHD-RS  1.38089758  200.0000000,mg,Nasser,2021b,NCT3247517 200 mg RCT (parallel, crossover, open-label),MD  94,104  198,outcomes,NA  4.6000000000, 0.690000000, 8.510000e+00,NA NA,NA NA,NA NA NA NA 100 100 100 100 100,100,100,some some,low,low,low Placebo,  0, 37.363636,13.847475 NA,DSM-5 1 1 0.5,1.0 1.0,1.0 0 1 3,1 1 1 1,0.5,0,0,0,1  186,Nasser_2021b,< 2 months NA,13-19 yo,8.45 13.9015384615385 NA,NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8997,Yu (2024) Yu,2024 10.1001/jamanetworkopen.2024.45885 100,  0 100 100,Low,Viloxazine Viloxazine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Questionnaire,ADHD-RS, 1.38089758, 400.0000000,mg Nasser 2021b,NCT3247517 400 mg RCT (parallel, crossover, open-label) MD,103 104  207 outcomes NA, 5.1000000000, 1.280000000, 8.920000e+00,NA NA,NA NA NA NA,NA,NA,100 100 100,100,100,100,100 some some,low low,low,Placebo   0  39.622222,13.899517,NA DSM-5 1 1,0.5 1.0,1.0,1.0 0,1 3,1 1,1,1 0.5,0 0 0,1  187 Nasser_2021b,< 2 months NA 13-19 yo,8.45,13.9015384615385 NA,NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA,NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
8997 Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885,100   0 100,100,Low,Viloxazine Viloxazine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Questionnaire ADHD-RS, 1.84119678  200.0000000 mg,Nasser,2021c,NCT3247543 200 mg RCT (parallel, crossover, open-label) MD 107, 97, 204,outcomes NA  5.9000000000  1.870000000, 9.930000e+00 NA NA,NA,NA NA NA NA,NA,100,100,100,100 100 100 100 some low low low low,Placebo,  0  33.795588  8.500000,NA DSM-5 1 1,0.5 1.0,1.0,1.0 0,1,3 1 1 1 1 0.5,0,0 0 1, 188 Nasser_2021c < 2 months NA 6-12 yo 8.45,13.9015384615385,NA NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8997,Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885 100   0,100 100 Low Viloxazine,Viloxazine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire,ADHD-RS, 1.84119678, 400.0000000 mg Nasser 2021c,NCT3247543 400 mg RCT (parallel, crossover, open-label) MD  97, 97, 194 outcomes NA, 5.8000000000, 1.670000000  9.930000e+00 NA NA NA NA NA NA,NA,NA 100 100,100 100 100 100,100,some,low low,low low,Placebo,  0  38.150000  8.450000 NA DSM-5,1,1,0.5 1.0,1.0,1.0,0,1 3 1,1 1 1,0.5,0,0,0,1, 189 Nasser_2021c,< 2 months NA,6-12 yo 8.45,13.9015384615385,NA NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8997,Yu (2024) Yu 2024,10.1001/jamanetworkopen.2024.45885 100,  0 100 100,Low,Viloxazine,Viloxazine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire,ADHD-RS  1.84119678  100.0000000,mg Johnson 2020,100 mg RCT (parallel, crossover, open-label),MD, 45, 24   69,outcomes,NA, 6.2000000000,-9.420000000, 2.182000e+01 NA,NA NA NA NA NA,NA NA,100,100,100,100 100,100 100 low,low,low,low low,Placebo   0  44.939130, 8.569565,NA DSM-5 1,1 0.5 1.0,1.0,1.0 0 1,3 1 1,1 1,0.5,0,0,0 1, 190 Johnson_2020,< 2 months NA,6-12 yo 8.45,13.9015384615385,NA NA   6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA,NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
8997,Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885,100   0 100,100,Low Viloxazine,Viloxazine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire,ADHD-RS, 1.84119678, 200.0000000,mg,Johnson,2020,200 mg RCT (parallel, crossover, open-label) MD, 46, 24,  70 outcomes NA, 7.9000000000,-7.660000000  2.346000e+01,NA NA NA,NA NA NA,NA NA 100 100 100 100,100,100,100 low low low low,low,Placebo,  0  37.180000, 8.897143 NA DSM-5,1,1,0.5,1.0,1.0,1.0 0,1 3,1 1,1,1 0.5,0,0 0 1  191,Johnson_2020 < 2 months,NA 6-12 yo,8.45 13.9015384615385,NA,NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8997 Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885 100,  0,100,100 Low Viloxazine Viloxazine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire,ADHD-RS  1.84119678, 300.0000000,mg,Johnson,2020,300 mg RCT (parallel, crossover, open-label) MD, 47  24,  71 outcomes NA, 8.1000000000 -7.410000000  2.361000e+01 NA NA,NA,NA NA NA NA NA,100,100,100 100 100 100 100,low low low,low low,Placebo   0, 33.811268  8.898592 NA,DSM-5,1 1,0.5 1.0,1.0,1.0 0 1 3 1 1,1,1 0.5,0 0 0,1, 192,Johnson_2020 < 2 months NA 6-12 yo 8.45,13.9015384615385 NA,NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA,NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8997,Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885,100   0,100 100,Low Viloxazine Viloxazine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire,ADHD-RS, 1.84119678, 400.0000000,mg,Johnson 2020,400 mg RCT (parallel, crossover, open-label),MD  44  24,  68,outcomes NA  8.5000000000 -7.190000000, 2.419000e+01,NA NA,NA NA NA,NA,NA NA 100 100,100 100 100 100 100 low low low low low Placebo   0  38.217647, 8.894118 NA DSM-5,1,1 0.5,1.0,1.0,1.0,0,1,3,1,1,1 1,0.5,0,0,0 1  193 Johnson_2020 < 2 months NA,6-12 yo,8.45 13.9015384615385,NA,NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8997,Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885 100,  0,100,100 Low,Viloxazine,Viloxazine,  0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  1.38089758, 100.0000000,mg Nasser,2020 NCT3247530 100 mg RCT (parallel, crossover, open-label) RR 147,155  302,outcomes,reverse  4.9200000000  1.440000000  1.677000e+01 NA,NA NA NA NA,NA NA,NA 100,100,100,100 100,100 100 some,low low low low,Placebo,  0  36.767219, 8.500000 NA,DSM-5,1 1 0.5 1.0 1.0,1.0 0 1 3 1,1 1,1,0.5,0 0,0,1  194,Nasser_2020,< 2 months,NA 6-12 yo,8.45,13.9015384615385,NA,NA   6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
8997 Yu (2024) Yu 2024,10.1001/jamanetworkopen.2024.45885,100   0,100 100 Low Viloxazine,Viloxazine,  0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  1.38089758, 200.0000000 mg,Nasser 2020,NCT3247530 200 mg,RCT (parallel, crossover, open-label),RR,158,155, 313 outcomes,reverse, 4.5800000000  1.340000000  1.562000e+01 NA NA,NA NA NA NA NA NA,100,100,100 100 100,100,100 some low,low low low,Placebo,  0, 37.498083, 8.500000,NA,DSM-5,1,1 0.5 1.0 1.0 1.0 0 1 3 1 1,1,1,0.5,0 0,0,1, 195 Nasser_2020 < 2 months NA 6-12 yo 8.45 13.9015384615385,NA,NA   6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
8997 Yu (2024) Yu,2024 10.1001/jamanetworkopen.2024.45885,100   0,100,100,Low,Viloxazine,Viloxazine   0 NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 1.61104718, 400.0000000 mg,Nasser 2021a,NCT3247556 400 mg RCT (parallel, crossover, open-label),RR  99  96  195,outcomes reverse, 4.2000000000  1.240000000, 1.428000e+01 NA,NA NA,NA NA NA NA NA,100 100 100,100,100,100,100 some,low low,low,low Placebo,  0  34.875385 13.901538 NA,DSM-5 1 1,0.5,1.0,1.0,1.0,0 1 3 1 1,1 1 0.5 0 0 0,1, 196,Nasser_2021a,< 2 months,NA 13-19 yo 8.45,13.9015384615385 NA,NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA NA,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8997,Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885,100,  0,100 100 Low Viloxazine,Viloxazine,  0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  1.61104718, 600.0000000 mg Nasser 2021a,NCT3247556 600 mg RCT (parallel, crossover, open-label) RR, 97  96  193 outcomes reverse, 5.6100000000  1.700000000, 1.852000e+01 NA NA NA NA,NA NA,NA,NA,100,100,100,100 100,100 100 some low,low low low,Placebo,  0, 31.624870,13.749741,NA DSM-5,1,1,0.5,1.0 1.0,1.0 0,1 3,1,1 1 1 0.5,0 0,0,1, 197,Nasser_2021a,< 2 months,NA,13-19 yo,8.45,13.9015384615385 NA NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
8997 Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885 100   0,100,100,Low,Viloxazine Viloxazine   0 NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  1.38089758, 200.0000000,mg Nasser,2021b NCT3247517 200 mg,RCT (parallel, crossover, open-label) RR, 94 104  198 outcomes,reverse  2.0500000000  0.860000000, 4.930000e+00,NA NA NA NA,NA NA NA NA 100 100 100,100 100 100 100,some some low,low low Placebo   0, 37.363636,13.847475 NA,DSM-5 1,1,0.5,1.0,1.0 1.0 0 1 3 1 1,1 1 0.5,0,0,0,1, 198 Nasser_2021b < 2 months,NA 13-19 yo,8.45 13.9015384615385,NA,NA   6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA NA,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8997 Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885 100,  0,100,100 Low,Viloxazine Viloxazine,  0 NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  1.38089758, 400.0000000,mg Nasser,2021b,NCT3247517 400 mg RCT (parallel, crossover, open-label),RR,103 104  207 outcomes reverse, 2.1600000000, 0.920000000, 5.090000e+00 NA,NA,NA NA,NA NA,NA,NA,100,100 100,100,100 100,100,some some low low low Placebo,  0, 39.622222 13.899517,NA,DSM-5,1 1,0.5,1.0,1.0 1.0 0 1 3 1,1,1 1 0.5,0,0 0 1, 199 Nasser_2021b < 2 months,NA 13-19 yo,8.45,13.9015384615385,NA,NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
8997 Yu (2024) Yu 2024,10.1001/jamanetworkopen.2024.45885 100,  0,100,100 Low Viloxazine,Viloxazine,  0 NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA, 1.84119678  200.0000000 mg,Nasser,2021c NCT3247543 200 mg,RCT (parallel, crossover, open-label),RR,107  97, 204,outcomes,reverse 13.6000000000  1.830000000  1.010300e+02 NA,NA NA NA,NA NA NA,NA,100 100,100,100 100,100,100,some,low,low,low,low Placebo,  0  33.795588, 8.500000,NA DSM-5,1,1 0.5,1.0 1.0,1.0,0 1,3,1 1 1,1 0.5 0,0 0,1  200,Nasser_2021c,< 2 months NA 6-12 yo 8.45,13.9015384615385 NA NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45,34.7573446327684,NA NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8997 Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885 100,  0,100,100 Low Viloxazine,Viloxazine   0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  1.84119678  400.0000000 mg Nasser 2021c,NCT3247543 400 mg,RCT (parallel, crossover, open-label),RR, 97, 97, 194 outcomes,reverse,14.0000000000  1.880000000, 1.044000e+02,NA NA,NA NA,NA,NA NA NA 100 100 100 100,100 100 100 some low,low,low low,Placebo,  0  38.150000, 8.450000 NA,DSM-5 1 1 0.5 1.0 1.0 1.0 0,1,3,1,1 1 1 0.5 0 0 0 1  201 Nasser_2021c < 2 months,NA 6-12 yo 8.45 13.9015384615385 NA NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8997,Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885 100,  0 100 100 Low Viloxazine,Viloxazine   0 NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 1.84119678, 100.0000000 mg Johnson 2020 100 mg,RCT (parallel, crossover, open-label),RR, 45, 24,  69,outcomes reverse  3.7300000000, 0.490000000, 2.859000e+01 NA NA NA NA,NA NA NA NA 100,100,100 100 100,100 100,low low low low low Placebo   0, 44.939130, 8.569565,NA DSM-5 1 1,0.5,1.0 1.0 1.0 0 1 3 1 1 1 1 0.5,0 0 0,1, 202,Johnson_2020,< 2 months,NA 6-12 yo,8.45 13.9015384615385 NA,NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA,NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8997 Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885 100,  0 100 100 Low,Viloxazine,Viloxazine,  0 NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA, 1.84119678  200.0000000,mg Johnson 2020,200 mg RCT (parallel, crossover, open-label) RR  46, 24,  70 outcomes,reverse  5.2200000000  0.710000000  3.838000e+01 NA,NA NA,NA NA NA NA,NA 100,100 100,100,100,100 100,low low,low low low,Placebo   0, 37.180000  8.897143,NA,DSM-5,1 1 0.5,1.0,1.0 1.0,0 1,3 1,1,1 1,0.5,0 0 0 1  203 Johnson_2020 < 2 months NA,6-12 yo 8.45 13.9015384615385,NA,NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684,NA,NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8997,Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885,100,  0,100,100 Low,Viloxazine,Viloxazine   0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  1.84119678, 300.0000000,mg,Johnson 2020,300 mg RCT (parallel, crossover, open-label) RR, 47, 24,  71 outcomes reverse  5.6200000000, 0.770000000  4.098000e+01,NA NA NA,NA,NA NA,NA NA,100,100 100 100,100,100 100,low low low,low low,Placebo,  0  33.811268, 8.898592 NA DSM-5,1 1,0.5,1.0,1.0,1.0 0,1,3,1,1 1,1 0.5 0,0,0,1, 204 Johnson_2020 < 2 months,NA,6-12 yo 8.45 13.9015384615385,NA NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
8997,Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885 100   0 100,100 Low Viloxazine,Viloxazine   0 NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 1.84119678, 400.0000000,mg,Johnson,2020 400 mg RCT (parallel, crossover, open-label),RR, 44, 24,  68,outcomes reverse, 6.5500000000  0.910000000  4.733000e+01 NA,NA,NA,NA NA NA NA NA,100,100,100,100 100 100,100 low low low low,low,Placebo,  0  38.217647  8.894118,NA DSM-5 1,1 0.5,1.0,1.0,1.0,0 1,3,1 1,1 1,0.5 0 0,0 1, 205 Johnson_2020 < 2 months NA 6-12 yo,8.45,13.9015384615385,NA,NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA NA,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
8997,Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885,100   0,100 100,Low Viloxazine Viloxazine   0,NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.61104718  400.0000000 mg,Nasser 2021a NCT3247556 400 mg,RCT (parallel, crossover, open-label),RR, 99, 96  195,outcomes,reverse, 2.9100000000, 0.600000000  1.406000e+01,NA,NA,NA NA NA NA,NA,NA,100 100 100 100 100 100 100,some low low low,low Placebo   0  34.875385 13.901538,NA DSM-5 1 1 0.5 1.0 1.0,1.0,0,1,3 1,1 1 1,0.5 0 0 0,1, 206 Nasser_2021a,< 2 months NA,13-19 yo,8.45,13.9015384615385 NA NA   6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA NA Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8997 Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885 100,  0,100,100 Low,Viloxazine,Viloxazine   0 NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 1.61104718  600.0000000 mg,Nasser 2021a NCT3247556 600 mg,RCT (parallel, crossover, open-label),RR, 97  96, 193,outcomes,reverse  2.9700000000, 0.610000000  1.435000e+01 NA NA NA,NA,NA NA NA,NA 100 100 100 100,100 100,100,some low low,low,low Placebo   0  31.624870,13.749741,NA,DSM-5 1 1,0.5,1.0 1.0,1.0,0 1 3,1 1,1 1,0.5 0,0 0,1  207,Nasser_2021a,< 2 months NA,13-19 yo,8.45 13.9015384615385 NA,NA   6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8997 Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885,100   0 100 100 Low,Viloxazine,Viloxazine,  0,NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA, 1.38089758, 200.0000000,mg,Nasser 2021b NCT3247517 200 mg RCT (parallel, crossover, open-label),RR  94 104  198 outcomes,reverse 12.1600000000  0.680000000  2.169600e+02 NA NA,NA NA NA,NA,NA NA 100,100 100 100 100 100,100 some some low low low Placebo,  0, 37.363636 13.847475,NA DSM-5,1 1 0.5,1.0,1.0,1.0 0,1 3,1,1 1,1,0.5,0 0,0 1  208 Nasser_2021b,< 2 months,NA,13-19 yo 8.45 13.9015384615385,NA NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45,34.7573446327684,NA NA Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
8997,Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885,100,  0,100 100,Low Viloxazine Viloxazine,  0,NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 1.38089758  400.0000000 mg,Nasser,2021b NCT3247517 400 mg,RCT (parallel, crossover, open-label),RR,103,104, 207 outcomes reverse,19.1800000000, 1.130000000  3.253400e+02 NA,NA,NA,NA NA NA,NA,NA,100 100 100 100 100 100 100 some,some,low,low,low,Placebo,  0, 39.622222 13.899517,NA DSM-5 1,1,0.5,1.0 1.0 1.0 0,1 3,1 1,1,1 0.5,0,0,0 1  209 Nasser_2021b,< 2 months,NA 13-19 yo 8.45 13.9015384615385,NA NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA NA,Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
8997 Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885,100   0,100,100 Low,Viloxazine Viloxazine   0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 1.84119678, 200.0000000 mg,Nasser,2021c,NCT3247543 200 mg RCT (parallel, crossover, open-label),RR,107, 97  204,outcomes reverse,15.4300000000  0.900000000, 2.637700e+02,NA NA NA NA NA,NA NA NA 100 100 100 100 100,100 100 some,low,low,low low Placebo,  0, 33.795588  8.500000 NA,DSM-5,1,1,0.5,1.0 1.0 1.0 0 1,3 1 1,1,1,0.5 0 0 0,1, 210,Nasser_2021c < 2 months NA 6-12 yo 8.45 13.9015384615385,NA NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA NA Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8997 Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885 100   0,100 100 Low,Viloxazine,Viloxazine,  0,NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.84119678  400.0000000,mg,Nasser,2021c NCT3247543 400 mg,RCT (parallel, crossover, open-label),RR, 97  97, 194 outcomes reverse 17.0000000000  0.990000000  2.905000e+02,NA NA NA,NA NA NA NA,NA,100,100 100,100 100 100 100 some low low low,low,Placebo,  0  38.150000, 8.450000 NA,DSM-5 1 1 0.5 1.0,1.0 1.0 0,1 3 1,1 1,1,0.5 0,0,0,1  211,Nasser_2021c < 2 months NA,6-12 yo,8.45,13.9015384615385,NA NA   6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
8997,Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885,100,  0,100,100 Low,Viloxazine Viloxazine   0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,NA  1.38089758  100.0000000 mg,Nasser 2020,NCT3247530 100 mg RCT (parallel, crossover, open-label),RR 147,155  302 outcomes,reverse, 2.6360544218  0.519472592, 1.337661e+01,NA NA NA NA,NA,NA NA,NA 100 100 100,100,100 100 100,some low low low,low Placebo,  0  36.767219  8.500000,NA,DSM-5,1,1 0.5,1.0 1.0 1.0 0 1,3,1,1,1,1,0.5 0,0 0 1, 212,Nasser_2020 < 2 months NA 6-12 yo 8.45 13.9015384615385 NA NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA,NA Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8997,Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885,100,  0 100 100,Low,Viloxazine,Viloxazine,  0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,NA  1.38089758  200.0000000 mg Nasser 2020,NCT3247530 200 mg,RCT (parallel, crossover, open-label),RR 158,155  313 outcomes,reverse, 0.9810126582  0.139936191  6.877319e+00,NA,NA NA,NA NA NA NA,NA 100,100,100,100 100,100 100 some,low,low low low Placebo   0, 37.498083, 8.500000,NA DSM-5,1 1 0.5,1.0 1.0 1.0,0,1,3,1 1,1 1 0.5,0 0,0 1, 213 Nasser_2020,< 2 months NA,6-12 yo 8.45,13.9015384615385 NA NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA NA Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8997,Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885 100,  0,100,100 Low Viloxazine Viloxazine,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA NA  1.61104718, 400.0000000,mg Nasser,2021a NCT3247556 400 mg,RCT (parallel, crossover, open-label),RR  99  96  195,outcomes reverse, 3.8787878788, 0.441434763  3.408204e+01,NA NA NA NA,NA NA NA,NA 100,100,100 100 100,100,100 some,low low,low low,Placebo,  0, 34.875385 13.901538 NA DSM-5,1,1 0.5 1.0 1.0,1.0 0,1 3 1 1 1 1 0.5,0,0 0,1  214,Nasser_2021a < 2 months NA,13-19 yo,8.45 13.9015384615385,NA NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025),8.45,34.7573446327684,NA NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
8997 Yu (2024) Yu 2024,10.1001/jamanetworkopen.2024.45885 100,  0 100 100,Low,Viloxazine Viloxazine,  0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,NA, 1.61104718  600.0000000,mg,Nasser 2021a NCT3247556 600 mg RCT (parallel, crossover, open-label) RR, 97, 96  193,outcomes reverse  4.9484536082, 0.588996099  4.157446e+01,NA NA NA,NA,NA,NA,NA NA,100 100 100 100 100,100,100 some,low,low,low,low,Placebo   0  31.624870,13.749741,NA,DSM-5 1 1,0.5,1.0,1.0 1.0 0 1 3,1,1,1,1,0.5,0 0,0 1, 215,Nasser_2021a,< 2 months,NA,13-19 yo,8.45 13.9015384615385 NA NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8997 Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885 100   0 100,100,Low,Viloxazine Viloxazine,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,NA  1.38089758  200.0000000 mg Nasser,2021b NCT3247517 200 mg,RCT (parallel, crossover, open-label),RR  94,104  198 outcomes reverse, 9.9473684211  0.542686697, 1.823338e+02,NA NA NA,NA,NA,NA,NA,NA 100 100 100 100,100 100 100 some some low low,low,Placebo   0, 37.363636,13.847475,NA DSM-5,1,1,0.5,1.0 1.0,1.0 0 1,3 1 1 1,1 0.5 0 0 0,1  216 Nasser_2021b < 2 months NA,13-19 yo 8.45 13.9015384615385 NA NA   6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
8997,Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885,100,  0,100 100 Low Viloxazine Viloxazine   0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,NA  1.38089758, 400.0000000 mg Nasser 2021b NCT3247517 400 mg,RCT (parallel, crossover, open-label),RR 103,104  207,outcomes,reverse, 5.0480769231  0.245311962, 1.038803e+02,NA,NA,NA,NA,NA,NA,NA NA,100 100 100 100,100 100 100 some some,low low,low Placebo,  0  39.622222 13.899517 NA,DSM-5,1,1,0.5,1.0,1.0 1.0 0,1 3,1 1 1 1,0.5 0,0 0,1  217 Nasser_2021b,< 2 months,NA,13-19 yo 8.45,13.9015384615385,NA,NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8997,Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885,100,  0,100,100 Low Viloxazine,Viloxazine,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA NA, 1.84119678  200.0000000 mg Nasser,2021c NCT3247543 200 mg,RCT (parallel, crossover, open-label),RR 107  97, 204 outcomes reverse  1.8130841121, 0.466097070  7.052767e+00 NA NA,NA NA,NA NA NA,NA,100,100 100 100 100,100 100 some low low low low,Placebo,  0  33.795588, 8.500000,NA,DSM-5,1 1 0.5,1.0 1.0,1.0,0 1 3 1,1 1,1,0.5 0,0,0 1  218,Nasser_2021c,< 2 months NA,6-12 yo 8.45,13.9015384615385 NA,NA   6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025),8.45,34.7573446327684,NA NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
8997,Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885 100,  0 100,100 Low,Viloxazine Viloxazine   0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA NA, 1.84119678  400.0000000,mg,Nasser,2021c NCT3247543 400 mg,RCT (parallel, crossover, open-label),RR  97, 97  194,outcomes reverse, 1.3333333333  0.306489579, 5.800451e+00 NA NA NA,NA NA NA,NA NA,100 100 100,100 100,100 100,some,low low,low low,Placebo   0, 38.150000  8.450000,NA,DSM-5 1,1 0.5 1.0,1.0 1.0,0,1 3,1 1 1,1 0.5 0 0 0,1  219 Nasser_2021c,< 2 months NA,6-12 yo 8.45 13.9015384615385 NA NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8997,Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885,100,  0 100,100,Low,Viloxazine Viloxazine   0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA NA  1.84119678  100.0000000,mg,Johnson 2020,100 mg RCT (parallel, crossover, open-label) RR  45, 24,  69 outcomes reverse, 4.8913043478, 0.274333680, 8.721079e+01,NA,NA NA NA NA NA NA,NA,100 100,100,100 100,100,100,low,low low low,low Placebo   0, 44.939130, 8.569565,NA DSM-5,1 1 0.5,1.0 1.0,1.0,0 1 3,1 1 1 1 0.5 0 0 0,1, 220,Johnson_2020 < 2 months NA,6-12 yo,8.45,13.9015384615385,NA NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684,NA NA Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8997,Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885 100,  0 100,100,Low,Viloxazine,Viloxazine   0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA NA, 1.84119678, 200.0000000 mg Johnson 2020 200 mg,RCT (parallel, crossover, open-label),RR  46  24   70,outcomes,reverse, 3.7234042553, 0.200175760  6.925783e+01,NA NA,NA NA,NA NA NA NA,100 100,100,100,100,100 100,low,low,low low,low,Placebo   0  37.180000  8.897143,NA,DSM-5 1,1 0.5,1.0,1.0 1.0,0 1 3,1,1 1,1,0.5,0,0,0 1, 221,Johnson_2020 < 2 months NA 6-12 yo,8.45,13.9015384615385 NA,NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8997,Yu (2024) Yu,2024 10.1001/jamanetworkopen.2024.45885,100,  0,100 100 Low,Viloxazine,Viloxazine,  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA NA, 1.84119678, 300.0000000,mg Johnson,2020 300 mg,RCT (parallel, crossover, open-label),RR  47  24   71,outcomes,reverse  1.5625000000  0.066032837  3.697261e+01 NA,NA NA,NA NA NA,NA NA,100,100 100 100 100 100,100 low,low,low low low,Placebo   0, 33.811268, 8.898592 NA DSM-5 1,1,0.5 1.0 1.0 1.0 0 1,3,1,1 1 1,0.5 0 0,0,1, 222,Johnson_2020 < 2 months NA 6-12 yo,8.45 13.9015384615385 NA NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8997,Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885 100,  0 100,100 Low Viloxazine,Viloxazine,  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,NA, 1.84119678, 400.0000000,mg Johnson,2020 400 mg,RCT (parallel, crossover, open-label),RR  44  24,  68 outcomes,reverse, 6.1111111111  0.352265518  1.060157e+02 NA NA,NA NA NA NA,NA,NA 100,100,100 100,100,100,100 low,low low low,low,Placebo   0, 38.217647, 8.894118,NA DSM-5,1,1 0.5,1.0,1.0 1.0 0,1 3,1 1,1,1,0.5,0 0,0,1, 223 Johnson_2020 < 2 months,NA 6-12 yo 8.45 13.9015384615385,NA,NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8997 Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885,100,  0,100,100 Low Viloxazine,Viloxazine   0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA NA  1.38089758, 100.0000000 mg,Nasser 2020,NCT3247530 100 mg,RCT (parallel, crossover, open-label) RR,147 155, 302 outcomes reverse, 1.2106324011, 0.761216050, 1.925381e+00,NA,NA,NA,NA,NA,NA,NA NA 100 100,100 100 100,100,100,some,low low low low Placebo   0  36.767219  8.500000,NA DSM-5,1,1 0.5 1.0 1.0 1.0 0,1,3 1,1,1 1,0.5,0 0 0,1, 224,Nasser_2020,< 2 months NA,6-12 yo,8.45,13.9015384615385 NA,NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8997,Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885,100   0 100,100,Low,Viloxazine Viloxazine,  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,NA  1.38089758  200.0000000 mg Nasser,2020 NCT3247530 200 mg RCT (parallel, crossover, open-label) RR 158 155, 313,outcomes reverse  0.7266760431, 0.425979136  1.239634e+00 NA NA NA,NA,NA NA,NA NA,100,100,100 100,100,100,100 some,low,low low low,Placebo   0, 37.498083, 8.500000 NA,DSM-5,1 1,0.5 1.0,1.0,1.0,0 1,3,1,1 1,1 0.5,0 0,0,1  225 Nasser_2020,< 2 months NA 6-12 yo,8.45 13.9015384615385,NA,NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8997 Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885,100   0,100,100,Low,Viloxazine Viloxazine,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,NA  1.61104718, 400.0000000 mg,Nasser 2021a NCT3247556 400 mg RCT (parallel, crossover, open-label),RR  99, 96  195,outcomes,reverse, 0.9696969697, 0.458380861  2.051378e+00,NA,NA NA,NA,NA NA NA,NA 100 100 100 100 100,100,100,some low low,low,low Placebo   0  34.875385 13.901538 NA DSM-5 1,1 0.5 1.0 1.0 1.0 0 1,3,1,1,1,1 0.5,0,0 0,1, 226 Nasser_2021a < 2 months,NA 13-19 yo 8.45 13.9015384615385,NA,NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
8997 Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885 100   0 100,100 Low,Viloxazine Viloxazine,  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA, 1.61104718, 600.0000000 mg Nasser 2021a NCT3247556 600 mg,RCT (parallel, crossover, open-label),RR  97  96  193,outcomes,reverse, 1.4845360825, 0.756818278  2.911990e+00,NA NA,NA NA NA NA NA,NA,100,100 100 100,100 100,100,some low low,low,low Placebo   0, 31.624870,13.749741 NA DSM-5,1 1,0.5,1.0,1.0 1.0 0 1 3,1,1 1 1 0.5 0,0 0,1  227 Nasser_2021a,< 2 months NA 13-19 yo,8.45,13.9015384615385,NA,NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8997,Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885,100   0 100 100,Low Viloxazine,Viloxazine,  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,NA  1.38089758  200.0000000,mg,Nasser 2021b NCT3247517 200 mg,RCT (parallel, crossover, open-label) RR, 94 104, 198 outcomes,reverse, 2.7659574468  1.279385610  5.979839e+00 NA NA,NA NA,NA,NA,NA,NA 100 100 100 100 100,100,100,some,some,low low low Placebo,  0, 37.363636 13.847475,NA DSM-5 1,1 0.5,1.0 1.0,1.0,0 1 3 1,1 1,1,0.5,0,0,0 1  228 Nasser_2021b < 2 months,NA,13-19 yo 8.45 13.9015384615385,NA,NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA,NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8997 Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885,100   0,100 100 Low Viloxazine Viloxazine,  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,NA  1.38089758, 400.0000000 mg Nasser,2021b NCT3247517 400 mg RCT (parallel, crossover, open-label) RR 103 104, 207,outcomes,reverse, 1.7669902913  0.774491014  4.031363e+00 NA NA,NA,NA,NA NA,NA NA,100 100 100 100,100,100,100,some,some,low,low,low Placebo,  0, 39.622222 13.899517,NA,DSM-5,1,1 0.5 1.0 1.0,1.0,0 1,3 1,1,1,1 0.5 0,0 0 1  229,Nasser_2021b < 2 months NA,13-19 yo,8.45,13.9015384615385,NA,NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8997,Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885,100   0,100 100,Low Viloxazine,Viloxazine   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA NA  1.84119678  200.0000000 mg,Nasser 2021c NCT3247543 200 mg RCT (parallel, crossover, open-label) RR 107, 97, 204,outcomes reverse, 1.0131940627  0.559488495, 1.834823e+00 NA,NA NA,NA NA NA NA,NA,100 100,100,100,100,100,100,some,low,low,low low Placebo   0, 33.795588  8.500000 NA,DSM-5 1,1,0.5,1.0,1.0 1.0,0 1 3,1,1,1,1,0.5,0 0,0 1  230,Nasser_2021c < 2 months NA 6-12 yo,8.45,13.9015384615385,NA NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA,NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8997,Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885,100   0 100 100,Low Viloxazine,Viloxazine   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,NA, 1.84119678, 400.0000000,mg Nasser,2021c,NCT3247543 400 mg,RCT (parallel, crossover, open-label),RR, 97, 97  194,outcomes reverse, 1.3529411765, 0.772686173  2.368943e+00 NA,NA NA,NA NA,NA,NA NA 100 100 100 100 100 100,100,some,low low,low low,Placebo,  0  38.150000, 8.450000 NA,DSM-5 1,1,0.5 1.0,1.0 1.0 0,1,3,1 1,1,1,0.5,0,0,0 1  231 Nasser_2021c < 2 months,NA,6-12 yo,8.45,13.9015384615385 NA,NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8997,Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885,100,  0,100 100,Low Viloxazine,Viloxazine,  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA  1.84119678, 100.0000000 mg Johnson,2020 100 mg,RCT (parallel, crossover, open-label),RR  45, 24   69,outcomes,reverse, 1.9555555556, 0.602973907, 6.342227e+00 NA,NA NA NA NA NA,NA,NA,100 100 100,100 100,100,100,low low,low low low,Placebo,  0  44.939130  8.569565 NA,DSM-5 1,1 0.5,1.0 1.0,1.0,0 1,3,1,1,1 1 0.5 0,0,0,1  232,Johnson_2020 < 2 months NA 6-12 yo 8.45 13.9015384615385 NA NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
8997 Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885,100,  0 100 100,Low,Viloxazine Viloxazine,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,NA, 1.84119678, 200.0000000,mg Johnson 2020 200 mg RCT (parallel, crossover, open-label) RR, 46  24   70,outcomes reverse  2.9565217391  0.961012862  9.095634e+00 NA,NA,NA NA NA,NA NA,NA,100 100 100,100 100,100 100,low low,low low low,Placebo   0  37.180000, 8.897143,NA,DSM-5,1,1 0.5,1.0,1.0,1.0 0 1,3,1,1,1 1 0.5,0 0 0,1  233,Johnson_2020,< 2 months NA 6-12 yo 8.45 13.9015384615385,NA,NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA,NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8997,Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885 100   0,100 100 Low,Viloxazine,Viloxazine,  0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA NA, 1.84119678, 300.0000000,mg,Johnson 2020 300 mg,RCT (parallel, crossover, open-label) RR, 47, 24   71,outcomes reverse  2.3829787234  0.757640155  7.495099e+00,NA NA NA NA,NA,NA,NA,NA,100,100 100 100 100,100,100 low low low low low Placebo,  0  33.811268, 8.898592,NA,DSM-5,1,1,0.5,1.0,1.0,1.0 0,1,3,1,1 1 1 0.5,0,0 0 1  234,Johnson_2020,< 2 months NA 6-12 yo 8.45 13.9015384615385 NA NA   6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8997 Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885,100   0 100,100,Low,Viloxazine,Viloxazine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA, 1.84119678  400.0000000 mg,Johnson 2020 400 mg RCT (parallel, crossover, open-label),RR  44  24   68,outcomes,reverse, 3.0909090909  1.006394808  9.493013e+00,NA NA,NA NA NA,NA NA,NA,100,100 100,100 100,100 100,low,low,low,low low,Placebo   0  38.217647, 8.894118,NA,DSM-5 1 1,0.5 1.0 1.0 1.0 0 1,3,1 1 1 1,0.5 0 0 0,1  235 Johnson_2020 < 2 months NA,6-12 yo,8.45,13.9015384615385 NA,NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA NA,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
1056,Elliott (2020) Elliott 2020 10.1371/journal.pone.0240584 100,  0,100 100,Critically low Atomoxetine Atomoxetine   0 NA Executive functioning (report),Mixed At study endpoint (closest to 12 weeks),Questionnaire BRIEF-A  2.30149597 NA mg/d,Goto,2017 NA,RCT (parallel, crossover, open-label) SMD,195,196  391,NA,reverse,-0.3800000000 -0.580000000,-1.800000e-01 NA NA,NA NA,NA,NA,13.6000000,10.4000000,  0,  0 100   0,100   0,100,some,high low,low high Placebo   0  52.347315 32.248593,NA DSM-IV-TR,2,1 0.0,0.0 1.0,1.0 1,1 1 1,1,1 0 1.0,1 1 1 1, 236 Goto_2017,2-6 months NA,>= 20 yo,32.2485933503836,37,NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA Elliott (2020)_Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Elliott (2020) - Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
1056,Elliott (2020),Elliott,2020 10.1371/journal.pone.0240584 100,  0 100,100 Critically low Atomoxetine,Atomoxetine,  0,NA Executive functioning (report),Mixed,At study endpoint (closest to 12 weeks),Questionnaire,BRIEF-A  1.84119678 NA mg/d,Sutherland 2012,NA RCT (parallel, crossover, open-label) SMD  97  47  144 NA reverse -0.3900000000,-0.740000000,-4.000000e-02,NA NA NA NA,NA,NA 25.6000000 26.3000000   0   0 100   0,  0,  0 100,some,high,high,some,high,Placebo   0, 41.000000,37.000000 NA DSM-IV-TR 2 1 0.0 0.0 1.0 1.0 1 1,1,1,1 1,0 1.0 1 1 1,1  237,Sutherland_2012,< 2 months,NA,>= 20 yo 32.2485933503836 37,NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA Elliott (2020)_Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Elliott (2020) - Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
3442,Stuhec (2015) Stuhec 2015,10.1016/j.jad.2015.03.006,  0,  0 100 100 Critically low,Bupropion Bupropion,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire Conners' Parent Rating Scale, 0.92059839    5.3000000,mg/d Clay,1998,NA,RCT (parallel, crossover, open-label) G  18, 10,  28,NA,reverse,-0.3900000000 -1.170000000  3.900000e-01,  7.2000000   7.3000000 NA NA,NA,NA NA,NA   0,  0 100,100,  0,  0,100,some low high,low high,Placebo   0,  3.600000,NA,NA DSM-III 3 0,1.0,0.0 1.0 1.0 0 1,2,1,1,1 0 0.5 1 0,1 1  238 Clay_1998 < 2 months,NA,NA 8.5,8.5,NA,NA  10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25,NA,NA,Stuhec (2015)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Stuhec (2015) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
3442,Stuhec (2015),Stuhec 2015,10.1016/j.jad.2015.03.006 100,  0,100,100,Critically low Bupropion,Bupropion   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire,Conners' Parent Rating Scale  0.92059839,NA,NA Conners 1996 NA RCT (parallel, crossover, open-label) G  62  34   96,NA,reverse,-0.2900000000,-0.710000000  1.300000e-01 NA,NA NA,NA,NA NA, 6.2000000  6.8000000 100,100,100,100,100,100 100 low low some,some low,Placebo   0, 10.000000  8.500000,NA,DSM-III 3,0,1.0 0.0 1.0 1.0 0 1 2 1,1,1 0,0.5 1 0,1,1, 239,Conners_1996 < 2 months,NA,6-12 yo,8.5 8.5,NA,NA, 10, 7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25,NA,NA,Stuhec (2015)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Stuhec (2015) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3681,Verbeeck (2017),Verbeeck,2017 10.1002/14651858.CD009504.pub2 100,  0,100,100,High,Bupropion Bupropion,  0 NA,Depressive disorder symptoms Mixed,At study endpoint (closest to 12 weeks),Questionnaire,HAM-D, 1.61104718  300.0000000 mg/d,Kuperman,2001,NA RCT (parallel, crossover, open-label),MD, 11  11   22,NA,reverse  1.4000000000 -1.750000000, 4.550000e+00,NA NA,NA,NA NA,NA, 4.4000000, 3.0000000,100 100,100 100   0,100 100,some,some,high some some,Placebo,  0  30.000000 32.700000 NA,DSM-IV 0 1 1.0 1.0 1.0,1.0 1,1 0 1 1 1,1,1.0,1,1 1 1  240,Kuperman_2001,< 2 months,NA >= 20 yo,32.7 40.25 NA,NA, 10  7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25 NA,NA,Verbeeck (2017)_Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Verbeeck (2017) - Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
3681,Verbeeck (2017) Verbeeck,2017,10.1002/14651858.CD009504.pub2,100,  0 100 100 High Bupropion,Bupropion   0,NA Depressive disorder symptoms,Mixed,At study endpoint (closest to 12 weeks) Questionnaire,HAM-D  1.84119678, 450.0000000,mg/d,Wilens 2005 NA RCT (parallel, crossover, open-label),MD, 81, 81  162,NA reverse  0.4300000000 -0.600000000  1.460000e+00,NA NA,NA,NA,NA,NA  3.1000000  3.6000000,100,100,100,100,  0,100,100 some,low,high some,some Placebo   0  40.000000,40.250000 NA,DSM-IV,0,1 1.0 1.0 1.0 1.0,1 1,0,1 1 1 1,1.0 1,1 1,1  241,Wilens_2005,< 2 months NA >= 20 yo,32.7 40.25,NA NA  10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25 NA NA,Verbeeck (2017)_Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Verbeeck (2017) - Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
3681,Verbeeck (2017),Verbeeck,2017 10.1002/14651858.CD009504.pub2,100,  0 100,100,High,Bupropion Bupropion   0,NA Generalized anxiety Mixed At study endpoint (closest to 12 weeks),Questionnaire HAM-A  1.61104718, 300.0000000,mg/d,Kuperman 2001,NA,RCT (parallel, crossover, open-label) MD, 11  11   22,NA reverse -0.5000000000,-2.910000000  1.910000e+00,NA NA,NA NA NA,NA, 3.6000000  1.9000000 100 100,100,100   0 100,100,some some high,some,some Placebo,  0, 30.000000,32.700000,NA DSM-IV,0 1,1.0 1.0 1.0,1.0,1 1 0 1,1,1 1,1.0,1,1,1 1  242 Kuperman_2001 < 2 months NA,>= 20 yo 32.7,40.25 NA NA  10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25 NA,NA Verbeeck (2017)_Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Verbeeck (2017) - Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
3681,Verbeeck (2017),Verbeeck,2017,10.1002/14651858.CD009504.pub2,100,  0,100 100,High Bupropion,Bupropion   0 NA Generalized anxiety,Mixed At study endpoint (closest to 12 weeks) Questionnaire,HAM-A, 1.84119678, 450.0000000,mg/d Wilens,2005 NA,RCT (parallel, crossover, open-label),MD  81, 81  162,NA reverse, 0.5700000000 -0.630000000  1.770000e+00,NA NA NA NA NA NA  4.0000000  3.8000000,100,100,100 100   0,100,100 some low high some some Placebo   0, 40.000000 40.250000,NA DSM-IV,0,1,1.0,1.0,1.0 1.0 1,1 0,1 1,1,1 1.0,1 1,1 1, 243,Wilens_2005,< 2 months NA,>= 20 yo 32.7 40.25,NA NA  10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25,NA NA Verbeeck (2017)_Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Verbeeck (2017) - Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
8991,Maiti - Children (2024) Maiti - Children,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100 100 Critically low,Dasotraline Dasotraline,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire,ADHD Rating Scale IV  1.38089758,   2.0000000,mg/d Findling 2019 Subgroup 1: Dasotreline 2mg vs Placebo RCT (parallel, crossover, open-label),SMD,107  58, 165,outcomes reverse -0.0300000000 -0.350000000, 2.900000e-01,NA,NA NA NA NA,NA,13.4500000,14.0000000,100 100,100,100 100 100,100,low low,low low low Placebo,  0 NA, 9.000000,NA,DSM 5,2,1 0.5 0.0 1.0,1.0,0 1,2 1,1 1,1,1.0,0,0,1 1  244,Findling_2019 < 2 months NA,6-12 yo,9,9 NA NA   5  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024),9,36.5 NA,NA Maiti - Children (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Maiti - Children (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
8991 Maiti - Children (2024),Maiti - Children,2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100,  0 100 100 Critically low Dasotraline,Dasotraline,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire,ADHD Rating Scale IV, 1.38089758    4.0000000,mg/d,Findling 2019,Subgroup 2: Dasotreline 4mg vs Placebo,RCT (parallel, crossover, open-label),SMD,113, 58  171,outcomes reverse,-0.4400000000,-0.760000000 -1.200000e-01 NA,NA NA NA,NA,NA,13.8200000 14.0000000 100,100,100,100 100,100 100 low,low low low,low,Placebo   0,NA, 9.000000,NA,DSM 5 2 1 0.5,0.0 1.0,1.0,0,1,2,1 1 1,1,1.0,0 0 1,1, 245,Findling_2019 < 2 months,NA,6-12 yo,9,9 NA NA   5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5,NA NA Maiti - Children (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Maiti - Children (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8991 Maiti - Children (2024) Maiti - Children 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100,100,Critically low Dasotraline,Dasotraline,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Observational tool,Swanson, Kotkin, Agler, M-Flynn, and Pelham rating scale (SCAMP-CS)  0.46029919    4.0000000,mg/d Wigal 2020,NA,RCT (parallel, crossover, open-label) SMD, 56, 56, 112 NA,reverse,-0.7700000000,-1.150000000,-3.800000e-01,NA NA NA,NA NA,NA, 6.7300000  6.7300000,100 100 100 100,100 100,100 low,low low,low low Placebo   0,NA, 9.000000,NA DSM 5,2 1 0.5 0.0 1.0 1.0,0,1 2 1,1 1,1 1.0 0 0 1,1, 246 Wigal_2020,< 2 months,NA 6-12 yo,9 9,NA NA,  5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024),9,36.5,NA,NA,Maiti - Children (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Maiti - Children (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
8991 Maiti - Children (2024) Maiti - Children 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100,100,Critically low,Dasotraline,Dasotraline,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Observational tool,Swanson, Kotkin, Agler, M-Flynn, and Pelham rating scale (SCAMP-CS)  0.46029919    2.0000000 mg/d Wigal 2022 NA RCT (parallel, crossover, open-label),SMD, 47  48,  95,NA,reverse -0.9500000000 -1.380000000,-5.300000e-01,NA,NA,NA NA NA NA  5.4800000  5.5400000,100 100 100,100 100,100,100,low low low low low Placebo,  0 NA  9.000000 NA,DSM 5,2,1,0.5,0.0 1.0 1.0,0,1 2 1 1,1,1,1.0,0,0,1 1  247,Wigal_2022,< 2 months,NA 6-12 yo 9,9,NA NA,  5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024),9,36.5 NA,NA,Maiti - Children (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Maiti - Children (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8991 Maiti - Adults (2024) Maiti - Adults,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100 100,Critically low Dasotraline Dasotraline   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire,ADHD Rating Scale IV  0.92059839    4.0000000,mg/d,Koblan,2015,Subgroup 3: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label),SMD 114  55, 169 outcomes reverse -0.2300000000,-0.550000000  9.000000e-02,NA,NA,NA,NA NA,NA,11.7400000,11.5400000 100,100,100 100,100 100,100,low,low,some low low,Placebo,  0 NA,36.500000,NA DSM 5,2,1,0.5 0.0 1.0,1.0 0 1,2,1 1 1,1,1.0,0 0 1 1, 248,Koblan_2015 < 2 months NA,>= 20 yo 36.5 36.5 NA,NA,  5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024),9 36.5,NA,NA Maiti - Adults (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Maiti - Adults (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
8991 Maiti - Adults (2024) Maiti - Adults,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100,  0,100,100 Critically low,Dasotraline,Dasotraline   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire ADHD Rating Scale IV  0.92059839    8.0000000,mg/d Koblan,2015 Subgroup 4: Dasotreline 8mg vs Placebo RCT (parallel, crossover, open-label) SMD 107  55  162 outcomes reverse -0.3400000000 -0.670000000,-2.000000e-02,NA NA,NA NA,NA,NA 12.4100000,11.5400000 100 100,100,100 100,100,100 low low some low low Placebo   0 NA,36.500000 NA DSM 5,2,1 0.5,0.0,1.0,1.0 0 1,2 1 1,1 1,1.0,0,0,1 1  249,Koblan_2015,< 2 months NA,>= 20 yo 36.5 36.5,NA,NA   5  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2 Maiti - Children (2024) | Maiti - Adults (2024),9 36.5,NA,NA Maiti - Adults (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Maiti - Adults (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
8991,Maiti - Adults (2024) Maiti - Adults,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100 100,Critically low,Dasotraline Dasotraline,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire,ADHD Rating Scale IV  1.84119678    4.0000000 mg/d,Adler 2021 Subgroup 5: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label) SMD,207,106, 313,outcomes,reverse,-0.0800000000 -0.320000000, 1.500000e-01 NA NA,NA,NA NA,NA,12.9500000,13.0700000,100 100 100,100,100,100 100,low,low some,low low Placebo   0,NA 36.500000 NA DSM 5,2 1 0.5,0.0,1.0,1.0,0 1 2 1,1 1 1,1.0,0,0 1 1  250,Adler_2021 < 2 months NA >= 20 yo 36.5,36.5 NA NA   5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024),9 36.5 NA,NA Maiti - Adults (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Maiti - Adults (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
8991,Maiti - Adults (2024),Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100,100,Critically low Dasotraline,Dasotraline   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire,ADHD Rating Scale IV  1.84119678,   6.0000000,mg/d,Adler,2021,Subgroup 6: Dasotreline 6mg vs Placebo,RCT (parallel, crossover, open-label),SMD 206,105  311,outcomes,reverse,-0.2000000000 -0.440000000  4.000000e-02 NA,NA,NA,NA,NA,NA,12.9200000,13.0700000,100 100 100 100,100 100 100 low low,some low,low Placebo,  0,NA 36.500000 NA DSM 5,2,1 0.5 0.0,1.0 1.0,0,1 2,1,1 1 1,1.0 0,0,1,1  251 Adler_2021 < 2 months,NA,>= 20 yo 36.5,36.5,NA NA   5  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5 NA,NA,Maiti - Adults (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Maiti - Adults (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
8991 Maiti - Adults (2024),Maiti - Adults,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100   0,100 100 Critically low,Dasotraline Dasotraline   0 NA CGI,Mixed,At study endpoint (closest to 12 weeks) Observational tool Clinical Global Impression-Severity scale, 0.92059839    4.0000000,mg/d,Koblan 2015,Subgroup 3: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label) G 114, 55  169 outcomes,reverse -0.3750856347,-0.700259573 -4.991170e-02   1.0677000   1.0488000 NA NA NA,NA  1.0700000  1.0500000 100 100 100,100 100 100,100,low low some low low Placebo   0 NA 36.500000 NA,DSM 5 2 1 0.5,0.0 1.0,1.0,0,1 2,1 1 1,1,1.0 0 0 1 1  252 Koblan_2015,< 2 months,NA,>= 20 yo,36.5,36.5,NA,NA   5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5 NA NA,Maiti - Adults (2024)_Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Maiti - Adults (2024) - Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
8991,Maiti - Adults (2024),Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100   0 100,100,Critically low,Dasotraline Dasotraline,  0,NA,CGI,Mixed At study endpoint (closest to 12 weeks),Observational tool,Clinical Global Impression-Severity scale  0.92059839    8.0000000,mg/d Koblan 2015,Subgroup 4: Dasotreline 8mg vs Placebo,RCT (parallel, crossover, open-label),G 107  55, 162,outcomes reverse,-0.3830735622 -0.711896716,-5.425041e-02,  1.0344000,  1.0488000 NA,NA NA,NA, 1.0300000, 1.0500000,100 100,100,100,100,100 100 low low some,low low,Placebo,  0,NA 36.500000 NA DSM 5 2,1,0.5 0.0,1.0 1.0 0 1 2 1 1 1,1,1.0,0,0 1 1  253 Koblan_2015 < 2 months,NA >= 20 yo 36.5 36.5 NA,NA   5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5,NA NA,Maiti - Adults (2024)_Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Maiti - Adults (2024) - Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
8991,Maiti - Adults (2024) Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100,100,Critically low,Dasotraline Dasotraline   0,NA,CGI,Mixed,At study endpoint (closest to 12 weeks) Observational tool,Clinical Global Impression-Severity scale, 1.84119678    4.0000000,mg/d Adler,2021 Subgroup 5: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label) G 207,106, 313,outcomes,reverse,-0.0691132538 -0.303613144  1.653866e-01   1.4387000   1.4526000,NA NA,NA NA, 1.4400000  1.4500000 100 100,100,100,100,100,100 low low,some,low,low Placebo   0,NA,36.500000,NA,DSM 5,2,1 0.5,0.0,1.0 1.0 0,1,2 1,1 1 1 1.0 0 0 1 1, 254,Adler_2021 < 2 months,NA,>= 20 yo,36.5,36.5,NA,NA,  5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5 NA NA,Maiti - Adults (2024)_Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Maiti - Adults (2024) - Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
8991 Maiti - Adults (2024) Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100   0 100,100 Critically low Dasotraline Dasotraline   0 NA CGI,Mixed At study endpoint (closest to 12 weeks),Observational tool Clinical Global Impression-Severity scale  1.84119678    6.0000000 mg/d Adler,2021,Subgroup 6: Dasotreline 6mg vs Placebo,RCT (parallel, crossover, open-label) G 206,105, 311 outcomes,reverse,-0.2076619509,-0.443599809, 2.827591e-02   1.4353000,  1.4526000 NA,NA NA NA, 1.4400000, 1.4500000,100 100 100,100 100,100,100 low low some low,low Placebo,  0,NA 36.500000 NA DSM 5,2,1 0.5 0.0 1.0 1.0,0,1,2 1 1,1,1,1.0 0,0,1 1, 255,Adler_2021 < 2 months NA,>= 20 yo,36.5 36.5,NA NA,  5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024),9 36.5,NA,NA Maiti - Adults (2024)_Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Maiti - Adults (2024) - Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
8991,Maiti - Children (2024) Maiti - Children 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100,100 Critically low Dasotraline,Dasotraline   0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 1.38089758,   2.0000000 mg/d,Findling 2019 Subgroup 1: Dasotreline 2mg vs Placebo RCT (parallel, crossover, open-label),RR 111  58, 169,outcomes reverse  2.9609609610, 0.904771963, 9.690055e+00 NA,NA NA NA,NA NA NA NA,100,100,100,100,100 100 100,low,low,low,low low Placebo,  0 NA  9.000000,NA,DSM 5 2,1 0.5,0.0 1.0,1.0,0,1 2 1,1,1,1,1.0,0,0 1,1  256 Findling_2019,< 2 months NA,6-12 yo,9 9,NA NA   5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5,NA,NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Maiti - Children (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
8991,Maiti - Children (2024) Maiti - Children 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100 100 Critically low Dasotraline,Dasotraline,  0 NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  0.46029919,   2.0000000 mg/d Wigal,2022,NA,RCT (parallel, crossover, open-label),RR  47, 48,  95,NA reverse  4.0851063830, 0.473912738  3.521343e+01 NA NA NA,NA NA NA NA NA,100,100 100,100,100 100,100 low low low,low,low,Placebo   0,NA, 9.000000 NA,DSM 5 2,1 0.5 0.0,1.0,1.0,0,1,2,1,1,1,1 1.0 0,0,1 1, 257,Wigal_2022 < 2 months NA,6-12 yo,9 9 NA NA,  5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5 NA NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Maiti - Children (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8991,Maiti - Children (2024) Maiti - Children 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100,100,Critically low,Dasotraline,Dasotraline   0,NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA  1.38089758,   4.0000000 mg/d,Findling 2019,Subgroup 2: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label),RR,115  58  173 outcomes reverse  6.3043478261  1.546479302, 2.570018e+01 NA NA NA,NA,NA,NA NA,NA 100,100,100 100,100 100,100,low low low low low,Placebo,  0,NA, 9.000000,NA DSM 5,2 1 0.5,0.0,1.0 1.0,0,1 2 1,1 1,1 1.0 0 0 1,1, 258,Findling_2019,< 2 months,NA 6-12 yo,9,9,NA,NA,  5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5,NA NA Maiti - Children (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Maiti - Children (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8991,Maiti - Children (2024) Maiti - Children,2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100   0 100 100 Critically low,Dasotraline,Dasotraline   0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  0.46029919,   4.0000000 mg/d Wigal,2020 NA RCT (parallel, crossover, open-label),RR, 56, 56, 112 NA reverse  5.5000000000, 1.276793143  2.369217e+01,NA,NA,NA,NA NA NA,NA,NA,100,100,100 100 100 100,100,low low low low,low,Placebo,  0 NA  9.000000 NA DSM 5,2 1,0.5,0.0 1.0 1.0,0,1 2 1 1 1,1 1.0,0,0,1,1  259,Wigal_2020 < 2 months NA 6-12 yo,9,9,NA NA   5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024),9,36.5 NA,NA Maiti - Children (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Maiti - Children (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
8991 Maiti - Adults (2024),Maiti - Adults 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100,100 Critically low,Dasotraline Dasotraline   0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  0.92059839,   4.0000000,mg/d,Koblan,2015,Subgroup 3: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label) RR 116  56, 172,outcomes,reverse  2.4137931034  1.212101884  4.806854e+00,NA,NA NA NA NA NA,NA,NA,100,100,100,100 100 100,100,low,low some,low,low,Placebo   0 NA,36.500000 NA DSM 5,2,1,0.5,0.0,1.0,1.0,0 1,2,1 1,1 1 1.0,0,0,1,1  260 Koblan_2015 < 2 months,NA,>= 20 yo 36.5 36.5,NA NA,  5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5 NA NA Maiti - Adults (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Maiti - Adults (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
8991 Maiti - Adults (2024) Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0,100 100 Critically low,Dasotraline,Dasotraline   0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA, 1.84119678,   4.0000000,mg/d,Adler 2021,Subgroup 5: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label) RR 210 110  320 outcomes,reverse, 4.3869047619  2.187382061  8.798158e+00 NA,NA,NA,NA NA,NA NA,NA,100 100,100 100 100,100 100,low,low,some,low,low Placebo,  0,NA,36.500000,NA DSM 5,2,1 0.5 0.0,1.0 1.0,0,1,2,1,1,1,1 1.0 0 0,1 1, 261,Adler_2021 < 2 months,NA >= 20 yo,36.5,36.5,NA NA   5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5,NA NA Maiti - Adults (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Maiti - Adults (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
8991,Maiti - Adults (2024) Maiti - Adults,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100,100 Critically low,Dasotraline Dasotraline,  0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  1.84119678,   6.0000000,mg/d Adler 2021,Subgroup 6: Dasotreline 6mg vs Placebo,RCT (parallel, crossover, open-label) RR,207,109  316 outcomes reverse  2.8303140097, 1.750332805  4.576660e+00,NA NA,NA NA,NA NA NA,NA,100 100 100 100,100,100,100 low,low some low,low Placebo,  0 NA 36.500000,NA,DSM 5 2 1,0.5 0.0,1.0,1.0,0,1 2,1,1 1 1,1.0,0 0 1 1  262,Adler_2021,< 2 months NA,>= 20 yo,36.5 36.5,NA NA   5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5 NA,NA Maiti - Adults (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Maiti - Adults (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
8991 Maiti - Adults (2024) Maiti - Adults,2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100 100 Critically low,Dasotraline Dasotraline,  0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA  0.92059839    8.0000000,mg/d,Koblan,2015,Subgroup 4: Dasotreline 8mg vs Placebo RCT (parallel, crossover, open-label),RR 111  55  166 outcomes,reverse  2.7527527528, 1.463417284  5.178050e+00,NA,NA NA,NA,NA NA NA,NA 100,100 100,100,100 100 100 low low,some,low,low,Placebo,  0 NA,36.500000 NA,DSM 5 2,1,0.5 0.0 1.0,1.0,0 1 2,1 1,1 1 1.0,0 0 1,1  263,Koblan_2015,< 2 months NA >= 20 yo 36.5,36.5 NA,NA   5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024),9 36.5,NA,NA,Maiti - Adults (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Maiti - Adults (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
8991,Maiti - Children (2024) Maiti - Children,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100   0 100 100,Critically low,Dasotraline Dasotraline,  0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 1.38089758    2.0000000 mg/d,Findling,2019,Subgroup 1: Dasotreline 2mg vs Placebo RCT (parallel, crossover, open-label),RR 111  58  169,outcomes reverse, 2.4384384384  0.730171042, 8.143273e+00 NA,NA,NA NA,NA NA,NA NA 100,100 100 100 100 100 100,low low low low low,Placebo,  0,NA, 9.000000 NA DSM 5,2,1 0.5,0.0,1.0,1.0 0,1,2,1,1 1,1,1.0 0,0,1 1  264 Findling_2019,< 2 months NA,6-12 yo,9,9 NA NA   5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024),9 36.5,NA,NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Maiti - Children (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8991,Maiti - Children (2024),Maiti - Children 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0,100,100 Critically low Dasotraline Dasotraline   0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 0.46029919,   2.0000000,mg/d,Wigal,2022 NA RCT (parallel, crossover, open-label),RR, 47  48,  95 outcomes,reverse, 5.1041666667, 0.251552256, 1.035670e+02,NA,NA,NA,NA NA NA NA NA,100 100 100,100 100,100,100,low low,low,low,low,Placebo   0 NA  9.000000 NA,DSM 5,2 1 0.5,0.0 1.0,1.0,0 1 2,1 1 1 1,1.0 0 0,1,1  265 Wigal_2022 < 2 months NA 6-12 yo 9,9 NA,NA   5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2 Maiti - Children (2024) | Maiti - Adults (2024),9,36.5 NA NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Maiti - Children (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
8991 Maiti - Children (2024),Maiti - Children 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0,100,100,Critically low Dasotraline,Dasotraline,  0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.38089758,   4.0000000 mg/d,Findling 2019,Subgroup 2: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label),RR,115, 58  173 outcomes,reverse, 4.2028985507  1.323877714  1.334289e+01 NA NA NA NA NA,NA NA NA 100 100 100,100,100,100 100,low,low low low,low,Placebo   0 NA  9.000000 NA DSM 5 2 1,0.5 0.0,1.0 1.0,0,1,2 1,1 1 1,1.0 0,0 1,1, 266 Findling_2019 < 2 months NA 6-12 yo,9,9 NA NA,  5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5,NA NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Maiti - Children (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
8991 Maiti - Children (2024),Maiti - Children 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100,  0,100 100 Critically low,Dasotraline,Dasotraline,  0,NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  0.46029919,   4.0000000,mg/d,Wigal 2020,NA RCT (parallel, crossover, open-label) RR, 56, 56, 112,outcomes,reverse, 3.0000000000, 0.632398010  1.423154e+01,NA NA NA NA NA,NA,NA NA,100,100,100 100,100 100 100 low,low low low low Placebo,  0 NA  9.000000 NA DSM 5,2,1,0.5,0.0,1.0,1.0,0 1,2 1 1 1 1,1.0,0,0,1,1, 267 Wigal_2020,< 2 months NA,6-12 yo,9,9,NA,NA   5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024),9,36.5,NA NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Maiti - Children (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8991,Maiti - Adults (2024),Maiti - Adults,2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0,100 100,Critically low Dasotraline,Dasotraline,  0 NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  0.92059839,   4.0000000 mg/d Koblan 2015,Subgroup 3: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label),RR 116, 56, 172 outcomes reverse  5.7931034483  0.772407525  4.344863e+01 NA NA NA NA,NA NA,NA,NA 100,100 100,100 100 100,100 low,low some,low low,Placebo,  0,NA 36.500000 NA DSM 5 2,1 0.5 0.0 1.0,1.0 0 1 2 1 1 1,1 1.0,0,0 1,1  268,Koblan_2015 < 2 months,NA >= 20 yo,36.5 36.5,NA,NA,  5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024),9 36.5 NA NA,Maiti - Adults (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Maiti - Adults (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
8991,Maiti - Adults (2024),Maiti - Adults,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100,100,Critically low,Dasotraline Dasotraline   0 NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA  1.84119678    4.0000000 mg/d,Adler 2021,Subgroup 5: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label) RR,210 109  319,outcomes reverse, 2.9066666667  1.154878171  7.315673e+00,NA NA,NA,NA,NA NA,NA NA,100 100,100 100 100,100,100 low,low,some,low low Placebo   0,NA 36.500000 NA DSM 5,2 1,0.5,0.0,1.0,1.0 0,1 2,1,1 1 1,1.0 0 0,1 1, 269 Adler_2021 < 2 months,NA >= 20 yo 36.5,36.5 NA NA,  5  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5 NA,NA Maiti - Adults (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Maiti - Adults (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
8991 Maiti - Adults (2024) Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0,100 100 Critically low,Dasotraline Dasotraline   0 NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 1.84119678,   6.0000000 mg/d Adler 2021 Subgroup 6: Dasotreline 6mg vs Placebo,RCT (parallel, crossover, open-label),RR,207 110  317,outcomes,reverse, 4.2512077295, 1.878791830, 9.619356e+00,NA NA,NA NA NA,NA,NA NA,100 100,100 100 100,100 100 low,low,some low low Placebo,  0,NA,36.500000,NA DSM 5,2,1,0.5,0.0,1.0,1.0 0 1 2 1 1 1,1 1.0,0 0,1 1  270,Adler_2021 < 2 months,NA >= 20 yo 36.5 36.5,NA NA   5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024),9,36.5 NA,NA Maiti - Adults (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Maiti - Adults (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
8991 Maiti - Adults (2024) Maiti - Adults 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100   0 100 100 Critically low,Dasotraline,Dasotraline   0 NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  0.92059839,   8.0000000 mg/d Koblan 2015,Subgroup 4: Dasotreline 8mg vs Placebo,RCT (parallel, crossover, open-label),RR,111, 55, 166 outcomes,reverse  6.1936936937  1.521942965  2.520583e+01,NA NA NA NA NA,NA,NA NA 100 100 100,100,100,100 100 low low,some low low Placebo   0,NA,36.500000,NA,DSM 5 2 1 0.5 0.0,1.0,1.0 0,1 2 1 1 1,1 1.0 0,0 1,1  271 Koblan_2015 < 2 months,NA >= 20 yo 36.5 36.5,NA,NA,  5  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024),9 36.5 NA NA,Maiti - Adults (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Maiti - Adults (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 381 Boesen (2022),Boesen,2022,10.1002/14651858.CD012857.pub2,100,  0,100 100,High Methylphenidate,OROS methylphenidate   0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Interview,Interview, 1.61104718,  72.0000000 mg/daily Adler,2006 NA,RCT (parallel, crossover, open-label),RR,110 116  226 NA reverse  4.2181818182, 1.921901135  9.258051e+00 NA,NA,NA,NA NA NA,NA,NA,  0,  0 100,100,  0,  0,100 low some,high some,high Placebo,  0  44.000000 39.000000 NA,DSM-IV 0 1,1.0 1.0 1.0 1.0,1,1 0,1,1,1 1 1.0,1,1,1,1, 272 Adler_2006,< 2 months,NA,>= 20 yo,33,42,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high,high
 381 Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2,100   0 100,100,High Methylphenidate,OROS methylphenidate,  0,NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Interview,Interview  1.38089758   40.0000000,mg/daily Biederman 2003 NA,RCT (parallel, crossover, open-label),RR 109,114  223 NA reverse  4.5321100917  1.941029323  1.058203e+01,NA,NA,NA,NA,NA,NA NA,NA,  0,  0,100,100   0   0,100,low,some,high,some high,Placebo,  0, 45.000000,36.000000,NA DSM-IV 0 1 1.0,1.0 1.0 1.0,1 1,0 1,1,1,1 1.0 1,1 1,1  273,Biederman_2003,< 2 months,NA,>= 20 yo 33 42,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high,high
 381 Boesen (2022),Boesen,2022 10.1002/14651858.CD012857.pub2 100   0 100,100 High,Methylphenidate OROS methylphenidate   0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview Interview  2.99194476   63.0000000,mg/daily Casas,2008 NA,RCT (parallel, crossover, open-label) RR 181, 97  278,NA,reverse, 4.6088397790  1.887661173, 1.125276e+01,NA NA,NA,NA,NA,NA NA NA 100,100 100,100   0 100,100,low,some high some,some,Placebo   0, 48.000000,36.000000,NA DSM-IV TR,0,1,1.0 1.0,1.0,1.0,1 1 0 1,1,1 1,1.0 1 1,1,1, 274 Casas_2008,2-6 months,NA,>= 20 yo,33,42 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 381 Boesen (2022) Boesen 2022,10.1002/14651858.CD012857.pub2,100,  0 100 100 High Methylphenidate extended-release methylphenidate   0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Interview,Interview 11.96777906,  70.0000000 mg/daily,Compas 2007 NA,RCT (parallel, crossover, open-label),RR 205 209  414,NA,reverse  5.8621951220, 2.837349694  1.211177e+01 NA,NA NA,NA,NA NA,NA NA,100 100,100,100   0,100,100,low some,high,some,low,Placebo,  0, 50.100000 35.000000 NA DSM-IV,0,1,1.0,1.0,1.0 1.0 1 1 0,1,1,1,1 1.0 1 1 1 1  275,Compas_2007 7-12 months,NA >= 20 yo,33,42,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 381 Boesen (2022) Boesen,2022,10.1002/14651858.CD012857.pub2 100   0 100,100,High,Methylphenidate,OROS methylphenidate   0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Interview,Interview  1.15074799   72.0000000 mg/daily,Ginsberg 2007,NA,RCT (parallel, crossover, open-label) RR  15, 15,  30 NA reverse, 9.0000000000, 0.526684293  1.537923e+02,NA NA NA,NA NA NA,NA NA 100,100,100,100 100 100 100 low,some,some some low Placebo   0   0.000000 34.000000,NA,DSM-IV,0 1 1.0 1.0,1.0,1.0 1 1,0 1 1 1 1,1.0 1,1,1 1, 276,Ginsberg_2007 < 2 months,NA >= 20 yo 33 42,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 381 Boesen (2022) Boesen,2022 10.1002/14651858.CD012857.pub2,100,  0 100 100,High Methylphenidate,OROS methylphenidate,  0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview Interview  1.38089758   45.0000000 mg/daily Goodman,2009 NA,RCT (parallel, crossover, open-label) RR,174 175  349 NA,reverse  3.5919540230  1.595635195  8.085892e+00 NA NA NA NA NA NA NA,NA   0,  0,100,100,  0,  0,100,low,some,high,some,high,Placebo,  0, 46.000000,36.000000 NA,DSM-IV 0 1,1.0 1.0,1.0,1.0 1 1 0 1,1 1 1,1.0 1 1 1 1  277,Goodman_2009 < 2 months NA >= 20 yo 33 42,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no high high
 381 Boesen (2022),Boesen,2022,10.1002/14651858.CD012857.pub2 100,  0 100,100 High Methylphenidate,Long-acting (LA) methylphenidate,  0,NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview Interview  2.07134638,  60.0000000,mg/daily,Huss,2010 NA,RCT (parallel, crossover, open-label) RR 542 180, 722 NA,reverse, 5.6457564576, 2.823802336, 1.128782e+01 NA NA NA,NA,NA,NA NA,NA   0   0,100,100   0,  0,100 low,some high,some,high,Placebo,  0, 45.000000,35.000000,NA DSM-IV,0,1,1.0 1.0,1.0 1.0,1 1 0,1,1 1,1 1.0,1 1,1,1, 278 Huss_2010 2-6 months NA >= 20 yo 33 42,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
 381 Boesen (2022),Boesen,2022,10.1002/14651858.CD012857.pub2 100,  0,100 100 High Methylphenidate,OROS methylphenidate   0,NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Interview Interview  5.52359033,  99.0000000,mg/daily Konstenius 2007,NA RCT (parallel, crossover, open-label) RR  27  27   54,NA reverse,15.0000000000, 0.899130072  2.502419e+02,NA NA NA,NA NA NA,NA,NA,  0,  0,100 100,  0   0,100,low,some,high some,high Placebo,  0   0.000000 42.000000 NA,DSM-IV 0,1,1.0 1.0 1.0 1.0 1 1,0 1 1,1 1,1.0,1 1,1,1, 279,Konstenius_2007 2-6 months,NA >= 20 yo,33 42 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high,high
 381 Boesen (2022),Boesen 2022 10.1002/14651858.CD012857.pub2,100   0 100,100 High Methylphenidate,OROS methylphenidate,  0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Interview,Interview, 1.15074799,  45.0000000,mg/daily Medori,2005,NA,RCT (parallel, crossover, open-label),RR,305  96  401 NA,reverse, 3.4622950820  1.653631531  7.249189e+00 NA NA,NA NA,NA,NA,NA NA 100,100,100 100   0 100 100 low some high,some,some Placebo,  0  46.000000 34.000000 NA,DSM-IV 0,1,1.0,1.0,1.0 1.0 1,1,0,1,1,1,1,1.0 1 1,1,1, 280,Medori_2005 < 2 months NA >= 20 yo 33,42 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 381,Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2 100,  0 100 100 High,Methylphenidate extended-release methylphenidate   0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Interview,Interview, 1.84119678  160.0000000 mg/daily,Retz,2008,NA RCT (parallel, crossover, open-label),RR, 84, 78  162,NA reverse  4.6428571429, 2.320115480, 9.290970e+00,NA NA NA,NA NA NA,NA NA   0   0,100 100,100   0 100,low some,low some,high,Placebo,  0, 53.000000,37.000000 NA,DSM-IV 0,1,1.0 1.0,1.0,1.0 1,1,0 1 1,1,1 1.0,1 1 1 1  281 Retz_2008 < 2 months NA,>= 20 yo 33,42,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high high
 381,Boesen (2022) Boesen,2022,10.1002/14651858.CD012857.pub2 100   0 100,100,High,Methylphenidate Extended-release (ER) methylphenidate   0 NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Interview Interview  5.52359033,  70.0000000,mg/daily Rsler 2004 NA RCT (parallel, crossover, open-label),RR 241,118, 359 NA,reverse, 3.0030428769  1.822608354, 4.948000e+00,NA,NA,NA NA NA,NA NA NA   0,  0,100,100   0   0,100 some some,high some,high,Placebo,  0  50.000000,35.000000,NA,DSM-IV,0 1,1.0,1.0 1.0 1.0 1,1,0 1 1,1,1 1.0 1,1,1,1  282,Rsler_2004,2-6 months,NA,>= 20 yo,33 42 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
 381,Boesen (2022) Boesen,2022,10.1002/14651858.CD012857.pub2 100   0,100 100,High,Methylphenidate,dex-methylphenidate extended-release
Spencer 2003a
Extended-release   0 NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Interview,Interview, 1.15074799,  30.0000000,mg/daily,Spencer 2003,NA RCT (parallel, crossover, open-label),RR,165, 53, 218,NA reverse, 1.6060606061  0.707303932, 3.646849e+00 NA,NA,NA,NA,NA,NA NA NA   0   0,100,100,  0,  0,100,some,some high,some,high,Placebo,  0, 42.000000,39.000000,NA,DSM-IV 0,1 1.0 1.0,1.0,1.0 1 1,0 1 1,1 1,1.0,1,1 1 1  283,Spencer_2003 < 2 months,NA >= 20 yo 33 42,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high,high
 381,Boesen (2022) Boesen,2022 10.1002/14651858.CD012857.pub2,100,  0 100 100 High Methylphenidate OROS methylphenidate,  0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Interview Interview  1.84119678   45.0000000,mg/daily,Takahashi,2011 NA,RCT (parallel, crossover, open-label),RR,143,141  284 NA,reverse, 5.6202797203  2.992051366  1.055715e+01,NA,NA,NA NA NA,NA NA,NA   0   0 100 100,100,  0 100 low,some,low,some,high,Placebo,  0  51.000000 34.000000,NA,DSM-IV TR,0,1 1.0,1.0 1.0,1.0 1,1 0 1 1 1,1 1.0,1,1,1 1  284,Takahashi_2011 < 2 months NA >= 20 yo,33 42,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high,high
 381 Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2,100   0 100 100 High,Methylphenidate,OROS methylphenidate,  0,NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview Interview, 1.38089758   54.0000000 mg/daily Weisler,2009 NA RCT (parallel, crossover, open-label),RR, 68  73, 141 NA reverse  5.6360294118, 2.038542515, 1.558213e+01,NA NA,NA NA,NA NA,NA,NA   0,  0,100 100,  0   0 100 low some high,some high,Placebo   0  38.000000,33.000000,NA,DSM-IV TR 0 1 1.0 1.0 1.0,1.0 1 1,0 1 1 1 1 1.0 1 1 1 1  285 Weisler_2009 < 2 months NA >= 20 yo,33 42 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no high,high
 381,Boesen (2022) Boesen,2022 10.1002/14651858.CD012857.pub2,100,  0 100 100 High,Methylphenidate,Controlled-release (CR) methylphenidate,  0 NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Interview Interview  0.92059839,  62.5000000,mg/daily Weiss 2014,NA RCT (parallel, crossover, open-label) RR 297, 78, 375,NA reverse  4.3333333333, 1.062905986, 1.766645e+01 NA NA NA,NA NA NA NA NA   0,  0 100,100,  0,  0,100,low,some,high,some high Placebo,  0  53.000000 36.000000 NA DSM-5 0,1,1.0,1.0 1.0,1.0 1,1,0,1 1 1,1 1.0 1 1 1 1  286 Weiss_2014,< 2 months,NA,>= 20 yo 33 42 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high,high
 381,Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2 100   0 100 100,High Methylphenidate,OROS methylphenidate,  0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Interview,Interview  2.53164557   45.0000000,mg/daily,Winhusen 2005 NA RCT (parallel, crossover, open-label) RR,127 128, 255,NA reverse  3.3115860517, 1.473694598  7.441570e+00,NA NA NA NA,NA,NA NA NA   0,  0,100,100,  0   0,100 low some,high some,high,Placebo   0  43.000000,38.000000 NA DSM-IV,0,1 1.0,1.0 1.0 1.0 1 1,0,1 1 1,1 1.0,1 1,1,1  287,Winhusen_2005,2-6 months,NA >= 20 yo,33,42 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high high
 381,Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2 100,  0,100 100 High,Methylphenidate OROS methylphenidate   0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Interview Interview  1.61104718   72.0000000,mg/daily,Adler 2006,NA RCT (parallel, crossover, open-label) RR 110,116, 226 NA,reverse  2.1090909091  0.653584043  6.805956e+00,NA NA NA,NA,NA NA NA NA,  0   0,100,100,  0,  0 100 low some high some high,Placebo   0, 44.000000 39.000000,NA DSM-IV 0 1 1.0,1.0,1.0,1.0,1,1 0,1 1 1 1 1.0,1,1,1,1, 288,Adler_2006,< 2 months NA,>= 20 yo,33,42,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high,high
 381,Boesen (2022),Boesen 2022,10.1002/14651858.CD012857.pub2,100,  0 100 100 High,Methylphenidate OROS methylphenidate   0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Interview,Interview  1.38089758,  40.0000000 mg/daily,Biederman,2003 NA,RCT (parallel, crossover, open-label) RR,109,114, 223,NA reverse, 3.1376146789, 1.043687498  9.432542e+00 NA NA NA NA NA NA NA,NA   0   0 100 100,  0   0,100 low some high some,high,Placebo,  0  45.000000,36.000000 NA,DSM-IV,0 1,1.0 1.0 1.0,1.0 1 1,0,1,1,1 1 1.0,1,1 1,1, 289 Biederman_2003 < 2 months,NA >= 20 yo 33,42,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
 381 Boesen (2022) Boesen 2022,10.1002/14651858.CD012857.pub2,100   0,100 100 High,Methylphenidate OROS methylphenidate,  0 NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview,Interview, 2.99194476   63.0000000,mg/daily,Casas 2008,NA RCT (parallel, crossover, open-label),RR 181  97, 278 NA,reverse, 4.2872928177  1.006541050, 1.826143e+01 NA,NA,NA NA NA,NA,NA NA,100,100 100,100,  0,100,100 low some high,some some,Placebo   0  48.000000,36.000000,NA DSM-IV TR,0,1 1.0,1.0 1.0,1.0,1,1 0,1 1 1,1 1.0 1 1 1 1, 290,Casas_2008 2-6 months NA,>= 20 yo 33 42,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 381 Boesen (2022),Boesen,2022,10.1002/14651858.CD012857.pub2 100   0 100,100,High,Methylphenidate,extended-release methylphenidate   0 NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview Interview 11.96777906   70.0000000 mg/daily,Compas,2007 NA,RCT (parallel, crossover, open-label),RR,205 209  414 NA,reverse  1.8351219512  0.868041890  3.879620e+00,NA NA NA,NA,NA NA NA,NA,100,100,100,100   0 100,100,low some,high,some,low Placebo,  0  50.100000,35.000000,NA DSM-IV 0,1 1.0 1.0,1.0,1.0 1,1,0 1,1,1,1 1.0,1,1 1 1, 291 Compas_2007,7-12 months NA,>= 20 yo,33,42 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 381 Boesen (2022),Boesen 2022 10.1002/14651858.CD012857.pub2 100   0 100,100 High Methylphenidate OROS methylphenidate,  0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Interview Interview  1.15074799,  72.0000000 mg/daily Ginsberg 2007 NA,RCT (parallel, crossover, open-label) RR, 15  15,  30 NA,reverse, 0.3333333333, 0.014650138  7.584305e+00,NA,NA,NA,NA NA NA,NA NA,100,100 100,100 100 100,100,low some,some some low,Placebo   0,  0.000000 34.000000 NA DSM-IV,0 1 1.0,1.0,1.0 1.0,1 1,0 1 1,1 1,1.0,1 1 1 1  292,Ginsberg_2007 < 2 months NA >= 20 yo 33,42 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 381 Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2 100   0,100,100,High,Methylphenidate,OROS methylphenidate,  0,NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview Interview, 1.38089758,  45.0000000,mg/daily Goodman 2009 NA RCT (parallel, crossover, open-label) RR 174,175  349,NA reverse, 5.6992337165  1.700672407, 1.909907e+01 NA NA,NA,NA NA NA NA,NA,  0,  0,100 100,  0,  0 100,low,some,high some high,Placebo,  0, 46.000000,36.000000,NA,DSM-IV,0 1 1.0,1.0,1.0 1.0,1 1 0 1,1 1,1 1.0 1,1,1 1, 293 Goodman_2009 < 2 months NA >= 20 yo 33 42,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
 381 Boesen (2022) Boesen 2022,10.1002/14651858.CD012857.pub2,100,  0,100 100,High Methylphenidate Long-acting (LA) methylphenidate,  0 NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Interview,Interview, 2.07134638,  60.0000000,mg/daily,Huss 2010 NA,RCT (parallel, crossover, open-label) RR,542 180, 722 NA reverse  4.6494464945, 1.118674605  1.932408e+01,NA,NA NA,NA NA,NA,NA,NA,  0,  0 100 100,  0   0 100,low some high,some,high Placebo   0, 45.000000 35.000000,NA DSM-IV,0,1 1.0,1.0 1.0,1.0,1,1,0,1 1 1 1 1.0,1 1 1 1  294 Huss_2010 2-6 months NA >= 20 yo 33,42,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no high high
 381,Boesen (2022) Boesen,2022,10.1002/14651858.CD012857.pub2 100,  0 100 100 High Methylphenidate,OROS methylphenidate,  0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Interview Interview, 5.52359033   99.0000000 mg/daily Konstenius 2007 NA RCT (parallel, crossover, open-label),RR  27, 27,  54 NA,reverse  3.0000000000, 0.663538308, 1.356365e+01,NA NA,NA NA,NA,NA,NA,NA,  0   0 100,100   0   0,100,low,some,high,some,high Placebo   0   0.000000 42.000000 NA DSM-IV,0 1,1.0,1.0,1.0,1.0,1 1,0,1 1 1,1 1.0,1 1 1,1, 295,Konstenius_2007 2-6 months,NA,>= 20 yo,33 42,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
 381 Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2 100,  0 100 100,High Methylphenidate,methylphenidate sustained-release (SR)   0 NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Interview,Interview, 2.99194476  100.0000000 mg/daily Levin,1998,NA,RCT (parallel, crossover, open-label) RR, 53, 53  106 NA,reverse  5.0000000000  0.604371002, 4.136532e+01 NA,NA,NA NA,NA NA NA,NA,  0,  0 100,100   0,  0,100,some,some,high some high,Placebo   0  17.000000,37.000000,NA DSM-IV,0 1 1.0 1.0,1.0 1.0,1 1,0 1,1,1 1,1.0,1 1,1 1, 296,Levin_1998,2-6 months NA >= 20 yo 33,42 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high high
 381,Boesen (2022),Boesen,2022 10.1002/14651858.CD012857.pub2,100   0 100,100 High,Methylphenidate,OROS methylphenidate   0 NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Interview Interview, 1.15074799   45.0000000 mg/daily Medori 2005 NA RCT (parallel, crossover, open-label),RR,305, 96, 401 NA reverse, 1.5737704918, 0.350890689, 7.058476e+00 NA,NA NA NA NA,NA,NA NA 100,100 100 100   0 100,100,low some,high some some Placebo,  0, 46.000000,34.000000,NA,DSM-IV 0 1,1.0,1.0 1.0 1.0 1,1,0 1 1 1,1 1.0,1 1,1,1  297,Medori_2005 < 2 months,NA,>= 20 yo 33 42 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 381,Boesen (2022),Boesen 2022,10.1002/14651858.CD012857.pub2,100   0 100 100,High Methylphenidate,Extended-release (ER) methylphenidate   0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Interview Interview  5.52359033   70.0000000 mg/daily,Rsler 2004 NA RCT (parallel, crossover, open-label) RR,241,118, 359 NA reverse  1.3989330172, 0.896035917  2.184079e+00,NA,NA NA NA,NA NA,NA,NA,  0   0,100,100   0,  0 100,some,some,high,some,high,Placebo   0, 50.000000 35.000000 NA DSM-IV 0,1 1.0 1.0,1.0 1.0,1 1 0,1 1 1 1 1.0,1 1,1,1  298 Rsler_2004,2-6 months,NA >= 20 yo,33 42 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high high
 381 Boesen (2022),Boesen,2022 10.1002/14651858.CD012857.pub2 100   0 100,100,High Methylphenidate,dex-methylphenidate extended-release
Spencer 2003a
Extended-release   0 NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Interview Interview, 1.15074799,  30.0000000 mg/daily Spencer 2003,NA RCT (parallel, crossover, open-label),RR 165, 53, 218 NA,reverse  1.9272727273, 0.237364655, 1.564841e+01,NA,NA NA NA,NA,NA,NA NA,  0   0,100 100,  0,  0 100 some some,high,some,high,Placebo   0  42.000000,39.000000 NA DSM-IV 0 1,1.0,1.0 1.0,1.0,1 1 0 1,1,1,1 1.0,1,1 1,1, 299 Spencer_2003 < 2 months NA,>= 20 yo,33 42 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high,high
 381 Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2 100   0 100,100,High,Methylphenidate OROS methylphenidate   0 NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Interview,Interview, 1.84119678   45.0000000,mg/daily,Takahashi,2011 NA RCT (parallel, crossover, open-label) RR,143 141, 284 NA,reverse, 1.0564435564  0.529779537  2.106674e+00,NA,NA,NA NA,NA,NA,NA NA   0,  0 100 100 100   0,100 low some low,some,high Placebo,  0, 51.000000,34.000000 NA DSM-IV TR,0,1,1.0 1.0 1.0 1.0,1,1,0,1 1 1 1,1.0,1,1 1 1, 300,Takahashi_2011 < 2 months,NA >= 20 yo,33 42 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high,high
 381,Boesen (2022) Boesen,2022,10.1002/14651858.CD012857.pub2,100   0 100,100,High,Methylphenidate OROS methylphenidate,  0,NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Interview Interview, 1.38089758   54.0000000 mg/daily Weisler 2009 NA RCT (parallel, crossover, open-label),RR, 68  73, 141 NA reverse, 3.2205882353  1.237216820  8.383485e+00,NA NA,NA NA,NA,NA,NA,NA,  0,  0,100 100   0   0 100,low,some high,some high Placebo,  0, 38.000000 33.000000,NA DSM-IV TR,0,1,1.0,1.0 1.0 1.0 1 1,0 1 1,1 1,1.0,1 1,1 1  301 Weisler_2009,< 2 months,NA >= 20 yo 33 42,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high high
 381,Boesen (2022),Boesen,2022,10.1002/14651858.CD012857.pub2,100   0,100 100,High,Methylphenidate Controlled-release (CR) methylphenidate   0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Interview Interview, 0.92059839   62.5000000,mg/daily Weiss 2014 NA RCT (parallel, crossover, open-label),RR,297  78  375 NA reverse, 4.7272727273  0.640937648  3.486627e+01 NA,NA NA,NA NA,NA NA,NA,  0   0 100,100   0,  0 100,low some high,some high,Placebo   0  53.000000,36.000000,NA,DSM-5,0,1 1.0,1.0,1.0 1.0 1 1,0 1,1 1,1,1.0,1,1,1,1  302,Weiss_2014,< 2 months NA >= 20 yo,33,42,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
 381,Boesen (2022),Boesen 2022,10.1002/14651858.CD012857.pub2,100,  0 100 100 High Methylphenidate,OROS methylphenidate,  0 NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview Interview  2.53164557,  45.0000000,mg/daily,Winhusen,2005 NA RCT (parallel, crossover, open-label),RR 127,128, 255 NA reverse  1.8141732283  0.625209239, 5.264197e+00,NA,NA,NA,NA,NA,NA NA,NA,  0,  0 100,100   0,  0,100 low some,high,some high,Placebo,  0  43.000000,38.000000 NA,DSM-IV,0,1,1.0 1.0 1.0,1.0 1 1,0,1,1 1 1,1.0,1 1 1,1  303 Winhusen_2005 2-6 months NA >= 20 yo,33 42,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no high high
1056,Elliott (2020) Elliott 2020,10.1371/journal.pone.0240584,100   0,100 100,Critically low Methylphenidate,Methylphenidate Hydrochloride  Long-Acting Capsule   0,NA Executive functioning (report),Self-rated At study endpoint (closest to 12 weeks),Questionnaire Brief Rating Inventory of Executive Function for Adults [BRIEF-A]  2.07134638   60.0000000 mg/d Huss,2014 NA RCT (parallel, crossover, open-label),SMD 544 181  725 NA reverse,-0.3800000000 -0.550000000,-2.100000e-01,NA,NA NA,NA,NA NA,NA,NA,  0   0,100   0,100,  0 100,low,high,some low,high Placebo   0, 42.774345 35.299310 NA DSM-IV, ADHD-RS 2 1 0.0 0.0,1.0,1.0 1,1 1 1 1,1,0,1.0,1 1,1 1, 304 Huss_2014 2-6 months NA,>= 20 yo,33.9675810473815 42,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Elliott (2020) - Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
1056,Elliott (2020),Elliott 2020 10.1371/journal.pone.0240584,100   0,100 100 Critically low Methylphenidate,Methylphenidate Osmotic-Controlled Release Oral System,  0 NA Executive functioning (report) Self-rated,At study endpoint (closest to 12 weeks) Questionnaire,Brief Rating Inventory of Executive Function for Adults [BRIEF-A], 1.15074799   54.0000000,mg/d,Ginsberg 2012,NA,RCT (parallel, crossover, open-label),SMD  15  15   30 NA,reverse -2.4000000000,-3.360000000,-1.430000e+00,NA NA NA NA NA NA NA NA,  0,  0 100,  0 100   0,100 low,high,low low high Placebo,  0   0.000000,34.400000 NA,DSM-IV 2,1,0.0,0.0,1.0 1.0 1 1 1 1 1,1,0 1.0 1,1,1,1, 305 Ginsberg_2012 < 2 months,NA,>= 20 yo,33.9675810473815 42 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Elliott (2020) - Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high high
1056,Elliott (2020) Elliott,2020 10.1371/journal.pone.0240584 100   0 100 100,Critically low Methylphenidate,Methylphenidate Osmotic-Controlled Release Oral System,  0 NA Executive functioning (report) Self-rated,At study endpoint (closest to 12 weeks),Questionnaire,Brief Rating Inventory of Executive Function for Adults [BRIEF-A], 1.38089758   72.0000000,mg/d Goodman 2017 NA,RCT (parallel, crossover, open-label),SMD 178,179  357,NA reverse,-0.5300000000 -0.740000000 -3.200000e-01 NA NA NA,NA NA NA NA,NA,  0,  0,100,  0 100   0,100,low high,low,low high,Placebo,  0, 47.100000,35.747059 NA DSM-IV 2 1,0.0 0.0,1.0,1.0,1,1 1 1,1 1 0,1.0,1 1 1 1  306,Goodman_2017,< 2 months,NA >= 20 yo,33.9675810473815 42,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Elliott (2020) - Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high,high
1056,Elliott (2020) Elliott,2020,10.1371/journal.pone.0240584,100,  0,100,100 Critically low,Methylphenidate,Methylphenidate Osmotic-Controlled Release Oral System,  0,NA Executive functioning (report) Self-rated At study endpoint (closest to 12 weeks),Questionnaire,Brief Rating Inventory of Executive Function for Adults [BRIEF-A]  1.15074799   36.0000000,mg/d Medori 2008 NA RCT (parallel, crossover, open-label),SMD 305  96  401,NA reverse,-0.3700000000,-0.600000000,-1.400000e-01 NA,NA NA,NA NA NA NA,NA   0   0,100   0 100   0 100 low,high,low some,high Placebo,  0, 50.973815 33.967581,NA DSM-IV by CAADID,2,1,0.0,0.0 1.0 1.0 1,1,1,1 1,1,0,1.0,1,1 1 1  307,Medori_2008 < 2 months,NA >= 20 yo,33.9675810473815 42 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Elliott (2020) - Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no high,high
1056 Elliott (2020) Elliott 2020 10.1371/journal.pone.0240584 100,  0,100 100,Critically low,Methylphenidate,Methylphenidate Immediate-Release,  0 NA,Executive functioning (report),Self-rated At study endpoint (closest to 12 weeks),Questionnaire Brief Rating Inventory of Executive Function for Adults [BRIEF-A], 2.07134638   27.5000000 mg/d Tenenbaum 2002,NA,RCT (parallel, crossover, open-label) SMD, 33, 33,  66,NA reverse -0.0300000000 -0.510000000, 4.500000e-01 NA NA,NA,NA NA,NA NA,NA   0,  0,100,  0   0   0,100 some,high,high,low high,Placebo,  0, 54.200000 42.000000,NA,DSM-IV, ADSA,2 1,0.0 0.0 1.0 1.0,1 1,1,1,1 1 0,1.0 1 1 1,1, 308 Tenenbaum_2002 2-6 months,NA,>= 20 yo 33.9675810473815 42 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Elliott (2020) - Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
2785 Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0 100 100 Critically low Methylphenidate methylphenidate   0,NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689   15.0000000,mg Agay 2010 NA RCT (parallel, crossover, open-label),G  13, 13,  26,outcomes,NA, 0.8600000000 NA,NA, 11.5600000, 13.6600000,NA NA,NA,NA,NA NA 100,100,100 100   0 100 100,some,low,high low low,Placebo,  0  58.000000,32.450000,NA NA,2,0,0.0 1.0,1.0 1.0 1 1 2,1,1 1 0,0.5,0,1 1 1, 309 Agay_2010,< 2 months NA >= 20 yo 28.44 50.1 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
2785 Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100,  0 100,100,Critically low,Methylphenidate,methylphenidate,  0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689,  15.0000000,mg,Agay 2010 NA RCT (parallel, crossover, open-label) G, 13, 13,  26 outcomes,NA, 1.2200000000,NA,NA   6.8700000   7.3300000 NA NA NA NA,NA,NA 100 100,100 100   0,100,100,some,low,high low low Placebo,  0, 58.000000 32.450000,NA NA 2 0 0.0 1.0 1.0,1.0,1,1,2 1 1,1,0,0.5,0 1,1 1  310,Agay_2010,< 2 months NA,>= 20 yo 28.44,50.1,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
2785 Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012   0,  0,100 100,Critically low,Methylphenidate,methylphenidate Immediate release,  0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689    0.2800000,mg/kg Agay,2014 NA RCT (parallel, crossover, open-label) G, 20  20,  40,outcomes NA  0.0100000000,NA,NA  62.8800000  67.6800000 NA,NA NA,NA NA,NA   0   0,100 100   0   0,100,low,low high low,high,Placebo   0 NA NA NA NA,2 0,0.0 1.0,1.0,1.0 1 1,2 1 1 1 0,0.5,0,1 1,1, 311 Agay_2014 < 2 months NA NA,28.44 50.1 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high,high
2785 Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012   0   0,100,100,Critically low,Methylphenidate,methylphenidate Immediate release,  0 NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689,   0.2800000,mg/kg,Agay,2014,NA RCT (parallel, crossover, open-label) G, 20, 20   40,outcomes NA,-0.0100000000,NA NA  39.8100000, 38.3500000 NA,NA,NA,NA NA NA   0,  0,100 100,  0,  0 100 low low high low,high Placebo,  0,NA NA,NA,NA 2 0,0.0 1.0 1.0 1.0,1,1 2 1 1,1 0,0.5,0 1,1 1, 312 Agay_2014,< 2 months,NA,NA,28.44,50.1,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high high
2785,Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012   0   0,100,100,Critically low,Methylphenidate,methylphenidate Immediate release   0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689,   0.2800000 mg/kg,Agay 2014,NA RCT (parallel, crossover, open-label),G, 20  20   40 outcomes NA  0.0400000000,NA,NA, 66.2700000, 61.6200000 NA,NA,NA NA NA,NA   0   0 100,100,  0,  0 100,low low high,low high Placebo,  0 NA NA NA,NA,2 0 0.0 1.0,1.0 1.0,1 1 2,1,1,1 0,0.5 0 1 1 1, 313 Agay_2014 < 2 months NA NA,28.44 50.1,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
2785,Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012,  0,  0 100 100 Critically low,Methylphenidate,methylphenidate Immediate release   0 NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689,   0.2800000,mg/kg Agay 2014 NA RCT (parallel, crossover, open-label) G  20, 20,  40,outcomes NA,-0.0300000000,NA NA  19.0800000  26.0700000 NA NA NA NA NA,NA,  0,  0,100,100   0,  0,100,low,low,high,low high,Placebo   0,NA,NA,NA NA,2 0,0.0,1.0 1.0,1.0 1 1 2,1,1,1,0,0.5,0 1,1 1, 314,Agay_2014 < 2 months,NA,NA 28.44,50.1,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
2785,Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100,  0,100 100,Critically low Methylphenidate methylphenidate Immediate release   0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918   49.0000000 mg,Biehl 2016 NA,RCT (parallel, crossover, open-label) G  15, 14   29 outcomes,NA  0.4000000000,NA NA   3.2000000,  6.0000000,NA,NA,NA NA NA NA,100 100 100,100,100 100 100 some low low,low,low Placebo,  0, 38.000000 36.100000 NA,NA,2 0 0.0 1.0,1.0 1.0,1,1 2,1 1 1 0 0.5,0,1,1 1  315 Biehl_2016,< 2 months NA,>= 20 yo,28.44 50.1,NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
2785,Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100   0,100 100,Critically low,Methylphenidate,methylphenidate Immediate release,  0 NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000 mg,Biehl 2016 NA,RCT (parallel, crossover, open-label) G  15, 14,  29,outcomes,NA, 0.0900000000 NA,NA   3.0000000,  3.7000000,NA,NA NA,NA NA,NA,100 100,100 100 100 100 100,some low,low,low,low,Placebo,  0, 38.000000 36.100000,NA NA,2,0 0.0,1.0 1.0,1.0,1 1 2 1 1 1 0,0.5,0,1,1,1  316 Biehl_2016,< 2 months,NA,>= 20 yo 28.44 50.1 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
2785,Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100   0 100 100 Critically low,Methylphenidate methylphenidate Immediate release,  0,NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918,  49.0000000 mg Biehl,2016 NA RCT (parallel, crossover, open-label) G  15  14,  29 outcomes NA, 0.7200000000,NA NA   0.6000000   3.1000000 NA,NA,NA,NA,NA NA,100 100,100 100 100,100 100,some,low,low,low low Placebo,  0, 38.000000 36.100000 NA NA,2,0 0.0,1.0,1.0,1.0,1,1,2 1 1,1 0,0.5 0 1 1 1, 317,Biehl_2016 < 2 months,NA,>= 20 yo,28.44,50.1,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
2785 Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100,  0 100 100 Critically low Methylphenidate methylphenidate Immediate release,  0 NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000 mg Biehl,2016 NA,RCT (parallel, crossover, open-label),G  15  14,  29,outcomes,NA, 0.1700000000 NA NA  15.9000000, 19.7000000 NA NA NA,NA,NA,NA,100,100,100 100,100 100,100 some low low,low low,Placebo   0  38.000000 36.100000,NA,NA 2,0,0.0 1.0,1.0 1.0 1 1 2,1 1,1,0,0.5,0 1 1 1, 318 Biehl_2016 < 2 months,NA,>= 20 yo,28.44,50.1,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2785,Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100   0,100,100 Critically low,Methylphenidate methylphenidate Immediate release   0,NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918   49.0000000,mg Biehl,2016,NA RCT (parallel, crossover, open-label),G, 15, 14   29,outcomes NA, 0.0600000000 NA,NA   6.1000000,  6.8000000,NA NA,NA,NA,NA NA,100,100,100,100 100,100 100,some,low,low,low,low,Placebo,  0, 38.000000,36.100000 NA NA,2,0,0.0,1.0,1.0 1.0,1 1 2,1 1 1,0,0.5,0,1,1,1, 319 Biehl_2016 < 2 months,NA,>= 20 yo 28.44,50.1 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2785 Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0,100,100,Critically low Methylphenidate methylphenidate Immediate release,  0,NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918   49.0000000,mg Biehl 2016 NA RCT (parallel, crossover, open-label) G  15, 14,  29 outcomes,NA, 0.1700000000 NA,NA, 14.9000000  16.2000000,NA NA,NA,NA NA NA 100 100 100,100,100 100,100,some low low low,low Placebo   0, 38.000000,36.100000,NA NA,2,0 0.0,1.0 1.0,1.0 1,1 2 1 1 1 0,0.5 0,1,1 1, 320 Biehl_2016,< 2 months NA >= 20 yo 28.44,50.1,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
2785,Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012,100   0 100 100 Critically low Methylphenidate methylphenidate Immediate release,  0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918   49.0000000 mg,Biehl 2016,NA RCT (parallel, crossover, open-label) G  15  14,  29,outcomes NA -0.1900000000 NA,NA  21.7000000, 21.6000000 NA,NA NA,NA NA NA 100,100,100,100 100,100,100,some,low low,low low Placebo,  0, 38.000000,36.100000,NA NA,2 0,0.0 1.0 1.0 1.0 1,1 2 1,1,1 0 0.5,0,1,1 1, 321,Biehl_2016 < 2 months NA >= 20 yo,28.44,50.1,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
2785 Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0 100 100 Critically low Methylphenidate,methylphenidate Immediate release,  0 NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918,  49.0000000 mg,Biehl,2016,NA RCT (parallel, crossover, open-label),G, 15, 14,  29,outcomes,NA, 0.0300000000 NA NA  13.8000000   9.8000000,NA NA NA NA,NA NA,100,100 100,100,100 100,100 some,low low low,low Placebo,  0  38.000000 36.100000,NA NA 2,0 0.0 1.0 1.0 1.0,1,1 2 1 1 1 0,0.5,0 1,1,1  322,Biehl_2016,< 2 months,NA,>= 20 yo 28.44,50.1 NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2785,Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100,  0 100 100 Critically low Methylphenidate,methylphenidate Immediate release   0 NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918   49.0000000,mg Biehl 2016,NA RCT (parallel, crossover, open-label),G, 15  14,  29,outcomes NA,-0.2300000000,NA NA, 19.6000000  20.7000000,NA,NA,NA,NA,NA,NA,100 100,100,100 100,100,100,some low,low,low,low,Placebo,  0, 38.000000 36.100000,NA NA,2 0,0.0,1.0,1.0,1.0,1,1,2 1 1,1,0,0.5,0 1 1,1  323,Biehl_2016 < 2 months,NA >= 20 yo,28.44 50.1 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100,  0 100 100 Critically low Methylphenidate methylphenidate Immediate release,  0,NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918,  49.0000000,mg,Biehl 2016 NA,RCT (parallel, crossover, open-label),G  15, 14,  29 outcomes,NA -0.0700000000,NA NA,  2.1000000   3.2000000,NA,NA NA,NA NA,NA 100,100,100 100,100,100,100,some low low,low,low Placebo,  0  38.000000,36.100000,NA,NA,2,0,0.0,1.0 1.0,1.0 1 1 2,1,1,1 0 0.5 0,1,1 1, 324 Biehl_2016,< 2 months,NA >= 20 yo 28.44,50.1,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2785 Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100,  0,100 100,Critically low,Methylphenidate,methylphenidate Immediate release,  0 NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000,mg Biehl 2016 NA RCT (parallel, crossover, open-label),G, 15  14   29,outcomes NA -0.0800000000,NA NA   2.1000000,  2.6000000,NA NA,NA NA,NA NA 100 100 100 100,100 100 100,some low,low low,low,Placebo,  0, 38.000000 36.100000 NA NA,2 0 0.0,1.0 1.0 1.0 1 1,2 1 1,1,0,0.5,0 1 1 1  325 Biehl_2016,< 2 months NA >= 20 yo 28.44,50.1,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
2785,Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100   0,100 100,Critically low,Methylphenidate,methylphenidate Immediate release   0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000 mg,Biehl 2016,NA,RCT (parallel, crossover, open-label),G, 15, 14   29 outcomes,NA, 0.1300000000 NA NA   0.6000000   0.9000000,NA NA NA NA NA,NA,100 100,100,100,100,100,100,some low low,low low,Placebo,  0  38.000000 36.100000 NA NA 2,0 0.0,1.0,1.0 1.0,1 1 2 1 1,1,0 0.5 0 1 1,1  326 Biehl_2016,< 2 months,NA,>= 20 yo,28.44,50.1 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
2785,Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100,  0,100,100,Critically low Methylphenidate,methylphenidate Immediate release,  0,NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918   49.0000000,mg,Biehl,2016,NA,RCT (parallel, crossover, open-label),G  15  14   29 outcomes,NA,-0.1200000000 NA NA, 17.0000000, 13.2000000,NA NA NA,NA,NA NA,100,100 100,100,100,100,100,some,low,low,low,low,Placebo   0  38.000000,36.100000,NA NA,2 0 0.0,1.0 1.0 1.0,1 1,2,1 1,1,0 0.5,0,1 1,1  327,Biehl_2016,< 2 months,NA,>= 20 yo 28.44 50.1,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2785 Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100,  0 100,100,Critically low,Methylphenidate methylphenidate Immediate release   0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000 mg Biehl 2016 NA,RCT (parallel, crossover, open-label) G, 15  14,  29,outcomes NA,-0.2500000000,NA NA  12.0000000,  5.3000000,NA NA NA,NA,NA NA,100,100 100,100,100 100,100,some,low,low,low low,Placebo   0, 38.000000 36.100000 NA,NA 2 0 0.0,1.0 1.0 1.0 1 1 2 1 1 1,0,0.5,0,1,1,1, 328,Biehl_2016,< 2 months NA >= 20 yo,28.44,50.1,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2785 Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100,  0,100 100 Critically low Methylphenidate methylphenidate Immediate release,  0,NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918   49.0000000,mg,Biehl 2016,NA,RCT (parallel, crossover, open-label) G  15  14,  29,outcomes NA, 0.0400000000,NA NA, 12.0000000, 12.6000000,NA NA NA NA NA,NA 100 100,100 100 100,100 100 some,low low,low,low,Placebo,  0  38.000000,36.100000,NA,NA,2 0,0.0 1.0,1.0,1.0,1 1 2,1 1,1,0,0.5 0 1 1 1, 329 Biehl_2016 < 2 months NA >= 20 yo,28.44,50.1 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
2785,Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0,100,100 Critically low,Methylphenidate methylphenidate Immediate release   0,NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918   49.0000000 mg,Biehl,2016 NA RCT (parallel, crossover, open-label) G, 15  14   29 outcomes NA,-0.0600000000,NA,NA  18.0000000, 17.0000000 NA,NA NA,NA,NA,NA,100,100,100 100 100 100 100,some low low low low Placebo   0, 38.000000 36.100000 NA,NA 2 0,0.0 1.0,1.0 1.0 1,1,2,1,1 1 0 0.5,0 1 1 1, 330 Biehl_2016,< 2 months,NA,>= 20 yo 28.44 50.1,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2785,Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0,100 100 Critically low,Methylphenidate,methylphenidate Immediate release   0 NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000,mg Biehl 2016,NA RCT (parallel, crossover, open-label) G, 15, 14,  29 outcomes,NA, 0.2600000000,NA,NA, 11.2000000  24.7000000,NA NA NA,NA NA NA,100 100 100 100,100 100 100 some,low low low,low Placebo,  0  38.000000,36.100000,NA NA,2 0 0.0 1.0 1.0,1.0 1 1,2 1,1 1,0 0.5 0,1,1,1, 331 Biehl_2016 < 2 months,NA >= 20 yo,28.44,50.1 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
2785 Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100   0,100 100,Critically low,Methylphenidate methylphenidate Immediate release,  0,NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918,  49.0000000,mg,Biehl 2016 NA,RCT (parallel, crossover, open-label),G  15, 14   29,outcomes,NA -0.0900000000,NA,NA  16.6000000  17.9000000 NA NA NA NA NA,NA 100,100 100,100 100,100,100,some,low,low,low,low Placebo,  0, 38.000000 36.100000,NA NA 2,0,0.0 1.0 1.0 1.0,1,1,2,1,1 1,0 0.5 0 1,1 1  332 Biehl_2016,< 2 months,NA,>= 20 yo,28.44 50.1,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
2785,Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100   0,100 100 Critically low Methylphenidate,Methylphenidate   0,NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.60655738    0.9000000,mg/kg Kuperman,2001 NA RCT (parallel, crossover, open-label) G,  8  10   18,outcomes,NA  0.1500000000,NA NA,NA NA NA,NA,NA,NA,NA NA,  0,  0 100 100 100   0,  0 some low,low,high,high Placebo,  0, 26.000000,31.840000 NA,NA 2,0 0.0 1.0 1.0 1.0 1,1,2,1,1 1,0,0.5,0 1,1 1  333 Kuperman_2001 < 2 months,NA,>= 20 yo 28.44 50.1 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high,high
2785 Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100   0,100,100,Critically low Methylphenidate Methylphenidate   0,NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689,  30.0000000 mg,Turner,2005,NA,RCT (parallel, crossover, open-label),G, 18  18,  36 outcomes,NA,-0.0800000000 NA NA,  7.4900000,  7.8000000 NA,NA,NA NA,NA NA 100,100 100 100 100 100,100 low low,low low low Placebo,  0  30.000000,28.440000 NA NA 2 0 0.0,1.0,1.0,1.0,1 1,2,1 1,1,0,0.5,0 1 1,1  334 Turner_2005 < 2 months NA >= 20 yo,28.44 50.1 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2785,Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012,100,  0,100 100,Critically low,Methylphenidate,Methylphenidate,  0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689,  30.0000000,mg Turner 2005,NA,RCT (parallel, crossover, open-label),G, 18, 18,  36 outcomes,NA  0.8600000000,NA NA   3.1000000,  6.7000000,NA NA,NA,NA,NA NA 100,100,100 100,100 100,100,low low low,low,low,Placebo,  0  30.000000,28.440000 NA,NA 2 0,0.0,1.0 1.0 1.0,1 1,2 1 1,1 0,0.5,0 1,1 1, 335 Turner_2005,< 2 months,NA,>= 20 yo,28.44 50.1,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
2785 Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100,  0 100 100,Critically low Methylphenidate Methylphenidate,  0,NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689   30.0000000,mg,Turner,2005,NA,RCT (parallel, crossover, open-label),G, 18  18,  36 outcomes,NA, 0.1400000000,NA NA, 10.6000000  10.9000000,NA NA,NA,NA NA NA 100,100,100,100 100,100 100 low,low,low,low,low,Placebo   0  30.000000 28.440000 NA NA,2,0,0.0,1.0 1.0 1.0 1,1,2,1 1,1 0,0.5 0 1 1 1  336 Turner_2005 < 2 months NA,>= 20 yo,28.44,50.1 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
2785,Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012,100   0,100 100 Critically low,Methylphenidate,Methylphenidate,  0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689,  30.0000000,mg Turner 2005 NA,RCT (parallel, crossover, open-label),G, 18, 18   36,outcomes NA, 0.3300000000,NA NA,  4.1000000,  5.4000000 NA,NA NA,NA,NA,NA 100 100,100 100 100 100,100 low low,low low,low,Placebo,  0  30.000000 28.440000,NA NA,2 0 0.0 1.0 1.0,1.0 1 1 2 1 1,1,0 0.5,0,1 1 1  337,Turner_2005,< 2 months,NA,>= 20 yo 28.44 50.1 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
2785,Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100,  0 100 100 Critically low Methylphenidate,Methylphenidate,  0 NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689   30.0000000,mg Turner,2005 NA,RCT (parallel, crossover, open-label) G, 18, 18   36,outcomes,NA, 0.0000000000,NA NA,  1.3400000   1.1500000,NA NA NA NA NA,NA,100 100 100,100 100 100 100 low low low,low low,Placebo,  0, 30.000000 28.440000,NA,NA 2 0,0.0 1.0 1.0 1.0 1 1 2 1 1 1 0 0.5 0,1 1 1, 338,Turner_2005 < 2 months NA >= 20 yo,28.44,50.1 NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
2785,Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0 100,100,Critically low,Methylphenidate Methylphenidate   0 NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689   30.0000000,mg Turner 2005,NA,RCT (parallel, crossover, open-label),G  18, 18,  36,outcomes,NA  0.0200000000,NA NA, 27.1000000  22.3000000,NA,NA NA NA NA,NA 100,100 100 100 100 100 100,low,low,low low,low Placebo   0, 30.000000 28.440000 NA,NA 2,0,0.0 1.0,1.0,1.0,1 1 2,1 1 1,0,0.5,0 1,1,1, 339 Turner_2005 < 2 months NA,>= 20 yo,28.44,50.1,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
2785,Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100,  0 100 100,Critically low,Methylphenidate,methylphenidate   0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689   15.0000000,mg Agay,2010,NA,RCT (parallel, crossover, open-label),G, 13, 13   26,outcomes NA  0.1800000000 NA NA,  8.7100000,  8.5400000,NA NA,NA,NA,NA NA 100,100 100 100,  0,100,100,some low high,low,low,Placebo,  0, 58.000000,32.450000,NA NA 2,0 0.0 1.0 1.0,1.0 1,1,2,1 1 1 0 0.5,0,1,1 1  340,Agay_2010,< 2 months,NA >= 20 yo 28.44 50.1,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
2785,Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0,100,100,Critically low,Methylphenidate methylphenidate Immediate release   0 NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689   15.0000000,mg Barkley 2005,NA RCT (parallel, crossover, open-label) G, 52, 52  104 outcomes,NA, 0.1400000000 NA,NA,  7.1000000   6.8000000,NA NA NA,NA,NA NA 100,100,100,100 100 100 100 low low low low,low Placebo   0, 26.000000,31.300000,NA,NA 2,0 0.0,1.0,1.0 1.0,1,1,2,1,1,1,0,0.5,0,1,1 1  341,Barkley_2005,< 2 months,NA >= 20 yo,28.44 50.1 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
2785,Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0,100 100,Critically low Methylphenidate,methylphenidate Immediate release,  0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689   15.0000000 mg Barkley,2005 NA,RCT (parallel, crossover, open-label),G  52  52  104 outcomes,NA, 0.2000000000 NA NA,  6.5000000   6.8000000 NA NA NA,NA NA NA,100,100 100,100,100 100 100,low,low low low,low,Placebo   0, 26.000000 31.300000 NA NA,2,0,0.0 1.0 1.0 1.0 1 1 2 1 1 1,0 0.5,0 1,1,1  342,Barkley_2005,< 2 months,NA >= 20 yo,28.44 50.1 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
2785,Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0,100,100,Critically low,Methylphenidate,methylphenidate mixed release,  0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 1.37704918,  84.6000000,mg Biederman 2011 NA RCT (parallel, crossover, open-label) G  40, 47   87,NA,NA -0.0800000000,NA,NA 126.2200000,159.8400000,NA NA NA,NA,NA NA 100,100 100,100,100 100 100,low,low some low,low Placebo   0, 39.000000,33.870000,NA NA 2,0 0.0,1.0 1.0,1.0 1 1,2,1 1,1 0 0.5,0,1 1 1  343,Biederman_2011 < 2 months,NA >= 20 yo 28.44 50.1 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2785 Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100,  0,100 100 Critically low Methylphenidate,Methylphenidate   0,NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.68852459,  70.6000000 mg Boonstra,2005,NA RCT (parallel, crossover, open-label) G, 43  43,  86 NA,NA  0.3900000000,NA NA   7.2000000,  7.6000000 NA,NA,NA NA,NA,NA,100 100,100 100,100 100,100 low,low,low,low,low Placebo,  0, 51.000000,38.900000,NA NA 2 0 0.0 1.0,1.0 1.0,1,1 2 1 1,1,0 0.5 0,1 1 1, 344 Boonstra_2005 < 2 months NA,>= 20 yo 28.44 50.1,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
2785,Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100,  0,100 100,Critically low Methylphenidate,Methylphenidate,  0,NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 0.03278689,  37.5000000 mg Bouffard,2003 NA RCT (parallel, crossover, open-label),G  30  30,  60,outcomes,NA, 0.5900000000 NA,NA  14.1000000, 13.2000000,NA NA,NA NA NA NA   0,  0,  0 100 100,100 100,high low,low low low,Placebo,  0, 20.000000 34.000000 NA,NA 2,0 0.0,1.0,1.0,1.0 1 1,2,1 1,1 0 0.5 0 1,1,1  345 Bouffard_2003,< 2 months,NA,>= 20 yo 28.44,50.1,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low high
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100   0 100,100 Critically low Methylphenidate,Methylphenidate   0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 0.03278689,  37.5000000,mg Bouffard,2003,NA RCT (parallel, crossover, open-label),G, 30  30   60,outcomes NA  0.6300000000 NA NA, 14.3000000  14.1000000 NA,NA NA NA,NA NA   0   0   0,100 100 100 100,high low low,low low Placebo   0, 20.000000,34.000000 NA NA 2 0,0.0 1.0 1.0,1.0,1 1 2 1 1 1 0 0.5 0 1 1 1, 346 Bouffard_2003 < 2 months,NA,>= 20 yo,28.44,50.1 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,high
2785,Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100   0,100,100 Critically low,Methylphenidate,methylphenidate mixed release,  0,NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.45901639,  72.0000000 mg Bron 2014,NA,RCT (parallel, crossover, open-label),G, 22, 22   44 outcomes,NA  0.3300000000 NA,NA NA NA NA,NA NA NA NA NA 100 100,100 100 100 100 100 low,low,low low,low Placebo,  0  23.000000 30.500000 NA,NA 2,0 0.0 1.0,1.0 1.0,1 1,2,1 1,1 0 0.5,0,1,1,1  347,Bron_2014,< 2 months,NA >= 20 yo,28.44 50.1 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2785 Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100,  0,100,100,Critically low,Methylphenidate methylphenidate mixed release,  0,NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.45901639,  72.0000000 mg Bron,2014,NA,RCT (parallel, crossover, open-label) G, 22  22,  44,outcomes NA  0.3100000000,NA,NA,NA,NA NA,NA NA NA,NA,NA,100,100,100,100 100 100,100 low low,low,low low,Placebo   0  23.000000,30.500000,NA,NA 2 0,0.0,1.0 1.0 1.0 1,1,2,1,1 1 0,0.5 0 1,1,1, 348 Bron_2014,< 2 months NA,>= 20 yo,28.44 50.1,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
2785,Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012,100   0 100,100 Critically low,Methylphenidate,Methylphenidate   0,NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689,  20.0000000 mg Epstein 2007 NA RCT (parallel, crossover, open-label) G, 15  15   30 NA NA, 0.1900000000,NA NA   6.6400000   9.2700000 NA NA,NA NA,NA NA,100 100,100,100 100,100 100 some,low,low low low Placebo,  0  67.000000,50.100000 NA NA,2 0,0.0 1.0 1.0,1.0 1 1 2 1,1,1 0,0.5,0 1 1 1  349 Epstein_2007 < 2 months NA >= 20 yo,28.44 50.1 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2785 Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100   0,100 100,Critically low Methylphenidate Methylphenidate,  0,NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 0.03278689,   2.0000000,mg,Kollins,2013,NA,RCT (parallel, crossover, open-label),G, 16, 16   32 outcomes,NA,-0.1200000000,NA NA  10.6800000,  8.7500000 NA,NA,NA,NA,NA,NA   0,  0,100,100,100   0,100,low low,low,low,high,Placebo   0  50.000000,29.800000 NA,NA 2 0,0.0,1.0,1.0,1.0 1 1,2 1,1,1 0 0.5,0,1 1 1, 350 Kollins_2013,< 2 months NA >= 20 yo 28.44 50.1 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
2785 Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100   0,100,100 Critically low,Methylphenidate,Methylphenidate   0 NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 0.03278689    2.0000000 mg,Kollins 2013,NA RCT (parallel, crossover, open-label),G  16, 16   32,outcomes,NA,-0.2600000000 NA,NA   9.3900000,  8.7500000,NA,NA,NA NA NA,NA   0   0 100 100 100,  0,100 low,low low low high,Placebo,  0  50.000000 29.800000 NA NA 2 0 0.0 1.0 1.0,1.0,1,1,2,1 1 1 0,0.5 0,1,1,1, 351,Kollins_2013 < 2 months NA >= 20 yo 28.44,50.1 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high high
2785 Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100   0,100,100,Critically low,Methylphenidate,methylphenidate Sustained release,  0 NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.91803279   20.0000000 mg Levin 2001,NA,RCT (parallel, crossover, open-label) G,  9,  7   16,outcomes,NA -0.4700000000 NA NA,  8.1000000   7.1400000 NA,NA NA,NA,NA NA,  0,  0 100 100   0,  0,100 some,low,high,low,high,Placebo   0  35.000000 37.750000,NA,NA 2,0 0.0 1.0 1.0 1.0 1,1,2 1,1 1,0,0.5,0 1 1 1, 352,Levin_2001 < 2 months,NA >= 20 yo 28.44,50.1 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high high
2785,Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100   0 100 100,Critically low Methylphenidate methylphenidate Sustained release   0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 0.91803279   20.0000000,mg Levin 2001,NA RCT (parallel, crossover, open-label),G   9,  7,  16 outcomes,NA, 0.1100000000 NA,NA,  7.2000000   8.4700000 NA NA NA,NA,NA NA,  0   0,100 100   0,  0,100 some low high,low high,Placebo,  0  35.000000 37.750000 NA,NA,2,0,0.0,1.0 1.0 1.0 1 1,2,1 1 1 0 0.5 0,1,1,1  353,Levin_2001,< 2 months,NA >= 20 yo,28.44 50.1,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no high,high
2785,Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100   0 100 100 Critically low Methylphenidate Methylphenidate,  0,NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689,   0.5000000,mg/kg Overtoom 2009 NA RCT (parallel, crossover, open-label) G  12, 12   24 outcomes,NA, 0.0500000000,NA NA   2.1000000   1.6000000,NA,NA,NA NA NA,NA,100,100,100,100,100,100,100 some,low low low,low Placebo,  0  50.000000 35.900000 NA,NA 2,0 0.0 1.0,1.0 1.0,1 1,2 1,1,1 0 0.5,0 1 1 1, 354,Overtoom_2009,< 2 months,NA >= 20 yo,28.44,50.1,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
2785 Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100   0,100 100 Critically low Methylphenidate,Methylphenidate   0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689    0.5000000,mg/kg Overtoom 2009 NA RCT (parallel, crossover, open-label) G, 12, 12   24 outcomes,NA,-0.4100000000,NA,NA   9.6000000,  3.8000000,NA NA,NA,NA,NA,NA,100 100 100 100 100,100 100 some low,low low low Placebo,  0, 50.000000 35.900000 NA NA,2,0,0.0,1.0,1.0,1.0 1,1,2,1 1 1,0 0.5 0 1 1,1  355 Overtoom_2009 < 2 months,NA,>= 20 yo 28.44 50.1 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
2785,Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100,  0,100,100 Critically low Methylphenidate Methylphenidate,  0,NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689,   0.5000000,mg/kg Overtoom,2009,NA,RCT (parallel, crossover, open-label),G  12, 12   24,outcomes,NA  0.4300000000,NA,NA, 60.0000000, 47.0000000,NA,NA,NA,NA NA,NA,100,100 100 100,100 100 100,some low low,low low Placebo,  0, 50.000000 35.900000 NA,NA,2 0,0.0,1.0 1.0,1.0,1 1,2,1 1,1,0,0.5 0,1,1,1, 356 Overtoom_2009,< 2 months,NA >= 20 yo,28.44 50.1,NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2785,Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012,100   0,100 100 Critically low Methylphenidate Methylphenidate,  0 NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689    0.5000000,mg/kg,Overtoom,2009 NA,RCT (parallel, crossover, open-label) G  12  12   24 outcomes,NA, 0.9000000000,NA NA,  1.5000000   1.6000000,NA,NA,NA,NA,NA NA,100,100 100,100,100,100,100,some,low low,low low,Placebo,  0, 50.000000,35.900000 NA NA 2,0,0.0,1.0 1.0 1.0,1,1,2,1 1,1 0 0.5 0,1,1,1, 357 Overtoom_2009 < 2 months NA,>= 20 yo,28.44,50.1 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
2785 Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100,  0,100,100 Critically low Methylphenidate,Methylphenidate,  0 NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 0.03278689,   0.5000000,mg/kg Overtoom,2009 NA RCT (parallel, crossover, open-label),G  12, 12   24 outcomes NA, 0.5100000000,NA,NA   4.7000000   3.8000000 NA NA,NA NA,NA NA 100,100 100,100 100,100 100 some low,low low low Placebo   0, 50.000000 35.900000 NA NA 2,0 0.0,1.0,1.0,1.0 1 1 2,1,1 1 0 0.5,0 1,1,1, 358 Overtoom_2009 < 2 months NA,>= 20 yo 28.44 50.1 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
2785 Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100   0 100 100,Critically low Methylphenidate,Methylphenidate,  0,NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689,   0.5000000 mg/kg Overtoom 2009,NA RCT (parallel, crossover, open-label) G  12, 12,  24,outcomes NA, 0.6100000000,NA NA, 55.0000000, 47.0000000 NA,NA NA NA NA,NA 100,100,100 100 100 100 100,some,low low,low,low,Placebo   0, 50.000000 35.900000,NA,NA 2 0,0.0,1.0 1.0,1.0 1 1 2 1 1,1,0 0.5 0 1,1 1  359 Overtoom_2009 < 2 months NA >= 20 yo,28.44 50.1 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
2785,Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012 100,  0,100 100,Critically low Methylphenidate,methylphenidate mixed release   0,NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,CNSVS Shifting Attention Test accuracy + Trails B, 1.37704918   52.0000000 mg,Goodman,2016 NA RCT (parallel, crossover, open-label) G 169 172  341,NA,NA  0.0400000000,NA,NA, 17.6700000  17.4000000 NA NA,NA NA NA NA 100,100 100,100,100 100 100 some low,low,low,low,Placebo,  0  47.000000,35.740000,NA,NA,2,0 0.0,1.0,1.0,1.0,1 1 2 1 1,1 0 0.5,0 1 1,1, 360,Goodman_2016 < 2 months NA >= 20 yo 28.44,50.1,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2785,Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012 100,  0 100,100,Critically low Methylphenidate,Methylphenidate,  0 NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test CNSVS Shifting Attention Test accuracy + Trails B, 1.60655738,   0.9000000,mg/kg Kuperman,2001,NA RCT (parallel, crossover, open-label),G   8, 10   18 outcomes NA -0.0100000000,NA NA NA,NA NA NA NA NA,NA NA   0   0 100,100,100,  0,  0 some,low,low high,high,Placebo,  0  26.000000 31.840000,NA,NA,2,0,0.0,1.0 1.0 1.0,1,1,2,1 1,1 0 0.5,0,1 1,1, 361,Kuperman_2001 < 2 months,NA,>= 20 yo,28.44,50.1 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high,high
2785,Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012,100,  0 100 100,Critically low,Methylphenidate methylphenidate Immediate release   0,NA Driving,Clinician-rated,At study endpoint (closest to 12 weeks),Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689,  15.0000000 mg,Barkley,2005 NA RCT (parallel, crossover, open-label),G  52  52  104 outcomes NA  0.0000000000,NA NA,  2.2000000,  1.7000000 NA,NA,NA,NA,NA,NA,100 100,100,100,100,100,100 low,low,low low,low Placebo,  0  26.000000 31.300000,NA NA,2,0,0.0,1.0 1.0 1.0 1,1,2,1 1 1,0 0.5 0,1 1 1  362 Barkley_2005,< 2 months,NA,>= 20 yo 22.14 38.3,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
2785,Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012,100   0 100 100 Critically low Methylphenidate methylphenidate Immediate release,  0,NA Driving,Clinician-rated,At study endpoint (closest to 12 weeks),Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689,  15.0000000 mg Barkley 2005 NA RCT (parallel, crossover, open-label),G  52  52, 104 outcomes,NA  0.0000000000 NA NA,  1.2000000   1.1000000 NA NA,NA,NA NA,NA 100 100 100 100,100,100 100 low,low low low low,Placebo,  0  26.000000 31.300000,NA,NA,2,0 0.0 1.0,1.0,1.0,1,1 2,1 1,1 0,0.5 0,1 1,1, 363 Barkley_2005,< 2 months,NA,>= 20 yo 22.14 38.3 NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
2785 Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012 100   0,100,100 Critically low,Methylphenidate,methylphenidate Immediate release,  0,NA Driving Clinician-rated,At study endpoint (closest to 12 weeks),Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689   15.0000000 mg Barkley 2005 NA RCT (parallel, crossover, open-label),G  52, 52, 104 outcomes NA  0.1700000000 NA NA, 19.4000000  24.3000000 NA NA,NA NA,NA NA,100 100 100,100 100 100 100 low low low,low low Placebo,  0, 26.000000 31.300000 NA NA,2,0 0.0,1.0 1.0,1.0,1,1 2 1 1,1,0,0.5,0,1,1,1, 364 Barkley_2005,< 2 months NA >= 20 yo,22.14,38.3,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
2785,Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0,100,100,Critically low Methylphenidate methylphenidate Immediate release   0,NA,Driving Clinician-rated,At study endpoint (closest to 12 weeks) Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689   15.0000000 mg Barkley 2005 NA RCT (parallel, crossover, open-label) G, 52  52  104 outcomes NA, 0.2100000000,NA,NA,  3.8000000   4.0000000,NA NA,NA,NA NA,NA,100 100 100 100 100 100,100 low low,low,low low,Placebo   0, 26.000000,31.300000 NA,NA,2 0,0.0 1.0 1.0,1.0,1 1 2 1,1 1,0 0.5 0,1,1,1, 365,Barkley_2005,< 2 months NA,>= 20 yo,22.14 38.3,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2785,Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100   0,100 100 Critically low Methylphenidate methylphenidate Immediate release   0 NA,Driving,Clinician-rated At study endpoint (closest to 12 weeks) Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689,  15.0000000 mg,Barkley,2005,NA,RCT (parallel, crossover, open-label) G, 52, 52, 104,outcomes NA, 0.0000000000,NA,NA,  1.8000000,  1.7000000,NA NA,NA NA,NA,NA,100 100,100,100,100 100 100 low,low,low,low low Placebo,  0  26.000000,31.300000,NA,NA,2 0,0.0,1.0,1.0,1.0,1,1 2,1,1,1 0 0.5 0,1 1,1, 366,Barkley_2005,< 2 months NA >= 20 yo,22.14,38.3 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
2785,Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100   0 100,100,Critically low Methylphenidate methylphenidate Immediate release   0,NA,Driving Clinician-rated,At study endpoint (closest to 12 weeks),Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689   15.0000000 mg,Barkley 2005 NA,RCT (parallel, crossover, open-label) G, 52, 52, 104,outcomes NA  0.2000000000,NA,NA,  0.9000000   1.1000000 NA NA,NA NA,NA NA 100 100,100 100,100,100,100 low,low low low low Placebo,  0  26.000000 31.300000 NA NA,2,0,0.0 1.0 1.0 1.0,1 1 2,1 1,1 0,0.5 0,1,1,1, 367 Barkley_2005,< 2 months,NA,>= 20 yo 22.14,38.3,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
2785,Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0 100,100,Critically low,Methylphenidate,methylphenidate Immediate release   0 NA Driving,Clinician-rated,At study endpoint (closest to 12 weeks) Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689,  15.0000000 mg Barkley,2005 NA,RCT (parallel, crossover, open-label) G  52, 52  104 outcomes,NA  0.4200000000 NA,NA  11.6000000, 24.3000000,NA NA NA NA NA,NA,100,100,100 100 100 100 100,low,low low low,low,Placebo,  0, 26.000000 31.300000 NA NA 2 0 0.0,1.0 1.0 1.0,1 1,2,1 1,1,0 0.5,0 1 1 1  368 Barkley_2005,< 2 months NA,>= 20 yo 22.14,38.3,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100   0 100 100,Critically low,Methylphenidate methylphenidate Immediate release,  0 NA Driving,Clinician-rated At study endpoint (closest to 12 weeks) Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689   15.0000000 mg Barkley 2005 NA RCT (parallel, crossover, open-label),G, 52  52, 104,outcomes,NA  0.0500000000 NA,NA   3.9000000,  4.0000000 NA,NA,NA,NA NA NA,100,100,100 100 100,100 100 low low,low,low,low,Placebo,  0, 26.000000,31.300000,NA,NA,2,0,0.0 1.0 1.0 1.0,1 1 2 1,1 1,0,0.5,0,1 1,1  369,Barkley_2005 < 2 months NA,>= 20 yo,22.14 38.3,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
2785,Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0,100 100 Critically low,Methylphenidate,methylphenidate Immediate release   0 NA Driving Clinician-rated At study endpoint (closest to 12 weeks) Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689   10.0000000,mg Cox 2000 NA,RCT (parallel, crossover, open-label) G,  7,  7   14,NA NA  1.3700000000,NA,NA NA,NA,NA NA NA NA,NA NA   0,  0   0,100,  0,100 100 high,low,high,low low,Placebo   0,  0.000000,22.140000,NA NA,2 0 0.0,1.0 1.0,1.0 1 1,2 1 1,1 0,0.5 0,1,1 1, 370,Cox_2000 < 2 months NA >= 20 yo 22.14 38.3,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low high
2785,Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100,  0 100 100 Critically low Methylphenidate methylphenidate Immediate release   0,NA Driving Clinician-rated At study endpoint (closest to 12 weeks),Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689 NA NA,Verster 2008 NA RCT (parallel, crossover, open-label),G, 18, 18,  36,outcomes NA, 0.8700000000 NA NA,  1.0000000,  3.1000000,NA,NA NA,NA,NA,NA,  0   0 100,100,100   0,100 low,low,low low high Placebo   0  39.000000 38.300000 NA NA,2 0,0.0,1.0,1.0 1.0,1 1,2 1,1,1,0,0.5 0,1 1 1  371,Verster_2008,< 2 months,NA,>= 20 yo 22.14 38.3,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high,high
2785 Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012 100,  0 100 100,Critically low,Methylphenidate methylphenidate Immediate release   0 NA,Driving Clinician-rated At study endpoint (closest to 12 weeks) Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689,NA,NA,Verster 2008,NA,RCT (parallel, crossover, open-label),G  18, 18,  36 outcomes,NA, 0.7700000000 NA,NA, 18.0000000, 47.6000000 NA,NA,NA NA NA NA,  0,  0 100,100,100   0 100 low,low low,low high,Placebo   0, 39.000000,38.300000 NA NA,2 0 0.0 1.0,1.0 1.0 1 1,2,1 1 1,0,0.5,0 1,1,1, 372,Verster_2008 < 2 months,NA >= 20 yo,22.14,38.3 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high,high
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0 100,100 Critically low Methylphenidate,methylphenidate Immediate release,  0,NA,Driving Clinician-rated At study endpoint (closest to 12 weeks),Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689,NA NA,Verster 2008,NA,RCT (parallel, crossover, open-label),G, 18, 18   36,outcomes NA  0.6400000000 NA,NA,  3.5000000,  4.0000000,NA NA,NA,NA NA NA,  0   0 100 100 100,  0,100 low,low,low,low,high Placebo,  0  39.000000,38.300000,NA,NA,2,0,0.0 1.0,1.0,1.0 1,1 2,1 1 1,0,0.5 0 1,1 1, 373 Verster_2008 < 2 months,NA >= 20 yo 22.14,38.3,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
2785,Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100   0,100 100,Critically low Methylphenidate methylphenidate Immediate release   0,NA Driving,Clinician-rated,At study endpoint (closest to 12 weeks) Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689 NA,NA Verster 2008 NA RCT (parallel, crossover, open-label) G, 18, 18   36,outcomes NA  0.6100000000,NA NA   3.5000000   4.0000000 NA,NA NA NA,NA NA,  0,  0 100 100 100,  0 100 low,low,low low,high Placebo,  0, 39.000000 38.300000 NA NA 2 0 0.0,1.0,1.0 1.0,1,1 2,1,1,1 0,0.5 0,1 1,1, 374,Verster_2008 < 2 months NA,>= 20 yo,22.14,38.3,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high high
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100   0 100 100,Critically low Methylphenidate methylphenidate Immediate release   0,NA,Driving,Clinician-rated,At study endpoint (closest to 12 weeks),Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689 NA NA,Verster,2008,NA,RCT (parallel, crossover, open-label) G, 18, 18   36,outcomes NA  0.0600000000,NA,NA, 20.1000000  16.8000000,NA NA,NA,NA,NA,NA   0   0 100,100 100,  0 100,low low,low low,high,Placebo,  0, 39.000000,38.300000 NA NA,2 0,0.0 1.0,1.0,1.0 1,1 2,1 1 1 0,0.5 0 1 1,1  375,Verster_2008 < 2 months NA >= 20 yo 22.14 38.3 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no high,high
 529 Candido (2021),Candido 2021,10.1002/14651858.CD013011.pub2,100,  0,100,100,High,Methylphenidate methylphenidate immediate release 100 mono,CGI,Clinician-rated,At study endpoint (closest to 12 weeks),Observational tool,Clinical impression: severity (change scores), 3.91254315,  40.0000000 mg/daily Schrantee 2016,NA RCT (parallel, crossover, open-label),MD  25, 24,  49,outcomes reverse -0.6000000000,-0.920000000,-2.800000e-01,NA NA NA,NA NA NA  0.6300000  0.5000000,  0   0 100 100,100,  0,100,low,low low some high Placebo,  0,  0.000000,28.600000 NA,DSM-IV, Diagnostic Interview
for ADHA in Adults (DIVA),0 1 1.0,1.0,1.0 1.0,1,1,0,1 1,1,1,1.0 1,1,1 1, 376,Schrantee_2016,2-6 months,NA,>= 20 yo,28.6,39,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Candido (2021)_Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Candido (2021) - Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
 529,Candido (2021),Candido 2021,10.1002/14651858.CD013011.pub2 100,  0,100 100 High Methylphenidate methylphenidate immediate release,100 mono,CGI,Clinician-rated,At study endpoint (closest to 12 weeks) Observational tool Clinical impression: severity (change scores)  1.61104718   10.0000000 mg/4-5timesad Kooij,2004 NA RCT (parallel, crossover, open-label),MD, 45, 45   90 NA,reverse,-0.4400000000,-1.050000000, 1.700000e-01,NA NA NA NA,NA NA  1.4700000  1.4700000,  0,  0 100,100,100,  0,100 some low,low,some high,Placebo,  0  46.670000 39.000000,NA,DSM-IV 0 1 1.0,1.0 1.0 1.0 1 1,0 1,1 1 1,1.0 1 1 1 1, 377,Kooij_2004 < 2 months NA >= 20 yo 28.6 39,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Candido (2021)_Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Candido (2021) - Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high high
 529,Candido (2021) Candido 2021 10.1002/14651858.CD013011.pub2,100,  0 100,100,High Methylphenidate methylphenidate immediate release,100 mono,CGI Clinician-rated,At study endpoint (closest to 12 weeks),Observational tool Clinical Global Impression Scale (CGI)  Improvement (-I) ; End scores  3.91254315   40.0000000 mg/daily Schrantee,2016,NA RCT (parallel, crossover, open-label) MD  25  24,  49,outcomes,reverse,-0.9400000000 -1.370000000 -5.100000e-01 NA NA NA,NA NA,NA, 0.8700000, 0.6600000,  0   0,100 100 100   0 100 low,low,low some,high,Placebo,  0   0.000000,28.600000,NA,DSM-IV, Diagnostic Interview
for ADHA in Adults (DIVA) 0,1,1.0,1.0 1.0,1.0 1 1,0,1 1,1 1 1.0 1,1 1,1  378 Schrantee_2016 2-6 months,NA >= 20 yo,28.6 39,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Candido (2021)_Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Candido (2021) - Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high high
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100,  0 100,100 High Methylphenidate,LA-MPH 100,Omega3/6,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) Questionnaire,ADHD-RS 11.96777906    0.6500000,mg/kg/d Barragan 2017 NA,RCT (parallel, crossover, open-label) G, 30  30   60,NA reverse -0.5100000000 -1.030000000, 0.000000e+00,NA,NA,NA,NA NA NA NA,NA   0   0   0   0   0 100,  0,high high high,high some,Active (any credible active intervention) 100, 33.300000, 8.270000 NA,DSM-IV-TR 0 1,1.0 1.0,1.0 1.0,1,1 0 1 1,1,1,1.0,1,1 1,1, 379 Barragan_2017 7-12 months NA,6-12 yo,8.27 8.4 100.4 100.4 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low,high
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100 100 100 100 High,Methylphenidate MPH,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,SNAP Inattention and Hyperactivity-Impulsivity subscale 13.80897583,  37.8000000,mg/d Jensen 1999 NA,RCT (parallel, crossover, open-label),G,133 129, 262,NA,reverse,-0.5800000000,-0.820000000,-3.300000e-01,NA,NA NA NA,NA NA NA NA,  0   0 100   0   0,100,  0,low,high high,high,low TAU   0  20.000000  8.400000,100.40000,DSM-IV,0,1,1.0,1.0,1.0,1.0 1 1 0,1,1 1 1,1.0,1 1 1 1  380,Jensen_1999 > 12 months,Average (80-119) 6-12 yo,8.27,8.4 100.4 100.4,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Storebo (2023)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low high
3425,Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3 100,  0,100,100 High,Methylphenidate ER-MPH   0,NA,Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks) Questionnaire,Child Health Questionnaire (CHQ), 1.38089758,  39.9000000,mg/d,Newcorn,2008 NA RCT (parallel, crossover, open-label),G 193, 64  257,NA NA, 0.5400000000  0.250000000  8.300000e-01,NA NA,NA NA,NA,NA,NA NA,100,100 100 100,100,100 100 some low,low low low,Placebo,  0, 28.200000,10.175097,NA,DSM-IV 0,1 1.0 1.0 1.0,1.0,1 1,0,1,1,1 1,1.0 1 1 1 1  381 Newcorn_2008 < 2 months,NA 6-12 yo 10.1750972762646 11.6 94.7,100 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,100,100 100 High,Methylphenidate,SODAS-MPH   0,NA,Quality of life (patients),Mixed At study endpoint (closest to 12 weeks) Questionnaire Childrens Global Assessment Scale (CGAS),NA,   0.7200000 mg/kg/d Szobot 2004 NA RCT (parallel, crossover, open-label),G  19  17,  36,NA,NA  0.7900000000, 0.100000000, 1.470000e+00,NA,NA NA NA,NA NA NA NA,100,100,100,100,100 100 100 low,low,low low some,Placebo,  0   0.000000,11.600000  94.70000 DSM-IV 0,1 1.0,1.0 1.0,1.0,1,1,0 1,1,1,1,1.0 1,1 1 1, 382 Szobot_2004 NA Average (80-119),6-12 yo 10.1750972762646 11.6,94.7,100,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3425 Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3 100,100,100 100,High,Methylphenidate,ER-MPH   0,NA Quality of life (patients),Mixed At study endpoint (closest to 12 weeks),Questionnaire Child Health and Illness Profile  2.76179517   45.4000000,mg/d Coghill 2013 NA,RCT (parallel, crossover, open-label),G 111,110, 221,NA NA, 0.6400000000, 0.370000000  9.100000e-01 NA,NA,NA,NA,NA NA,NA NA,100 100 100,100 100 100 100 low low,some,low,low Placebo,  0, 18.000000,10.900000,100.00000,DSM-IV-TR,0 1 1.0 1.0 1.0 1.0 1,1 0,1,1,1 1,1.0,1,1 1 1, 383,Coghill_2013,2-6 months,Average (80-119),6-12 yo,10.1750972762646,11.6,94.7 100 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Storebo (2023)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3425 Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3 100 100,100,100,High Methylphenidate MPH   0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Questionnaire Barkley Side Effects Rating Scale:, 0.23014960,   0.8000000 mg/kg/d,Barkley 1989 NA RCT (parallel, crossover, open-label) RR  82  82  164,NA,reverse, 7.4500000000, 3.510000000, 1.581000e+01,NA,NA,NA NA,NA NA NA NA 100,100,100,100 100,100,100 some,low some low low,Placebo   0, 14.450000, 8.200000 105.10000 DSM-III-R 0,1 1.0 1.0 1.0 1.0,1,1,0 1,1 1 1 1.0 1 1 1,1  384 Barkley_1989 < 2 months Average (80-119) 6-12 yo,4.76 15 85,109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425 Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0 100,100 High,Methylphenidate MPH,  0 NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Questionnaire,Barkley Side Effects Rating Scale, 0.46029919,   0.5000000,mg/kg/d,Bhat,2020,NA RCT (parallel, crossover, open-label),RR,526 526 1052 NA,reverse 18.2200000000 10.380000000, 3.197000e+01,NA NA NA NA NA,NA NA,NA,100 100,100,100,100,100 100,low,low some,low,low,Placebo   0  22.400000  9.030000 NA DSM-IV,0,1 1.0,1.0 1.0 1.0,1,1 0,1,1,1 1,1.0,1 1 1 1  385,Bhat_2020,< 2 months NA 6-12 yo,4.76,15,85 109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3425,Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3 100,  0 100 100 High,Methylphenidate ER-d-MPH   0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Interview,Spontaneously reported Aes, 0.46029919,  20.0000000 mg/d Brams,2012 NA,RCT (parallel, crossover, open-label),RR,163 159  322,NA reverse,21.8200000000, 1.270000000  3.756200e+02 NA NA,NA NA NA,NA NA,NA,100,100,100 100 100,100,100 low low low low some,Placebo,  0  38.400000, 9.500000 NA DSM-IV 0 1,1.0,1.0,1.0,1.0,1 1 0,1 1 1 1 1.0 1 1,1,1  386,Brams_2012,< 2 months,NA,6-12 yo,4.76 15,85 109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100,100 100,100 High Methylphenidate MPH   0,NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Questionnaire,Adverse effects checklist  2.30149597    0.6000000,mg/kg/d,Buitelaar 1995,NA,RCT (parallel, crossover, open-label),RR, 26  11   37 NA,reverse  0.8200000000  0.130000000  5.290000e+00 NA,NA,NA NA,NA NA,NA,NA 100,100 100 100,100 100,100,some low low,some some Placebo,  0, 11.500000  9.300000  94.20000 DSM-III-R,0 1,1.0 1.0,1.0,1.0 1,1 0 1,1 1,1 1.0 1 1 1,1  387 Buitelaar_1995 2-6 months,Average (80-119),6-12 yo,4.76,15,85,109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3425,Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100,  0 100 100 High,Methylphenidate MPH,  0 NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Questionnaire,Side Effects Rating Scale, 0.23014960    0.4500000,mg/kg/d Bukstein,1998,NA RCT (parallel, crossover, open-label) RR, 18  18,  36,NA,reverse  2.8100000000, 2.150000000, 3.680000e+00,NA NA NA,NA,NA NA NA,NA 100 100,100,100,100,100,100,some,low,low,low some Placebo   0  22.200000, 9.400000 NA,DSM-III-R 0,1 1.0,1.0,1.0 1.0 1 1 0 1,1 1 1,1.0,1 1 1 1, 388,Bukstein_1998 < 2 months,NA 6-12 yo,4.76 15,85 109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425,Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3,100 100 100,100,High,Methylphenidate,MPH   0 NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),AEs, 2.07134638,   0.9500000,mg/kg/d Castellanos 1997 NA,RCT (parallel, crossover, open-label),RR  22  22   44 NA reverse, 3.3200000000  0.320000000  3.465000e+01,NA,NA NA,NA NA NA,NA NA,  0,  0 100 100   0   0,100 some low,high some high Placebo,  0   0.000000  9.400000, 98.80000 DSM-III,0,1,1.0 1.0 1.0 1.0,1,1 0 1 1 1 1 1.0,1,1 1,1, 389,Castellanos_1997 2-6 months Average (80-119),6-12 yo,4.76 15 85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high,high
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0,100,100,High Methylphenidate MPH   0 NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Questionnaire,daily ratings of the presence and severity
of common stimulant side effects  1.38089758,   0.4500000,mg/kg/d,Chacko 2005 NA,RCT (parallel, crossover, open-label) RR  36, 36   72 NA,reverse, 6.5400000000, 1.320000000  3.244000e+01 NA,NA,NA NA,NA,NA NA NA,  0   0 100,100,100   0 100 some low,low,some,high Placebo   0, 11.000000  6.130000 NA,DSM-III-R 0 1,1.0 1.0 1.0 1.0 1,1,0,1 1 1,1,1.0,1 1 1,1, 390 Chacko_2005 < 2 months,NA 6-12 yo 4.76 15 85,109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100 100 100,100,High,Methylphenidate IR-MPH,  0,NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Questionnaire,Pittsburgh Side Effects Rating Scale, 1.84119678    0.6000000,mg/kg/d,Chronis 2003,NA RCT (parallel, crossover, open-label) RR, 21, 21,  42 NA reverse, 1.6000000000  0.410000000, 6.190000e+00,NA NA NA NA,NA,NA NA,NA 100,100,100,100,100,100 100 some low some low,low,Placebo,  0   9.500000,10.300000 109.90000 DSM-IV,0,1,1.0 1.0,1.0 1.0,1,1,0,1,1,1,1,1.0,1 1 1 1, 391 Chronis_2003 < 2 months Average (80-119) 6-12 yo,4.76 15 85,109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425 Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3,100   0 100,100 High Methylphenidate LA-MPH,  0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),Monitoring and reporting of Aes  1.84119678   40.0000000 mg/d CRIT124US02,NA NA RCT (parallel, crossover, open-label),RR 102,101  203,NA,reverse 30.7000000000, 1.860000000  5.062100e+02,NA,NA NA,NA NA NA,NA NA   0   0,100 100   0,  0 100,some low high,some high Placebo,  0 100.000000,13.800000,NA DSM/DISC-4,0 1 1.0 1.0,1.0 1.0,1,1 0 1 1 1,1 1.0,1 1 1,1, 392,CRIT124US02_NA,< 2 months,NA 13-19 yo 4.76,15 85,109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
3425 Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3 100   0 100,100 High Methylphenidate,MPH,  0 NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Questionnaire Barkley Side Effects Rating Scale, 0.92059839    0.5800000 mg/kg/d DuPaul 1996 NA,RCT (parallel, crossover, open-label),RR, 24, 24   48 NA reverse  2.1000000000  0.240000000  1.821000e+01,NA,NA NA,NA,NA,NA,NA,NA,100,100 100 100,100 100 100,low low,low,low,low,Placebo,  0, 20.800000 11.090000,NA,DSM-III-R 0 1 1.0 1.0,1.0 1.0 1,1,0 1 1 1 1,1.0,1,1,1 1, 393,DuPaul_1996 < 2 months NA 6-12 yo 4.76,15,85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0 100,100,High Methylphenidate MPH,  0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Questionnaire Side Effects/Behavior Monitoring Scale, 0.92059839,  30.0000000,mg/d,Findling 2007 NA RCT (parallel, crossover, open-label),RR, 16  16   32,NA reverse  6.8200000000  0.690000000, 6.691000e+01,NA NA,NA NA NA,NA,NA,NA,100,100,100,100,100 100 100,low low,low low,some Placebo,  0, 20.000000 10.430000 NA DSM-IV 0 1 1.0 1.0,1.0,1.0,1,1 0,1,1,1 1,1.0 1,1,1 1, 394 Findling_2007 < 2 months NA,6-12 yo 4.76,15,85 109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3425,Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3 100,  0,100 100,High,Methylphenidate MPH   0,NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Questionnaire,Side effects questionnaire:, 0.23014960,   0.9000000 mg/kg/d,Fine,1993 NA,RCT (parallel, crossover, open-label),RR  12, 12   24 NA,reverse, 2.0300000000  0.890000000, 4.660000e+00 NA,NA NA NA,NA NA NA NA 100 100,100,100,100,100,100,low low some,low,some,Placebo,  0,NA  8.500000 NA,DSM-III-R 0,1 1.0 1.0,1.0 1.0,1,1 0,1 1 1,1 1.0 1,1 1,1, 395,Fine_1993,< 2 months,NA,6-12 yo 4.76 15,85,109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3425,Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100,  0 100,100,High,Methylphenidate MPH,100 ER-MPH, Standard-MPH or combination Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Interview,Interviewed: 12 side effect symptoms: drawn from Subjects Treatment Emergent Symptom Scale, 0.46029919,  18.5000000,mg/d Fitzpatrick 1992,NA RCT (parallel, crossover, open-label),RR  19  19,  38 NA,reverse, 3.3800000000  0.320000000  3.579000e+01 NA NA NA NA NA,NA NA NA   0   0   0,100,100 100,100,high,low,some some some,Placebo   0, 10.500000, 8.710000,NA,DSM-III 0,1 1.0 1.0 1.0 1.0,1,1,0,1 1 1 1,1.0,1,1,1 1  396 Fitzpatrick_1992,< 2 months NA 6-12 yo,4.76 15,85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100,100,100 100,High Methylphenidate ER-MPH   0 NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Questionnaire,Pittsburgh Side Effect Rating Scale  0.92059839,  36.0000000 mg/d Froehlich 2018,NA,RCT (parallel, crossover, open-label),RR 171,171  342,NA,reverse  3.5000000000  1.180000000, 1.042000e+01,NA NA NA NA,NA NA,NA NA,  0   0 100 100,100,  0 100,low,low,low low,high,Placebo,  0  28.600000, 8.400000,105.60000 DSM-IV 0,1 1.0 1.0,1.0,1.0,1 1 0 1,1 1,1 1.0 1,1 1,1, 397 Froehlich_2018,< 2 months Average (80-119) 6-12 yo 4.76 15 85 109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
3425,Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3 100   0,100,100,High,Methylphenidate,LA-MPH,  0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Interview,A structured interview  0.46029919   30.0000000,mg/d,Huang 2021,NA RCT (parallel, crossover, open-label) RR,110,101, 211,NA reverse,48.6600000000  6.860000000, 3.453900e+02 NA NA NA NA,NA,NA NA NA,  0   0 100 100,100   0,100,some,some,low,some,high,Placebo,  0, 29.200000  9.160000 NA DSM-5 0,1 1.0 1.0 1.0,1.0,1 1 0,1 1,1 1 1.0,1 1,1 1, 398,Huang_2021 < 2 months,NA 6-12 yo 4.76,15 85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100 100 100,100,High,Methylphenidate MPH,  0,NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA  1.38089758   35.2100000,mg/d,Klorman,1990 NA RCT (parallel, crossover, open-label) RR  48  48,  96,NA,reverse  3.1900000000  1.040000000  9.830000e+00,NA,NA NA,NA NA NA NA,NA 100 100,100 100,100,100 100,low low some low,some,Placebo,  0, 12.500000 15.000000,108.62000,DSM-III 0 1 1.0,1.0,1.0 1.0,1,1,0 1,1 1,1,1.0 1,1,1 1  399,Klorman_1990 < 2 months,Average (80-119),13-19 yo,4.76,15 85 109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100,100 100,100,High Methylphenidate MPH   0,NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Questionnaire,Pittsburgh Side Effects Rating Scale  0.92059839   14.2200000,mg/d Kollins 2006,NA RCT (parallel, crossover, open-label) RR,136 160, 296,NA reverse, 1.0100000000, 0.450000000  2.260000e+00 NA,NA,NA NA,NA NA NA NA 100,100 100 100 100 100,100 low,low,low low low,Placebo,  0, 25.400000  4.760000, 97.45000 DSM-IV 0 1 1.0,1.0,1.0 1.0 1 1 0,1 1,1 1 1.0 1,1 1,1  400,Kollins_2006 < 2 months Average (80-119),< 6 yo 4.76,15,85 109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3425 Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0,100,100,High,Methylphenidate,MPH   0 NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Questionnaire,Side Effects Behavior Monitoring Scale, 0.92059839,   9.7000000,mg/d,Manos 1999 NA RCT (parallel, crossover, open-label),RR,177,177, 354,NA reverse, 2.7200000000, 1.300000000, 5.660000e+00,NA,NA,NA NA NA NA NA,NA,  0,  0,  0   0 100,100   0,high high some high some Placebo,  0,NA,10.100000,NA,DSM-IV,0 1 1.0,1.0,1.0,1.0,1,1 0 1,1,1,1,1.0,1 1,1 1, 401,Manos_1999 < 2 months NA 6-12 yo,4.76,15,85 109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
3425 Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100   0,100,100 High Methylphenidate MPH,  0,NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 0.92059839    0.7200000,mg/kg/d,McBride 1988,NA RCT (parallel, crossover, open-label),RR  48, 48   96 NA reverse, 8.0200000000, 0.950000000, 6.798000e+01,NA NA NA,NA NA NA,NA NA   0,  0   0 100,100,100,100,high,low low some,low Placebo   0  24.300000,11.500000 NA,DSM-III 0,1 1.0,1.0 1.0,1.0 1 1,0 1,1,1 1,1.0 1 1 1 1  402 McBride_1988,< 2 months,NA,6-12 yo 4.76,15 85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3 100   0,100 100 High Methylphenidate,MPH transdermal   0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  0.46029919   18.0000000,mg/d,McGough 2006 NA,RCT (parallel, crossover, open-label),RR  80  80  160 NA reverse, 5.1300000000, 0.240000000, 1.085100e+02 NA NA,NA NA,NA,NA,NA,NA,100,100 100 100,100 100,100 low low,low,low,low Placebo   0  28.000000, 9.100000,NA,DSM-IV-TR,0,1,1.0 1.0,1.0 1.0,1,1,0,1,1,1,1 1.0 1 1,1,1, 403,McGough_2006 < 2 months,NA,6-12 yo 4.76,15 85,109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100   0 100,100,High,Methylphenidate,ER-d-MPH   0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),monitoring and recording all Aes  1.15074799,  37.0000000 mg/d,Muniz,2008,NA,RCT (parallel, crossover, open-label) RR  84  83, 167,NA,reverse  3.0000000000  0.120000000  7.470000e+01,NA NA NA NA NA NA NA NA 100,100 100,100,100,100 100 some,low low,low low,Placebo   0, 34.500000, 9.500000,NA DSM-IV,0,1 1.0,1.0,1.0 1.0,1,1 0 1 1,1 1 1.0,1 1 1 1, 404,Muniz_2008,< 2 months,NA 6-12 yo 4.76,15 85,109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3425 Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,100,100 100,High Methylphenidate,MPH   0 NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Questionnaire,Side Effects Rating Scale (Barkley 1990)  0.69044879    0.8000000,mg/kg/d,Musten,1997 NA RCT (parallel, crossover, open-label),RR  41, 41   82,NA reverse, 3.2700000000  2.040000000, 5.240000e+00,NA NA NA NA,NA,NA NA,NA 100 100,100,100   0 100,100 low,low,high,low some Placebo,  0  12.200000  4.800000, 99.26000 DSM-III-R 0 1,1.0,1.0,1.0 1.0 1,1,0 1 1 1,1,1.0 1 1,1,1, 405 Musten_1997 < 2 months Average (80-119),< 6 yo 4.76 15,85 109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0,100 100 High,Methylphenidate MPH,  0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Questionnaire Pittsburgh Side Effect Rating Scale, 0.92059839,  36.0000000 mg/d,NCT02039908,NA NA,RCT (parallel, crossover, open-label),RR,138 129  267 NA,reverse, 1.0200000000, 0.810000000, 1.290000e+00,NA,NA NA NA NA NA,NA NA,100 100,100,100 100 100 100,some,some some,some low Placebo,  0, 20.200000, 9.000000 NA DSM-IV 0 1,1.0 1.0 1.0,1.0 1,1,0,1 1,1,1 1.0,1,1 1,1  406,NCT02039908_NA < 2 months NA 6-12 yo 4.76 15 85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100   0,100 100,High,Methylphenidate ER-MPH   0,NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA  0.92059839   45.0000000 mg/d,NCT02536105,NA NA RCT (parallel, crossover, open-label) RR, 80, 74  154 NA,reverse 37.9200000000  5.350000000, 2.688100e+02,NA NA,NA,NA NA,NA,NA NA   0   0 100,100 100   0,100,low low,low,low,high Placebo,  0  27.600000, 9.450000 NA DSM-5,0 1 1.0 1.0,1.0 1.0,1,1 0 1,1 1 1,1.0 1,1,1,1, 407,NCT02536105_NA,< 2 months NA,6-12 yo,4.76,15,85,109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high,high
3425,Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100,100,100 100 High,Methylphenidate MPH   0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  0.92059839    0.6900000 mg/kg/d Pearson 2013,NA,RCT (parallel, crossover, open-label),RR  24  24   48,NA,reverse,13.8000000000  1.580000000, 1.203800e+02,NA NA NA,NA,NA NA,NA,NA,100,100,100,  0,  0 100 100 low high high low low,Placebo,  0, 20.800000  8.800000, 85.00000,DSM-IV,0,1 1.0,1.0,1.0 1.0,1,1 0,1,1 1 1,1.0,1,1,1,1, 408,Pearson_2013 < 2 months Average (80-119) 6-12 yo 4.76,15,85,109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3 100,100 100 100 High Methylphenidate,IR-MPH or ER-MPH   0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Questionnaire side effect checklist,NA NA,NA,Pelham,1990 NA RCT (parallel, crossover, open-label) RR, 22  22   44,NA,reverse  4.0800000000, 1.110000000, 1.502000e+01,NA NA NA NA,NA,NA,NA,NA 100,100 100,100 100,100,100,some low,low some,some Placebo,  0   0.000000 10.390000 105.68000 DSM-III-R 0,1,1.0,1.0 1.0 1.0 1 1 0,1 1,1 1 1.0 1,1 1 1, 409 Pelham_1990 NA,Average (80-119),6-12 yo 4.76,15,85 109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3425,Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3,100,  0 100,100 High Methylphenidate IR-MPH   0,NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  1.38089758   27.0000000,mg/d,Pelham 1999,NA,RCT (parallel, crossover, open-label),RR  25, 25   50 NA,reverse, 2.8800000000, 0.500000000, 1.648000e+01,NA,NA NA,NA NA NA,NA,NA,100 100,100 100,100,100,100,some,some,some,some some,Placebo   0  16.000000  9.600000 NA DSM-IV 0,1 1.0 1.0,1.0,1.0 1 1,0,1,1 1,1,1.0,1 1,1 1  410,Pelham_1999,< 2 months NA 6-12 yo 4.76 15 85 109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3425 Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3,100,100 100,100,High,Methylphenidate,IR-MPH or ER-MPH,  0,NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Interview,parents provided responses to questions on Aes  0.69044879,   0.7500000 mg/kg/d Pelham,2001 NA RCT (parallel, crossover, open-label) RR, 68, 68  136,NA reverse  4.6400000000, 1.250000000, 1.729000e+01 NA,NA,NA,NA,NA NA NA NA 100 100 100 100,100 100 100 some low some low some,Placebo   0  11.000000  9.100000,104.80000,DSM-IV 0 1,1.0 1.0,1.0 1.0,1 1,0,1 1 1,1 1.0,1 1,1 1  411,Pelham_2001 < 2 months Average (80-119),6-12 yo,4.76,15,85,109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3425 Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3,100 100,100,100 High,Methylphenidate,MPH transdermal,  0,NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Questionnaire Pittsburgh Side Effects Rating Scale, 0.23014960    1.1250000,mg/h/d,Pelham,2005,NA,RCT (parallel, crossover, open-label) RR, 36  36   72 NA reverse,10.8200000000  2.240000000  5.229000e+01,NA NA,NA NA,NA NA,NA,NA 100,100,100,100,  0,100,100,some,low,high low some,Placebo   0,  8.300000, 9.600000,105.30000,DSM-IV,0 1,1.0,1.0,1.0 1.0,1 1 0 1 1,1,1,1.0,1 1,1,1  412,Pelham_2005,< 2 months Average (80-119) 6-12 yo 4.76,15 85,109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425,Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3,100,100,100 100,High,Methylphenidate,IR-MPH or transdermal-MPH   0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),AEs, 0.69044879   30.0000000 mg/d Pelham,2011 NA,RCT (parallel, crossover, open-label),RR  10  10   20,NA reverse, 1.7100000000, 0.220000000  1.341000e+01 NA,NA,NA,NA,NA,NA,NA,NA,100 100 100 100,100,100,100 some,low low,low some Placebo   0   0.000000  8.600000, 95.30000,DSM-IV,0,1,1.0 1.0,1.0,1.0 1 1,0,1,1,1,1 1.0,1 1 1 1  413 Pelham_2011 < 2 months Average (80-119) 6-12 yo 4.76 15,85,109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100 100 100 100 High Methylphenidate MPH,  0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Questionnaire Barkley Side Effect Rating Scale  1.38089758   35.0000000,mg/d,Ramtvedt 2013 NA RCT (parallel, crossover, open-label),RR, 34  34,  68,NA,reverse  1.7300000000, 1.070000000, 2.810000e+00,NA NA NA NA,NA NA NA NA 100,100 100,  0,100 100,100 some,high,some some,some,Placebo   0, 19.400000 11.400000, 90.90000,DSM-IV-TR 0,1 1.0,1.0 1.0,1.0 1 1 0,1,1 1 1,1.0 1,1 1,1, 414 Ramtvedt_2013 < 2 months Average (80-119),6-12 yo,4.76 15 85 109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100 100,100,100,High Methylphenidate,IR-MPH,  0 NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 1.15074799,  12.5000000,mg/d Rapport 2008,NA RCT (parallel, crossover, open-label) RR  65  65  130 NA reverse, 2.1100000000, 0.890000000, 5.010000e+00 NA,NA NA NA,NA,NA,NA,NA 100 100 100 100 100 100 100,low,low low low low,Placebo   0  10.700000  8.560000 102.80000 DSM-IV,0,1,1.0,1.0,1.0,1.0,1 1 0 1 1 1,1,1.0 1 1 1 1, 415 Rapport_2008 < 2 months Average (80-119),6-12 yo 4.76 15 85,109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0 100 100,High,Methylphenidate,ER-MPH   0,NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),NA, 0.69044879,  20.0000000 mg/d,Schulz,2010,NA RCT (parallel, crossover, open-label),RR,147,146, 293,NA,reverse  1.5000000000, 0.250000000  9.110000e+00,NA,NA,NA,NA,NA,NA NA,NA 100 100,100,100,100,100,100 some low low low some Placebo,  0, 19.000000,10.200000 NA,DSM-IV,0 1 1.0 1.0 1.0 1.0,1,1,0 1,1,1 1,1.0,1,1 1 1, 416 Schulz_2010,< 2 months NA 6-12 yo,4.76 15 85,109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100,  0 100 100,High Methylphenidate MPH,  0 NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  0.69044879    0.8650000 mg/kg/d,Sharp,1999,NA RCT (parallel, crossover, open-label),RR  48  48,  96 NA reverse,64.1200000000  3.730000000  1.101910e+03,NA,NA NA,NA,NA NA,NA NA 100 100,100,100,100 100,100,some low,some low,some Placebo,  0  43.000000  9.100000 NA,DSM-IV,0 1 1.0 1.0 1.0 1.0,1,1,0 1,1 1 1 1.0 1 1,1 1  417 Sharp_1999,< 2 months,NA,6-12 yo 4.76,15 85 109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0 100 100 High,Methylphenidate,ER-MPH   0 NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Interview Recorded AEs described  0.46029919,  20.0000000,mg/d Silva 2006,NA RCT (parallel, crossover, open-label) RR  54  54  108,NA,reverse 12.1100000000  0.650000000  2.246700e+02,NA,NA,NA NA NA NA NA NA 100,100,100,100,100 100 100 low,low,low,low,some Placebo   0, 30.000000  9.400000 NA DSM-IV 0 1,1.0 1.0 1.0,1.0,1,1,0 1,1,1 1 1.0 1,1 1 1, 418 Silva_2006,< 2 months,NA 6-12 yo,4.76 15,85,109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3425 Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3,100   0,100,100 High Methylphenidate MPH,  0 NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Questionnaire Stimulant Side Effects Rating Scale (SSERS), 1.15074799    0.7500000 mg/kg/d Stein 1996 NA RCT (parallel, crossover, open-label) RR  25, 25,  50 NA,reverse, 5.4600000000  1.630000000  1.836000e+01 NA NA NA,NA,NA NA NA NA 100,100,100,100 100,100 100 low low,low low,low Placebo,  0,  0.000000, 8.000000 NA,DSM-III-R,0 1 1.0 1.0,1.0 1.0,1,1,0 1 1 1 1 1.0,1,1,1,1  419,Stein_1996 < 2 months,NA 6-12 yo 4.76,15,85 109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3425 Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100 100,100 100,High,Methylphenidate,MPH   0 NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Questionnaire,Side Effect Rating Scale (SERS; Barkley 1990)  0.92059839,  36.0000000,mg/d,Stein,2003,NA,RCT (parallel, crossover, open-label),RR, 47  47   94,NA,reverse, 5.6500000000  2.320000000  1.377000e+01 NA,NA NA NA NA,NA NA,NA,  0,  0 100   0 100,  0 100 some high,some,low,high,Placebo,  0  30.000000, 9.020000,106.80000 DSM-IV 0,1,1.0 1.0,1.0 1.0 1 1,0 1 1,1,1,1.0 1,1,1,1, 420 Stein_2003,< 2 months,Average (80-119) 6-12 yo,4.76 15 85,109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high high
3425,Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100,  0,100 100 High Methylphenidate ER-MPH   0 NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Questionnaire Stimulant Side Effects Rating Scale (Barkley 1990), 1.84119678   20.0000000 mg/d,Stein,2011 NA,RCT (parallel, crossover, open-label) RR, 42  45   87 NA reverse  3.3800000000  0.340000000  3.389000e+01 NA,NA NA,NA,NA,NA,NA,NA,100,100,100,100 100,100 100,low,low low low,low Placebo   0  27.000000 11.780000,NA,DSM-IV 0 1,1.0,1.0 1.0 1.0 1,1 0,1 1 1,1 1.0,1,1,1,1  421 Stein_2011 < 2 months NA 6-12 yo,4.76,15 85 109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3,100,  0,100 100 High,Methylphenidate,ER-MPH   0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Questionnaire Barkley Side Effects Rating Scale  0.69044879   39.0000000 mg/d,Swanson 2004 NA,RCT (parallel, crossover, open-label),RR,181 183  364 NA,reverse, 6.2400000000  0.740000000  5.236000e+01 NA NA NA,NA,NA NA NA,NA,100 100,100,100 100 100,100 some low,low,some,some Placebo,  0, 26.000000  9.600000,NA,DSM-IV 0 1 1.0 1.0,1.0 1.0 1 1,0,1 1,1 1,1.0,1,1,1,1, 422,Swanson_2004 < 2 months NA 6-12 yo,4.76,15 85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3425 Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3 100   0,100,100,High Methylphenidate,MPH transdermal   0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),AEs, 0.92059839,  20.0000000 mg/d,Wilens,2010,NA,RCT (parallel, crossover, open-label),RR, 30  30,  60 NA reverse,47.0600000000  2.630000000  8.410900e+02 NA NA NA,NA,NA NA,NA NA 100 100 100,100,  0 100,100,some some,high,some low Placebo,  0, 16.600000, 9.170000 NA,DSM-IV 0 1,1.0 1.0,1.0,1.0 1 1,0 1 1 1,1 1.0,1 1 1 1, 423,Wilens_2010 < 2 months,NA 6-12 yo 4.76,15,85 109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100,  0 100 100 High,Methylphenidate,MPH 100,MPH and aripiprazol,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Questionnaire,Serious Adverse Event Rating Scale (SAERS), 0.92059839,  25.0000000,mg/d Zeni 2009,NA RCT (parallel, crossover, open-label),RR, 16  16   32,NA,reverse  0.8300000000  0.410000000  1.660000e+00,NA,NA,NA NA NA,NA,NA NA 100,100 100,100,100,100 100,low low low low low Placebo + aripiprazol,  0, 43.700000 10.710000 NA DSM-IV,0 1 1.0,1.0 1.0 1.0,1 1,0,1 1,1 1 1.0,1,1 1 1, 424 Zeni_2009 < 2 months NA 6-12 yo 4.76 15,85 109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100 100 100 100,High,Methylphenidate MPH,  0 NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Questionnaire Barkley Side Effects Rating Scale:, 0.23014960,   0.8000000,mg/kg/d,Barkley 1989 NA,RCT (parallel, crossover, open-label),RR, 82, 82  164 NA reverse, 3.2000000000, 1.680000000  6.070000e+00,NA NA NA,NA NA NA NA NA,100,100 100,100 100,100,100,some,low some low,low,Placebo,  0  14.450000, 8.200000 105.10000,DSM-III-R,0,1 1.0 1.0,1.0 1.0,1,1 0 1 1 1 1,1.0 1 1 1,1  425,Barkley_1989,< 2 months Average (80-119),6-12 yo,4.76 15,85 109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3425 Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3 100,  0,100 100 High Methylphenidate,MPH   0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Questionnaire Barkley Side Effects Rating Scale, 0.46029919    0.5000000 mg/kg/d,Bhat 2020,NA RCT (parallel, crossover, open-label) RR,526 526,1052 NA,reverse, 8.8200000000  4.850000000  1.604000e+01,NA NA,NA,NA,NA,NA NA NA 100,100,100 100,100,100,100 low low some,low,low Placebo,  0, 22.400000, 9.030000,NA DSM-IV 0 1 1.0 1.0 1.0,1.0,1 1,0 1 1 1 1,1.0,1,1,1,1, 426,Bhat_2020 < 2 months,NA 6-12 yo 4.76,15,85 109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3 100   0 100,100 High,Methylphenidate ER-d-MPH   0,NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Interview Spontaneously reported Aes, 0.46029919,  20.0000000,mg/d,Brams,2012 NA RCT (parallel, crossover, open-label) RR,163 159, 322 NA,reverse  6.9600000000, 0.360000000, 1.357800e+02,NA NA NA,NA NA NA,NA NA 100,100 100 100 100 100 100 low low low,low,some,Placebo,  0, 38.400000, 9.500000,NA DSM-IV 0 1 1.0,1.0 1.0,1.0,1 1 0 1 1 1 1,1.0,1,1 1 1  427,Brams_2012 < 2 months NA 6-12 yo 4.76 15 85 109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100,100,100 100,High Methylphenidate MPH   0,NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Questionnaire Adverse effects checklist, 2.30149597    0.6000000,mg/kg/d Buitelaar,1995,NA,RCT (parallel, crossover, open-label),RR, 26, 11,  37,NA reverse  1.6700000000  0.360000000  7.810000e+00,NA NA,NA,NA NA,NA,NA,NA 100 100,100,100,100,100 100 some low,low some some Placebo,  0, 11.500000  9.300000, 94.20000 DSM-III-R,0,1 1.0,1.0,1.0,1.0,1 1,0,1 1,1 1 1.0 1 1 1 1  428 Buitelaar_1995 2-6 months,Average (80-119) 6-12 yo 4.76 15,85 109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3425,Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100 100,100,100,High Methylphenidate,MPH,  0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) AEs  2.07134638,   0.9500000 mg/kg/d,Castellanos,1997,NA RCT (parallel, crossover, open-label) RR  22  22   44 NA reverse, 2.1000000000  0.180000000  2.501000e+01 NA,NA NA,NA NA,NA,NA,NA   0   0,100 100,  0,  0 100,some,low,high,some,high,Placebo   0,  0.000000, 9.400000  98.80000,DSM-III 0 1 1.0,1.0 1.0,1.0 1,1 0,1 1,1 1 1.0 1 1,1,1  429 Castellanos_1997,2-6 months,Average (80-119),6-12 yo 4.76,15,85,109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,100,100 100,High Methylphenidate IR-MPH   0,NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Questionnaire Pittsburgh Side Effects Rating Scale  1.84119678    0.6000000 mg/kg/d,Chronis,2003 NA,RCT (parallel, crossover, open-label) RR, 21  21,  42 NA,reverse, 0.7500000000, 0.170000000  3.310000e+00,NA NA NA NA NA NA,NA NA 100,100 100 100 100,100 100,some,low some,low low Placebo,  0   9.500000 10.300000 109.90000,DSM-IV 0 1,1.0,1.0 1.0,1.0 1 1 0,1 1,1 1,1.0,1 1,1,1, 430 Chronis_2003,< 2 months,Average (80-119) 6-12 yo,4.76 15 85 109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0 100 100 High,Methylphenidate,IR-MPH,  0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) Sleep Disturbances Scale for Children; Actigraphy; Sleep diary  0.69044879   30.0000000 mg/d Corkum,2008 NA,RCT (parallel, crossover, open-label),RR  21  21,  42,NA reverse  2.9500000000  1.540000000  5.660000e+00,NA NA NA,NA NA,NA NA NA 100 100 100 100,100,100,100,low low some,low low Placebo   0, 28.500000, 9.000000,NA,DSM-IV 0,1,1.0 1.0,1.0,1.0,1 1 0 1 1,1,1 1.0,1 1 1 1  431 Corkum_2008,< 2 months NA 6-12 yo,4.76,15 85 109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3425,Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3 100   0 100,100,High Methylphenidate LA-MPH   0 NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) Monitoring and reporting of Aes, 1.84119678   40.0000000 mg/d CRIT124US02,NA,NA RCT (parallel, crossover, open-label),RR 102 101  203 NA,reverse, 0.9900000000, 0.300000000, 3.320000e+00 NA NA NA,NA NA,NA,NA NA,  0,  0 100 100,  0,  0 100 some,low high,some high Placebo,  0,100.000000,13.800000 NA DSM/DISC-4 0,1 1.0,1.0,1.0,1.0 1,1,0 1 1 1 1 1.0 1,1,1,1  432 CRIT124US02_NA < 2 months,NA,13-19 yo 4.76 15 85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100   0 100,100 High,Methylphenidate MPH,  0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Questionnaire Barkley Side Effects Rating Scale, 0.92059839    0.5800000,mg/kg/d DuPaul 1996,NA RCT (parallel, crossover, open-label),RR, 24  24   48,NA reverse, 1.3600000000  0.770000000  2.410000e+00,NA,NA NA NA,NA,NA NA,NA,100,100 100 100,100,100,100 low,low,low,low low,Placebo   0, 20.800000,11.090000,NA,DSM-III-R 0,1 1.0 1.0,1.0,1.0 1,1 0,1,1,1 1 1.0 1,1,1 1  433 DuPaul_1996 < 2 months,NA 6-12 yo,4.76 15,85,109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3425,Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3 100,  0 100,100,High,Methylphenidate MPH,  0 NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Questionnaire Side Effects/Behavior Monitoring Scale, 0.92059839,  30.0000000 mg/d Findling 2007 NA RCT (parallel, crossover, open-label) RR  16, 16,  32 NA,reverse  3.1800000000, 0.520000000  1.964000e+01,NA,NA,NA,NA NA NA NA NA,100 100,100,100 100,100,100 low low low,low some,Placebo,  0, 20.000000,10.430000 NA DSM-IV 0,1 1.0 1.0,1.0 1.0,1,1,0 1 1 1 1 1.0,1,1 1,1  434 Findling_2007,< 2 months NA 6-12 yo,4.76,15 85 109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3425 Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3 100   0,100 100 High,Methylphenidate MPH,  0,NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Questionnaire,Side effects questionnaire:  0.23014960,   0.9000000,mg/kg/d,Fine 1993,NA,RCT (parallel, crossover, open-label),RR  12  12   24,NA reverse  1.4100000000, 0.630000000, 3.170000e+00 NA,NA,NA NA NA,NA NA,NA,100,100,100 100,100,100 100 low,low some low some Placebo,  0,NA  8.500000 NA,DSM-III-R 0 1,1.0 1.0,1.0,1.0 1,1,0,1,1,1 1,1.0 1 1 1 1, 435,Fine_1993,< 2 months NA,6-12 yo,4.76,15,85 109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100,  0,100,100 High,Methylphenidate MPH,100 ER-MPH, Standard-MPH or combination Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Interview Interviewed: 12 side effect symptoms: drawn from Subjects Treatment Emergent Symptom Scale, 0.46029919,  18.5000000,mg/d Fitzpatrick 1992 NA,RCT (parallel, crossover, open-label),RR, 19, 19,  38,NA,reverse  3.8800000000  0.840000000, 1.796000e+01,NA,NA NA NA NA,NA NA,NA,  0   0,  0 100,100 100 100 high low some,some,some,Placebo   0  10.500000, 8.710000,NA DSM-III,0,1,1.0 1.0 1.0 1.0,1,1 0 1,1,1,1,1.0,1 1,1,1  436 Fitzpatrick_1992 < 2 months NA 6-12 yo 4.76,15 85,109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
3425 Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3 100,100,100,100 High,Methylphenidate ER-MPH,  0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Questionnaire,Pittsburgh Side Effect Rating Scale  0.92059839,  36.0000000 mg/d Froehlich,2018,NA RCT (parallel, crossover, open-label),RR 171 171  342 NA reverse 14.0000000000  1.860000000  1.052900e+02 NA NA,NA NA NA,NA NA NA,  0   0 100,100,100   0,100 low,low,low,low,high Placebo,  0  28.600000  8.400000 105.60000,DSM-IV,0,1 1.0,1.0,1.0 1.0,1 1,0,1 1 1 1,1.0 1,1,1,1  437 Froehlich_2018,< 2 months Average (80-119),6-12 yo,4.76,15 85 109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
3425 Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100   0,100,100,High,Methylphenidate,LA-MPH,  0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Interview A structured interview, 0.46029919,  30.0000000,mg/d Huang 2021 NA,RCT (parallel, crossover, open-label),RR,110 101  211 NA reverse 41.3500000000  2.540000000  6.728500e+02,NA,NA,NA,NA,NA,NA,NA NA,  0,  0,100 100 100,  0 100 some some low,some,high Placebo   0, 29.200000, 9.160000,NA,DSM-5,0,1 1.0 1.0 1.0 1.0 1 1,0 1,1,1 1,1.0,1,1,1,1  438 Huang_2021,< 2 months,NA,6-12 yo,4.76 15 85 109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3 100,100 100,100 High,Methylphenidate MPH,  0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.38089758,  35.2100000,mg/d,Klorman 1990 NA RCT (parallel, crossover, open-label) RR  48  48   96 NA,reverse  1.1700000000  0.390000000  3.530000e+00,NA NA,NA NA,NA NA NA NA,100 100 100,100,100,100 100 low,low some,low,some,Placebo,  0  12.500000,15.000000 108.62000 DSM-III,0,1,1.0 1.0 1.0 1.0 1 1 0,1,1 1,1 1.0,1 1,1 1  439,Klorman_1990 < 2 months Average (80-119),13-19 yo,4.76,15 85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100,100 100,100,High,Methylphenidate,MPH,  0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Questionnaire Parent Adverse Events Checklist  0.92059839   14.2200000 mg/d Kollins,2006 NA,RCT (parallel, crossover, open-label) RR 136,160  296,NA,reverse, 1.2000000000, 0.530000000, 2.670000e+00,NA NA,NA NA NA,NA NA,NA 100 100 100 100,100 100 100 low,low,low low,low Placebo,  0  25.400000, 4.760000, 97.45000 DSM-IV,0,1 1.0 1.0 1.0 1.0 1 1,0 1 1,1,1 1.0 1,1 1,1, 440,Kollins_2006 < 2 months,Average (80-119) < 6 yo,4.76,15,85 109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425,Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100   0 100,100 High Methylphenidate,MPH   0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Questionnaire,Side Effects Behavior Monitoring Scale  0.92059839,   9.7000000 mg/d,Manos,1999,NA RCT (parallel, crossover, open-label),RR 177,177  354,NA reverse  2.4500000000  0.920000000, 6.520000e+00,NA,NA NA NA NA NA,NA NA   0   0,  0,  0 100,100   0 high high some,high some Placebo,  0,NA,10.100000 NA DSM-IV,0,1,1.0,1.0 1.0,1.0,1,1,0 1 1,1 1,1.0,1 1,1,1  441 Manos_1999,< 2 months NA,6-12 yo 4.76 15,85,109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100   0,100 100 High,Methylphenidate ER-d-MPH   0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) monitoring and recording all Aes  1.15074799   37.0000000 mg/d Muniz,2008 NA RCT (parallel, crossover, open-label),RR  84  83, 167,NA,reverse  3.0000000000  0.120000000, 7.470000e+01 NA,NA,NA NA,NA,NA NA NA 100 100 100 100 100,100 100,some low,low low,low,Placebo   0  34.500000  9.500000,NA DSM-IV,0,1 1.0,1.0,1.0,1.0 1,1,0 1 1,1,1,1.0,1,1 1,1, 442,Muniz_2008,< 2 months NA 6-12 yo 4.76,15,85 109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3425 Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3 100,100 100 100 High,Methylphenidate,MPH,  0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Questionnaire,Side Effects Rating Scale (Barkley 1990), 0.69044879,   0.8000000,mg/kg/d,Musten 1997 NA RCT (parallel, crossover, open-label),RR  41  41,  82 NA reverse, 0.4900000000, 0.310000000, 7.600000e-01 NA NA NA NA,NA NA NA,NA,100,100 100 100,  0 100 100 low low high,low some,Placebo   0  12.200000, 4.800000, 99.26000 DSM-III-R 0 1 1.0 1.0,1.0,1.0,1,1 0,1 1 1 1,1.0,1 1 1,1  443,Musten_1997 < 2 months Average (80-119),< 6 yo 4.76,15 85,109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0,100 100 High,Methylphenidate,MPH   0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Questionnaire Pittsburgh Side Effect Rating Scale  0.92059839   36.0000000 mg/d NCT02039908 NA NA RCT (parallel, crossover, open-label) RR 138,129, 267 NA reverse  1.0100000000  0.750000000, 1.350000e+00,NA NA NA,NA NA NA,NA NA 100 100,100 100 100,100,100,some some some some,low Placebo,  0  20.200000  9.000000 NA DSM-IV 0,1 1.0 1.0 1.0,1.0 1 1,0,1,1,1,1 1.0 1 1 1,1, 444 NCT02039908_NA < 2 months NA 6-12 yo 4.76 15 85 109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3425 Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100   0 100,100 High Methylphenidate ER-MPH,  0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA, 0.92059839   45.0000000 mg/d,NCT02536105 NA,NA,RCT (parallel, crossover, open-label),RR, 80  74, 154,NA,reverse 28.6700000000  4.010000000, 2.048000e+02 NA NA NA NA,NA NA,NA,NA   0   0 100,100,100   0,100,low,low,low,low high Placebo,  0, 27.600000, 9.450000,NA DSM-5,0 1,1.0 1.0,1.0 1.0,1 1 0 1,1,1 1,1.0 1 1,1,1  445 NCT02536105_NA,< 2 months NA 6-12 yo 4.76,15,85 109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high,high
3425 Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3,100,100 100,100,High Methylphenidate,MPH   0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  0.92059839    0.6900000 mg/kg/d Pearson 2013 NA,RCT (parallel, crossover, open-label),RR  24  24   48 NA reverse, 3.8000000000, 1.070000000, 1.352000e+01,NA,NA NA NA,NA NA,NA,NA,100,100 100   0   0,100 100,low,high,high low low,Placebo   0  20.800000  8.800000  85.00000,DSM-IV,0 1,1.0,1.0,1.0 1.0,1,1 0 1 1 1 1,1.0 1,1,1,1, 446 Pearson_2013 < 2 months,Average (80-119) 6-12 yo,4.76,15,85 109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425,Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100 100,100 100,High Methylphenidate IR-MPH or ER-MPH,  0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Questionnaire side effect checklist NA NA NA,Pelham 1990 NA,RCT (parallel, crossover, open-label),RR  22  22   44,NA,reverse, 4.6700000000, 0.270000000  7.963000e+01 NA NA NA NA NA,NA NA,NA,100,100,100,100 100 100,100 some,low,low,some,some Placebo,  0   0.000000,10.390000 105.68000 DSM-III-R,0 1 1.0 1.0,1.0 1.0 1,1,0,1,1,1 1,1.0,1 1,1,1, 447 Pelham_1990 NA Average (80-119),6-12 yo 4.76,15,85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100,  0 100,100 High,Methylphenidate,IR-MPH   0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA  1.38089758   27.0000000,mg/d,Pelham,1999 NA,RCT (parallel, crossover, open-label) RR, 25  25,  50 NA reverse, 2.3200000000  0.510000000  1.054000e+01,NA,NA,NA,NA,NA NA NA NA 100,100,100 100 100,100,100,some,some,some,some,some Placebo,  0  16.000000, 9.600000 NA,DSM-IV,0,1 1.0 1.0 1.0 1.0 1,1 0,1,1,1,1 1.0 1,1,1 1, 448 Pelham_1999 < 2 months,NA 6-12 yo 4.76 15 85 109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100 100,100 100 High Methylphenidate,IR-MPH or ER-MPH,  0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Interview,parents provided responses to questions on Aes  0.69044879    0.7500000 mg/kg/d,Pelham 2001 NA,RCT (parallel, crossover, open-label),RR  68  68, 136 NA reverse, 0.6900000000, 0.210000000, 2.300000e+00,NA NA,NA,NA,NA NA NA,NA 100,100 100,100,100,100 100,some,low some,low,some Placebo,  0  11.000000  9.100000 104.80000 DSM-IV,0 1,1.0 1.0,1.0,1.0 1,1 0 1,1,1,1 1.0 1 1,1,1, 449 Pelham_2001 < 2 months Average (80-119),6-12 yo,4.76,15,85 109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3425 Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3,100 100 100,100 High Methylphenidate,MPH transdermal,  0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Questionnaire Pittsburgh Side Effects Rating Scale, 0.23014960    1.1250000 mg/h/d,Pelham,2005,NA RCT (parallel, crossover, open-label) RR  36  36   72 NA reverse, 2.6600000000, 0.630000000  1.122000e+01 NA,NA,NA NA NA,NA NA NA 100 100 100,100,  0,100,100,some low high,low some,Placebo,  0,  8.300000  9.600000,105.30000 DSM-IV,0,1,1.0 1.0,1.0,1.0 1,1,0 1 1 1,1,1.0 1,1 1 1  450 Pelham_2005 < 2 months,Average (80-119),6-12 yo 4.76 15 85 109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100 100 100 100 High Methylphenidate,MPH   0,NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Questionnaire,Barkley Side Effect Rating Scale  1.38089758   35.0000000 mg/d Ramtvedt 2013 NA RCT (parallel, crossover, open-label) RR, 34  34,  68 NA,reverse, 1.3200000000, 0.820000000, 2.130000e+00 NA,NA NA,NA NA,NA,NA NA 100 100,100   0,100,100,100,some,high,some,some some Placebo,  0  19.400000,11.400000, 90.90000,DSM-IV-TR,0 1,1.0,1.0 1.0,1.0 1,1 0,1,1 1 1 1.0,1,1 1,1, 451,Ramtvedt_2013,< 2 months Average (80-119) 6-12 yo 4.76 15 85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3425,Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3,100 100,100,100,High Methylphenidate IR-MPH,  0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 1.15074799,  12.5000000 mg/d Rapport,2008,NA RCT (parallel, crossover, open-label) RR, 65, 65, 130,NA,reverse  0.6900000000, 0.210000000, 2.300000e+00 NA,NA NA,NA NA NA,NA NA 100,100,100,100,100 100 100 low,low low low low,Placebo   0, 10.700000, 8.560000 102.80000 DSM-IV 0,1,1.0,1.0 1.0 1.0 1,1,0 1,1,1 1,1.0 1,1,1 1  452 Rapport_2008,< 2 months Average (80-119),6-12 yo,4.76,15,85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100,  0,100 100 High,Methylphenidate,MPH   0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA  0.69044879    0.8650000,mg/kg/d,Sharp,1999,NA,RCT (parallel, crossover, open-label) RR  48  48,  96 NA reverse  2.2000000000  0.910000000  5.350000e+00,NA,NA,NA,NA NA,NA,NA,NA,100 100,100,100 100 100,100 some low some,low,some Placebo,  0, 43.000000, 9.100000,NA DSM-IV 0 1,1.0 1.0 1.0,1.0,1 1,0,1 1 1 1 1.0 1,1 1,1, 453,Sharp_1999,< 2 months,NA 6-12 yo 4.76,15 85,109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100   0 100 100,High Methylphenidate ER-MPH,  0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Interview,Recorded AEs described  0.46029919,  20.0000000 mg/d,Silva 2006,NA RCT (parallel, crossover, open-label) RR  54  54, 108 NA reverse, 5.1900000000  0.240000000, 1.106900e+02 NA NA,NA,NA NA,NA,NA NA 100,100,100,100 100 100 100,low,low low low some Placebo,  0, 30.000000, 9.400000 NA,DSM-IV 0 1 1.0 1.0 1.0,1.0 1 1,0 1,1 1 1 1.0 1,1,1,1, 454 Silva_2006,< 2 months,NA,6-12 yo,4.76 15,85,109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100   0 100 100 High,Methylphenidate,MPH   0,NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Observational tool Sleep log, 1.15074799    0.7500000 mg/kg/d Stein 1996 NA,RCT (parallel, crossover, open-label),RR  25  25   50,NA,reverse  1.6200000000, 0.530000000, 4.980000e+00,NA,NA NA NA,NA NA,NA,NA,100 100 100 100,100,100,100 low,low,low low,low Placebo   0,  0.000000, 8.000000 NA,DSM-III-R 0,1 1.0 1.0,1.0 1.0 1,1,0,1 1,1 1 1.0,1,1 1,1  455,Stein_1996,< 2 months NA,6-12 yo,4.76 15,85,109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100,100 100 100 High,Methylphenidate,MPH,  0,NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Questionnaire,Side Effect Rating Scale (SERS; Barkley 1990)  0.92059839   36.0000000,mg/d,Stein,2003,NA RCT (parallel, crossover, open-label),RR  47, 47   94,NA reverse, 2.1800000000, 0.960000000, 5.000000e+00,NA,NA NA NA,NA,NA NA NA   0   0,100   0 100,  0,100 some high,some low high Placebo   0, 30.000000, 9.020000,106.80000 DSM-IV 0,1,1.0 1.0 1.0 1.0 1 1,0,1 1 1,1 1.0,1,1,1 1  456,Stein_2003 < 2 months,Average (80-119),6-12 yo 4.76,15,85,109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high high
3425 Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3 100   0 100 100 High Methylphenidate ER-MPH   0 NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Observational tool Sleep measured by actigraphy and questionnaires  1.84119678,  20.0000000,mg/d Stein,2011 NA,RCT (parallel, crossover, open-label) RR, 42, 45   87,NA reverse  1.6500000000, 0.260000000  1.042000e+01,NA NA NA NA,NA NA,NA,NA 100,100 100 100,100 100,100,low low low,low,low Placebo,  0, 27.000000,11.780000 NA DSM-IV,0,1 1.0,1.0,1.0,1.0 1 1 0 1,1 1,1 1.0 1 1 1 1, 457,Stein_2011 < 2 months,NA,6-12 yo 4.76,15 85,109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100   0,100,100,High,Methylphenidate ER-MPH,  0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Questionnaire Barkley Side Effects Rating Scale, 0.69044879   39.0000000,mg/d,Swanson 2004,NA RCT (parallel, crossover, open-label),RR 181,183  364 NA reverse  0.5000000000  0.120000000  2.020000e+00,NA NA,NA NA NA,NA,NA NA,100 100,100,100,100 100,100,some low low,some,some Placebo,  0  26.000000  9.600000 NA,DSM-IV 0,1 1.0,1.0 1.0,1.0 1,1,0 1 1,1,1,1.0,1,1,1 1  458,Swanson_2004 < 2 months,NA,6-12 yo,4.76,15 85 109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425 Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3 100,  0 100,100 High Methylphenidate MPH-MLR,  0 NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  0.46029919   32.0000000,mg/d,Wigal 2014,NA RCT (parallel, crossover, open-label),RR  21  22   43 NA reverse  0.3500000000, 0.010000000  8.110000e+00 NA NA,NA NA NA,NA NA,NA   0,  0   0 100 100 100 100 high low low,low low,Placebo   0  38.000000  8.700000,NA DSM-IV-TR/KSADS,0 1 1.0,1.0 1.0,1.0 1,1 0 1 1 1 1 1.0 1,1 1 1  459 Wigal_2014,< 2 months NA,6-12 yo 4.76,15,85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3 100,  0,100 100 High Methylphenidate,MPH transdermal,  0,NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),AEs, 0.92059839   20.0000000,mg/d Wilens 2010 NA,RCT (parallel, crossover, open-label),RR  30  30   60,NA reverse 23.0400000000, 1.260000000  4.203500e+02 NA NA NA NA,NA,NA,NA,NA 100,100,100 100   0,100,100 some,some,high some low,Placebo,  0  16.600000  9.170000 NA DSM-IV 0,1 1.0,1.0 1.0,1.0 1,1,0 1 1 1,1,1.0,1,1,1,1  460 Wilens_2010 < 2 months,NA,6-12 yo,4.76 15 85,109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0,100 100 High Methylphenidate MPH 100 MPH and aripiprazol,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Questionnaire Serious Adverse Event Rating Scale (SAERS), 0.92059839,  25.0000000,mg/d,Zeni 2009,NA,RCT (parallel, crossover, open-label),RR, 16, 16   32 NA reverse, 0.9600000000  0.480000000  1.920000e+00,NA NA NA NA NA NA,NA,NA 100 100,100 100 100,100 100 low low low low low Placebo + aripiprazol   0  43.700000 10.710000 NA DSM-IV,0 1,1.0,1.0,1.0,1.0,1,1 0,1 1,1,1,1.0,1 1,1,1  461,Zeni_2009,< 2 months,NA 6-12 yo 4.76,15,85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100   0,100,100 High,Methylphenidate,ER-MPH   0,NA,Suicidal ideation/behavior Mixed,At study endpoint (closest to 12 weeks),Questionnaire,C-SSRS, 0.23014960,   0.4000000 mg/d Childress,2017 NA RCT (parallel, crossover, open-label) RR  44, 41,  85 outcomes,reverse, 0.9333333333, 0.018943386  4.598497e+01 NA NA,NA NA NA NA NA,NA 100,100,100 100,100 100 100,some,some low some low Placebo   0  34.100000, 9.200000,NA,DSM-IV-TR 0,1,1.0,1.0,1.0 1.0 1,1,0 1 1 1,1 1.0 1 1,1 1  462,Childress_2017 < 2 months,NA 6-12 yo 9 14.7,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100   0,100,100,High Methylphenidate ER-MPH   0,NA,Suicidal ideation/behavior Mixed,At study endpoint (closest to 12 weeks),Questionnaire,C-SSRS, 0.23014960,  55.0000000,mg/d,Childress,2020 NA RCT (parallel, crossover, open-label) RR  74  73, 147,outcomes,reverse, 0.9866666667  0.019837640, 4.907394e+01 NA NA,NA NA,NA,NA NA NA,100,100 100 100 100,100,100 low,low low,low low,Placebo   0  34.600000, 9.400000 NA DSM-5,0 1 1.0 1.0,1.0,1.0,1 1 0 1,1 1,1 1.0,1 1 1 1  463 Childress_2020,< 2 months,NA,6-12 yo 9,14.7,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3425,Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3,100   0 100,100 High,Methylphenidate MPH,  0 NA Suicidal ideation/behavior Mixed At study endpoint (closest to 12 weeks) Questionnaire C-SSRS  0.92059839,NA,NA NCT02293655 NA,NA,RCT (parallel, crossover, open-label),RR  18  92  110,NA reverse, 1.6315789474, 0.069059072  3.854743e+01 NA,NA NA,NA,NA NA,NA NA,  0,  0 100 100,100,  0 100 some low,some low,high Placebo,  0, 34.000000, 9.000000,NA,DSM-5,0,1 1.0,1.0 1.0 1.0,1 1 0,1,1,1,1,1.0 1 1,1 1  464 NCT02293655_NA,< 2 months,NA,6-12 yo 9 14.7 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high,high
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3,100   0 100,100,High Methylphenidate ER-MPH   0 NA Suicidal ideation/behavior,Mixed At study endpoint (closest to 12 weeks),Questionnaire,C-SSRS  1.84119678   44.4700000,mg/d Newcorn,2017a,NA RCT (parallel, crossover, open-label),RR 184, 91  275,NA,reverse, 0.4972972973, 0.009946719  2.486293e+01 NA NA NA,NA NA,NA,NA,NA 100 100,100 100   0,100,100,some low high some low Placebo   0, 33.600000 14.700000,NA,DSM-IV-TR,0 1,1.0,1.0,1.0,1.0 1 1,0 1,1,1 1,1.0 1 1 1 1, 465 Newcorn_2017a < 2 months,NA,13-19 yo 9,14.7,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100,  0 100 100,High Methylphenidate,ER-MPH,  0 NA,Suicidal ideation/behavior Mixed At study endpoint (closest to 12 weeks) Questionnaire,C-SSRS, 1.38089758,  45.0000000,mg/d,Newcorn,2017b,NA RCT (parallel, crossover, open-label) RR 219,110, 329,NA reverse, 0.5045454545, 0.010078225, 2.525902e+01 NA NA,NA NA NA,NA NA NA 100 100 100 100   0,100,100,some low,high,some,low Placebo   0, 34.000000,14.700000,NA DSM-IV-TR,0,1,1.0,1.0 1.0,1.0,1 1,0,1,1 1 1 1.0,1 1,1,1  466 Newcorn_2017b < 2 months NA,13-19 yo 9,14.7,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425,Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3,100   0 100,100,High,Methylphenidate,ER-MPH,  0 NA,Suicidal ideation/behavior Mixed At study endpoint (closest to 12 weeks),Questionnaire C-SSRS  0.23014960,  40.0000000 mg/d,Wigal,2017,NA RCT (parallel, crossover, open-label),RR  42  44,  86 outcomes reverse, 1.0465116279  0.021234712, 5.157530e+01,NA NA NA NA,NA NA NA,NA 100 100 100,100,100,100 100 low some,low,low low,Placebo,  0  37.600000, 9.600000 NA DSM-IV-TR/KSADS 0,1 1.0 1.0,1.0 1.0 1,1,0 1 1,1,1,1.0,1,1 1,1  467,Wigal_2017,< 2 months,NA,6-12 yo,9,14.7,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100,  0 100,100 High Methylphenidate ER-MPH,  0,NA Suicidal ideation/behavior Mixed At study endpoint (closest to 12 weeks),Questionnaire,C-SSRS, 0.23014960   55.0000000 mg/d,Childress 2020 NA RCT (parallel, crossover, open-label),RR, 74, 73, 147,outcomes,reverse  0.9866666667  0.019837640, 4.907394e+01 NA NA,NA,NA NA,NA NA,NA,100 100,100 100 100 100,100,low,low low,low,low,Placebo   0  34.600000  9.400000,NA,DSM-5,0 1 1.0 1.0 1.0 1.0,1,1,0,1,1,1 1,1.0,1 1 1 1, 468,Childress_2020,< 2 months NA 6-12 yo,9,14.7 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100   0 100,100 High,Methylphenidate ER-MPH   0 NA,Suicidal ideation/behavior Mixed At study endpoint (closest to 12 weeks),Questionnaire,C-SSRS  0.23014960,  40.0000000,mg/d,Wigal 2017,NA,RCT (parallel, crossover, open-label) RR, 42  44,  86,outcomes,reverse  1.0465116279, 0.021234712, 5.157530e+01,NA,NA NA NA,NA,NA NA,NA,100,100,100,100,100 100 100 low,some low,low low Placebo   0, 37.600000, 9.600000 NA DSM-IV-TR/KSADS 0 1 1.0 1.0 1.0,1.0,1 1,0,1,1 1 1,1.0 1,1 1,1  469,Wigal_2017,< 2 months NA,6-12 yo 9,14.7 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8992,Farhat (2024),Farhat,2024 10.1089/cap.2024.0049 100   0,100,100 High Methylphenidate NA   0 NA Tics/Tourette disorder symptoms Mixed,At study endpoint (closest to 12 weeks) Observational tool,YGTSS, Yale Global Tic Severity Scale, 0.69044879   57.5000000 mg/d Castellanos,1997,NA RCT (crossover) SMD   5,  5,  10,NA reverse, 0.4400000000,-0.450000000, 1.330000e+00 NA NA NA NA NA NA,NA,NA,100,100 100,100,100,100,100,some some some,some some,Placebo   0,  0.000000  9.500000,NA,DSM-III-R,0 1 1.0,1.0 1.0 1.0,1 1,1,1 1 1 1 1.0,1 1 0,1  470 Castellanos_1997,< 2 months NA,6-12 yo 8.9 10.2 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Farhat (2024)_Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Farhat (2024) - Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8992 Farhat (2024),Farhat,2024 10.1089/cap.2024.0049 100,  0,100,100 High,Methylphenidate,NA,  0 NA Tics/Tourette disorder symptoms,Mixed At study endpoint (closest to 12 weeks),Observational tool,YGTSS, Yale Global Tic Severity Scale, 0.46029919,   0.6000000 mg/kg/d Gadow 2007 NA,RCT (crossover),SMD  36, 35   71 NA,reverse -0.0500000000,-0.380000000  2.800000e-01,NA,NA,NA NA NA NA,NA NA 100 100 100,100 100 100,100,some,low,some low,low,Placebo,  0, 19.700000, 8.900000 NA DSM-III-R,0 1,1.0 1.0 1.0 1.0 1 1,1,1 1,1,1 1.0,1 1,0 1  471,Gadow_2007 < 2 months NA,6-12 yo,8.9 10.2 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Farhat (2024)_Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Farhat (2024) - Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8992 Farhat (2024) Farhat 2024 10.1089/cap.2024.0049 100   0,100,100 High Methylphenidate,NA   0 NA,Tics/Tourette disorder symptoms,Mixed,At study endpoint (closest to 12 weeks) Observational tool,YGTSS, Yale Global Tic Severity Scale, 3.68239356,  25.7000000 mg/d,TSSG,2002,NA,RCT (parallel) SMD, 68, 68, 136 NA reverse -0.5900000000 -1.070000000,-1.100000e-01 NA NA NA NA NA NA NA,NA 100 100 100 100 100 100,100 low,low some low low Placebo,  0  14.600000,10.200000,NA,DSM-IV,0 1,1.0,1.0 1.0,1.0,1,1 1,1 1,1,1 1.0 1 1,0,1, 472 TSSG_2002,2-6 months,NA,6-12 yo,8.9 10.2,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Farhat (2024)_Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Farhat (2024) - Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3836 Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100,  0,100 100,High,Cognitive training NA,  0,NA Academic/job performance NA At follow-up (closest to 26 weeks),NA,Reading Comprehension Test  1.15074799    2.6000000 h/week Bigorra 2016,NA RCT G  22  20,  42,NA,NA -0.1000000000 -0.730000000  5.300000e-01,NA NA,NA,NA,NA NA,NA NA,  0,  0,100 100,100   0,100 low,low some,low,high Non-adaptive   0,NA  8.980000,NA,DSM-IV 0,1,1.0,1.0,1.0 1.0,1,1 1 1,1 1,1,0.5,0 1 1 1  473,Bigorra_2016,< 2 months,NA 6-12 yo,8.98 11.59,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no high,high
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0 100 100 High,Cognitive training NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA,CRS-R  1.15074799    2.6000000,h/week Bigorra 2016 NA,RCT G, 30  27   57 outcomes,NA  0.0300000000 -0.500000000  5.600000e-01 NA NA,NA,NA NA NA NA,NA,  0   0,100,100,100,  0,100 low,low some,low,high Non-adaptive   0 NA  8.980000,NA,DSM-IV,0 1,1.0 1.0 1.0,1.0,1 1,1,1,1 1 1,0.5,0,1,1 1  474,Bigorra_2016 < 2 months NA,6-12 yo,8.4,12.41 NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0 100,100,High Cognitive training NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks) NA CRS-R  1.15074799    2.6000000 h/week,Bigorra,2016 NA RCT G, 30, 27,  57,outcomes NA  0.2700000000,-0.260000000  8.000000e-01 NA NA NA,NA,NA NA NA NA,  0   0 100 100 100,  0 100 low,low,some low high Non-adaptive,  0 NA  8.980000 NA,DSM-IV,0 1,1.0,1.0 1.0,1.0,1 1,1,1,1 1 1 0.5,0,1 1 1  475,Bigorra_2016 < 2 months NA,6-12 yo 6.55 10.6,NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0,100,100,High Cognitive training,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) NA,CRS-R  1.15074799,   2.6000000 h/week Bigorra,2016,NA RCT G  22  20   42,NA,NA, 0.3700000000,-0.240000000  9.800000e-01 NA NA,NA NA NA NA,NA,NA,  0,  0 100 100,100,  0,100 low low some low,high Non-adaptive   0 NA, 8.980000 NA DSM-IV,0,1,1.0 1.0 1.0 1.0 1 1,1,1 1 1,1,0.5 0 1 1 1  476,Bigorra_2016 < 2 months,NA,6-12 yo,8.98 12.41 NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,high high
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0,100,100,High,Cognitive training,NA,  0,NA,Executive functioning (report),Parent-rated At study endpoint (closest to 12 weeks) NA,BRIEF, 1.15074799    2.6000000 h/week,Bigorra,2016 NA RCT,G  30  27   57 NA NA,-0.2400000000 -0.770000000  2.900000e-01 NA,NA NA,NA,NA NA,NA NA   0,  0,100,100 100   0 100,low,low some low,high,Non-adaptive,  0,NA, 8.980000 NA DSM-IV 0 1,1.0 1.0 1.0 1.0,1 1 1,1,1 1 1 0.5 0 1,1 1, 477,Bigorra_2016,< 2 months NA 6-12 yo 6.55,11.59 NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0 100 100 High,Cognitive training,NA,  0,NA,Executive functioning (report),Parent-rated At follow-up (closest to 26 weeks) NA,BRIEF, 1.15074799,   2.6000000,h/week Bigorra 2016,NA RCT G, 22, 20,  42,NA,NA  0.2600000000,-0.270000000, 7.900000e-01,NA,NA NA,NA,NA NA NA,NA   0   0,100,100 100   0,100,low,low,some low,high Non-adaptive   0,NA, 8.980000,NA,DSM-IV 0,1 1.0 1.0,1.0 1.0,1,1 1,1,1,1,1,0.5,0 1,1,1, 478,Bigorra_2016,< 2 months,NA 6-12 yo,8.98,11.59,NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,high,high
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0,100 100,High Cognitive training NA   0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA Conners' CPT-II - oms, 1.15074799    2.6000000 h/week Bigorra,2016,NA,RCT G  30  27   57 outcomes,NA  0.2100000000 -0.320000000, 7.400000e-01 NA NA NA,NA,NA NA NA NA,  0   0 100 100 100   0 100,low low some,low high Non-adaptive,  0 NA  8.980000 NA DSM-IV,0,1,1.0,1.0 1.0 1.0 1 1,1,1,1 1 1,0.5 0,1,1 1  479 Bigorra_2016 < 2 months,NA,6-12 yo 6.55,12.41 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
3836,Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0,100 100 High Cognitive training NA,  0 NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA Conners' CPT-II - coms  1.15074799,   2.6000000,h/week,Bigorra,2016 NA,RCT G  30  27,  57,outcomes NA, 0.4500000000 -0.080000000, 9.800000e-01,NA,NA,NA NA NA,NA,NA,NA,  0,  0 100,100,100,  0 100,low low some,low high Non-adaptive,  0 NA, 8.980000,NA,DSM-IV,0,1,1.0 1.0 1.0 1.0 1 1 1 1,1,1,1 0.5,0 1 1,1  480,Bigorra_2016 < 2 months NA,6-12 yo 6.55 12.41,NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0 100 100 High Cognitive training NA   0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA TMT B  1.15074799,   2.6000000 h/week Bigorra,2016,NA RCT,G  31  29,  60 outcomes,NA, 0.5100000000, 0.000000000, 1.020000e+00 NA NA NA,NA,NA NA,NA NA,  0,  0 100 100,100,  0,100,low,low,some,low high,Non-adaptive,  0,NA  8.980000 NA DSM-IV 0 1,1.0,1.0,1.0,1.0,1 1,1 1,1,1,1,0.5,0,1,1,1, 481 Bigorra_2016 < 2 months NA 6-12 yo,6.55,12.41,NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0 100,100,High,Cognitive training,NA   0 NA,Executive functioning (tests),NA,At follow-up (closest to 26 weeks),NA,Conners' CPT-II - oms, 1.15074799    2.6000000 h/week,Bigorra,2016 NA,RCT,G  22  20,  42,outcomes,NA -0.3700000000,-0.860000000, 1.200000e-01,NA,NA NA NA NA,NA NA,NA   0   0,100 100 100   0 100 low low,some low high Non-adaptive,  0,NA  8.980000,NA,DSM-IV,0,1,1.0,1.0 1.0,1.0 1 1 1,1,1,1,1,0.5 0 1 1 1  482,Bigorra_2016,< 2 months NA 6-12 yo 8.98 12.41 NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,high,high
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100   0,100,100 High,Cognitive training,NA,  0 NA Executive functioning (tests),NA,At follow-up (closest to 26 weeks),NA Conners' CPT-II - coms  1.15074799    2.6000000 h/week Bigorra,2016 NA RCT G  22, 20,  42 outcomes,NA  0.2000000000 -0.410000000, 8.100000e-01,NA NA,NA NA,NA,NA NA NA,  0,  0,100 100,100,  0,100 low,low,some,low,high,Non-adaptive   0,NA  8.980000 NA DSM-IV,0 1 1.0 1.0,1.0,1.0 1,1 1 1 1,1,1 0.5,0,1 1 1  483 Bigorra_2016 < 2 months NA,6-12 yo,8.98 12.41,NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,high,high
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0 100 100,High Cognitive training NA   0,NA Academic/job performance NA,At study endpoint (closest to 12 weeks) NA WRAT - Word Reading  1.15074799    3.1250000,h/week,Chacko 2014 NA,RCT G, 44, 41,  85,outcomes,NA -0.0500000000,-0.480000000, 3.800000e-01 NA NA,NA NA,NA NA NA NA 100,100 100 100   0,100 100 low low high low some Non-adaptive,  0,NA  8.400000,NA DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)",0,1 1.0,1.0,1.0,1.0 1,1,1 1 1,1,1 0.5 0 1,1,1, 484,Chacko_2014 < 2 months,NA,6-12 yo 8.4 11.59,NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0,100 100,High Cognitive training NA   0 NA Academic/job performance NA,At study endpoint (closest to 12 weeks),NA,WRAT-Math Computation  1.15074799    3.1250000 h/week,Chacko 2014 NA,RCT G, 44, 41   85,outcomes NA, 0.1000000000,-0.330000000, 5.300000e-01 NA NA NA,NA,NA,NA,NA NA 100 100,100,100   0 100 100,low low high,low some Non-adaptive,  0 NA, 8.400000 NA,DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)",0,1 1.0 1.0,1.0 1.0,1 1,1,1,1 1,1 0.5,0 1,1 1, 485,Chacko_2014,< 2 months NA,6-12 yo,8.4 11.59 NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0 100 100,High,Cognitive training NA,  0,NA Academic/job performance NA,At study endpoint (closest to 12 weeks),NA,WRAT Sentence Comprehension  1.15074799    3.1250000,h/week,Chacko,2014,NA RCT,G, 44, 41   85 outcomes NA  0.3000000000 -0.130000000  7.300000e-01 NA,NA NA,NA NA NA NA,NA 100 100,100 100   0,100 100 low,low,high low,some Non-adaptive   0 NA, 8.400000,NA,DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)",0,1 1.0,1.0,1.0,1.0 1,1,1,1 1,1 1,0.5 0,1,1 1  486 Chacko_2014,< 2 months NA,6-12 yo 8.4 11.59 NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0 100,100 High,Cognitive training,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,DBD (Pelham et al., 1992), 1.15074799    3.1250000 h/week,Chacko,2014 NA RCT,G  44, 41   85,outcomes,NA,-0.2400000000,-0.550000000  7.000000e-02 NA,NA NA NA NA,NA,NA NA,100 100 100 100,  0,100,100 low low,high,low,some Non-adaptive   0,NA, 8.400000,NA DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)" 0,1,1.0,1.0,1.0,1.0,1 1 1,1 1,1,1 0.5 0,1,1 1  487,Chacko_2014,< 2 months,NA,6-12 yo 8.4,12.41 NA NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0,100 100 High Cognitive training NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks) NA,DBD, 1.15074799,   3.1250000,h/week Chacko 2014 NA,RCT,G  44  41,  85,outcomes NA  0.0200000000,-0.270000000, 3.100000e-01,NA,NA NA,NA,NA NA NA NA,100 100,100,100,  0 100,100,low,low high low some,Non-adaptive,  0 NA, 8.400000,NA,DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)",0,1 1.0,1.0 1.0,1.0,1,1 1 1,1 1 1,0.5,0 1 1,1, 488 Chacko_2014 < 2 months,NA,6-12 yo,6.55 10.6,NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0,100,100 High,Cognitive training,NA,  0 NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA A-X CPT Coms, 1.15074799    3.1250000,h/week Chacko 2014,NA RCT,G  44, 41   85,outcomes NA -0.0200000000,-0.450000000  4.100000e-01 NA NA NA,NA,NA NA NA NA,100,100,100 100,  0 100 100,low,low high low some,Non-adaptive,  0,NA  8.400000,NA,DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)" 0,1,1.0 1.0 1.0 1.0 1,1,1,1 1 1,1,0.5 0 1 1 1  489 Chacko_2014,< 2 months,NA,6-12 yo 6.55,12.41,NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0,100,100,High Cognitive training NA   0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,A-X CPT Oms  1.15074799,   3.1250000,h/week,Chacko 2014,NA,RCT G  44  41   85 outcomes NA  0.0700000000 -0.360000000, 5.000000e-01,NA,NA NA,NA,NA,NA NA NA 100,100 100 100,  0 100,100,low low high low some Non-adaptive,  0,NA, 8.400000,NA DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)",0 1,1.0 1.0 1.0 1.0,1 1 1,1,1,1,1,0.5,0,1 1,1, 490 Chacko_2014,< 2 months NA 6-12 yo 6.55,12.41,NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0,100,100 High,Cognitive training NA   0 NA,Academic/job performance,NA At study endpoint (closest to 12 weeks),NA,WIAT-II Mathematical Reasoning, 1.15074799    3.1250000 h/week Dentz,2020a,NA,RCT G  17, 18,  35 outcomes NA  0.0200000000 -0.650000000, 6.900000e-01,NA NA NA,NA,NA NA NA NA,100 100,100,100,  0 100,100,low,low,high low,some Non-adaptive,  0 NA,10.020000 NA DSM-IV,0 1,1.0,1.0,1.0 1.0,1,1 1,1,1,1,1,0.5,0,1,1 1  491 Dentz_2020a,< 2 months NA,6-12 yo 8.4 11.59,NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0 100,100,High Cognitive training,NA,  0,NA Academic/job performance NA,At study endpoint (closest to 12 weeks),NA WIAT-II Reading Comprehension  1.15074799    3.1250000,h/week Dentz,2020a NA RCT,G  17, 18   35,outcomes,NA, 0.1700000000,-0.500000000  8.400000e-01,NA,NA NA,NA NA,NA,NA,NA,100,100 100 100   0,100,100 low,low,high low,some Non-adaptive,  0,NA 10.020000,NA DSM-IV,0,1,1.0,1.0,1.0,1.0,1,1,1,1,1 1,1 0.5,0,1 1 1  492,Dentz_2020a,< 2 months NA 6-12 yo 8.4,11.59 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0,100 100 High,Cognitive training NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,Conners-3AI  1.15074799    3.1250000 h/week,Dentz,2020a,NA,RCT,G, 17  15   32,NA NA -0.0400000000 -0.730000000  6.500000e-01,NA NA,NA NA,NA,NA,NA,NA 100 100 100 100,  0,100 100,low,low,high low some,Non-adaptive   0 NA 10.020000 NA DSM-IV,0,1 1.0,1.0 1.0 1.0 1,1 1 1,1 1 1 0.5 0 1,1,1, 493 Dentz_2020a,< 2 months,NA,6-12 yo 8.4 12.41 NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0 100 100,High,Cognitive training NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks),NA,Conners-3AI  1.15074799,   3.1250000 h/week,Dentz,2020a NA,RCT,G  17, 14   31,NA,NA,-0.4100000000,-0.941759707  1.217597e-01 NA,NA,NA,NA NA NA,NA,NA,100,100,100,100,  0,100,100 low,low high low some,Non-adaptive,  0 NA 10.020000,NA DSM-IV,0 1,1.0 1.0 1.0,1.0 1,1 1 1 1,1 1 0.5,0 1 1 1  494,Dentz_2020a,< 2 months NA 6-12 yo,8.98 12.41,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low low
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0,100 100 High Cognitive training,NA,  0,NA Executive functioning (report),NA At study endpoint (closest to 12 weeks) NA,BRIEF  1.15074799    3.1250000 h/week Dentz,2020a,NA,RCT G, 17  15,  32 NA NA -0.1400000000 -0.830000000  5.500000e-01,NA,NA NA NA NA,NA NA NA,100,100 100,100,  0,100,100,low low,high low,some,Non-adaptive,  0,NA 10.020000,NA DSM-IV 0,1 1.0 1.0 1.0 1.0,1 1,1 1 1 1 1 0.5 0,1 1 1, 495,Dentz_2020a < 2 months,NA,6-12 yo 10.02,12.41,NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0,100,100,High,Cognitive training,NA   0,NA Executive functioning (report) NA At follow-up (closest to 26 weeks) NA BRIEF, 1.15074799,   3.1250000 h/week,Dentz,2020a NA,RCT G  17, 14   31,NA NA  0.1500000000 -0.565830375  8.658304e-01,NA NA NA,NA,NA,NA NA NA 100,100 100 100,  0,100,100,low,low high low some,Non-adaptive,  0,NA 10.020000,NA,DSM-IV,0 1,1.0,1.0,1.0,1.0,1,1,1 1,1 1 1 0.5,0,1,1,1  496 Dentz_2020a < 2 months NA 6-12 yo 10.02,12.41 NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low low
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100 100,High Cognitive training NA,  0 NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA Raven's porgressive matrices  1.15074799,   3.1250000,h/week Dentz,2020a,NA RCT,G, 17  19,  36 outcomes,NA,-0.2000000000 -0.870000000  4.700000e-01 NA,NA NA NA NA NA NA NA,100,100 100,100   0,100 100,low,low high low,some,Non-adaptive,  0,NA,10.020000,NA,DSM-IV,0 1 1.0,1.0 1.0,1.0 1,1 1 1,1,1,1,0.5,0,1,1,1  497,Dentz_2020a < 2 months NA 6-12 yo 6.55,12.41 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3836 Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100   0,100 100 High Cognitive training NA   0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA CPT  1.15074799    3.1250000,h/week,Dentz 2020a NA RCT,G, 17  19   36,outcomes NA -0.0800000000 -0.730000000, 5.700000e-01 NA NA NA NA NA NA NA NA,100 100 100,100,  0 100 100 low low,high,low some,Non-adaptive   0 NA,10.020000,NA,DSM-IV 0 1,1.0,1.0,1.0,1.0,1,1,1 1 1 1,1 0.5 0 1 1 1, 498,Dentz_2020a,< 2 months NA 6-12 yo 6.55 12.41 NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0,100 100 High,Cognitive training,NA   0 NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA,Conners' CPT-II - Oms, 1.15074799    3.1250000 h/week,Dentz,2020a,NA RCT G, 17  19   36 outcomes NA, 0.2400000000 -0.410000000  8.900000e-01,NA,NA,NA NA,NA NA,NA NA,100,100 100,100,  0 100 100 low low,high low some Non-adaptive,  0,NA,10.020000 NA DSM-IV 0 1,1.0,1.0,1.0,1.0 1 1,1 1,1,1,1 0.5,0,1 1 1, 499,Dentz_2020a,< 2 months NA,6-12 yo 6.55 12.41 NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0,100 100 High,Cognitive training NA   0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,Wechsler Spatial Span (Combined Forward/Backward)  1.15074799,   3.1250000,h/week Dentz,2020a,NA RCT G, 17, 19,  36 outcomes NA  0.1300000000,-0.340000000  6.000000e-01,NA NA NA NA NA NA,NA,NA,100 100 100 100,  0,100,100 low,low,high low,some Non-adaptive,  0,NA 10.020000,NA,DSM-IV,0 1 1.0,1.0,1.0,1.0 1,1,1 1 1 1 1,0.5 0 1 1,1  500,Dentz_2020a,< 2 months,NA 6-12 yo 6.55,12.41,NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0,100,100 High,Cognitive training,NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA WISC-IV Digit Span Backward & Forward  1.15074799    3.1250000,h/week,Dentz,2020a NA,RCT G, 17  19   36 outcomes,NA, 0.5700000000, 0.100000000, 1.040000e+00,NA NA,NA NA NA NA NA NA,100 100,100,100,  0 100 100,low low,high low some Non-adaptive,  0 NA 10.020000 NA,DSM-IV,0,1 1.0 1.0 1.0,1.0 1 1 1,1,1,1,1 0.5 0 1,1 1, 501,Dentz_2020a,< 2 months,NA 6-12 yo,6.55 12.41 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3836 Westwood - Adults (2024) Westwood - Adults 2024,10.1038/s41380-023-02000-7 100   0,100,100 High,Cognitive training NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA Conners-3AI, 1.15074799    3.1250000,h/week,Dentz 2020b NA RCT,G  23, 21   44,NA NA  0.2500000000 -0.340000000, 8.400000e-01 NA NA,NA,NA,NA NA NA,NA,100,100,100,100   0,100 100,low low,high,low some,Cognitive placebo   0 NA 38.910000 NA,DSM-IV 0,1,1.0 1.0 1.0,1.0,1,1 1 1,1,1 1,0.5,0 1,1,1, 502,Dentz_2020b,< 2 months NA,>= 20 yo 38.91 38.91,NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA Westwood - Adults (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Adults (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
3836 Westwood - Adults (2024) Westwood - Adults,2024,10.1038/s41380-023-02000-7,100,  0,100,100 High,Cognitive training NA   0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA WAIS-III Matrix Reasoning subtest, 1.15074799,   3.1250000,h/week,Dentz,2020b NA RCT,G, 23  21,  44 outcomes NA  0.1000000000,-0.490000000  6.900000e-01,NA,NA,NA,NA NA NA NA,NA 100 100,100,100,  0 100 100 low,low,high low,some Cognitive placebo,  0 NA 38.910000 NA,DSM-IV 0,1,1.0,1.0 1.0 1.0,1,1 1 1,1,1,1 0.5,0,1,1,1  503,Dentz_2020b < 2 months,NA >= 20 yo,22.2,38.91 NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
3836,Westwood - Adults (2024) Westwood - Adults,2024,10.1038/s41380-023-02000-7 100   0,100,100,High Cognitive training,NA   0 NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA Corsi Block Tapping Task (Combined Forward/Backward)  1.15074799    3.1250000,h/week,Dentz 2020b,NA,RCT G  23  21   44 outcomes,NA  0.2100000000 -0.380000000, 8.000000e-01,NA,NA,NA,NA,NA,NA,NA,NA 100,100 100,100,  0 100 100 low,low high low some Cognitive placebo,  0,NA 38.910000 NA,DSM-IV,0,1,1.0,1.0,1.0 1.0 1 1,1,1,1 1 1 0.5 0 1,1 1  504 Dentz_2020b < 2 months NA >= 20 yo 22.2 38.91,NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
3836 Westwood - Adults (2024) Westwood - Adults,2024,10.1038/s41380-023-02000-7 100   0,100,100,High Cognitive training,NA   0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA WAIS-III Digit Span (Combined Forward/Backward)  1.15074799    3.1250000,h/week Dentz 2020b NA RCT G  23, 21   44 outcomes,NA  0.5300000000 -0.080000000  1.140000e+00 NA NA NA,NA NA NA,NA NA,100,100 100 100,  0,100,100 low,low high,low some Cognitive placebo,  0 NA 38.910000 NA DSM-IV 0 1 1.0 1.0,1.0,1.0,1 1,1,1,1 1 1,0.5,0 1 1,1  505 Dentz_2020b,< 2 months,NA,>= 20 yo 22.2 38.91 NA NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
3836 Westwood - Adults (2024) Westwood - Adults 2024,10.1038/s41380-023-02000-7 100,  0,100,100 High,Cognitive training,NA,  0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,Attentional Network Task (aka Flanker Task), Flanker RT Effect (No-cue Incongruent-Congruent) NA,NA NA,Dotare 2020,NA RCT G  14, 16   30 NA,NA, 1.3900000000  0.590000000  2.190000e+00 NA,NA,NA NA NA NA,NA NA   0,  0,  0,100 100,100,100 high some,low some some Non-adaptive   0 NA 24.500000 NA,DSM-IV-TR 0 1,1.0,1.0 1.0,1.0,1 1 1 1 1,1 1 0.5,0 1 1 1, 506 Dotare_2020,NA,NA,>= 20 yo,22.2 38.91 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low high
3836 Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100,  0,100,100 High,Cognitive training NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks) NA DBDRS  1.15074799,   2.5000000 h/week Dovis,2015,NA,RCT G, 31  30   61,NA NA  0.1500000000,-0.200000000  5.000000e-01,NA NA NA NA,NA NA,NA,NA,100 100,100,100,  0 100 100,low low,high,low,some,Non-adaptive,  0,NA 10.600000 NA,DSM-IV-TR 0,1,1.0,1.0,1.0,1.0 1,1 1,1 1,1,1 0.5,0,1 1 1, 507 Dovis_2015,< 2 months,NA,6-12 yo,6.55,10.6,NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0 100 100 High Cognitive training,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) NA,DBDRS, 1.15074799    2.5000000,h/week,Dovis 2015,NA,RCT G, 31  30   61 NA,NA  0.1800000000,-0.170000000, 5.300000e-01 NA NA NA NA,NA,NA,NA NA 100,100,100 100   0 100,100 low,low,high,low,some Non-adaptive,  0 NA 10.600000,NA DSM-IV-TR 0 1 1.0 1.0,1.0 1.0,1 1,1 1,1,1,1 0.5 0,1 1 1  508 Dovis_2015,< 2 months NA,6-12 yo,8.4,12.41 NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0 100 100,High Cognitive training,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),NA DBDRS  1.15074799    2.5000000,h/week Dovis,2015 NA,RCT G, 31  30   61,NA,NA, 0.0500000000,-0.300000000, 4.000000e-01 NA,NA NA,NA NA,NA,NA NA,100 100,100,100,  0,100,100 low,low,high low some Non-adaptive,  0,NA,10.600000 NA,DSM-IV-TR 0,1,1.0 1.0,1.0 1.0,1 1 1,1,1,1,1,0.5 0,1,1 1, 509,Dovis_2015,< 2 months NA 6-12 yo 8.98,12.41 NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low,low
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0 100,100 High Cognitive training NA   0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,Raven coloured progressive matrices  1.15074799    2.5000000 h/week Dovis,2015 NA,RCT G  31, 30,  61 outcomes,NA  0.0000000000,-0.510000000, 5.100000e-01 NA,NA NA NA,NA,NA,NA,NA 100,100 100,100   0,100,100 low low,high low some Non-adaptive   0,NA 10.600000,NA,DSM-IV-TR 0,1,1.0 1.0,1.0,1.0,1 1 1 1 1,1,1 0.5,0 1,1 1, 510 Dovis_2015 < 2 months NA,6-12 yo 6.55 12.41,NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0 100,100,High,Cognitive training,NA,  0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA,WISC-III Digit Span (Combined Forward/Backward), 1.15074799    2.5000000 h/week,Dovis 2015,NA,RCT G, 31, 30   61,outcomes NA  0.1800000000,-0.330000000, 6.900000e-01 NA,NA NA NA,NA,NA,NA NA 100 100,100,100   0 100 100,low,low high low some Non-adaptive   0,NA,10.600000,NA,DSM-IV-TR 0 1 1.0 1.0,1.0 1.0 1 1 1,1 1 1,1 0.5,0,1,1 1  511 Dovis_2015,< 2 months NA 6-12 yo,6.55 12.41 NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0,100 100,High Cognitive training NA   0 NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA Stop task, 1.15074799,   2.5000000 h/week Dovis,2015 NA,RCT,G  31, 30,  61,outcomes NA  0.5900000000, 0.080000000, 1.100000e+00 NA NA,NA NA,NA,NA,NA,NA 100,100 100 100   0 100,100 low,low high,low some Non-adaptive,  0,NA,10.600000 NA,DSM-IV-TR,0,1,1.0 1.0 1.0,1.0 1,1 1 1 1,1,1 0.5,0 1 1 1, 512 Dovis_2015 < 2 months NA 6-12 yo,6.55,12.41 NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3836 Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100,  0,100 100 High,Cognitive training,NA   0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,Corsi Block Tapping Task (Combined Forward/Backward), 1.15074799    2.5000000 h/week Dovis,2015,NA,RCT,G, 31, 30   61 outcomes,NA  0.6400000000  0.290000000  9.900000e-01,NA,NA NA,NA,NA,NA,NA NA 100 100,100 100,  0,100,100 low,low,high,low,some,Non-adaptive,  0,NA,10.600000,NA DSM-IV-TR,0,1 1.0,1.0 1.0,1.0 1 1 1,1,1 1,1 0.5 0 1 1 1, 513 Dovis_2015,< 2 months NA 6-12 yo 6.55 12.41 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0 100 100,High Cognitive training,NA   0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA,Stroop Colour & Word Test, Stroop RT Effect, 1.15074799,   2.5000000 h/week,Dovis,2015 NA RCT G, 31  30   61,outcomes NA, 0.1100000000 -0.400000000, 6.200000e-01,NA,NA NA NA NA,NA,NA NA,100 100,100,100,  0 100,100,low,low,high low,some Non-adaptive,  0,NA,10.600000,NA DSM-IV-TR,0 1 1.0,1.0 1.0 1.0 1,1,1 1,1 1 1 0.5 0 1 1 1  514 Dovis_2015 < 2 months NA 6-12 yo,6.55,12.41,NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100,  0 100 100,High,Cognitive training,NA   0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA TMT, 1.15074799,   2.5000000,h/week Dovis,2015,NA,RCT G, 31  30   61 outcomes,NA  0.0700000000,-0.440000000  5.800000e-01 NA,NA NA NA NA NA NA,NA,100 100,100 100,  0 100 100,low low high low some,Non-adaptive,  0,NA,10.600000 NA,DSM-IV-TR 0,1,1.0 1.0 1.0 1.0,1,1,1 1,1 1 1 0.5,0,1 1 1, 515 Dovis_2015 < 2 months,NA,6-12 yo 6.55 12.41 NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3836 Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100   0,100 100 High,Cognitive training,NA   0,NA Executive functioning (tests),NA,At follow-up (closest to 26 weeks),NA WISC-III Digiti Span Foward & Backward (Digit Recall), 1.15074799    2.5000000,h/week Dovis 2015 NA,RCT G  31  30,  61,outcomes NA, 0.3200000000 -0.190000000, 8.300000e-01 NA,NA NA NA,NA,NA,NA,NA,100,100 100,100   0,100,100 low,low high,low,some,Non-adaptive,  0,NA,10.600000,NA,DSM-IV-TR 0 1,1.0,1.0 1.0 1.0 1,1,1 1 1,1 1,0.5,0,1,1,1  516,Dovis_2015,< 2 months NA 6-12 yo 8.98 12.41 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low low
3836,Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0,100 100 High Cognitive training,NA,  0 NA,Executive functioning (tests),NA,At follow-up (closest to 26 weeks),NA Stop task, 1.15074799    2.5000000 h/week,Dovis,2015,NA RCT,G  31, 30,  61 outcomes,NA, 0.5100000000  0.000000000  1.020000e+00 NA,NA NA NA,NA NA NA,NA 100,100 100,100,  0 100,100,low low high low some Non-adaptive,  0 NA 10.600000 NA,DSM-IV-TR,0,1 1.0 1.0 1.0,1.0 1 1,1 1 1 1,1,0.5 0,1 1,1, 517 Dovis_2015,< 2 months NA 6-12 yo 8.98 12.41,NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low,low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100,100 High,Cognitive training,NA,  0 NA Academic/job performance,NA,At study endpoint (closest to 12 weeks) NA,Key Math NA NA NA,Egeland,2013 NA,RCT G  33, 34   67 outcomes NA, 0.2800000000 -0.210000000  7.700000e-01,NA NA,NA,NA,NA,NA,NA NA,  0,  0 100 100 100 100,  0 low low some,high some,TAU,  0,NA 10.500000,NA,F-90 ICD-10 0 1 1.0,1.0 1.0,1.0 1,1 1 1 1 1 1 0.5,0,1 1 1  518 Egeland_2013 NA,NA 6-12 yo 8.4,11.59 NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0,100 100,High,Cognitive training,NA,  0,NA,Academic/job performance,NA At study endpoint (closest to 12 weeks),NA,LOGOS Reading Fluency,NA NA,NA,Egeland,2013,NA RCT G  33  34   67 outcomes,NA  0.4500000000 -0.040000000  9.400000e-01 NA NA NA,NA,NA,NA,NA NA,  0,  0,100,100,100 100,  0 low low some high,some,TAU,  0,NA 10.500000,NA F-90 ICD-10,0 1 1.0 1.0,1.0 1.0 1 1,1 1,1 1,1 0.5,0 1 1 1, 519 Egeland_2013 NA,NA,6-12 yo,8.4 11.59 NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100,  0,100,100 High Cognitive training,NA,  0,NA,Academic/job performance NA,At study endpoint (closest to 12 weeks),NA,LOGOS Word Decoding Quality NA,NA NA Egeland 2013 NA,RCT,G, 33  34,  67 outcomes NA, 0.5600000000, 0.070000000, 1.050000e+00,NA NA NA,NA NA,NA NA NA   0,  0,100 100,100,100,  0 low,low some high,some,TAU   0,NA 10.500000,NA F-90 ICD-10 0 1,1.0 1.0 1.0 1.0 1 1 1,1,1 1,1,0.5,0 1 1 1, 520,Egeland_2013,NA,NA 6-12 yo 8.4,11.59 NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
3836,Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0 100 100 High,Cognitive training,NA   0 NA Academic/job performance,NA,At follow-up (closest to 26 weeks),NA,LOGOS Word Decoding Quality NA NA NA,Egeland,2013,NA RCT,G, 33  34,  67 NA NA, 0.0600000000,-0.650000000, 7.700000e-01 NA,NA,NA,NA,NA NA,NA NA,  0,  0,100 100 100 100   0 low low some,high,some TAU   0,NA 10.500000 NA,F-90 ICD-10,0 1 1.0 1.0 1.0,1.0,1 1 1 1,1,1 1 0.5 0 1 1 1  521,Egeland_2013,NA,NA,6-12 yo 8.98,11.59 NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low,high
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0,100,100,High Cognitive training NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) NA,ADHD-RS (DuPaul et al., 1998),NA,NA NA Egeland,2013 NA,RCT,G  33  34   67 NA,NA  0.2500000000 -0.240000000  7.400000e-01,NA NA,NA,NA NA NA NA,NA,  0,  0,100,100 100 100,  0,low low,some,high,some,TAU,  0 NA,10.500000,NA F-90 ICD-10,0,1,1.0,1.0,1.0,1.0 1 1,1 1,1 1,1 0.5 0 1 1,1, 522,Egeland_2013,NA NA,6-12 yo,6.55 10.6 NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0,100 100 High,Cognitive training,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At follow-up (closest to 26 weeks) NA ADHD-RS NA NA,NA,Egeland,2013,NA,RCT G, 33  34,  67,NA NA, 0.2900000000,-0.180000000  7.600000e-01,NA NA NA NA NA,NA NA NA   0,  0,100,100 100 100,  0,low,low some high some TAU,  0 NA,10.500000 NA,F-90 ICD-10 0 1 1.0 1.0,1.0,1.0,1,1,1 1,1,1,1,0.5 0,1 1 1  523 Egeland_2013 NA NA,6-12 yo 10.5 10.5,NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low,high
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100 100 High,Cognitive training,NA   0,NA Executive functioning (report),NA At study endpoint (closest to 12 weeks),NA BRIEF,NA NA NA,Egeland,2013 NA RCT,G  33  34   67 NA NA, 0.0700000000 -0.400000000, 5.400000e-01 NA NA,NA,NA NA NA NA NA   0   0 100 100 100,100,  0,low low some,high some,TAU,  0 NA 10.500000 NA F-90 ICD-10,0,1,1.0 1.0,1.0 1.0,1 1,1,1 1,1 1,0.5,0 1 1,1, 524,Egeland_2013 NA,NA,6-12 yo,10.02,12.41 NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100   0 100,100,High,Cognitive training,NA   0 NA Executive functioning (report) NA At follow-up (closest to 26 weeks),NA BRIEF,NA NA,NA,Egeland,2013 NA RCT G  33  34   67,NA NA, 0.1700000000,-0.309313098  6.400000e-01,NA,NA,NA NA,NA,NA NA NA,  0,  0,100 100 100,100,  0 low low,some,high some TAU   0 NA,10.500000 NA,F-90 ICD-10 0 1 1.0 1.0,1.0 1.0,1,1 1,1 1,1 1 0.5,0,1 1,1, 525 Egeland_2013 NA NA 6-12 yo,10.02,12.41,NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low high
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0 100,100 High Cognitive training NA   0 NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA Conners' CPT-II,NA NA NA Egeland 2013 NA RCT,G  33, 34   67 outcomes,NA,-0.1400000000 -0.610000000, 3.300000e-01,NA NA,NA,NA,NA NA NA NA   0   0 100 100 100,100,  0 low low,some high,some,TAU   0 NA 10.500000 NA,F-90 ICD-10 0,1,1.0 1.0,1.0 1.0 1,1 1,1,1 1 1,0.5,0 1 1 1, 526 Egeland_2013,NA NA,6-12 yo,6.55 12.41 NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0,100 100 High,Cognitive training,NA,  0 NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA Conners CPT-II NA NA NA,Egeland 2013,NA,RCT,G, 33, 34   67 outcomes,NA  0.3400000000,-0.130000000  8.100000e-01 NA NA,NA NA NA NA,NA,NA,  0   0 100,100 100,100,  0 low,low,some high some TAU   0,NA 10.500000 NA F-90 ICD-10 0,1 1.0 1.0,1.0,1.0,1 1 1,1 1,1,1,0.5,0 1 1 1, 527 Egeland_2013 NA NA,6-12 yo 6.55,12.41,NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0 100,100,High,Cognitive training,NA   0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA LOGOS Word Decoding Quality NA,NA,NA Egeland 2013 NA,RCT G  33  34   67,outcomes,NA  0.5600000000  0.070000000, 1.050000e+00 NA,NA,NA NA,NA,NA,NA NA,  0   0,100 100,100 100   0,low,low,some,high,some,TAU   0,NA 10.500000,NA,F-90 ICD-10 0,1,1.0 1.0 1.0,1.0,1 1 1 1,1 1 1 0.5 0 1 1,1  528 Egeland_2013 NA,NA,6-12 yo,6.55,12.41 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0 100,100 High Cognitive training NA,  0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA D-KEFS Color Word Interference Condition Trials, CW Interference Time,NA NA NA,Egeland 2013 NA,RCT,G  33  34   67 outcomes,NA,-0.0200000000 -0.490000000, 4.500000e-01 NA,NA NA,NA NA,NA NA NA,  0,  0 100,100 100,100,  0,low low some,high,some,TAU,  0 NA 10.500000 NA F-90 ICD-10 0 1 1.0,1.0,1.0 1.0 1,1,1,1 1 1 1,0.5 0,1,1 1  529,Egeland_2013 NA,NA 6-12 yo,6.55 12.41,NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
3836,Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0 100 100,High,Cognitive training,NA,  0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA TMT (Task 4),NA,NA NA Egeland 2013,NA,RCT,G, 33, 34   67 outcomes,NA  0.0500000000,-0.420000000, 5.200000e-01,NA NA NA,NA,NA NA,NA NA,  0,  0,100,100,100,100,  0,low,low,some high,some,TAU   0 NA,10.500000,NA F-90 ICD-10,0 1 1.0 1.0 1.0,1.0,1 1 1 1,1 1 1,0.5 0,1,1,1  530 Egeland_2013,NA,NA,6-12 yo,6.55 12.41,NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
3836,Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0,100 100 High,Cognitive training,NA,  0,NA,Executive functioning (tests) NA At follow-up (closest to 26 weeks) NA,Conners' CPT-II,NA NA,NA,Egeland,2013 NA,RCT,G  33, 34,  67 outcomes NA, 0.0400000000,-0.570000000  6.500000e-01 NA,NA NA NA NA,NA,NA,NA,  0,  0,100 100,100 100,  0,low low some,high,some TAU   0 NA 10.500000,NA,F-90 ICD-10,0 1,1.0,1.0,1.0 1.0,1,1,1,1 1,1 1 0.5 0,1,1,1  531 Egeland_2013,NA NA,6-12 yo 8.98,12.41,NA NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low,high
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0,100,100,High Cognitive training NA,  0 NA Executive functioning (tests) NA,At follow-up (closest to 26 weeks) NA Conners CPT-II,NA,NA,NA Egeland 2013 NA RCT G  33, 34   67 outcomes,NA  0.2700000000,-0.200000000  7.400000e-01,NA NA,NA NA,NA,NA,NA NA,  0,  0,100,100,100,100   0,low,low some,high some TAU   0 NA,10.500000 NA,F-90 ICD-10,0,1,1.0 1.0,1.0 1.0,1,1,1 1,1 1 1,0.5 0,1 1,1, 532 Egeland_2013 NA,NA 6-12 yo 8.98,12.41 NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low high
3836,Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0 100,100,High Cognitive training,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA CPRS NA NA NA Green,2012,NA,RCT,G  12, 14   26 outcomes NA -0.2100000000 -0.990000000, 5.700000e-01 NA,NA,NA NA NA NA,NA,NA 100,100,100,100 100 100,100 some low some low some Non-adaptive   0 NA, 9.750000,NA DSM-IV,0 1,1.0,1.0,1.0 1.0 1 1 1,1,1 1 1,0.5,0,1 1,1, 533 Green_2012,NA,NA,6-12 yo 8.4 12.41,NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100,100 High,Cognitive training,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,CPRS,NA,NA NA,Green 2012,NA RCT,G  12  14,  26 outcomes,NA -0.2100000000 -0.990000000, 5.700000e-01,NA NA,NA,NA NA,NA,NA,NA,100,100 100 100 100 100,100,some low some low,some,Non-adaptive,  0,NA  9.750000,NA,DSM-IV,0 1,1.0,1.0,1.0,1.0,1,1 1 1 1,1 1 0.5,0 1 1 1, 534 Green_2012 NA NA,6-12 yo,8.4,12.41,NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3836,Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0 100 100,High Cognitive training NA   0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA WISC-IV Digit Span (Combined Forward/Backward) NA NA,NA,Green 2012 NA RCT G, 12, 14   26,NA,NA  0.3900000000,-0.390000000, 1.170000e+00,NA,NA,NA NA,NA,NA NA NA,100,100,100,100 100 100 100 some,low some,low some Non-adaptive   0 NA, 9.750000 NA DSM-IV,0 1 1.0 1.0,1.0,1.0 1 1 1,1,1 1,1 0.5,0,1 1 1  535 Green_2012 NA,NA 6-12 yo,6.55,12.41 NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100 100,High Cognitive training NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,Conners Rating Scale, 1.15074799,   3.7500000,h/week Hasslinger 2021,NA RCT,G, 50  49,  99 NA NA, 0.1200000000 -0.270000000, 5.100000e-01,NA,NA NA,NA,NA,NA NA,NA   0   0,100,100 100 100   0 some low,low,high some TAU   0 NA 12.410000 NA,ICD-10 0,1 1.0 1.0,1.0 1.0,1,1 1,1,1,1 1 0.5 0,1,1,1, 536 Hasslinger_2021,< 2 months,NA 6-12 yo,8.4,12.41 NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0,100 100,High,Cognitive training,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks),NA,Conners Rating Scale  1.15074799,   3.7500000 h/week,Hasslinger,2021,NA RCT G  50  49   99 NA NA, 0.2000000000,-0.190000000  5.900000e-01,NA,NA,NA,NA NA,NA,NA,NA,  0,  0,100 100 100 100,  0,some low,low,high,some,TAU   0 NA 12.410000 NA ICD-10,0 1,1.0,1.0,1.0,1.0 1 1,1,1,1 1 1 0.5 0 1,1 1  537 Hasslinger_2021,< 2 months NA 6-12 yo,8.98 12.41 NA NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low high
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0 100,100 High,Cognitive training NA,  0,NA Executive functioning (report),NA,At study endpoint (closest to 12 weeks) NA,BRIEF  1.15074799    3.7500000,h/week Hasslinger,2022,NA,RCT,G, 48, 48   96,NA NA  0.1800000000 -0.210000000, 5.700000e-01,NA NA NA NA NA,NA,NA,NA   0,  0 100,100   0,100   0,some,low high high,some,TAU,  0,NA,12.410000 NA,ICD-10 0 1,1.0 1.0,1.0,1.0 1 1 1,1 1,1,1 0.5,0 1,1,1  538 Hasslinger_2022,< 2 months NA,6-12 yo 10.02,12.41 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0,100,100,High Cognitive training,NA   0,NA,Executive functioning (report),NA At follow-up (closest to 26 weeks),NA BRIEF, 1.15074799,   3.7500000 h/week Hasslinger 2022 NA,RCT G, 48, 49,  97 NA NA, 0.1500000000,-0.240000000, 5.400000e-01,NA,NA,NA,NA NA NA NA NA   0,  0,100,100,  0 100,  0 some low,high,high some TAU,  0 NA 12.410000 NA ICD-10,0,1,1.0 1.0,1.0,1.0 1,1 1,1 1 1 1,0.5,0,1,1 1  539 Hasslinger_2022 < 2 months,NA,6-12 yo 10.02,12.41 NA NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low,high
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0 100,100 High,Cognitive training NA   0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,CPT-II  1.15074799    3.7500000,h/week Hasslinger,2022 NA RCT,G  50  49,  99 outcomes,NA -0.2200000000,-0.610000000  1.700000e-01 NA,NA NA,NA,NA NA,NA NA   0,  0 100,100,  0 100,  0,some,low,high high,some TAU,  0,NA,12.410000 NA ICD-10,0,1 1.0,1.0,1.0 1.0 1 1 1 1,1,1 1,0.5 0,1 1,1, 540,Hasslinger_2022,< 2 months,NA 6-12 yo,6.55,12.41,NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100 100,High Cognitive training,NA   0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,Conners' CPT-II  1.15074799,   3.7500000,h/week,Hasslinger,2022 NA,RCT,G, 50  49   99 outcomes,NA -0.1900000000 -0.580000000  2.000000e-01 NA NA,NA NA NA NA NA NA,  0,  0 100 100   0,100,  0 some,low,high,high,some TAU,  0 NA 12.410000 NA ICD-10 0 1,1.0,1.0 1.0,1.0,1 1,1 1,1,1,1 0.5 0,1 1,1, 541,Hasslinger_2022,< 2 months,NA 6-12 yo 6.55,12.41,NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0 100,100,High Cognitive training,NA   0,NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA,WISC-IV/WAIS-IV Digit Span (Combined Forward/Backward)  1.15074799,   3.7500000 h/week,Hasslinger,2022,NA,RCT G, 51  50  101,outcomes NA, 0.2800000000  0.010000000  5.500000e-01,NA,NA,NA NA,NA,NA,NA NA,  0   0,100,100   0 100   0 some low high high some,TAU   0 NA 12.410000,NA ICD-10,0 1 1.0,1.0 1.0 1.0,1,1,1,1,1,1 1,0.5 0 1,1,1, 542,Hasslinger_2022 < 2 months,NA 6-12 yo 6.55 12.41,NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0 100,100,High,Cognitive training NA,  0 NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA Block Tapping (Combined Forward/Backward)  1.15074799    3.7500000 h/week,Hasslinger 2022 NA RCT,G, 51, 50  101 outcomes NA  0.5900000000, 0.300000000, 8.800000e-01 NA,NA NA,NA,NA,NA NA NA   0,  0 100 100,  0 100,  0 some low,high,high some TAU   0 NA 12.410000,NA ICD-10,0,1,1.0 1.0 1.0,1.0 1,1 1 1 1 1,1,0.5,0 1 1,1, 543 Hasslinger_2022,< 2 months NA,6-12 yo 6.55 12.41,NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100   0 100,100,High Cognitive training NA,  0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,CPT Hit MRTs, 1.15074799,   3.7500000 h/week Hasslinger,2022,NA RCT,G, 50  49,  99,outcomes,NA,-0.1200000000,-0.510000000  2.700000e-01,NA NA,NA NA NA,NA,NA,NA   0,  0,100,100,  0 100,  0,some low high high some TAU,  0,NA,12.410000 NA,ICD-10 0,1,1.0 1.0 1.0 1.0,1,1 1,1,1 1,1,0.5,0 1 1 1, 544,Hasslinger_2022,< 2 months,NA,6-12 yo 6.55 12.41 NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0 100 100,High Cognitive training NA   0,NA,Executive functioning (tests),NA At follow-up (closest to 26 weeks) NA Conners' CPT-II  1.15074799,   3.7500000,h/week Hasslinger,2022,NA RCT,G  50  49,  99 outcomes,NA,-0.0300000000 -0.420000000, 3.600000e-01 NA,NA,NA NA NA,NA,NA NA,  0,  0 100,100   0,100,  0,some low,high high some,TAU,  0,NA 12.410000,NA ICD-10 0,1,1.0 1.0,1.0,1.0 1 1,1 1,1 1 1 0.5,0,1 1 1, 545,Hasslinger_2022 < 2 months NA,6-12 yo 8.98,12.41,NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low,high
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100 100,High Cognitive training,NA   0 NA,Executive functioning (tests),NA At follow-up (closest to 26 weeks) NA,CPT-II, 1.15074799    3.7500000,h/week,Hasslinger 2022,NA RCT,G, 50, 49,  99,outcomes,NA,-0.0300000000 -0.420000000, 3.600000e-01,NA,NA,NA,NA NA,NA NA NA,  0   0,100,100   0 100   0,some,low high,high,some TAU   0 NA 12.410000 NA ICD-10 0 1 1.0,1.0,1.0 1.0,1 1 1,1 1,1,1 0.5 0 1,1 1  546,Hasslinger_2022 < 2 months NA,6-12 yo,8.98 12.41 NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low high
3836,Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0,100,100 High,Cognitive training NA   0,NA Executive functioning (tests) NA At follow-up (closest to 26 weeks),NA,WISC-IV/WAIS-IV Digit Span (Forward)  1.15074799    3.7500000,h/week Hasslinger 2022 NA RCT G, 51  50, 101,outcomes,NA  0.2800000000, 0.010000000  5.500000e-01 NA,NA NA NA NA NA NA NA,  0,  0 100,100   0,100,  0 some,low,high high some,TAU   0 NA,12.410000,NA,ICD-10 0 1 1.0 1.0 1.0 1.0,1 1 1,1,1,1,1,0.5 0 1 1 1  547,Hasslinger_2022,< 2 months,NA,6-12 yo,8.98,12.41 NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,high
3836,Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0 100,100,High Cognitive training NA,  0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA WISC-IV Digit Span Forward & Backward NA,NA NA,Hovik,2013,NA RCT G  33, 34,  67 NA NA, 0.6000000000, 0.110000000, 1.090000e+00,NA NA,NA,NA NA NA,NA NA,  0   0 100,100,100 100,  0 low low some,high,some,TAU,  0,NA 10.500000 NA,F-90 ICD-10 0 1,1.0 1.0 1.0,1.0,1,1,1 1 1,1 1,0.5 0,1,1,1  548 Hovik_2013 NA,NA 6-12 yo,6.55,12.41 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0,100,100 High,Cognitive training NA   0 NA,Executive functioning (tests) NA,At follow-up (closest to 26 weeks),NA WISC-IV Digit Span Forward & Backward,NA NA,NA,Hovik,2013 NA RCT G, 33, 34,  67,NA,NA, 0.4800000000 -0.010000000, 9.700000e-01 NA,NA NA,NA,NA,NA NA,NA   0   0 100,100,100 100,  0 low,low,some,high some,TAU,  0,NA 10.500000,NA,F-90 ICD-10 0 1 1.0 1.0 1.0 1.0 1 1 1,1,1,1 1 0.5,0 1,1 1  549,Hovik_2013 NA NA,6-12 yo 8.98,12.41,NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,high
3836 Westwood - Adults (2024),Westwood - Adults,2024,10.1038/s41380-023-02000-7 100   0,100 100 High Cognitive training,NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA WAIS-IV Digit Span (Combined Forward/Backward),NA,NA NA Jaquerod 2020,NA RCT,G, 14  14,  28,NA,NA  0.1300000000,-0.610000000  8.700000e-01 NA,NA NA NA,NA,NA,NA NA   0,  0,  0 100,100 100 100 high some,low,some some Non-adaptive,  0 NA 22.200000,NA,DSM-IV,0 1,1.0 1.0 1.0 1.0 1 1 1 1,1 1 1,0.5,0,1,1,1, 550 Jaquerod_2020,NA,NA,>= 20 yo,22.2 38.91,NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,high
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0,100,100,High,Cognitive training NA   0 NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA,GNG  1.15074799,   2.5000000,h/week,Johnstone 2010 NA RCT G, 15, 14,  29,outcomes,NA -0.0800000000,-0.810000000, 6.500000e-01,NA,NA NA,NA NA,NA NA,NA,100 100,100 100,  0 100 100,some low high,low,some,Non-adaptive,  0,NA,10.700000 NA DSM-IV 0,1,1.0 1.0,1.0,1.0,1 1 1 1,1,1 1,0.5 0,1 1 1, 551,Johnstone_2010 < 2 months,NA 6-12 yo 6.55 12.41 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3836,Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7 100   0,100 100 High Cognitive training,NA   0 NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA GNG, 1.15074799,   2.5000000 h/week,Johnstone,2010,NA RCT,G, 15  14   29 outcomes,NA  0.2100000000,-0.520000000, 9.400000e-01 NA,NA NA NA,NA NA NA NA 100 100 100 100,  0,100 100,some,low,high low some,Non-adaptive,  0,NA,10.700000,NA,DSM-IV,0,1,1.0,1.0,1.0,1.0 1 1 1 1 1,1 1 0.5 0 1,1,1, 552,Johnstone_2010,< 2 months,NA,6-12 yo,6.55 12.41 NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0,100 100 High Cognitive training,NA   0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,GNG, Go MRTs  1.15074799,   2.5000000 h/week,Johnstone,2010 NA,RCT G  15, 14,  29 outcomes NA,-0.3700000000 -1.110000000, 3.700000e-01 NA NA NA,NA,NA NA NA,NA 100,100 100 100,  0 100 100,some,low high low,some,Non-adaptive,  0,NA,10.700000,NA,DSM-IV,0,1 1.0,1.0 1.0,1.0 1 1,1,1,1 1,1,0.5,0 1 1,1  553 Johnstone_2010,< 2 months,NA 6-12 yo,6.55,12.41,NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0 100 100,High Cognitive training,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA Conners Rating Scale,NA NA,NA,Klingberg 2005 NA RCT G  26  27   53,outcomes NA  0.2000000000,-0.390000000  7.900000e-01 NA,NA NA NA NA,NA NA,NA 100,100 100,100   0,100,100 low low high,low some Non-adaptive   0 NA, 9.900000 NA,DSM-IV 0,1,1.0 1.0 1.0,1.0 1,1 1,1,1,1,1,0.5,0,1 1,1  554 Klingberg_2005 NA NA 6-12 yo,6.55 10.6,NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0 100,100 High,Cognitive training,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,Conners Rating Scale,NA,NA NA,Klingberg,2005 NA,RCT G, 26  27   53 outcomes,NA, 0.5500000000,-0.040000000  1.140000e+00 NA NA NA,NA,NA NA NA NA 100 100 100 100,  0 100,100,low low,high low,some,Non-adaptive,  0,NA  9.900000,NA,DSM-IV,0,1 1.0 1.0 1.0,1.0,1 1 1,1,1 1 1 0.5 0,1 1 1  555,Klingberg_2005,NA,NA,6-12 yo,8.4 12.41,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3836,Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0,100,100,High,Cognitive training NA   0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA Raven's Matrix,NA NA NA,Klingberg 2005 NA RCT G, 20  24   44 outcomes NA  0.2300000000,-0.360000000, 8.200000e-01,NA NA NA NA NA NA,NA,NA,100,100,100,100   0,100 100,low low,high low,some Non-adaptive,  0,NA  9.900000 NA DSM-IV,0 1 1.0,1.0 1.0,1.0,1,1 1 1,1 1 1 0.5 0,1 1,1, 556 Klingberg_2005 NA NA,6-12 yo 6.55 12.41 NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0,100,100,High,Cognitive training,NA,  0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,Digit Span (Combined Forward/Backward),NA NA,NA Klingberg,2005 NA,RCT G, 20, 24   44 outcomes,NA, 0.5700000000,-0.040000000  1.180000e+00 NA NA NA NA,NA NA NA,NA,100,100,100,100,  0,100,100,low low high,low,some Non-adaptive,  0 NA  9.900000 NA,DSM-IV,0,1,1.0,1.0,1.0,1.0,1,1 1,1,1,1,1,0.5 0,1,1,1, 557,Klingberg_2005,NA,NA,6-12 yo 6.55,12.41 NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3836,Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100,  0,100 100,High,Cognitive training NA,  0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA Span-Board (Combined Forward/Backward),NA,NA NA,Klingberg,2005,NA,RCT,G, 20, 24   44,outcomes,NA, 0.7800000000  0.170000000, 1.390000e+00 NA,NA NA,NA NA NA NA NA 100,100,100,100   0,100,100 low low high low some Non-adaptive,  0,NA  9.900000 NA,DSM-IV 0 1 1.0,1.0 1.0 1.0,1,1,1,1,1,1,1,0.5 0,1 1 1, 558,Klingberg_2005 NA NA,6-12 yo 6.55,12.41 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3836,Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7 100   0 100,100,High Cognitive training NA,  0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA Stroop Task Incongruent Trials, Accuracy NA,NA,NA Klingberg 2005 NA,RCT,G, 20, 23,  43,outcomes,NA, 0.4800000000 -0.130000000  1.090000e+00,NA NA,NA NA NA NA,NA NA,100 100,100,100,  0 100 100 low low high,low some Non-adaptive,  0 NA  9.900000,NA DSM-IV 0 1 1.0 1.0,1.0,1.0 1,1,1 1 1 1,1,0.5,0 1,1,1, 559 Klingberg_2005,NA,NA,6-12 yo 6.55 12.41,NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3836,Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0,100,100,High,Cognitive training NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,Digit Span (Forward & Backward) NA NA NA,Klingberg,2005 NA RCT G  18, 23,  41,outcomes NA  0.5200000000 -0.110000000  1.150000e+00,NA,NA,NA NA,NA NA NA,NA,100,100,100 100   0,100 100,low,low,high,low,some,Non-adaptive   0,NA  9.900000,NA,DSM-IV 0 1 1.0,1.0 1.0,1.0,1 1 1,1 1 1 1 0.5 0,1 1,1  560,Klingberg_2005 NA NA 6-12 yo,6.55 12.41 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3836 Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100,  0 100,100 High Cognitive training NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA,CRS-R, 0.92059839,   1.2500000 h/week,Meyer 2020 NA,RCT G, 20, 20,  40 outcomes,NA  0.0600000000,-0.370000000  4.900000e-01,NA NA NA,NA,NA NA NA NA   0,  0,  0,100,100,100 100 high low low low some,Non-adaptive,  0,NA 10.330000,NA DSM-IV --> "Confirmation of ADHD diagnosis was performed using the DISC-IV",0 1 1.0 1.0,1.0 1.0,1,1 1 1,1 1,1,0.5,0,1 1 1, 561 Meyer_2020 < 2 months NA,6-12 yo 6.55 10.6,NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
3836 Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7,100   0 100 100,High,Cognitive training NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA SNAP-IV  0.92059839,   1.2500000,h/week Meyer 2020,NA,RCT,G  20  20   40,outcomes NA  0.4100000000,-0.020000000  8.400000e-01,NA NA NA NA,NA,NA,NA,NA   0   0,  0 100,100,100,100 high,low,low low,some,Non-adaptive,  0 NA 10.330000 NA DSM-IV --> "Confirmation of ADHD diagnosis was performed using the DISC-IV",0,1,1.0 1.0 1.0 1.0 1,1 1 1 1,1,1 0.5 0 1,1 1  562,Meyer_2020,< 2 months NA,6-12 yo 8.4 12.41 NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
3836 Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100,  0 100 100 High,Cognitive training NA   0,NA,Academic/job performance NA At follow-up (closest to 26 weeks) NA WIAT-II Reading Comprehension, 1.15074799    3.1250000,h/week Rivard (Dentz 2020a),2020 NA,RCT,G, 17, 14,  31 NA NA  0.2500000000 -0.300000000, 8.000000e-01,NA,NA,NA,NA NA NA NA,NA,100,100,100 100,  0,100,100 low,low high low,some,Non-adaptive   0 NA 10.000000,NA,DSM-IV,0,1 1.0,1.0 1.0 1.0,1 1,1,1,1 1,1 0.5 0 1,1 1  563 Rivard (Dentz 2020a)_2020,< 2 months,NA 6-12 yo,8.98,11.59,NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low low
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0 100,100,High,Cognitive training,NA   0,NA Executive functioning (tests),NA,At follow-up (closest to 26 weeks) NA CPT  1.15074799    3.1250000 h/week Rivard (Dentz 2020a) 2020,NA RCT G, 17, 14,  31 outcomes,NA  0.1500000000,-0.560000000  8.600000e-01 NA,NA,NA NA NA NA,NA,NA 100 100 100,100,  0,100 100 low low high,low some Non-adaptive   0,NA 10.000000,NA DSM-IV 0 1 1.0 1.0 1.0 1.0,1 1 1,1 1,1 1 0.5 0,1,1 1, 564,Rivard (Dentz 2020a)_2020,< 2 months NA,6-12 yo,8.98 12.41 NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100   0 100 100 High,Cognitive training NA,  0 NA,Executive functioning (tests) NA At follow-up (closest to 26 weeks),NA WISC-IV Digit Span Forward & Backward Combined  1.15074799,   3.1250000 h/week,Rivard (Dentz 2020a),2020,NA RCT G  17  14,  31 outcomes,NA  0.1400000000 -0.510000000  7.900000e-01 NA NA NA NA,NA NA,NA,NA 100 100,100 100,  0 100 100 low,low high,low some,Non-adaptive,  0,NA 10.000000,NA,DSM-IV,0,1 1.0 1.0 1.0 1.0,1,1,1 1,1,1 1,0.5,0 1 1 1  565,Rivard (Dentz 2020a)_2020 < 2 months,NA,6-12 yo,8.98 12.41 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low,low
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100,  0 100 100,High Cognitive training,NA,  0,NA,Executive functioning (tests) NA,At follow-up (closest to 26 weeks),NA CPT - Oms, 1.15074799    3.1250000,h/week Rivard (Dentz 2020a) 2020 NA,RCT G  17  19,  36 outcomes,NA, 0.4600000000,-0.250000000, 1.170000e+00,NA NA NA NA,NA,NA NA,NA 100,100 100 100   0,100 100,low,low,high,low,some Non-adaptive   0,NA 10.000000,NA DSM-IV 0,1 1.0 1.0 1.0,1.0 1 1,1 1,1,1,1,0.5 0,1,1,1  566 Rivard (Dentz 2020a)_2020 < 2 months NA,6-12 yo,8.98 12.41 NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,low
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0 100 100,High,Cognitive training,NA,  0 NA Executive functioning (tests) NA,At follow-up (closest to 26 weeks) NA Conners' CPT-II - Coms  1.15074799,   3.1250000,h/week,Rivard (Dentz 2020a),2020,NA RCT,G, 17, 14   31 outcomes NA  0.4600000000,-0.250000000  1.170000e+00 NA,NA NA NA NA,NA NA,NA,100,100 100,100   0 100 100,low,low high low,some Non-adaptive   0 NA,10.000000 NA,DSM-IV 0,1 1.0 1.0,1.0 1.0 1 1,1 1 1 1 1 0.5,0,1,1,1  567 Rivard (Dentz 2020a)_2020 < 2 months,NA,6-12 yo,8.98 12.41,NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low low
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0,100,100 High Cognitive training,NA,  0 NA Academic/job performance NA At study endpoint (closest to 12 weeks) NA WIAT-III Math  2.30149597    1.7500000,h/week,Sandberg 2021 NA,RCT G, 20, 20,  40 outcomes,NA -0.1300000000 -0.760000000, 5.000000e-01,NA NA,NA,NA NA,NA NA,NA,  0   0 100 100 100,100   0 some low,low,high some WLC,  0,NA,11.590000,NA,DSM-V,0,1 1.0 1.0,1.0,1.0 1,1 1 1 1,1 1,0.5,0 1 1 1  568,Sandberg_2021,2-6 months,NA,6-12 yo 8.4 11.59,NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0,100,100 High Cognitive training NA,  0 NA Academic/job performance NA,At study endpoint (closest to 12 weeks),NA WIAT - Reading Comprehension, 2.30149597    1.7500000,h/week Sandberg,2021 NA,RCT,G, 20  20   40,outcomes NA  0.0300000000,-0.600000000  6.600000e-01,NA NA NA NA,NA,NA NA,NA   0   0,100 100 100 100   0 some,low low,high some,WLC,  0 NA 11.590000,NA,DSM-V,0,1 1.0 1.0 1.0 1.0,1,1,1 1 1 1 1 0.5,0,1,1,1, 569 Sandberg_2021 2-6 months,NA,6-12 yo 8.4,11.59,NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0,100,100,High Cognitive training,NA,  0 NA,Academic/job performance,NA At study endpoint (closest to 12 weeks),NA WIAT - Reading Fluency  2.30149597    1.7500000,h/week Sandberg 2021,NA RCT G, 25, 25   50,outcomes NA  0.3100000000 -0.320000000  9.400000e-01 NA NA NA NA,NA,NA NA NA,  0,  0,100 100,100 100   0,some low,low high,some WLC   0,NA,11.590000,NA DSM-V,0 1,1.0,1.0,1.0 1.0 1,1,1 1,1 1,1 0.5,0,1 1 1  570 Sandberg_2021 2-6 months NA,6-12 yo 8.4,11.59 NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0 100,100,High,Cognitive training NA   0,NA Academic/job performance,NA At follow-up (closest to 26 weeks) NA WIAT - Reading Comprehension, 2.30149597    1.7500000 h/week,Sandberg,2021,NA,RCT G  20, 20,  40,NA NA, 0.6300000000  0.140000000, 1.120000e+00,NA,NA NA,NA,NA,NA NA,NA   0,  0 100 100,100 100   0 some,low,low high,some,WLC   0 NA,11.590000 NA,DSM-V 0,1,1.0 1.0,1.0 1.0,1 1,1,1,1,1,1,0.5 0 1,1 1, 571 Sandberg_2021 2-6 months,NA 6-12 yo,8.98 11.59,NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,high
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100,100,High,Cognitive training NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA CBCL, 2.30149597,   1.7500000 h/week Sandberg 2021 NA,RCT G, 20, 20,  40 NA,NA, 0.1800000000 -0.450000000  8.100000e-01 NA NA NA,NA,NA NA NA,NA,  0,  0,100,100 100 100   0,some,low low,high,some,WLC,  0 NA 11.590000,NA DSM-V,0 1 1.0 1.0 1.0 1.0 1,1 1,1,1 1,1 0.5 0 1 1 1, 572 Sandberg_2021,2-6 months,NA,6-12 yo,8.4 12.41,NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0,100 100,High,Cognitive training NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),NA CBCL - ADHD Total, 2.30149597,   1.7500000 h/week Sandberg 2021 NA,RCT,G, 20  20   40 NA NA  0.6000000000 -0.030000000  1.230000e+00,NA,NA,NA NA,NA NA NA NA   0   0 100 100 100,100,  0,some low,low,high,some,WLC,  0,NA,11.590000 NA,DSM-V 0,1 1.0,1.0 1.0 1.0,1,1 1 1,1 1 1,0.5,0,1,1,1  573,Sandberg_2021 2-6 months NA 6-12 yo,8.98 12.41 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low high
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100   0 100,100 High Cognitive training,NA   0 NA Executive functioning (report) Parent-rated At study endpoint (closest to 12 weeks),NA BRIEF, 2.30149597    1.7500000 h/week,Sandberg,2021 NA RCT,G  20, 20,  40 NA NA  0.2600000000 -0.370000000  8.900000e-01,NA NA,NA,NA,NA NA NA,NA,  0   0,100,100,100,100   0 some low low,high some WLC,  0,NA,11.590000,NA DSM-V 0 1,1.0,1.0,1.0 1.0 1 1 1 1,1,1,1,0.5,0,1 1,1  574 Sandberg_2021,2-6 months,NA 6-12 yo 6.55,11.59,NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0 100,100 High Cognitive training,NA   0,NA,Executive functioning (report) Parent-rated,At follow-up (closest to 26 weeks),NA BRIEF  2.30149597    1.7500000,h/week Sandberg 2021 NA RCT G, 20  20,  40,NA,NA  0.7000000000  0.050000000  1.350000e+00 NA NA NA,NA NA,NA,NA NA,  0,  0,100,100,100,100   0 some,low,low high some,WLC   0 NA 11.590000,NA DSM-V 0,1 1.0,1.0,1.0,1.0 1,1,1,1,1 1,1,0.5,0,1,1,1, 575,Sandberg_2021,2-6 months,NA 6-12 yo,8.98 11.59,NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low high
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0,100 100 High,Cognitive training NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA BOSS  4.60299194    1.5000000,h/week Steiner 2014,NA RCT G, 34, 36   70 NA NA  0.0700000000,-0.260000000, 4.000000e-01 NA NA,NA,NA NA,NA,NA NA 100,100 100,100,100 100,100,low low some some,some WLC,  0,NA, 8.650000 NA DSM-IV,0,1 1.0,1.0,1.0,1.0 1,1,1,1,1,1 1 0.5 0,1,1 1, 576,Steiner_2014 2-6 months,NA 6-12 yo,6.55 8.65 NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0 100,100 High,Cognitive training NA   0,NA,Executive functioning (report),Parent-rated At study endpoint (closest to 12 weeks),NA,BRIEF  4.60299194,   1.5000000 h/week Steiner,2014 NA RCT G  34, 36   70 NA,NA, 0.0600000000 -0.410000000, 5.300000e-01 NA,NA NA NA NA NA NA NA,100,100,100 100,100,100,100 low low some,some some WLC   0 NA  8.650000 NA,DSM-IV 0 1 1.0,1.0,1.0,1.0,1,1,1 1 1 1 1 0.5,0,1,1 1  577,Steiner_2014,2-6 months NA,6-12 yo,6.55 11.59 NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3836,Westwood - Adults (2024) Westwood - Adults 2024 10.1038/s41380-023-02000-7 100,  0 100,100 High,Cognitive training,NA   0 NA Executive functioning (report),Self-rated,At study endpoint (closest to 12 weeks) NA BRIEF,NA,NA h/week Stern,2016,NA,RCT,G, 26, 13   39 NA NA,-0.0500000000 -0.720000000  6.200000e-01,NA,NA,NA NA,NA NA,NA NA,  0,  0 100   0,  0,100,  0,low,high high high,some Non-adaptive   0,NA 37.200000 NA DSM-IV-TR 0,1 1.0 1.0 1.0 1.0,1 1 1 1 1 1,1 0.5,0,1,1 1  578 Stern_2016,NA,NA,>= 20 yo 37.2,37.2 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA,Westwood - Adults (2024)_Cognitive training_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,high
3836,Westwood - Adults (2024) Westwood - Adults,2024 10.1038/s41380-023-02000-7 100   0 100 100,High Cognitive training,NA,  0 NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA GNG - Coms,NA,NA h/week,Stern,2016,NA,RCT,G, 26  13   39 outcomes NA -0.3900000000,-1.060000000  2.800000e-01 NA,NA,NA NA NA,NA NA NA   0,  0 100   0,  0 100   0,low high,high,high some Non-adaptive   0,NA 37.200000 NA,DSM-IV-TR 0 1,1.0 1.0,1.0 1.0,1,1 1,1 1 1 1,0.5,0 1 1 1  579,Stern_2016 NA,NA >= 20 yo,22.2,38.91,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low high
3836 Westwood - Adults (2024),Westwood - Adults 2024,10.1038/s41380-023-02000-7 100   0 100,100 High Cognitive training NA   0,NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,IntegNeuro - Digit Span (Combined
Forward/Backward),NA NA h/week Stern,2016,NA,RCT G  26  13,  39 outcomes,NA  0.1100000000,-0.630000000  8.500000e-01,NA NA NA,NA NA,NA,NA NA   0,  0,100,  0   0 100   0,low,high high,high some Non-adaptive   0,NA 37.200000,NA,DSM-IV-TR 0,1,1.0 1.0 1.0 1.0,1 1,1,1,1 1 1 0.5,0,1 1,1  580,Stern_2016 NA,NA,>= 20 yo 22.2 38.91,NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low high
3836 Westwood - Adults (2024) Westwood - Adults,2024,10.1038/s41380-023-02000-7 100   0 100 100 High Cognitive training NA,  0 NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA,GNG - Oms NA,NA,h/week Stern,2016 NA,RCT G, 26, 13,  39,outcomes,NA  0.3900000000 -0.280000000  1.060000e+00,NA NA NA NA,NA NA,NA NA   0,  0,100   0,  0,100   0 low high high high,some Non-adaptive   0,NA,37.200000,NA DSM-IV-TR,0 1 1.0,1.0,1.0 1.0 1 1,1,1,1 1 1,0.5,0 1,1,1  581 Stern_2016,NA NA,>= 20 yo 22.2 38.91 NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA NA,Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low high
3836 Westwood - Adults (2024) Westwood - Adults,2024,10.1038/s41380-023-02000-7 100   0 100,100,High Cognitive training,NA,  0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA IntegNeuro - Choice RT, MRT,NA NA h/week,Stern 2016,NA,RCT,G, 23  10   33,outcomes,NA -1.0000000000,-1.780000000,-2.200000e-01 NA,NA,NA,NA,NA,NA,NA,NA   0,  0 100   0,  0 100   0 low high high,high,some,Non-adaptive,  0,NA,37.200000,NA,DSM-IV-TR 0,1 1.0,1.0 1.0,1.0,1,1,1 1,1,1,1,0.5 0,1 1,1, 582 Stern_2016 NA NA,>= 20 yo,22.2,38.91 NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low high
3836,Westwood - Adults (2024) Westwood - Adults 2024 10.1038/s41380-023-02000-7 100,  0 100 100,High Cognitive training,NA,  0 NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA IntegNeuro - Switching of Attention,NA,NA h/week Stern,2016 NA RCT,G  26  13,  39 outcomes,NA  0.6900000000  0.000000000  1.380000e+00 NA,NA NA NA,NA NA NA NA   0,  0,100,  0,  0,100   0 low high high high some Non-adaptive   0,NA 37.200000 NA,DSM-IV-TR,0,1 1.0,1.0,1.0,1.0,1 1,1 1 1 1 1 0.5,0 1,1,1  583 Stern_2016,NA NA,>= 20 yo,22.2,38.91,NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,high
3836 Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100   0,100,100 High Cognitive training NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,DBDRS,NA    1.2500000,h/week,van da oord 2014,NA RCT,G, 18, 22,  40 NA NA, 0.9500000000  0.480000000, 1.420000e+00 NA,NA,NA NA,NA,NA,NA,NA   0   0,100 100 100,100   0 low low some high,some,WLC,  0,NA  9.790000 NA DSM-IV,0 1,1.0 1.0,1.0,1.0,1 1 1 1 1 1,1,0.5 0 1,1,1  584 van da oord_2014,NA NA,6-12 yo,8.4,12.41 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0 100 100 High,Cognitive training,NA,  0 NA Executive functioning (report) Parent-rated,At study endpoint (closest to 12 weeks) NA BRIEF NA,   1.2500000,h/week van da oord 2014,NA RCT,G, 18  22   40,NA NA, 0.5600000000,-0.070000000, 1.190000e+00 NA,NA,NA,NA NA,NA NA NA,  0   0 100,100,100,100   0 low low,some high,some WLC   0,NA  9.790000,NA,DSM-IV,0 1 1.0 1.0,1.0 1.0,1 1 1,1,1,1 1 0.5,0,1,1 1  585 van da oord_2014,NA NA 6-12 yo,6.55 11.59 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
3836,Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100,100,High Cognitive training NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),NA,ADHD-RS  1.15074799    1.2500000 h/week van Dongen-Boomsma 2014 NA,RCT G  18, 14,  32,NA NA,-0.0100000000,-0.724795360, 7.047954e-01 NA,NA,NA,NA NA NA,NA,NA 100 100 100 100,100,100,100,low low some,low some,Non-adaptive   0,NA, 6.550000 NA DSM-IV-TR 0,1,1.0,1.0 1.0,1.0 1 1,1 1,1,1 1,0.5,0 1 1 1, 586 van Dongen-Boomsma_2014,< 2 months NA,6-12 yo 6.55,10.6 NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100   0,100 100,High Cognitive training,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA ADHD-RS  1.15074799,   1.2500000,h/week,van Dongen-Boomsma 2014,NA,RCT,G, 22  19,  41 NA,NA, 0.2800000000,-0.350000000, 9.100000e-01,NA,NA NA NA NA NA NA,NA,100,100,100,100 100 100 100,low low,some low,some,Non-adaptive,  0,NA  6.550000,NA DSM-IV-TR,0,1 1.0 1.0,1.0,1.0,1 1,1,1,1 1 1,0.5,0,1 1 1, 587,van Dongen-Boomsma_2014,< 2 months,NA 6-12 yo 6.55,8.65 NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100,100,High Cognitive training,NA   0,NA Executive functioning (report) Parent-rated At study endpoint (closest to 12 weeks),NA,BRIEF  1.15074799,   1.2500000,h/week van Dongen-Boomsma,2014,NA RCT G  15, 16,  31 NA,NA -0.0300000000 -0.740000000, 6.800000e-01,NA,NA,NA NA NA NA NA,NA,100 100,100,100 100,100 100 low low,some low,some,Non-adaptive   0 NA, 6.550000,NA,DSM-IV-TR,0 1,1.0,1.0 1.0,1.0 1,1 1,1 1,1,1,0.5 0 1,1,1  588 van Dongen-Boomsma_2014,< 2 months,NA,6-12 yo 6.55,11.59 NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3836 Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100,  0 100,100 High Cognitive training NA   0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA Shortened Raven Coloured Progressive Matrices  1.15074799,   1.2500000,h/week van Dongen-Boomsma 2014,NA RCT,G, 26  21,  47,outcomes,NA -0.0800000000 -0.650000000  4.900000e-01 NA,NA NA,NA NA,NA,NA NA,100,100 100 100 100 100,100,low,low,some low some,Non-adaptive   0 NA, 6.550000 NA DSM-IV-TR 0 1 1.0 1.0 1.0 1.0,1,1 1,1,1 1 1 0.5 0,1,1 1  589 van Dongen-Boomsma_2014,< 2 months NA 6-12 yo 6.55,12.41 NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0,100,100,High Cognitive training NA,  0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA Knox Cubes LDT (Combined Forward/Backward)  1.15074799    1.2500000 h/week van Dongen-Boomsma 2014,NA,RCT G  26  19   45,outcomes NA, 0.0800000000,-0.330000000, 4.900000e-01 NA NA NA NA NA NA,NA NA,100,100 100,100 100,100,100 low,low,some low some Non-adaptive   0,NA  6.550000 NA,DSM-IV-TR,0,1 1.0 1.0 1.0 1.0,1,1,1 1,1,1,1,0.5 0,1,1,1  590,van Dongen-Boomsma_2014,< 2 months NA 6-12 yo,6.55,12.41,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0 100,100,High,Cognitive training,NA   0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,SA-DOTS-02K  1.15074799    1.2500000,h/week,van Dongen-Boomsma,2014 NA RCT G  23  20   43 outcomes NA, 0.2900000000,-0.230000000  7.900000e-01,NA,NA,NA,NA,NA,NA,NA,NA,100,100 100 100 100 100 100 low low some,low some Non-adaptive   0,NA  6.550000 NA DSM-IV-TR,0,1,1.0,1.0 1.0,1.0 1,1,1,1,1,1,1,0.5,0 1,1,1, 591 van Dongen-Boomsma_2014 < 2 months,NA 6-12 yo 6.55,12.41,NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0 100,100,High,Cognitive training,NA,  0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA,Adapted WISC-III Digit Span (Combined Forward/Backward)  1.15074799    1.2500000 h/week,van Dongen-Boomsma 2014,NA,RCT G  22, 21,  43,outcomes NA  0.5500000000,-0.140000000, 1.240000e+00 NA NA,NA,NA NA,NA NA NA,100 100 100,100 100 100,100,low,low some,low some,Non-adaptive,  0,NA  6.550000,NA DSM-IV-TR,0,1 1.0,1.0,1.0,1.0,1,1 1,1 1,1 1 0.5,0,1,1,1, 592,van Dongen-Boomsma_2014 < 2 months NA 6-12 yo,6.55 12.41 NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100   0 100 100 High,Cognitive training NA,  0,NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA Day-Night Stroop Task, Completion Time (Congruent-Incongruent controlling for correct responses)  1.15074799,   1.2500000 h/week,van Dongen-Boomsma 2014 NA,RCT,G  20, 20,  40,outcomes,NA,-0.6100000000,-1.240000000, 2.000000e-02,NA,NA,NA NA,NA NA,NA NA 100,100,100,100,100,100,100 low,low some low some,Non-adaptive   0,NA, 6.550000,NA,DSM-IV-TR 0,1,1.0 1.0,1.0,1.0 1,1,1,1,1,1 1,0.5 0,1,1 1, 593,van Dongen-Boomsma_2014 < 2 months,NA,6-12 yo 6.55,12.41,NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0 100,100 High,Cognitive training NA   0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,SA-DOTS-02K, Hit MRT controlling for N, 1.15074799,   1.2500000 h/week,van Dongen-Boomsma 2014,NA RCT G, 23, 20,  43 outcomes NA,-0.2800000000,-0.890000000, 3.300000e-01 NA,NA,NA NA,NA,NA,NA NA,100 100 100,100 100 100,100,low,low,some,low some,Non-adaptive,  0,NA, 6.550000 NA DSM-IV-TR,0,1 1.0 1.0 1.0,1.0,1 1,1,1 1,1 1,0.5,0 1 1 1  594,van Dongen-Boomsma_2014 < 2 months,NA,6-12 yo,6.55,12.41,NA NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100,Moderate Neurofeedback NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At follow-up (closest to 26 weeks),NA ADHD FBB-HKS  2.30149597,   1.6700000,h/week,Aggensteiner 2019,NA RCT,G  65  60, 125,NA,NA, 0.2000000000 -0.150000000  5.500000e-01,NA NA NA NA,NA NA NA,NA   0   0,100,100,100 100,  0 low,low low high some Sham_semi_active,  0,NA, 8.590000,NA,DSM-IV,0 1,0.5 1.0 1.0 1.0,1,1,2 0,1 1 1 0.5,0,1,1 1, 595 Aggensteiner_2019 2-6 months,NA,6-12 yo,8.59 8.59 NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100   0,100,100 Moderate Neurofeedback NA   0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,CPT  2.30149597    1.6700000 h/week,Aggensteiner,2021,NA RCT G  40, 37   77 outcomes NA -0.2700000000,-0.720000000, 1.800000e-01 NA NA NA,NA NA NA NA,NA   0,  0,100 100 100,100   0,low low low high,some,Sham_semi_active   0 NA, 8.590000 NA DSM-IV 0 1 0.5,1.0 1.0 1.0,1,1,2,0,1 1,1 0.5 0 1 1 1  596 Aggensteiner_2021 2-6 months NA 6-12 yo 8.59,16.1 NA,NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate Neurofeedback NA,  0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,CPT, 2.30149597,   1.6700000,h/week Aggensteiner 2021 NA RCT G  40, 37   77,outcomes NA, 0.0000000000,-0.450000000, 4.500000e-01,NA,NA,NA,NA,NA,NA,NA,NA   0   0 100 100,100,100,  0 low low,low high some Sham_semi_active   0,NA, 8.590000 NA,DSM-IV,0,1 0.5 1.0,1.0,1.0 1 1,2,0 1 1 1 0.5 0,1,1,1, 597,Aggensteiner_2021,2-6 months,NA 6-12 yo 8.59 16.1 NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998,Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0 100,100,Moderate Neurofeedback,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) NA,ADHS -RS  0.46029919,NA,h/week Alegria,2017,NA,RCT,G  18, 13   31 outcomes,NA  0.2000000000,-0.510000000, 9.100000e-01,NA NA NA NA,NA NA NA NA 100 100,100 100 100 100 100,low,low low,low,some,Sham_semi_active   0 NA 13.900000 NA DSM-IV 0 1 0.5,1.0 1.0 1.0 1,1,2 0,1,1,1,0.5,0 1,1,1, 598 Alegria_2017,< 2 months NA,13-19 yo,8.57 13.9 NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0 100 100,Moderate,Neurofeedback NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks,NA ADHS -RS  0.46029919 NA,h/week Alegria 2017,NA RCT,G, 13  10   23,outcomes,NA  0.3900000000,-0.450000000, 1.220000e+00,NA NA,NA,NA NA,NA,NA NA 100,100,100 100 100,100,100 low,low low,low some Sham_semi_active   0 NA 13.900000 NA DSM-IV,0 1 0.5,1.0,1.0,1.0 1 1 2 0,1 1 1 0.5 0,1,1 1, 599 Alegria_2017 < 2 months,NA 13-19 yo,8.58,13.9,NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000,no low,low
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0,100 100,Moderate,Neurofeedback NA   0 NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA Continuous Performance Task  0.46029919 NA,h/week Alegria 2017 NA,RCT,G  18  13,  31,outcomes NA -0.5800000000 -1.310000000, 1.500000e-01 NA NA NA NA,NA NA NA,NA,100 100,100,100 100 100 100 low,low,low low,some,Sham_semi_active   0,NA,13.900000 NA DSM-IV 0,1 0.5,1.0 1.0 1.0,1,1 2,0,1,1 1 0.5,0 1,1,1  600 Alegria_2017 < 2 months NA,13-19 yo 8.59,16.1 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0 100 100 Moderate Neurofeedback,NA,  0 NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA CPT, 0.46029919 NA,h/week,Alegria,2017,NA,RCT,G  18  13   31 outcomes NA  2.0700000000, 1.170000000, 2.970000e+00,NA,NA,NA NA,NA NA NA,NA 100,100,100 100,100 100,100,low low low,low,some Sham_semi_active,  0 NA,13.900000,NA,DSM-IV,0 1,0.5,1.0,1.0 1.0,1,1,2,0 1,1,1 0.5,0,1 1,1  601 Alegria_2017 < 2 months NA,13-19 yo 8.59 16.1,NA,NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100,  0,100,100 Moderate Neurofeedback,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA,Conners 3P, 2.99194476,   1.7500000 h/week Arnold,2021 NA,RCT,G, 84, 58, 142 NA NA -0.0600000000 -0.297246446, 1.772464e-01 NA,NA,NA,NA,NA NA NA NA,100,100,100,100,100 100,100,low low some,low,low,Sham_semi_active   0,NA  8.580000 NA,DSM-5,0 1,0.5 1.0 1.0,1.0 1 1 2 0,1,1 1,0.5,0,1,1 1, 602 Arnold_2021 2-6 months NA 6-12 yo 8.57 13.9,NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100,  0 100,100,Moderate Neurofeedback,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA,SNAP-IV  3.91254315,   1.8800000 h/week Arnold 2013,NA,RCT,G, 25, 11   36,NA NA, 0.2600000000,-0.450000000, 9.700000e-01,NA,NA,NA,NA,NA,NA,NA,NA   0,  0,100,100,100 100   0,some,low,low high,some Sham_semi_active,  0,NA  8.850000,NA,DSM-IV,0 1,0.5 1.0,1.0 1.0,1 1,2,0 1 1,1,0.5,0,1 1 1  603,Arnold_2013 2-6 months NA 6-12 yo 8.57,13.9 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated Closest to 52 weeks,NA Conners 3P, 2.99194476,   1.7500000 h/week Arnold 2023 NA RCT,G, 48  50   98,outcomes NA -0.1000000000,-0.460000000  2.700000e-01,NA,NA,NA NA NA,NA NA NA,100 100,100,100,100,100,100,low,low some low low Sham_semi_active   0 NA, 8.580000 NA,DSM-5,0,1,0.5 1.0 1.0 1.0 1 1,2,0 1,1,1,0.5,0 1 1,1  604,Arnold_2023 2-6 months,NA 6-12 yo 8.58,8.58,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_Closest to 52 weeks,1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_Closest to 52 weeks_6-17 yo,100.00000 no,low,low
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0 100 100 Moderate,Neurofeedback,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,Closest to 52 weeks NA,Conners 3P  2.99194476    1.7500000,h/week Arnold 2023 NA,RCT G, 48  50,  98 outcomes,NA, 0.1200000000,-0.237297176  4.772972e-01,NA,NA NA,NA,NA,NA NA,NA 100,100 100,100,100,100,100 low,low some low low,Sham_semi_active   0,NA  8.580000 NA,DSM-5 0 1,0.5,1.0 1.0 1.0,1 1 2 0,1 1 1,0.5 0,1,1 1, 605,Arnold_2023 2-6 months NA 6-12 yo 8.58,13.9 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000 no,low low
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100,  0,100,100 Moderate,Neurofeedback,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),NA SNAP-IV, 3.91254315,   1.8800000 h/week Arnold,2013,NA RCT G  25, 11   36,NA,NA,-0.1900000000 -0.900000000, 5.200000e-01,NA NA NA NA,NA,NA,NA,NA,  0,  0,100 100 100 100,  0 some low,low high,some,Sham_semi_active,  0 NA  8.850000,NA DSM-IV 0 1,0.5 1.0,1.0,1.0,1 1,2,0,1 1 1,0.5,0 1,1 1  606 Arnold_2013,2-6 months,NA,6-12 yo,8.58,12.4,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998,Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100,100 Moderate,Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks) NA Conners 3P  2.99194476,   1.7500000 h/week,Arnold 2021 NA,RCT G  84, 58, 142 NA,NA, 0.1400000000,-0.090000000  3.772464e-01 NA,NA,NA NA NA,NA NA,NA 100,100 100,100,100,100,100 low,low,some low,low Sham_semi_active   0,NA  8.580000,NA DSM-5 0,1,0.5,1.0,1.0,1.0 1,1 2 0,1 1 1,0.5 0 1 1,1, 607,Arnold_2021 2-6 months,NA,6-12 yo,8.58 12.4 NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100   0,100,100,Moderate Neurofeedback,NA,  0 NA,Executive functioning (report),Parent-rated At study endpoint (closest to 12 weeks),NA BRIEF  3.91254315,   1.8800000 h/week,Arnold,2013 NA RCT,G, 25  11   36,outcomes,NA  0.1700000000 -0.540000000  8.800000e-01 NA,NA NA NA NA,NA,NA NA,  0,  0 100 100,100 100   0 some,low low high,some Sham_semi_active   0,NA, 8.850000 NA,DSM-IV,0,1,0.5 1.0 1.0 1.0 1 1,2 0 1 1,1,0.5,0 1 1 1, 608,Arnold_2013,2-6 months,NA,6-12 yo 8.57 12.4,NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0 100 100 Moderate,Neurofeedback,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA,FBB-HKS  2.99194476,   1.2500000,h/week,Bakhshayesh,2011,NA RCT G  18  17   35 NA,NA, 0.7600000000, 0.070000000, 1.450000e+00,NA,NA,NA,NA,NA,NA,NA NA   0,  0 100 100,100,100   0,low,low low,high,some Sham_semi_active   0 NA  9.340000,NA,ICD-10,0,1 0.5,1.0,1.0 1.0,1 1,2,0 1,1 1,0.5,0 1 1,1, 609 Bakhshayesh_2011,2-6 months NA,6-12 yo,8.57 13.9,NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0,100,100 Moderate,Neurofeedback,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),NA,FBB-HKS, 2.99194476,   1.2500000 h/week,Bakhshayesh 2011 NA RCT,G, 18, 17   35 NA NA  0.4000000000,-0.270000000, 1.070000e+00 NA NA,NA,NA NA,NA NA NA,  0   0,100,100 100 100,  0 low low low high some Sham_semi_active   0 NA  9.340000,NA,ICD-10 0,1,0.5,1.0 1.0,1.0,1 1 2,0,1 1 1,0.5,0,1,1,1, 610 Bakhshayesh_2011 2-6 months NA 6-12 yo,8.58,12.4 NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100,  0 100,100,Moderate Neurofeedback NA,  0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA CPT  2.99194476    1.2500000 h/week Bakhshayesh 2011,NA,RCT,G, 18  17   35 outcomes,NA  0.5900000000 -0.090000000  1.270000e+00,NA NA NA NA NA,NA NA,NA   0,  0,100 100 100 100   0,low,low low,high some Sham_semi_active   0,NA, 9.340000,NA ICD-10 0 1 0.5 1.0 1.0 1.0,1 1,2,0 1 1 1,0.5 0,1 1,1  611 Bakhshayesh_2011,2-6 months,NA,6-12 yo,8.59,16.1 NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
 998 Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0 100,100 Moderate,Neurofeedback,NA,  0 NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA CPT, 2.99194476    1.2500000,h/week Bakhshayesh 2011 NA,RCT G  18  17,  35 outcomes NA, 0.6400000000,-0.040000000, 1.330000e+00 NA,NA,NA NA NA NA NA NA   0   0,100,100 100,100,  0,low,low,low high,some,Sham_semi_active   0,NA, 9.340000,NA ICD-10 0 1,0.5 1.0 1.0,1.0,1,1,2,0 1 1 1,0.5 0 1,1 1  612 Bakhshayesh_2011,2-6 months,NA 6-12 yo,8.59,16.1 NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0,100,100 Moderate,Neurofeedback,NA,  0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,CPT  2.99194476    1.2500000,h/week Bakhshayesh 2011 NA RCT,G  18  17   35 outcomes NA  0.9900000000  0.290000000, 1.700000e+00,NA NA NA NA,NA NA,NA NA   0,  0 100,100 100 100   0 low,low low high some Sham_semi_active,  0,NA  9.340000,NA ICD-10 0,1,0.5 1.0,1.0 1.0,1,1 2 0,1 1 1,0.5 0 1 1,1, 613,Bakhshayesh_2011 2-6 months NA,6-12 yo 8.59 16.1,NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998 Westwood - Adults (2025),Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702 100   0 100,100 Moderate Neurofeedback,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 26 weeks) 4_mprox ADHD-SB Global, 4.14269275    1.6000000,h/week Barth,2021,NA NA G, 21, 20,  41 outcomes,NA, 0.4900000000, 0.050000000  9.300000e-01,NA,NA NA,NA,NA NA,NA NA   0,  0,100 100 100,100,  0,some low,low,high low,Sham_semi_active,  0,NA,33.640000,NA DSM-IV,0,1,0.5,1.0,1.0 1.0,1 1,2 0 1,1,1 0.5 0 1 1 1, 614,Barth_2021 2-6 months NA,>= 20 yo,33.64,33.64,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no low high
 998,Westwood - Adults (2025) Westwood - Adults 2025 10.1001/jamapsychiatry.2024.3702 100   0,100,100 Moderate,Neurofeedback,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),1_mprox,ADHD-SB Global  4.14269275    1.6000000,h/week Barth 2021,NA,NA G  21, 20,  41 outcomes,NA  0.6800000000  0.040000000  1.310000e+00 NA,NA,NA,NA,NA,NA,NA,NA,  0   0,100,100 100 100,  0 some,low low high low Sham_semi_active   0,NA 33.640000,NA,DSM-IV 0 1 0.5,1.0 1.0,1.0 1,1 2 0,1,1 1,0.5 0,1,1,1  615 Barth_2021,2-6 months,NA >= 20 yo 33.64 36.9,NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,high
 998,Westwood - Adults (2025),Westwood - Adults 2025 10.1001/jamapsychiatry.2024.3702,100,  0,100 100,Moderate,Neurofeedback,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 26 weeks) 4_mprox ADHD-SB Global, 4.14269275,   1.6000000 h/week Barth 2021 NA,NA G, 24, 20   44,outcomes,NA,-0.5600000000,-1.160000000  5.000000e-02,NA NA NA,NA,NA,NA NA NA,  0,  0,100,100 100,100,  0,some,low low,high low,Sham_semi_active   0 NA,33.640000,NA DSM-IV,0 1,0.5 1.0,1.0 1.0 1,1 2,0,1,1 1,0.5,0 1,1,1  616 Barth_2021 2-6 months,NA,>= 20 yo 33.64,33.64,NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low,high
 998,Westwood - Adults (2025) Westwood - Adults 2025,10.1001/jamapsychiatry.2024.3702 100,  0 100 100,Moderate Neurofeedback,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At follow-up (closest to 26 weeks) 1_mprox,ADHD-SB Global  4.14269275,   1.6000000 h/week,Barth,2021 NA NA,G  26  20   46 outcomes NA -0.1000000000,-0.690000000, 4.900000e-01 NA,NA NA NA NA NA,NA,NA   0   0 100 100 100 100,  0,some low low,high,low,Sham_semi_active,  0 NA 33.640000,NA DSM-IV 0 1,0.5 1.0 1.0,1.0,1 1 2,0 1,1 1,0.5 0,1 1 1, 617,Barth_2021,2-6 months NA >= 20 yo 33.64 33.64,NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no,low high
 998,Westwood - Adults (2025),Westwood - Adults 2025 10.1001/jamapsychiatry.2024.3702 100   0 100,100,Moderate Neurofeedback NA,  0 NA,Executive functioning (tests) Self-rated At study endpoint (closest to 12 weeks),NA d2-R Accuracy  4.14269275,   1.6000000,h/week,Barth 2021,NA,NA,G, 21, 20   41 outcomes NA, 0.1300000000 -0.450000000, 7.200000e-01 NA,NA NA NA,NA,NA NA NA   0,  0 100 100,100,100,  0 some,low,low,high,low,Sham_semi_active,  0 NA,33.640000 NA,DSM-IV,0,1 0.5 1.0 1.0,1.0,1,1,2 0,1,1,1,0.5,0 1,1,1, 618,Barth_2021 2-6 months,NA >= 20 yo,33.64 36.9,NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low high
 998,Westwood - Adults (2025),Westwood - Adults,2025 10.1001/jamapsychiatry.2024.3702 100   0,100,100,Moderate,Neurofeedback,NA,  0,NA,Executive functioning (tests) Self-rated At study endpoint (closest to 12 weeks) NA d2-R Accuracy, 4.14269275,   1.6000000,h/week,Barth 2021 NA NA G, 26  20   46,outcomes NA -0.2300000000 -0.820000000  3.500000e-01,NA NA,NA,NA NA,NA NA,NA   0,  0 100 100 100,100   0,some low low,high low Sham_semi_active,  0,NA,33.640000,NA DSM-IV 0 1,0.5,1.0,1.0 1.0 1 1 2,0 1 1 1 0.5,0 1,1,1  619 Barth_2021 2-6 months,NA >= 20 yo,33.64 36.9 NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,high
 998,Westwood - Adults (2025),Westwood - Adults,2025 10.1001/jamapsychiatry.2024.3702 100   0 100,100,Moderate,Neurofeedback,NA,  0,NA Executive functioning (tests) Self-rated At study endpoint (closest to 12 weeks),NA,GNG - False alarms, 4.14269275,   1.6000000 h/week Barth 2021,NA,NA G, 21  20   41,outcomes NA -0.0400000000,-0.650000000  5.700000e-01,NA NA,NA,NA,NA,NA,NA,NA,  0   0 100,100 100 100,  0 some,low low high,low,Sham_semi_active,  0,NA 33.640000,NA,DSM-IV 0 1 0.5 1.0,1.0,1.0,1,1 2 0,1,1 1,0.5,0,1 1 1  620 Barth_2021 2-6 months NA >= 20 yo,33.64 36.9,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low high
 998 Westwood - Adults (2025) Westwood - Adults,2025 10.1001/jamapsychiatry.2024.3702,100,  0 100,100 Moderate,Neurofeedback,NA,  0,NA Executive functioning (tests),Self-rated,At study endpoint (closest to 12 weeks),NA GNG - False alarms, 4.14269275    1.6000000,h/week,Barth,2021 NA NA G, 26, 20   46,outcomes,NA -0.4900000000 -1.080000000, 1.000000e-01 NA,NA,NA,NA NA,NA NA,NA,  0   0 100,100 100,100,  0,some,low,low,high,low Sham_semi_active   0 NA,33.640000,NA DSM-IV,0 1 0.5,1.0 1.0,1.0,1,1 2 0 1 1,1,0.5,0 1 1,1, 621,Barth_2021,2-6 months,NA,>= 20 yo 33.64 36.9,NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,high
 998 Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100,Moderate,Neurofeedback,NA   0 NA,Executive functioning (tests),Self-rated,At study endpoint (closest to 12 weeks),NA n-back Composite Combined 1-back & 2-back  4.14269275    1.6000000,h/week,Barth 2021 NA NA,G  21  20,  41 outcomes,NA, 0.0400000000 -0.390000000  4.800000e-01,NA,NA NA,NA NA NA NA NA   0   0,100 100 100,100,  0,some,low,low,high,low,Sham_semi_active,  0,NA 33.640000 NA DSM-IV 0,1,0.5 1.0,1.0,1.0,1,1,2,0,1,1 1,0.5,0,1,1 1, 622,Barth_2021 2-6 months,NA >= 20 yo,33.64,36.9,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low high
 998 Westwood - Adults (2025),Westwood - Adults 2025,10.1001/jamapsychiatry.2024.3702,100,  0,100,100 Moderate Neurofeedback NA,  0 NA,Executive functioning (tests),Self-rated At study endpoint (closest to 12 weeks) NA n-back Composite Combined 1-back & 2-back, 4.14269275    1.6000000 h/week Barth 2021,NA,NA,G  26  20   46,outcomes,NA  0.0900000000 -0.520000000  3.300000e-01,NA,NA NA,NA NA NA,NA,NA   0,  0,100,100,100 100,  0 some low low high low,Sham_semi_active   0 NA,33.640000 NA,DSM-IV,0 1 0.5,1.0,1.0 1.0,1,1 2 0,1,1 1 0.5,0,1,1,1  623,Barth_2021,2-6 months NA,>= 20 yo,33.64 36.9,NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low high
 998 Westwood - Adults (2025),Westwood - Adults 2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate Neurofeedback,NA   0 NA,Executive functioning (tests),Self-rated,At study endpoint (closest to 12 weeks),NA nback Reaction time 0b  4.14269275    1.6000000,h/week Barth,2021,NA NA,G, 21  20,  41,outcomes,NA  0.7000000000  0.070000000  1.330000e+00 NA,NA NA,NA,NA NA,NA NA   0,  0 100 100,100,100,  0 some,low low,high low Sham_semi_active,  0 NA 33.640000 NA,DSM-IV,0 1,0.5,1.0 1.0,1.0 1 1,2,0,1 1 1,0.5 0 1,1,1, 624,Barth_2021 2-6 months,NA,>= 20 yo,33.64 36.9,NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,high
 998,Westwood - Adults (2025) Westwood - Adults,2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback NA   0,NA Executive functioning (tests),Self-rated At study endpoint (closest to 12 weeks) NA,nback Reaction time 0b  4.14269275    1.6000000 h/week,Barth,2021,NA NA,G, 26  20   46,outcomes,NA  0.6400000000, 0.040000000, 1.240000e+00 NA,NA NA NA,NA,NA,NA NA,  0   0,100,100 100 100,  0 some low low high low,Sham_semi_active,  0,NA,33.640000 NA DSM-IV 0 1 0.5,1.0,1.0 1.0 1,1 2,0 1 1,1,0.5 0,1,1 1, 625,Barth_2021,2-6 months,NA,>= 20 yo 33.64,36.9 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low high
 998,Westwood - Adults (2025),Westwood - Adults 2025 10.1001/jamapsychiatry.2024.3702 100   0,100,100 Moderate,Neurofeedback,NA,  0,NA,Executive functioning (tests) Self-rated,At follow-up (closest to 26 weeks),NA,d2-R Accuracy  4.14269275,   1.6000000 h/week,Barth,2021 NA,NA,G  21  20,  41,outcomes,NA  0.4800000000,-0.140000000, 1.100000e+00,NA,NA NA,NA NA NA,NA NA,  0   0 100 100,100 100,  0,some low low high low Sham_semi_active   0 NA,33.640000,NA DSM-IV,0,1 0.5,1.0,1.0,1.0 1,1,2 0,1,1,1,0.5 0,1 1 1  626,Barth_2021,2-6 months NA,>= 20 yo 33.64,33.64 NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no low,high
 998,Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702 100   0,100 100,Moderate Neurofeedback,NA   0,NA,Executive functioning (tests),Self-rated,At follow-up (closest to 26 weeks) NA d2-R Accuracy, 4.14269275    1.6000000,h/week,Barth 2021,NA,NA G  26  20   46,outcomes NA,-0.0700000000,-0.650000000, 5.100000e-01,NA NA,NA NA,NA NA,NA NA   0,  0,100,100,100,100,  0 some,low low,high,low Sham_semi_active   0,NA 33.640000 NA,DSM-IV 0 1,0.5 1.0 1.0 1.0,1 1 2,0 1 1,1 0.5,0,1,1 1  627 Barth_2021 2-6 months NA,>= 20 yo,33.64 33.64,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no,low high
 998 Westwood - Adults (2025),Westwood - Adults,2025 10.1001/jamapsychiatry.2024.3702 100   0,100 100,Moderate Neurofeedback NA,  0 NA,Executive functioning (tests) Self-rated At follow-up (closest to 26 weeks),NA GNG - False alarms  4.14269275,   1.6000000 h/week Barth,2021 NA,NA,G  26  26,  52 outcomes,NA,-0.0100000000,-0.590000000, 5.800000e-01 NA NA NA,NA NA NA,NA NA,  0,  0,100,100,100 100,  0,some,low,low high low,Sham_semi_active   0 NA,33.640000 NA DSM-IV 0,1,0.5,1.0 1.0 1.0,1 1,2,0,1,1 1,0.5,0,1,1 1, 628 Barth_2021,2-6 months,NA,>= 20 yo,33.64 33.64,NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no,low,high
 998 Westwood - Adults (2025) Westwood - Adults,2025 10.1001/jamapsychiatry.2024.3702 100   0,100 100,Moderate Neurofeedback,NA   0,NA,Executive functioning (tests) Self-rated At follow-up (closest to 26 weeks),NA GNG - False alarms  4.14269275,   1.6000000 h/week,Barth 2021,NA NA G, 21, 21   42,outcomes NA,-0.3600000000,-0.970000000, 2.500000e-01 NA,NA NA NA NA,NA,NA,NA,  0,  0 100,100,100,100   0,some,low low high,low,Sham_semi_active,  0,NA,33.640000,NA DSM-IV,0 1,0.5 1.0,1.0 1.0,1 1 2 0,1,1 1 0.5,0 1 1,1  629,Barth_2021,2-6 months NA >= 20 yo 33.64 33.64,NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no,low high
 998,Westwood - Adults (2025) Westwood - Adults 2025,10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate,Neurofeedback NA,  0,NA Executive functioning (tests) Self-rated,At follow-up (closest to 26 weeks),NA,nback Reaction time 0b  4.14269275,   1.6000000 h/week Barth 2021 NA NA,G, 21  20   41 outcomes,NA  0.5300000000,-0.100000000  1.150000e+00 NA NA NA NA NA,NA,NA NA   0   0 100,100 100,100,  0 some,low,low high low Sham_semi_active,  0 NA 33.640000 NA,DSM-IV 0 1 0.5,1.0,1.0 1.0 1 1 2 0,1 1 1 0.5 0,1,1 1  630 Barth_2021,2-6 months,NA,>= 20 yo 33.64,33.64,NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no low high
 998 Westwood - Adults (2025),Westwood - Adults,2025 10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate Neurofeedback NA,  0,NA Executive functioning (tests),Self-rated At follow-up (closest to 26 weeks) NA,nback Reaction time 0b, 4.14269275,   1.6000000,h/week Barth 2021,NA,NA,G  26  20,  46,outcomes,NA, 0.2000000000,-0.380000000  7.900000e-01,NA NA,NA NA NA,NA NA NA   0   0,100 100 100 100,  0 some,low,low high,low Sham_semi_active,  0,NA,33.640000,NA DSM-IV 0,1 0.5,1.0 1.0 1.0,1 1 2 0 1 1 1 0.5 0 1,1,1  631 Barth_2021 2-6 months NA >= 20 yo 33.64,33.64 NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no,low,high
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100   0 100 100 Moderate Neurofeedback,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA DISYPS-II,NA NA h/week Baumeister 2018 NA,RCT G,  8   7,  15,outcomes,NA, 0.9000000000 -0.288202761  2.088203e+00 NA NA NA NA NA NA NA NA 100,100 100,100,100,100,100,some low low,low some Sham_semi_active,  0,NA,11.750000 NA DSM-IV 0 1 0.5 1.0,1.0,1.0,1,1 2,0,1,1,1 0.5 0 1 1,1, 632 Baumeister_2018 NA NA 6-12 yo,8.57 13.9,NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0,100,100,Moderate,Neurofeedback,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) NA DISYPS-II,NA,NA,h/week Baumeister 2018 NA RCT,G   8,  7,  15,outcomes,NA  0.9000000000,-0.288202761  2.088203e+00 NA NA NA,NA,NA,NA NA,NA,100 100 100,100 100,100,100,some,low low,low some Sham_semi_active,  0,NA 11.750000 NA DSM-IV 0 1,0.5 1.0 1.0,1.0 1 1,2,0,1 1 1,0.5,0 1,1,1  633,Baumeister_2018,NA,NA,6-12 yo,8.57,13.9,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0,100 100,Moderate,Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA,CPRS-R  2.99194476,   3.0000000 h/week,Beauregard,2006,NA RCT,G, 15,  5,  20 NA NA, 1.1700000000, 0.410000000, 1.930000e+00,NA NA,NA NA,NA NA NA NA   0   0 100 100,100 100   0 some low low high,some,WLC,  0 NA,10.200000 NA,DSM-IV,0 1,0.5 1.0,1.0 1.0 1,1,2,0,1,1,1,0.5,0 1 1 1  634,Beauregard_2006,2-6 months,NA,6-12 yo,8.57,13.9,NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 998,Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100,  0,100 100,Moderate,Neurofeedback,NA   0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA Digit Span  2.99194476    3.0000000,h/week,Beauregard 2006,NA,RCT,G  15,  5,  20,outcomes NA  0.2100000000 -0.800000000  1.230000e+00,NA,NA,NA NA,NA NA,NA NA   0,  0 100 100 100 100,  0 some low low high,some,WLC   0 NA,10.200000,NA,DSM-IV,0,1 0.5 1.0,1.0,1.0 1,1 2,0 1,1 1 0.5 0 1 1 1, 635 Beauregard_2006 2-6 months NA,6-12 yo 8.59,16.1 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0 100 100 Moderate Neurofeedback,NA,  0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA Go/No-go Task  2.99194476,   3.0000000,h/week,Beauregard,2006,NA,RCT G  15,  5,  20 outcomes NA  0.4300000000 -0.590000000, 1.460000e+00 NA NA NA NA,NA,NA,NA,NA   0   0,100,100,100 100   0,some low low high,some WLC   0,NA 10.200000 NA DSM-IV,0,1,0.5,1.0 1.0 1.0 1 1,2,0 1,1,1 0.5 0 1,1 1  636,Beauregard_2006 2-6 months,NA,6-12 yo 8.59,16.1,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100,  0,100 100 Moderate,Neurofeedback NA,  0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA Integrated Visual and Auditory (IVA) CPT, 2.99194476    3.0000000,h/week Beauregard 2006 NA,RCT,G  15   5,  20,outcomes NA  0.3100000000 -0.710000000, 1.330000e+00 NA NA NA NA NA,NA NA NA   0   0,100,100 100,100   0,some low,low,high some,WLC   0 NA 10.200000,NA,DSM-IV,0,1 0.5 1.0,1.0,1.0 1 1 2,0,1,1 1 0.5,0 1 1 1, 637,Beauregard_2006,2-6 months NA 6-12 yo 8.59,16.1,NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),NA,At study endpoint (closest to 12 weeks) NA ADHS -RS, 3.79746835,NA h/week Bink,2016 NA,RCT,G, 45  26,  71,outcomes NA, 0.0300000000,-0.260000000, 3.200000e-01 NA NA,NA,NA NA NA,NA,NA,  0   0,100 100 100,100,  0 low,low,low high some,TAU,  0,NA 16.100000,NA,DSM-IV,0,1,0.5,1.0 1.0 1.0,1,1,2,0,1,1 1 0.5 0,1,1,1  638 Bink_2016,2-6 months,NA 13-19 yo,16.1,16.1 NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0,100,100 Moderate Neurofeedback NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),NA,At study endpoint (closest to 12 weeks),NA,ADHS -RS, 3.79746835,NA h/week,Bink 2016 NA RCT G  41, 19,  60 outcomes,NA  0.3700000000,-0.020000000, 7.600000e-01,NA NA NA NA,NA NA NA,NA   0   0,100 100,100,100   0 low low,low high,some,TAU   0 NA,16.100000 NA DSM-IV 0 1,0.5,1.0 1.0,1.0 1 1,2,0,1 1,1 0.5,0,1 1,1, 639,Bink_2016 2-6 months NA,13-19 yo,16.1 16.1 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0 100,100 Moderate Neurofeedback,NA   0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,D2 Test of attention, 3.79746835 NA h/week Bink 2016 NA RCT,G  44  26   70 outcomes,NA  0.0200000000,-0.470000000, 5.000000e-01,NA,NA NA NA NA NA,NA,NA,  0,  0 100 100,100 100,  0 low low low,high some,TAU,  0 NA,16.100000,NA DSM-IV 0 1,0.5,1.0 1.0,1.0 1,1 2,0,1,1 1 0.5,0,1,1 1  640,Bink_2016,2-6 months NA,13-19 yo 8.59,16.1,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
 998,Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0,100,100,Moderate,Neurofeedback,NA,  0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,stroop color word test, 3.79746835 NA h/week,Bink 2016 NA,RCT,G  43, 26   69 outcomes NA -0.0100000000 -0.500000000  4.700000e-01,NA NA NA NA,NA NA NA,NA,  0   0,100 100,100,100   0,low,low,low high,some,TAU   0,NA 16.100000,NA DSM-IV 0,1,0.5,1.0 1.0 1.0 1,1 2,0 1 1,1 0.5,0,1 1 1, 641,Bink_2016,2-6 months,NA 13-19 yo,8.59 16.1,NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0,100,100,Moderate,Neurofeedback,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA,Conners3 - DSM-IV NA,NA,h/week,Blume,2020 NA,RCT,G  12, 11,  23 outcomes,NA,-0.4600000000 -1.050000000  1.300000e-01,NA NA,NA NA,NA,NA NA,NA,100,100,100 100,100,100,100,low,low,low,some,low Sham_semi_active,  0,NA  9.030000 NA DSM-5,0 1 0.5 1.0 1.0,1.0,1 1,2 0,1,1,1,0.5,0 1,1,1, 642 Blume_2020 NA NA 6-12 yo,8.58,12.4,NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 998 Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate Neurofeedback,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),NA Conners3 - DSM-IV,NA,NA,h/week Blume,2020 NA RCT,G, 12, 11,  23,outcomes,NA,-0.1000000000,-0.680000000, 4.800000e-01 NA,NA NA,NA,NA,NA NA,NA,100,100,100 100,100 100 100,low,low low,some low Sham_semi_active,  0 NA, 9.030000,NA,DSM-5 0 1 0.5 1.0 1.0 1.0 1,1 2 0,1,1,1 0.5,0,1 1,1, 643 Blume_2020 NA NA 6-12 yo,8.58,12.4 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100   0 100 100,Moderate,Neurofeedback NA   0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA Conner's CPT - Coms NA,NA,h/week Blume 2020 NA,RCT G,  9, 10,  19,outcomes,NA,-0.3200000000,-1.220000000, 5.900000e-01,NA,NA NA NA NA NA,NA NA 100,100,100 100,100,100 100 low low,low,some,low,Sham_semi_active   0 NA  9.030000 NA DSM-5 0,1 0.5,1.0,1.0 1.0 1 1,2 0 1 1,1 0.5 0 1 1,1, 644,Blume_2020 NA NA,6-12 yo,8.59 16.1 NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0 100,100,Moderate,Neurofeedback,NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA Conner's CPT - Coms,NA,NA,h/week Blume 2020 NA,RCT,G  11  10,  21 outcomes,NA -0.1400000000,-1.000000000, 7.100000e-01 NA,NA,NA,NA NA,NA NA,NA 100,100 100 100 100 100,100,low,low low,some,low,Sham_semi_active,  0 NA  9.030000,NA,DSM-5,0,1 0.5,1.0,1.0 1.0 1,1,2,0,1,1,1 0.5,0 1 1,1, 645,Blume_2020,NA NA 6-12 yo 8.59 16.1 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0 100 100 Moderate Neurofeedback NA   0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,Conner's CPT - Oms NA NA,h/week,Blume,2020 NA RCT,G, 12, 11,  23,outcomes,NA, 0.0700000000,-0.790000000, 9.200000e-01 NA NA NA NA,NA NA NA NA,100,100,100 100,100,100,100,low low low,some low,Sham_semi_active   0 NA  9.030000,NA DSM-5 0,1,0.5,1.0,1.0 1.0 1 1,2 0,1,1 1 0.5 0 1 1 1, 646 Blume_2020,NA,NA 6-12 yo 8.59 16.1,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 998,Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100,  0 100 100 Moderate Neurofeedback NA   0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,Conner's CPT - Oms,NA NA,h/week,Blume 2020 NA RCT,G  12  11   23,outcomes,NA -0.6000000000,-1.520000000  3.200000e-01,NA,NA,NA,NA,NA,NA NA,NA,100 100 100 100,100,100,100 low low low some low,Sham_semi_active,  0,NA, 9.030000 NA,DSM-5,0,1 0.5,1.0 1.0,1.0 1 1,2 0 1 1 1,0.5,0 1,1,1  647,Blume_2020,NA,NA 6-12 yo,8.59,16.1 NA,NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 998 Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0,100 100 Moderate Neurofeedback,NA,  0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA n-back,NA NA h/week Dobrakowski 2020,NA,RCT,G, 24  24,  48,NA,NA, 0.3400000000,-0.230000000, 9.100000e-01,NA,NA,NA,NA NA,NA NA NA 100,100 100,100,  0 100 100 low low,high,low,some WLC,  0,NA  8.730000 NA ICD-10,0,1,0.5 1.0,1.0,1.0 1,1,2,0 1,1,1,0.5 0,1 1 1  648 Dobrakowski_2020,NA NA,6-12 yo,8.59,16.1 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0 100,100,Moderate Neurofeedback,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA,SWAN, 2.53164557 NA h/week Gelade,2016,NA RCT,G, 39  37   76,NA NA  0.1600000000,-0.150000000, 4.700000e-01,NA,NA,NA,NA NA,NA,NA NA   0   0 100,100 100,100   0,low low some high some Sham_semi_active   0 NA  9.600000,NA,DSM-IV 0 1 0.5,1.0,1.0 1.0 1,1 2 0 1 1 1 0.5,0,1,1 1  649 Gelade_2016,2-6 months,NA 6-12 yo 8.57 13.9 NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100,  0 100,100 Moderate,Neurofeedback,NA   0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA Oddball task, 2.53164557 NA,h/week Gelade 2017,NA,RCT,G  30  30,  60 outcomes,NA, 0.0000000000 -0.510000000, 5.100000e-01 NA NA NA NA,NA,NA NA,NA   0   0,100 100,100 100,  0,low,low,some,high,some Sham_semi_active   0,NA  9.600000,NA DSM-IV 0 1 0.5,1.0 1.0 1.0 1,1 2,0 1,1,1,0.5,0 1 1 1, 650 Gelade_2017,2-6 months,NA,6-12 yo 8.59,16.1,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0 100,100 Moderate Neurofeedback,NA   0 NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,Oddball task, 2.53164557 NA,h/week Gelade 2017,NA RCT G, 30  30   60,outcomes,NA, 0.1700000000 -0.340000000, 6.800000e-01,NA,NA NA,NA,NA,NA,NA NA   0   0 100 100 100,100   0,low,low some,high some Sham_semi_active   0 NA  9.600000 NA,DSM-IV,0 1,0.5,1.0,1.0 1.0 1,1,2,0 1 1 1,0.5,0 1 1,1, 651 Gelade_2017,2-6 months NA 6-12 yo 8.59 16.1,NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100,  0,100,100,Moderate,Neurofeedback NA   0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA Stop-signal task, 2.53164557 NA,h/week,Gelade 2017,NA,RCT,G  36  33,  69 outcomes NA  0.1200000000,-0.360000000, 5.900000e-01 NA,NA NA,NA NA,NA,NA,NA,  0,  0 100,100 100 100,  0,low,low,some,high some,Sham_semi_active,  0 NA, 9.600000,NA,DSM-IV 0 1,0.5,1.0 1.0,1.0 1,1 2,0,1,1,1 0.5 0 1,1 1  652,Gelade_2017,2-6 months NA 6-12 yo 8.59 16.1 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate Neurofeedback NA   0 NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA,VSWM, 2.53164557 NA h/week Gelade,2017,NA RCT,G, 39, 37,  76,outcomes NA -0.0700000000,-0.380000000  2.500000e-01 NA NA NA,NA,NA NA,NA,NA,  0   0,100 100 100,100,  0 low,low,some,high some,Sham_semi_active   0,NA, 9.600000 NA,DSM-IV 0,1 0.5 1.0,1.0 1.0,1 1,2,0,1,1 1,0.5,0,1 1,1  653 Gelade_2017 2-6 months NA 6-12 yo 8.59 16.1 NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0,100 100,Moderate Neurofeedback NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA FBB-HKS, 1.38089758 NA,h/week,Gevensleben 2009,NA,RCT G, 59  35   94 NA,NA  0.5300000000  0.100000000, 9.600000e-01 NA NA NA,NA NA NA,NA,NA   0   0 100,100,100 100   0,low low low,high,some Sham_semi_active,  0,NA, 9.700000,NA,DSM-IV 0,1 0.5,1.0,1.0,1.0 1,1,2 0,1 1 1,0.5 0 1,1 1  654,Gevensleben_2009,< 2 months,NA,6-12 yo 8.57 13.9,NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100,100,Moderate,Neurofeedback,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks) NA,FBB-HKS, 1.38089758 NA h/week,Gevensleben,2010,NA RCT G  38  23,  61,NA,NA  0.6400000000, 0.110000000  1.170000e+00 NA NA NA NA NA NA NA NA,  0,  0 100 100,100 100   0 low,low low,high some Sham_semi_active   0,NA  9.700000,NA,DSM-IV 0 1 0.5 1.0 1.0,1.0 1 1 2 0 1 1,1,0.5 0 1 1,1, 655,Gevensleben_2010 < 2 months NA 6-12 yo,8.57 13.2 NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low high
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0,100 100 Moderate,Neurofeedback,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),NA,FBB-HKS  1.38089758 NA h/week Gevensleben,2009 NA,RCT G, 59, 35,  94 NA NA  0.4200000000, 0.000000000, 8.400000e-01,NA,NA,NA NA,NA,NA,NA,NA,  0   0,100,100 100 100,  0,low low low,high,some Sham_semi_active,  0 NA, 9.700000 NA DSM-IV,0 1 0.5 1.0 1.0 1.0,1,1,2,0 1,1,1 0.5,0,1 1 1, 656 Gevensleben_2009 < 2 months NA 6-12 yo,8.58 12.4 NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100,  0 100,100,Moderate,Neurofeedback,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,ADHD-C3 parent, 1.15074799,NA,h/week,Hasslinger 2021,NA RCT G  49, 49   98,outcomes NA, 0.1300000000,-0.260000000  5.300000e-01 NA,NA,NA NA,NA NA NA NA   0,  0 100,100,100 100,  0 some low low high some,TAU,  0,NA 12.400000,NA DSM-5 0,1,0.5 1.0,1.0 1.0,1,1 2,0 1,1 1 0.5,0 1 1 1  657 Hasslinger_2021,< 2 months,NA 6-12 yo 8.57 13.9,NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0,100,100 Moderate Neurofeedback NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA ADHD-C3 parent, 1.15074799,NA,h/week Hasslinger,2021 NA,RCT G, 51, 49, 100 outcomes NA  0.1700000000,-0.220000000, 5.700000e-01,NA,NA,NA NA,NA,NA,NA,NA,  0   0,100 100 100,100   0,some low low,high some TAU   0 NA 12.400000,NA DSM-5,0 1 0.5 1.0,1.0 1.0 1,1,2 0 1 1,1 0.5 0 1 1,1  658,Hasslinger_2021,< 2 months,NA,6-12 yo 8.57 13.9,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0 100,100,Moderate,Neurofeedback,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),NA ADHD-C3 parent  1.15074799 NA h/week Hasslinger,2021,NA,RCT G, 51  49  100,outcomes NA, 0.1000000000,-0.257204142  4.572041e-01,NA NA,NA,NA NA,NA NA NA   0   0 100,100,100,100,  0 some low low,high,some,TAU   0 NA,12.400000,NA DSM-5,0,1,0.5 1.0,1.0 1.0,1 1,2,0 1 1 1 0.5,0,1,1 1  659 Hasslinger_2021 < 2 months NA,6-12 yo 8.57,13.2,NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low high
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate,Neurofeedback,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) NA ADHD-C3 parent  1.15074799 NA h/week,Hasslinger,2021 NA,RCT G  49  49   98,outcomes,NA, 0.1800000000 -0.177297176, 5.372972e-01,NA NA,NA,NA NA,NA,NA NA,  0,  0 100 100 100 100   0 some,low,low,high,some,TAU,  0,NA 12.400000,NA,DSM-5 0,1 0.5,1.0 1.0,1.0 1 1,2 0,1,1 1,0.5 0,1 1 1  660,Hasslinger_2021 < 2 months,NA,6-12 yo,8.57 13.2 NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,high
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate,Neurofeedback,NA   0 NA Executive functioning (report),NA,At study endpoint (closest to 12 weeks) NA,BRIEF, 1.15074799,NA h/week,Hasslinger 2021,NA,RCT G, 50, 49,  99,outcomes NA, 0.2100000000,-0.180000000  6.069446e-01,NA,NA NA,NA NA NA NA,NA,  0,  0 100 100 100,100   0,some low,low high,some,TAU   0,NA 12.400000 NA DSM-5 0,1 0.5 1.0 1.0 1.0 1,1 2,0 1,1,1,0.5,0 1 1 1  661,Hasslinger_2021,< 2 months,NA,6-12 yo 10.3,12.4,NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100,  0 100 100,Moderate Neurofeedback,NA,  0 NA,Executive functioning (report),NA,At study endpoint (closest to 12 weeks),NA BRIEF, 1.15074799,NA,h/week Hasslinger 2021 NA,RCT G  51  49  100,outcomes,NA  0.4700000000, 0.073106509, 8.668935e-01,NA NA NA,NA NA,NA,NA,NA,  0   0,100 100 100,100   0,some,low,low high some TAU,  0,NA,12.400000,NA,DSM-5,0,1,0.5 1.0,1.0,1.0 1 1 2,0,1,1 1 0.5 0 1,1,1  662,Hasslinger_2021,< 2 months,NA 6-12 yo 10.3 12.4 NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0,100 100 Moderate Neurofeedback,NA   0 NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA Block-tapping task - Combined Forward & Backward, 1.15074799,NA h/week,Hasslinger,2021 NA RCT,G, 51  50  101,outcomes NA -0.0900000000 -0.370000000  1.900000e-01 NA,NA NA NA,NA NA,NA,NA   0   0,100 100 100 100   0,some low,low high some,TAU   0 NA 12.400000 NA,DSM-5 0,1,0.5 1.0,1.0,1.0 1,1 2,0 1,1 1,0.5 0,1,1 1  663,Hasslinger_2021,< 2 months NA 6-12 yo 8.59 16.1 NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0 100,100,Moderate Neurofeedback,NA   0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,Block-tapping task - Combined Forward & Backward, 1.15074799 NA,h/week Hasslinger,2021,NA,RCT,G  51, 50  101,outcomes,NA,-0.0300000000,-0.300000000  2.500000e-01 NA,NA NA,NA,NA,NA NA,NA   0,  0,100,100,100 100,  0 some,low,low,high some,TAU   0,NA,12.400000 NA,DSM-5 0 1,0.5,1.0,1.0,1.0,1,1 2,0,1 1,1 0.5,0,1,1 1, 664 Hasslinger_2021 < 2 months,NA,6-12 yo,8.59,16.1 NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100,Moderate,Neurofeedback NA   0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,CPT-II - Hit RT, 1.15074799,NA,h/week,Hasslinger,2021,NA RCT G  50  49,  99 outcomes,NA,-0.0700000000,-0.460000000  3.300000e-01 NA NA,NA NA,NA,NA NA,NA,  0   0,100,100,100 100   0 some,low,low,high,some,TAU   0,NA,12.400000,NA DSM-5 0 1 0.5 1.0,1.0,1.0 1,1 2,0,1,1,1,0.5 0,1,1 1  665,Hasslinger_2021 < 2 months NA,6-12 yo,8.59 16.1,NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback NA   0,NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA CPT-II - Hit RT  1.15074799 NA,h/week,Hasslinger,2021 NA RCT G, 51  49, 100 outcomes NA,-0.0600000000 -0.450000000  3.300000e-01 NA NA,NA NA NA,NA NA NA   0   0 100,100,100,100   0 some low,low,high some TAU   0,NA,12.400000,NA DSM-5,0 1,0.5 1.0 1.0,1.0 1 1 2 0,1,1,1 0.5 0,1 1 1, 666 Hasslinger_2021,< 2 months,NA,6-12 yo 8.59,16.1 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
 998,Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100,  0 100,100,Moderate,Neurofeedback NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA CPT-II Commission, 1.15074799 NA h/week,Hasslinger,2021 NA RCT,G  50  49   99 outcomes NA,-0.1100000000,-0.506944637, 2.800000e-01 NA NA NA,NA,NA,NA,NA NA   0,  0 100,100,100 100,  0,some,low low,high,some,TAU,  0 NA 12.400000 NA DSM-5,0 1 0.5,1.0 1.0 1.0,1 1 2 0 1,1 1,0.5 0,1 1 1  667 Hasslinger_2021,< 2 months NA 6-12 yo 8.59 16.1 NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate,Neurofeedback,NA   0 NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,CPT-II Commission, 1.15074799,NA,h/week Hasslinger 2022,NA,RCT G  51  49  100 outcomes NA  0.0200000000 -0.380000000, 4.200000e-01 NA,NA,NA NA NA NA NA NA,  0   0 100,100 100,100   0 some,low low,high,some TAU,  0,NA 12.400000,NA,DSM-5 0 1,0.5,1.0 1.0 1.0 1,1 2,0,1,1 1 0.5,0 1 1 1, 668,Hasslinger_2022 < 2 months NA,6-12 yo,8.59,16.1 NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998,Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0,100 100,Moderate Neurofeedback NA,  0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA CPT-II Commission, 1.15074799 NA h/week,Hasslinger,2022,NA RCT G, 51  49  100 outcomes NA, 0.0700000000,-0.326893491, 4.668935e-01,NA NA,NA NA,NA NA,NA,NA   0,  0 100,100,100,100   0 some low,low,high some TAU   0,NA 12.400000,NA,DSM-5 0,1,0.5 1.0 1.0,1.0,1 1 2 0 1,1,1,0.5 0,1 1 1, 669 Hasslinger_2022,< 2 months NA,6-12 yo 8.59,16.1 NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100,  0 100,100 Moderate Neurofeedback,NA,  0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA CPT-II Commission, 1.15074799 NA h/week Hasslinger 2022 NA,RCT,G  50, 49   99 outcomes NA, 0.1700000000,-0.226944637  5.669446e-01,NA NA NA,NA NA,NA,NA NA   0   0,100 100 100 100   0 some low low,high,some TAU,  0 NA,12.400000 NA,DSM-5 0 1 0.5,1.0,1.0 1.0 1,1 2 0,1,1,1 0.5,0 1 1 1, 670 Hasslinger_2022,< 2 months,NA 6-12 yo 8.59,16.1 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0,100,100,Moderate,Neurofeedback,NA   0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA,CPT-II Omission  1.15074799 NA h/week,Hasslinger,2022 NA RCT,G  50, 49   99,outcomes NA,-0.1700000000 -0.566944637  2.269446e-01 NA NA NA NA NA NA NA,NA   0,  0 100,100,100 100,  0,some,low low,high,some TAU,  0 NA,12.400000,NA DSM-5 0,1,0.5,1.0,1.0 1.0,1,1 2 0,1,1 1 0.5 0,1,1 1, 671,Hasslinger_2022,< 2 months NA 6-12 yo,8.59 16.1,NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0 100,100 Moderate,Neurofeedback,NA,  0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA CPT-II Omission  1.15074799 NA h/week,Hasslinger 2022 NA,RCT G  51, 49  100 outcomes,NA  0.0400000000 -0.356893491, 4.300000e-01,NA NA NA,NA,NA,NA NA,NA   0,  0 100 100 100,100,  0 some,low low high,some TAU   0 NA 12.400000,NA DSM-5,0,1,0.5,1.0 1.0,1.0,1,1 2 0,1,1,1 0.5,0 1,1,1, 672,Hasslinger_2022 < 2 months NA,6-12 yo,8.59,16.1 NA,NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998 Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100,100,Moderate Neurofeedback,NA,  0 NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA Digit Span Composite, 1.15074799,NA,h/week,Hasslinger 2021,NA,RCT,G, 49  50   99,outcomes NA -0.1300000000,-0.407861246, 1.478612e-01 NA NA,NA,NA,NA NA NA NA,  0,  0 100 100,100 100,  0,some,low,low high some,TAU   0,NA,12.400000 NA,DSM-5,0 1 0.5,1.0 1.0,1.0 1 1 2 0,1,1,1,0.5 0,1,1 1, 673 Hasslinger_2021 < 2 months NA,6-12 yo,8.59,16.1 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998 Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0 100,100 Moderate Neurofeedback NA   0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA Digit Span Composite  1.15074799 NA h/week Hasslinger,2021 NA,RCT G, 51  50, 101,outcomes NA -0.0800000000 -0.357790373  1.900000e-01 NA NA NA NA,NA NA NA,NA,  0   0,100,100,100 100   0 some,low low high,some,TAU   0 NA 12.400000,NA DSM-5,0,1,0.5 1.0 1.0,1.0 1,1 2 0,1,1 1,0.5 0,1 1,1  674 Hasslinger_2021,< 2 months,NA 6-12 yo 8.59 16.1 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100 100 Moderate Neurofeedback,NA   0,NA Executive functioning (tests) NA At follow-up (closest to 26 weeks),NA,CPT-II - Hit RT, 1.15074799 NA,h/week,Hasslinger 2021,NA RCT G, 50, 50  100,outcomes,NA -0.0800000000,-0.470000000  3.100000e-01,NA NA,NA,NA NA NA NA NA,  0,  0 100,100,100,100   0 some,low low,high some TAU   0,NA 12.400000,NA DSM-5,0 1,0.5,1.0 1.0,1.0,1 1 2,0,1,1 1 0.5 0,1 1 1, 675 Hasslinger_2021 < 2 months NA 6-12 yo,12.4 13.2 NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0,100,100 Moderate,Neurofeedback NA   0 NA,Executive functioning (tests),NA,At follow-up (closest to 26 weeks),NA,CPT-II - Hit RT  1.15074799 NA,h/week,Hasslinger 2021 NA RCT G  51  50, 101,outcomes NA -0.0700000000,-0.470000000  3.200000e-01 NA NA,NA,NA NA,NA,NA,NA   0   0,100,100,100,100,  0 some low low high,some TAU,  0 NA,12.400000 NA,DSM-5,0 1,0.5,1.0,1.0,1.0 1,1 2 0 1,1,1 0.5,0 1 1,1  676,Hasslinger_2021,< 2 months,NA 6-12 yo 12.4,13.2 NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low high
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100,  0,100 100,Moderate Neurofeedback NA,  0,NA Executive functioning (tests),NA At follow-up (closest to 26 weeks),NA CPT-II Omission  1.15074799 NA,h/week,Hasslinger 2022,NA,RCT G, 51, 49  100,outcomes NA, 0.0900000000,-0.300000000, 4.800000e-01 NA,NA,NA NA NA NA NA NA   0   0,100 100 100,100,  0,some,low,low high some,TAU   0,NA,12.400000,NA,DSM-5 0 1 0.5 1.0 1.0,1.0 1,1 2 0 1 1 1,0.5 0 1,1,1  677 Hasslinger_2022,< 2 months NA,6-12 yo 12.4 13.2 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low,high
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100,Moderate Neurofeedback,NA   0 NA Executive functioning (tests) NA At follow-up (closest to 26 weeks) NA CPT-II Omission  1.15074799,NA h/week,Hasslinger,2022,NA,RCT,G  50, 49,  99,outcomes,NA  0.1700000000 -0.220000000  5.700000e-01,NA,NA,NA NA NA NA,NA,NA,  0   0,100 100 100 100   0 some low low,high,some TAU,  0 NA,12.400000 NA DSM-5 0 1 0.5,1.0 1.0,1.0,1 1,2 0,1 1,1,0.5,0,1 1,1  678,Hasslinger_2022 < 2 months NA,6-12 yo 12.4,13.2,NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0 100,100 Moderate Neurofeedback,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,FBB-HKS,NA NA,h/week Heinrich,2004 NA,RCT,G, 13   9,  22 NA,NA, 0.8400000000 -0.060000000, 1.740000e+00 NA,NA,NA,NA NA NA,NA NA   0   0,100 100 100,100   0 low low,low high some,WLC   0 NA,10.800000 NA DSM-IV 0 1 0.5,1.0 1.0 1.0,1 1,2,0,1,1 1 0.5 0,1 1,1  679,Heinrich_2004 NA,NA,6-12 yo 8.57,13.9,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate,Neurofeedback NA   0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA,CPT,NA NA,h/week,Heinrich 2004 NA,RCT,G  13,  9   22,outcomes,NA,-0.3400000000,-1.200000000, 5.100000e-01 NA,NA,NA NA NA NA,NA NA,  0,  0 100 100 100,100,  0,low,low,low high some WLC   0,NA,10.800000 NA,DSM-IV 0,1,0.5 1.0,1.0 1.0 1,1 2,0,1 1,1 0.5 0 1 1 1, 680 Heinrich_2004 NA,NA,6-12 yo 8.59 16.1 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0,100,100 Moderate,Neurofeedback,NA   0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA CPT,NA NA,h/week Heinrich 2004,NA RCT,G, 13   9   22 outcomes NA  0.3800000000 -0.480000000, 1.240000e+00,NA,NA,NA,NA,NA NA NA NA,  0   0,100 100 100 100,  0,low,low low,high some WLC,  0 NA 10.800000,NA DSM-IV 0 1,0.5,1.0 1.0 1.0 1 1 2,0 1,1 1,0.5 0 1 1 1  681 Heinrich_2004,NA NA 6-12 yo,8.59,16.1 NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0 100 100,Moderate,Neurofeedback,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) NA,FBB-HKS - Total Score,NA,NA,NA,Holtmann 2009,NA,NA,G, 20  14   34 NA,NA  0.0000000000 -0.690000000  6.900000e-01,NA NA NA NA NA NA NA,NA,  0,  0 100,100,100 100   0,low,low,low high some,Active (any credible active intervention) 100 NA 10.250000,NA,NA 0 1 0.5,1.0 1.0,1.0,1 1,2,0,1 1,1,0.5,0,1,1 1, 682,Holtmann_2009 NA,NA 6-12 yo 8.57 13.9,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate Neurofeedback,NA   0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA Stop signal - Commissions,NA,NA NA Holtmann 2009,NA,NA G  20, 14   34 outcomes,NA  0.8500000000  0.130000000  1.560000e+00,NA NA NA,NA NA,NA,NA,NA,  0   0 100,100 100,100   0,low low low high,some Active (any credible active intervention) 100 NA 10.250000 NA,NA 0,1,0.5,1.0,1.0 1.0 1 1 2 0,1 1,1 0.5 0,1 1,1, 683 Holtmann_2009,NA NA,6-12 yo,8.59,16.1,NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998 Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate Neurofeedback,NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,Stop signal - Omission,NA,NA NA,Holtmann,2009 NA NA,G  20  14   34,outcomes NA, 0.2700000000 -0.410000000, 9.600000e-01,NA NA NA,NA,NA NA NA,NA   0   0 100 100,100 100   0 low low,low,high some Active (any credible active intervention),100,NA,10.250000,NA,NA 0 1,0.5 1.0,1.0 1.0,1,1,2,0,1 1,1 0.5 0 1,1 1  684 Holtmann_2009 NA NA 6-12 yo,8.59,16.1 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0,100,100,Moderate Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,ADHD-RS NA,NA h/week,Lam 2022 NA RCT,G  43  43,  86 outcomes,NA -0.2300000000 -0.660000000  1.900000e-01 NA,NA,NA,NA,NA,NA NA,NA,100,100,100 100,100,100,100 low low,low some low,Sham_semi_active,  0 NA,13.200000 NA,DSM-5,0,1 0.5,1.0 1.0 1.0 1,1,2 0 1 1,1 0.5 0,1,1 1  685 Lam_2022,NA NA 13-19 yo 8.57 13.9 NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate,Neurofeedback,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks),NA ADHD-RS,NA,NA h/week Lam 2022,NA,RCT,G, 43  40,  83,outcomes NA,-0.0600000000 -0.490000000, 3.700000e-01 NA NA,NA,NA NA NA NA NA 100 100,100 100,100,100 100 low low,low some low,Sham_semi_active   0,NA 13.200000 NA,DSM-5,0,1 0.5 1.0 1.0 1.0,1,1 2,0,1 1,1,0.5 0,1,1,1  686 Lam_2022,NA,NA 13-19 yo 8.57,13.2 NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low low
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0 100 100,Moderate,Neurofeedback NA,  0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA,CPT,NA NA,h/week,Lam 2022 NA,RCT G  38, 40   78 outcomes NA,-0.1700000000 -0.620000000, 2.700000e-01 NA,NA,NA,NA,NA,NA NA,NA,100,100,100,100 100 100 100 low,low,low,some low Sham_semi_active   0,NA,13.200000,NA DSM-5 0 1,0.5,1.0 1.0 1.0 1 1 2 0 1 1 1,0.5 0,1 1,1  687 Lam_2022 NA,NA,13-19 yo 8.59,16.1 NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 998,Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100 100,Moderate Neurofeedback,NA   0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA CPT NA NA,h/week Lam,2022 NA RCT,G, 44, 43,  87 outcomes,NA,-0.1200000000 -0.537536261  2.975363e-01,NA,NA,NA NA,NA NA NA,NA 100,100,100,100 100 100 100,low low,low,some,low,Sham_semi_active,  0,NA 13.200000,NA DSM-5,0 1,0.5 1.0 1.0 1.0,1 1,2,0,1 1 1,0.5 0 1,1,1, 688 Lam_2022,NA NA 13-19 yo 8.59 16.1,NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate,Neurofeedback,NA   0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA CPT - Oms NA,NA h/week Lam,2022 NA,RCT G, 44, 43   87,outcomes,NA, 0.0300000000 -0.387536261, 4.475363e-01,NA,NA,NA,NA,NA,NA NA NA 100,100 100 100,100 100,100,low,low,low some,low Sham_semi_active   0 NA,13.200000 NA DSM-5 0,1 0.5,1.0 1.0,1.0 1,1 2,0,1 1 1 0.5 0 1 1,1  689 Lam_2022,NA,NA,13-19 yo,8.59,16.1 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0 100,100,Moderate Neurofeedback,NA,  0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,WIH WM Sorting NA,NA h/week,Lam,2022 NA,RCT,G  44  43,  87 outcomes,NA,-0.1900000000 -0.627418940, 2.474189e-01,NA,NA NA,NA,NA,NA,NA,NA 100,100,100 100,100 100 100 low,low low,some,low,Sham_semi_active,  0,NA 13.200000,NA,DSM-5,0 1 0.5 1.0 1.0 1.0,1,1,2,0 1,1,1 0.5 0 1,1,1, 690 Lam_2022,NA,NA 13-19 yo,8.59,16.1 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 998 Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100,100 Moderate,Neurofeedback NA,  0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA,CPT -MRT NA NA,h/week,Lam 2022,NA RCT,G  44  43   87 outcomes NA  0.1100000000 -0.310000000  5.300000e-01,NA NA NA NA,NA,NA,NA,NA,100,100 100,100,100 100,100 low,low,low some,low Sham_semi_active   0,NA 13.200000 NA DSM-5,0 1 0.5 1.0 1.0,1.0,1 1,2 0 1 1 1,0.5 0 1,1,1, 691,Lam_2022 NA NA 13-19 yo,8.59 16.1 NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 998 Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0 100,100 Moderate,Neurofeedback NA   0,NA,Executive functioning (tests),NA,At follow-up (closest to 26 weeks) NA CPT - Oms,NA,NA h/week,Lam 2022 NA RCT G  38, 40   78 outcomes,NA, 0.0600000000,-0.387536261  5.180847e-01,NA,NA NA,NA,NA,NA NA,NA,100,100,100,100 100,100 100,low low,low,some,low,Sham_semi_active   0 NA 13.200000,NA,DSM-5 0,1,0.5,1.0,1.0,1.0 1,1,2 0,1 1 1,0.5 0 1 1 1, 692,Lam_2022,NA NA,13-19 yo,12.4 13.2 NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low low
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0,100,100,Moderate Neurofeedback,NA   0,NA Executive functioning (tests),NA At follow-up (closest to 26 weeks),NA,CPT -MRT NA NA h/week Lam 2022 NA,RCT,G  38  40,  78,outcomes NA -0.0200000000,-0.470000000, 4.200000e-01,NA,NA,NA NA,NA NA NA,NA 100,100,100 100,100 100,100,low,low low,some low Sham_semi_active   0,NA 13.200000 NA DSM-5,0,1,0.5,1.0 1.0,1.0,1,1,2 0 1 1 1,0.5,0 1 1 1, 693 Lam_2022,NA NA,13-19 yo 12.4,13.2 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low,low
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100 Moderate Neurofeedback NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA ADHD-RS  1.84119678,NA,h/week,Lim 2019,NA RCT,G, 81  82  163,NA NA,-0.2800000000 -0.590000000  3.000000e-02 NA NA NA,NA NA,NA NA,NA,  0   0,100 100 100 100,  0 some low low,high,some,WLC   0 NA  8.600000,NA DSM-IV 0,1 0.5 1.0,1.0 1.0,1 1 2 0,1 1 1,0.5,0 1,1 1  694,Lim_2019,< 2 months,NA 6-12 yo 8.57,10.6,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0 100,100,Moderate,Neurofeedback NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA ADHD-RS, 1.84119678,NA,h/week,Lim,2019 NA,RCT G, 81  82  163,NA NA, 0.5100000000, 0.200000000  8.200000e-01 NA NA,NA,NA NA,NA NA,NA,  0   0,100 100,100 100   0,some low,low high some,WLC,  0 NA, 8.600000,NA DSM-IV 0,1 0.5 1.0,1.0 1.0 1,1 2,0,1 1,1,0.5,0 1 1 1, 695 Lim_2019,< 2 months,NA 6-12 yo,8.57 13.9 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100 Moderate,Neurofeedback NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA CPRS, 3.45224396 NA,h/week Maurizio 2014,NA,RCT G  13  12,  25,NA NA, 0.3300000000,-0.450000000, 1.110000e+00 NA,NA,NA,NA,NA,NA NA,NA,  0   0 100,100,100,100,  0,some low,low,high some Sham_semi_active   0,NA,10.300000,NA,DSM-IV 0,1,0.5,1.0,1.0 1.0,1 1,2 0,1,1,1,0.5 0,1,1,1, 696,Maurizio_2014 2-6 months NA,6-12 yo,8.57 13.9,NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0,100 100 Moderate,Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) NA,CTRS  3.45224396,NA h/week,Maurizio 2014 NA,RCT G  13  12   25,NA,NA,-0.1000000000 -0.890000000  6.800000e-01,NA NA NA,NA NA NA,NA NA   0   0,100,100 100 100   0 some low,low,high,some Sham_semi_active,  0 NA,10.300000 NA,DSM-IV 0,1,0.5 1.0 1.0,1.0,1 1,2 0 1,1 1 0.5 0,1,1 1, 697 Maurizio_2014,2-6 months NA,6-12 yo,8.58 12.4,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100,Moderate Neurofeedback,NA,  0,NA,Executive functioning (report) NA At study endpoint (closest to 12 weeks),NA BRIEF  3.45224396 NA h/week,Maurizio,2014,NA RCT G  13  12   25 NA,NA  0.0100000000 -0.550000000  5.600000e-01,NA NA,NA NA NA,NA,NA,NA,  0,  0 100,100,100,100   0 some low low,high,some,Sham_semi_active,  0,NA,10.300000 NA DSM-IV 0,1,0.5,1.0,1.0 1.0 1,1,2,0,1,1,1 0.5,0,1 1 1  698 Maurizio_2014 2-6 months,NA 6-12 yo,10.3 12.4,NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0,100 100 Moderate,Neurofeedback,NA,  0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA D2 - Total Score, 3.45224396 NA,h/week Maurizio 2014 NA RCT G  13  12   25 NA,NA -0.2400000000,-1.030000000  5.500000e-01 NA NA,NA NA NA NA,NA,NA   0   0,100,100,100,100,  0 some low low high some Sham_semi_active,  0,NA 10.300000,NA DSM-IV,0,1 0.5 1.0,1.0 1.0,1,1 2,0 1 1,1 0.5,0 1 1,1, 699,Maurizio_2014,2-6 months,NA 6-12 yo 8.59 16.1,NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100,  0,100,100 Moderate,Neurofeedback,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,ADHD-RS  2.76179517,NA h/week Rahami,2022,NA RCT,G, 26, 26,  52,NA NA, 0.8500000000, 0.280000000, 1.420000e+00 NA,NA,NA NA,NA NA NA NA   0,  0 100 100 100,100   0,low,low,low high some,WLC   0 NA,11.560000 NA,DSM-5 0 1,0.5,1.0 1.0,1.0,1 1 2,0 1,1,1,0.5,0,1,1 1  700 Rahami_2022 2-6 months,NA 6-12 yo 8.57 13.9 NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0 100 100 Moderate,Neurofeedback NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,ADHD RS, 3.91254315    1.3300000,h/week,Shereena,2019,NA RCT,G, 15, 15   30 outcomes NA, 1.3200000000, 0.520000000  2.120000e+00,NA,NA,NA NA NA NA NA NA   0,  0,100 100,  0,100,  0 some low high high,some,TAU   0 NA  9.200000 NA,ICD-10,0,1 0.5 1.0 1.0 1.0,1,1,2 0,1,1 1 0.5 0 1,1,1, 701 Shereena_2019 2-6 months,NA 6-12 yo 8.57,13.9,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate Neurofeedback,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),NA,ADHD RS, 3.91254315    1.3300000 h/week,Shereena 2019 NA RCT G  14, 11,  25,outcomes,NA  1.3200000000  0.430000000  2.200000e+00 NA,NA,NA,NA NA,NA NA NA   0,  0 100 100   0,100,  0 some,low,high high,some TAU   0 NA  9.200000,NA ICD-10 0 1,0.5,1.0,1.0 1.0 1,1,2,0 1 1,1 0.5,0 1 1,1  702 Shereena_2019 2-6 months NA,6-12 yo,8.58,12.4 NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate,Neurofeedback NA,  0,NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,Go/No-go test, 3.91254315    1.3300000,h/week Shereena,2019,NA RCT G, 15  15   30,outcomes,NA -0.4100000000 -1.130000000  3.100000e-01,NA,NA,NA NA,NA NA,NA,NA   0   0,100 100   0 100   0,some,low high,high some TAU   0 NA  9.200000 NA ICD-10 0,1 0.5 1.0 1.0 1.0 1 1,2,0 1,1,1 0.5 0 1,1 1  703 Shereena_2019,2-6 months,NA,6-12 yo 8.59,16.1,NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0,100,100,Moderate,Neurofeedback,NA,  0 NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA Go/No-go test  3.91254315    1.3300000,h/week Shereena,2019,NA,RCT G, 15, 15,  30,outcomes NA, 0.6200000000 -0.110000000  1.360000e+00 NA NA,NA,NA,NA NA,NA NA,  0,  0,100,100,  0,100,  0,some,low high,high some,TAU,  0 NA, 9.200000 NA,ICD-10 0,1,0.5,1.0,1.0 1.0,1 1 2,0,1,1 1 0.5 0 1 1,1, 704 Shereena_2019 2-6 months NA,6-12 yo,8.59,16.1 NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
 998,Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0,100 100,Moderate Neurofeedback NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,n-back, 3.91254315,   1.3300000 h/week Shereena,2019 NA RCT,G, 26  20   46,outcomes NA  0.4600000000,-0.460000000  1.380000e+00 NA NA,NA NA NA NA NA,NA,  0   0,100 100   0 100   0 some low high,high,some TAU,  0,NA  9.200000,NA ICD-10 0 1 0.5 1.0,1.0,1.0 1 1,2 0 1 1,1 0.5 0 1,1 1  705,Shereena_2019,2-6 months NA 6-12 yo 8.59,16.1 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100 100 Moderate Neurofeedback,NA,  0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA Spatial Span Test, 3.91254315    1.3300000,h/week Shereena 2019,NA,RCT,G  15  15,  30,outcomes NA -0.1000000000 -0.600000000  4.100000e-01 NA NA,NA NA,NA,NA NA,NA,  0   0 100,100,  0 100,  0,some,low high high some,TAU   0,NA  9.200000,NA ICD-10 0 1 0.5,1.0 1.0,1.0 1,1 2 0,1 1 1 0.5 0 1 1 1  706 Shereena_2019,2-6 months,NA,6-12 yo,8.59,16.1,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0 100 100 Moderate Neurofeedback NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA BOSS Classroom Observation, 2.99194476    2.2500000,h/week,Steiner,2014 NA RCT,G, 34  36   70,NA NA, 0.0100000000 -0.810000000  8.200000e-01,NA,NA NA,NA,NA NA,NA,NA   0   0,100 100,100,100,  0 low low low,high,some,TAU   0,NA, 8.570000 NA DSM-IV 0 1,0.5 1.0 1.0 1.0 1,1,2 0 1 1 1 0.5 0,1 1 1, 707,Steiner_2014,2-6 months NA,6-12 yo,8.57,10.6,NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0 100,100,Moderate,Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,Conners 3 P  2.99194476,   2.2500000 h/week,Steiner 2014 NA,RCT G, 34, 36   70 NA NA, 0.4300000000 -0.060000000  9.200000e-01,NA NA NA,NA NA,NA,NA,NA,  0   0 100 100,100,100,  0 low,low low,high,some TAU,  0 NA  8.570000,NA,DSM-IV,0,1,0.5 1.0 1.0,1.0 1,1,2,0,1,1 1,0.5,0 1 1,1, 708,Steiner_2014,2-6 months,NA,6-12 yo 8.57 13.9,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate Neurofeedback NA   0 NA,Executive functioning (report) Parent-rated,At study endpoint (closest to 12 weeks) NA BRIEF, 2.99194476,   2.2500000 h/week,Steiner 2014 NA RCT G, 34, 36,  70,NA,NA, 0.6300000000, 0.150000000  1.110000e+00,NA,NA,NA,NA NA NA NA,NA   0,  0 100 100 100,100,  0,low low low,high some,TAU   0 NA, 8.570000,NA DSM-IV,0 1,0.5,1.0 1.0 1.0,1,1,2,0,1,1,1,0.5 0,1 1,1  709 Steiner_2014 2-6 months NA 6-12 yo 8.57 12.4 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998,Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate Neurofeedback,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks) NA Conners 3 P  2.99194476    2.2500000,h/week Steiner,2014 NA,RCT,G, 34, 36,  70,NA,NA  0.5400000000, 0.150000000  9.300000e-01 NA,NA NA,NA,NA NA,NA NA   0,  0 100 100,100,100,  0,low,low,low,high some TAU   0,NA  8.570000 NA,DSM-IV,0,1 0.5,1.0 1.0,1.0,1,1,2,0 1,1 1 0.5 0 1,1,1, 710 Steiner_2014,2-6 months NA,6-12 yo 8.57,13.2 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low,high
 998 Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100,  0,100 100,Moderate Neurofeedback NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,CRS-R, 3.68239356,   1.0000000,h/week Steiner,2011 NA NA G   9  11,  20 NA,NA, 1.1900000000  0.230000000  2.150000e+00 NA,NA NA,NA NA,NA NA NA   0   0 100 100,100,100,  0,low low,low high,some,WLC   0 NA 12.400000,NA,NA 0,1,0.5,1.0 1.0,1.0,1,1,2 0 1 1 1,0.5,0,1,1 1  711 Steiner_2011 2-6 months NA,6-12 yo,8.57,13.9 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100 Moderate Neurofeedback NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) NA CRS-R  3.68239356,   1.0000000,h/week,Steiner 2011,NA,NA G   9  13,  22,NA,NA -0.2500000000 -1.110000000, 6.000000e-01 NA NA NA,NA NA NA,NA NA   0,  0,100,100,100 100,  0,low,low low high some,WLC,  0,NA,12.400000 NA NA,0 1 0.5,1.0,1.0,1.0,1 1 2,0 1 1 1 0.5 0 1 1,1  712,Steiner_2011 2-6 months NA,6-12 yo 8.58,12.4,NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0,100 100,Moderate Neurofeedback NA,  0,NA Executive functioning (report) Parent-rated At study endpoint (closest to 12 weeks),NA,BRIEF, 3.68239356,   1.0000000 h/week,Steiner 2011,NA NA,G   9, 11,  20,NA NA  0.1900000000,-0.700000000  1.070000e+00 NA NA,NA,NA,NA,NA NA NA   0,  0,100,100,100,100,  0,low low,low high,some,WLC,  0 NA 12.400000,NA,NA 0 1 0.5,1.0 1.0 1.0,1,1,2,0,1 1,1 0.5,0 1,1,1  713 Steiner_2011,2-6 months NA,6-12 yo,8.57 12.4,NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0 100,100 Moderate Neurofeedback,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA,ADHD FBB-HKS, 2.30149597,   1.6700000 h/week,Strehl,2017,NA RCT,G  75, 69  144 NA NA, 0.3900000000, 0.060000000, 7.200000e-01 NA NA NA NA NA NA NA,NA   0,  0,100 100,100 100   0,low low,low high,some Sham_semi_active,  0,NA, 8.590000 NA DSM-IV 0,1 0.5,1.0 1.0,1.0 1 1,2 0 1,1,1,0.5 0 1,1 1, 714,Strehl_2017,2-6 months NA,6-12 yo,8.57 13.9,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100,100 Moderate Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),NA,ADHD FBB-HKS, 2.30149597    1.6700000,h/week,Strehl 2017,NA RCT,G  75, 69, 144 NA NA  0.1200000000,-0.210000000, 4.500000e-01,NA NA,NA NA,NA,NA,NA,NA   0   0 100 100,100,100,  0 low,low,low,high some,Sham_semi_active   0 NA, 8.590000 NA DSM-IV 0,1 0.5,1.0,1.0 1.0 1 1,2,0,1,1,1,0.5,0,1,1,1  715 Strehl_2017 2-6 months,NA,6-12 yo 8.58 12.4,NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100,  0,100 100 Moderate,Neurofeedback,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA ADHD-RS  3.45224396,NA,h/week,van Dongen-Boomsma 2013 NA,RCT G  22, 19,  41 NA,NA, 0.1700000000,-0.440000000  7.800000e-01,NA,NA NA,NA NA,NA NA,NA,100 100 100,100 100 100,100 low low low low some Sham_semi_active   0 NA,10.600000,NA,DSM-IV 0 1 0.5,1.0 1.0,1.0 1 1 2 0 1 1 1,0.5 0,1 1 1, 716,van Dongen-Boomsma_2013 2-6 months,NA,6-12 yo 8.57 10.6 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100,100 Moderate,Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),NA ADHD-RS, 3.45224396 NA,h/week,van Dongen-Boomsma 2013 NA RCT G  22  19   41 NA,NA -0.1400000000,-0.760000000  4.700000e-01,NA,NA NA,NA,NA NA NA NA 100,100 100,100,100 100,100 low low,low low,some Sham_semi_active   0 NA,10.600000,NA,DSM-IV,0,1,0.5,1.0 1.0,1.0,1,1,2,0,1 1 1,0.5 0,1 1 1  717 van Dongen-Boomsma_2013,2-6 months,NA 6-12 yo,8.58,12.4,NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0 100 100,Moderate,Neurofeedback,NA   0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA Digit span WISC III  3.45224396,NA,h/week,Vollebregt,2014 NA RCT G, 22  19,  41,outcomes NA -0.2000000000,-0.827034185  4.270342e-01,NA NA,NA,NA NA NA,NA,NA,100,100 100 100 100,100,100,low low low low,some,Sham_semi_active   0 NA 10.600000,NA DSM-IV 0 1 0.5 1.0 1.0,1.0,1 1 2,0 1 1,1,0.5 0 1 1 1, 718 Vollebregt_2014 2-6 months NA 6-12 yo 8.59,16.1,NA,NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100 100,Moderate Neurofeedback NA,  0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,Sustained Attention dots task (SA-DOTS)  3.45224396 NA h/week,Vollebregt,2014,NA RCT,G, 22  19,  41,outcomes NA -0.2100000000 -0.830000000  4.100000e-01 NA NA,NA,NA NA,NA NA NA 100,100 100,100 100,100,100,low,low low low some Sham_semi_active   0,NA,10.600000 NA DSM-IV,0,1,0.5,1.0,1.0,1.0 1,1,2,0,1,1 1,0.5 0 1,1,1  719,Vollebregt_2014,2-6 months,NA,6-12 yo 8.59,16.1,NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate,Neurofeedback,NA,  0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA Sustained Attention dots task (SA-DOTS)  3.45224396,NA h/week,Vollebregt,2014,NA,RCT,G  22  19   41,outcomes,NA,-0.1100000000 -0.737034185  5.170342e-01 NA,NA NA,NA NA,NA NA NA,100 100 100 100,100 100 100 low,low,low,low some,Sham_semi_active,  0,NA,10.600000,NA,DSM-IV,0 1 0.5 1.0 1.0 1.0,1,1,2,0 1 1,1 0.5,0 1 1,1, 720,Vollebregt_2014,2-6 months NA,6-12 yo 8.59 16.1,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 998 Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0 100 100 Moderate Neurofeedback NA   0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA,Visuospatial Sequencing (VSS), 3.45224396 NA h/week,Vollebregt,2014,NA,RCT,G  22, 19   41,outcomes,NA,-0.5800000000,-1.227261094  6.726109e-02,NA NA NA,NA NA,NA,NA NA,100 100 100,100 100 100,100,low low low low,some Sham_semi_active   0,NA 10.600000 NA DSM-IV 0 1 0.5,1.0 1.0,1.0 1,1 2 0,1 1,1,0.5 0 1 1 1  721 Vollebregt_2014,2-6 months,NA,6-12 yo 8.59,16.1,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0 100,100 Moderate Neurofeedback,NA,  0 NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA Attention Network Test - Conflict  1.38089758,NA,h/week Wangler,2011,NA,RCT G  56, 28,  84,outcomes NA -0.2900000000 -0.747543268  1.675433e-01 NA NA,NA,NA NA,NA NA NA   0   0 100 100 100,100   0,low low some,high some Sham_semi_active,  0 NA  9.700000 NA DSM-IV,0 1 0.5 1.0 1.0,1.0,1,1,2 0,1 1 1 0.5 0 1 1,1, 722,Wangler_2011 < 2 months,NA 6-12 yo 8.59 16.1,NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100 100,Moderate Neurofeedback,NA,  0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,Attention Network Test - MRT  1.38089758 NA,h/week Wangler,2011,NA RCT,G  56, 28   84 outcomes NA, 0.3200000000,-0.100000000, 7.400000e-01,NA NA,NA,NA,NA NA,NA NA,  0   0,100,100 100,100,  0 low,low,some,high some Sham_semi_active,  0,NA  9.700000 NA DSM-IV 0 1 0.5 1.0 1.0,1.0,1,1 2 0 1 1,1,0.5,0 1 1 1  723 Wangler_2011 < 2 months NA,6-12 yo,8.59 16.1 NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0 100 100 Moderate,Neurofeedback NA   0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,Attention Network Test - Orienting  1.38089758 NA h/week,Wangler 2011 NA RCT,G  56  28   84,outcomes,NA,-0.1000000000 -0.560000000, 3.500000e-01 NA NA NA,NA NA NA NA NA   0   0,100,100,100 100   0,low,low,some,high,some Sham_semi_active   0 NA, 9.700000 NA,DSM-IV,0,1,0.5 1.0,1.0,1.0 1 1 2 0,1,1 1,0.5,0 1 1 1, 724 Wangler_2011,< 2 months,NA,6-12 yo 8.59 16.1 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998,Westwood - Adults (2025) Westwood - Adults,2025 10.1001/jamapsychiatry.2024.3702,100   0 100,100 Moderate,Neurofeedback NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA,ADHD DSM-IV rating scale - Combined, 0.92059839 NA h/week,Zilverstand 2017 NA,RCT G,  7,  6,  13,NA,NA  0.3400000000 -0.826522135  1.506522e+00 NA,NA NA NA NA NA NA,NA 100,100 100 100,100 100,100,low low low low,some,Sham_semi_active,  0,NA 36.900000,NA DSM-IV,0,1 0.5 1.0,1.0 1.0 1 1,2,0 1,1 1,0.5,0,1,1,1  725,Zilverstand_2017 < 2 months NA >= 20 yo 33.64,36.9,NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA,Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 998 Westwood - Adults (2025),Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702 100   0,100,100 Moderate,Neurofeedback,NA,  0 NA,Executive functioning (tests),Self-rated At study endpoint (closest to 12 weeks) NA 2-back visuospatial task % correct  0.92059839,NA,h/week Zilverstand 2017 NA RCT G,  7   6   13 outcomes,NA, 0.2600000000,-0.840000000  1.350000e+00 NA NA,NA NA,NA,NA NA,NA 100,100,100,100 100 100,100,low,low low,low,some,Sham_semi_active   0,NA 36.900000,NA,DSM-IV,0,1 0.5,1.0,1.0,1.0,1,1,2 0 1 1,1 0.5,0,1 1,1, 726 Zilverstand_2017 < 2 months NA,>= 20 yo 33.64 36.9,NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 998 Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702 100   0 100 100,Moderate,Neurofeedback,NA   0,NA,Executive functioning (tests),Self-rated,At study endpoint (closest to 12 weeks),NA Digit Span IQ, 0.92059839,NA,h/week Zilverstand,2017 NA RCT G,  7,  6,  13,outcomes NA -0.1400000000,-1.230000000  9.500000e-01 NA NA,NA NA NA NA,NA NA,100,100 100,100 100,100 100,low,low low low some Sham_semi_active   0 NA,36.900000,NA DSM-IV 0,1,0.5,1.0,1.0 1.0 1,1 2 0,1,1,1 0.5,0,1,1 1  727,Zilverstand_2017 < 2 months,NA >= 20 yo,33.64,36.9 NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 998 Westwood - Adults (2025) Westwood - Adults,2025 10.1001/jamapsychiatry.2024.3702 100   0,100 100,Moderate Neurofeedback NA,  0,NA Executive functioning (tests),Self-rated,At study endpoint (closest to 12 weeks),NA,SA-DOTS - False Alarms  0.92059839 NA,h/week Zilverstand 2017 NA RCT G,  7   6,  13,outcomes,NA  0.5100000000,-0.610000000  1.620000e+00 NA NA NA NA NA NA,NA NA,100,100 100,100,100 100 100,low,low low,low,some Sham_semi_active   0 NA 36.900000,NA,DSM-IV 0 1 0.5,1.0,1.0,1.0,1 1 2 0 1 1,1,0.5,0,1 1 1  728,Zilverstand_2017,< 2 months NA >= 20 yo 33.64,36.9 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 998,Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702 100   0,100,100,Moderate Neurofeedback,NA   0 NA Executive functioning (tests),Self-rated At study endpoint (closest to 12 weeks) NA,SART (equivalent to GNG) - Coms, 0.92059839 NA,h/week Zilverstand,2017,NA,RCT,G,  7,  6   13,outcomes,NA, 0.1600000000 -0.940000000, 1.250000e+00,NA,NA NA NA,NA,NA NA NA,100 100 100 100,100,100,100 low low,low low some,Sham_semi_active,  0 NA 36.900000 NA,DSM-IV,0 1,0.5,1.0,1.0,1.0,1 1 2 0 1 1 1,0.5 0,1 1 1, 729 Zilverstand_2017,< 2 months,NA >= 20 yo 33.64,36.9 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
2118 Liu (2023),Liu 2023,10.1111/papt.12455,100,  0,100 100 Low,Mindfulness Mindfulness-based CBT 100 TAU Depressive disorder symptoms Mixed,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  1.38089758    1.0000000,session/week Gu 2018,NA,RCT (parallel, crossover, open-label) SMD  28, 26,  54,NA,reverse,-0.7700000000,-1.330000000,-2.200000e-01,  2.9000000,  3.1400000,NA NA,NA NA,NA NA,  0,  0 100   0 100 100   0 some,high low,high,low WLC (wait-list control),  0  44.444444 20.291852,NA,DSM-V 1 1 0.0 1.0,1.0,1.0 1 1,1 1 1,1,1 1.0,0,1,1 1  730 Gu_2018 < 2 months NA,>= 20 yo,20.2918518518519,35.8941747572816,NA NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA,NA,Liu (2023)_Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Liu (2023) - Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,high
2118,Liu (2023) Liu,2023 10.1111/papt.12455,100   0 100,100 Low,Mindfulness Mindfulness-based CBT 100,TAU Depressive disorder symptoms Mixed At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 2.76179517,   1.0000000 session/week Hepark 2019,NA RCT (parallel, crossover, open-label),SMD, 55  48  103 NA,reverse -0.2800000000,-0.670000000  1.000000e-01   5.2900000,  5.9000000 NA,NA NA NA NA,NA,100,100 100   0,100 100,100 some high,low low,low,WLC (wait-list control)   0, 54.543689 35.894175,NA DSM-IV,1,1 0.0,1.0 1.0,1.0 1 1,1 1,1 1 1 1.0 0,1 1 1  731,Hepark_2019,2-6 months NA >= 20 yo 20.2918518518519 35.8941747572816 NA,NA, 13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA,NA,Liu (2023)_Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Liu (2023) - Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
2118 Liu (2023) Liu 2023 10.1111/papt.12455 100   0 100 100,Low,Mindfulness Mindfulness-based CBT,100,TAU Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 2.76179517    1.0000000 session/week,Hepark 2019,NA RCT (parallel, crossover, open-label) SMD, 55, 48, 103 NA reverse, 0.2700000000,-0.120000000  6.600000e-01, 12.0400000, 14.5000000,NA NA,NA,NA NA,NA,100 100,100   0 100,100 100,some high,low low,low,WLC (wait-list control),  0, 54.543689,35.894175 NA,DSM-IV,1 1,0.0 1.0 1.0,1.0 1 1 1 1,1 1 1 1.0,0 1 1,1, 732,Hepark_2019 2-6 months,NA >= 20 yo 35.8941747572816,39.35,NA,NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA,NA,Liu (2023)_Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Liu (2023) - Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
2118 Liu (2023) Liu 2023,10.1111/papt.12455 100   0 100 100,Low,Mindfulness Mindfulness-based CBT 100,TAU,Quality of life (patients),Mixed At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 1.84119678    1.0000000,session/week,Janssen 2019 NA,RCT (parallel, crossover, open-label) SMD  60, 60  120 NA,reverse -0.0100000000,-0.370000000, 3.500000e-01  10.9700000  13.5200000 NA,NA,NA NA NA,NA,  0,  0   0   0 100 100 100 high,high low,low low,TAU   0  53.000000,39.350000,NA,DSM-IV 1 1 0.0,1.0,1.0 1.0 1,1 1,1,1 1 1 1.0,0 1,1,1  733,Janssen_2019 < 2 months NA,>= 20 yo,35.8941747572816 39.35,NA NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA,NA,Liu (2023)_Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Liu (2023) - Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,high
8996 Yin - adults (2024) Yin - adults 2024,10.3390/brainsci14121237   0,  0,100,100,Critically low tDCS (transcranial direct current stimulation),NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire NA,NA,  20.0000000,min/session,Allenby,2018 NA,RCT (parallel, crossover, open-label) G, 37  37   74 outcomes,reverse,-0.2679117000 -0.733457100, 1.976336e-01 NA NA,NA NA,NA,NA,NA NA   0   0 100,100 100 100   0 low low low,high low Sham   0, 25.710000,NA,NA,NA 2 1,0.0,0.0,1.0,1.0,1,1,3 1,1 0,1,0.5 0 1,0 1, 734 Allenby_2018,NA NA NA,22,38.3 NA,NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA NA Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low high
8996,Yin - adults (2024),Yin - adults 2024 10.3390/brainsci14121237 100,  0 100 100,Critically low tDCS (transcranial direct current stimulation) NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Questionnaire NA,NA,  20.0000000,min/session,Barham 2022 NA RCT (parallel, crossover, open-label) G, 11  11,  22 NA reverse -0.4700000000,-1.320000000, 3.800000e-01,  1.0700000,  1.3400000,NA,NA,NA NA,NA,NA,100 100,100 100,100,100 100,low,some,low,some low Sham   0, 68.200000 22.000000 NA NA,2 1 0.0,0.0,1.0 1.0 1 1,3,1,1 0 1,0.5,0,1 0 1  735 Barham_2022,NA,NA >= 20 yo 22,38.3,NA NA  19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
8996,Yin - adults (2024),Yin - adults 2024 10.3390/brainsci14121237,100,  0 100,100 Critically low tDCS (transcranial direct current stimulation),NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Questionnaire,ASRS,NA,  20.0000000 min/session Cachoeria,2017 NA,RCT (parallel, crossover, open-label) G   9   8   17,outcomes reverse -0.8500000000 NA NA,NA,NA NA,NA,NA,NA,NA NA 100 100,100,100,100,100,100,low,some,low,low,low,Sham   0, 52.940000,32.294118 NA NA,2,1 0.0,0.0,1.0 1.0,1 1 3,1,1,0 1 0.5 0,1 0,1  736,Cachoeria_2017 NA,NA >= 20 yo 22 38.3 NA NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA,NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
8996 Yin - adults (2024) Yin - adults 2024 10.3390/brainsci14121237 100   0 100 100 Critically low,tDCS (transcranial direct current stimulation) NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire NA,NA,  20.0000000 min/session Jacoby 2018 NA,RCT (parallel, crossover, open-label) G  20, 20   40 outcomes reverse,-0.1000000000 -0.720000000  5.200000e-01  50.8300000, 53.4800000,NA,NA,NA,NA NA,NA 100,100,100 100,100,100,100 low,some,low,low,low Sham   0  55.000000 22.750000 NA,NA 2,1,0.0 0.0 1.0 1.0,1 1,3,1 1 0,1,0.5 0 1,0,1  737 Jacoby_2018 NA,NA >= 20 yo,22 38.3,NA NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA,NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
8996 Yin - adults (2024),Yin - adults 2024 10.3390/brainsci14121237 100,  0 100,100 Critically low tDCS (transcranial direct current stimulation),NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire,ASRS NA,  30.0000000 min/session Leffa 2022,NA RCT (parallel, crossover, open-label),G, 32, 32   64,outcomes,reverse -0.9500000000,-1.460000000 -4.300000e-01   5.7900000,  3.9700000 NA NA NA NA,NA,NA,100 100,100,100,100 100,100,low low,low low low,Sham   0, 46.880000,38.300000 NA NA 2,1,0.0 0.0,1.0,1.0,1,1,3 1 1 0 1,0.5,0,1,0,1, 738 Leffa_2022,NA NA >= 20 yo 22,38.3,NA NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA NA Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
8996 Yin - children (2024),Yin - children 2024 10.3390/brainsci14121237 100   0 100,100,Critically low,tDCS (transcranial direct current stimulation) NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire NA NA,  30.0000000 min/session Guimaraes 2024 NA,RCT (parallel, crossover, open-label),G  15, 15,  30 NA reverse -0.0800000000,-0.800000000  6.400000e-01, 24.3000000, 27.7500000,NA,NA,NA NA NA,NA 100,100 100 100 100,100 100,low low low,low low,Sham,  0  33.330000 11.200000 NA NA,2 1 0.0 0.0 1.0,1.0,1 1,3 1 1 0 1,0.5,0,1,0 1  739 Guimaraes_2024 NA,NA 6-12 yo 11.2 14.2,NA,NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
8996 Yin - children (2024) Yin - children 2024 10.3390/brainsci14121237 100,  0,100 100,Critically low,tDCS (transcranial direct current stimulation),NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Questionnaire FBB-ADHD,NA   20.0000000 min/session Soff 2017,NA,RCT (parallel, crossover, open-label),G, 15  15,  30,outcomes,reverse  0.6200000000 -0.120000000  1.360000e+00   0.4600000   0.5700000,NA NA NA,NA,NA NA 100 100,100 100 100,100 100 low some low,some,low Sham,  0, 20.000000 14.200000 NA NA 2,1,0.0 0.0 1.0,1.0 1 1,3,1,1,0,1 0.5,0 1,0 1, 740,Soff_2017,NA NA 13-19 yo 11.2 14.2,NA,NA  19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857,NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8996 Yin - adults (2024) Yin - adults,2024,10.3390/brainsci14121237 100,  0 100,100 Critically low tDCS (transcranial direct current stimulation) NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire,ASRS NA,  20.0000000 min/session,Cachoeria 2017 NA,RCT (parallel, crossover, open-label) G   9   8,  17 outcomes,reverse -0.6000000000 NA NA,NA NA,NA,NA,NA,NA,NA NA,100,100 100,100,100,100 100,low,some low,low low,Sham,  0, 52.940000,32.294118,NA NA,2,1,0.0,0.0,1.0,1.0 1 1,3 1 1,0,1,0.5 0,1,0,1, 741 Cachoeria_2017 NA NA,>= 20 yo,22,38.3,NA NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA,NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
8996 Yin - adults (2024) Yin - adults,2024,10.3390/brainsci14121237,100   0 100 100,Critically low,tDCS (transcranial direct current stimulation) NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire NA NA,  20.0000000,min/session,Jacoby,2018,NA,RCT (parallel, crossover, open-label) G, 20, 20   40,outcomes,reverse -0.4700000000 -1.100000000, 1.600000e-01   4.4300000,  6.3300000 NA,NA NA,NA NA,NA,100,100 100 100 100,100,100,low,some,low,low low,Sham,  0, 55.000000,22.750000,NA NA 2,1,0.0 0.0,1.0 1.0 1 1,3,1,1,0,1,0.5,0 1 0 1, 742 Jacoby_2018 NA,NA,>= 20 yo,22,38.3 NA,NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA NA Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
8996,Yin - adults (2024),Yin - adults 2024 10.3390/brainsci14121237,100   0 100,100,Critically low tDCS (transcranial direct current stimulation) NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire ASRS,NA,  30.0000000 min/session,Leffa 2022 NA RCT (parallel, crossover, open-label) G  32, 32   64 outcomes,reverse,-0.2700000000,-0.760000000  2.200000e-01   7.5500000,  6.7000000,NA NA NA,NA NA NA 100,100 100 100,100,100 100 low low,low low,low Sham,  0, 46.880000,38.300000 NA,NA 2 1 0.0 0.0,1.0,1.0 1,1 3 1 1,0,1 0.5,0,1 0,1, 743,Leffa_2022,NA NA,>= 20 yo 22 38.3,NA NA, 19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA,NA Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
8996 Yin - children (2024) Yin - children,2024,10.3390/brainsci14121237 100,  0 100 100 Critically low tDCS (transcranial direct current stimulation),NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire FBB-ADHD NA   20.0000000,min/session Soff 2017,NA,RCT (parallel, crossover, open-label),G  15  15   30,outcomes reverse, 0.3800000000,-0.340000000, 1.110000e+00,  0.4800000   0.6300000,NA,NA,NA NA,NA,NA,100 100,100 100 100,100 100,low some low,some low Sham,  0  20.000000,14.200000 NA,NA,2,1 0.0,0.0,1.0,1.0,1 1 3,1 1,0,1,0.5,0,1 0,1, 744 Soff_2017 NA,NA,13-19 yo 11.2 14.2 NA,NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
8996 Yin - adults (2024) Yin - adults,2024 10.3390/brainsci14121237   0,  0,100,100,Critically low,tDCS (transcranial direct current stimulation),NA,  0 NA,Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks) Test,stop-signal task,NA   20.0000000 min/session Allenby,2018 NA,RCT (parallel, crossover, open-label),G  37  37   74,outcomes reverse,-0.2600000000 -0.720000000  2.000000e-01, 12.5000000, 11.2000000,NA,NA,NA NA,NA NA   0,  0 100,100 100 100   0,low,low low,high low,Sham   0, 25.710000 NA,NA NA 2 1,0.0,0.0,1.0,1.0,1 1,3,1,1 0 1 0.5,0 1,0 1  745,Allenby_2018 NA NA,NA 22 32.25 NA NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,high
8996,Yin - adults (2024),Yin - adults 2024 10.3390/brainsci14121237,100,  0 100 100 Critically low,tDCS (transcranial direct current stimulation) NA   0,NA Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks) Test,stroop task NA,  20.0000000 min/session Barham 2022 NA RCT (parallel, crossover, open-label) G, 11  11,  22,outcomes reverse,-0.9800000000 -1.870000000 -8.000000e-02   0.0001000   0.5000000,NA NA NA,NA,NA NA 100 100,100 100 100 100 100 low some low some,low,Sham   0  68.200000,22.000000,NA NA 2,1 0.0,0.0,1.0 1.0 1 1 3 1 1 0,1 0.5 0,1,0,1  746,Barham_2022 NA,NA,>= 20 yo 22,32.25,NA,NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
8996,Yin - adults (2024),Yin - adults 2024 10.3390/brainsci14121237,100   0 100 100 Critically low,tDCS (transcranial direct current stimulation),NA,  0 NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks),Test,go/no-go NA   20.0000000,min/session Cosmo,2015,NA,RCT (parallel, crossover, open-label),G  30, 30   60,NA,reverse -0.0700000000 -0.570000000, 4.400000e-01  17.1400000  20.4100000,NA NA,NA,NA,NA,NA,100 100,100,100,100 100 100 low,some,some low,low Sham,  0  41.665000,32.250000 NA,NA 2 1,0.0 0.0,1.0 1.0 1,1,3 1,1,0 1,0.5 0 1,0,1, 747,Cosmo_2015 NA NA,>= 20 yo,22,32.25,NA,NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
8996 Yin - children (2024),Yin - children,2024 10.3390/brainsci14121237 100,  0 100 100,Critically low tDCS (transcranial direct current stimulation),NA,  0 NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),Test flanker NA,  20.0000000 min/session Breitling 2016,NA,RCT (parallel, crossover, open-label),G,  7   7,  14,outcomes reverse,-0.2200000000 -1.270000000  8.300000e-01   7.8000000   9.2000000 NA,NA NA NA NA,NA   0   0,100 100,100,  0 100 some,some low low high Sham,  0   0.000000 13.300000 NA NA 2,1,0.0 0.0 1.0 1.0,1 1 3 1,1,0,1 0.5 0,1 0,1, 748,Breitling_2016,NA,NA 13-19 yo,8.86 16.06 NA,NA, 19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high,high
8996 Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237,100,  0 100 100,Critically low tDCS (transcranial direct current stimulation),NA   0 NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) Test flanker NA,  20.0000000 min/session,Breitling,2016,NA RCT (parallel, crossover, open-label),G,  7   7   14,outcomes reverse,-0.0900000000,-1.130000000  9.600000e-01,  8.3000000   9.2000000 NA NA NA,NA NA,NA,  0   0 100,100,100   0 100 some,some low low,high Sham   0   0.000000 13.300000,NA NA 2 1 0.0 0.0,1.0 1.0 1 1,3 1 1 0,1,0.5 0,1 0,1, 749 Breitling_2016 NA,NA,13-19 yo,8.86,16.06,NA,NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high,high
8996 Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237,100   0 100,100,Critically low tDCS (transcranial direct current stimulation),NA,  0,NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),Test,go/no-go,NA,  20.0000000,min/session Breitling-Ziegler 2021,NA RCT (parallel, crossover, open-label) G,  9  13   22 outcomes,reverse  0.4600000000,-0.410000000, 1.320000e+00, 18.1300000, 12.7300000,NA NA,NA,NA,NA NA 100,100,100,100,100 100,100 low,some,low low,low Sham,  0  13.630000 13.409091,NA NA 2,1 0.0,0.0,1.0 1.0,1,1,3 1 1,0 1,0.5,0 1,0,1, 750,Breitling-Ziegler_2021 NA,NA,13-19 yo,8.86,16.06 NA NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8996 Yin - children (2024),Yin - children,2024,10.3390/brainsci14121237,100,  0 100,100,Critically low,tDCS (transcranial direct current stimulation) NA   0,NA,Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),Test,stop-signal task,NA,  20.0000000 min/session,D'Aiello 2023 NA RCT (parallel, crossover, open-label) G  26, 26,  52 outcomes,reverse -0.1000000000 -0.640000000  4.400000e-01  15.1600000  20.6800000 NA NA,NA,NA NA NA,100,100 100 100,100,100,100 low,some,low,some low,Sham,  0,  7.700000,10.630000 NA,NA,2 1 0.0,0.0 1.0 1.0 1 1,3,1 1,0 1 0.5 0,1 0,1  751 D'Aiello_2023,NA,NA 6-12 yo,8.86 16.06 NA NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8996 Yin - children (2024),Yin - children 2024 10.3390/brainsci14121237 100,  0 100 100,Critically low tDCS (transcranial direct current stimulation),NA,  0,NA Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks),Test,go/no-go NA   15.0000000 min/session Nejati 2020,NA RCT (parallel, crossover, open-label),G  15  15,  30 outcomes reverse -0.0900000000,-0.800000000  6.300000e-01, 11.4200000   7.8000000 NA,NA NA NA NA NA   0,  0 100,100,100,  0,100,low,some some,low high Sham,  0  50.000000  9.000000,NA NA 2 1,0.0,0.0,1.0 1.0,1,1,3,1,1 0,1 0.5,0 1 0,1  752,Nejati_2020,NA NA,6-12 yo 8.86,16.06,NA,NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high high
8996,Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237,100   0,100,100 Critically low tDCS (transcranial direct current stimulation),NA   0 NA,Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks),Test go/no-go NA   15.0000000 min/session,Nejati 2020,NA RCT (parallel, crossover, open-label),G  10, 10   20 outcomes reverse -1.0400000000 -1.990000000 -9.000000e-02   1.2200000   4.3900000 NA,NA,NA NA,NA,NA,  0,  0 100 100,100,  0,100,low,some some low,high,Sham,  0, 50.000000, 9.000000,NA,NA,2,1,0.0,0.0 1.0 1.0 1,1,3 1,1,0,1,0.5 0,1 0,1, 753 Nejati_2020,NA,NA 6-12 yo,8.86,16.06 NA NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
8996 Yin - children (2024),Yin - children 2024 10.3390/brainsci14121237,100   0 100,100,Critically low,tDCS (transcranial direct current stimulation),NA,  0 NA Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks) Test,go/no-go,NA   15.0000000 min/session,Nejati 2020 NA RCT (parallel, crossover, open-label) G, 10  10   20 outcomes,reverse -0.5900000000 -1.490000000  3.100000e-01,  1.3300000,  4.3900000 NA NA,NA,NA NA NA   0   0 100 100,100,  0,100 low some,some,low high,Sham,  0, 50.000000  9.000000,NA,NA,2,1 0.0 0.0,1.0 1.0,1 1 3,1 1,0 1 0.5 0 1,0,1, 754 Nejati_2020 NA,NA,6-12 yo 8.86 16.06 NA,NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high high
8996,Yin - children (2024) Yin - children,2024,10.3390/brainsci14121237 100,  0,100,100,Critically low,tDCS (transcranial direct current stimulation),NA,  0 NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks) Test go/no-go,NA   20.0000000,min/session Nejati,2021 NA,RCT (parallel, crossover, open-label) G, 11  11,  22,outcomes,reverse -0.6400000000,-1.500000000  2.200000e-01   8.4700000  17.0000000 NA NA,NA NA,NA,NA 100,100 100,100 100,100,100,some,some low some low,Sham   0  36.370000  9.250000 NA,NA 2 1,0.0 0.0 1.0,1.0 1,1 3,1 1 0,1 0.5,0,1,0,1  755 Nejati_2021 NA NA 6-12 yo,8.86,16.06 NA,NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857,NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8996,Yin - children (2024),Yin - children,2024 10.3390/brainsci14121237 100,  0 100,100,Critically low,tDCS (transcranial direct current stimulation) NA   0,NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) Test go/no-go NA   20.0000000 min/session Nejati,2021 NA RCT (parallel, crossover, open-label) G, 13, 13,  26 outcomes,reverse  0.6500000000 -0.140000000  1.440000e+00  17.5900000, 13.2800000,NA NA NA,NA NA,NA 100,100,100 100,100,100,100 some,some,low some low,Sham,  0  36.370000, 9.250000,NA,NA 2,1 0.0 0.0 1.0,1.0 1 1 3,1 1 0,1,0.5,0 1 0 1, 756 Nejati_2021 NA NA,6-12 yo,8.86,16.06 NA NA  19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8996,Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237,100   0 100 100 Critically low tDCS (transcranial direct current stimulation),NA,  0,NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks) Test,go/no-go NA,  20.0000000 min/session Nejati 2022,NA,RCT (parallel, crossover, open-label),G  24, 24   48,outcomes reverse,-0.1100000000,-0.680000000  4.600000e-01  14.8200000  16.5600000,NA,NA,NA NA NA,NA 100 100,100,100,100,100 100 some some low,low,low,Sham,  0  33.330000  9.250000 NA,NA,2,1 0.0 0.0 1.0,1.0 1 1 3 1 1 0 1 0.5,0 1 0 1  757,Nejati_2022,NA NA 6-12 yo 8.86,16.06,NA NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8996 Yin - children (2024),Yin - children,2024 10.3390/brainsci14121237 100,  0,100,100 Critically low tDCS (transcranial direct current stimulation) NA,  0,NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) Test,go/no-go NA,  23.0000000,min/session,Salehinejad,2020,NA RCT (parallel, crossover, open-label) G, 17, 17,  34 NA,reverse -0.2300000000,-0.900000000, 4.400000e-01  23.1060000, 26.4570000 NA NA NA NA NA NA,100,100 100 100 100 100 100 some,low,low,some,low Sham   0, 29.410000  9.530000,NA,NA,2,1 0.0 0.0,1.0,1.0 1,1,3,1 1,0 1,0.5,0 1 0,1  758 Salehinejad_2020,NA NA,6-12 yo,8.86 16.06,NA,NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8996 Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237 100,  0 100,100,Critically low tDCS (transcranial direct current stimulation) NA   0,NA Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks),Test,go/no-go,NA   15.0000000 min/session Salehinejad,2022 NA,RCT (parallel, crossover, open-label),G, 22, 22,  44,outcomes,reverse -0.1500000000 -0.740000000, 4.400000e-01  19.5100000  27.1320000,NA NA,NA,NA NA NA,100,100,100,100,100,100,100 some,some,low some,low,Sham   0, 50.000000, 8.860000 NA,NA 2,1 0.0,0.0 1.0 1.0 1 1,3,1 1 0,1 0.5,0 1 0,1, 759,Salehinejad_2022 NA,NA,6-12 yo,8.86 16.06 NA,NA, 19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8996 Yin - children (2024) Yin - children 2024,10.3390/brainsci14121237 100   0,100,100 Critically low tDCS (transcranial direct current stimulation) NA   0 NA Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks),Test go/no-go NA,  15.0000000,min/session Soltaninejad,2019 NA,RCT (parallel, crossover, open-label) G  20, 20,  40 outcomes reverse -0.7300000000 -1.370000000,-9.000000e-02   1.8600000   6.8900000 NA NA,NA,NA NA NA   0   0,100 100 100   0 100,some some,low,low,high,Sham   0 NA,16.060000 NA NA 2 1 0.0,0.0,1.0,1.0 1 1,3 1,1 0 1,0.5 0,1,0,1  760,Soltaninejad_2019,NA NA,13-19 yo,8.86 16.06,NA,NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
8996 Yin - children (2024) Yin - children,2024,10.3390/brainsci14121237 100,  0,100 100 Critically low,tDCS (transcranial direct current stimulation),NA,  0 NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks) Test,go/no-go,NA,  15.0000000 min/session,Soltaninejad 2019,NA,RCT (parallel, crossover, open-label),G  20  20   40,outcomes reverse,-0.0500000000,-0.670000000, 5.700000e-01,  8.2000000   6.8900000 NA,NA,NA NA NA,NA   0   0 100 100,100,  0 100 some,some,low low,high Sham,  0 NA,16.060000,NA NA 2,1,0.0 0.0 1.0 1.0 1 1 3 1,1,0 1 0.5,0 1 0,1, 761,Soltaninejad_2019,NA,NA,13-19 yo,8.86,16.06 NA,NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
8996,Yin - adults (2024),Yin - adults,2024,10.3390/brainsci14121237   0   0,100,100 Critically low tDCS (transcranial direct current stimulation) NA   0 NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) Test n-bask task NA   20.0000000 min/session Allenby,2018,NA RCT (parallel, crossover, open-label) G, 37, 37,  74 outcomes,NA  0.4600000000  0.000000000  9.300000e-01,  1.6000000   2.2000000,NA NA NA NA,NA NA   0,  0,100,100 100 100,  0,low low,low,high low,Sham   0, 25.710000,NA,NA NA,2 1,0.0,0.0 1.0,1.0 1 1,3,1,1 0,1 0.5 0,1 0 1  762,Allenby_2018 NA,NA NA 22,32.25 NA NA, 19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA,NA Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low high
8996,Yin - adults (2024) Yin - adults 2024,10.3390/brainsci14121237 100,  0,100 100,Critically low tDCS (transcranial direct current stimulation) NA,  0,NA,Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks),Test,digit span task NA,  20.0000000 min/session Barham 2022,NA RCT (parallel, crossover, open-label),G, 11  11   22,outcomes NA, 0.4000000000 -0.440000000, 1.250000e+00,  1.0500000   1.0000000,NA,NA NA,NA NA NA 100 100 100 100,100 100,100 low some low some low,Sham   0  68.200000,22.000000,NA NA,2 1 0.0,0.0 1.0 1.0 1 1 3,1,1 0,1 0.5,0,1,0 1  763,Barham_2022 NA NA,>= 20 yo,22 32.25,NA NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA,NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
8996 Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237 100,  0 100,100 Critically low tDCS (transcranial direct current stimulation) NA   0 NA,Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks),Test n-bask task,NA,  20.0000000,min/session Breitling,2020 NA RCT (parallel, crossover, open-label) G  14, 14   28 outcomes NA, 0.1400000000,-0.600000000  8.900000e-01   4.4000000,  8.4000000,NA NA NA,NA NA,NA,  0,  0,  0 100,100 100,100 high some,low some,low Sham   0  13.330000,13.300000 NA NA,2,1 0.0,0.0 1.0 1.0 1,1,3 1,1,0,1,0.5 0 1,0,1, 764,Breitling_2020,NA NA,13-19 yo,8.86 16.06,NA,NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
8996 Yin - children (2024) Yin - children 2024 10.3390/brainsci14121237 100,  0 100 100 Critically low,tDCS (transcranial direct current stimulation),NA,  0,NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) Test,n-bask task NA   20.0000000,min/session Breitling,2020 NA,RCT (parallel, crossover, open-label) G  14, 14   28,outcomes,NA, 0.3600000000,-0.390000000, 1.100000e+00   3.9000000   8.4000000,NA,NA,NA NA,NA NA   0   0   0,100 100,100 100,high some low,some,low Sham   0  13.330000,13.300000,NA,NA 2 1 0.0 0.0,1.0 1.0 1,1 3 1,1,0 1,0.5 0,1 0,1, 765,Breitling_2020,NA NA,13-19 yo 8.86,16.06,NA NA, 19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
8996 Yin - children (2024),Yin - children,2024,10.3390/brainsci14121237,100,  0,100,100 Critically low,tDCS (transcranial direct current stimulation),NA   0,NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),Test,n-bask task NA,  20.0000000,min/session Breitling-Ziegler,2021 NA,RCT (parallel, crossover, open-label) G   9  13   22,outcomes NA,-0.3100000000 -1.170000000  5.400000e-01, 24.0500000, 27.2300000,NA,NA NA,NA,NA NA,100 100 100,100 100 100 100 low,some,low,low low Sham,  0, 13.630000 13.409091 NA,NA,2,1 0.0 0.0,1.0 1.0,1,1 3,1 1,0 1 0.5,0,1 0 1, 766 Breitling-Ziegler_2021 NA NA 13-19 yo,8.86,16.06 NA NA, 19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8996 Yin - children (2024),Yin - children,2024,10.3390/brainsci14121237,100,  0,100,100 Critically low tDCS (transcranial direct current stimulation),NA   0 NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks),Test,n-bask task NA,  20.0000000,min/session D'Aiello,2023,NA,RCT (parallel, crossover, open-label),G, 26  26   52 outcomes NA  0.4200000000,-0.130000000  9.700000e-01   0.4000000,  0.3400000 NA,NA NA NA,NA NA,100 100,100 100,100,100,100 low,some low,some low,Sham   0,  7.700000 10.630000 NA NA,2,1,0.0 0.0 1.0 1.0,1,1 3 1 1,0 1 0.5,0,1,0 1, 767,D'Aiello_2023,NA,NA,6-12 yo 8.86,16.06,NA NA, 19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
8996 Yin - children (2024) Yin - children 2024,10.3390/brainsci14121237,100   0 100,100 Critically low tDCS (transcranial direct current stimulation) NA   0 NA Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks) Test,digit span task,NA   30.0000000 min/session,Guimaraes,2024,NA RCT (parallel, crossover, open-label),G, 15, 15   30,NA NA -0.3300000000,-1.050000000, 4.000000e-01   1.4700000   1.7500000,NA NA NA NA NA,NA 100,100 100,100,100,100 100,low,low low,low,low Sham   0, 33.330000 11.200000 NA,NA,2,1,0.0,0.0 1.0,1.0,1,1 3 1 1,0 1 0.5,0,1 0,1  768,Guimaraes_2024,NA,NA 6-12 yo,8.86,16.06 NA NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8996 Yin - children (2024) Yin - children 2024,10.3390/brainsci14121237 100   0,100 100,Critically low,tDCS (transcranial direct current stimulation) NA   0,NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks),Test,n-bask task NA,  15.0000000 min/session Nejati 2020 NA,RCT (parallel, crossover, open-label),G  15  15   30,outcomes NA, 0.1100000000,-0.610000000, 8.200000e-01,  8.3200000,  7.4200000 NA NA NA NA,NA,NA   0   0 100 100 100   0,100 low some some,low,high,Sham,  0  50.000000  9.000000,NA,NA,2 1 0.0,0.0,1.0,1.0,1,1,3 1 1,0 1,0.5 0,1,0,1, 769,Nejati_2020 NA NA,6-12 yo,8.86,16.06,NA NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
8996 Yin - children (2024),Yin - children,2024,10.3390/brainsci14121237 100,  0 100 100,Critically low tDCS (transcranial direct current stimulation),NA   0 NA,Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks) Test,n-bask task,NA   15.0000000 min/session,Nejati 2020,NA,RCT (parallel, crossover, open-label),G  10, 10   20 outcomes,NA  1.9400000000, 0.830000000  3.040000e+00   2.2600000   3.7000000 NA NA NA NA NA,NA,  0,  0,100,100,100,  0 100,low,some some,low,high Sham   0, 50.000000, 9.000000,NA NA,2,1,0.0,0.0,1.0,1.0,1 1 3,1,1,0 1,0.5,0 1,0,1  770 Nejati_2020 NA NA 6-12 yo,8.86 16.06 NA NA, 19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
8996 Yin - children (2024),Yin - children 2024 10.3390/brainsci14121237 100,  0 100,100,Critically low tDCS (transcranial direct current stimulation) NA   0,NA,Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks) Test n-bask task,NA   15.0000000,min/session Nejati 2020 NA,RCT (parallel, crossover, open-label) G, 10, 10   20,outcomes NA, 1.4400000000, 0.430000000  2.440000e+00,  2.2700000,  3.7000000 NA,NA,NA NA NA NA,  0,  0,100,100,100,  0 100 low some,some,low,high,Sham   0, 50.000000, 9.000000 NA NA,2 1 0.0,0.0 1.0,1.0,1 1 3 1 1,0,1,0.5,0,1 0,1  771 Nejati_2020 NA NA 6-12 yo 8.86,16.06 NA,NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
8996,Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237,100   0 100,100,Critically low tDCS (transcranial direct current stimulation) NA   0 NA,Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks) Test,n-bask task,NA,  20.0000000 min/session,Nejati,2022 NA RCT (parallel, crossover, open-label),G  25, 25   50,outcomes NA  0.1100000000,-0.440000000, 6.700000e-01, 32.9500000, 22.6900000 NA NA,NA,NA NA,NA 100,100,100 100 100 100 100,some some low low,low Sham   0  33.330000, 9.250000,NA NA,2,1,0.0 0.0 1.0,1.0 1 1 3 1,1 0,1 0.5 0,1 0,1  772 Nejati_2022,NA,NA,6-12 yo,8.86,16.06 NA,NA, 19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8996,Yin - children (2024) Yin - children 2024,10.3390/brainsci14121237 100,  0 100,100 Critically low tDCS (transcranial direct current stimulation) NA   0 NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks) Test,n-bask task NA,  15.0000000 min/session,Salehinejad,2022 NA RCT (parallel, crossover, open-label) G, 22  22,  44 outcomes NA,-0.0300000000 -0.620000000, 5.600000e-01, 15.6800000, 14.0200000,NA,NA NA,NA,NA NA 100,100 100 100 100 100,100,some,some,low some low,Sham   0, 50.000000, 8.860000 NA NA 2 1,0.0 0.0,1.0 1.0,1 1 3,1 1,0 1 0.5,0,1 0,1, 773,Salehinejad_2022 NA,NA 6-12 yo,8.86 16.06,NA NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8996 Yin - children (2024),Yin - children 2024 10.3390/brainsci14121237,100   0,100,100,Critically low,tDCS (transcranial direct current stimulation) NA,  0,NA,Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks) Test wisconsin card sorting NA   15.0000000 min/session Nejati 2020 NA RCT (parallel, crossover, open-label) G, 15  15,  30,outcomes reverse,-0.0600000000,-0.770000000, 6.600000e-01   3.6000000,  8.9800000,NA,NA NA,NA,NA NA,  0   0 100,100 100   0 100 low some some low high,Sham   0  50.000000  9.000000,NA,NA 2 1,0.0,0.0,1.0 1.0,1 1,3,1 1 0 1 0.5 0 1 0,1  774,Nejati_2020 NA NA 6-12 yo 8.86,16.06 NA NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
8996 Yin - children (2024),Yin - children,2024,10.3390/brainsci14121237 100   0 100,100,Critically low,tDCS (transcranial direct current stimulation) NA,  0,NA Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks) Test wisconsin card sorting NA   15.0000000 min/session,Nejati,2020 NA,RCT (parallel, crossover, open-label) G  10  10   20 outcomes,reverse,-2.1400000000,-3.290000000,-9.900000e-01   2.4400000,  3.7000000,NA NA NA,NA NA NA,  0   0,100 100 100,  0 100,low some,some low high Sham,  0  50.000000  9.000000,NA NA 2,1 0.0,0.0,1.0 1.0 1 1,3,1,1,0,1,0.5 0,1 0,1, 775,Nejati_2020 NA NA,6-12 yo 8.86,16.06 NA,NA, 19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
8996 Yin - children (2024) Yin - children 2024,10.3390/brainsci14121237,100,  0,100,100,Critically low,tDCS (transcranial direct current stimulation) NA,  0,NA,Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),Test,wisconsin card sorting NA   15.0000000 min/session,Nejati 2020,NA RCT (parallel, crossover, open-label) G  10, 10   20,outcomes,reverse -0.8200000000,-1.740000000  1.000000e-01,  3.2900000   3.7000000,NA NA NA NA,NA NA,  0   0,100,100,100,  0 100 low,some some low high,Sham   0, 50.000000, 9.000000,NA NA 2 1 0.0 0.0,1.0,1.0 1,1 3 1 1 0 1 0.5,0,1 0 1  776 Nejati_2020,NA,NA 6-12 yo,8.86 16.06,NA,NA, 19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
8996,Yin - children (2024) Yin - children 2024,10.3390/brainsci14121237,100   0,100,100,Critically low,tDCS (transcranial direct current stimulation) NA,  0,NA Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks),Test wisconsin card sorting NA   15.0000000 min/session Salehinejad,2022,NA,RCT (parallel, crossover, open-label),G  22  22,  44,outcomes reverse  0.1500000000 -0.440000000, 7.400000e-01   8.3090000   9.7720000 NA NA,NA,NA,NA,NA,100 100,100 100,100 100 100,some some low,some low,Sham,  0, 50.000000  8.860000,NA NA 2,1 0.0 0.0 1.0 1.0,1,1,3,1 1,0 1,0.5,0,1,0 1, 777,Salehinejad_2022,NA NA,6-12 yo,8.86,16.06,NA,NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
2118,Liu (2022) Liu 2022,10.1111/papt.12455   0   0 100,100,Low,Cognitive Behavioral Therapy (CBT) CBT,  0,NA,CGI,Clinician-rated At study endpoint (closest to 12 weeks),Questionnaire Clinical global impression (CGI)  1.84119678,NA NA Emilsson 2011,NA RCT (parallel, crossover, open-label) SMD  27  27   54 NA,reverse,-0.5300000000,-1.070000000  2.000000e-02   0.8800000   0.8400000 NA,NA,NA NA,NA NA,100,100 100   0,100 100,100 some,high,low low low TAU,  0, 30.000000,NA NA DSM-IV, DSM-V,1 1,0.0 1.0 1.0,1.0 1,1 1,1 1 1 1 1.0,0 1,1 1, 778,Emilsson_2011 < 2 months NA NA 35.1695789473684 39.4609375 NA,NA, 20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA NA,Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2118,Liu (2022),Liu 2022 10.1111/papt.12455 100,  0 100 100 Low Cognitive Behavioral Therapy (CBT) CBT,  0 NA,CGI,Clinician-rated,At study endpoint (closest to 12 weeks),Questionnaire Clinical global impression (CGI), 1.84119678,NA NA Nakashima 2021 NA,RCT (parallel, crossover, open-label),SMD, 24  24,  48,NA reverse,-2.8500000000 -3.680000000 -2.030000e+00   0.6400000,  0.6000000 NA,NA NA,NA NA,NA   0   0,  0,  0,100,100 100 high,high low,low low TAU   0  88.000000 39.105000 NA DSM-IV, DSM-V 1,1 0.0,1.0 1.0 1.0,1,1,1 1,1,1 1 1.0 0,1,1,1  779,Nakashima_2021,< 2 months,NA >= 20 yo,35.1695789473684 39.4609375,NA,NA  20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA NA Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,high
2118 Liu (2022),Liu,2022,10.1111/papt.12455,  0   0,100,100,Low Cognitive Behavioral Therapy (CBT) CBT,  0 NA CGI Clinician-rated,At study endpoint (closest to 12 weeks),Questionnaire Clinical global impression (CGI)  3.45224396,NA NA Safren 2005,NA,RCT (parallel, crossover, open-label),SMD  16, 15   31 NA,reverse,-1.3500000000,-2.140000000 -5.600000e-01   0.7600000   0.9100000 NA NA,NA,NA,NA NA,100,100 100 100,100,100 100 some,low,low low,low,TAU,  0  55.000000,NA NA DSM-IV, DSM-V,1 1,0.0,1.0 1.0 1.0 1 1,1 1,1,1 1,1.0 0 1,1,1, 780,Safren_2005,2-6 months NA,NA 35.1695789473684,39.4609375,NA NA  20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA NA Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
2118 Liu (2022) Liu,2022,10.1111/papt.12455 100   0 100 100 Low,Cognitive Behavioral Therapy (CBT),CBT,  0,NA CGI Clinician-rated At study endpoint (closest to 12 weeks) Questionnaire,Clinical global impression (CGI), 2.76179517,NA NA,Vidal 2013 NA,RCT (parallel, crossover, open-label) SMD, 17, 15,  32 NA,reverse,-0.3200000000,-1.020000000  3.700000e-01   0.4000000,  0.4900000,NA NA NA NA NA NA,  0,  0,100 100 100 100   0 some low,low,high low,TAU,  0, 51.718750 39.460938 NA,DSM-IV, DSM-V,1,1,0.0 1.0 1.0,1.0 1 1 1 1 1,1,1,1.0 0,1,1,1  781,Vidal_2013 2-6 months,NA >= 20 yo,35.1695789473684 39.4609375,NA NA, 20  9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA NA,Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low high
2118 Liu (2022),Liu 2022 10.1111/papt.12455 100,  0 100,100 Low,Cognitive Behavioral Therapy (CBT),CBT,  0,NA,CGI Clinician-rated At study endpoint (closest to 12 weeks),Questionnaire Clinical global impression (CGI)  1.84119678 NA NA Young,2015 NA RCT (parallel, crossover, open-label) SMD  48  47,  95,NA reverse,-0.9200000000 -1.340000000,-4.900000e-01,  0.8600000   0.8900000 NA,NA NA,NA NA NA 100,100,100,  0 100 100,100 low,high,low,low,low,TAU   0  65.473684,35.169579,NA DSM-IV, DSM-V 1,1 0.0 1.0 1.0,1.0,1 1,1 1,1,1 1 1.0,0,1,1,1  782 Young_2015 < 2 months NA >= 20 yo 35.1695789473684,39.4609375 NA NA, 20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA NA,Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2154 Lopez (2018) Lopez 2018 10.1002/14651858.CD010840.pub2,100   0 100 100 High,Cognitive Behavioral Therapy (CBT),CBT,  0 NA Depressive disorder symptoms,Self-rated At study endpoint (closest to 12 weeks),Questionnaire,Anxiety and Depression - Hospital anxiety and depression scale, 1.38089758 NA NA,Moell,2015,NA RCT (parallel, crossover, open-label) G  29, 28,  57 NA reverse,-0.2300000000,-0.750000000  2.900000e-01,  4.5000000   4.7000000 NA NA NA NA,NA NA 100,100 100,  0,100 100 100,some,high low,low low WLC (wait-list control)   0  68.421053,36.791228,NA,DSM-IV,0,1 1.0 1.0 1.0 1.0,1 1 0,1,1,1,1,1.0 1 1 1 1, 783,Moell_2015,< 2 months,NA >= 20 yo 33.5 41.5,NA NA  20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA,NA,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
2154,Lopez (2018) Lopez,2018,10.1002/14651858.CD010840.pub2 100,  0,100 100 High Cognitive Behavioral Therapy (CBT),CBT   0 NA,Depressive disorder symptoms Self-rated,At study endpoint (closest to 12 weeks) Questionnaire Beck Depression Inventory, second edition  2.30149597,NA,NA,Pettersson 2017,NA,RCT (parallel, crossover, open-label) G  27, 18,  45 NA,reverse -0.1600000000,-0.760000000, 4.400000e-01  12.6000000, 10.3000000,NA NA NA,NA,NA,NA 100,100 100   0,  0,100 100,low high high,low,low,WLC (wait-list control)   0  64.444444 37.400000,NA DSM-IV-TR,0 1,1.0 1.0,1.0,1.0,1 1,0 1 1 1,1,1.0 1,1,1 1  784,Pettersson_2017,2-6 months NA >= 20 yo,33.5,41.5,NA NA  20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA,NA Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
2154 Lopez (2018),Lopez 2018,10.1002/14651858.CD010840.pub2 100   0,100 100 High Cognitive Behavioral Therapy (CBT),CBT   0,NA Depressive disorder symptoms,Self-rated,At study endpoint (closest to 12 weeks) Questionnaire,Beck Depression Inventory, second edition, 2.30149597,NA NA,Virta,2010 NA RCT (parallel, crossover, open-label) G, 10,  9,  19,NA reverse -0.3700000000 -1.280000000  5.400000e-01,  8.9000000,  6.9000000 NA,NA NA NA NA,NA 100 100 100,  0 100 100 100 some high low,low,low,WLC (wait-list control),  0  51.724138,33.500000,NA,DSM-IV,0 1 1.0,1.0 1.0 1.0,1 1 0,1,1,1 1,1.0 1,1,1 1, 785,Virta_2010,2-6 months,NA,>= 20 yo 33.5,41.5,NA,NA  20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA NA Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2154,Lopez (2018) Lopez,2018,10.1002/14651858.CD010840.pub2 100,  0,100 100 High Cognitive Behavioral Therapy (CBT) CBT,  0,NA Generalized anxiety,Self-rated At study endpoint (closest to 12 weeks),Questionnaire Anxiety and Depression - Hospital anxiety and depression scale  1.38089758,NA NA Moell,2015,NA RCT (parallel, crossover, open-label) G  29  28,  57 NA,reverse -0.2400000000 -0.760000000  2.800000e-01   4.1000000,  2.8000000,NA NA NA NA,NA NA 100,100 100,  0,100,100 100,some high low low,low,WLC (wait-list control),  0, 68.421053,36.791228,NA,DSM-IV 0,1 1.0,1.0 1.0,1.0 1,1,0 1 1,1,1,1.0,1,1,1 1  786 Moell_2015,< 2 months NA >= 20 yo,33.8,41.5,NA NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA NA,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
2154 Lopez (2018) Lopez 2018,10.1002/14651858.CD010840.pub2,100   0,100,100,High,Cognitive Behavioral Therapy (CBT) CBT,  0,NA,Generalized anxiety,Self-rated,At study endpoint (closest to 12 weeks) Questionnaire Anxiety - Beck Anxiety Inventory, 2.30149597 NA,NA,Pettersson,2017 NA RCT (parallel, crossover, open-label) G, 27  18   45 NA reverse -0.1400000000 -0.730000000, 4.600000e-01, 11.5000000  10.5000000 NA,NA,NA,NA,NA NA,100 100 100,  0   0,100,100 low,high high low,low WLC (wait-list control)   0  64.444444,37.400000,NA DSM-IV-TR 0,1,1.0,1.0,1.0 1.0,1 1,0 1 1 1,1 1.0 1 1,1,1, 787,Pettersson_2017 2-6 months NA >= 20 yo,33.8 41.5 NA NA  20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA,NA Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
2154 Lopez (2018) Lopez,2018 10.1002/14651858.CD010840.pub2 100   0,100 100,High Cognitive Behavioral Therapy (CBT) CBT 100,Medication Depressive disorder symptoms Self-rated,At study endpoint (closest to 12 weeks),Questionnaire Beck Depression Inventory (BDI), 1.84119678   90.0000000 mn/session Emilsson,2011 NA RCT (parallel, crossover, open-label),G  18, 17   35,NA,reverse -0.9680120502,-1.680325383 -2.556987e-01,  6.8000000,  9.6000000 NA,NA,NA NA NA,NA 100 100 100   0,  0,100 100,some,high high low low,Active (any credible active intervention) 100  62.962963 33.800000,NA DSM-IV,0,1,1.0 1.0,1.0 1.0,1,1 0 1,1 1,1,1.0,1 1 1 1  788,Emilsson_2011 < 2 months NA,>= 20 yo,33.5,41.5 NA,NA, 20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA NA,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
2154,Lopez (2018) Lopez,2018 10.1002/14651858.CD010840.pub2,100,  0 100 100,High Cognitive Behavioral Therapy (CBT),CBT,100,Medication Depressive disorder symptoms Self-rated,At study endpoint (closest to 12 weeks),Questionnaire Depression - Hamilton Depression Scale (HAM-D), 2.76179517,NA,NA Safren 2005,NA,RCT (parallel, crossover, open-label),G  16  15,  31,NA reverse,-0.7564656748,-1.498789783 -1.414157e-02,  4.3000000   7.7000000 NA,NA,NA,NA NA,NA,100,100 100,  0 100,100,100 low high low low,low,Active (any credible active intervention),100  44.186047 41.500000 NA,DSM-IV 0 1 1.0 1.0,1.0,1.0 1,1 0,1,1,1 1 1.0 1 1,1 1, 789 Safren_2005,2-6 months NA,>= 20 yo,33.5,41.5 NA NA  20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA,NA,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
2154 Lopez (2018) Lopez,2018,10.1002/14651858.CD010840.pub2,100,  0 100 100 High Cognitive Behavioral Therapy (CBT),CBT 100 Medication,Generalized anxiety,Self-rated At study endpoint (closest to 12 weeks),Questionnaire,Beck Anxiety Inventory, 1.84119678   90.0000000,mn/session Emilsson 2011,NA,RCT (parallel, crossover, open-label),G  18, 17   35 NA,reverse,-0.3945495027,-1.073656048, 2.845570e-01, 10.6000000, 10.7000000,NA NA,NA NA NA,NA 100 100,100   0,  0,100,100,some,high,high low low,Active (any credible active intervention) 100  62.962963,33.800000,NA DSM-IV 0,1,1.0,1.0,1.0 1.0,1,1,0,1,1,1,1 1.0,1 1,1 1  790 Emilsson_2011 < 2 months,NA >= 20 yo 33.8 41.5,NA NA  20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA NA,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2154 Lopez (2018),Lopez 2018 10.1002/14651858.CD010840.pub2,100   0,100 100 High Cognitive Behavioral Therapy (CBT) CBT 100,Medication Generalized anxiety Self-rated,At study endpoint (closest to 12 weeks),Questionnaire,Anxiety - Hamilton Anxiety Scale (HAM-A), 2.76179517,NA,NA,Safren,2005 NA,RCT (parallel, crossover, open-label),G  16  15   31 NA,reverse -0.8050345542,-1.550797125,-5.927198e-02   3.5000000,  4.9000000,NA,NA,NA NA NA NA 100,100 100,  0,100 100,100 low,high,low low low Active (any credible active intervention),100  44.186047 41.500000 NA DSM-IV,0 1 1.0,1.0,1.0,1.0 1 1 0 1,1,1 1,1.0 1 1,1 1, 791 Safren_2005 2-6 months NA >= 20 yo,33.8,41.5 NA,NA, 20  9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA NA,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
8888,Bellato - adults (2024),Bellato - adults,2024 10.1016/j.jaac.2024.05.023,100   0,100 100,High Amphetamine,LDX   0 NA,Quality of life (patients),Self-rated,At study endpoint (closest to 12 weeks) Questionnaire The ADHD Impact ModuleAdult  2.30149597,NA NA,Adler,2013 NA RCT (parallel, crossover, open-label),G, 80, 81  161 outcomes NA  0.8384000000  0.516100000  1.160800e+00,NA NA,NA NA NA NA NA,NA 100,100,100 100 100,100 100,low,low some,low low,Placebo   0, 47.790062 34.500000,NA DSM-III, DSM-IV, DSM-V,0 1,1.0,1.0 1.0 1.0,1 1 1 1 1,1,1,1.0,0,1,1 1, 792,Adler_2013 2-6 months,NA >= 20 yo,34.5 36.5,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
8888 Bellato - adults (2024),Bellato - adults,2024,10.1016/j.jaac.2024.05.023 100,  0,100,100 High,Amphetamine LDX,  0,NA Quality of life (patients),Self-rated At study endpoint (closest to 12 weeks) Questionnaire,The ADHD Impact ModuleAdult  2.30149597 NA NA Adler 2013 NA,RCT (parallel, crossover, open-label) G  80  81, 161,outcomes,NA  0.6521000000  0.335000000, 9.692000e-01,NA,NA,NA,NA NA NA NA NA,100 100,100,100,100 100 100,low low some,low,low Placebo   0  47.790062 34.500000,NA,DSM-III, DSM-IV, DSM-V 0,1,1.0 1.0,1.0 1.0 1 1,1,1 1,1,1,1.0 0 1 1,1, 793,Adler_2013,2-6 months NA >= 20 yo 34.5 36.5 NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
8888 Bellato - adults (2024),Bellato - adults,2024 10.1016/j.jaac.2024.05.023,100   0 100 100,High Amphetamine LDX   0 NA,Quality of life (patients) Self-rated At study endpoint (closest to 12 weeks) Questionnaire,The ADHD Impact ModuleAdult, 2.30149597,NA NA,Adler,2013 NA RCT (parallel, crossover, open-label) G  80  81  161 outcomes,NA, 0.5873000000  0.271700000  9.029000e-01 NA,NA NA,NA,NA NA,NA NA,100,100 100,100 100,100,100 low,low,some low low Placebo,  0, 47.790062,34.500000,NA DSM-III, DSM-IV, DSM-V 0,1,1.0,1.0,1.0 1.0,1,1,1 1,1 1 1,1.0,0,1,1 1, 794 Adler_2013 2-6 months NA,>= 20 yo,34.5 36.5 NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
8888 Bellato - adults (2024) Bellato - adults 2024 10.1016/j.jaac.2024.05.023,100,  0,100 100 High,Amphetamine LDX   0,NA Quality of life (patients) Self-rated,At study endpoint (closest to 12 weeks),Questionnaire The ADHD Impact ModuleAdult, 2.30149597 NA,NA,Adler 2013,NA,RCT (parallel, crossover, open-label),G, 80  81  161,outcomes NA  0.3447000000, 0.033500000  6.560000e-01,NA NA,NA,NA,NA,NA,NA NA 100,100 100 100 100,100 100 low low,some low low Placebo   0, 47.790062,34.500000 NA DSM-III, DSM-IV, DSM-V,0 1,1.0,1.0,1.0,1.0 1 1 1,1,1,1,1,1.0 0,1 1 1  795 Adler_2013 2-6 months,NA,>= 20 yo 34.5 36.5,NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
8888 Bellato - adults (2024),Bellato - adults,2024,10.1016/j.jaac.2024.05.023 100,  0 100,100 High,Amphetamine LDX,  0 NA,Quality of life (patients) Self-rated,At study endpoint (closest to 12 weeks),Questionnaire The ADHD Impact ModuleAdult  2.30149597,NA NA Adler 2013 NA RCT (parallel, crossover, open-label) G, 80, 81  161 outcomes NA  0.7723000000, 0.451900000, 1.092600e+00,NA NA NA NA NA NA,NA,NA 100,100 100,100,100 100 100 low,low,some low,low Placebo,  0, 47.790062,34.500000 NA DSM-III, DSM-IV, DSM-V 0 1,1.0 1.0 1.0 1.0 1 1 1 1 1 1,1,1.0 0,1,1 1, 796,Adler_2013,2-6 months,NA,>= 20 yo,34.5 36.5 NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
8888,Bellato - adults (2024),Bellato - adults,2024 10.1016/j.jaac.2024.05.023 100,  0 100,100 High Amphetamine,LDX   0 NA,Quality of life (patients) Self-rated,At study endpoint (closest to 12 weeks),Questionnaire The ADHD Impact ModuleAdult  2.30149597 NA NA Adler 2013 NA RCT (parallel, crossover, open-label) G  80, 81  161,outcomes NA  0.6983000000, 0.380000000, 1.016600e+00 NA NA NA,NA NA NA,NA NA,100 100,100 100 100 100 100,low low some,low low Placebo   0, 47.790062 34.500000,NA DSM-III, DSM-IV, DSM-V 0 1,1.0 1.0 1.0 1.0 1 1 1,1,1 1,1,1.0 0,1 1 1  797,Adler_2013 2-6 months,NA >= 20 yo,34.5 36.5,NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
8888,Bellatto - children (2024),Bellatto - children 2024 10.1016/j.jaac.2024.05.023 100,  0 100 100,High Amphetamine,LDX   0 NA,Quality of life (patients) Self-rated,At study endpoint (closest to 12 weeks) Questionnaire Child Health and Illness ProfileChild Edition, 1.61104718 NA,NA Coghill,2013,NA,RCT (parallel, crossover, open-label) G 104,106  210 outcomes,NA  0.9867000000, 0.700100000  1.273300e+00 NA,NA,NA NA,NA NA,NA,NA,100,100 100 100   0,100 100 low,low high,low,low,Placebo   0, 19.429524,10.900000,NA DSM-III, DSM-IV, DSM-V 0,1 1.0,1.0,1.0,1.0 1 1 1,1,1,1 1 1.0 0 1,1 1, 798,Coghill_2013 < 2 months NA 6-12 yo,10.9,15 NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Bellatto - children (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Bellatto - children (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
8888,Bellatto - children (2024),Bellatto - children,2024 10.1016/j.jaac.2024.05.023,100   0,100 100 High Amphetamine,LDX,  0,NA,Quality of life (patients),Self-rated,At study endpoint (closest to 12 weeks) Questionnaire Youth Quality of LifeResearch Version, 0.92059839 NA,NA,Findling,2011 NA,RCT (parallel, crossover, open-label),G 232, 79, 311,outcomes,NA,-0.0321000000,-0.287400000, 2.232000e-01,NA,NA NA,NA NA NA,NA NA,100 100,100,100 100,100 100 low low low,low,low Placebo,  0, 29.700000,15.000000,NA DSM-III, DSM-IV, DSM-V 0 1,1.0 1.0,1.0 1.0 1,1,1,1 1,1 1,1.0 0,1,1,1  799,Findling_2011 < 2 months,NA 13-19 yo,10.9,15 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Bellatto - children (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellatto - children (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8888 Bellato - adults (2024) Bellato - adults,2024 10.1016/j.jaac.2024.05.023,100,  0 100,100 High Amphetamine,Triple Bead MAS,  0,NA Quality of life (patients),Self-rated,At study endpoint (closest to 12 weeks),Questionnaire The ADHD Impact ModuleAdult, 1.61104718 NA,NA,Spencer,2008 NA,RCT (parallel, crossover, open-label) G,136 132  268,outcomes,NA, 0.4377000000, 0.195300000, 6.800000e-01 NA NA NA,NA NA,NA,NA NA 100 100,100,100   0 100 100,low,low,high,low,low Placebo,  0  49.994030 36.500000,NA DSM-III, DSM-IV, DSM-V 0,1,1.0,1.0,1.0 1.0 1,1,1 1,1,1,1 1.0 0,1 1 1  800 Spencer_2008,< 2 months,NA,>= 20 yo 34.5,36.5 NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
8888,Bellato - adults (2024),Bellato - adults 2024 10.1016/j.jaac.2024.05.023 100   0 100,100,High Amphetamine Triple Bead MAS   0,NA Quality of life (patients),Self-rated,At study endpoint (closest to 12 weeks) Questionnaire,The ADHD Impact ModuleAdult  1.61104718,NA,NA,Spencer,2008,NA RCT (parallel, crossover, open-label),G,136,132  268 outcomes NA, 0.4234000000  0.181300000, 6.656000e-01 NA NA NA,NA,NA,NA,NA,NA 100 100 100,100   0 100 100 low low high low low Placebo,  0, 49.994030 36.500000,NA DSM-III, DSM-IV, DSM-V 0 1 1.0,1.0,1.0 1.0,1,1,1,1,1,1 1 1.0,0 1 1 1, 801,Spencer_2008,< 2 months NA,>= 20 yo 34.5,36.5 NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
8888,Bellato - adults (2024) Bellato - adults,2024,10.1016/j.jaac.2024.05.023 100,  0,100 100,High,Amphetamine Triple Bead MAS,  0 NA Quality of life (patients),Self-rated At study endpoint (closest to 12 weeks) Questionnaire The ADHD Impact ModuleAdult, 1.61104718,NA NA Spencer,2008 NA,RCT (parallel, crossover, open-label) G 136 132, 268,outcomes,NA  0.6954000000  0.448700000  9.420000e-01 NA,NA NA NA NA,NA NA,NA,100,100 100 100   0,100,100 low,low,high low,low,Placebo   0, 49.994030 36.500000 NA,DSM-III, DSM-IV, DSM-V,0 1 1.0 1.0 1.0 1.0,1,1 1,1,1,1 1 1.0,0 1 1,1, 802,Spencer_2008 < 2 months,NA >= 20 yo 34.5 36.5,NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
8888 Bellato - adults (2024) Bellato - adults,2024 10.1016/j.jaac.2024.05.023,100   0,100,100,High Amphetamine,Triple Bead MAS,  0,NA Quality of life (patients),Self-rated,At study endpoint (closest to 12 weeks),Questionnaire The ADHD Impact ModuleAdult, 1.61104718 NA NA,Spencer,2008 NA RCT (parallel, crossover, open-label) G 136,132, 268,outcomes,NA  0.5441000000, 0.300300000  7.880000e-01 NA,NA NA,NA NA,NA,NA,NA,100 100,100 100   0 100,100 low,low high low low Placebo   0  49.994030,36.500000,NA,DSM-III, DSM-IV, DSM-V 0,1,1.0,1.0 1.0,1.0,1 1 1 1,1 1,1,1.0 0,1 1 1  803 Spencer_2008 < 2 months,NA,>= 20 yo 34.5,36.5,NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
8888 Bellato - adults (2024) Bellato - adults,2024 10.1016/j.jaac.2024.05.023,100,  0 100,100 High,Amphetamine Triple Bead MAS   0 NA Quality of life (patients) Self-rated At study endpoint (closest to 12 weeks) Questionnaire,The ADHD Impact ModuleAdult, 1.61104718,NA NA,Spencer,2008 NA RCT (parallel, crossover, open-label),G,136 132, 268,outcomes,NA, 0.2289000000 -0.011400000  4.691000e-01,NA,NA NA NA NA NA,NA NA,100,100 100,100   0,100,100 low low high,low low,Placebo   0, 49.994030 36.500000 NA DSM-III, DSM-IV, DSM-V 0 1 1.0 1.0,1.0,1.0,1,1,1 1 1,1,1,1.0,0 1,1,1, 804,Spencer_2008,< 2 months NA >= 20 yo 34.5,36.5 NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
8888 Bellato - adults (2024) Bellato - adults 2024,10.1016/j.jaac.2024.05.023 100   0,100,100,High Amphetamine,Triple Bead MAS,  0 NA Quality of life (patients),Self-rated At study endpoint (closest to 12 weeks),Questionnaire,The ADHD Impact ModuleAdult  1.61104718,NA NA Spencer 2008,NA RCT (parallel, crossover, open-label) G 136 132, 268,outcomes NA  0.3183000000  0.077300000, 5.592000e-01 NA NA,NA NA NA,NA NA,NA 100 100 100,100,  0,100,100,low,low high,low,low Placebo   0  49.994030 36.500000 NA,DSM-III, DSM-IV, DSM-V 0,1,1.0,1.0 1.0 1.0 1,1 1 1 1,1,1,1.0,0 1,1 1  805,Spencer_2008,< 2 months NA,>= 20 yo 34.5 36.5,NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
8888 Bellatto - children (2024) Bellatto - children 2024 10.1016/j.jaac.2024.05.023,100   0 100 100 High,Atomoxetine NA,  0 NA,Quality of life (patients),NA At study endpoint (closest to 12 weeks) Questionnaire NA, 1.84119678 NA NA Bangs 2008 NA RCT (parallel, crossover, open-label),G,151  67  218 outcomes NA, 0.3887000000  0.099000000, 6.784000e-01 NA,NA,NA,NA,NA NA,NA NA 100,100,100,100,100,100 100 low,low,low low,some Placebo,  0,  8.300000, 9.000000,NA,DSM-III, DSM-IV, DSM-V 0,1 1.0 1.0,1.0 1.0 1 1,1 1,1,1,1,1.0 0 1,1 1, 806 Bangs_2008,< 2 months,NA,6-12 yo 9,13,NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
8888 Bellatto - children (2024),Bellatto - children 2024,10.1016/j.jaac.2024.05.023 100   0 100,100,High Atomoxetine NA,  0,NA,Quality of life (patients),NA,At study endpoint (closest to 12 weeks) Questionnaire NA  1.84119678 NA NA Bangs 2008,NA,RCT (parallel, crossover, open-label),G,151  67  218 outcomes,NA,-0.0399000000,-0.329100000, 2.494000e-01 NA,NA NA,NA,NA NA,NA,NA 100 100 100 100,100,100,100,low,low,low,low some,Placebo,  0,  8.300000, 9.000000 NA,DSM-III, DSM-IV, DSM-V 0,1,1.0,1.0,1.0,1.0 1 1 1 1,1 1 1,1.0,0 1,1 1  807,Bangs_2008 < 2 months,NA,6-12 yo,9 13,NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8888 Bellatto - children (2024),Bellatto - children 2024,10.1016/j.jaac.2024.05.023 100,  0,100 100 High,Atomoxetine NA   0 NA Quality of life (patients) NA,At study endpoint (closest to 12 weeks),Questionnaire,NA, 1.84119678,NA NA Bangs 2008 NA,RCT (parallel, crossover, open-label) G,151, 67  218 outcomes,NA  0.3006000000, 0.011500000  5.897000e-01 NA NA NA NA,NA,NA,NA NA,100,100 100 100 100 100,100,low,low,low,low,some Placebo,  0   8.300000, 9.000000,NA,DSM-III, DSM-IV, DSM-V 0,1,1.0,1.0 1.0 1.0,1 1 1 1,1 1,1 1.0,0,1 1 1, 808 Bangs_2008,< 2 months NA,6-12 yo 9 13,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8888 Bellatto - children (2024),Bellatto - children 2024,10.1016/j.jaac.2024.05.023,100   0,100 100,High,Atomoxetine NA,  0 NA Quality of life (patients) NA At study endpoint (closest to 12 weeks) Questionnaire,NA  1.84119678,NA,NA,Dittmann,2011,NA RCT (parallel, crossover, open-label) G,118, 59, 177 NA NA, 0.2657000000,-0.048000000  5.795000e-01,NA,NA NA NA,NA NA NA NA 100 100 100,100,  0 100,100 low low,high,low,some,Placebo,  0  16.000000 13.000000,NA DSM-III, DSM-IV, DSM-V 0,1,1.0,1.0 1.0,1.0,1,1 1 1 1 1,1,1.0,0 1,1,1, 809 Dittmann_2011,< 2 months,NA 13-19 yo,9 13,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8888 Bellatto - children (2024),Bellatto - children 2024 10.1016/j.jaac.2024.05.023 100   0,100 100 High,Atomoxetine NA   0 NA Quality of life (patients) NA At study endpoint (closest to 12 weeks) Questionnaire,NA, 1.84119678 NA,NA Michelson 2001 NA,RCT (parallel, crossover, open-label),G,213  83  296 outcomes,NA  0.4656000000, 0.092800000  8.384000e-01,NA,NA,NA,NA NA,NA NA NA   0   0,  0,100,  0,100 100,high,low,high,low,some Placebo   0  28.600000,11.000000,NA DSM-III, DSM-IV, DSM-V 0 1 1.0 1.0,1.0 1.0,1,1,1,1 1 1,1,1.0 0 1 1 1  810,Michelson_2001,< 2 months,NA,6-12 yo,9 13 NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
8888,Bellatto - children (2024) Bellatto - children,2024 10.1016/j.jaac.2024.05.023,100   0 100 100 High Atomoxetine,NA,  0,NA,Quality of life (patients),NA,At study endpoint (closest to 12 weeks) Questionnaire NA, 1.84119678 NA,NA Michelson 2001,NA RCT (parallel, crossover, open-label),G 213  83, 296,outcomes,NA, 0.6551000000  0.343600000, 9.665000e-01,NA NA NA NA,NA,NA,NA NA   0   0,  0 100   0 100,100,high,low,high,low some,Placebo   0  28.600000,11.000000 NA,DSM-III, DSM-IV, DSM-V 0,1 1.0 1.0,1.0,1.0 1,1,1,1,1,1 1 1.0,0 1 1 1, 811,Michelson_2001,< 2 months NA 6-12 yo 9,13,NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
8888 Bellatto - children (2024),Bellatto - children,2024 10.1016/j.jaac.2024.05.023 100,  0 100,100 High Atomoxetine,NA,  0 NA Quality of life (patients),NA,At study endpoint (closest to 12 weeks),Questionnaire NA  1.84119678 NA NA Michelson 2001,NA RCT (parallel, crossover, open-label),G,213  83, 296,outcomes NA, 0.8688000000  0.549400000, 1.188100e+00 NA NA,NA NA NA,NA,NA NA   0   0,  0 100,  0,100 100 high,low high low,some Placebo,  0  28.600000,11.000000 NA,DSM-III, DSM-IV, DSM-V 0 1,1.0 1.0 1.0 1.0 1,1,1,1,1,1,1 1.0,0,1,1,1, 812,Michelson_2001 < 2 months,NA 6-12 yo 9,13,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
8888,Bellatto - children (2024),Bellatto - children 2024 10.1016/j.jaac.2024.05.023 100   0,100 100 High Atomoxetine NA,  0 NA,Quality of life (patients),NA,At study endpoint (closest to 12 weeks) Questionnaire,NA, 2.07134638 NA NA Newcorn,2008,NA RCT (parallel, crossover, open-label) G,193  64  257,NA,NA  0.3679000000, 0.083400000  6.524000e-01 NA NA,NA,NA,NA NA NA NA,100 100 100 100 100,100,100 low,low some,low low,Placebo   0  25.700000 11.000000 NA DSM-III, DSM-IV, DSM-V 0,1,1.0,1.0 1.0,1.0 1 1 1,1,1 1 1,1.0 0,1,1 1, 813,Newcorn_2008,2-6 months,NA 6-12 yo 9 13 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
8888 Bellatto - children (2024),Bellatto - children 2024 10.1016/j.jaac.2024.05.023,100   0 100 100 High Atomoxetine NA,  0,NA Quality of life (patients) NA At study endpoint (closest to 12 weeks),Questionnaire NA  1.84119678,NA,NA,Svanborg,2009,NA,RCT (parallel, crossover, open-label) G, 49, 50,  99 NA NA, 0.1662000000 -0.228500000, 5.609000e-01,NA NA NA,NA NA NA NA,NA 100 100 100 100,100 100,100,some,low low low some,Placebo,  0  19.200000,11.500000,NA,DSM-III, DSM-IV, DSM-V,0 1 1.0,1.0,1.0 1.0 1 1 1 1,1,1 1 1.0 0,1,1 1  814 Svanborg_2009,< 2 months NA,6-12 yo,9,13 NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8888 Bellatto - children (2024),Bellatto - children 2024,10.1016/j.jaac.2024.05.023 100   0 100 100,High Atomoxetine NA,  0 NA Quality of life (patients),NA At study endpoint (closest to 12 weeks),Questionnaire NA  1.84119678,NA,NA Weiss,2005,NA,RCT (parallel, crossover, open-label) G  84, 48  132,NA NA  0.2916000000 -0.056700000, 6.400000e-01,NA NA,NA,NA NA NA NA,NA,100 100,100,100,100 100,100,low,low,low low some,Placebo   0 NA  9.900000,NA,DSM-III, DSM-IV, DSM-V 0,1,1.0 1.0,1.0,1.0,1 1 1 1,1,1 1,1.0 0,1 1 1, 815 Weiss_2005,< 2 months NA,6-12 yo 9 13,NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
1318,Gillies (2023) Gillies 2023,10.1002/14651858.CD007986.pub2,100   0,100,100,High,Polyunsaturated fatty acids,NA,100,Metilphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  0.46029919  354.0000000,mg/d,Assareh,2017 NA RCT (parallel, crossover, open-label) G, 20  20,  40,NA,reverse, 0.0000000000 -0.620000000, 6.200000e-01,NA,NA,NA,NA,NA NA,NA NA,100,100,100,100 100 100 100,some,some some some low Active (any credible active intervention) 100 NA, 9.100000,NA,DSM-IV 0 1 1.0 1.0 1.0,1.0 1 1 0,1,1 1 1,1.0,1 1,1 1, 816,Assareh_2017 < 2 months,NA 6-12 yo,7.94166666666667,9.1,NA NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
1318 Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2,100,  0,100 100 High,Polyunsaturated fatty acids,NA,100,Metilphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998. 12.00000000, 792.0000000 mg/d Barragan,2017,NA,RCT (parallel, crossover, open-label),G, 30  30,  60,NA,reverse, 0.7800000000  0.260000000  1.310000e+00 NA,NA,NA,NA NA,NA NA NA   0,  0   0   0 100 100,  0,high high some high,low Active (any credible active intervention),100,NA, 8.270000 NA DSM-IV TR,0,1,1.0,1.0,1.0,1.0,1 1 0 1 1,1 1,1.0 1,1,1,1, 817,Barragan_2017 7-12 months,NA,6-12 yo,7.94166666666667 9.1,NA,NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
1318,Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0 100 100,High Polyunsaturated fatty acids NA 100,Metilphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 1.84119678  600.0000000 mg/d,Behdani,2013,NA RCT (parallel, crossover, open-label) G  36, 33,  69 NA reverse, 0.2520209000,-0.694158300  1.198200e+00 NA,NA,NA NA,NA NA,NA,NA,100,100,100,100 100,100,100,some some,some some,low,Active (any credible active intervention),100  20.300000, 8.700000,NA,DSM-IV TR 0,1,1.0 1.0,1.0 1.0 1,1 0,1,1,1,1,1.0 1,1,1,1  818 Behdani_2013,< 2 months,NA,6-12 yo 7.94166666666667 9.1 NA NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
1318,Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2 100   0,100,100,High Polyunsaturated fatty acids,NA,100 MPH,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  1.84119678  600.0000000,mg/d Mohammadzadeh,2019,NA RCT (parallel, crossover, open-label) G  31, 29   60 NA,reverse  0.2200000000,-0.290000000  7.300000e-01 NA,NA,NA,NA NA NA,NA NA   0   0,100 100 100   0 100,low low some,low high,Active (any credible active intervention) 100  25.760000, 7.941667,NA DSM-IV TR 0 1 1.0,1.0,1.0,1.0,1,1 0 1 1 1 1 1.0,1 1,1 1  819,Mohammadzadeh_2019 < 2 months,NA,6-12 yo,7.94166666666667,9.1,NA,NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
1318,Gillies (2023) Gillies 2023,10.1002/14651858.CD007986.pub2,100   0,100,100,High Polyunsaturated fatty acids,NA 100 MPH,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 1.84119678, 250.0000000,mg/d,Salehi,2016,NA,RCT (parallel, crossover, open-label) G, 50  50  100 NA,reverse  0.0600000000,-0.340000000  4.500000e-01,NA,NA NA NA NA NA NA,NA,100,100 100 100,100 100,100,some,some some,some,some,Active (any credible active intervention),100, 29.000000  8.850000,NA DSM-IV TR 0,1,1.0 1.0 1.0 1.0,1 1,0,1,1,1,1,1.0,1,1 1 1, 820,Salehi_2016 < 2 months,NA,6-12 yo,7.94166666666667 9.1 NA NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
1318,Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2 100   0,100 100,High,Polyunsaturated fatty acids,NA 100 Atomoxetine Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  4.00000000, 300.0000000,mg/d Anand,2016,NA,RCT (parallel, crossover, open-label),G, 25  25   50 NA,reverse,-0.3600000000 -0.920000000  2.000000e-01,  2.2100000,  2.1800000,NA,NA NA NA NA,NA,100,100 100,100,100,100 100 low some low,some,some,Active (any credible active intervention) 100  30.000000, 6.000000,NA,DSM-IV,0,1 1.0,1.0 1.0,1.0 1,1,0 1 1 1,1,1.0 1 1 1,1  821 Anand_2016 2-6 months,NA,6-12 yo,6 13.7 NA,NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low low
1318 Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2,100,  0,100,100,High,Polyunsaturated fatty acids,NA 100,Metilphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.,12.00000000, 792.0000000,mg/d,Barragan,2017 NA RCT (parallel, crossover, open-label),G  30  30   60 NA reverse  0.2600000000 -0.250000000  7.700000e-01   5.5400000,  4.7000000 NA,NA NA,NA,NA NA,  0,  0,  0,  0,100 100,  0,high high some,high,low Active (any credible active intervention) 100,NA  8.270000,NA,DSM-IV TR,0 1 1.0 1.0,1.0 1.0,1,1,0,1,1 1,1,1.0 1,1,1 1  822 Barragan_2017,7-12 months,NA 6-12 yo,6,13.7,NA NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low,high
1318 Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2,100   0,100,100,High Polyunsaturated fatty acids,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  3.68239356 1300.0000000,mg/d,Bos 2015 NA RCT (parallel, crossover, open-label) G, 19  19   38 NA,reverse,-0.8400000000,-1.500000000 -1.700000e-01,  3.5000000   2.2000000 NA NA NA,NA NA,NA,  0,  0,  0 100,100,100,100 high,low low,low some,Placebo,  0   0.000000 10.300000,NA DSM-IV 0,1,1.0,1.0 1.0 1.0,1,1 0 1 1,1,1,1.0 1 1 1 1  823,Bos_2015,2-6 months NA 6-12 yo,6 13.7 NA,NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,high
1318 Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0 100,100,High,Polyunsaturated fatty acids,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 2.76179517 NA,mg/d,Chang,2019 NA RCT (parallel, crossover, open-label) G  48  48   96 NA,reverse, 0.2800000000,-0.130000000, 6.900000e-01  10.0200000  10.1700000,NA NA,NA,NA,NA,NA 100,100 100,100,100 100 100 some some some,low,some,Placebo   0  14.130000, 9.490000 NA,DSM-5 0,1 1.0,1.0 1.0 1.0 1 1 0 1,1,1,1 1.0 1 1 1 1, 824,Chang_2019 2-6 months,NA,6-12 yo,6 13.7 NA NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low low
1318 Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2 100   0,100,100 High Polyunsaturated fatty acids NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 3.00000000  630.0000000 mg/d,Cornu 2018 NA RCT (parallel, crossover, open-label) G  77  77  154 NA,reverse, 0.2000000000 -0.120000000, 5.100000e-01  11.4000000  10.9000000 NA NA NA,NA,NA NA 100,100 100,100,100,100,100,low low low,low some,Placebo,  0, 26.200000  9.900000 NA,DSM-IV TR,0,1,1.0,1.0,1.0,1.0,1 1 0 1 1,1 1 1.0,1 1,1 1  825,Cornu_2018,2-6 months,NA 6-12 yo,6,13.7 NA,NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low low
1318 Gillies (2023),Gillies,2023,10.1002/14651858.CD007986.pub2 100,  0,100 100,High Polyunsaturated fatty acids NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 6.00000000  500.0000000 mg/d Crippa,2019 NA,RCT (parallel, crossover, open-label),G  25, 25,  50 NA,reverse, 0.0000000000 -0.560000000  5.500000e-01,  8.6700000  11.8900000,NA,NA NA NA NA,NA   0,  0 100,100,100   0,100 low,low,low,low high Placebo,  0   8.000000 10.985000 NA DSM-IV TR 0,1 1.0 1.0 1.0 1.0 1,1 0 1 1,1 1,1.0,1,1 1,1  826,Crippa_2019 2-6 months NA,6-12 yo,6 13.7 NA,NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no high high
1318,Gillies (2023),Gillies,2023,10.1002/14651858.CD007986.pub2,100   0,100,100 High Polyunsaturated fatty acids,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 3.45224396  502.7000000,mg/d,Gustafsson,2010 NA RCT (parallel, crossover, open-label),G  36, 36   72,NA,reverse  0.2400000000 -0.170000000, 6.500000e-01, 18.6000000, 18.4000000 NA NA NA NA NA NA 100,100 100 100 100,100 100,some low some low,low Placebo,  0 NA, 9.500000,NA,DSM-IV,0 1,1.0 1.0 1.0 1.0 1,1,0,1,1,1,1,1.0,1 1 1,1  827,Gustafsson_2010,2-6 months NA,6-12 yo 6,13.7,NA,NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,low
1318 Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2,100,  0 100,100 High,Polyunsaturated fatty acids,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  3.45224396, 420.0000000 mg/d,Manor,2012,NA,RCT (parallel, crossover, open-label),G, 20  20   40,NA,reverse -0.1900000000,-0.550000000  1.700000e-01, 10.0600000,  9.4400000 NA NA NA NA NA NA   0,  0,100,100   0,  0,100 low low,high low,high Placebo   0  29.200000  9.200000,NA,DSM-IV,0 1 1.0,1.0 1.0 1.0 1 1 0 1,1 1 1 1.0 1,1 1 1  828,Manor_2012 2-6 months,NA 6-12 yo,6 13.7,NA,NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,high high
1318,Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2 100   0,100,100,High Polyunsaturated fatty acids NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 2.76179517  792.0000000 mg/d Matsudaira 2015,NA,RCT (parallel, crossover, open-label),G, 19  19   38,NA,reverse, 0.2400000000,-0.430000000, 9.100000e-01,  4.7100000   6.7900000 NA,NA NA NA,NA NA,100 100,100,100 100 100 100,low,some,some,some,low,Placebo   0   0.000000,13.700000,NA,DSM-IV 0 1 1.0,1.0,1.0,1.0 1,1,0,1 1 1 1,1.0 1,1 1,1, 829 Matsudaira_2015 2-6 months,NA,13-19 yo 6 13.7,NA NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,low
1318 Gillies (2023) Gillies 2023,10.1002/14651858.CD007986.pub2 100   0 100,100 High Polyunsaturated fatty acids NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998. NA  600.0000000,mg/d NCT01807299 2013,NA,RCT (parallel, crossover, open-label) G  11  13   24,NA reverse,-0.4400000000,-1.260000000, 3.700000e-01, 12.7500000, 12.1000000,NA,NA NA,NA NA NA 100 100 100 100 100 100,100,some some,some,some low Placebo,  0,  0.000000,10.510000 NA DSM (clinical diag),0,1 1.0 1.0,1.0,1.0 1 1,0,1 1 1,1 1.0,1,1,1,1  830,NCT01807299_2013,NA NA,6-12 yo 6,13.7 NA,NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low low
1318,Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2 100,  0,100 100,High Polyunsaturated fatty acids,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  6.00000000, 954.2400000 mg/d,Perera 2012,NA,RCT (parallel, crossover, open-label) G, 48, 46,  94,NA reverse -0.2500000000,-0.660000000  1.500000e-01,  3.6500000, 29.3000000 NA NA NA,NA,NA NA,100 100,100,100 100,100 100,some low some,low low Placebo,  0, 26.600000  9.300000,NA DSM (clinical diag) 0,1 1.0,1.0 1.0,1.0,1,1,0,1 1 1,1 1.0 1 1,1 1, 831,Perera_2012 2-6 months NA 6-12 yo 6,13.7 NA NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low low
1318 Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2,100,  0 100,100 High Polyunsaturated fatty acids NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  6.00000000,1090.0000000,mg/d Rodriguez,2019 NA,RCT (parallel, crossover, open-label),G, 33  33   66 NA reverse, 0.0800000000 -0.410000000  5.600000e-01,  3.9000000   3.8000000,NA NA NA NA NA NA,100,100 100,100,  0,100,100 some low,high,low,low Placebo   0 NA 11.700000 NA,DSM-5 0,1,1.0,1.0 1.0 1.0,1,1 0,1 1,1 1,1.0 1 1,1 1  832 Rodriguez_2019 2-6 months,NA 6-12 yo,6 13.7,NA,NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low low
1318,Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2 100   0 100 100,High Polyunsaturated fatty acids,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  4.00000000  656.0000000,mg/d Stevens,2003,NA RCT (parallel, crossover, open-label) G  18  18   36,NA reverse -0.3500000000 -1.040000000  3.400000e-01   3.7500000,  4.0000000 NA NA,NA,NA NA,NA,100,100 100 100   0,100 100 some low high,low low Placebo,  0  14.600000  9.800000 NA DSM (clinical diag) 0,1 1.0 1.0 1.0 1.0,1,1 0 1,1 1,1,1.0 1,1,1 1, 833,Stevens_2003,2-6 months NA 6-12 yo 6,13.7,NA,NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low,low
1318,Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2 100,  0,100 100 High Polyunsaturated fatty acids,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 3.00000000, 145.0000000 mg/d Vaisman,2008,NA,RCT (parallel, crossover, open-label) G, 29, 26   55,NA reverse,-0.4000000000,-0.930000000, 1.400000e-01,  3.2200000   3.7300000,NA,NA NA NA,NA,NA,100 100,100,100   0 100 100,some,low,high,low low,Placebo,  0  25.000000, 9.300000 NA DSM (clinical diag) 0,1,1.0 1.0,1.0 1.0 1 1 0,1 1,1 1 1.0 1,1 1,1  834 Vaisman_2008 2-6 months,NA 6-12 yo,6 13.7 NA NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low low
1318 Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2 100   0,100,100 High,Polyunsaturated fatty acids NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  3.68239356, 720.0000000,mg/d Widenhorn-Muller,2014 NA,RCT (parallel, crossover, open-label),G  45  45,  90,NA reverse  0.0200000000 -0.390000000  4.300000e-01   0.5400000   0.5500000 NA NA,NA NA,NA NA 100 100 100 100,100,100 100 some,low,some,low low,Placebo   0, 22.100000, 8.900000,NA DSM-IV,0 1 1.0 1.0 1.0,1.0,1 1,0 1,1 1 1 1.0,1,1,1,1  835 Widenhorn-Muller_2014 2-6 months,NA,6-12 yo 6,13.7 NA,NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low,low
1318 Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2,  0,  0 100 100,High Polyunsaturated fatty acids NA,100 Dexamfetamine Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 1.00000000  390.0000000,mg/d,Arnold,1989,NA RCT (parallel, crossover, open-label) G  18, 18,  36 NA,reverse -0.4000000000,-1.060000000, 2.600000e-01   0.5800000,  0.3900000 NA NA NA NA,NA,NA   0   0 100,100,100   0,100 some,some,some,low high,Active (any credible active intervention),100,  0.000000 NA,NA DSM-III,0,1 1.0,1.0,1.0 1.0,1 1,0,1,1,1,1,1.0 1,1 1,1  836,Arnold_1989,< 2 months NA,NA,8.7 11,NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
1318 Gillies (2023),Gillies,2023,10.1002/14651858.CD007986.pub2 100,  0,100 100 High,Polyunsaturated fatty acids,NA 100 Metilphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 1.84119678  600.0000000,mg/d,Behdani 2013,NA,RCT (parallel, crossover, open-label) G  36, 33,  69 NA reverse, 0.7200000000  0.230000000, 1.210000e+00   2.7500000   9.5500000 NA NA,NA NA,NA NA,100,100 100,100,100,100 100 some,some some some,low,Active (any credible active intervention) 100  20.300000, 8.700000,NA,DSM-IV TR 0,1,1.0 1.0,1.0 1.0,1 1,0 1 1 1 1,1.0,1,1 1,1  837 Behdani_2013,< 2 months NA,6-12 yo 8.7,11 NA,NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
1318,Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2,100,  0,100 100,High Polyunsaturated fatty acids NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  1.84119678  600.0000000 mg/d Dubnov-Raz 2014 NA,RCT (parallel, crossover, open-label),G,  8,  9,  17 NA,reverse, 1.4300000000, 0.330000000, 2.530000e+00   7.3000000   2.5000000 NA,NA,NA,NA NA NA,100,100 100 100,  0 100 100,low some high,some low Placebo   0, 41.180000,11.000000,NA DSM (clinical diag) 0,1 1.0,1.0,1.0,1.0,1 1 0,1 1 1,1 1.0 1 1,1 1  838 Dubnov-Raz_2014,< 2 months NA,6-12 yo 8.7 11,NA,NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
1318,Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0 100,100,High,Polyunsaturated fatty acids NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 1.61104718  600.0000000 mg/d,Raz 2009,NA,RCT (parallel, crossover, open-label) G, 32  31,  63,NA,reverse -0.0200000000 -0.510000000, 4.800000e-01,  1.4800000   1.1200000 NA NA,NA,NA,NA NA,  0,  0 100,100   0,  0,100,some some,high low high,Placebo,  0, 39.700000,10.500000,NA,DSM (clinical diag),0,1 1.0,1.0 1.0 1.0 1,1 0,1,1 1 1 1.0,1 1,1 1  839 Raz_2009,< 2 months NA 6-12 yo,8.7 11,NA,NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
1318,Gillies (2023) Gillies 2023,10.1002/14651858.CD007986.pub2,100,  0 100 100,High Polyunsaturated fatty acids NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At follow-up (closest to 26 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 2.76179517 NA,mg/d,Chang,2019 NA RCT (parallel, crossover, open-label) G, 44, 39,  83,NA,reverse  0.4500000000  0.010000000  8.900000e-01  13.3200000   9.5000000 NA,NA NA,NA NA,NA,100,100,100 100,100,100,100 some,some,some,low some Placebo,  0  14.130000  9.490000,NA DSM-5,0 1 1.0 1.0 1.0,1.0,1 1 0,1,1 1 1,1.0 1,1 1,1, 840,Chang_2019 2-6 months,NA,6-12 yo 8.9,13.7,NA NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,low
1318 Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0,100,100,High,Polyunsaturated fatty acids NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At follow-up (closest to 26 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  3.45224396  502.7000000,mg/d Gustafsson,2010 NA RCT (parallel, crossover, open-label),G, 46, 46,  92,NA,reverse  0.1300000000,-0.280000000  5.400000e-01  18.8000000  17.9000000 NA NA NA NA NA,NA,100,100,100 100 100 100 100 some low,some,low low Placebo,  0,NA, 9.500000,NA,DSM-IV 0 1 1.0,1.0 1.0,1.0,1 1 0 1,1,1 1,1.0 1 1 1,1, 841,Gustafsson_2010,2-6 months,NA,6-12 yo 8.9,13.7 NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low low
1318,Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0 100 100 High Polyunsaturated fatty acids,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At follow-up (closest to 26 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  3.45224396  420.0000000 mg/d,Manor,2012,NA,RCT (parallel, crossover, open-label),G, 94, 42  136 NA,reverse, 0.0700000000,-0.290000000  4.400000e-01   8.5700000,  8.8700000,NA,NA NA,NA NA NA,  0   0 100,100   0   0,100,low,low,high low,high Placebo,  0, 29.200000  9.200000 NA,DSM-IV,0 1,1.0 1.0,1.0,1.0,1,1,0 1 1,1 1 1.0,1,1 1 1, 842 Manor_2012 2-6 months NA,6-12 yo 8.9 13.7 NA NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,high,high
1318 Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2 100   0,100 100,High,Polyunsaturated fatty acids,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At follow-up (closest to 26 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  2.76179517  792.0000000,mg/d,Matsudaira,2015 NA RCT (parallel, crossover, open-label),G  33  36   69 NA reverse,-0.1800000000,-0.650000000, 2.900000e-01  10.6000000, 11.5000000,NA NA,NA NA,NA,NA,100,100 100,100 100 100 100,low,some,some,some low,Placebo   0   0.000000,13.700000,NA DSM-IV,0 1 1.0 1.0,1.0 1.0 1,1,0 1,1 1 1,1.0 1,1 1 1  843,Matsudaira_2015,2-6 months NA,13-19 yo,8.9,13.7,NA NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low low
1318,Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0 100 100 High Polyunsaturated fatty acids,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At follow-up (closest to 26 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  4.00000000  656.0000000,mg/d,Stevens,2003,NA RCT (parallel, crossover, open-label),G, 18, 15,  33,NA,reverse,-0.1200000000,-0.810000000, 5.600000e-01   2.7500000   5.0000000 NA,NA NA NA NA NA,100,100,100 100   0 100,100,some low,high low,low,Placebo   0, 14.600000, 9.800000,NA DSM (clinical diag),0,1,1.0,1.0,1.0 1.0,1,1 0 1,1,1 1 1.0,1,1 1 1, 844,Stevens_2003 2-6 months NA 6-12 yo,8.9 13.7,NA,NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low,low
1318,Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0,100 100,High Polyunsaturated fatty acids,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At follow-up (closest to 26 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 3.68239356  720.0000000,mg/d,Widenhorn-Muller 2014 NA RCT (parallel, crossover, open-label) G  40, 45   85,NA,reverse,-0.1200000000,-0.550000000  3.100000e-01,  0.6200000   0.5400000,NA NA,NA,NA NA NA,100 100,100,100,100,100 100 some,low some,low low Placebo,  0  22.100000  8.900000,NA DSM-IV 0,1,1.0 1.0,1.0,1.0,1,1,0,1,1 1 1,1.0 1 1,1 1, 845 Widenhorn-Muller_2014 2-6 months NA 6-12 yo,8.9 13.7,NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low low
1318,Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2   0   0 100,100 High,Polyunsaturated fatty acids NA,100 Dexamfetamine,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA NA, 1.00000000, 390.0000000,mg/d,Arnold,1989,NA,RCT (parallel, crossover, open-label) RR, 18  18,  36,NA reverse  1.0000000000  0.020900000, 4.784689e+01 NA,NA,NA NA,NA,NA,NA NA,  0,  0,100 100,100,  0,100,some some,some,low high Active (any credible active intervention),100   0.000000,NA NA,DSM-III 0 1,1.0,1.0,1.0,1.0 1 1,0,1 1 1,1,1.0 1,1 1,1  846,Arnold_1989 < 2 months,NA NA 7.95 11,NA NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
1318,Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0 100 100,High,Polyunsaturated fatty acids NA,100,Metilphenidate,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA, 1.84119678, 600.0000000,mg/d Behdani,2013,NA RCT (parallel, crossover, open-label) RR, 40  35,  75,NA reverse  1.7500000000, 0.340950096, 8.982253e+00 NA NA NA NA NA NA,NA,NA 100,100 100 100 100 100 100,some,some some some low,Active (any credible active intervention) 100  20.300000  8.700000 NA DSM-IV TR 0,1 1.0 1.0,1.0,1.0,1 1,0,1 1 1,1,1.0 1 1 1,1, 847 Behdani_2013,< 2 months,NA 6-12 yo 7.95 11 NA NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
1318,Gillies (2023) Gillies 2023,10.1002/14651858.CD007986.pub2,100   0 100 100 High Polyunsaturated fatty acids,NA   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA  1.84119678  600.0000000,mg/d,Dubnov-Raz 2014 NA,RCT (parallel, crossover, open-label),RR, 20, 20   40,NA,reverse  1.0909090909  0.639525307, 1.860884e+00 NA NA NA,NA NA,NA NA NA,100,100 100 100,  0,100,100 low,some,high,some low,Placebo   0, 41.180000 11.000000 NA DSM (clinical diag),0,1 1.0,1.0,1.0,1.0 1 1,0,1,1 1 1 1.0 1 1 1 1  848,Dubnov-Raz_2014,< 2 months,NA 6-12 yo 7.95,11 NA NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
1318,Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2,100,  0,100 100,High Polyunsaturated fatty acids,NA,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA, 2.00000000  614.2857143 mg/d Hirayama 2004 NA RCT (parallel, crossover, open-label),RR  20  20,  40,NA,reverse  1.0000000000  0.020796283  4.808552e+01 NA,NA NA NA,NA,NA,NA,NA 100,100 100,100,100,100 100,low low low,low low Placebo   0, 20.000000  9.000000 NA,DSM-IV,0,1 1.0 1.0,1.0,1.0 1 1,0,1 1 1 1 1.0,1,1 1 1, 849,Hirayama_2004 2-6 months NA,6-12 yo,7.95 11,NA NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
1318 Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2 100   0,100 100 High Polyunsaturated fatty acids NA   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA  3.45224396  420.0000000,mg/d Manor 2012,NA,RCT (parallel, crossover, open-label) RR 137  63  200,NA,reverse  1.0634124088  0.641855392  1.761839e+00,NA,NA,NA NA NA NA NA NA   0   0,100,100   0,  0 100,low,low high low,high Placebo   0, 29.200000, 9.200000,NA,DSM-IV,0,1,1.0,1.0 1.0 1.0 1,1 0 1,1 1 1,1.0 1 1 1 1, 850 Manor_2012 2-6 months,NA 6-12 yo 7.95,11,NA NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
1318 Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2 100   0,100,100 High Polyunsaturated fatty acids,NA 100,MPH Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA  1.84119678  600.0000000,mg/d,Mohammadzadeh,2019 NA RCT (parallel, crossover, open-label),RR  33  33,  66,NA reverse, 0.5000000000, 0.098224424  2.545192e+00 NA,NA NA,NA,NA,NA,NA,NA,  0   0,100,100,100   0,100 low low some low high Active (any credible active intervention) 100, 25.760000, 7.950000 NA DSM-IV TR,0 1,1.0,1.0 1.0 1.0,1,1 0 1 1,1,1 1.0,1,1,1,1  851 Mohammadzadeh_2019 < 2 months NA 6-12 yo,7.95 11 NA,NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
1318 Gillies (2023) Gillies 2023,10.1002/14651858.CD007986.pub2 100,  0,100,100,High Polyunsaturated fatty acids NA,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA NA, 3.00000000  145.0000000 mg/d Vaisman,2008 NA RCT (parallel, crossover, open-label) RR  57, 26   83,NA reverse  1.6421052632  0.684164340, 3.941319e+00 NA NA,NA,NA,NA NA NA,NA 100,100 100,100   0,100 100,some,low,high,low low,Placebo   0, 25.000000  9.300000,NA,DSM (clinical diag) 0 1,1.0,1.0,1.0,1.0,1,1,0,1,1,1,1 1.0 1 1,1 1, 852 Vaisman_2008,2-6 months NA 6-12 yo,7.95 11 NA,NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA NA,Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
1318,Gillies (2023),Gillies,2023,10.1002/14651858.CD007986.pub2 100   0,100,100,High,Polyunsaturated fatty acids,NA   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA  4.00000000, 345.0000000,mg/d,Voigt 2001 NA,RCT (parallel, crossover, open-label),RR, 32, 31   63 NA reverse, 0.9687500000  0.310775922, 3.019785e+00 NA NA NA NA NA NA NA,NA   0   0,100,100,  0   0 100,some,low high low high Placebo,  0  22.200000, 9.300000,NA DSM (clinical diag),0 1 1.0 1.0 1.0 1.0 1 1 0,1 1,1,1,1.0,1,1,1,1  853,Voigt_2001,2-6 months,NA 6-12 yo 7.95,11,NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
1318,Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0,100 100,High,Polyunsaturated fatty acids,NA   0 NA Conduct Disorder symptoms,Mixed,At follow-up (closest to 26 weeks),Questionnaire Measured by scales such as the Child Behavior Checklist, 2.76179517 NA,mg/d,Chang,2019,NA,RCT (parallel, crossover, open-label) G, 48  44   92,NA reverse, 0.1400000000 -0.260000000  5.500000e-01,  2.0400000   1.9200000,NA,NA,NA NA,NA NA,100,100,100 100,100,100 100 some,some some low,some Placebo   0  14.130000  9.490000 NA,DSM-5 0,1,1.0 1.0,1.0 1.0,1 1,0 1 1,1 1,1.0,1 1,1,1, 854 Chang_2019 2-6 months,NA 6-12 yo 8.82 10.985,NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,low
1318 Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2,100   0 100,100 High Polyunsaturated fatty acids NA,  0 NA Conduct Disorder symptoms,Mixed,At follow-up (closest to 26 weeks) Questionnaire,Measured by scales such as the Child Behavior Checklist  6.00000000, 500.0000000,mg/d Crippa,2019 NA RCT (parallel, crossover, open-label),G  25, 25,  50,NA reverse -0.0900000000 -0.650000000, 4.600000e-01   1.7000000,  2.1800000,NA,NA NA,NA NA NA,  0   0,100,100 100,  0,100 low,low,low,low,high Placebo   0,  8.000000,10.985000 NA DSM-IV TR 0 1,1.0 1.0 1.0 1.0 1 1 0 1,1,1 1 1.0,1 1,1 1, 855,Crippa_2019,2-6 months,NA 6-12 yo,8.82 10.985,NA NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,high,high
1318 Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0 100 100,High,Polyunsaturated fatty acids,NA   0,NA Conduct Disorder symptoms,Mixed At follow-up (closest to 26 weeks),Questionnaire,Measured by scales such as the Child Behavior Checklist, 3.22209436   55.5000000,mg/d Kean,2017,NA RCT (parallel, crossover, open-label),G  29  36   65 NA reverse  0.2200000000 -0.270000000  7.100000e-01, 14.4300000, 17.1600000 NA,NA,NA,NA,NA NA   0,  0 100,100,  0,  0 100 low low high low,high,Placebo   0  14.600000, 8.820000 NA,DSM-IV,0,1,1.0 1.0,1.0,1.0,1,1,0 1 1 1,1 1.0 1,1,1,1  856 Kean_2017,2-6 months NA 6-12 yo,8.82,10.985,NA,NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA NA Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no high high
1318,Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0,100 100,High,Polyunsaturated fatty acids,NA   0 NA Conduct Disorder symptoms,Mixed At follow-up (closest to 26 weeks) Questionnaire Measured by scales such as the Child Behavior Checklist  4.00000000  656.0000000 mg/d,Stevens 2003,NA RCT (parallel, crossover, open-label) G  18, 15   33,outcomes,reverse, 0.3100000000 -0.380000000  1.000000e+00,  4.0000000,  4.2500000,NA NA NA,NA,NA,NA,100,100,100,100,  0,100 100,some low high low,low,Placebo,  0  14.600000, 9.800000,NA DSM (clinical diag) 0,1 1.0 1.0 1.0,1.0,1,1 0,1 1,1,1,1.0 1 1 1 1  857,Stevens_2003 2-6 months NA 6-12 yo 8.82 10.985 NA,NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low low
1318 Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2 100,  0 100 100 High Polyunsaturated fatty acids NA   0 NA Conduct Disorder symptoms,Mixed At follow-up (closest to 26 weeks) Questionnaire,Measured by scales such as the Child Behavior Checklist, 3.68239356  720.0000000 mg/d Widenhorn-Muller 2014,NA RCT (parallel, crossover, open-label),G, 45  47   92,outcomes,reverse  0.2300000000 -0.180000000  6.400000e-01   7.1100000,  7.6100000,NA NA NA NA NA,NA 100 100,100 100,100 100,100 some,low,some,low,low,Placebo,  0, 22.100000  8.900000 NA DSM-IV 0,1,1.0 1.0,1.0 1.0,1 1 0 1,1 1 1 1.0,1,1,1 1  858 Widenhorn-Muller_2014,2-6 months NA,6-12 yo 8.82 10.985,NA,NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA NA Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low low
1318 Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0 100 100 High Polyunsaturated fatty acids,NA,  0 NA Conduct Disorder symptoms Mixed At follow-up (closest to 26 weeks),Questionnaire,Measured by scales such as the Child Behavior Checklist, 4.00000000, 656.0000000,mg/d Stevens 2003 NA,RCT (parallel, crossover, open-label),G  18, 15   33,outcomes,reverse  0.0500000000,-0.640000000, 7.300000e-01   5.0000000   2.5000000 NA NA NA NA NA NA,100 100 100 100,  0,100,100,some,low,high low,low,Placebo,  0, 14.600000, 9.800000 NA,DSM (clinical diag) 0,1,1.0,1.0 1.0 1.0,1 1 0,1 1,1,1 1.0 1 1,1 1  859 Stevens_2003,2-6 months NA,6-12 yo,8.82,10.985 NA NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low,low
1318 Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2 100   0 100 100 High Polyunsaturated fatty acids NA   0,NA Conduct Disorder symptoms Mixed,At follow-up (closest to 26 weeks) Questionnaire Measured by scales such as the Child Behavior Checklist  3.68239356, 720.0000000,mg/d,Widenhorn-Muller,2014,NA,RCT (parallel, crossover, open-label) G, 40, 45,  85 outcomes reverse -0.0500000000 -0.480000000, 3.700000e-01   5.1200000   5.1000000,NA,NA NA NA,NA NA 100,100,100 100,100 100 100 some low,some,low low,Placebo   0, 22.100000  8.900000,NA DSM-IV,0,1 1.0 1.0 1.0,1.0,1,1,0 1,1,1 1 1.0,1,1 1,1, 860,Widenhorn-Muller_2014,2-6 months,NA 6-12 yo,8.82 10.985,NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,low
1318 Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2 100   0,100 100,High Polyunsaturated fatty acids,NA,  0 NA Oppositional Defiant Disorder symptoms,Mixed At follow-up (closest to 26 weeks) Questionnaire,Measured by scales such as the Child Behavior Checklist  2.76179517 NA,mg/d Chang 2019,NA,RCT (parallel, crossover, open-label),G, 48  44,  92,NA reverse  0.1500000000,-0.260000000  5.600000e-01   6.0300000   5.4400000 NA,NA,NA,NA NA NA,100 100 100,100,100 100,100,some some,some,low,some,Placebo   0, 14.130000  9.490000,NA,DSM-5,0 1 1.0 1.0,1.0,1.0,1,1,0,1,1 1,1,1.0,1,1 1,1, 861 Chang_2019 2-6 months NA,6-12 yo,8.82,9.8,NA NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low,low
1318,Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2,100   0 100,100 High,Polyunsaturated fatty acids NA,  0,NA Oppositional Defiant Disorder symptoms Mixed At follow-up (closest to 26 weeks) Questionnaire Measured by scales such as the Child Behavior Checklist  3.45224396, 502.7000000 mg/d Gustafsson 2010,NA,RCT (parallel, crossover, open-label),G, 46, 46,  92 outcomes,reverse  0.2400000000,-0.170000000  6.500000e-01, 18.6000000  18.4000000 NA,NA NA,NA NA NA,100 100 100,100,100,100 100,some,low,some low,low Placebo,  0,NA  9.500000 NA DSM-IV,0,1 1.0,1.0 1.0,1.0,1,1 0,1,1,1,1 1.0,1 1,1 1  862,Gustafsson_2010 2-6 months NA,6-12 yo,8.82 9.8 NA NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA NA Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,low
1318 Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2 100,  0,100 100,High,Polyunsaturated fatty acids,NA   0,NA Oppositional Defiant Disorder symptoms,Mixed,At follow-up (closest to 26 weeks) Questionnaire Measured by scales such as the Child Behavior Checklist, 3.22209436,  55.5000000,mg/d,Kean 2017,NA,RCT (parallel, crossover, open-label) G, 29, 36   65 NA,reverse  0.0900000000,-0.400000000  5.800000e-01, 18.6700000  15.5100000 NA,NA,NA NA NA NA   0   0 100,100   0   0 100,low low high,low,high,Placebo,  0  14.600000, 8.820000 NA,DSM-IV,0 1 1.0,1.0,1.0 1.0 1 1 0,1 1 1 1 1.0 1 1 1 1, 863 Kean_2017 2-6 months,NA 6-12 yo,8.82,9.8 NA,NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no high high
1318,Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0,100,100 High,Polyunsaturated fatty acids NA,  0,NA Oppositional Defiant Disorder symptoms Mixed,At follow-up (closest to 26 weeks) Questionnaire,Measured by scales such as the Child Behavior Checklist  3.45224396, 420.0000000 mg/d Manor 2012,NA,RCT (parallel, crossover, open-label),G, 99  42, 141 outcomes reverse, 0.0300000000,-0.330000000, 3.900000e-01, 10.2500000, 12.2600000 NA,NA NA NA NA NA   0   0,100,100   0   0,100 low low high low,high Placebo,  0, 29.200000, 9.200000,NA,DSM-IV 0 1,1.0,1.0,1.0 1.0,1 1,0,1 1,1 1,1.0,1,1,1 1  864 Manor_2012 2-6 months,NA 6-12 yo 8.82 9.8,NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA NA Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no high high
1318,Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2,100   0,100 100,High Polyunsaturated fatty acids NA,  0,NA,Oppositional Defiant Disorder symptoms,Mixed,At follow-up (closest to 26 weeks) Questionnaire Measured by scales such as the Child Behavior Checklist, 4.00000000  656.0000000,mg/d Stevens 2003 NA,RCT (parallel, crossover, open-label) G  18, 15,  33,NA reverse,-0.0200000000 -0.700000000, 6.700000e-01   5.2500000   6.0000000 NA,NA NA NA,NA,NA,100 100 100 100,  0 100 100,some low high low,low,Placebo   0, 14.600000  9.800000,NA DSM (clinical diag) 0 1 1.0,1.0 1.0 1.0,1,1 0,1 1,1,1,1.0 1 1 1,1  865 Stevens_2003 2-6 months,NA,6-12 yo 8.82 9.8,NA NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low low
1318 Gillies (2023) Gillies 2023,10.1002/14651858.CD007986.pub2 100   0 100 100,High,Polyunsaturated fatty acids NA,  0 NA Oppositional Defiant Disorder symptoms Mixed,At follow-up (closest to 26 weeks) Questionnaire Measured by scales such as the Child Behavior Checklist  3.45224396  502.7000000 mg/d,Gustafsson 2010,NA,RCT (parallel, crossover, open-label) G  46, 46   92 outcomes,reverse, 0.2400000000,-0.170000000, 6.500000e-01, 18.6000000  18.4000000 NA,NA NA,NA NA NA 100 100,100,100 100,100 100 some,low some,low,low,Placebo   0,NA, 9.500000 NA DSM-IV 0 1,1.0,1.0,1.0,1.0 1,1 0 1,1,1 1 1.0,1,1,1,1  866 Gustafsson_2010 2-6 months,NA 6-12 yo 8.82 9.8 NA NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,low
1318,Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2,100   0 100,100,High Polyunsaturated fatty acids NA,  0,NA Oppositional Defiant Disorder symptoms,Mixed At follow-up (closest to 26 weeks),Questionnaire,Measured by scales such as the Child Behavior Checklist  3.45224396, 420.0000000 mg/d,Manor,2012 NA RCT (parallel, crossover, open-label) G  92  40  132,outcomes,reverse -0.0200000000,-0.390000000  3.500000e-01  11.9800000  12.3200000,NA NA,NA,NA,NA,NA   0,  0 100,100,  0   0,100,low low,high low high Placebo,  0  29.200000  9.200000,NA DSM-IV 0 1,1.0,1.0 1.0,1.0 1,1 0 1 1,1 1,1.0,1 1,1 1, 867,Manor_2012 2-6 months,NA,6-12 yo 8.82 9.8 NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no high,high
1318,Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0,100 100,High Polyunsaturated fatty acids,NA   0 NA Social-communication skills,Mixed At follow-up (closest to 26 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 4.00000000, 345.0000000,mg/d,Voigt,2001,NA RCT (parallel, crossover, open-label),G  27  26   53,NA reverse  0.0500000000 -0.490000000, 5.900000e-01,  8.3100000   7.6500000 NA NA,NA,NA NA,NA,  0,  0 100 100   0   0 100 some,low high low,high,Placebo,  0  22.200000, 9.300000,NA,DSM (clinical diag) 0,1 1.0 1.0 1.0,1.0,1,1 0 1 1,1,1 1.0 1 1,1 1  868 Voigt_2001,2-6 months NA 6-12 yo 8.9,9.3 NA NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no high high
1318,Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0 100,100,High,Polyunsaturated fatty acids NA   0,NA,Social-communication skills,Mixed At follow-up (closest to 26 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  3.68239356, 720.0000000 mg/d Widenhorn-Muller 2014 NA RCT (parallel, crossover, open-label) G, 45  47,  92,outcomes reverse  0.4000000000 -0.010000000, 8.100000e-01  10.1300000   7.6100000,NA NA NA,NA NA,NA,100,100 100 100 100 100 100 some,low,some,low,low Placebo   0  22.100000, 8.900000 NA DSM-IV 0,1,1.0,1.0,1.0,1.0,1 1 0,1 1 1 1 1.0 1,1,1,1  869,Widenhorn-Muller_2014,2-6 months,NA,6-12 yo,8.9 9.3,NA,NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA NA,Gillies (2023)_Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks) 1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low,low
1318 Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2,100,  0 100,100,High,Polyunsaturated fatty acids,NA,  0 NA Social-communication skills,Mixed At follow-up (closest to 26 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 3.68239356  720.0000000 mg/d,Widenhorn-Muller,2014,NA RCT (parallel, crossover, open-label) G, 40, 45,  85,outcomes,reverse -0.1600000000,-0.580000000  2.700000e-01   5.3100000   6.4400000 NA,NA,NA NA,NA,NA 100,100,100,100,100,100,100,some low,some low,low Placebo   0, 22.100000, 8.900000 NA DSM-IV 0,1,1.0,1.0 1.0,1.0,1,1 0,1 1,1 1 1.0,1,1,1 1, 870,Widenhorn-Muller_2014 2-6 months NA 6-12 yo 8.9,9.3,NA NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low,low
1318 Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2,100,  0,100,100 High,Polyunsaturated fatty acids,NA 100 Metilphenidate,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA 12.00000000, 792.0000000 mg/d Barragan 2017 NA,RCT (parallel, crossover, open-label),RR  30, 30   60 NA,reverse, 0.0769230769  0.004525704  1.307456e+00 NA NA,NA,NA,NA NA,NA,NA   0,  0   0,  0 100 100   0,high high,some,high low Active (any credible active intervention),100 NA  8.270000 NA,DSM-IV TR 0,1,1.0,1.0 1.0,1.0,1 1,0 1,1 1,1,1.0 1,1,1,1  871,Barragan_2017,7-12 months,NA,6-12 yo 7.93387096774194 8.27,NA NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
1318,Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2,100   0,100,100 High,Polyunsaturated fatty acids,NA 100,MPH Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 1.84119678  600.0000000 mg/d,Mohammadzadeh,2019 NA RCT (parallel, crossover, open-label),RR  33  29,  62,NA,reverse, 0.8787878788, 0.132043510, 5.848588e+00,NA NA NA,NA NA NA NA,NA   0,  0,100 100,100,  0 100 low low some low,high,Active (any credible active intervention) 100  25.760000  7.933871,NA,DSM-IV TR 0,1,1.0,1.0 1.0 1.0,1,1,0 1 1 1,1,1.0,1,1 1 1, 872,Mohammadzadeh_2019 < 2 months NA 6-12 yo,7.93387096774194 8.27 NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
1459 Handel (2021),Handel 2021,10.3390/nu13041226 100,  0 100,100,Moderate Polyunsaturated fatty acids Supplementation of PUFAs:  omega 3 and 6 fatty acids   0,NA,Quality of life (patients),Mixed,At follow-up (closest to 26 weeks) NA,NA, 6.00000000 1000.0000000,mg/d Crippa,2019,NA RCT (parallel, crossover, open-label) SMD, 25, 25,  50,NA reverse, 0.0700000000 -0.490000000, 6.200000e-01,  0.8600000   1.1300000 NA,NA NA NA NA,NA   0,  0,100 100,100,100,  0,some,some,low,high low,Placebo   0,  9.000000 10.985000 NA DSM 0,1,0.5,1.0,1.0 1.0 1 1 2 1,1 1 1 1.0 1 0 0,1  873,Crippa_2019,2-6 months,NA 6-12 yo,9.2,10.985 NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA Handel (2021)_Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous Handel (2021) - Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low,high
1459,Handel (2021) Handel 2021 10.3390/nu13041226 100   0,100 100,Moderate Polyunsaturated fatty acids,Supplementation of PUFAs:  omega 3 and 6 fatty acids,  0,NA,Quality of life (patients) Mixed At follow-up (closest to 26 weeks),NA NA, 3.45224396  420.0000000 mg/d Manor 2011,NA,RCT (parallel, crossover, open-label),SMD  94, 44, 138,NA reverse,-0.0100000000,-0.370000000, 3.500000e-01   9.5500000, 10.2600000 NA NA,NA,NA NA NA,  0   0 100 100   0   0,100,low,low,high low,high,Placebo   0  29.275362  9.200000,NA,DSM,0,1 0.5 1.0,1.0 1.0 1,1,2,1 1 1,1,1.0,1,0,0 1  874 Manor_2011 2-6 months NA 6-12 yo 9.2,10.985,NA,NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA NA,Handel (2021)_Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous Handel (2021) - Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no high,high
3367 Sonuga-Barke (2014) Sonuga-Barke,2014,10.1176/appi.ajp.2012.12070991,100   0 100,100,Moderate Diet (restricted/elimination),oligoantigenic diet,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire CTRS  0.23014960,NA,NA Schmidt,1997 NA RCT (parallel, crossover, open-label),G  49  49,  98,outcomes NA  0.0529284165 -0.340997831, 4.467679e-01 NA,NA,NA NA NA,NA,NA,NA,  0   0,100,  0 100   0,100,some high some,low high Not a therapeutic intervention,  0,  4.000000, 9.500000 NA,DSM-III-R 0,1 0.5 1.0,1.0,1.0,1,1 2 1,1 1 0,1.0 0 1 1,1, 875 Schmidt_1997 < 2 months,NA 6-12 yo 4.5,9.5 NA,NA,  8  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5 9.5 NA,NA Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Mixed Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious,high high
3367 Sonuga-Barke (2014) Sonuga-Barke,2014,10.1176/appi.ajp.2012.12070991 100   0 100 100 Moderate,Diet (restricted/elimination) known antigenic food,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Questionnaire CPRS, 0.80552359,NA NA Kaplan,1989 NA,RCT (parallel, crossover, open-label),G, 25, 25   50,outcomes,NA  0.5113232104 -0.060390456, 1.090499e+00 NA NA NA,NA,NA NA,NA,NA,  0   0,  0   0 100   0 100 high,high,some,low,high Placebo,  0   0.000000, 4.500000,NA,DSM-III,0,1,0.5,1.0 1.0,1.0 1,1 2,1,1 1,0 1.0 0 1,1,1  876 Kaplan_1989,< 2 months,NA < 6 yo 4.5 9.5,NA NA,  8  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Sonuga-Barke (2014) | Catala-Lopez (2017),4.5,9.5 NA,NA Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Mixed Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious high,high
3367,Sonuga-Barke (2014) Sonuga-Barke 2014,10.1176/appi.ajp.2012.12070991,100,  0 100 100,Moderate Diet (restricted/elimination),specific provoking food,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire CPRS, 0.23014960,NA,NA Carter 1993,NA,RCT (parallel, crossover, open-label) G  19  19   38 outcomes NA, 0.6170932755,-0.046941432, 1.281302e+00 NA,NA,NA,NA NA NA,NA NA   0,  0,100,  0,100,  0,100 low high some low,high Placebo,  0  26.000000, 7.500000 NA,DSM-III,0 1 0.5 1.0,1.0 1.0 1,1,2,1 1,1 0,1.0 0 1,1 1  877 Carter_1993 < 2 months,NA,6-12 yo 4.5 9.5 NA,NA,  8, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5 NA,NA Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Mixed,Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,high high
3367,Sonuga-Barke (2014) Sonuga-Barke,2014 10.1176/appi.ajp.2012.12070991,100,  0 100 100,Moderate Diet (restricted/elimination) known antigenic food   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire CPRS  0.23014960,NA NA,Boris,1994 NA,RCT (parallel, crossover, open-label),G, 16  16   32 outcomes,NA  1.9661605206, 1.093275488  2.831497e+00 NA,NA NA,NA NA NA,NA NA,  0,  0,100,  0,100   0,100 low high some,low high,Placebo,  0  31.000000, 7.500000 NA DSM-III-R 0 1,0.5 1.0 1.0 1.0,1,1 2 1,1,1,0,1.0,0,1,1,1, 878,Boris_1994,< 2 months NA,6-12 yo,4.5 9.5 NA,NA,  8, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5 9.5 NA,NA,Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Mixed,Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious,high high
3367,Sonuga-Barke (2014) Sonuga-Barke,2014,10.1176/appi.ajp.2012.12070991 100   0,100 100 Moderate Diet (restricted/elimination),oligoantigenic diet,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Questionnaire CTRS, 0.23014960,NA,NA,Schmidt,1997,NA,RCT (parallel, crossover, open-label),G  49, 49,  98 outcomes NA  0.0542438058 -0.350370705, 4.514005e-01,NA,NA,NA NA,NA,NA,NA NA,  0,  0,100   0,100,  0 100,some,high,some low,high Not a therapeutic intervention   0,  4.000000, 9.500000 NA,DSM-III-R,0,1 0.5 1.0,1.0 1.0,1,1 2 1 1,1,0,1.0,0,1 1,1  879,Schmidt_1997,< 2 months,NA 6-12 yo,4.5 9.5,NA,NA,  8, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Sonuga-Barke (2014) | Catala-Lopez (2017),4.5 9.5 NA NA Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Mixed,Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious,high high
3367 Sonuga-Barke (2014) Sonuga-Barke,2014,10.1176/appi.ajp.2012.12070991,100   0 100,100,Moderate,Diet (restricted/elimination) known antigenic food,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire,CTRS, 0.80552359,NA,NA,Kaplan,1989 NA,RCT (parallel, crossover, open-label) G, 25  25,  50 outcomes,NA, 0.2633533859 -0.652644458, 1.164086e+00 NA,NA NA NA NA,NA NA NA   0   0   0   0,100   0,100 high,high,some,low high,Placebo   0   0.000000  4.500000 NA DSM-III 0 1 0.5 1.0 1.0,1.0 1,1 2,1 1,1,0,1.0 0,1,1,1  880 Kaplan_1989 < 2 months,NA < 6 yo 4.5,9.5 NA NA   8  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5 NA,NA Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Mixed Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,high,high
3367 Sonuga-Barke (2014),Sonuga-Barke 2014 10.1176/appi.ajp.2012.12070991 100,  0 100 100 Moderate Diet (restricted/elimination) specific provoking food   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Observational tool,Test session observation, 0.23014960,NA NA Carter,1993 NA RCT (parallel, crossover, open-label),G  19, 19,  38 outcomes,NA, 0.7339227710, 0.062255109, 1.405590e+00 NA,NA,NA NA,NA NA,NA NA,  0   0,100,  0 100,  0 100 low high some,low high Placebo   0, 26.000000, 7.500000 NA DSM-III 0 1 0.5 1.0 1.0 1.0 1,1 2 1 1 1 0,1.0,0 1,1,1, 881,Carter_1993 < 2 months,NA 6-12 yo 4.5,9.5,NA,NA,  8, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5,NA,NA,Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Mixed Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious high,high
3367 Sonuga-Barke (2014) Sonuga-Barke 2014 10.1176/appi.ajp.2012.12070991 100,  0,100,100,Moderate Diet (restricted/elimination) known antigenic food   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire,CPRS  0.23014960,NA NA Boris,1994,NA RCT (parallel, crossover, open-label) G, 16  16   32 outcomes,NA, 1.9756456382, 1.105355920  2.838303e+00 NA,NA NA NA NA,NA NA,NA,  0,  0,100   0,100,  0 100,low,high some low,high,Placebo,  0  31.000000, 7.500000,NA DSM-III-R 0 1 0.5 1.0 1.0,1.0,1 1,2 1,1 1,0,1.0 0 1,1,1, 882 Boris_1994 < 2 months NA,6-12 yo 4.5,9.5 NA,NA,  8, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5 NA NA Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Mixed,Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,high,high
4036 Zhang (2023) Zhang,2023 10.1177/10870547231154897 100   0 100,100 Critically low Mindfulness,yoga,  0,NA Executive functioning (mixed),Mixed,At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),NA  1.38089758,NA NA Rezaei,2018,NA,RCT (parallel, crossover, open-label),SMD   7   7   14 NA reverse,-1.1000000000 -2.250000000  6.000000e-02,NA,NA NA NA,NA NA NA,NA   0,  0,  0   0,100   0   0,high,high,low high,high WLC (wait-list control),  0 NA  9.000000 NA,DSM-5 2,1 1.0,0.0 1.0,1.0,0,1 2,1 1 1 1,0.5,0,0,1,1, 883 Rezaei_2018 < 2 months NA 6-12 yo,9 11.1864077669903 NA NA, 13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA NA Zhang (2023)_Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Zhang (2023) - Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
4036 Zhang (2023) Zhang,2023,10.1177/10870547231154897 100,  0 100,100 Critically low Mindfulness,mindfulness based intervention,  0,NA,Executive functioning (mixed) Mixed,At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),NA NA,NA NA,Robe 2022,NA RCT (parallel, crossover, open-label) SMD  35  35   70 NA reverse -0.6100000000 -1.090000000,-1.300000e-01 NA,NA,NA,NA NA NA,NA,NA   0,  0,  0,  0,100   0,100,high high low,low high,Not a therapeutic intervention   0 NA 11.030000,NA DSM-5,2 1 1.0,0.0 1.0,1.0 0,1 2,1 1,1 1,0.5,0,0 1 1, 884,Robe_2022,NA NA 6-12 yo 9 11.1864077669903 NA NA  13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35 NA NA,Zhang (2023)_Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Zhang (2023) - Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
4036 Zhang (2023),Zhang,2023 10.1177/10870547231154897,100,  0,100 100,Critically low,Mindfulness,mindfulness based intervention,  0,NA,Executive functioning (mixed) Mixed At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) NA, 1.84119678 NA,NA,Siebelink,2022 NA,RCT (parallel, crossover, open-label),SMD, 55  48  103 NA,reverse -0.0400000000 -0.430000000, 3.400000e-01,NA,NA,NA NA,NA NA NA NA,100,100 100   0 100,100 100,low high low low low TAU   0,NA 11.186408,NA,DSM-5 2 1 1.0 0.0,1.0 1.0,0 1 2,1 1,1,1,0.5,0 0 1,1  885 Siebelink_2022 < 2 months NA,6-12 yo 9,11.1864077669903 NA,NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA,NA Zhang (2023)_Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Zhang (2023) - Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
4036 Zhang (2023),Zhang 2023,10.1177/10870547231154897,100   0,  0 100,Critically low Mindfulness,mindful parent training   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire,CTRS, 1.84119678 NA,NA Amiri,2022 NA,RCT (parallel, crossover, open-label),SMD  12  12,  24,outcomes,reverse,-0.6600000000 -1.480000000, 1.700000e-01,NA,NA,NA NA NA NA,NA,NA,  0   0   0   0,  0,  0,  0,high high,high,high high NA   0 NA  9.750000 NA,DSM-5,2,1,1.0,0.0,1.0,1.0,0,1 2 1 1,1 1,0.5,0,0,1 1, 886 Amiri_2022,< 2 months,NA 6-12 yo 6.08 11.1864077669903 NA NA  13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo  90.66148 no high,high
4036,Zhang (2023),Zhang,2023 10.1177/10870547231154897 100   0,100 100,Critically low,Mindfulness family based mindfullness intervention   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Questionnaire,SWAN, 1.38089758 NA,NA Lo 2020 NA,RCT (parallel, crossover, open-label) SMD, 50, 50, 100 outcomes reverse  0.0600000000 -0.330000000  4.500000e-01,NA NA,NA,NA,NA,NA,NA,NA   0,  0 100,  0 100   0   0 low,high,low,high high WLC (wait-list control),  0 NA, 6.080000,NA DSM-5,2 1,1.0,0.0,1.0 1.0 0 1,2 1,1 1,1,0.5,0,0,1,1  887 Lo_2020 < 2 months,NA 6-12 yo 6.08,11.1864077669903,NA,NA  13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA,NA,Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo, 90.66148 no,high,high
4036,Zhang (2023),Zhang 2023,10.1177/10870547231154897 100   0,100,100 Critically low Mindfulness,mindfulness based intervention,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire,CPRS  1.84119678,NA NA,Siebelink 2022 NA,RCT (parallel, crossover, open-label),SMD  55  48  103,outcomes,reverse -0.0900000000 -0.470000000, 3.000000e-01 NA NA NA,NA NA,NA NA,NA 100,100 100   0,100 100,100,low high,low,low low TAU,  0 NA 11.186408,NA,DSM-5 2 1 1.0 0.0 1.0 1.0,0 1 2,1,1,1,1,0.5 0,0 1,1  888 Siebelink_2022,< 2 months NA,6-12 yo 6.08,11.1864077669903,NA,NA, 13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA NA,Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo, 90.66148,no,low,low
4036,Zhang (2023),Zhang,2023 10.1177/10870547231154897 100   0,100 100,Critically low,Mindfulness mindfulness based intervention,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire,Conners-3  1.84119678 NA NA,Valero 2022 NA,RCT (parallel, crossover, open-label),SMD  15, 15,  30,outcomes reverse,-0.2000000000 -0.910000000  5.200000e-01 NA NA,NA NA,NA NA,NA NA,  0,  0   0,  0,100   0   0,high high,low high high,WLC (wait-list control),  0 NA 10.965000 NA,DSM-5 2,1,1.0,0.0,1.0 1.0,0,1,2,1,1,1,1,0.5,0,0 1 1  889,Valero_2022 < 2 months NA,6-12 yo,6.08,11.1864077669903 NA,NA  13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo, 90.66148 no high,high
4036 Zhang (2023) Zhang,2023,10.1177/10870547231154897 100,  0   0 100,Critically low Mindfulness mindful parent training   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire CTRS  1.84119678 NA,NA Amiri,2022 NA RCT (parallel, crossover, open-label) SMD, 12  12,  24,outcomes,reverse -0.7400000000 -1.570000000  9.000000e-02,NA,NA,NA,NA,NA NA NA,NA,  0,  0   0   0   0   0,  0 high high high,high,high,NA,  0,NA, 9.750000 NA DSM-5 2,1 1.0 0.0 1.0 1.0 0,1 2,1,1 1 1,0.5 0,0,1,1, 890 Amiri_2022 < 2 months NA 6-12 yo,6.08 11.1864077669903,NA NA, 13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35 NA NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo  90.66148,no,high,high
4036 Zhang (2023) Zhang,2023,10.1177/10870547231154897,100,  0,100,100,Critically low,Mindfulness,family based mindfullness intervention   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire,SWAN, 1.38089758,NA,NA Lo,2020,NA,RCT (parallel, crossover, open-label) SMD  50  50, 100,outcomes reverse,-0.0500000000,-0.450000000, 3.400000e-01 NA NA NA,NA,NA NA NA NA   0,  0 100   0 100   0,  0 low,high,low,high high WLC (wait-list control),  0,NA  6.080000,NA DSM-5,2,1 1.0,0.0 1.0,1.0,0 1,2,1,1,1,1 0.5,0,0 1,1, 891,Lo_2020,< 2 months,NA 6-12 yo,6.08 11.1864077669903 NA NA  13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35 NA NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo  90.66148,no high high
4036 Zhang (2023) Zhang 2023,10.1177/10870547231154897 100,  0,100 100 Critically low Mindfulness,mindfulness based intervention,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire,CPRS, 1.84119678,NA,NA,Siebelink 2022,NA RCT (parallel, crossover, open-label) SMD  55  48  103,outcomes reverse,-0.1600000000,-0.550000000, 2.200000e-01,NA NA,NA NA NA,NA NA NA,100,100 100   0,100,100,100,low high,low,low low TAU   0 NA 11.186408 NA DSM-5,2 1,1.0,0.0,1.0,1.0 0 1,2,1 1,1 1 0.5,0 0,1,1  892,Siebelink_2022 < 2 months,NA 6-12 yo,6.08,11.1864077669903 NA,NA  13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA NA,Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo, 90.66148,no,low,low
4036 Zhang (2023) Zhang 2023 10.1177/10870547231154897 100   0 100 100 Critically low Mindfulness,mindfulness based intervention,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire Conners-3, 1.84119678,NA NA Valero 2022 NA,RCT (parallel, crossover, open-label),SMD, 15  15,  30,outcomes reverse -0.7100000000 -1.450000000, 3.000000e-02 NA,NA,NA,NA NA NA,NA NA   0,  0   0,  0 100   0   0 high high,low,high,high WLC (wait-list control)   0 NA 10.965000,NA DSM-5,2 1,1.0,0.0,1.0 1.0,0,1 2 1 1 1,1,0.5 0,0 1,1  893 Valero_2022,< 2 months,NA 6-12 yo,6.08 11.1864077669903,NA,NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA,NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo, 90.66148 no,high high
9002,Groenman - Preschool (2022) Groenman - Preschool,2022 10.1016/j.jaac.2021.02.024,100,  0,100 100,Critically low Parent-mediated behavioral interventions,Triple P Online,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire Conners Early Childhood Behaviour scale (mother-rated) Inattention/ hyperactivity scales (T-score) NA,NA NA,Franke 2016 NA,RCT (parallel, crossover, open-label) G, 27  26,  53 NA,reverse,-0.6378940566,-1.195411778 -8.037634e-02 NA NA,NA,NA,NA NA,NA,NA   0   0 100   0,100,100,  0 some,high low high some WLC (wait-list control)   0  71.700000  3.970000,NA DSM,3 1,0.5 0.0 1.0 1.0 0,0 1,1 1,1,1 0.5,0 1 1 1, 894 Franke_2016 NA NA < 6 yo 3.51 5.36 NA NA  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000 no,low,high
9002 Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024,100,100 100 100,Critically low Parent-mediated behavioral interventions,Behavioral parent training with consequence-based techniques only   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire SWAN total  2.00000000,NA NA Hornstra 2021 NA,RCT (parallel, crossover, open-label),G  32, 30   62 outcomes,reverse, 0.4415557687,-0.066627758  9.497393e-01 NA,NA NA,NA,NA NA NA NA 100,100,100 100 100 100 100 low low low some low,WLC (wait-list control),  0  31.520000, 8.350000  95.59000,DSM 3,1 0.5,0.0,1.0,1.0 0 0,1 1,1 1 1 0.5,0 1 1 1  895,Hornstra_2021,2-6 months Average (80-119),6-12 yo 7.28 13.99 95.59,108.21  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
9002 Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024,100 100,100 100,Critically low,Parent-mediated behavioral interventions Behavioral parent training with consequence-based techniques only   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire SWAN total  2.00000000,NA,NA Hornstra 2021 NA,RCT (parallel, crossover, open-label),G, 30, 30,  60,outcomes reverse  0.4889622303 -0.028927533  1.006852e+00,NA NA,NA,NA NA,NA,NA,NA 100,100,100 100 100 100,100 low low,low some,low,WLC (wait-list control)   0, 31.520000, 8.350000, 95.59000 DSM 3,1 0.5,0.0,1.0 1.0 0 0 1 1,1,1 1 0.5 0,1,1,1, 896,Hornstra_2021,2-6 months,Average (80-119),6-12 yo,7.28,13.99,95.59 108.21  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
9002,Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024 100,  0,100 100,Critically low,Parent-mediated behavioral interventions,New Forest Parenting Programme Self Help   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,Dupaul ADHD rating scale, 7.00000000 NA NA,Daley,2013 NA,RCT (parallel, crossover, open-label) G, 24  19   43 NA reverse -0.1713102406,-0.781187646, 4.385672e-01 NA,NA NA,NA NA,NA NA NA,  0   0,100   0 100 100   0,low high,some high some,WLC (wait-list control),  0  18.600000  7.280000,NA,DSM,3,1 0.5 0.0,1.0 1.0 0 0,1 1,1 1,1 0.5,0 1 1,1, 897 Daley_2013,7-12 months,NA 6-12 yo 7.28,13.99 95.59,108.21  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
9002,Groenman - Preschool (2022),Groenman - Preschool 2022,10.1016/j.jaac.2021.02.024,100   0,100,100 Critically low Parent-mediated behavioral interventions Parenting Your Hyperactive Preschooler (parent training and emotion socialization),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,DBRS mother total symptoms 14.00000000 NA NA,Herbert,2013,NA RCT (parallel, crossover, open-label),G  17, 14   31,NA reverse -0.5874048955,-1.322267483, 1.474577e-01,NA NA NA,NA,NA,NA NA NA   0,  0 100   0,100,100   0,some high,low,high some,WLC (wait-list control)   0  25.800000  4.580000 NA,DSM 3 1,0.5,0.0 1.0,1.0 0 0 1 1,1 1,1 0.5,0 1 1 1, 898,Herbert_2013 > 12 months,NA,< 6 yo 3.51 5.36,NA,NA, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15 108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no,low,high
9002,Groenman - Preschool (2022) Groenman - Preschool 2022,10.1016/j.jaac.2021.02.024 100   0,100 100,Critically low Parent-mediated behavioral interventions,New forest parenting plan,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire Werry Weis peters total score, 8.00000000,NA NA,Thompson,2009 NA,RCT (parallel, crossover, open-label),G  21, 20,  41 NA,reverse,-1.3920060263 -2.085358577 -6.986535e-01 NA,NA NA NA,NA,NA NA,NA,100 100,100   0   0 100,100 some,high high low some TAU,  0,100.000000  4.180000 NA,DSM,3,1,0.5 0.0 1.0,1.0,0 0,1 1,1 1 1,0.5,0,1 1,1  899 Thompson_2009,7-12 months,NA < 6 yo 3.51 5.36,NA,NA, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no,low low
9002 Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024 100,100,100,100 Critically low,Parent-mediated behavioral interventions,Behavioral parent training Groningen   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,CPRS ADHD index t scores,22.00000000,NA,NA,Vdhoofdakker,2007 NA,RCT (parallel, crossover, open-label) G, 47, 47   94,NA,reverse  0.0385037474,-0.367882293  4.448898e-01,NA NA,NA NA NA NA NA,NA,  0   0 100   0,100,100,  0 some high low,high,some,TAU,  0  19.100000, 7.430000  97.45000,DSM,3,1,0.5,0.0 1.0,1.0,0,0 1,1 1,1,1 0.5 0 1 1,1  900 Vdhoofdakker_2007 > 12 months Average (80-119),6-12 yo 7.28,13.99 95.59 108.21  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
9002 Groenman - Preschool (2022),Groenman - Preschool 2022,10.1016/j.jaac.2021.02.024,100   0 100 100 Critically low Parent-mediated behavioral interventions Incredible years   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners parent ADHD Dsm total,20.00000000 NA NA Websterstratton,2011,NA RCT (parallel, crossover, open-label) G  49  50   99 NA reverse,-0.6723302242 -1.079400817,-2.652596e-01 NA,NA NA NA,NA NA,NA NA   0,  0 100,  0,100,100,  0,some high,low high,some,WLC (wait-list control)   0, 24.200000, 5.360000 NA DSM 3,1 0.5,0.0,1.0,1.0,0,0,1 1 1 1 1,0.5,0,1 1,1, 901,Websterstratton_2011 > 12 months,NA,< 6 yo 3.51 5.36 NA NA  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000,no,low high
9002 Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024,100,  0,100,100 Critically low Parent-mediated behavioral interventions Learning skills training for adolescents with ADHD (LeJa),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Fremdbeurteilungsbogen fur hyperkinetische storungen (ADHD symptom checklist),NA,NA NA,Schramm 2016,NA RCT (parallel, crossover, open-label) G  40, 73  113 outcomes reverse -0.2158837638,-0.604100426, 1.723329e-01 NA NA,NA,NA NA NA,NA,NA,  0,  0,100,  0 100,100   0,low,high low high,some WLC (wait-list control),  0, 14.200000 13.990000 NA DSM,3 1,0.5,0.0 1.0 1.0,0,0 1,1,1 1,1 0.5,0 1,1,1, 902 Schramm_2016 NA,NA 13-19 yo 7.28,13.99 95.59,108.21, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
9002 Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024,100   0,100,100,Critically low Parent-mediated behavioral interventions Learning skills training for adolescents with ADHD (LeJa)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Fremdbeurteilungsbogen fur hyperkinetische storungen (ADHD symptom checklist),NA NA NA Schramm 2016 NA RCT (parallel, crossover, open-label),G, 40, 73  113,outcomes,reverse,-0.3938465026 -0.784483747 -3.209258e-03 NA,NA,NA NA,NA,NA,NA,NA,  0,  0,100   0,100 100,  0,low,high,low,high,some WLC (wait-list control)   0  14.200000,13.990000,NA,DSM 3 1 0.5,0.0 1.0,1.0 0,0 1 1 1,1 1,0.5,0,1,1 1, 903 Schramm_2016,NA NA 13-19 yo 7.28 13.99 95.59 108.21, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
9002,Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024,100,100,100,100,Critically low Parent-mediated behavioral interventions Child life and attentions kills program   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,average score Child symptom Inverntory 12.00000000,NA,NA Pfiffner,2007,NA,RCT (parallel, crossover, open-label),G  36, 33,  69 NA reverse,-0.7616490510 -1.254569511,-2.687286e-01 NA,NA,NA,NA NA NA,NA NA   0,  0,100,  0 100 100   0,some high,low high some TAU,  0  33.300000, 8.670000,108.06000 DSM 3 1,0.5,0.0,1.0 1.0 0 0,1,1 1 1 1 0.5 0 1 1,1  904,Pfiffner_2007,7-12 months,Average (80-119) 6-12 yo,7.28,13.99,95.59,108.21, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
9002 Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024 100 100 100,100 Critically low,Parent-mediated behavioral interventions,Parent Focused treatment+Child life and attentions kills program (IPT)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire average score Child symptom Inventory NA NA,NA Pfiffner,2014 NA,RCT (parallel, crossover, open-label),G, 74, 51  125 outcomes reverse,-0.3461667704 -0.706821588  1.448805e-02 NA NA,NA,NA NA,NA NA,NA   0   0 100   0 100,100,  0 some,high low,high,some,TAU   0  41.700000, 8.640000,103.76000 DSM 3,1,0.5 0.0,1.0,1.0,0,0,1,1,1,1 1 0.5 0,1 1 1, 905 Pfiffner_2014,NA Average (80-119),6-12 yo,7.28 13.99 95.59,108.21, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
9002 Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024 100 100 100,100 Critically low,Parent-mediated behavioral interventions,Parent Focused treatment+Child life and attentions kills program (IPT),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire average score Child symptom Inventory,NA,NA NA,Pfiffner 2014 NA RCT (parallel, crossover, open-label),G  74, 51  125 outcomes reverse,-0.7545966507,-1.124891273 -3.843020e-01,NA NA,NA NA NA,NA,NA NA   0   0,100,  0 100,100,  0 some high low,high,some,TAU   0  41.700000, 8.640000 103.76000,DSM,3 1 0.5,0.0 1.0,1.0 0,0 1 1 1 1 1 0.5 0 1,1 1  906,Pfiffner_2014,NA,Average (80-119) 6-12 yo 7.28 13.99,95.59 108.21, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
9002,Groenman - Preschool (2022) Groenman - Preschool 2022 10.1016/j.jaac.2021.02.024,100,  0 100 100 Critically low,Parent-mediated behavioral interventions,Incredible years+a-New forest parenting program   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,SNAP ADHD sum score,12.00000000,NA NA,SonugaBarkeCoppi,2018 NA RCT (parallel, crossover, open-label) G,131, 42, 173 outcomes reverse -0.1066478409,-0.455315785  2.420201e-01 NA NA,NA,NA NA NA NA,NA 100,100,100   0,100,100 100,low high low,low,low,TAU   0, 26.800000, 3.510000,NA DSM,3,1,0.5 0.0 1.0 1.0 0,0 1,1 1,1 1 0.5,0,1 1,1, 907,SonugaBarkeCoppi_2018,7-12 months NA < 6 yo 3.51 5.36 NA NA, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000 no,low,low
9002,Groenman - Preschool (2022) Groenman - Preschool,2022 10.1016/j.jaac.2021.02.024 100   0 100,100,Critically low Parent-mediated behavioral interventions,Incredible years+a-New forest parenting program   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,SNAP ADHD sum score,12.00000000 NA NA SonugaBarkeCoppi,2018,NA RCT (parallel, crossover, open-label) G,133  42, 175,outcomes reverse,-0.1869915795 -0.535387227  1.614041e-01,NA NA NA NA NA NA NA,NA 100 100,100,  0 100 100,100 low high,low,low,low,TAU   0, 26.800000  3.510000 NA DSM 3 1 0.5,0.0,1.0 1.0,0 0,1 1,1 1,1 0.5 0 1,1,1, 908 SonugaBarkeCoppi_2018,7-12 months NA < 6 yo,3.51 5.36,NA NA, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no,low low
9002,Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024 100 100 100,100 Critically low Parent-mediated behavioral interventions,parent training, child docused treatment and a school-based intervention,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,SNAP total ADHD parent,NA NA,NA,MTA,1999 NA,RCT (parallel, crossover, open-label),G 143 144, 287,NA reverse,-0.1711623932,-0.403350697, 6.102591e-02 NA NA,NA,NA NA NA NA,NA,  0,  0 100   0,100,100   0 low high,low,high some,TAU   0, 19.900000, 7.760000,101.97000,DSM 3 1 0.5,0.0,1.0 1.0,0 0,1 1 1 1,1,0.5 0,1,1 1  909 MTA_1999,NA Average (80-119) 6-12 yo,7.28 13.99 95.59 108.21, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
9002,Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024 100,  0 100 100 Critically low Parent-mediated behavioral interventions collaborative life skills,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,Child symptom Inventory ADHD severity,12.00000000 NA NA,Pfiffner,2016 NA,RCT (parallel, crossover, open-label),G, 72, 63  135 NA,reverse -0.9682391688,-1.327001384,-6.094770e-01 NA NA NA NA NA NA,NA NA   0,  0 100   0,100,100,  0 some,high low,high,low,TAU,  0, 28.900000  8.390000 NA,DSM,3 1,0.5 0.0,1.0 1.0 0 0,1,1 1,1,1 0.5,0 1,1 1, 910,Pfiffner_2016,7-12 months NA,6-12 yo,7.28 13.99,95.59 108.21  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
9002 Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024,100   0,100,100 Critically low Parent-mediated behavioral interventions,online BPT+Face to face BPT   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Conners early beahvior inattention hyperactivity t scores 10.00000000 NA NA,Dupaul,2018 NA RCT (parallel, crossover, open-label),G  15  15,  30 outcomes,reverse,-0.6173421811,-1.363155874  1.284715e-01,NA,NA NA,NA,NA NA NA,NA   0   0,100,  0,100 100,  0,some high low,high some,WLC (wait-list control),  0, 24.400000  8.580000,NA DSM 3 1 0.5,0.0 1.0 1.0 0,0 1,1 1,1 1,0.5,0,1 1,1  911,Dupaul_2018,7-12 months NA,6-12 yo,7.28,13.99,95.59 108.21, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
9002,Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024,100   0 100 100 Critically low Parent-mediated behavioral interventions,online BPT+Face to face BPT,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners early beahvior inattention hyperactivity t scores,10.00000000 NA NA,Dupaul 2018 NA RCT (parallel, crossover, open-label),G  15, 15,  30,outcomes,reverse,-0.6051650524,-1.350280480, 1.399504e-01 NA NA,NA,NA,NA NA,NA NA,  0,  0 100   0 100 100   0 some high low high some,WLC (wait-list control)   0, 24.400000, 8.580000 NA DSM 3,1,0.5,0.0,1.0 1.0 0 0 1,1 1 1,1 0.5 0,1,1 1  912,Dupaul_2018 7-12 months NA 6-12 yo,7.28 13.99,95.59 108.21  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
9002,Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024 100,  0 100,100 Critically low,Parent-mediated behavioral interventions psychoeducation   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,CPRS ADHD index scores, 6.00000000 NA,NA Ferrin 2016 NA,RCT (parallel, crossover, open-label),G, 35  34   69 NA,reverse, 0.3957439141,-0.084218664  8.757065e-01,NA NA,NA,NA NA NA,NA,NA   0,  0,100,  0,100,100,  0 low high,low,high low TAU   0, 13.000000,10.710000 NA DSM 3,1 0.5 0.0 1.0 1.0,0 0,1 1,1 1,1 0.5,0 1,1 1  913,Ferrin_2016 2-6 months,NA,6-12 yo 7.28 13.99 95.59,108.21, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
9002 Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024 100 100,100,100,Critically low,Parent-mediated behavioral interventions NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire SNAP mother SUM 13.00000000 NA,NA Shimabukuro,2020,NA RCT (parallel, crossover, open-label) G  28, 24   52,NA,reverse -0.2814034121,-0.834486828  2.716800e-01 NA NA NA NA NA NA NA,NA,100,100,100,100 100 100,100 some low,low,some some,WLC (wait-list control),  0  17.650000  8.350000 100.69000,DSM 3,1,0.5 0.0,1.0 1.0 0 0,1 1 1,1,1 0.5 0 1 1,1  914 Shimabukuro_2020 > 12 months,Average (80-119),6-12 yo,7.28,13.99,95.59 108.21, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
9002,Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024 100   0,100,100,Critically low Parent-mediated behavioral interventions,Telephone-assisted self-help (TASH) intervention,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,German questionnaire FBB-ADHS 26.00000000,NA NA Dose 2017,NA RCT (parallel, crossover, open-label),G  51  90  141,NA reverse,-0.5086079752 -0.858434182,-1.587818e-01,NA NA NA NA NA NA,NA,NA,  0,  0 100 100 100 100,  0,some some,low high some TAU   0  20.570000  9.790000 NA,DSM,3 1,0.5,0.0 1.0,1.0 0,0,1 1,1,1,1 0.5 0 1,1,1, 915 Dose_2017,> 12 months,NA 6-12 yo,7.28 13.99 95.59,108.21, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
9002,Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024,100,  0 100,100 Critically low Parent-mediated behavioral interventions COACHES   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,DBD rating symptoms NA NA,NA,Fabiano 2012,NA RCT (parallel, crossover, open-label) G, 28, 27,  55,NA,reverse,-0.4721724333 -1.013063943, 6.871908e-02,NA NA,NA,NA,NA,NA NA NA   0,  0 100   0,100,100   0,some,high,low,high some WLC (wait-list control)   0, 13.000000  8.510000 NA,DSM,3 1 0.5,0.0,1.0,1.0 0,0,1,1 1 1,1 0.5,0,1,1,1  916 Fabiano_2012 NA,NA 6-12 yo,7.28 13.99 95.59,108.21  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
9002 Groenman (2022),Groenman 2022 10.1016/j.jaac.2021.02.024 100 100,100,100 Critically low,Parent-mediated behavioral interventions,Standard Behavioral Parent Training (BPT)+Combination of Standard BPT & Child training+Attention and social skills child training   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Conners total,10.00000000 NA,NA,Lauth,2005 NA,RCT (parallel, crossover, open-label) G  15, 15   30,outcomes reverse,-0.9043031843 -1.670315228 -1.382911e-01,NA NA NA,NA NA,NA,NA,NA,100 100,100,100 100 100 100,some,some low,low,some WLC (wait-list control),  0  11.670000  9.370000 108.21000,DSM,3 1,0.5,0.0,1.0,1.0 0 0,1 1,1,1,1,0.5 0,1,1,1, 917,Lauth_2005,7-12 months,Average (80-119) 6-12 yo 7.28 13.99 95.59 108.21, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
9002,Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024,100,100 100 100,Critically low,Parent-mediated behavioral interventions Standard Behavioral Parent Training (BPT)+Combination of Standard BPT & Child training+Attention and social skills child training   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire Conners total,10.00000000,NA,NA Lauth 2005 NA RCT (parallel, crossover, open-label) G, 15  15   30,outcomes,reverse -1.1088053434,-1.893384699,-3.242260e-01,NA,NA NA NA NA NA,NA NA 100,100 100 100 100 100,100 some some,low low,some,WLC (wait-list control),  0  11.670000, 9.370000,108.21000,DSM 3,1,0.5,0.0 1.0,1.0,0,0 1,1,1 1,1,0.5 0,1,1,1  918 Lauth_2005,7-12 months Average (80-119),6-12 yo,7.28,13.99,95.59,108.21, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
9002 Groenman (2022),Groenman 2022 10.1016/j.jaac.2021.02.024,100 100 100 100 Critically low,Parent-mediated behavioral interventions,Standard Behavioral Parent Training (BPT)+Combination of Standard BPT & Child training+Attention and social skills child training,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Conners total,10.00000000,NA,NA Lauth 2005 NA RCT (parallel, crossover, open-label),G  15, 15   30 outcomes,reverse -1.1459221216,-1.934222396 -3.576218e-01,NA NA,NA,NA NA NA,NA NA,100 100,100,100 100 100,100 some some low,low,some WLC (wait-list control)   0, 11.670000, 9.370000 108.21000,DSM,3,1 0.5,0.0 1.0 1.0,0,0,1,1 1,1,1,0.5 0 1 1 1, 919 Lauth_2005 7-12 months Average (80-119) 6-12 yo,7.28,13.99 95.59 108.21, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
9002,Groenman (2022),Groenman,2022,10.1016/j.jaac.2021.02.024,100,  0,100 100,Critically low Parent-mediated behavioral interventions,Cognitive-behavioral Training (BPT)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire CBCL Attention Scale,11.00000000,NA,NA,Lauthprecondis 2013 NA RCT (parallel, crossover, open-label) G 190  95, 285 NA,reverse -0.0850366254,-0.331819404, 1.617462e-01,NA,NA,NA NA NA,NA,NA NA,  0   0,  0,  0   0,  0   0 high high high high,high,WLC (wait-list control),  0, 14.740000  8.580000 NA DSM 3,1 0.5,0.0,1.0,1.0,0 0 1 1 1 1 1,0.5,0,1,1,1  920 Lauthprecondis_2013,7-12 months NA,6-12 yo 7.28,13.99 95.59 108.21, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high,high
9002 Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024,100   0 100,100 Critically low,Parent-mediated behavioral interventions Tuning into Kids+Mindful Parenting   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,SNAP ADHD symptoms, 8.00000000,NA,NA Shum,2025,NA,RCT (parallel, crossover, open-label),G, 18, 17,  35 outcomes reverse,-0.7938007608,-1.493258395 -9.434313e-02 NA,NA,NA NA NA NA NA,NA,  0   0,  0   0   0,  0,  0 high high,high high,high,WLC (wait-list control),  0, 25.000000  8.290000 NA,DSM 3 1 0.5,0.0 1.0,1.0 0 0 1 1,1 1 1,0.5,0 1 1,1  921,Shum_2025,7-12 months,NA,6-12 yo 7.28,13.99,95.59 108.21  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
9002 Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024 100,  0 100 100 Critically low,Parent-mediated behavioral interventions,Tuning into Kids+Mindful Parenting   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,SNAP ADHD symptoms  8.00000000,NA,NA,Shum 2025 NA RCT (parallel, crossover, open-label),G, 17  17,  34,outcomes,reverse -0.8742891557 -1.589796072 -1.587822e-01,NA NA,NA,NA NA NA,NA,NA,  0   0   0,  0,  0,  0   0,high high,high high,high WLC (wait-list control),  0  25.000000  8.290000 NA DSM,3,1 0.5 0.0,1.0 1.0 0 0 1 1,1 1 1,0.5 0 1 1 1  922 Shum_2025 7-12 months NA,6-12 yo 7.28,13.99,95.59,108.21  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high,high
9002,Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024,100,100,100 100 Critically low,Parent-mediated behavioral interventions Behavioral parent training with consequence-based techniques only   0,NA,Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,SDQ conduct problems  2.00000000,NA,NA,Hornstra,2021,NA,RCT (parallel, crossover, open-label) G  32, 30,  62 outcomes,reverse,-0.3855293514 -0.892239582  1.211809e-01,NA,NA NA,NA NA NA,NA NA 100 100,100 100 100 100 100 low low low,some,low WLC (wait-list control),  0, 31.520000  8.350000  95.59000,DSM 3 1,0.5 0.0 1.0,1.0 0,0 1 1,1 1 1,0.5 0 1,1,1, 923,Hornstra_2021,2-6 months,Average (80-119),6-12 yo 7.76,13.99,95.59,108.06  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
9002,Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024 100,100 100 100,Critically low Parent-mediated behavioral interventions,Behavioral parent training with consequence-based techniques only,  0,NA,Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks) Questionnaire SDQ conduct problems  2.00000000 NA NA Hornstra,2021,NA RCT (parallel, crossover, open-label) G, 30  30   60,outcomes reverse  0.1003588313,-0.410094841  6.108125e-01 NA,NA,NA,NA NA NA,NA,NA 100,100 100 100,100 100,100,low low low,some,low WLC (wait-list control)   0, 31.520000  8.350000  95.59000 DSM,3,1 0.5 0.0 1.0,1.0 0 0,1 1,1 1 1,0.5 0,1,1 1  924 Hornstra_2021,2-6 months Average (80-119) 6-12 yo,7.76 13.99,95.59,108.06, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
9002,Groenman - Preschool (2022) Groenman - Preschool 2022,10.1016/j.jaac.2021.02.024 100   0,100 100,Critically low Parent-mediated behavioral interventions,New forest parenting plan,  0,NA,Conduct Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,PACS conduct problems in last 6 months  8.00000000 NA,NA,Thompson,2009,NA RCT (parallel, crossover, open-label) G  21  20,  41,NA reverse,-0.4211132822 -1.047936837  2.057103e-01,NA,NA NA,NA,NA NA,NA NA 100 100 100,  0   0 100 100,some,high high low,some TAU   0 100.000000  4.180000 NA,DSM 3,1 0.5,0.0,1.0 1.0,0,0 1 1,1 1 1 0.5,0 1,1,1, 925 Thompson_2009 7-12 months,NA,< 6 yo 3.51,5.36,NA NA, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no,low,low
9002 Groenman - Preschool (2022) Groenman - Preschool,2022 10.1016/j.jaac.2021.02.024,100,  0 100,100,Critically low,Parent-mediated behavioral interventions,Incredible years   0,NA Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,Child symptom inventory CD symptoms 20.00000000,NA,NA Websterstratton 2011 NA,RCT (parallel, crossover, open-label),G, 49  50,  99,NA,reverse,-0.4427435009 -0.843509435 -4.197757e-02,NA,NA NA NA NA NA,NA,NA   0,  0 100   0,100,100   0,some,high,low high some WLC (wait-list control)   0, 24.200000  5.360000,NA,DSM,3 1,0.5,0.0,1.0,1.0,0 0 1,1,1 1 1 0.5 0,1 1 1, 926,Websterstratton_2011,> 12 months NA,< 6 yo,3.51,5.36 NA NA  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000,no low,high
9002 Groenman (2022),Groenman 2022 10.1016/j.jaac.2021.02.024,100,  0 100 100 Critically low,Parent-mediated behavioral interventions Learning skills training for adolescents with ADHD (LeJa),  0 NA Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire SDQ conduct problems NA NA,NA Schramm,2016 NA RCT (parallel, crossover, open-label),G  40  73, 113 NA reverse -0.1570135045,-0.544738620  2.307116e-01,NA NA,NA NA NA NA,NA NA,  0,  0 100   0 100,100   0 low,high,low high,some WLC (wait-list control)   0  14.200000 13.990000 NA,DSM,3 1,0.5,0.0,1.0,1.0,0 0,1,1 1 1,1,0.5,0,1,1 1  927,Schramm_2016 NA NA 13-19 yo 7.76 13.99,95.59 108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
9002 Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024 100 100,100 100,Critically low Parent-mediated behavioral interventions Child life and attentions kills program   0 NA Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks) Questionnaire CSI average CD 12.00000000 NA NA,Pfiffner,2007,NA,RCT (parallel, crossover, open-label),G  36, 33   69,NA,reverse -0.1964409963,-0.673239626  2.803576e-01,NA,NA NA NA NA,NA,NA,NA,  0   0 100   0 100 100,  0,some,high low,high some TAU,  0, 33.300000, 8.670000 108.06000,DSM 3 1,0.5 0.0 1.0 1.0 0,0,1 1 1,1 1,0.5,0,1,1,1, 928,Pfiffner_2007 7-12 months,Average (80-119) 6-12 yo,7.76,13.99 95.59,108.06  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
9002 Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024,100 100,100 100 Critically low,Parent-mediated behavioral interventions,Parent Focused treatment+Child life and attentions kills program (IPT),  0,NA,Conduct Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,CSI average CD,NA,NA NA Pfiffner 2014 NA RCT (parallel, crossover, open-label),G, 74, 51, 125 outcomes reverse -0.0767943948 -0.434965083, 2.813763e-01 NA,NA,NA NA NA NA,NA,NA   0,  0,100   0,100 100,  0,some,high,low,high,some TAU,  0, 41.700000, 8.640000,103.76000 DSM,3 1 0.5,0.0 1.0,1.0,0,0,1,1 1,1,1,0.5 0,1,1,1, 929,Pfiffner_2014,NA,Average (80-119),6-12 yo,7.76 13.99,95.59 108.06  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
9002,Groenman (2022),Groenman,2022,10.1016/j.jaac.2021.02.024 100 100 100,100,Critically low,Parent-mediated behavioral interventions Parent Focused treatment+Child life and attentions kills program (IPT)   0 NA Conduct Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire CSI average CD,NA,NA NA,Pfiffner,2014,NA,RCT (parallel, crossover, open-label),G, 74, 51  125 outcomes,reverse,-0.2764918239,-0.636202759  8.321911e-02,NA NA,NA,NA,NA,NA NA,NA   0,  0 100   0,100,100,  0 some,high,low,high some TAU,  0  41.700000, 8.640000,103.76000 DSM,3,1,0.5 0.0,1.0 1.0,0 0,1,1 1,1,1 0.5,0,1 1 1  930 Pfiffner_2014,NA,Average (80-119) 6-12 yo,7.76,13.99 95.59 108.06  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
9002 Groenman - Preschool (2022),Groenman - Preschool 2022 10.1016/j.jaac.2021.02.024 100   0,100 100,Critically low Parent-mediated behavioral interventions Incredible years+a-New forest parenting program   0,NA,Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,ECBI CD symptoms 12.00000000 NA NA,SonugaBarkeCoppi,2018 NA RCT (parallel, crossover, open-label),G,131, 42  173,outcomes,reverse, 0.1671022032,-0.181832895  5.160373e-01 NA NA NA,NA,NA NA NA NA 100 100 100   0 100,100 100 low,high,low,low low,TAU   0  26.800000  3.510000 NA DSM,3 1,0.5 0.0 1.0 1.0,0,0 1 1 1 1,1 0.5,0,1,1 1, 931,SonugaBarkeCoppi_2018 7-12 months,NA < 6 yo 3.51 5.36 NA NA  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15 108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000,no,low low
9002 Groenman - Preschool (2022) Groenman - Preschool 2022,10.1016/j.jaac.2021.02.024 100,  0 100,100,Critically low Parent-mediated behavioral interventions,Incredible years+a-New forest parenting program,  0 NA,Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks) Questionnaire ECBI CD symptoms 12.00000000,NA,NA,SonugaBarkeCoppi,2018,NA RCT (parallel, crossover, open-label) G,133, 42  175 outcomes reverse -0.1248219118,-0.472907753  2.232639e-01 NA NA NA NA NA,NA NA,NA 100 100,100   0 100 100,100,low high,low low,low,TAU,  0  26.800000  3.510000 NA DSM,3 1 0.5,0.0,1.0 1.0,0,0,1,1 1 1,1 0.5,0 1 1,1, 932,SonugaBarkeCoppi_2018 7-12 months,NA < 6 yo 3.51 5.36,NA,NA, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000 no low low
9002 Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024,100 100 100 100 Critically low,Parent-mediated behavioral interventions parent training, child docused treatment and a school-based intervention   0 NA Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,Aggression-Conduct Problems Scale - DSM-IV NA,NA NA,MTA,1999 NA,RCT (parallel, crossover, open-label),G,143,144, 287,NA,reverse -0.0465873133,-0.278381007  1.852064e-01,NA,NA NA,NA NA NA,NA,NA   0   0,100   0 100 100   0 low,high,low,high some,TAU   0, 19.900000  7.760000,101.97000,DSM,3 1 0.5 0.0 1.0,1.0,0,0,1 1,1,1 1 0.5 0,1 1 1  933 MTA_1999 NA Average (80-119) 6-12 yo 7.76 13.99 95.59 108.06  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
9002 Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024 100,  0,100,100,Critically low,Parent-mediated behavioral interventions,collaborative life skills,  0,NA,Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire CSI average CD 12.00000000,NA,NA,Pfiffner,2016,NA RCT (parallel, crossover, open-label) G, 72, 63, 135,NA,reverse -0.4959255478,-0.840439353 -1.514117e-01,NA NA,NA NA,NA,NA,NA NA,  0,  0,100   0,100 100   0 some high low high low,TAU,  0, 28.900000, 8.390000,NA DSM,3 1 0.5,0.0 1.0 1.0,0,0,1,1 1,1,1 0.5 0,1,1 1, 934,Pfiffner_2016,7-12 months NA 6-12 yo 7.76 13.99,95.59 108.06  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
9002 Groenman (2022),Groenman 2022 10.1016/j.jaac.2021.02.024 100,  0,100,100,Critically low Parent-mediated behavioral interventions psychoeducation,  0,NA Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,SDQ conduct problems, 6.00000000 NA,NA,Ferrin 2016,NA,RCT (parallel, crossover, open-label),G, 35  34,  69,NA reverse  0.0000000000,-0.475229065, 4.752291e-01,NA NA NA NA,NA,NA,NA NA   0,  0 100   0 100 100   0 low,high low high low TAU   0  13.000000 10.710000 NA,DSM,3,1 0.5,0.0,1.0 1.0 0,0,1 1,1,1 1 0.5 0,1 1,1, 935,Ferrin_2016,2-6 months,NA 6-12 yo,7.76,13.99 95.59 108.06, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
9002 Groenman (2022),Groenman,2022,10.1016/j.jaac.2021.02.024,100,100,100 100,Critically low,Parent-mediated behavioral interventions NA   0,NA Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,CBCL DSM conduct problems subscale,13.00000000 NA NA,Shimabukuro 2020 NA RCT (parallel, crossover, open-label),G  28  24,  52 NA,reverse,-0.1638734483,-0.715118565  3.873717e-01 NA NA,NA,NA NA,NA,NA NA 100,100,100 100 100 100,100,some,low low some,some,WLC (wait-list control)   0, 17.650000, 8.350000 100.69000 DSM 3 1 0.5,0.0,1.0 1.0 0,0 1 1,1 1,1,0.5 0 1,1,1, 936,Shimabukuro_2020,> 12 months,Average (80-119),6-12 yo,7.76 13.99 95.59,108.06  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
9002 Groenman (2022),Groenman,2022,10.1016/j.jaac.2021.02.024,100   0,100 100 Critically low Parent-mediated behavioral interventions Telephone-assisted self-help (TASH) intervention,  0 NA,Conduct Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,German questionnaire FBB-SSV Conduct Problems 26.00000000,NA,NA,Dose 2017,NA,RCT (parallel, crossover, open-label),G, 51, 90  141,NA reverse,-0.1446149404 -0.489697977  2.004681e-01 NA,NA NA,NA,NA,NA,NA,NA   0,  0,100,100 100 100   0 some some,low,high,some,TAU,  0  20.570000, 9.790000 NA DSM 3 1 0.5,0.0,1.0 1.0,0,0 1 1 1 1,1,0.5 0,1,1 1, 937,Dose_2017 > 12 months NA 6-12 yo,7.76 13.99,95.59,108.06  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
9002,Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024,100   0 100,100,Critically low,Parent-mediated behavioral interventions,COACHES,  0,NA,Conduct Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire DBD rating conduct symptoms NA NA NA,Fabiano 2012 NA,RCT (parallel, crossover, open-label),G  28  27,  55 NA,reverse  0.1011849543 -0.432466866  6.348368e-01 NA,NA,NA,NA NA,NA,NA NA,  0   0,100   0 100,100,  0,some,high low,high,some WLC (wait-list control),  0  13.000000, 8.510000 NA DSM 3,1 0.5 0.0,1.0,1.0,0,0,1,1,1,1 1 0.5 0,1,1 1  938 Fabiano_2012,NA NA,6-12 yo,7.76,13.99 95.59 108.06  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
9002 Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024,100   0,100 100,Critically low Parent-mediated behavioral interventions Cognitive-behavioral Training (BPT),  0 NA Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks) Questionnaire CBCL Rule-breaking behavior 11.00000000 NA NA Lauthprecondis,2013,NA RCT (parallel, crossover, open-label),G 190, 95, 285 NA reverse,-0.1973774979,-0.444596831, 4.984184e-02,NA NA,NA NA,NA,NA NA NA   0   0   0,  0,  0,  0   0,high,high,high high,high,WLC (wait-list control)   0  14.740000  8.580000 NA DSM 3,1,0.5,0.0 1.0,1.0,0,0,1 1 1 1,1 0.5 0 1 1,1  939,Lauthprecondis_2013 7-12 months,NA 6-12 yo,7.76 13.99,95.59,108.06  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high,high
9002 Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024,100,  0 100,100,Critically low,Parent-mediated behavioral interventions Tuning into Kids+Mindful Parenting   0 NA,Conduct Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,SDQ CD symptoms, 8.00000000 NA,NA Shum,2025 NA RCT (parallel, crossover, open-label) G  18, 17,  35,outcomes,reverse -0.4566739863 -1.138078945, 2.247310e-01 NA NA,NA NA,NA NA,NA NA   0   0,  0,  0,  0,  0,  0 high high high,high high WLC (wait-list control),  0, 25.000000, 8.290000,NA,DSM,3 1 0.5,0.0 1.0,1.0,0 0,1,1,1 1,1 0.5,0,1 1 1  940,Shum_2025 7-12 months,NA 6-12 yo 7.76,13.99 95.59,108.06  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
9002,Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024,100,  0,100 100 Critically low Parent-mediated behavioral interventions Tuning into Kids+Mindful Parenting,  0,NA Conduct Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,SDQ CD symptoms, 8.00000000,NA,NA Shum 2025 NA,RCT (parallel, crossover, open-label) G, 17  17   34 outcomes,reverse,-0.3291908465,-1.016157112  3.577754e-01 NA,NA NA NA,NA,NA,NA,NA,  0,  0   0   0,  0,  0   0,high,high high high high,WLC (wait-list control)   0, 25.000000  8.290000,NA,DSM 3,1,0.5 0.0,1.0 1.0,0 0,1 1 1,1 1,0.5,0,1 1,1  941 Shum_2025 7-12 months,NA 6-12 yo,7.76 13.99,95.59 108.06  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
9002,Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024,100 100 100,100 Critically low,Parent-mediated behavioral interventions Behavioral parent training with consequence-based techniques only,  0,NA Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Dutch version of Disruptive Behavior Disorder Rating Scale, 2.00000000 NA,NA Hornstra,2021 NA RCT (parallel, crossover, open-label),G, 32  30,  62,outcomes reverse -0.1669015859 -0.669751537  3.359484e-01,NA NA NA NA NA NA,NA NA,100,100,100 100,100,100 100,low low low,some low,WLC (wait-list control),  0, 31.520000  8.350000, 95.59000 DSM,3,1 0.5 0.0 1.0,1.0,0,0 1,1 1 1,1 0.5,0,1 1,1  942 Hornstra_2021,2-6 months,Average (80-119),6-12 yo,7.43,10.71 95.59,108.06, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
9002,Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024 100 100 100,100,Critically low Parent-mediated behavioral interventions Behavioral parent training with consequence-based techniques only,  0,NA,Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire Dutch version of Disruptive Behavior Disorder Rating Scale, 2.00000000 NA NA,Hornstra,2021,NA,RCT (parallel, crossover, open-label),G, 30, 30   60 outcomes reverse  0.0086657646,-0.501460840, 5.187924e-01,NA,NA,NA,NA,NA NA NA,NA 100,100 100 100,100 100 100 low low,low some low WLC (wait-list control)   0  31.520000  8.350000, 95.59000 DSM,3,1 0.5,0.0,1.0,1.0,0,0 1,1,1,1,1,0.5 0,1,1,1, 943 Hornstra_2021 2-6 months,Average (80-119) 6-12 yo 7.43,10.71,95.59,108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
9002 Groenman - Preschool (2022) Groenman - Preschool,2022,10.1016/j.jaac.2021.02.024 100   0 100,100,Critically low,Parent-mediated behavioral interventions,Parenting Your Hyperactive Preschooler (parent training and emotion socialization),  0,NA Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,DBRS ODD average score mother 14.00000000 NA NA,Herbert 2013,NA RCT (parallel, crossover, open-label),G  17  14   31 NA reverse,-0.0310645730 -0.749958831  6.878297e-01 NA,NA NA NA NA,NA NA NA   0,  0 100,  0,100,100   0,some,high low high some,WLC (wait-list control),  0, 25.800000  4.580000 NA DSM 3,1,0.5,0.0 1.0,1.0 0,0 1 1 1 1 1,0.5 0 1,1 1, 944 Herbert_2013 > 12 months,NA < 6 yo,3.51,5.36 NA NA  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000,no low,high
9002,Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024 100 100,100,100,Critically low,Parent-mediated behavioral interventions,Behavioral parent training Groningen   0 NA Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,CPRS oppositional,22.00000000,NA NA Vdhoofdakker 2007,NA,RCT (parallel, crossover, open-label),G, 47, 47,  94,NA,reverse -0.1460338352 -0.552931806  2.608641e-01,NA,NA NA NA,NA,NA NA,NA,  0,  0 100,  0,100,100,  0 some,high,low high,some,TAU   0, 19.100000, 7.430000, 97.45000 DSM 3,1 0.5,0.0,1.0,1.0,0,0 1,1,1 1 1,0.5 0 1,1,1, 945 Vdhoofdakker_2007 > 12 months Average (80-119),6-12 yo,7.43 10.71 95.59 108.06  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
9002 Groenman - Preschool (2022),Groenman - Preschool,2022 10.1016/j.jaac.2021.02.024 100   0 100,100,Critically low Parent-mediated behavioral interventions,Incredible years,  0,NA,Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire Conners parent oppositional,20.00000000 NA,NA,Websterstratton 2011 NA RCT (parallel, crossover, open-label),G, 49, 50   99,NA,reverse,-0.4268176823 -0.827239741,-2.639562e-02,NA,NA NA,NA,NA,NA NA NA   0,  0 100   0,100 100,  0 some high low high some WLC (wait-list control),  0  24.200000  5.360000 NA,DSM 3,1,0.5 0.0,1.0 1.0 0 0 1,1 1 1 1 0.5 0,1,1,1, 946,Websterstratton_2011 > 12 months NA < 6 yo 3.51,5.36,NA,NA, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no low high
9002,Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024,100,100,100,100,Critically low,Parent-mediated behavioral interventions,Child life and attentions kills program   0,NA Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks) Questionnaire CSI ODD average score 12.00000000,NA,NA,Pfiffner 2007 NA RCT (parallel, crossover, open-label) G  36, 33   69 NA,reverse -0.1460573683,-0.622333281, 3.302185e-01,NA NA NA NA NA NA,NA NA,  0,  0,100,  0,100 100   0,some,high,low high some,TAU   0  33.300000  8.670000 108.06000 DSM,3 1 0.5 0.0,1.0 1.0 0 0 1,1,1 1,1,0.5 0 1 1 1  947,Pfiffner_2007 7-12 months,Average (80-119) 6-12 yo,7.43,10.71 95.59,108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
9002,Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024,100 100 100 100 Critically low Parent-mediated behavioral interventions Parent Focused treatment+Child life and attentions kills program (IPT)   0 NA Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire CSI ODD average score NA,NA,NA Pfiffner 2014 NA,RCT (parallel, crossover, open-label) G, 74  51, 125,outcomes reverse,-0.1266997883 -0.485092597, 2.316930e-01 NA NA,NA NA,NA NA NA,NA   0,  0 100   0 100 100   0,some high low high,some TAU,  0  41.700000, 8.640000 103.76000,DSM,3 1 0.5 0.0 1.0,1.0,0 0 1 1,1,1,1 0.5,0,1,1 1  948 Pfiffner_2014,NA,Average (80-119),6-12 yo 7.43 10.71 95.59,108.06  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
9002,Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024 100 100 100,100,Critically low Parent-mediated behavioral interventions,Parent Focused treatment+Child life and attentions kills program (IPT),  0,NA,Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire CSI ODD average score,NA NA NA Pfiffner,2014,NA,RCT (parallel, crossover, open-label) G  74  51, 125,outcomes,reverse -0.0369691649,-0.395040714  3.211024e-01,NA,NA,NA,NA NA NA NA NA   0,  0,100   0 100,100,  0,some,high low high some,TAU,  0  41.700000  8.640000 103.76000,DSM 3,1,0.5,0.0 1.0,1.0,0 0,1,1 1,1,1 0.5 0,1,1,1, 949,Pfiffner_2014 NA,Average (80-119) 6-12 yo,7.43,10.71,95.59,108.06  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
9002,Groenman - Preschool (2022) Groenman - Preschool 2022,10.1016/j.jaac.2021.02.024 100,  0,100 100,Critically low,Parent-mediated behavioral interventions Incredible years+a-New forest parenting program   0 NA Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire SNAP ODD average score 12.00000000 NA NA,SonugaBarkeCoppi,2018,NA RCT (parallel, crossover, open-label) G,131, 42, 173,outcomes reverse,-0.0929521691 -0.441575964, 2.556716e-01 NA NA NA,NA NA NA,NA NA,100,100 100,  0 100,100 100 low,high,low low,low,TAU,  0  26.800000, 3.510000 NA DSM 3 1,0.5,0.0,1.0,1.0 0 0,1,1,1,1 1,0.5,0 1 1 1  950 SonugaBarkeCoppi_2018 7-12 months,NA,< 6 yo,3.51,5.36 NA,NA  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000 no low,low
9002,Groenman - Preschool (2022),Groenman - Preschool,2022,10.1016/j.jaac.2021.02.024 100   0,100 100 Critically low Parent-mediated behavioral interventions Incredible years+a-New forest parenting program   0,NA Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,SNAP ODD average score 12.00000000,NA NA SonugaBarkeCoppi,2018 NA,RCT (parallel, crossover, open-label),G,133, 42  175 outcomes reverse,-0.2317176379 -0.580412311, 1.169770e-01 NA NA,NA NA,NA,NA NA NA,100 100,100   0 100,100 100,low,high low low,low,TAU   0  26.800000, 3.510000 NA,DSM,3 1 0.5 0.0 1.0,1.0,0 0,1,1 1,1,1,0.5,0,1 1 1  951,SonugaBarkeCoppi_2018,7-12 months NA,< 6 yo,3.51 5.36,NA,NA  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000,no low low
9002 Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024,100 100 100,100 Critically low Parent-mediated behavioral interventions,parent training, child docused treatment and a school-based intervention,  0 NA Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,SNAP ODD NA,NA,NA,MTA 1999 NA,RCT (parallel, crossover, open-label),G 143 144, 287,NA,reverse,-0.0613724024,-0.293189335, 1.704445e-01 NA NA NA NA,NA NA,NA NA,  0,  0,100   0 100 100   0,low high,low high,some,TAU,  0  19.900000, 7.760000 101.97000 DSM 3,1,0.5 0.0,1.0 1.0 0 0,1,1 1,1,1,0.5,0 1 1 1  952,MTA_1999 NA,Average (80-119),6-12 yo,7.43 10.71 95.59,108.06  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
9002 Groenman (2022),Groenman 2022 10.1016/j.jaac.2021.02.024 100   0,100 100 Critically low,Parent-mediated behavioral interventions,collaborative life skills   0 NA,Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,CSI ODD average score 12.00000000,NA NA,Pfiffner,2016 NA RCT (parallel, crossover, open-label) G  72  63, 135 NA reverse,-0.7490821357 -1.100161591,-3.980027e-01 NA,NA NA NA NA NA NA,NA,  0,  0,100,  0 100,100,  0 some,high,low,high,low TAU   0  28.900000, 8.390000 NA DSM 3 1 0.5,0.0,1.0,1.0,0,0,1,1,1,1,1 0.5 0,1 1,1, 953 Pfiffner_2016 7-12 months NA 6-12 yo,7.43 10.71,95.59 108.06, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
9002 Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024,100,  0 100 100 Critically low,Parent-mediated behavioral interventions,online BPT+Face to face BPT,  0 NA Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,CERS defiant temp t score 10.00000000,NA NA Dupaul 2018 NA,RCT (parallel, crossover, open-label),G  15  15,  30,outcomes reverse,-0.3724467948 -1.106808222  3.619146e-01,NA NA NA,NA,NA NA,NA NA   0   0,100,  0 100,100   0 some high low,high,some WLC (wait-list control),  0  24.400000  8.580000 NA DSM,3 1,0.5,0.0 1.0 1.0,0,0 1 1 1 1,1 0.5 0,1 1 1, 954,Dupaul_2018,7-12 months NA,6-12 yo,7.43,10.71,95.59,108.06, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
9002 Groenman (2022),Groenman,2022,10.1016/j.jaac.2021.02.024 100,  0 100,100 Critically low,Parent-mediated behavioral interventions,online BPT+Face to face BPT   0 NA,Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire CERS defiant temp t score,10.00000000,NA NA,Dupaul 2018,NA RCT (parallel, crossover, open-label) G  15, 15   30,outcomes,reverse -0.5095131795 -1.249608231  2.305819e-01 NA,NA,NA NA NA,NA NA NA   0,  0,100   0,100 100,  0,some high low,high,some WLC (wait-list control),  0  24.400000, 8.580000,NA DSM 3,1,0.5,0.0 1.0,1.0,0 0 1 1,1,1 1,0.5,0 1,1 1, 955 Dupaul_2018,7-12 months NA 6-12 yo,7.43,10.71,95.59,108.06, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
9002 Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024 100,  0,100 100,Critically low Parent-mediated behavioral interventions,psychoeducation   0,NA,Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,CPRS oppositional  6.00000000,NA,NA Ferrin,2016,NA,RCT (parallel, crossover, open-label) G, 35  34,  69,NA reverse  0.0759972208 -0.399407243, 5.514017e-01 NA NA,NA NA,NA,NA NA,NA,  0,  0,100,  0,100 100,  0,low high low high,low TAU   0  13.000000,10.710000 NA,DSM 3,1,0.5,0.0,1.0,1.0 0,0 1,1,1,1 1,0.5,0,1,1 1  956 Ferrin_2016,2-6 months NA 6-12 yo 7.43 10.71 95.59,108.06, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
9002,Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024,100 100 100,100,Critically low Parent-mediated behavioral interventions,NA,  0,NA Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,SNAP ODD sum Mother 13.00000000,NA,NA,Shimabukuro,2020 NA RCT (parallel, crossover, open-label),G, 28  24,  52,NA,reverse -0.3592135094 -0.914042205, 1.956152e-01 NA,NA NA NA,NA,NA NA NA,100,100 100,100 100,100,100,some,low low,some,some,WLC (wait-list control),  0  17.650000  8.350000 100.69000,DSM,3,1 0.5 0.0,1.0 1.0,0,0,1,1 1,1 1,0.5 0 1 1 1  957 Shimabukuro_2020 > 12 months Average (80-119),6-12 yo,7.43,10.71 95.59 108.06, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
9002,Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024,100   0 100 100 Critically low Parent-mediated behavioral interventions Telephone-assisted self-help (TASH) intervention,  0 NA Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire German questionnaire FBB-SSV Oppositional,26.00000000,NA,NA,Dose 2017 NA,RCT (parallel, crossover, open-label) G, 51, 90  141,NA reverse -0.4464192672,-0.795066730 -9.777180e-02 NA NA,NA NA,NA,NA,NA,NA,  0,  0,100,100 100,100   0 some some low,high,some,TAU   0  20.570000, 9.790000,NA DSM 3,1 0.5,0.0 1.0 1.0,0,0,1,1,1,1 1 0.5 0,1,1,1, 958 Dose_2017,> 12 months NA,6-12 yo,7.43 10.71 95.59,108.06, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
9002,Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024,100,  0,100,100,Critically low,Parent-mediated behavioral interventions COACHES   0,NA,Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire DBD rating oppositional symptoms,NA NA NA,Fabiano 2012,NA,RCT (parallel, crossover, open-label) G, 28, 27,  55 NA reverse,-0.4134090170,-0.952538297  1.257203e-01 NA,NA NA,NA NA,NA NA NA,  0,  0,100   0 100,100   0 some,high low,high some WLC (wait-list control)   0, 13.000000, 8.510000,NA,DSM,3,1 0.5 0.0 1.0 1.0 0 0 1,1,1 1,1,0.5 0 1 1 1  959 Fabiano_2012,NA,NA 6-12 yo 7.43,10.71,95.59 108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
9002,Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024,100,  0 100 100 Critically low Parent-mediated behavioral interventions Cognitive-behavioral Training (BPT),  0,NA,Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,CBCL Aggression Scale 11.00000000 NA,NA,Lauthprecondis 2013,NA,RCT (parallel, crossover, open-label),G 190  95  285,NA,reverse,-0.1923454883 -0.439537860  5.484688e-02,NA,NA NA,NA,NA NA,NA,NA   0,  0,  0,  0,  0,  0   0 high high high high high WLC (wait-list control),  0  14.740000, 8.580000 NA,DSM 3,1,0.5,0.0 1.0 1.0 0,0 1 1,1,1,1 0.5,0,1 1 1  960,Lauthprecondis_2013,7-12 months,NA,6-12 yo,7.43 10.71 95.59,108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
9002 Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024,100   0,100 100 Critically low,Parent-mediated behavioral interventions Tuning into Kids+Mindful Parenting,  0 NA,Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire SNAP ODD symptoms, 8.00000000 NA,NA,Shum,2025,NA,RCT (parallel, crossover, open-label),G  18  17   35,outcomes reverse,-0.4444159794 -1.125341503  2.365095e-01,NA NA NA NA NA,NA NA NA   0   0   0   0   0,  0   0,high,high,high high,high WLC (wait-list control)   0, 25.000000, 8.290000 NA,DSM,3 1,0.5,0.0,1.0,1.0,0,0 1,1,1 1,1,0.5 0 1 1,1  961,Shum_2025 7-12 months,NA 6-12 yo,7.43,10.71 95.59,108.06, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
9002 Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024 100   0,100 100 Critically low Parent-mediated behavioral interventions Tuning into Kids+Mindful Parenting   0 NA,Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire SNAP ODD symptoms, 8.00000000 NA,NA Shum,2025 NA,RCT (parallel, crossover, open-label) G, 17  17   34,outcomes reverse -0.5331651194,-1.227899093, 1.615689e-01,NA NA NA,NA,NA,NA NA,NA,  0   0,  0   0   0   0   0,high high high,high high WLC (wait-list control),  0  25.000000, 8.290000,NA DSM 3,1 0.5 0.0,1.0,1.0,0,0 1,1 1 1,1,0.5 0,1 1 1, 962,Shum_2025 7-12 months NA 6-12 yo 7.43,10.71,95.59 108.06  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
 973,Doffer (2023),Doffer 2023,10.1002/jcv2.12196,100 100,100,100 Critically low,Parent-mediated behavioral interventions,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks Questionnaire,CPRS-H/I NA,   2.0000000 h/wk Ferrin 2016,NA,RCT (parallel, crossover, open-label),G, 35, 34,  69,outcomes NA  0.1577953403,-0.322245004  6.378357e-01,  4.3600000   4.4600000 12.09, 4.800 12.71, 4.470,NA NA,  0,  0,100,  0,100 100   0 low,high,low high,low,TAU   0, 13.010145,10.712174, 94.58725 DSM-IV,3,0 1.0 0.5 1.0 0.0 0,1 2 1 1,1 1,1.0,0,0,1 1, 963 Ferrin_2016 NA,Average (80-119),6-12 yo 8.6368,13.97 94.15 104.416  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1 Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no low high
 973 Doffer (2023),Doffer 2023,10.1002/jcv2.12196,100 100,100,100,Critically low Parent-mediated behavioral interventions,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks,Questionnaire,CPRS-I NA,   2.0000000 h/wk,Ferrin,2016 NA,RCT (parallel, crossover, open-label),G  35, 34   69 outcomes,NA, 0.8027421646, 0.192052586  1.413432e+00   4.6300000,  3.8500000 13.94, 2.910,13.56, 4.180 NA,NA   0   0 100,  0,100,100,  0,low high low high low TAU,  0  13.010145,10.712174  94.58725 DSM-IV,3 0 1.0,0.5,1.0 0.0 0,1,2,1 1 1,1 1.0 0,0 1,1, 964,Ferrin_2016,NA Average (80-119),6-12 yo 8.6368 13.97 94.15 104.416, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1 Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000,no low high
 973,Doffer (2023) Doffer 2023 10.1002/jcv2.12196,100 100 100,100,Critically low,Parent-mediated behavioral interventions NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,Closest to 52 weeks,Questionnaire CTRS-Total NA,   2.0000000 h/wk,Ferrin,2016,NA RCT (parallel, crossover, open-label) G  35  34,  69 outcomes NA, 0.4573551539,-0.111379629  1.026090e+00  10.1300000, 10.2000000,21.40, 7.430,18.38, 9.640 NA,NA,  0   0 100,  0,100,100   0,low high,low high low,TAU,  0, 13.010145,10.712174, 94.58725,DSM-IV 3 0 1.0,0.5,1.0 0.0,0,1 2,1 1 1 1,1.0 0 0 1,1  965,Ferrin_2016 NA,Average (80-119) 6-12 yo,8.6368,13.97 94.15,104.416  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15 108.21 Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000,no,low high
 973,Doffer (2023),Doffer 2023 10.1002/jcv2.12196,100 100 100,100,Critically low,Parent-mediated behavioral interventions,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks,Questionnaire P-CSI NA,   0.9550000 h/wk,Pfiffner 2014 NA,RCT (parallel, crossover, open-label),G  70, 45, 115 outcomes NA, 0.5381217357  0.047630486, 1.028613e+00   0.3480000,  0.4360000, 1.32  0.351  1.42  0.363 NA NA,  0,  0 100   0 100 100   0 some,high,low,high some,TAU   0  45.820000  8.636800 104.41600,DSM-IV 3 0,1.0,0.5,1.0 0.0,0,1 2,1,1,1,1,1.0 0 0,1 1  966,Pfiffner_2014 NA,Average (80-119),6-12 yo 8.6368 13.97 94.15,104.416  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21 Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1 Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000,no low,high
 973,Doffer (2023) Doffer,2023,10.1002/jcv2.12196 100 100 100,100 Critically low Parent-mediated behavioral interventions,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks Questionnaire,T-CSI,NA,   0.9550000,h/wk,Pfiffner 2014 NA RCT (parallel, crossover, open-label) G  67  41, 108,outcomes,NA, 0.3433404824 -0.197044549, 8.837255e-01,  0.5370000   0.5060000, 1.33, 0.378, 1.36, 0.377,NA NA,  0,  0 100,  0 100,100,  0 some,high low high,some,TAU   0, 45.820000  8.636800 104.41600,DSM-IV 3,0 1.0 0.5 1.0,0.0,0 1,2 1 1,1 1,1.0,0 0,1,1, 967,Pfiffner_2014 NA Average (80-119),6-12 yo,8.6368 13.97 94.15,104.416, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000 no low,high
 973,Doffer (2023),Doffer 2023,10.1002/jcv2.12196,100 100 100,100,Critically low,Parent-mediated behavioral interventions,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,Closest to 52 weeks Questionnaire P-CSI,NA    0.9550000,h/wk Pfiffner 2014 NA,RCT (parallel, crossover, open-label) G, 73, 45, 118 outcomes,NA, 0.3413758758,-0.132470383, 8.152221e-01   0.4200000,  0.4360000, 1.49  0.414, 1.42  0.363,NA,NA   0,  0 100   0,100 100   0 some,high low,high some,TAU   0, 45.820000, 8.636800 104.41600,DSM-IV 3 0 1.0 0.5 1.0,0.0 0,1,2 1 1 1,1,1.0 0 0 1,1, 968 Pfiffner_2014 NA Average (80-119),6-12 yo,8.6368 13.97 94.15,104.416, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1,Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000,no,low,high
 973,Doffer (2023),Doffer,2023,10.1002/jcv2.12196 100 100,100 100,Critically low Parent-mediated behavioral interventions NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks Questionnaire T-CSI,NA    0.9550000 h/wk,Pfiffner 2014 NA,RCT (parallel, crossover, open-label),G, 71, 41  112 outcomes NA  0.1535822041,-0.357936601, 6.651010e-01   0.6120000,  0.5060000  1.30  0.435  1.36, 0.377 NA NA,  0,  0 100   0,100 100,  0 some,high low,high some TAU,  0, 45.820000, 8.636800 104.41600 DSM-IV 3,0,1.0,0.5 1.0 0.0 0 1,2,1 1,1,1 1.0,0 0 1 1  969 Pfiffner_2014,NA Average (80-119) 6-12 yo,8.6368,13.97,94.15 104.416, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21 Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000,no,low high
 973 Doffer - Preschool (2023),Doffer - Preschool 2023,10.1002/jcv2.12196 100,100,100 100 Critically low,Parent-mediated behavioral interventions NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks) Questionnaire Attention on-task parent supervised NA    1.0000000 h/wk Pisterman,1992,NA RCT (parallel, crossover, open-label),G  23  22   45,outcomes,NA,-0.5987930085,-2.529496282  1.331910e+00, 65.0000000 126.1000000,40.10 30.900,47.20,29.400 NA NA 100,100 100   0,  0,100 100 some,high,high,low some WLC (wait-list control),  0  15.800000  4.146000,103.44333 DSM-III,3 0,1.0 0.5 1.0,0.0 0,1,2 1 1,1,1 1.0,0 0 1,1  970,Pisterman_1992 NA,Average (80-119),< 6 yo 3.5 4.46,103.4433333 103.4433333, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo,100.00000,no,low low
 973 Doffer - Preschool (2023) Doffer - Preschool 2023 10.1002/jcv2.12196 100 100 100 100,Critically low,Parent-mediated behavioral interventions NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks) Questionnaire,Attention on-task independent,NA    1.0000000 h/wk Pisterman 1992 NA RCT (parallel, crossover, open-label),G  23, 22,  45 outcomes NA,-0.6833348711,-1.784832907, 4.181632e-01  32.0000000, 56.7000000 30.20 22.400,26.10,24.000,NA NA,100 100,100,  0,  0,100,100 some high high,low some WLC (wait-list control),  0, 15.800000, 4.146000,103.44333 DSM-III,3 0,1.0 0.5 1.0,0.0 0,1,2 1 1 1,1 1.0 0,0 1 1  971,Pisterman_1992,NA,Average (80-119),< 6 yo 3.5,4.46,103.4433333 103.4433333  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21 Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo,100.00000 no low,low
 973 Doffer - Preschool (2023) Doffer - Preschool 2023,10.1002/jcv2.12196 100 100 100 100 Critically low,Parent-mediated behavioral interventions NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks),Questionnaire,Attention free play,NA    1.0000000,h/wk Pisterman,1992 NA RCT (parallel, crossover, open-label) G, 23  22,  45 outcomes NA -0.5036784710,-1.148610777, 1.412538e-01, 30.0000000  38.9000000 72.00,51.100 59.90,30.800 NA NA,100 100 100   0,  0,100,100 some,high,high low,some WLC (wait-list control)   0  15.800000  4.146000 103.44333,DSM-III,3 0 1.0,0.5 1.0 0.0,0 1,2 1 1,1,1 1.0,0 0,1 1, 972,Pisterman_1992 NA Average (80-119) < 6 yo 3.5,4.46 103.4433333,103.4433333  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15 108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo 100.00000 no,low,low
 973,Doffer (2023) Doffer,2023,10.1002/jcv2.12196,100,100 100,100 Critically low,Parent-mediated behavioral interventions,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks Questionnaire DBD-Total,NA,   0.8333333,h/wk,Sibley,2016 NA RCT (parallel, crossover, open-label) G, 55, 51  106 outcomes,NA, 0.5549293816, 0.135308199  9.745506e-01   0.6000000,  0.5100000  1.85, 0.600, 1.87, 0.620,NA,NA   0,  0 100,  0 100 100   0,some high,low,high some TAU,  0  35.130469,12.745313 100.76367 DSM-IV 3,0,1.0 0.5,1.0 0.0,0,1,2,1 1,1,1,1.0,0,0 1,1, 973 Sibley_2016,NA Average (80-119),6-12 yo,8.6368,13.97,94.15 104.416  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000 no low high
 973,Doffer (2023) Doffer,2023 10.1002/jcv2.12196 100 100,100,100,Critically low Parent-mediated behavioral interventions NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,Closest to 52 weeks,Questionnaire DBD-Total NA    0.8333333,h/wk,Sibley,2016,NA,RCT (parallel, crossover, open-label),G, 55  51  106,outcomes NA  0.1253795149 -0.297280155, 5.480392e-01,  0.7200000   0.7200000  1.52  0.730, 1.54  0.620,NA,NA   0,  0 100,  0 100,100   0,some high,low,high some TAU   0, 35.130469 12.745313 100.76367 DSM-IV 3 0,1.0,0.5 1.0 0.0,0,1,2,1,1,1 1 1.0 0,0,1 1  974,Sibley_2016 NA Average (80-119) 6-12 yo,8.6368,13.97,94.15,104.416  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1 Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000,no,low high
 973 Doffer (2023) Doffer 2023 10.1002/jcv2.12196 100,100,100 100,Critically low Parent-mediated behavioral interventions,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,Closest to 52 weeks,Questionnaire,C3RS-H/I,NA,   1.0000000,h/wk,Sibley 2021,NA,RCT (parallel, crossover, open-label),G 138,140  278 outcomes NA  0.0935879873 -0.142079773  3.292557e-01  16.7100000, 15.3300000 65.37 17.190 63.02,16.710,NA NA   0,  0   0   0 100,100 100 high,high low low,low,TAU,  0, 29.700000 13.970000, 94.15000,DSM-V,3 0 1.0 0.5,1.0 0.0,0,1,2 1 1 1 1,1.0 0,0 1,1  975 Sibley_2021 NA Average (80-119),13-19 yo 8.6368,13.97 94.15,104.416  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21 Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1 Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no low high
 973 Doffer (2023) Doffer 2023 10.1002/jcv2.12196 100 100 100 100,Critically low Parent-mediated behavioral interventions,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,Closest to 52 weeks Questionnaire DSM-checklist-H/I-p NA    1.0000000 h/wk,Sibley 2021,NA RCT (parallel, crossover, open-label),G 138 140, 278 outcomes NA  0.0969748625,-0.140498045, 3.344478e-01   0.6900000,  0.7800000  1.02  0.790, 1.06, 0.780 NA NA,  0   0,  0,  0 100,100,100,high high,low,low,low,TAU,  0  29.700000 13.970000  94.15000 DSM-V 3 0,1.0,0.5,1.0 0.0 0 1 2 1,1,1 1,1.0,0,0,1 1, 976,Sibley_2021,NA,Average (80-119) 13-19 yo 8.6368,13.97 94.15 104.416, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000,no low,high
 973 Doffer (2023) Doffer 2023 10.1002/jcv2.12196 100,100 100 100 Critically low Parent-mediated behavioral interventions NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,Closest to 52 weeks,Questionnaire,DSM-checklist-H/I-t NA,   1.0000000 h/wk,Sibley,2021 NA,RCT (parallel, crossover, open-label),G 138,140, 278 outcomes,NA  0.0003843142,-0.235723607  2.364922e-01   0.7000000   0.7200000, 0.99, 0.870  0.90  0.810,NA NA,  0,  0,  0,  0 100 100,100,high high,low,low,low TAU,  0  29.700000 13.970000  94.15000,DSM-V 3,0 1.0,0.5,1.0 0.0 0 1,2 1 1,1 1,1.0,0 0,1,1, 977 Sibley_2021,NA,Average (80-119),13-19 yo,8.6368 13.97,94.15 104.416, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21 Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no low,high
 973,Doffer (2023) Doffer 2023,10.1002/jcv2.12196,100,100,100 100 Critically low Parent-mediated behavioral interventions,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated Closest to 52 weeks,Questionnaire,C3RS-I NA,   1.0000000 h/wk,Sibley 2021,NA RCT (parallel, crossover, open-label),G,138 140, 278 outcomes,NA  0.0420413916 -0.232863042, 3.169458e-01  14.6700000, 13.8400000,75.51 13.320 73.74 12.660 NA,NA,  0   0,  0,  0 100,100 100 high,high,low low,low TAU   0, 29.700000 13.970000, 94.15000,DSM-V,3,0 1.0 0.5,1.0,0.0,0 1 2,1 1 1,1 1.0 0 0 1,1, 978,Sibley_2021 NA,Average (80-119),13-19 yo,8.6368 13.97,94.15 104.416  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1,Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000,no low,high
 973 Doffer (2023),Doffer,2023,10.1002/jcv2.12196 100,100,100 100 Critically low Parent-mediated behavioral interventions NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,Closest to 52 weeks,Questionnaire DSM-checklist-I-p,NA,   1.0000000,h/wk,Sibley,2021,NA RCT (parallel, crossover, open-label),G 138 140  278,outcomes,NA, 0.1822005127,-0.093174112, 4.575751e-01,  0.6500000   0.7400000, 1.92, 0.690, 2.00, 0.660,NA,NA   0,  0,  0,  0 100 100 100 high,high low low,low TAU   0, 29.700000,13.970000  94.15000 DSM-V,3,0,1.0,0.5 1.0 0.0,0 1 2,1,1,1 1,1.0 0,0 1 1, 979,Sibley_2021,NA,Average (80-119) 13-19 yo,8.6368 13.97 94.15,104.416  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1 Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000,no low high
 973,Doffer (2023),Doffer 2023,10.1002/jcv2.12196,100,100 100 100,Critically low,Parent-mediated behavioral interventions,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,Closest to 52 weeks,Questionnaire DSM-checklist-I-t,NA,   1.0000000 h/wk Sibley,2021,NA,RCT (parallel, crossover, open-label) G,138 140  278 outcomes,NA, 0.0683508079 -0.214705343  3.514070e-01,  0.8300000,  0.8000000  1.84  0.660, 1.63  0.650,NA NA,  0,  0   0   0 100,100,100,high,high,low low low,TAU,  0, 29.700000,13.970000  94.15000,DSM-V,3 0,1.0 0.5 1.0 0.0 0,1,2,1,1 1,1,1.0 0,0 1 1  980 Sibley_2021 NA,Average (80-119) 13-19 yo 8.6368,13.97 94.15,104.416, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21 Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1,Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000,no,low,high
 973 Doffer - Preschool (2023),Doffer - Preschool,2023 10.1002/jcv2.12196 100   0 100 100 Critically low Parent-mediated behavioral interventions,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks) Questionnaire,PACS-ADHD NA    1.0000000,h/wk Sonuga-Barke,2004,NA,RCT (parallel, crossover, open-label),G  59  30   89,outcomes,NA, 0.6410065765,-0.085909944  1.367923e+00,  0.7830000,  0.2980000, 2.26  0.333  2.07, 0.202,NA NA,100 100 100   0 100 100 100 some high low,low some WLC (wait-list control),  0,NA  3.500000,NA,DSM-IV,3 0,1.0 0.5 1.0,0.0,0,1,2 1,1,1,1 1.0,0 0 1,1, 981,Sonuga-Barke_2004 NA,NA < 6 yo,3.5,4.46,103.4433333,103.4433333, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo,100.00000 no,low,low
 973 Doffer - Preschool (2023),Doffer - Preschool 2023,10.1002/jcv2.12196,100   0,100,100 Critically low,Parent-mediated behavioral interventions NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),Questionnaire WWP,NA,   1.0000000 h/wk,Sonuga-Barke,2004 NA RCT (parallel, crossover, open-label) G, 59, 30,  89,outcomes,NA,-0.0825475740,-0.826880975  6.617858e-01  11.2470000   8.1560000,28.18  5.623 30.97, 4.832,NA,NA,100 100 100,  0 100 100 100,some,high,low,low,some,WLC (wait-list control)   0,NA  3.500000,NA,DSM-IV,3,0,1.0,0.5 1.0 0.0,0 1 2 1 1,1,1 1.0 0,0 1,1  982 Sonuga-Barke_2004 NA,NA,< 6 yo,3.5,4.46 103.4433333 103.4433333  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo 100.00000,no low,low
 973,Doffer - Preschool (2023) Doffer - Preschool,2023 10.1002/jcv2.12196 100   0,100 100,Critically low Parent-mediated behavioral interventions,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks) Questionnaire,BCL-Hyperactivity NA,   1.0000000,h/wk,Sonuga-Barke 2004,NA RCT (parallel, crossover, open-label),G, 59  30,  89 outcomes NA  0.7279114069, 0.207791210  1.248032e+00,  1.6450000,  0.8790000, 3.83, 1.822, 3.57, 0.742 NA NA 100,100 100   0,100,100 100 some high low low some,WLC (wait-list control),  0 NA, 3.500000,NA,DSM-IV 3,0,1.0,0.5 1.0,0.0 0,1 2 1,1 1 1,1.0,0,0,1 1, 983,Sonuga-Barke_2004 NA NA,< 6 yo 3.5 4.46 103.4433333,103.4433333  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo 100.00000 no low low
 973,Doffer - Preschool (2023) Doffer - Preschool 2023,10.1002/jcv2.12196,100   0,100,100 Critically low Parent-mediated behavioral interventions,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks) Questionnaire,PACS-ADHD NA    1.2500000 h/wk Thompson 2009 NA,RCT (parallel, crossover, open-label) G  17  13   30,outcomes NA, 0.8542048151, 0.001501114  1.706909e+00   3.9900000   6.9300000,16.81, 6.100,17.77  6.020,NA NA 100,100 100   0   0 100 100,some,high high,low,some,TAU,  0, 24.400000, 4.460000,NA,DSM-IV,3,0 1.0 0.5,1.0 0.0,0 1,2,1,1 1,1 1.0,0 0,1,1, 984,Thompson_2009,NA NA,< 6 yo 3.5,4.46,103.4433333 103.4433333  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo,100.00000,no low low
 973 Doffer - Preschool (2023) Doffer - Preschool,2023 10.1002/jcv2.12196 100   0 100 100,Critically low,Parent-mediated behavioral interventions NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks),Questionnaire WWP,NA,   1.2500000,h/wk,Thompson,2009 NA,RCT (parallel, crossover, open-label) G  17  13   30 outcomes NA, 1.2338432246, 0.252271392  2.215415e+00  12.9300000   9.4400000 32.35  9.960,29.54  8.110 NA NA,100,100 100   0   0,100,100 some,high,high,low some TAU,  0, 24.400000  4.460000,NA,DSM-IV,3 0 1.0,0.5 1.0 0.0 0 1,2 1 1 1 1 1.0,0,0 1 1, 985,Thompson_2009,NA NA,< 6 yo,3.5 4.46,103.4433333,103.4433333, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo 100.00000 no low low
 973 Doffer - Preschool (2023),Doffer - Preschool 2023,10.1002/jcv2.12196,100   0 100,100,Critically low,Parent-mediated behavioral interventions,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),Questionnaire Observation FarmYard NA    1.2500000,h/wk Thompson,2009,NA RCT (parallel, crossover, open-label),G  17, 13   30 outcomes NA,-1.0633595591,-2.368632648  2.419135e-01   1.1100000,  0.8800000  4.09, 0.800  4.34  0.450 NA NA 100,100 100   0   0,100,100 some high high,low some,TAU   0  24.400000, 4.460000,NA DSM-IV,3,0,1.0,0.5,1.0,0.0,0,1 2 1 1,1,1,1.0,0,0 1 1  986,Thompson_2009 NA NA < 6 yo 3.5,4.46 103.4433333,103.4433333, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15 108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo 100.00000 no low,low
 973 Doffer (2023) Doffer,2023,10.1002/jcv2.12196 100,  0 100,100 Critically low Parent-mediated behavioral interventions,NA,  0 NA Oppositional Defiant Disorder symptoms Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,DBD-ODD NA,   2.5000000,h/wk Chacko,2009 NA,RCT (parallel, crossover, open-label) G, 40  40,  80 outcomes NA  0.2348050260,-0.205169997  6.747800e-01,  0.6500000   0.7200000  1.75  0.720, 1.54, 0.750,NA NA,100,100,100,  0,100,100,100,some,high,low,low some,WLC (wait-list control),  0, 29.333000  7.850000 NA,DSM-IV 3 0,1.0 0.5 1.0 0.0,0,1 2,1 1 1,1 1.0,0 0 1 1  987 Chacko_2009 NA NA 6-12 yo 7.85 10.71217391 94.58724638 94.58724638  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,low
 973,Doffer (2023),Doffer,2023,10.1002/jcv2.12196 100   0 100 100 Critically low,Parent-mediated behavioral interventions,NA,  0,NA Oppositional Defiant Disorder symptoms,Parent-rated,At follow-up (closest to 26 weeks),Questionnaire DBD-ODD,NA    2.5000000,h/wk,Chacko,2009 NA RCT (parallel, crossover, open-label),G, 40, 40   80 outcomes,NA  0.4189681530 -0.022282655, 8.602190e-01,  0.6200000,  0.7200000  1.51  0.690  1.54, 0.750,NA,NA,100,100,100   0 100 100,100 some,high,low,low some,WLC (wait-list control),  0, 29.333000  7.850000 NA,DSM-IV 3 0,1.0,0.5,1.0,0.0,0 1,2 1,1 1,1,1.0,0 0,1,1, 988,Chacko_2009,NA,NA 6-12 yo,7.85 10.71217391,94.58724638 94.58724638  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21 Doffer (2023)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low,low
 973,Doffer (2023) Doffer,2023 10.1002/jcv2.12196,100,100,100 100,Critically low Parent-mediated behavioral interventions,NA   0 NA,Oppositional Defiant Disorder symptoms Parent-rated,At follow-up (closest to 26 weeks),Questionnaire CPRS-Opposition NA,   2.0000000 h/wk,Ferrin,2016,NA RCT (parallel, crossover, open-label) G  35, 34,  69 outcomes,NA  0.2667691422 -0.252396099, 7.859344e-01,  4.1500000,  4.6200000,12.57  4.390 12.79  3.830,NA,NA,  0   0,100   0 100 100   0 low,high low,high,low TAU,  0, 13.010145,10.712174  94.58725,DSM-IV,3 0,1.0,0.5 1.0,0.0 0 1 2,1,1 1 1,1.0,0 0 1 1  989 Ferrin_2016 NA Average (80-119) 6-12 yo,7.85,10.71217391 94.58724638 94.58724638  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15 108.21 Doffer (2023)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low high
2027 Lenzi (2018) Lenzi 2018 10.1016/j.neubiorev.2017.08.010,100,  0 100 100,Critically low Atomoxetine,NA   0,NA Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks) NA,BRIEF-A (self-reported and informant), 2.30149597,  80.0000000,mg/d Goto,2017,NA NA,SMD 193,195  388,NA,reverse,-0.3300000000,-0.530000000,-1.300000e-01,NA,NA,NA,NA,NA NA NA NA,100 100 100,100 100 100 100,some,some,low some some Placebo,  0  52.344588 32.247165 NA,NA,2,1 1.0,1.0 1.0 0.0 0,1,3 1 1 1,1 1.0 0 0 0 1, 990,Goto_2017,2-6 months,NA >= 20 yo 24,41.1758252427185,NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Lenzi (2018) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
2027,Lenzi (2018),Lenzi,2018,10.1016/j.neubiorev.2017.08.010 100,  0 100,100,Critically low,Atomoxetine NA   0 NA,Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks) NA BADDS,NA, 100.0000000 mg/d Brown 2011 NA,NA,SMD 250,251, 501 NA,reverse,-0.3300000000,-0.530000000,-1.300000e-01,NA NA NA NA NA,NA,NA NA 100 100 100,100,100 100 100 low,low some some,some,Placebo   0  50.000000,37.549701,NA NA 2,1,1.0,1.0,1.0 0.0 0,1,3,1,1 1,1,1.0 0 0,0,1  991,Brown_2011 NA,NA,>= 20 yo,24 41.1758252427185,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Lenzi (2018) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
2027,Lenzi (2018),Lenzi 2018,10.1016/j.neubiorev.2017.08.010,100,  0 100 100 Critically low,Atomoxetine NA,  0 NA Emotional dysregulation Mixed At study endpoint (closest to 12 weeks) NA,WRAADDS, 2.30149597   90.0000000,mg/d Robison 2008 NA,NA,SMD 257 258, 515 NA reverse,-0.3100000000 -0.700000000  8.000000e-02 NA NA,NA,NA NA NA NA,NA 100,100 100,100,100,100 100 low low low,low some,Placebo,  0  34.000000,41.175825,NA NA 2,1,1.0,1.0,1.0 0.0 0 1,3 1 1 1,1,1.0,0,0,0 1, 992,Robison_2008 2-6 months,NA >= 20 yo 24,41.1758252427185 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA,Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Lenzi (2018) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2027 Lenzi (2018),Lenzi,2018 10.1016/j.neubiorev.2017.08.010 100,  0,100,100,Critically low Atomoxetine NA,  0,NA,Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks) NA BRIEF-A NA  100.0000000,mg/d Adler 2014b,NA NA,SMD,266,258  524,NA,reverse -0.2000000000,-0.400000000, 0.000000e+00,NA,NA NA,NA,NA NA,NA NA,100 100,100 100 100 100,100 some low low,low some,Placebo,  0  41.575191,33.059924,NA,NA 2,1,1.0 1.0,1.0 0.0 0,1,3,1 1,1,1,1.0,0,0,0 1  993,Adler_2014b NA NA,>= 20 yo,24 41.1758252427185 NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA,Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Lenzi (2018) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
2027 Lenzi (2018) Lenzi,2018,10.1016/j.neubiorev.2017.08.010 100   0,100 100 Critically low,Atomoxetine NA,  0,NA Emotional dysregulation Mixed At study endpoint (closest to 12 weeks),NA BRIEF-A, 2.76179517,  50.0000000,mg/dbid Adler 2014a NA,NA SMD 220 225, 445 NA reverse,-0.1000000000 -0.300000000, 1.000000e-01,NA,NA,NA NA NA NA,NA NA,100 100,100 100 100,100 100,low,low,low,some some,Placebo   0  41.800000,24.000000 NA,NA 2 1 1.0,1.0 1.0 0.0,0 1,3,1 1 1 1 1.0,0 0,0 1  994 Adler_2014a,2-6 months,NA,>= 20 yo 24,41.1758252427185 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Lenzi (2018) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
2027 Lenzi (2018),Lenzi,2018 10.1016/j.neubiorev.2017.08.010 100   0,100 100 Critically low Amphetamine NA   0,NA Emotional dysregulation Mixed At study endpoint (closest to 12 weeks) NA BADDS, 0.92059839   70.0000000,mg/d,Waxmonsky 2014 NA NA,SMD  14  14,  28 NA,reverse -0.8100000000,-1.670000000  5.000000e-02 NA NA NA NA NA,NA,NA NA 100 100 100 100,100 100,100,some,some,some,some some,Placebo,  0  51.500000,40.700000,NA NA 2 1,1.0 1.0,1.0,0.0,0 1 3,1 1,1,1 1.0 0,0 0,1  995,Waxmonsky_2014 < 2 months,NA >= 20 yo,20.085,40.7 NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Lenzi (2018)_Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Lenzi (2018) - Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
2027,Lenzi (2018),Lenzi,2018 10.1016/j.neubiorev.2017.08.010,100,  0,100 100 Critically low,Amphetamine,NA,  0 NA,Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks) NA,BRIEF-A  2.30149597   70.0000000 mg/d Adler 2013 NA,NA SMD, 79  80  159 NA reverse -0.4600000000,-0.770000000 -1.500000e-01 NA,NA,NA NA,NA,NA NA,NA 100 100,100 100 100 100,100 low,low,low some,some,Placebo   0, 47.789937 34.552201,NA,NA 2 1,1.0,1.0 1.0 0.0 0,1,3 1 1 1,1 1.0 0,0,0,1, 996,Adler_2013,2-6 months NA,>= 20 yo,20.085,40.7,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Lenzi (2018)_Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Lenzi (2018) - Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
2027 Lenzi (2018),Lenzi 2018,10.1016/j.neubiorev.2017.08.010 100   0,100,100 Critically low,Amphetamine NA,  0,NA,Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks) NA,CAARS, BRIEF-A, 3.68239356   70.0000000,mg/d DuPaul 2012 NA NA SMD, 24, 24   48 NA reverse,-0.2400000000 -0.360000000 -1.200000e-01,NA,NA NA,NA NA NA NA NA,100 100,100 100,100 100 100,some some some,low some,Placebo,  0  41.750000,20.085000,NA,NA 2,1 1.0,1.0,1.0,0.0,0,1 3,1 1,1,1,1.0 0,0 0,1, 997 DuPaul_2012 2-6 months,NA,>= 20 yo,20.085,40.7,NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Lenzi (2018)_Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Lenzi (2018) - Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2902 Radonjic (2023),Radonjic,2023 10.1007/s40263-023-01005-8 100   0,100 100 Critically low,Alpha-2 agonists (guanfacine / clonidine),Guanfacine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),NA,ADHD-RS Total NA NA,NA Iwanami 2020,NA RCT (parallel, crossover, open-label) G,101 100, 201 NA reverse -0.6628000000,-0.970900000,-3.548000e-01   5.9300000   6.8300000 NA NA,NA NA NA,NA   0,  0,  0 100,  0   0,  0 high,low high,high high,Placebo   0  35.500000,33.800000,NA DSM-V 2 1 1.0,0.0 1.0 0.5 0 1 3 1 1,1 1,1.0 0 0,0 1  998 Iwanami_2020,NA NA,>= 20 yo 33.8,41.2,NA,NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA NA,Radonjic (2023)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Radonjic (2023) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
2902 Radonjic (2023),Radonjic 2023,10.1007/s40263-023-01005-8 100,  0 100 100 Critically low,Alpha-2 agonists (guanfacine / clonidine),Guanfacine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) NA,ADHD Behavior Checklist for Adults, 0.46029919    1.1000000,mg,Taylor 2021,NA RCT (parallel, crossover, open-label) G  17  17   34 NA reverse,-0.6494000000,-1.340000000  4.120000e-02,  8.2000000  10.6000000 NA,NA,NA NA,NA NA,100 100 100,100,100 100,100,some,low some some,some,Placebo   0  59.000000,41.200000,NA,DSM/ICD,2,1,1.0,0.0 1.0 0.5,0 1,3,1,1 1,1 1.0,0,0,0,1, 999,Taylor_2021 < 2 months,NA >= 20 yo 33.8,41.2 NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA NA,Radonjic (2023)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Radonjic (2023) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
3448 Sugaya (2023) Sugaya 2023 10.1002/jcv2.12146 100   0 100 100,Low Methylphenidate MPH-IR,  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA NA  0.92059839,  14.2000000 mg/d,Greenhill 2006,NA,RCT (parallel, crossover, open-label) RR  61, 53, 114 NA reverse  0.3258196721, 0.166410122, 6.379327e-01,NA,NA,NA NA NA,NA,NA NA 100,100,100,100,  0 100 100 low,low,high,low,some,Placebo,  0, 25.000000, 4.760000 NA,NA,1 1,1.0,0.0,1.0,1.0,1,1 0,1 1 1,1 1.0 1 1 1 1,1000,Greenhill_2006,< 2 months NA,< 6 yo,4.76 5.02 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Sugaya (2023)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Sugaya (2023) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000,no low low
3448 Sugaya (2023),Sugaya 2023,10.1002/jcv2.12146 100   0,100 100 Low,Methylphenidate MPH-IR   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA  1.84119678   26.9900000,mg/d Sugaya 2022,NA RCT (parallel, crossover, open-label),RR, 51  51  102 NA reverse, 0.5000000000  0.095794107, 2.609764e+00,NA,NA NA,NA NA NA NA NA,100,100,100 100,100 100 100,low low,low low,low,Placebo   0  17.000000, 5.020000,NA,NA 1 1,1.0 0.0 1.0,1.0 1 1,0 1,1 1 1 1.0 1,1 1 1 1001,Sugaya_2022 < 2 months,NA,< 6 yo,4.76,5.02 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Sugaya (2023)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Sugaya (2023) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no,low,low
 474,Bryant (2021) Bryant 2021,10.1007/s00787-022-02004-8 100,  0 100 100 Critically low Methylphenidate NA,  0 NA,Generalized anxiety,Mixed,At study endpoint (closest to 12 weeks),NA,RBPC -Anxiety/ Withdrawal scale  0.92059839    0.4000000,mg/kg Aman 1993 NA RCT (parallel, crossover, open-label) SMD  28  28   56 NA reverse -0.3200000000,-0.850000000  2.000000e-01   0.4000000,  0.6100000,NA,NA NA NA NA,NA 100 100 100 100,  0,100 100 some low high,low,some Placebo,  0  28.600000, 8.800000 NA,DSM 4,1,0.0,0.0,1.0 1.0 0,0,6,1 1 0 0,1.0,0,0,0,0 1002,Aman_1993 < 2 months,NA,6-12 yo,8.8,13.6,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Bryant (2021)_Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Bryant (2021) - Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 474 Bryant (2021),Bryant 2021,10.1007/s00787-022-02004-8 100   0,100 100 Critically low Methylphenidate NA   0,NA Generalized anxiety,Mixed,At study endpoint (closest to 12 weeks) NA,CPRS - Anxiety subscale, 1.84119678    0.3250000 mg/kg,Brown 1988 NA RCT (parallel, crossover, open-label),SMD  11, 11   22,NA reverse,-1.1600000000 -2.080000000,-2.400000e-01,  0.8300000,  0.5100000,NA NA,NA,NA,NA NA 100,100,100   0   0 100,100,some,high,high low some Placebo   0,  0.000000,13.600000,NA DSM 4,1,0.0 0.0 1.0,1.0 0 0 6 1,1 0 0 1.0 0,0,0,0,1003 Brown_1988 < 2 months,NA 13-19 yo,8.8,13.6,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Bryant (2021)_Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Bryant (2021) - Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 474,Bryant (2021) Bryant 2021,10.1007/s00787-022-02004-8,100   0 100,100,Critically low,Atomoxetine NA,  0 NA,Generalized anxiety Mixed,At study endpoint (closest to 12 weeks),NA,SCARED, 1.84119678    1.2000000,mg/kg DellAgnello 2009 NA RCT (parallel, crossover, open-label) SMD 103, 32  135,NA reverse,-0.0500000000,-0.450000000  3.400000e-01   7.6000000,  6.5000000 NA,NA,NA,NA,NA,NA 100,100 100,100 100,100,100 some low low,low some,Placebo   0   7.300000  9.800000,NA DSM,4 1 0.0 0.0 1.0,1.0,0,0,6 1,1 0 0 1.0,0,0 0 0,1004,DellAgnello_2009 < 2 months,NA,6-12 yo 9.8,12 NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA Bryant (2021)_Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Bryant (2021) - Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 474 Bryant (2021),Bryant,2021,10.1007/s00787-022-02004-8,100   0,100 100,Critically low,Atomoxetine,NA   0,NA Generalized anxiety,Mixed At study endpoint (closest to 12 weeks) NA MASC, 2.30149597    1.2000000 mg/kg,Geller,2007,NA RCT (parallel, crossover, open-label),SMD, 75  76, 151,NA,reverse,-0.4700000000 -0.800000000,-1.500000e-01  15.2000000  12.8000000,NA,NA,NA NA,NA NA,100,100 100 100,100 100,100,some low low low some Placebo,  0  35.200000,12.000000,NA DSM 4,1,0.0 0.0,1.0 1.0 0,0 6,1,1 0 0,1.0,0,0 0,0 1005 Geller_2007 2-6 months NA 6-12 yo 9.8,12 NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Bryant (2021)_Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Bryant (2021) - Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 474 Bryant (2021) Bryant 2021 10.1007/s00787-022-02004-8 100,  0,100,100,Critically low Atomoxetine NA,  0,NA Generalized anxiety,Mixed,At study endpoint (closest to 12 weeks) NA STAI and STAI-C  1.38089758,   1.3500000 mg/kg Griffiths 2018 NA RCT (parallel, crossover, open-label) SMD,103,109  212,NA reverse, 0.0000000000 -0.270000000  2.600000e-01,  5.7600000,  6.3000000 NA NA,NA,NA,NA NA,100,100,100,100,100 100 100,low low,low low,some Placebo   0  21.500000,11.280000,NA DSM 4 1 0.0 0.0 1.0 1.0 0 0 6,1 1 0,0 1.0,0 0,0 0,1006 Griffiths_2018 < 2 months,NA,6-12 yo 9.8,12 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA,Bryant (2021)_Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Bryant (2021) - Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 474,Bryant (2021) Bryant 2021 10.1007/s00787-022-02004-8,100,  0,100,100,Critically low Methylphenidate NA   0,NA Generalized anxiety Mixed,At study endpoint (closest to 12 weeks) NA CBRS, 1.84119678   36.0000000,mg/d Lin 2014,NA,RCT (parallel, crossover, open-label) SMD  24  60   84 NA reverse, 0.0400000000 -0.440000000, 5.100000e-01,  8.3100000,  8.0000000 NA NA NA NA,NA NA,100 100,100,100 100 100 100,low low,low,low,low,Placebo   0, 29.900000,10.920000 NA DSM,4 1 0.0 0.0 1.0 1.0 0 0,6,1 1,0 0 1.0,0 0,0 0 1007,Lin_2014,< 2 months,NA,6-12 yo 8.8 13.6,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Bryant (2021)_Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Bryant (2021) - Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 474 Bryant (2021),Bryant,2021 10.1007/s00787-022-02004-8,100   0,100,100,Critically low Atomoxetine,NA,  0,NA,Depressive disorder symptoms Mixed,At study endpoint (closest to 12 weeks),NA,CDRS-R, 2.07134638,   1.5000000 mg/kg,Bangs,2007 NA RCT (parallel, crossover, open-label) SMD, 59  61, 120,NA reverse -0.1700000000 -0.530000000  1.900000e-01, 13.2600000, 10.4300000 NA NA,NA NA NA NA,100,100 100 100,100 100,100 some low,low,low,some Placebo   0, 26.800000,14.400000,NA,DSM,4,1,0.0,0.0 1.0 1.0,0 0 6 1,1 0 0,1.0 0 0 0 0,1008 Bangs_2007,2-6 months,NA,13-19 yo,9.8,14.4 NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA,Bryant (2021)_Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Bryant (2021) - Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 474,Bryant (2021) Bryant 2021,10.1007/s00787-022-02004-8,100   0,100,100 Critically low Atomoxetine,NA,  0,NA Depressive disorder symptoms Mixed,At study endpoint (closest to 12 weeks) NA,CDRS-R, 1.84119678    1.2000000,mg/kg,DellAgnello,2009 NA,RCT (parallel, crossover, open-label),SMD,105, 32, 137 NA,reverse -0.0900000000 -0.480000000, 3.100000e-01,  4.4000000 114.0000000,NA,NA NA,NA,NA,NA 100,100 100,100,100 100,100 some low low low,some,Placebo   0,  7.300000, 9.800000 NA DSM 4 1,0.0 0.0,1.0,1.0,0 0,6,1 1 0 0 1.0,0 0 0,0 1009 DellAgnello_2009 < 2 months NA 6-12 yo,9.8 14.4,NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA,Bryant (2021)_Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Bryant (2021) - Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 474 Bryant (2021) Bryant,2021,10.1007/s00787-022-02004-8 100   0 100,100,Critically low,Atomoxetine,NA,  0,NA,Depressive disorder symptoms Mixed At study endpoint (closest to 12 weeks),NA DASS, 1.38089758,   1.3500000 mg/kg,Griffiths,2018,NA RCT (parallel, crossover, open-label) SMD,111 114, 225 NA reverse, 0.0300000000,-0.230000000, 2.900000e-01   4.2300000,  4.1300000,NA NA NA NA NA,NA,100,100 100 100 100 100,100 low,low low low,some,Placebo   0  21.500000,11.280000,NA,DSM 4 1,0.0,0.0 1.0,1.0 0,0,6,1,1 0,0 1.0 0 0 0 0 1010 Griffiths_2018,< 2 months,NA,6-12 yo 9.8,14.4 NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Bryant (2021)_Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Bryant (2021) - Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 474 Bryant (2021) Bryant,2021,10.1007/s00787-022-02004-8 100   0,100,100 Critically low,Atomoxetine NA,  0 NA Depressive disorder symptoms Mixed At study endpoint (closest to 12 weeks) NA,CDRS-R, 1.84119678    1.1500000 mg/kg,Michelson,2001,NA,RCT (parallel, crossover, open-label),SMD,209  83, 292 NA reverse -0.3600000000 -0.620000000,-1.000000e-01,  7.3100000,  6.4000000,NA NA NA NA NA NA 100 100,100 100,100,100,100,some,low low some some,Placebo   0, 28.400000 11.000000 NA DSM,4,1 0.0 0.0,1.0,1.0 0 0 6,1,1,0,0,1.0 0,0 0 0 1011 Michelson_2001,< 2 months NA,6-12 yo 9.8,14.4 NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA Bryant (2021)_Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Bryant (2021) - Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 662,Chiu (2022),Chiu,2022 10.1192/j.eurpsy.2023.11,100 100 100,100 High,Methylphenidate MPH IR,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire SWAN total, inattention, hyperactivity/impulsivity  0.92059839,NA NA Abikoff 2007 NA RCT (parallel, crossover, open-label),G, 48  38   86 NA NA  0.2100000000 -0.210000000  6.400000e-01,  0.6900000,  0.7000000,NA NA NA NA,NA NA,100,100,100 100,  0,100 100 low low high,low,low,Placebo   0, 25.400000, 4.420000, 97.41000,DSM-IV,0 1,1.0,1.0 1.0 0.5 1 1,1,1 1 1,1 1.0,0,1 1,1 1012 Abikoff_2007 < 2 months,Average (80-119) < 6 yo 4.42 5.25,97.41,97.93 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000,no,low low
 662 Chiu (2022),Chiu 2022,10.1192/j.eurpsy.2023.11,100,100 100,100,High,Methylphenidate,MPH IR,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire CLAM/SKAMP composite, SKAMP Attention and SKAMP Deportment  0.23014960   12.3750000,mg/d Greenhill,2006 NA RCT (parallel, crossover, open-label) G 165,165, 330 NA NA  0.4300000000  0.210000000  6.500000e-01   0.6000000   0.6000000,NA NA,NA NA NA NA 100,100,100,100,100,100 100,low,low,low,low low,Placebo   0  26.000000, 4.740000, 97.93000,DSM-IV,0 1,1.0 1.0 1.0 0.5,1 1,1 1,1,1 1 1.0 0 1,1 1,1013 Greenhill_2006 < 2 months,Average (80-119),< 6 yo 4.42,5.25 97.41 97.93 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000,no low,low
 662,Chiu (2022) Chiu,2022 10.1192/j.eurpsy.2023.11 100   0,100,100,High Methylphenidate,MPH-MLR   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,ADHD-RS-IV total score  0.46029919,  27.5000000 mg/d Childress,2020 NA RCT (parallel, crossover, open-label) G  39  50   89,NA NA, 0.6100000000  0.180000000, 1.040000e+00, 23.0000000, 13.5800000,NA NA,NA,NA NA NA,100,100,100,100,100 100 100,some,low,low low,low Placebo   0 NA  4.900000 NA DSM-5 0,1,1.0,1.0,1.0 0.5 1 1 1,1 1 1 1,1.0 0 1 1 1,1014 Childress_2020,< 2 months,NA < 6 yo,4.42,5.25 97.41,97.93 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000,no,low,low
 662,Chiu (2022),Chiu,2022 10.1192/j.eurpsy.2023.11,100,  0,100 100,High Methylphenidate MPH IR,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire CPRS Learning, conduct and hyperactivity index  0.23014960,   0.4000000 mg/kg,Musten 1997,NA,RCT (parallel, crossover, open-label) G  31, 31   62 NA,NA, 0.7300000000, 0.210000000, 1.240000e+00  15.5700000  15.2500000,NA NA NA NA NA,NA 100 100 100 100,  0 100,100,some low high low,low,Placebo   0,NA, 4.890000 NA,DSM-III-R 0 1 1.0,1.0 1.0 0.5,1,1,1,1 1 1 1,1.0,0,1,1,1 1015,Musten_1997 < 2 months,NA < 6 yo,4.42 5.25 97.41,97.93,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000,no low,low
 662,Chiu (2022),Chiu 2022 10.1192/j.eurpsy.2023.11 100   0,100 100 High Methylphenidate MPH IR or MAS,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,NA  0.92059839,NA NA,Short,2004,NA RCT (parallel, crossover, open-label),G  28  28,  56 NA,NA  1.3800000000, 0.790000000  1.960000e+00  12.9500000  14.2300000,NA,NA,NA,NA NA,NA,100 100 100 100 100 100 100 some,low low low low,Placebo   0, 15.000000  5.250000 NA,DSM-IV,0,1 1.0 1.0 1.0,0.5,1 1,1,1,1,1 1,1.0 0,1,1 1,1016 Short_2004,< 2 months NA,< 6 yo,4.42,5.25,97.41 97.93,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000,no,low low
 662,Chiu (2022) Chiu 2022 10.1192/j.eurpsy.2023.11,100,100 100 100 High Methylphenidate,MPH IR   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire CLAM/SKAMP composite, SKAMP Attention and SKAMP Deportment, 0.23014960   12.3750000,mg/d Greenhill 2006,NA RCT (parallel, crossover, open-label) G,165,165  330,NA,NA, 0.1600000000,-0.060000000  3.700000e-01   0.7200000,  0.6700000,NA,NA NA NA,NA NA,100,100,100 100 100 100 100 low low,low low,low Placebo   0, 26.000000, 4.740000  97.93000 DSM-IV 0 1,1.0 1.0,1.0,0.5,1 1,1 1,1,1,1,1.0,0 1 1 1,1017,Greenhill_2006 < 2 months Average (80-119) < 6 yo 4.42 6.13,60,102 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no,low,low
 662 Chiu (2022) Chiu,2022 10.1192/j.eurpsy.2023.11,100 100,100 100,High,Methylphenidate,MPH IR,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire SWAN total, inattention, hyperactivity/impulsivity, 0.92059839 NA NA Abikoff 2007 NA RCT (parallel, crossover, open-label) G  32  32   64,NA NA  0.3200000000 -0.180000000  8.100000e-01,  0.7200000,  0.7800000 NA NA NA,NA NA,NA 100 100,100,100   0,100 100,low low high low,low Placebo,  0, 25.400000, 4.420000, 97.41000,DSM-IV 0,1 1.0,1.0 1.0,0.5 1,1 1 1 1 1 1 1.0,0,1 1 1 1018 Abikoff_2007 < 2 months,Average (80-119) < 6 yo 4.42 6.13 60 102,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000,no low,low
 662,Chiu (2022),Chiu,2022 10.1192/j.eurpsy.2023.11 100,  0,100 100 High Methylphenidate,MPH IR or MAS   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks),Questionnaire,NA  0.92059839,NA NA Short,2004,NA,RCT (parallel, crossover, open-label) G, 19  19   38,NA,NA, 0.8400000000  0.170000000, 1.510000e+00,  6.7000000,  7.5000000,NA NA,NA NA NA NA 100,100,100,100,100 100 100 some,low low low,low Placebo   0  15.000000, 5.250000,NA DSM-IV,0 1,1.0 1.0 1.0,0.5 1,1,1 1,1 1,1,1.0 0,1 1,1,1019 Short_2004,< 2 months,NA,< 6 yo,4.42,6.13,60 102 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no,low low
 662,Chiu (2022) Chiu,2022 10.1192/j.eurpsy.2023.11 100 100 100 100 High Methylphenidate,MPH IR   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),Questionnaire NA  0.69044879,   0.4500000,mg/kg Handen 1999 NA RCT (parallel, crossover, open-label) G  11  11,  22,NA,NA, 1.1700000000  0.250000000, 2.080000e+00   4.1200000,  3.9600000,NA NA NA,NA,NA NA,100,100 100,100 100 100,100 some low,low low,low,Placebo   0, 18.100000, 4.910000  60.00000 DSM-III-R 0,1 1.0 1.0 1.0 0.5 1 1 1,1 1,1,1 1.0,0,1,1 1,1020 Handen_1999 < 2 months Low (< 70),< 6 yo,4.42 6.13 60,102 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000 no low low
 662,Chiu (2022),Chiu,2022 10.1192/j.eurpsy.2023.11,100 100 100,100 High,Methylphenidate MPH IR   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks) Observational tool point system - Percentage following activity rules  1.38089758,   0.4500000,mg/kg,Chaco,2004 NA RCT (parallel, crossover, open-label),G, 36  36,  72,NA NA, 1.1700000000  0.670000000  1.670000e+00  12.5500000, 18.0300000,NA NA NA,NA NA,NA 100,100,100,100 100 100,100 some low some low low,Placebo,  0  11.000000  6.130000 102.00000,DSM-llI-R or DSM-IV,0 1,1.0 1.0,1.0,0.5 1,1 1,1,1 1,1 1.0 0,1,1 1 1021,Chaco_2004 < 2 months,Average (80-119) 6-12 yo 4.42 6.13,60,102,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000 no,low,low
8993,Maji (2024.0) Maji 2024 10.1016/j.jpsychires.2024.06.048 100   0 100 100,Critically low,Centafanadine NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire AISRS (modified ADHD-RS), 1.38089758  200.0000000 mg/d Adler,2022.0 200mg RCT (parallel, crossover, open-label) SMD,147 144, 291,outcomes reverse,-0.2254862000 -0.484004000, 3.303171e-02  11.8800000  11.7600000,NA NA NA,NA NA,NA 100 100 100 100 100,100 100,low,low,low,low low,Placebo,  0  49.053608 35.808247,NA,DSM-V,5,0 0.0,0.0,1.0,0.0,0,1,2 1 1 1,1,0.5,0 1,0,1 1022,Adler_2022.0 < 2 months NA,>= 20 yo 35.1494661921708 38 NA NA,  2  1 Combined ADHD symptoms (inattentive + hyperactive/impulsive), 1 Maji (2024.0),35.1494661921708 38,NA NA Maji (2024.0)_Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Maji (2024.0) - Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
8993,Maji (2024.0) Maji,2024 10.1016/j.jpsychires.2024.06.048,100,  0 100,100,Critically low Centafanadine,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire,AISRS (modified ADHD-RS)  1.38089758, 400.0000000,mg/d,Adler 2022.0 400mg RCT (parallel, crossover, open-label),SMD 140 141, 281,outcomes,reverse -0.3434915000 -0.622938300 -6.404464e-02  11.7100000  11.1600000 NA NA NA NA,NA NA 100,100 100,100,100,100,100 low,low low low low Placebo,  0  48.401068 35.149466,NA DSM-V,5,0 0.0 0.0,1.0,0.0,0,1,2 1 1 1 1 0.5 0 1 0,1,1023 Adler_2022.0,< 2 months,NA >= 20 yo 35.1494661921708 38,NA,NA,  2  1 Combined ADHD symptoms (inattentive + hyperactive/impulsive), 1 Maji (2024.0) 35.1494661921708 38,NA,NA,Maji (2024.0)_Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Maji (2024.0) - Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
8993,Maji (2024.0) Maji,2024,10.1016/j.jpsychires.2024.06.048,100   0,100,100,Critically low Centafanadine,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire ADHD-RS-IV, 0.69044879,NA,NA Wigal,2020.0,NA RCT (parallel, crossover, open-label),SMD  79  74, 153 NA reverse -0.6595719000,-1.073295000 -2.458487e-01, 11.3400000  10.5600000,NA NA,NA,NA,NA,NA 100 100,100,100,100 100 100 some,low,low,low low Placebo   0, 44.000000,38.000000 NA,DSM-IV,5,0 0.0,0.0,1.0 0.0,0,1,2 1 1 1 1 0.5 0,1 0,1,1024 Wigal_2020.0 < 2 months NA,>= 20 yo 35.1494661921708 38,NA,NA,  2, 1 Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1,Maji (2024.0) 35.1494661921708,38 NA NA,Maji (2024.0)_Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Maji (2024.0) - Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
9001 Liang (2024),Liang,2024,10.1192/bjo.2023.645,100   0 100 100 Moderate,Probiotics Probiotics,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) NA,ADHD rating scale, 2.76179517 NA NA,Kumperscak,2020 NA,RCT (parallel, crossover, open-label) SMD  18, 14   32,NA NA,-0.0200000000 -0.720000000  6.800000e-01,  8.7000000, 11.2000000,NA,NA,NA,NA NA,NA,100 100,100,100 100 100,100,some low,low low low,Placebo   0, 28.130000 11.880000 NA NA 0,1 1.0,1.0,1.0 1.0,1,1,3,1 1,0,1 0.5 0 0 1 1,1025 Kumperscak_2020,2-6 months NA 6-12 yo,8.8,12 NA NA,  5  2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation  1,Liang (2024),8.8,12 NA,NA Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Liang (2024) - Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
9001 Liang (2024),Liang 2024 10.1192/bjo.2023.645,100   0 100 100 Moderate Probiotics,Probiotics,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),NA SNAP, 2.07134638 NA,NA Skott 2020 NA RCT (parallel, crossover, open-label) SMD, 42  26,  68,NA NA, 0.2000000000 -0.290000000  6.900000e-01,  0.3200000,  0.3600000 NA NA,NA NA,NA NA 100,100,100 100,  0 100,100,some,low,high low,low,Placebo,  0, 26.500000,12.000000,NA NA,0 1,1.0,1.0,1.0,1.0,1 1 3,1,1 0,1 0.5,0,0,1,1 1026 Skott_2020,2-6 months NA,6-12 yo 8.8,12 NA,NA   5  2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation, 1 Liang (2024),8.8 12,NA NA,Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Liang (2024) - Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
9001 Liang (2024) Liang,2024,10.1192/bjo.2023.645 100,  0,100 100 Moderate,Probiotics,Probiotics,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) NA,DBD  0.92059839 NA,NA,Bazinet,2017 NA,RCT (parallel, crossover, open-label) SMD, 25, 23   48 NA NA, 0.0300000000 -0.540000000, 6.000000e-01,  8.9000000  10.7000000,NA NA NA NA NA NA,100 100,100 100 100,100 100 low,low low,low,low Placebo,  0  27.100000, 9.750000 NA,NA,0 1,1.0 1.0 1.0 1.0,1 1,3,1 1 0 1 0.5,0,0 1 1,1027,Bazinet_2017,< 2 months,NA 6-12 yo,8.8 12 NA NA,  5, 2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation  1 Liang (2024),8.8,12 NA,NA,Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Liang (2024) - Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
9001 Liang (2024) Liang 2024,10.1192/bjo.2023.645,100,  0,100 100 Moderate Probiotics,Probiotics,100,aug Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) NA CPRS-r: total  1.84119678 NA NA Ghanaatgar 2022,NA,RCT (parallel, crossover, open-label) SMD, 21  17,  38,NA NA, 1.3800000000, 0.660000000  2.100000e+00, 13.7100000, 15.7500000 NA NA NA NA,NA NA,100 100 100,100,  0 100,100 low,low high,low,low,Active (any credible active intervention),100  31.600000  8.800000 NA NA 0,1,1.0,1.0,1.0 1.0 1 1,3,1,1,0,1 0.5 0 0,1 1,1028,Ghanaatgar_2022 < 2 months,NA,6-12 yo 8.8 12 NA,NA,  5, 2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation  1,Liang (2024),8.8 12,NA NA,Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Liang (2024) - Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
9001 Liang (2024),Liang 2024 10.1192/bjo.2023.645 100   0 100,100 Moderate,Probiotics Probiotics 100,aug,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),NA,ADHD rating scale  1.84119678 NA,NA Sepehrmanesh,2021 NA,RCT (parallel, crossover, open-label),SMD, 17, 17   34 NA,NA  0.3100000000 -0.370000000  9.900000e-01  10.9500000,  7.6000000 NA NA,NA,NA,NA,NA 100,100 100 100 100,100,100,low low,low,low low Active (any credible active intervention) 100, 20.600000, 9.100000 NA,NA 0 1 1.0 1.0 1.0,1.0,1 1,3 1,1 0 1 0.5,0 0 1 1 1029,Sepehrmanesh_2021 < 2 months NA 6-12 yo,8.8 12,NA NA,  5, 2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation  1 Liang (2024),8.8 12,NA NA,Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Liang (2024) - Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
9001,Liang (2024),Liang,2024,10.1192/bjo.2023.645 100   0,100 100 Moderate,Probiotics,Probiotics   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA NA  2.76179517 NA NA,Kumperscak,2020,NA,RCT (parallel, crossover, open-label),RR, 21  14,  35,NA reverse, 0.6818181818  0.014298633  3.251192e+01 NA,NA,NA,NA,NA,NA NA,NA 100 100,100,100,100 100,100 some low low low low,Placebo,  0  28.130000,11.880000 NA NA,0,1 1.0,1.0,1.0,1.0 1,1 3,1,1 0 1,0.5,0,0 1 1,1030,Kumperscak_2020 2-6 months NA,6-12 yo,8.8 12 NA NA   5, 2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation  1 Liang (2024),8.8 12,NA NA,Liang (2024)_Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Liang (2024) - Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
9001 Liang (2024),Liang,2024 10.1192/bjo.2023.645 100   0,100 100,Moderate Probiotics,Probiotics,  0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA  2.07134638,NA NA Skott,2020,NA RCT (parallel, crossover, open-label),RR  65  34   99,NA reverse, 1.7186813187, 0.822165218, 3.592788e+00 NA NA,NA,NA,NA,NA,NA,NA,100 100 100 100   0,100 100 some low,high low,low Placebo   0, 26.500000 12.000000 NA NA,0 1,1.0 1.0 1.0,1.0 1,1,3,1 1,0 1 0.5 0 0,1,1,1031,Skott_2020,2-6 months NA,6-12 yo 8.8,12 NA NA   5  2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation, 1 Liang (2024),8.8,12,NA NA Liang (2024)_Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Liang (2024) - Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
9001,Liang (2024) Liang,2024,10.1192/bjo.2023.645 100,  0,100 100 Moderate,Probiotics,Probiotics,100,aug,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA, 1.84119678,NA,NA,Ghanaatgar 2022 NA,RCT (parallel, crossover, open-label) RR, 25, 25,  50 NA reverse  0.5000000000  0.172444453  1.449742e+00,NA NA NA NA,NA NA,NA NA 100 100 100 100   0 100,100,low,low,high low,low Active (any credible active intervention) 100  31.600000, 8.800000,NA,NA,0 1,1.0,1.0 1.0,1.0,1 1 3 1,1,0,1 0.5 0,0,1,1 1032 Ghanaatgar_2022 < 2 months,NA,6-12 yo,8.8 12,NA NA   5, 2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation  1,Liang (2024),8.8,12 NA,NA Liang (2024)_Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Liang (2024) - Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
9001,Liang (2024) Liang,2024 10.1192/bjo.2023.645,100   0 100,100 Moderate Probiotics,Probiotics 100 aug Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA NA  1.84119678,NA NA,Sepehrmanesh 2021 NA RCT (parallel, crossover, open-label),RR  20  20,  40,NA reverse  1.0000000000  0.228685567, 4.372816e+00 NA,NA,NA NA NA,NA NA,NA,100,100 100,100 100,100 100 low,low low low low Active (any credible active intervention) 100, 20.600000, 9.100000 NA NA,0,1 1.0,1.0 1.0 1.0 1,1,3,1 1 0,1,0.5 0 0 1 1,1033,Sepehrmanesh_2021,< 2 months NA,6-12 yo,8.8 12,NA NA   5, 2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation, 1,Liang (2024),8.8,12 NA,NA Liang (2024)_Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Liang (2024) - Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100 High Amphetamine,Amphetamine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA ADHD-SRS total, 0.92059839,  30.0000000 mg/d Weisler 2006,NA RCT G,128  60  188 outcomes reverse,-0.6520000000 -0.966000000,-3.370000e-01  12.0000000  12.2400000 NA NA,NA,NA NA NA 100,100 100 100   0,100,100,low,low,high low,low Placebo,  0, 36.425532 39.027660,NA NA,0,1 1.0 1.0,1.0,1.0 1 1 1 1 1,1 1 1.0 0,1 1 1 1034,Weisler_2006 < 2 months NA,>= 20 yo 22.2059016393443 39.0276595744681,NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High,Amphetamine Amphetamine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA,CAARS-S:S  0.92059839   30.0000000 mg/d,Weisler 2006 NA RCT G,119  58, 177 outcomes reverse -0.4800000000,-0.798000000,-1.610000e-01,  7.0000000   7.3680000 NA,NA,NA,NA,NA,NA 100 100,100 100   0,100,100 low low high low,low,Placebo,  0  36.370056 39.031073 NA NA 0,1 1.0,1.0,1.0 1.0,1,1,1,1 1,1 1,1.0 0 1 1,1 1035,Weisler_2006 < 2 months,NA,>= 20 yo,39.0310734463277 41.2,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100,100 High,Amphetamine,Amphetamine   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability, 0.92059839,  30.0000000,mg/d,Weisler,2006 NA,RCT,RR,130, 64, 194,outcomes reverse  0.7610000000, 0.488000000, 1.187000e+00 NA NA NA NA NA NA NA,NA 100 100,100,100 100 100,100,low,low,low,low low Placebo,  0  36.355670,39.031959,NA NA 0,1,1.0,1.0 1.0 1.0,1,1 1,1 1 1 1 1.0,0,1 1 1 1036 Weisler_2006,< 2 months,NA,>= 20 yo,22.2057971014493,39.0319587628866 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100,100 High Amphetamine Amphetamine   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 0.92059839   30.0000000 mg/d Weisler,2006,NA,RCT,RR 130  64  194 outcomes reverse  7.3850000000, 0.997000000, 5.467400e+01 NA NA,NA NA NA,NA,NA,NA 100,100 100,100 100,100 100 low,low low low low Placebo,  0  36.355670 39.031959 NA NA,0,1 1.0 1.0,1.0,1.0 1 1 1,1 1,1 1,1.0 0,1,1,1 1037,Weisler_2006 < 2 months NA >= 20 yo,22.2057971014493,39.0319587628866,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High Methylphenidate,Methylphenidate,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA,Other  0.46029919,  43.0701754 mg/d Wender 2011 NA,RCT,G, 57  57  114 outcomes reverse,-0.9020000000,-1.289000000 -5.150000e-01,  2.4985912   2.5355874,NA,NA NA,NA NA NA 100,100,100,100 100 100,100,low some some low,low,Placebo,  0  28.000000 36.900000 NA NA 0 1,1.0,1.0 1.0 1.0,1 1,1,1,1 1,1 1.0,0 1 1,1,1038,Wender_2011,< 2 months,NA,>= 20 yo,30.6 40,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0 100,100,High Methylphenidate,Methylphenidate   0,NA Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks) NA WRAADDS, 0.46029919   43.0701754 mg/d Wender 2011 NA RCT,G, 57  57, 114,outcomes,reverse -0.9140000000,-1.301000000 -5.260000e-01,  2.5000000   2.5000000,NA,NA NA,NA,NA NA 100,100,100,100,100,100,100,low some,some,low,low,Placebo   0  28.000000,36.900000,NA NA 0 1,1.0,1.0,1.0,1.0,1 1 1 1 1,1,1,1.0 0 1,1 1,1039 Wender_2011,< 2 months NA >= 20 yo 34.0471698113208 36.9,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100,100,High Methylphenidate Methylphenidate   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability  0.46029919   43.0701754,mg/d Wender,2011 NA,RCT RR  59, 57, 116,outcomes,reverse  0.9670000000, 0.020000000  4.791200e+01,NA NA NA,NA NA NA NA,NA 100,100 100,100,100,100 100,low some,low low low Placebo   0, 28.000000,36.900000 NA NA 0,1,1.0 1.0,1.0 1.0,1,1 1,1,1,1,1,1.0 0 1 1 1,1040 Wender_2011 < 2 months,NA >= 20 yo 28.7959183673469 40 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Methylphenidate Methylphenidate,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 0.46029919   43.0701754 mg/d Wender 2011 NA,RCT RR  59  57  116 outcomes reverse, 0.9670000000, 0.020000000  4.791200e+01 NA NA NA,NA NA NA NA NA,100 100,100,100 100 100 100,low,some,low,low,low,Placebo   0, 28.000000,36.900000,NA,NA 0,1,1.0 1.0 1.0 1.0,1 1,1 1 1,1,1,1.0,0,1 1,1,1041,Wender_2011,< 2 months NA >= 20 yo,28.7959183673469,40 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100,100,High,Bupropion Bupropion   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability  1.38089758, 362.0000000,mg/d Wilens 2001 NA,RCT,RR  21, 19   40 outcomes,reverse, 4.5450000000  0.232000000  8.907700e+01 NA NA,NA,NA,NA NA NA NA,100 100,100,100,100 100 100,some some,low low,low,Placebo   0  44.900000 38.235000 NA NA 0,1,1.0,1.0 1.0,1.0 1,1,1,1,1 1,1,1.0 0 1 1 1 1042 Wilens_2001 < 2 months NA,>= 20 yo 34.4220338983051 38.235,NA NA  10, 7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25 NA NA Ostinelli (2025)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Bupropion,Bupropion,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability, 1.38089758  362.0000000 mg/d,Wilens,2001 NA,RCT,RR, 21  19   40 outcomes reverse, 0.9090000000, 0.019000000  4.370900e+01 NA,NA,NA NA,NA NA,NA,NA,100,100 100 100 100 100 100,some,some,low low low,Placebo,  0, 44.900000,38.235000 NA,NA 0 1,1.0,1.0,1.0,1.0,1,1,1,1 1 1 1 1.0 0,1 1,1,1043 Wilens_2001 < 2 months NA >= 20 yo 34.4220338983051,38.235,NA NA  10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25 NA,NA,Ostinelli (2025)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100 High,Atomoxetine Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,CAARS-INV:SV  5.52359033,  90.3000000 mg/d,Young,2011,NA,RCT,G 264,232, 496 outcomes,reverse,-0.3780000000,-0.596000000,-1.590000e-01 NA,NA,NA NA NA NA,11.1000000,11.1000000 100 100 100,100   0,100,100,low,low,high,low,low Placebo   0  52.408065 41.293548,NA NA,0,1 1.0,1.0 1.0 1.0,1,1,1 1,1,1 1 1.0,0 1,1,1 1044,Young_2011 2-6 months NA >= 20 yo 24.7,42.1,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100 High,Atomoxetine Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At follow-up (closest to 26 weeks),NA CAARS-O:L  5.52359033   90.3000000,mg/d,Young 2011 NA,RCT G 264,232, 496 outcomes reverse,-0.4560000000 -0.672000000 -2.410000e-01 NA,NA NA NA NA,NA,11.0000000,11.0000000,100,100 100,100,  0,100 100 low,low high,low,low,Placebo,  0  52.408065 41.293548 NA,NA 0,1 1.0,1.0,1.0 1.0,1 1,1 1,1,1 1 1.0 0 1,1 1,1045,Young_2011 2-6 months,NA >= 20 yo 36.6921768707483,41.2935483870968,NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100,High,Atomoxetine Atomoxetine,  0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability, 5.52359033   90.3000000 mg/d Young 2011,NA,RCT,RR 268,234  502,outcomes reverse  1.3010000000, 1.084000000  1.562000e+00 NA NA,NA,NA,NA NA,NA NA,100 100 100,100,100,100 100,low low,low low low,Placebo,  0, 52.396016 41.293227 NA,NA,0 1 1.0 1.0 1.0 1.0,1 1 1 1,1 1,1 1.0,0 1,1 1,1046,Young_2011,2-6 months NA,>= 20 yo 24.7,42.10703125,NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100 100 High Atomoxetine,Atomoxetine   0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  5.52359033,  90.3000000,mg/d Young,2011 NA RCT RR 268,234, 502 outcomes reverse, 2.2620000000, 1.429000000, 3.582000e+00 NA NA NA,NA NA,NA,NA NA,100 100,100,100,100 100,100,low,low low,low,low Placebo   0  52.396016 41.293227,NA,NA 0,1 1.0 1.0 1.0 1.0 1,1,1 1 1 1,1,1.0 0,1 1 1,1047,Young_2011,2-6 months,NA,>= 20 yo 24.7 42.10703125 NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100 100,High,Atomoxetine Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA ADHD-SRS total, 2.76179517   89.9000000 mg/d Wilens 2008 NA RCT G  72  75  147,outcomes,reverse -0.4600000000 -0.854000000,-6.500000e-02,NA NA NA,NA NA,NA,11.4000000,11.4000000,100 100,100 100   0,100,100,low,low high,low some Placebo,  0, 14.993878,34.555102,NA NA 0 1,1.0 1.0 1.0,1.0 1,1,1 1 1,1,1,1.0 0,1,1 1,1048 Wilens_2008 2-6 months,NA >= 20 yo,24.7 42.1 NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA,ASRS  2.76179517   89.9000000 mg/d,Wilens 2008,NA,RCT,G, 72  75, 147,outcomes,reverse -0.3600000000 -0.737000000, 1.600000e-02,NA,NA NA NA NA NA 12.9000000 12.9000000 100,100 100 100,  0,100,100,low,low high,low,some Placebo,  0  14.993878 34.555102 NA NA,0 1,1.0,1.0 1.0,1.0 1 1,1 1 1 1 1 1.0,0 1,1 1,1049 Wilens_2008,2-6 months NA >= 20 yo 24.7,42.1 NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100,100 High Atomoxetine,Atomoxetine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability  2.76179517,  89.9000000 mg/d,Wilens,2008 NA RCT,RR, 72  75, 147 outcomes reverse, 1.5430000000, 1.071000000  2.225000e+00,NA,NA NA NA NA,NA,NA,NA,100,100 100 100 100 100 100 low,low low low,low Placebo,  0  14.993878 34.555102,NA NA,0 1 1.0,1.0,1.0 1.0 1,1,1 1,1 1,1,1.0,0 1 1 1 1050 Wilens_2008,2-6 months NA,>= 20 yo 24.7,42.10703125,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0 100,100 High Atomoxetine Atomoxetine,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability  2.76179517,  89.9000000 mg/d,Wilens,2008 NA,RCT RR, 72, 75, 147 outcomes reverse  3.6460000000  0.783000000  1.697000e+01,NA NA NA,NA NA NA,NA NA 100,100,100,100,100 100 100 low,low low low low,Placebo,  0, 14.993878 34.555102,NA NA 0,1,1.0 1.0,1.0,1.0 1 1,1,1,1,1 1 1.0 0,1 1 1,1051,Wilens_2008,2-6 months,NA >= 20 yo 24.7 42.10703125,NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High,Methylphenidate Methylphenidate,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA ADHD-RS total, 2.53164557,NA,NA Winhusen 2010,NA RCT,G,107 108, 215,outcomes,reverse -0.5970000000,-0.871000000 -3.230000e-01, 11.7600000, 12.3900000 NA,NA,NA NA,NA,NA,100 100,100 100 100 100,100,low low low,low,low,Placebo   0  43.569302,37.798605,NA,NA 0,1,1.0 1.0,1.0,1.0 1,1,1 1,1 1 1 1.0 0,1 1,1,1052,Winhusen_2010,2-6 months NA,>= 20 yo,30.6,40,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100,100,High,Methylphenidate Methylphenidate   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 2.53164557,NA,NA Winhusen 2010,NA RCT,RR 127 128, 255,outcomes,reverse  1.0080000000, 0.570000000, 1.781000e+00 NA NA,NA,NA,NA NA NA NA 100,100 100,100 100 100,100,low,low low,low low Placebo,  0  43.566275 37.798824 NA,NA 0 1,1.0,1.0 1.0 1.0,1 1 1 1 1,1 1,1.0,0,1,1,1 1053 Winhusen_2010 2-6 months NA >= 20 yo 28.7959183673469 40 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Methylphenidate,Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  2.53164557,NA NA,Winhusen 2010,NA RCT RR,127,128  255 outcomes reverse, 1.0080000000  0.020000000, 5.040400e+01,NA NA NA NA NA NA NA,NA,100 100 100 100,100,100,100 low,low low,low low,Placebo   0, 43.566275 37.798824 NA NA 0 1 1.0 1.0,1.0,1.0 1 1,1,1,1 1 1 1.0 0,1,1,1 1054,Winhusen_2010,2-6 months,NA,>= 20 yo,28.7959183673469,40,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100,High Atomoxetine,Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA CAARS-INV:SV  3.22209436   82.9000000 mg/d Adler,2009 NA,RCT,G,209,204  413,outcomes reverse,-0.4330000000 -0.628000000 -2.370000e-01, 11.2500000  10.5600000,NA NA,NA NA,NA,NA,100,100 100,100   0 100,100,low,low,high,low,low,Placebo,  0  46.384649,37.988668 NA NA 0,1,1.0,1.0 1.0 1.0,1 1 1 1 1 1 1,1.0 0,1,1,1,1055 Adler_2009,2-6 months NA,>= 20 yo,24.7 42.1 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100 High Atomoxetine,Atomoxetine   0 NA,Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks) NA AAQoL, 3.22209436,  82.9000000 mg/d Adler 2009 NA RCT,G 127 137  264,outcomes,reverse  0.1550000000,-0.087000000, 3.970000e-01  18.3000000, 16.5000000 NA NA NA NA NA NA,100 100 100,100   0 100,100 low,low high low low Placebo   0  46.427386 37.994167,NA NA 0,1,1.0 1.0 1.0,1.0 1,1,1 1 1,1 1,1.0 0 1 1,1 1056 Adler_2009 2-6 months,NA,>= 20 yo,24.7,37.9941666666667,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High,Atomoxetine Atomoxetine   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 3.22209436   82.9000000,mg/d,Adler 2009 NA,RCT RR,224,218, 442,outcomes reverse  1.1650000000, 0.927000000  1.465000e+00 NA,NA,NA,NA NA,NA NA,NA,100,100 100,100,100 100 100,low,low low low,low Placebo,  0, 46.383394 37.988507,NA NA 0,1 1.0 1.0,1.0 1.0,1,1,1 1,1,1,1,1.0,0 1,1 1,1057,Adler_2009,2-6 months,NA,>= 20 yo,24.7,42.10703125,NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Atomoxetine Atomoxetine,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 3.22209436   82.9000000,mg/d Adler,2009,NA RCT RR 224 218  442 outcomes reverse, 1.2440000000  0.691000000, 2.239000e+00,NA NA NA NA NA,NA NA,NA 100 100,100,100,100,100 100,low low low,low,low,Placebo   0, 46.383394,37.988507,NA NA,0 1 1.0 1.0 1.0,1.0 1,1 1 1,1,1,1,1.0 0,1,1,1,1058 Adler_2009 2-6 months,NA,>= 20 yo,24.7 42.10703125,NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Atomoxetine,Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At follow-up (closest to 26 weeks) NA,CAARS-INV:SV, 5.98388953,  85.2000000,mg/d,Adler 2008,NA RCT,G,185 109, 294 outcomes reverse,-0.0740000000 -0.360000000, 2.110000e-01,NA,NA,NA,NA NA,NA 12.3100000,12.3100000,100 100 100,100,100,100 100 low low,low low low Placebo   0  41.230612 36.692177,NA NA,0,1,1.0 1.0,1.0,1.0,1,1 1,1,1 1,1 1.0 0 1,1 1,1059 Adler_2008,2-6 months,NA,>= 20 yo,36.6921768707483,41.2935483870968,NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High Atomoxetine Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA CAARS-S:S, 5.98388953   85.2000000,mg/d,Adler 2008 NA RCT G 251 134  385,outcomes reverse,-0.2980000000 -0.509000000 -8.700000e-02   9.8226473,  9.4921863 NA,NA NA NA NA,NA 100,100 100 100,100 100,100 low low low,low low Placebo,  0, 41.394026,36.717143,NA NA 0,1,1.0,1.0 1.0,1.0,1 1,1 1 1 1 1,1.0 0,1 1,1,1060,Adler_2008,2-6 months NA >= 20 yo 24.7 42.1,NA NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Atomoxetine Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 26 weeks),NA CAARS-S:S, 5.98388953   85.2000000,mg/d Adler 2008 NA RCT,G 251,134  385 outcomes,reverse,-0.2710000000 -0.482000000 -6.000000e-02, 10.2000000, 10.3200000,NA NA NA,NA NA NA 100,100,100,100,100,100 100,low low low low low,Placebo,  0  41.394026 36.717143,NA,NA 0,1 1.0,1.0,1.0,1.0 1,1,1,1 1 1,1 1.0 0 1 1,1 1061 Adler_2008 2-6 months,NA >= 20 yo 36.7171428571429,37.5691375770021 NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100 High,Atomoxetine Atomoxetine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 5.98388953,  85.2000000,mg/d,Adler 2008 NA RCT RR 271 139  410 outcomes reverse, 1.2060000000  1.000000000  1.456000e+00 NA NA,NA NA NA NA,NA NA,100,100,100,100,100 100 100 low,low low low low Placebo   0, 41.459024 36.727073,NA NA,0 1,1.0,1.0,1.0 1.0,1 1,1 1 1 1 1 1.0,0 1,1,1 1062 Adler_2008 2-6 months NA,>= 20 yo,24.7 42.10703125 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High Atomoxetine Atomoxetine,  0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  5.98388953,  85.2000000 mg/d,Adler 2008,NA,RCT RR,271 139  410,outcomes,reverse  6.4970000000, 2.042000000  2.067300e+01,NA,NA,NA,NA,NA NA NA,NA 100,100 100,100,100,100,100 low,low low low,low,Placebo,  0  41.459024,36.727073 NA NA,0 1 1.0,1.0 1.0 1.0,1,1 1,1 1,1,1,1.0 0 1 1 1,1063 Adler_2008 2-6 months,NA >= 20 yo 24.7,42.10703125,NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Amphetamine,Amphetamine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,ADHD-RS total  0.92059839   50.0000000,mg/d,Adler 2008 NA,RCT,G 352  62  414,outcomes reverse,-0.1620000000,-0.466000000, 1.410000e-01 NA,NA,NA,NA NA,NA 11.2598313,11.2598313,100,100 100,100,100,100,100 low low low,low,low Placebo   0, 45.449275 35.114976,NA,NA,0 1 1.0 1.0,1.0 1.0 1,1,1 1,1 1 1 1.0,0,1,1 1,1064 Adler_2008 < 2 months NA >= 20 yo,22.2059016393443,39.0276595744681,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Amphetamine,Amphetamine,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  0.92059839,  50.0000000,mg/d Adler,2008,NA RCT,RR 358  62  420 outcomes reverse  1.0560000000, 0.573000000, 1.948000e+00 NA,NA NA,NA NA,NA,NA,NA,100,100,100,100,100 100 100,low low low low low,Placebo   0  45.442857,35.114762 NA,NA 0,1 1.0 1.0,1.0,1.0,1 1,1 1,1 1 1,1.0,0 1 1,1,1065 Adler_2008,< 2 months,NA,>= 20 yo,22.2057971014493 39.0319587628866,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High Amphetamine,Amphetamine,  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 0.92059839,  50.0000000,mg/d,Adler 2008,NA,RCT,RR,358, 62, 420 outcomes,reverse, 3.6370000000  0.498000000  2.655000e+01 NA NA,NA,NA NA,NA,NA NA 100,100,100,100 100 100 100 low,low,low,low,low Placebo,  0  45.442857 35.114762 NA,NA,0,1,1.0 1.0,1.0 1.0,1 1 1,1,1 1 1,1.0 0 1 1,1,1066 Adler_2008 < 2 months,NA >= 20 yo 22.2057971014493,39.0319587628866,NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100 High,Amphetamine Amphetamine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,ADHD-SRS total  2.30149597,  56.9000000 mg/d Adler,2013 NA RCT G  79, 75  154,outcomes reverse,-0.9130000000 -1.355000000,-4.710000e-01 NA,NA NA NA,NA NA 11.9511506 11.9511506 100,100,100,100 100,100,100 low low some low low Placebo,  0, 47.841558 34.540909 NA,NA 0 1,1.0,1.0,1.0,1.0,1 1,1,1,1 1,1,1.0,0,1 1,1 1067 Adler_2013,2-6 months,NA >= 20 yo,22.2059016393443,39.0276595744681,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100,100,High Amphetamine Amphetamine   0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability, 2.30149597   56.9000000,mg/d,Adler 2013 NA RCT,RR  80, 81  161 outcomes,reverse, 0.6510000000, 0.393000000  1.079000e+00,NA,NA,NA NA,NA NA,NA NA,100 100,100 100 100 100,100,low,low low low low Placebo,  0, 47.790062 34.552174 NA,NA,0 1 1.0,1.0 1.0 1.0,1,1,1 1,1,1 1 1.0,0 1 1,1 1068 Adler_2013 2-6 months NA,>= 20 yo 22.2057971014493,39.0319587628866,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100 100 High Amphetamine Amphetamine   0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,Tolerability, 2.30149597   56.9000000,mg/d Adler,2013 NA,RCT RR, 80, 81  161,outcomes reverse  3.0380000000  0.632000000, 1.460300e+01 NA,NA,NA,NA,NA,NA NA,NA,100 100 100 100 100,100,100 low low low,low low Placebo,  0, 47.790062,34.552174 NA NA 0 1,1.0 1.0,1.0 1.0 1,1 1,1,1 1,1,1.0 0,1 1 1,1069,Adler_2013,2-6 months,NA >= 20 yo,22.2057971014493,39.0319587628866 NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Atomoxetine,Atomoxetine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA Other, 5.98388953   84.5000000 mg/d Adler 2009,NA RCT,G,191,197  388 outcomes,reverse -0.4260000000,-0.690000000,-1.620000e-01 NA NA,NA NA,NA,NA,10.6671083,10.6671083 100,100,100 100 100 100,100,low low some low low Placebo,  0  49.288067 37.567835,NA NA,0 1 1.0,1.0,1.0 1.0 1 1 1 1,1 1 1,1.0,0,1,1 1 1070 Adler_2009,2-6 months NA >= 20 yo 24.7 42.1,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100 100,High Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At follow-up (closest to 26 weeks) NA Other  5.98388953   84.5000000 mg/d Adler,2009,NA RCT G,101 115  216,outcomes,reverse -0.4620000000,-0.834000000 -9.100000e-02 NA,NA,NA,NA,NA,NA,10.2948531,10.2948531 100 100,100,100,100,100,100,low,low,some,low low Placebo,  0  49.234028,37.560926 NA,NA,0,1 1.0 1.0 1.0 1.0 1,1,1 1,1 1 1,1.0,0,1,1 1,1071 Adler_2009 2-6 months NA,>= 20 yo 36.6921768707483,41.2935483870968,NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100 High,Atomoxetine,Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA ASRS  5.98388953,  84.5000000,mg/d,Adler,2009,NA,RCT G 242 245  487,outcomes,reverse -0.4320000000 -0.612000000,-2.520000e-01, 13.3100000  14.1300000 NA,NA NA,NA NA NA,100 100,100,100 100,100 100,low low some low,low Placebo,  0, 49.298255,37.569138,NA,NA,0,1,1.0 1.0 1.0,1.0 1,1 1 1 1 1 1,1.0,0 1 1,1,1072,Adler_2009,2-6 months NA >= 20 yo 24.7 42.1 NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100 High,Atomoxetine Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 26 weeks) NA ASRS  5.98388953,  84.5000000 mg/d,Adler 2009 NA,RCT G 242 245, 487,outcomes reverse -0.4150000000,-0.595000000,-2.360000e-01  14.4200000, 15.0400000 NA NA NA NA NA,NA,100 100 100,100 100 100 100,low low some,low,low,Placebo,  0  49.298255 37.569138,NA,NA 0 1 1.0 1.0 1.0,1.0,1,1 1 1,1 1,1 1.0 0,1,1,1,1073,Adler_2009 2-6 months NA >= 20 yo 36.7171428571429 37.5691375770021 NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100 100 High Atomoxetine Atomoxetine   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability  5.98388953,  84.5000000 mg/d,Adler 2009,NA RCT,RR 250,251  501 outcomes reverse  1.1270000000, 0.973000000  1.305000e+00 NA,NA NA,NA,NA,NA NA NA,100,100,100,100 100 100,100 low low low,low,low Placebo,  0, 49.302814,37.569721,NA NA 0,1 1.0,1.0 1.0,1.0,1,1 1,1,1 1 1 1.0,0 1,1 1 1074,Adler_2009,2-6 months NA,>= 20 yo 24.7 42.10703125,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100 High Atomoxetine,Atomoxetine,  0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability  5.98388953   84.5000000 mg/d,Adler 2009,NA RCT RR,250 251  501,outcomes,reverse  3.0840000000, 1.732000000, 5.492000e+00 NA NA,NA NA NA NA NA NA 100,100 100,100 100 100,100 low,low low,low low,Placebo,  0, 49.302814 37.569721,NA NA 0,1 1.0,1.0 1.0 1.0 1 1 1 1,1 1,1 1.0,0,1,1,1,1075 Adler_2009 2-6 months,NA,>= 20 yo 24.7 42.10703125,NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Methylphenidate,Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,Other  1.61104718   67.7000000,mg/d Adler,2009 NA RCT G,110 116  226 outcomes reverse,-0.3290000000 -0.627000000,-3.100000e-02 NA,NA NA,NA NA,NA 11.4165494 11.4165494 100 100 100,100 100 100,100 low low some low low,Placebo   0  43.777876 39.027434,NA NA 0 1 1.0 1.0 1.0 1.0,1,1,1,1,1,1 1,1.0,0 1 1 1,1076 Adler_2009,< 2 months,NA >= 20 yo,30.6,40 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100,100 High Methylphenidate,Methylphenidate   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability  1.61104718,  67.7000000 mg/d Adler,2009,NA,RCT RR 113,116  229 outcomes reverse  1.6580000000  1.095000000, 2.511000e+00 NA NA,NA,NA,NA,NA NA,NA,100 100 100,100 100,100,100 low low low,low,low,Placebo   0, 43.763755,39.038865 NA,NA 0,1,1.0,1.0,1.0,1.0 1 1,1,1 1,1,1,1.0,0 1,1,1 1077 Adler_2009,< 2 months NA,>= 20 yo,28.7959183673469 40 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Methylphenidate,Methylphenidate   0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability  1.61104718   67.7000000 mg/d Adler 2009 NA,RCT,RR 113 116  229,outcomes reverse  2.7370000000, 1.111000000, 6.745000e+00,NA NA,NA NA NA NA,NA NA,100 100,100,100,100,100 100,low low,low,low low Placebo,  0  43.763755,39.038865 NA,NA,0,1,1.0 1.0,1.0 1.0 1,1,1 1,1,1 1 1.0,0 1,1,1 1078 Adler_2009 < 2 months NA,>= 20 yo,28.7959183673469,40,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100 100 High,Modafinil,Modafinil,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA,ASRS  2.07134638  298.0000000,mg/d Arnold 2014,NA RCT,G 141  72, 213,outcomes reverse, 0.0340000000,-0.297000000  3.650000e-01 NA NA NA,NA,NA,NA,15.0300000,15.0300000 100,100,100 100,100 100 100 low,low,low low,low,Placebo,  0  39.718310 39.129577 NA,NA 0,1 1.0,1.0 1.0 1.0,1,1 1 1 1,1 1,1.0,0,1 1 1,1079 Arnold_2014 2-6 months,NA >= 20 yo,39.1295774647887,40.8,NA NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA NA Ostinelli (2025)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High Modafinil Modafinil   0 NA,Quality of life (patients) Mixed At study endpoint (closest to 12 weeks),NA Q-LES-Q, 2.07134638, 298.0000000 mg/d,Arnold,2014,NA,RCT G, 80  51  131,NA,reverse  0.1220000000 -0.254000000, 4.980000e-01,NA NA,NA NA,NA NA  8.6400000  8.6400000 100,100 100 100 100,100 100 low low low low low,Placebo   0  40.282443 39.088550,NA NA,0 1,1.0,1.0,1.0,1.0,1 1,1 1,1,1,1 1.0 0 1,1 1 1080 Arnold_2014 2-6 months,NA,>= 20 yo,39.0885496183206,39.0885496183206,NA NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA NA Ostinelli (2025)_Modafinil_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Modafinil_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA CAARS-INV:SV  0.92059839 NA NA Bain 2013 NA RCT,G  53 105, 158 outcomes,reverse,-2.0960000000 -2.768000000,-1.424000e+00,NA NA,NA,NA NA NA  7.7876826, 7.7876826,100 100 100 100,100,100,100 low,low,some low,low Placebo,  0, 47.000000,36.200000,NA NA 0,1 1.0,1.0 1.0 1.0 1,1 1 1 1,1 1 1.0,0,1 1 1 1081,Bain_2013,< 2 months NA,>= 20 yo,24.7,42.1,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,  0   0 100,100 High,Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA Other  1.38089758,NA,NA,Biederman 2006,NA,RCT G  67  74  141,outcomes,reverse,-0.6570000000 -0.998000000,-3.170000e-01   7.3668175   7.7420927 NA NA,NA,NA,NA,NA 100,100,100,100,100,100,100,low low,low low,some Placebo   0  48.248227 NA NA NA,0,1 1.0 1.0,1.0,1.0 1,1 1 1 1,1,1 1.0,0,1,1,1 1082 Biederman_2006 < 2 months NA NA 30.6 40,NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Amphetamine Amphetamine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA ADHD-SRS total  1.38089758 NA,NA,Biederman 2012 NA RCT G  31  30   61 outcomes,reverse -1.1590000000 -1.706000000,-6.110000e-01  10.2000000   9.9000000 NA NA NA NA NA,NA 100 100,100,100 100 100,100,some,some low some some,Placebo,  0, 43.472131,22.205902,NA,NA 0 1,1.0,1.0 1.0 1.0 1,1,1,1 1 1,1,1.0,0,1 1,1 1083 Biederman_2012 < 2 months,NA >= 20 yo,22.2059016393443 39.0276595744681 NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Amphetamine Amphetamine,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  1.38089758,NA NA,Biederman 2012 NA RCT RR, 35, 34   69,outcomes,reverse  0.9710000000, 0.264000000, 3.575000e+00,NA,NA NA,NA,NA NA NA,NA 100,100 100,100 100 100 100,some,some,low,some low Placebo,  0  43.478841,22.205797,NA NA,0,1 1.0 1.0,1.0,1.0 1,1 1 1,1 1 1 1.0 0 1,1 1,1084 Biederman_2012 < 2 months NA,>= 20 yo,22.2057971014493 39.0319587628866 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100,100 High Amphetamine Amphetamine,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability  1.38089758,NA,NA Biederman,2012,NA RCT,RR  35, 34   69 outcomes,reverse, 0.9710000000, 0.063000000  1.491500e+01,NA,NA,NA,NA,NA,NA,NA,NA,100 100 100,100 100,100 100,some,some low some,low,Placebo,  0, 43.478841,22.205797 NA NA,0,1,1.0 1.0 1.0 1.0,1,1,1,1 1,1 1 1.0 0,1 1,1,1085 Biederman_2012 < 2 months,NA >= 20 yo 22.2057971014493 39.0319587628866,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Methylphenidate Methylphenidate   0,NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) NA CPT omission, 0.46029919,  72.0000000,mg/d,Bron,2014 NA,RCT G  10, 12,  22,outcomes,reverse  0.0930000000,-0.767000000  9.540000e-01,NA NA NA,NA,NA,NA, 2.5600000, 2.5600000 100 100 100,100 100 100 100 low,low,low,low,low,Placebo   0  22.700000,30.500000 NA,NA,0,1,1.0 1.0,1.0,1.0 1 1 1,1 1 1,1,1.0,0 1,1 1 1086 Bron_2014 < 2 months,NA,>= 20 yo 30.5,38.4408163265306,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Methylphenidate,Methylphenidate   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 0.46029919   72.0000000,mg/d Bron,2014 NA RCT,RR, 14, 13,  27 outcomes reverse, 3.7140000000  0.475000000  2.906000e+01 NA,NA NA,NA,NA NA,NA,NA 100 100,100,100,100 100 100,low,low,low low,low,Placebo   0  22.700000,30.500000 NA,NA,0 1,1.0,1.0,1.0,1.0 1,1,1 1 1,1 1,1.0,0,1,1 1,1087,Bron_2014 < 2 months NA >= 20 yo,28.7959183673469,40,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100 High Methylphenidate,Methylphenidate   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability, 0.46029919,  72.0000000 mg/d,Bron,2014,NA RCT RR, 14  13,  27 outcomes,reverse  6.5330000000  0.370000000  1.154910e+02,NA NA,NA NA,NA,NA NA NA 100,100 100 100 100 100,100 low,low low low low,Placebo   0, 22.700000 30.500000,NA NA 0 1,1.0 1.0 1.0 1.0,1 1 1 1 1 1 1 1.0,0 1 1 1 1088 Bron_2014,< 2 months,NA >= 20 yo 28.7959183673469,40 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA,Other  2.99194476,NA NA,Casas,2013,NA,RCT G 182, 97, 279,outcomes reverse -0.3140000000,-0.562000000,-6.600000e-02,  6.0000000   6.1000000 NA,NA,NA,NA NA NA,100 100 100,100,  0 100,100 low,low,high,low low,Placebo,  0, 47.704659,35.695699,NA,NA,0,1,1.0 1.0 1.0 1.0 1,1,1,1 1,1,1 1.0,0,1 1,1,1089,Casas_2013 2-6 months,NA >= 20 yo 30.6,40,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100 High Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA,CAARS-S:S, 2.99194476 NA NA Casas 2013 NA RCT,G,182, 97, 279,outcomes,reverse,-0.3170000000 -0.565000000,-6.900000e-02, 15.4000000  14.5000000,NA,NA,NA NA,NA,NA,100 100,100,100   0,100,100,low,low high low low Placebo   0, 47.704659,35.695699,NA NA,0,1,1.0,1.0 1.0 1.0,1 1 1,1 1,1 1 1.0 0 1,1,1 1090,Casas_2013 2-6 months,NA >= 20 yo 33.7462897526502 42 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100 100,High Methylphenidate Methylphenidate   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability  2.99194476 NA,NA,Casas 2013 NA,RCT,RR,182  97, 279 outcomes reverse, 1.3230000000, 0.929000000, 1.885000e+00,NA NA NA,NA NA,NA,NA,NA,100 100 100 100,100 100,100,low low low,low,low,Placebo   0, 47.704659,35.695699,NA,NA 0,1 1.0,1.0 1.0 1.0,1,1,1,1,1,1,1,1.0 0 1 1,1 1091,Casas_2013,2-6 months,NA >= 20 yo 28.7959183673469 40 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100 High,Methylphenidate,Methylphenidate   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 2.99194476,NA NA Casas 2013,NA,RCT RR,182  97  279,outcomes,reverse, 9.0600000000  2.224000000, 3.691300e+01,NA,NA,NA NA,NA,NA,NA,NA,100 100,100,100,100 100,100,low,low,low,low low,Placebo,  0  47.704659,35.695699,NA,NA,0 1,1.0,1.0,1.0,1.0 1 1,1 1,1 1 1 1.0,0,1 1 1 1092 Casas_2013,2-6 months,NA,>= 20 yo,28.7959183673469 40 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High,Atomoxetine Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,CAARS-INV:SV  2.76179517   87.0000000 mg/kg/d,Durell 2013,NA,RCT G 119,134, 253 outcomes,reverse -0.5480000000 -0.885000000,-2.110000e-01,NA,NA,NA,NA,NA,NA  9.8394614, 9.8394614 100 100 100,100,  0,100,100 low,low,high low,low,Placebo,  0  42.753360 24.700000 NA NA,0 1,1.0,1.0,1.0 1.0 1 1 1 1 1,1,1,1.0 0 1 1,1 1093 Durell_2013 2-6 months NA,>= 20 yo,24.7 42.1,NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Atomoxetine Atomoxetine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA CAARS-S:S, 2.76179517   87.0000000,mg/d Durell,2013 NA RCT,G 189,197  386 outcomes reverse,-0.3850000000 -0.628000000,-1.430000e-01 NA,NA NA NA,NA NA,10.2460383 10.2460383 100 100 100 100   0,100,100,low,low high,low,low,Placebo,  0, 42.718653,24.700000,NA,NA 0,1 1.0,1.0 1.0,1.0,1 1,1 1 1 1 1,1.0 0,1 1,1,1094,Durell_2013,2-6 months,NA,>= 20 yo 24.7 42.1 NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High Atomoxetine,Atomoxetine   0 NA Quality of life (patients) Mixed At study endpoint (closest to 12 weeks),NA AAQoL, 2.76179517   87.0000000 mg/d Durell,2013 NA,RCT G 189,198  387,outcomes reverse  0.2680000000  0.067000000  4.680000e-01  17.2000000  15.6000000,NA NA,NA NA NA,NA 100,100 100 100   0 100,100 low low high,low low,Placebo   0  42.720930,24.700000,NA NA,0,1,1.0 1.0,1.0 1.0,1 1 1,1,1 1,1 1.0 0,1,1 1 1095 Durell_2013,2-6 months NA,>= 20 yo 24.7 37.9941666666667,NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA,Ostinelli (2025)_Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Atomoxetine Atomoxetine   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  2.76179517   87.0000000,mg/d Durell 2013 NA RCT RR 220,225  445 outcomes reverse, 1.1300000000  0.920000000, 1.389000e+00,NA,NA,NA,NA NA NA NA,NA 100 100,100 100 100,100 100 low,low,low,low,low,Placebo   0  42.710112 24.700000 NA,NA 0,1 1.0,1.0,1.0 1.0,1,1,1,1,1,1 1 1.0 0 1,1 1 1096,Durell_2013 2-6 months,NA,>= 20 yo,24.7,42.10703125,NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100,High,Atomoxetine,Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability  2.76179517   87.0000000,mg/d Durell,2013,NA RCT,RR,220 225, 445,outcomes,reverse, 3.5800000000, 1.473000000, 8.700000e+00 NA NA NA,NA NA,NA NA,NA,100,100,100,100 100 100 100 low low,low low,low Placebo,  0  42.710112,24.700000 NA NA 0,1 1.0 1.0,1.0,1.0,1 1,1 1,1,1,1 1.0,0 1 1 1 1097,Durell_2013,2-6 months NA,>= 20 yo 24.7,42.10703125,NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100,100,High,Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA CAARS-O:S  1.15074799,NA,NA,Ginsberg 2012 NA,RCT G  15  15,  30 outcomes,reverse,-2.1050000000 -3.021000000 -1.189000e+00  10.1800000,  5.5000000 NA,NA,NA NA,NA NA,100,100 100 100 100 100,100 low,low,low low,low Placebo,  0,  0.000000,34.400000 NA NA,0,1,1.0 1.0,1.0,1.0,1,1 1 1,1 1 1,1.0 0 1 1 1 1098 Ginsberg_2012,< 2 months,NA,>= 20 yo 30.6,40,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100 High,Methylphenidate Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA ASRS, 1.15074799 NA NA,Ginsberg 2012,NA,RCT,G, 15, 15   30 outcomes reverse -1.6380000000 -2.485000000,-7.910000e-01  12.1200000   8.9000000 NA,NA NA NA NA,NA,100,100 100 100,100 100,100 low low low,low low Placebo   0   0.000000 34.400000 NA,NA,0,1,1.0,1.0 1.0 1.0,1,1,1 1,1 1 1 1.0 0,1 1 1 1099,Ginsberg_2012,< 2 months,NA >= 20 yo,33.7462897526502 42 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100,100 High Methylphenidate,Methylphenidate,  0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.15074799,NA,NA,Ginsberg 2012,NA,RCT,RR  15, 15,  30,outcomes reverse, 1.0000000000  0.021000000, 4.738000e+01,NA,NA,NA NA,NA NA,NA,NA,100 100 100 100,100,100,100,low,low,low low,low,Placebo   0   0.000000,34.400000,NA NA,0 1,1.0 1.0 1.0,1.0 1 1,1,1 1,1 1,1.0,0 1 1,1,1100 Ginsberg_2012,< 2 months NA,>= 20 yo 28.7959183673469 40 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100 High Methylphenidate Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability  1.15074799,NA NA,Ginsberg,2012 NA,RCT RR, 15  15   30,outcomes,reverse  1.0000000000  0.021000000  4.738000e+01 NA,NA,NA NA,NA NA,NA NA 100,100 100 100,100 100,100,low low low,low low,Placebo,  0   0.000000,34.400000,NA,NA 0 1,1.0 1.0,1.0 1.0 1,1,1 1,1 1,1,1.0 0,1 1,1,1101 Ginsberg_2012 < 2 months,NA >= 20 yo 28.7959183673469,40,NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100 100 High Atomoxetine Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,ADHD-RS total  2.30149597 NA,NA Goto,2013,NA,RCT,G 191,195  386 outcomes,reverse,-0.4560000000 -0.715000000,-1.980000e-01,NA NA NA,NA,NA,NA  9.6000000  9.6000000 100,100,100 100,100 100 100 low low,low low,low,Placebo   0, 52.339119,32.244301 NA NA,0 1 1.0 1.0 1.0,1.0,1 1 1 1 1 1 1 1.0 0,1,1 1 1102 Goto_2013 2-6 months,NA,>= 20 yo,24.7 42.1,NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High Atomoxetine,Atomoxetine,  0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability, 2.30149597 NA,NA,Goto,2013,NA,RCT RR,195 196  391 outcomes reverse, 1.6080000000, 1.017000000, 2.544000e+00,NA NA,NA,NA NA NA,NA NA,100 100 100 100 100,100,100 low,low low,low low Placebo   0, 52.347315,32.248593,NA NA 0 1 1.0,1.0,1.0,1.0,1 1 1,1,1 1,1 1.0,0,1 1,1 1103 Goto_2013 2-6 months,NA,>= 20 yo,24.7,42.10703125,NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100 High,Atomoxetine,Atomoxetine   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 2.30149597,NA NA Goto 2013 NA RCT RR 195 196  391 outcomes reverse, 3.3500000000, 0.936000000, 1.198900e+01,NA,NA,NA NA,NA NA NA,NA 100,100,100 100,100,100 100 low,low low,low low,Placebo   0, 52.347315,32.248593,NA,NA,0,1 1.0 1.0 1.0 1.0,1 1 1 1 1,1,1,1.0,0,1,1,1,1104,Goto_2013,2-6 months,NA,>= 20 yo,24.7 42.10703125,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Methylphenidate Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,Other  0.92059839 NA,NA Herring 2012,NA RCT G, 39, 48   87,outcomes,reverse,-0.3620000000,-0.790000000  6.700000e-02, 20.6084934  21.4774300,NA,NA,NA,NA NA,NA 100,100,100,100 100 100 100 low,low,low,low,low,Placebo,  0  35.737931,38.434483 NA,NA,0,1 1.0 1.0 1.0,1.0 1 1,1,1 1 1,1 1.0,0,1 1,1,1105 Herring_2012,< 2 months,NA,>= 20 yo 30.6 40,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100 High,Methylphenidate,Methylphenidate   0,NA Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks) NA CPT commission, 0.92059839,NA NA Herring 2012 NA RCT,G, 23  26   49 outcomes,reverse -0.2640000000,-0.823000000, 2.960000e-01,NA NA NA,NA,NA NA  8.9100000  8.9100000,100 100 100,100 100 100,100 low low,low low,low Placebo,  0, 35.763265 38.440816 NA NA 0 1,1.0 1.0,1.0 1.0,1 1,1 1 1,1 1 1.0 0,1 1,1,1106,Herring_2012,< 2 months,NA >= 20 yo,30.5,38.4408163265306 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Methylphenidate,Methylphenidate   0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability, 0.92059839 NA NA Herring 2012,NA,RCT,RR, 39  48   87 outcomes,reverse  1.8460000000, 0.324000000  1.050300e+01 NA,NA NA NA,NA NA,NA NA   0,  0   0   0   0   0,  0 high,high high,high high,Placebo   0, 35.737931,38.434483,NA,NA,0,1 1.0,1.0,1.0 1.0 1,1,1,1,1 1,1 1.0,0,1 1,1 1107,Herring_2012,< 2 months NA >= 20 yo 28.7959183673469 40 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high,high
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High,Methylphenidate Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA,ADHD-SRS total, 2.07134638,NA,NA Huss,2014 NA,RCT G 471,161  632 outcomes reverse -0.5320000000,-0.754000000 -3.110000e-01 NA NA NA NA,NA,NA,11.0500000,11.0500000,100 100 100 100,100,100,100 low,low some,low,low Placebo   0  45.541456,35.384019 NA NA 0,1 1.0 1.0,1.0 1.0 1 1,1,1,1 1 1 1.0,0,1 1 1,1108 Huss_2014,2-6 months NA,>= 20 yo,30.6,40 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High,Methylphenidate,Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA ASRS  2.07134638,NA,NA Huss 2014 NA RCT G 455,147, 602,outcomes reverse -0.4860000000 -0.694000000 -2.790000e-01,NA,NA,NA,NA,NA NA,12.2000000,12.2000000,100,100 100 100 100,100,100,low,low some,low low,Placebo,  0, 45.560465,35.363953 NA NA 0 1 1.0,1.0 1.0,1.0 1 1 1 1 1,1,1,1.0 0,1 1,1 1109,Huss_2014 2-6 months,NA,>= 20 yo 33.7462897526502 42,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100 High Methylphenidate,Methylphenidate   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability, 2.07134638 NA NA,Huss,2014,NA RCT RR 544,181  725 outcomes reverse  1.3430000000, 0.920000000, 1.960000e+00 NA NA NA NA NA NA NA,NA 100 100 100,100,100 100,100 low low low low low,Placebo   0  45.550621 35.374345,NA NA,0 1 1.0,1.0 1.0,1.0 1 1 1,1 1 1 1,1.0 0 1,1,1,1110,Huss_2014 2-6 months NA,>= 20 yo,28.7959183673469 40 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100 100,High Methylphenidate Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability, 2.07134638 NA NA Huss 2014 NA RCT RR,544 181  725,outcomes reverse, 6.3220000000  2.004000000, 1.994000e+01 NA NA,NA,NA NA,NA,NA,NA,100 100 100,100,100 100 100 low,low low low low,Placebo   0, 45.550621 35.374345 NA,NA,0 1 1.0 1.0,1.0 1.0 1,1 1 1,1,1 1,1.0,0 1 1 1 1111,Huss_2014 2-6 months NA,>= 20 yo 28.7959183673469,40 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Bupropion,Bupropion   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),NA Other  1.61104718,NA NA,Kuperman 2001 NA RCT,G, 11, 11   22 outcomes,reverse -0.7530000000 -2.005000000, 5.000000e-01,NA,NA NA NA,NA NA,10.6000000,10.6000000 100 100 100,100,100,100,100,low,low low low low Placebo   0, 31.500000 32.700000,NA NA 0,1,1.0 1.0,1.0,1.0,1,1 1 1,1,1 1,1.0 0 1 1 1,1112,Kuperman_2001 < 2 months NA >= 20 yo 32.7,33.545 NA NA, 10, 7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25,NA,NA Ostinelli (2025)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100 High Bupropion,Bupropion   0,NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),NA CPT d'  1.61104718,NA,NA Kuperman 2001,NA RCT,G   8  10   18 NA reverse  0.2080000000 -0.722000000  1.137000e+00,NA,NA,NA NA,NA NA, 1.1000000, 1.1000000 100 100 100,100 100 100 100,low,low low low low Placebo,  0  31.000000 32.644444,NA NA,0 1,1.0 1.0 1.0 1.0,1,1 1,1 1,1,1 1.0 0 1,1,1,1113,Kuperman_2001,< 2 months,NA,>= 20 yo,32.6444444444444,32.6444444444444,NA,NA, 10, 7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25 NA NA Ostinelli (2025)_Bupropion_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Bupropion_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100 High,Atomoxetine Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),NA CAARS-S:L  2.76179517,NA,NA McRae-Clark,2010 NA RCT,G, 19, 19,  38 outcomes reverse -0.3350000000 -1.254000000, 5.830000e-01 NA,NA NA,NA,NA,NA  7.7300000  7.7300000,100,100,100,100,100 100,100,some low,low,low low,Placebo   0, 23.685000,29.900000 NA NA,0 1 1.0 1.0 1.0 1.0,1 1,1 1 1,1 1,1.0 0 1 1 1 1114,McRae-Clark_2010 2-6 months,NA >= 20 yo 24.7,42.1,NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100,100,High Atomoxetine Atomoxetine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability  2.76179517,NA,NA,McRae-Clark,2010 NA,RCT RR  39  39,  78 outcomes reverse  1.0000000000  0.649000000  1.541000e+00 NA,NA,NA NA NA NA,NA,NA,100 100 100,100 100,100,100 some,low low low low Placebo   0  23.685000,29.900000,NA,NA,0 1 1.0 1.0 1.0,1.0 1,1,1,1 1,1,1,1.0 0,1,1 1 1115 McRae-Clark_2010,2-6 months NA,>= 20 yo 24.7,42.10703125,NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0 100 100,High,Atomoxetine,Atomoxetine   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability, 2.76179517,NA NA McRae-Clark,2010 NA,RCT,RR, 39, 39   78,outcomes,reverse  1.0000000000  0.020000000, 4.917300e+01,NA NA,NA,NA,NA,NA NA NA 100,100 100,100,100 100,100,some low,low low,low,Placebo,  0  23.685000 29.900000,NA,NA,0,1,1.0,1.0 1.0,1.0,1,1 1 1 1 1 1 1.0 0,1,1 1 1116 McRae-Clark_2010,2-6 months,NA >= 20 yo 24.7 42.10703125 NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Methylphenidate,Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA,CAARS-O:S, 1.15074799,   0.5700000 mg/kg/d Medori,2008,NA,RCT G 299  95  394,outcomes reverse,-0.3740000000 -0.645000000,-1.040000e-01 NA,NA,NA NA,NA,NA, 9.9300000  9.9300000,100 100,100 100,100 100 100,low,low low low,low,Placebo   0  45.633503 34.044670 NA,NA 0,1 1.0,1.0,1.0 1.0 1 1 1 1 1,1,1 1.0,0,1,1 1 1117 Medori_2008 < 2 months,NA >= 20 yo 30.6,40 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA CAARS-S:S  1.15074799    0.5700000 mg/d,Medori,2008 NA RCT G 280  91  371,outcomes reverse,-0.3500000000,-0.607000000 -9.300000e-02,NA NA NA NA,NA NA 11.2600000 11.2600000,100 100 100 100 100 100,100,low low low,low low Placebo,  0  45.594340,34.047170,NA,NA,0 1 1.0,1.0,1.0,1.0,1 1,1,1,1,1,1 1.0 0,1,1,1 1118,Medori_2008 < 2 months,NA,>= 20 yo 33.7462897526502,42,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High,Methylphenidate Methylphenidate,  0,NA Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks),NA CAARS impulsivity/emotional lability  1.15074799    0.5700000,mg/d,Medori,2008 NA,RCT G,280  91, 371 outcomes,reverse -0.2810000000 -0.533000000 -2.900000e-02,NA,NA,NA,NA,NA,NA, 2.8228813  2.8228813,100,100 100 100 100,100 100 low,low,low,low,low,Placebo   0  45.594340,34.047170 NA NA,0,1 1.0,1.0,1.0 1.0 1 1,1 1 1 1,1,1.0 0,1 1 1,1119,Medori_2008,< 2 months NA,>= 20 yo,34.0471698113208,36.9 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100 100,High Methylphenidate Methylphenidate,  0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability  1.15074799    0.5700000 mg/d Medori 2008,NA RCT,RR 305, 96, 401,outcomes reverse, 4.0920000000  0.542000000  3.087500e+01 NA NA,NA,NA,NA NA NA,NA   0   0   0   0   0,  0,  0,high,high,high high,high Placebo   0  45.649626 34.043641 NA NA,0 1 1.0,1.0,1.0,1.0 1,1 1 1,1 1 1,1.0,0 1,1 1 1120 Medori_2008 < 2 months NA >= 20 yo,28.7959183673469,40 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high,high
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0 100 100,High Atomoxetine,Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,CAARS-INV:SV  2.30149597,NA,NA,Michelson,2003,NA,RCT,G 133 134  267,outcomes reverse -0.2940000000,-0.570000000,-1.800000e-02 NA,NA,NA NA NA,NA, 9.3000000  9.3000000 100,100,100,100 100 100 100 low,low,low,low low,Placebo,  0, 36.453558,40.250187,NA NA,0,1,1.0 1.0,1.0 1.0,1,1 1 1 1,1 1 1.0 0 1,1,1 1121 Michelson_2003 2-6 months NA >= 20 yo,24.7 42.1 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High Atomoxetine,Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA,CAARS-S:L, 2.30149597,NA,NA,Michelson,2003,NA,RCT G,133 134, 267 outcomes,reverse,-0.3210000000,-0.600000000 -4.300000e-02,NA,NA NA,NA NA NA,14.0000000 14.0000000,100,100,100,100 100,100 100 low low low,low,low,Placebo   0  36.453558 40.250187 NA,NA,0 1 1.0 1.0,1.0,1.0 1 1 1 1,1 1 1,1.0,0 1 1,1,1122 Michelson_2003 2-6 months NA >= 20 yo,24.7 42.1 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High Atomoxetine Atomoxetine   0 NA Emotional dysregulation Mixed At study endpoint (closest to 12 weeks) NA,WRAADDS, 2.30149597 NA NA Michelson 2003,NA RCT G 133,134  267 outcomes,reverse -0.1980000000 -0.466000000  7.100000e-02,NA,NA NA NA NA,NA  4.8000000, 4.8000000 100,100 100 100 100 100,100,low,low,low low low Placebo   0, 36.453558 40.250187 NA,NA 0 1,1.0 1.0 1.0,1.0 1,1 1 1,1,1,1 1.0,0,1 1 1 1123,Michelson_2003 2-6 months NA,>= 20 yo 40.2501872659176 42.1 NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100 100 High,Atomoxetine Atomoxetine   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 2.30149597,NA,NA Michelson 2003,NA,RCT,RR,141,139  280,outcomes,reverse  1.2010000000  0.802000000, 1.801000e+00,NA,NA NA NA NA NA,NA NA,100,100,100 100 100,100,100,low,low,low low,low Placebo,  0, 36.443214 40.249643 NA,NA,0,1 1.0 1.0,1.0 1.0,1,1 1 1,1,1 1,1.0 0,1,1,1 1124,Michelson_2003 2-6 months,NA >= 20 yo 24.7 42.10703125,NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100 High,Atomoxetine,Atomoxetine,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 2.30149597,NA NA,Michelson 2003,NA,RCT,RR,141,139  280,outcomes reverse, 1.8070000000, 0.687000000  4.752000e+00 NA,NA NA,NA NA,NA NA,NA,100 100 100,100 100,100,100 low,low,low,low,low,Placebo   0, 36.443214 40.249643,NA,NA,0,1 1.0,1.0 1.0,1.0 1 1,1,1 1 1,1,1.0,0 1 1 1,1125 Michelson_2003,2-6 months NA,>= 20 yo,24.7 42.10703125 NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,  0   0,100 100,High,Amphetamine,Amphetamine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA Other, 1.38089758 NA NA,Paterson 1999,NA RCT G  24, 21,  45,outcomes,reverse,-0.4570000000 -1.057000000, 1.430000e-01   6.2000000   7.8000000,NA,NA NA NA NA,NA 100 100 100,100,100 100 100 some low low,low,low Placebo,  0,NA NA,NA NA 0,1 1.0,1.0,1.0 1.0,1,1,1,1 1 1 1 1.0 0,1,1,1 1126,Paterson_1999,< 2 months NA NA,39.0310734463277 41.2 NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100 High Bupropion Bupropion,  0,NA,Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks),NA WRAADDS  1.38089758  298.0000000,mg/d,Reimherr 2005 NA RCT G, 29, 18,  47,NA,reverse -0.3270000000 -0.925000000  2.710000e-01,  5.6000000   5.1000000,NA,NA NA NA,NA,NA,  0   0   0,  0   0,  0   0,high,high,high high,high,Placebo,  0, 27.221277,34.414894,NA NA 0 1 1.0 1.0 1.0,1.0 1 1,1,1,1,1 1 1.0 0 1,1,1,1127,Reimherr_2005 < 2 months,NA,>= 20 yo,34.4148936170213,34.4148936170213 NA NA, 10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25,NA,NA Ostinelli (2025)_Bupropion_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Bupropion_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high,high
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100,High,Bupropion,Bupropion   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  1.38089758, 298.0000000 mg/d Reimherr 2005 NA RCT RR  35  24   59,outcomes reverse, 0.6860000000, 0.251000000  1.874000e+00,NA,NA NA NA,NA NA NA,NA 100 100,100,100 100,100,100 low,low,low low,low,Placebo   0, 27.135593,34.422034 NA NA,0 1,1.0 1.0 1.0 1.0,1 1 1,1 1 1 1 1.0 0 1 1,1,1128 Reimherr_2005 < 2 months,NA >= 20 yo 34.4220338983051,38.235 NA NA  10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25 NA NA,Ostinelli (2025)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Bupropion,Bupropion   0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability, 1.38089758  298.0000000,mg/d Reimherr 2005 NA,RCT RR  35, 24,  59 outcomes,reverse  0.6940000000  0.014000000  3.385000e+01 NA,NA NA NA,NA NA NA NA 100 100,100,100 100 100,100 low low low low,low Placebo   0  27.135593,34.422034,NA,NA 0 1 1.0 1.0 1.0 1.0,1 1 1 1,1 1 1 1.0,0 1,1,1 1129,Reimherr_2005 < 2 months,NA,>= 20 yo,34.4220338983051,38.235,NA NA  10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25 NA,NA,Ostinelli (2025)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100 100 High,Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA,Other  0.92059839,  60.5000000 mg/d,Reimherr,2007,NA RCT G, 41  41   82,outcomes reverse,-0.8530000000 -1.308000000 -3.980000e-01,  2.5270023   2.2253312 NA NA,NA NA NA NA 100,100,100,100,100,100 100 low low low low low Placebo,  0, 34.000000,30.600000 NA,NA,0,1 1.0 1.0 1.0 1.0 1 1,1,1 1,1,1 1.0,0,1 1 1 1130,Reimherr_2007,< 2 months NA >= 20 yo 30.6 40,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100,100 High,Methylphenidate Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At follow-up (closest to 26 weeks),NA,Other, 5.52359033   41.2000000,mg/d,Rosler 2009 NA RCT,G,241 118, 359,outcomes,reverse -0.3510000000,-0.573000000,-1.290000e-01   0.5952914,  0.6623094 NA,NA NA,NA NA,NA,100 100 100 100   0,100,100 low,low high low,low,Placebo   0  50.000000,34.739833,NA NA 0 1 1.0 1.0,1.0,1.0,1,1 1 1,1,1 1 1.0,0 1,1 1,1131,Rosler_2009,2-6 months,NA,>= 20 yo,34.7398328690808,35.3047619047619,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High,Methylphenidate,Methylphenidate,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA CAARS-S:L, 5.52359033   41.2000000 mg/d Rosler 2009,NA RCT G,239 118  357 outcomes,reverse -0.2750000000 -0.497000000 -5.300000e-02  36.3000000  38.5000000 NA NA,NA,NA,NA NA 100 100,100 100,  0,100,100 low low,high,low low,Placebo   0, 50.000000 34.737255,NA,NA 0,1 1.0 1.0 1.0 1.0 1,1,1 1,1,1,1,1.0,0,1,1 1,1132,Rosler_2009 2-6 months NA,>= 20 yo,33.7462897526502,42 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100,100,High,Methylphenidate Methylphenidate,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 26 weeks),NA CAARS-S:L, 5.52359033,  41.2000000 mg/d,Rosler,2009,NA RCT G 239,118  357,outcomes reverse,-0.2850000000 -0.507000000,-6.300000e-02  36.8000000, 39.8000000 NA,NA,NA,NA NA NA 100,100 100,100,  0,100,100,low,low,high,low low Placebo,  0  50.000000 34.737255,NA NA,0 1 1.0 1.0 1.0,1.0,1 1 1 1 1,1 1 1.0 0,1,1 1,1133 Rosler_2009,2-6 months NA,>= 20 yo 34.7372549019608,35.3120567375887,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100 100 High,Methylphenidate Methylphenidate,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  5.52359033   41.2000000,mg/d Rosler,2009,NA,RCT,RR 241,118  359,outcomes reverse  0.5460000000, 0.403000000, 7.390000e-01 NA NA NA,NA NA,NA NA NA,100,100 100,100 100,100,100 low,low low low low,Placebo   0, 50.000000 34.739833 NA,NA 0 1 1.0 1.0 1.0,1.0 1,1,1,1 1,1 1 1.0,0 1,1,1,1134 Rosler_2009 2-6 months,NA,>= 20 yo 28.7959183673469 40,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High,Methylphenidate,Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 5.52359033,  41.2000000,mg/d,Rosler,2009,NA,RCT,RR 241,118, 359 outcomes reverse  1.5180000000  0.771000000, 2.990000e+00,NA,NA,NA,NA NA NA,NA,NA,100 100,100 100,100 100,100 low,low low low,low Placebo,  0  50.000000,34.739833 NA NA,0,1 1.0,1.0 1.0 1.0 1,1,1,1 1,1,1 1.0 0,1,1,1,1135 Rosler_2009,2-6 months NA,>= 20 yo 28.7959183673469,40,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100,100,High Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,ADHD-SRS total  0.69044879,NA,NA Spencer,1995 NA RCT G  24, 25,  49 outcomes reverse -1.0180000000 -1.620000000 -4.150000e-01   7.2000000,  7.3000000,NA,NA,NA NA NA NA 100 100 100,100,100,100,100,some low,some,low,low Placebo,  0  57.000000,40.000000,NA,NA 0,1 1.0,1.0,1.0 1.0,1 1,1 1,1,1,1 1.0 0,1,1,1 1136,Spencer_1995,< 2 months,NA,>= 20 yo 30.6,40,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100 High Methylphenidate,Methylphenidate   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  0.69044879 NA NA,Spencer 1995 NA RCT RR, 25, 25   50 outcomes,reverse  3.0000000000, 0.128000000  7.029600e+01,NA,NA NA,NA,NA,NA NA NA,100 100 100,100,100 100,100,some low low low low,Placebo,  0  57.000000,40.000000,NA,NA 0 1 1.0,1.0 1.0,1.0 1,1,1,1 1,1 1 1.0 0,1 1,1,1137,Spencer_1995,< 2 months,NA,>= 20 yo,28.7959183673469 40 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High Methylphenidate Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability  0.69044879,NA NA,Spencer,1995 NA,RCT RR, 25  25   50 outcomes,reverse, 1.0000000000, 0.021000000, 4.852400e+01,NA NA NA,NA,NA,NA,NA,NA,100,100 100 100,100 100 100,some,low,low low,low,Placebo   0, 57.000000 40.000000 NA NA 0,1 1.0,1.0 1.0,1.0 1,1 1,1 1 1 1,1.0 0,1 1,1 1138 Spencer_1995 < 2 months NA >= 20 yo,28.7959183673469 40 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100 100 High Amphetamine,Amphetamine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA ADHD-SRS total, 0.69044879 NA NA,Spencer,2001 NA,RCT,G  15, 11   26 outcomes reverse -1.0330000000 -1.880000000,-1.860000e-01,  7.5000000   7.5000000,NA,NA,NA NA,NA NA 100 100,100 100 100,100,100,low low,some low,low Placebo,  0  44.000000 38.800000,NA,NA,0,1 1.0 1.0,1.0,1.0,1 1 1,1,1 1,1,1.0 0 1 1 1 1139,Spencer_2001,< 2 months NA >= 20 yo,22.2059016393443 39.0276595744681 NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100 High Amphetamine,Amphetamine   0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  0.69044879,NA,NA Spencer,2001 NA,RCT,RR  30  30   60 outcomes,reverse  0.3330000000, 0.014000000, 7.870000e+00,NA,NA,NA NA,NA NA,NA,NA 100,100,100,100,100,100 100,low,low low,low,low,Placebo,  0, 44.000000 38.800000 NA NA 0,1 1.0,1.0,1.0,1.0,1,1,1,1 1,1 1,1.0,0,1,1,1,1140 Spencer_2001,< 2 months NA,>= 20 yo 22.2057971014493,39.0319587628866,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Amphetamine Amphetamine   0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability, 0.69044879,NA,NA,Spencer,2001 NA RCT,RR  30, 30,  60,outcomes,reverse, 1.0000000000, 0.020000000, 4.882200e+01 NA,NA NA,NA NA,NA NA,NA,100,100 100,100,100 100 100,low low,low,low low,Placebo,  0, 44.000000 38.800000 NA NA,0,1,1.0 1.0 1.0,1.0,1 1,1,1 1,1 1,1.0 0 1,1 1,1141,Spencer_2001 < 2 months NA,>= 20 yo,22.2057971014493,39.0319587628866,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100 High,Methylphenidate Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA Other  1.38089758,NA,NA,Spencer,2005 NA RCT G  78, 32, 110 outcomes,reverse -0.7400000000,-1.165000000 -3.160000e-01, 10.2000000,  9.7000000 NA,NA NA NA,NA NA,100 100 100 100,  0,100,100 some low,high low,low,Placebo   0  41.796364,36.967273,NA,NA,0 1 1.0,1.0 1.0,1.0,1,1,1,1 1,1,1 1.0,0 1 1,1 1142,Spencer_2005,< 2 months,NA,>= 20 yo 30.6,40 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100 100,High Methylphenidate Methylphenidate,  0 NA,Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks) NA,Q-LES-Q  1.15074799 NA NA Spencer,2007 NA,RCT G,160, 48  208 outcomes,reverse  0.0510000000 -0.273000000  3.740000e-01,  7.6300000,  8.6200000,NA,NA NA,NA NA NA 100,100,100,100,100 100 100,low,some,low some low,Placebo   0, 49.060000 38.100000 NA,NA 0 1 1.0,1.0 1.0,1.0,1,1 1 1 1,1,1,1.0,0 1,1,1 1143 Spencer_2007,< 2 months NA,>= 20 yo,33.7475177304965 38.1 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High,Methylphenidate Methylphenidate   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability  1.15074799 NA,NA,Spencer,2007,NA RCT RR,168  53, 221 outcomes,reverse, 0.8520000000, 0.442000000  1.642000e+00,NA,NA NA,NA NA NA,NA NA 100 100 100,100,100 100 100 low,some,low some low Placebo   0, 49.060000 38.100000 NA,NA,0 1,1.0,1.0,1.0,1.0,1,1 1 1,1 1,1,1.0 0,1 1 1 1144,Spencer_2007,< 2 months NA,>= 20 yo 28.7959183673469 40,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100 High,Methylphenidate,Methylphenidate   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability, 1.15074799,NA,NA,Spencer,2007,NA RCT,RR 168, 53, 221 outcomes,reverse, 1.4200000000  0.503000000, 4.010000e+00,NA NA NA,NA NA,NA,NA NA,100 100,100 100 100 100 100,low,some low,some,low Placebo,  0, 49.060000 38.100000,NA NA,0 1,1.0 1.0 1.0 1.0,1 1,1,1 1 1,1,1.0 0,1,1,1,1145 Spencer_2007 < 2 months NA,>= 20 yo,28.7959183673469 40,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2   0   0,100 100 High Atomoxetine,Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA Other  1.84119678,  89.7000000,mg/d,Sutherland 2012,NA RCT,G, 97, 47, 144 outcomes reverse -0.3130000000,-0.665000000  3.800000e-02, 11.4000000  14.2000000 NA NA,NA NA,NA NA 100 100 100,100 100,100,100,low some,some,low low,Placebo,  0 NA NA NA NA,0,1,1.0,1.0 1.0,1.0,1,1 1,1,1 1,1 1.0,0,1 1,1 1146,Sutherland_2012 < 2 months,NA,NA,24.7,42.1 NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2   0   0 100,100 High Atomoxetine Atomoxetine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  1.84119678,  89.7000000,mg/d Sutherland,2012,NA RCT RR, 97, 47  144,outcomes,reverse  0.6540000000, 0.412000000, 1.038000e+00 NA,NA,NA NA NA NA,NA,NA,100,100,100 100,100 100 100,low some low some,low,Placebo   0 NA,NA,NA NA,0 1,1.0 1.0 1.0,1.0 1 1 1 1 1 1 1,1.0,0 1 1 1,1147,Sutherland_2012,< 2 months,NA NA 24.7,42.10703125,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2   0,  0 100 100 High Atomoxetine,Atomoxetine,  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 1.84119678,  89.7000000,mg/d,Sutherland,2012,NA RCT,RR, 97  47  144,outcomes,reverse  0.7610000000  0.315000000, 1.838000e+00,NA NA,NA NA NA NA NA,NA 100,100,100 100,100,100 100 low,some low some,low Placebo,  0,NA,NA NA,NA 0 1,1.0,1.0 1.0 1.0,1,1,1,1,1 1 1,1.0,0,1,1 1,1148,Sutherland_2012 < 2 months,NA NA,24.7 42.10703125 NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100 High,Methylphenidate Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA,CAARS-O:S  1.84119678,  51.5000000 mg/d,Takahashi,2014,NA RCT G 143 140  283 outcomes reverse,-0.5190000000 -0.817000000,-2.200000e-01 NA NA NA NA,NA,NA, 9.3500000, 9.3500000 100 100 100,100,100,100,100,low,low low low low Placebo   0, 51.042049,33.746290,NA,NA 0,1 1.0 1.0,1.0,1.0,1,1,1 1 1,1 1 1.0,0,1,1,1 1149 Takahashi_2014 < 2 months,NA >= 20 yo,30.6 40,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100 100 High,Methylphenidate Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA CAARS-S:S, 1.84119678   51.5000000 mg/d,Takahashi 2014 NA RCT,G 143 140  283,outcomes,reverse -0.4280000000 -0.704000000 -1.530000e-01,NA,NA NA,NA NA NA,10.0600000,10.0600000,100,100 100 100 100,100,100,low low,low low low,Placebo,  0, 51.042049,33.746290,NA NA,0,1 1.0 1.0 1.0,1.0 1,1,1,1,1 1,1 1.0 0,1,1,1,1150,Takahashi_2014,< 2 months NA >= 20 yo,33.7462897526502 42,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100 High Methylphenidate,Methylphenidate   0 NA Quality of life (patients),Mixed At study endpoint (closest to 12 weeks),NA,Q-LES-Q  1.84119678,  51.5000000,mg/d Takahashi 2014 NA RCT G 142 140, 282,outcomes reverse, 0.1080000000 -0.126000000, 3.420000e-01,NA NA NA,NA,NA NA,12.6900000 12.6900000 100,100 100,100 100,100,100,low,low low,low low,Placebo,  0  51.044681,33.747518,NA,NA 0,1,1.0,1.0,1.0 1.0 1,1,1,1,1,1,1,1.0,0,1 1,1,1151 Takahashi_2014,< 2 months NA >= 20 yo 33.7475177304965 38.1,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High,Methylphenidate,Methylphenidate   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  1.84119678   51.5000000 mg/d,Takahashi,2014,NA RCT,RR,143,141, 284 outcomes,reverse  1.4790000000  0.541000000  4.046000e+00 NA NA NA,NA NA NA NA NA 100 100,100 100,100,100,100 low low low low low Placebo,  0  51.044718,33.747535,NA,NA,0,1 1.0,1.0 1.0 1.0,1,1 1,1 1,1 1,1.0 0,1,1,1,1152,Takahashi_2014 < 2 months,NA,>= 20 yo 28.7959183673469,40 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Methylphenidate,Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,Tolerability, 1.84119678,  51.5000000 mg/d,Takahashi 2014 NA RCT,RR,143 141, 284,outcomes,reverse  5.9160000000, 0.721000000, 4.851400e+01 NA,NA,NA NA NA NA NA,NA 100 100 100 100,100,100,100 low,low,low,low low,Placebo   0, 51.044718,33.747535 NA,NA 0 1,1.0,1.0 1.0,1.0,1 1 1,1,1 1,1,1.0 0,1 1 1 1153 Takahashi_2014 < 2 months NA >= 20 yo 28.7959183673469 40,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100 100,High Modafinil,Modafinil   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),NA,Other  0.46029919, 206.8000000,mg/d Taylor 2000,NA RCT G, 22  22,  44,outcomes reverse -0.9710000000 -1.604000000,-3.380000e-01, 11.2000000, 10.0000000 NA,NA NA NA,NA NA 100,100 100 100,100 100 100,some low,low low low Placebo,  0  41.000000 40.800000 NA NA,0 1,1.0 1.0 1.0 1.0 1,1 1 1,1 1 1,1.0 0,1,1,1,1154 Taylor_2000,< 2 months NA >= 20 yo,39.1295774647887,40.8 NA,NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA,NA,Ostinelli (2025)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High Amphetamine,Amphetamine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA,Other  0.46029919,  21.8000000,mg/d Taylor 2000,NA,RCT,G  22  22   44 outcomes reverse,-0.8100000000,-1.432000000,-1.880000e-01  11.3000000  10.0000000 NA,NA,NA,NA,NA,NA,100 100 100 100,100 100 100,some low,low low,low,Placebo   0, 41.000000,40.800000 NA NA,0,1,1.0,1.0 1.0 1.0 1,1 1 1,1,1,1 1.0 0 1 1,1 1155 Taylor_2000,< 2 months,NA,>= 20 yo 39.0310734463277 41.2,NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA Other  0.46029919,   1.1000000 mg/d,Taylor 2001 NA,RCT G  17, 17   34 NA,reverse,-0.8350000000,-1.547000000 -1.220000e-01   8.2000000, 10.6000000 NA,NA,NA NA,NA NA 100,100 100,100 100,100,100 some low some,low,low,Placebo   0  59.000000,41.200000 NA NA 0 1 1.0 1.0 1.0 1.0 1,1 1 1,1,1 1 1.0,0,1,1,1,1156 Taylor_2001,< 2 months,NA >= 20 yo,41.2,41.2 NA,NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100 High Amphetamine,Amphetamine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA,Other  0.46029919,  10.2000000 mg/d Taylor 2001,NA,RCT G, 17, 17,  34 outcomes reverse,-0.5350000000,-1.229000000  1.600000e-01  12.0000000, 10.6000000 NA NA NA NA NA NA,100 100 100 100 100 100,100 some low some,low low Placebo,  0  59.000000 41.200000 NA NA 0 1,1.0 1.0,1.0,1.0,1,1 1 1 1 1 1 1.0,0,1 1,1,1157 Taylor_2001,< 2 months NA >= 20 yo,39.0310734463277,41.2 NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Methylphenidate Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA,BADDS-adults, 0.69044879 NA NA Tenenbaum,2002,NA,RCT,G, 24  24,  48 outcomes reverse,-0.0080000000,-0.580000000  5.630000e-01,  2.6000000   2.2000000,NA,NA NA NA NA NA 100 100 100   0 100 100,100 some,high,some low low,Placebo   0, 54.200000 42.000000 NA,NA,0 1,1.0,1.0 1.0,1.0 1,1 1,1,1,1,1 1.0 0,1,1 1 1158 Tenenbaum_2002,< 2 months NA,>= 20 yo 33.7462897526502 42,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High Methylphenidate Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,Other, 1.38089758,  54.9800000,mg/kg/d,Goodman,2016 NA,RCT G,169,172, 341 outcomes,reverse -0.3420000000,-0.556000000,-1.280000e-01, 12.7600000, 13.4700000 NA,NA NA,NA NA,NA 100,100,100,100 100,100 100 low low,some low,low,Placebo,  0, 47.231085 35.740762 NA NA 0,1,1.0,1.0 1.0,1.0,1,1 1 1,1 1 1,1.0 0 1 1 1 1159 Goodman_2016 < 2 months NA,>= 20 yo,30.6,40 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Methylphenidate,Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA ASRS  1.38089758,  54.9800000 mg/d,Goodman,2016,NA,RCT,G 166,167  333,outcomes,reverse -0.3020000000,-0.518000000,-8.600000e-02  16.0400000  16.3300000,NA,NA,NA,NA NA NA 100 100,100,100 100,100 100 low low some low,low,Placebo,  0, 47.243544,35.746847,NA NA,0,1,1.0 1.0 1.0 1.0,1,1 1 1,1 1,1,1.0,0 1 1,1,1160,Goodman_2016 < 2 months,NA >= 20 yo 33.7462897526502,42,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Methylphenidate Methylphenidate,  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.38089758,  54.9800000,mg/d,Goodman 2016,NA RCT,RR,178 179, 357,outcomes reverse, 0.9080000000, 0.613000000  1.344000e+00,NA NA NA,NA NA NA,NA NA,100 100 100,100 100,100,100,low,low low low low Placebo,  0, 47.243978,35.747059,NA NA,0,1 1.0,1.0,1.0,1.0 1 1,1 1,1 1,1 1.0,0,1,1 1,1161,Goodman_2016 < 2 months NA >= 20 yo,28.7959183673469 40 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Methylphenidate Methylphenidate   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability  1.38089758,  54.9800000,mg/d,Goodman 2016 NA RCT,RR 178 179  357 outcomes reverse  1.6090000000, 0.537000000  4.824000e+00,NA,NA NA NA,NA,NA,NA,NA,100,100 100,100,100,100,100,low low low low,low Placebo,  0  47.243978 35.747059 NA,NA 0 1 1.0 1.0,1.0 1.0 1 1 1,1 1,1,1 1.0,0 1 1,1 1162,Goodman_2016 < 2 months NA >= 20 yo,28.7959183673469,40 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA,CAARS-S:L, 1.38089758,  44.0000000 mg/d,Biehl,2016 NA,RCT,G  14  13   27 outcomes reverse -0.7500000000,-1.547000000  4.800000e-02, 12.6000000  13.8000000 NA NA,NA,NA NA NA 100 100,100 100 100,100 100 low,some low,low,some Placebo   0  37.814815 36.122222 NA,NA 0 1,1.0,1.0,1.0,1.0 1,1 1 1 1 1 1 1.0 0 1 1,1,1163,Biehl_2016,< 2 months NA >= 20 yo 33.7462897526502 42 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High Methylphenidate Methylphenidate   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  1.38089758,  44.0000000 mg/d,Biehl 2016,NA RCT,RR  19  16   35,outcomes,reverse, 0.2830000000, 0.012000000  6.511000e+00 NA,NA NA,NA NA NA,NA NA,100,100 100 100 100 100 100,low,low low low low,Placebo,  0, 37.571429,36.151429 NA,NA 0,1,1.0 1.0,1.0,1.0,1,1 1 1 1,1,1 1.0 0,1 1 1 1164,Biehl_2016 < 2 months NA >= 20 yo 28.7959183673469,40 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High Methylphenidate Methylphenidate   0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability, 1.38089758   44.0000000,mg/d,Biehl,2016,NA RCT,RR, 19  16,  35,outcomes reverse  0.8500000000, 0.018000000  4.059800e+01 NA NA,NA NA NA,NA NA,NA 100 100,100 100,100,100 100 low low,low low,low Placebo   0  37.571429,36.151429 NA NA,0 1 1.0 1.0,1.0,1.0 1,1 1,1,1 1 1 1.0,0,1,1 1 1165,Biehl_2016,< 2 months,NA,>= 20 yo,28.7959183673469 40 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Bupropion Bupropion,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA,CAARS-S:L, 1.38089758  150.0000000,mg/d,Hamedi 2014,NA,RCT G, 21, 21,  42 outcomes reverse,-0.8100000000 -1.448000000,-1.730000e-01, 15.3400000  10.0900000,NA,NA NA NA,NA,NA 100,100,100 100,100 100,100 low,low low,low,low,Placebo,  0  28.950000,33.545000 NA NA 0 1,1.0,1.0,1.0 1.0 1 1 1,1 1,1 1,1.0 0 1 1,1,1166,Hamedi_2014,< 2 months,NA >= 20 yo 32.7 33.545,NA NA, 10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25,NA,NA Ostinelli (2025)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Methylphenidate,Methylphenidate   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  3.68239356,NA NA,Schrantee,2016 NA RCT,RR, 25  24,  49 outcomes reverse, 0.6400000000  0.117000000, 3.501000e+00,NA NA NA NA NA,NA,NA,NA 100,100,100,100 100 100 100 low low low,low low,Placebo   0,  0.000000 28.795918,NA,NA 0 1,1.0 1.0,1.0,1.0,1 1,1,1 1 1 1 1.0 0 1,1,1,1167,Schrantee_2016 2-6 months NA >= 20 yo 28.7959183673469 40 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100 High Methylphenidate Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability  3.68239356 NA NA Schrantee,2016 NA RCT RR  25  24   49 outcomes reverse  0.9600000000, 0.064000000, 1.449500e+01,NA,NA NA,NA,NA NA,NA NA,100 100,100,100 100 100,100,low low,low low,low,Placebo   0,  0.000000,28.795918 NA,NA 0,1 1.0 1.0,1.0 1.0 1,1,1 1 1,1,1 1.0 0 1 1 1 1168,Schrantee_2016 2-6 months,NA >= 20 yo 28.7959183673469 40 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Atomoxetine,Atomoxetine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA,ASRS, 1.84119678 NA NA,Lin 2016 NA RCT,G  12  12   24 outcomes reverse -0.6630000000 -1.504000000  1.780000e-01,  6.4320613, 11.3366019 NA NA NA NA NA NA,100 100 100,100,100,100,100 some,some,low some some Placebo,  0  54.165000 30.125000,NA NA,0 1 1.0 1.0 1.0 1.0 1 1,1,1,1 1 1,1.0,0,1,1,1,1169,Lin_2016,< 2 months,NA >= 20 yo,24.7,42.1,NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High,Atomoxetine,Atomoxetine,  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  1.84119678 NA,NA,Lin,2016 NA,RCT,RR, 12, 12,  24 outcomes reverse, 1.0000000000  0.021000000, 4.670300e+01,NA NA NA,NA NA,NA,NA,NA 100,100 100 100,100,100,100,some some low some low Placebo   0  54.165000 30.125000 NA NA,0,1,1.0,1.0,1.0 1.0,1,1 1,1 1,1 1,1.0,0,1 1 1,1170 Lin_2016,< 2 months,NA,>= 20 yo 24.7 42.10703125,NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100,High,Atomoxetine Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  1.84119678 NA,NA Lin 2016,NA RCT,RR  12  12,  24,outcomes reverse, 1.0000000000  0.021000000  4.670300e+01 NA NA NA NA NA NA,NA NA,100,100,100,100 100 100,100,some,some,low some,low,Placebo   0, 54.165000 30.125000,NA,NA,0 1 1.0 1.0 1.0,1.0 1 1,1,1,1,1,1,1.0 0 1,1,1 1171 Lin_2016,< 2 months,NA >= 20 yo,24.7,42.10703125,NA NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100 100,High Atomoxetine Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,ADHD-RS total, 0.69044879,  76.0000000 mg/d Spencer 1998 NA RCT G  21, 21,  42,outcomes reverse,-0.8490000000,-1.489000000 -2.090000e-01  10.1000000   8.8000000 NA,NA NA,NA NA,NA 100 100,100 100 100 100,100,some some low,some some,Placebo,  0  52.380000 34.000000,NA NA,0 1 1.0 1.0 1.0,1.0 1,1,1,1 1,1,1 1.0,0 1,1,1,1172 Spencer_1998,< 2 months,NA,>= 20 yo 24.7,42.1 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0 100,100 High,Atomoxetine,Atomoxetine   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 0.69044879   76.0000000,mg/d Spencer 1998 NA,RCT,RR  22  22,  44 outcomes reverse  3.0000000000  0.129000000  6.986800e+01,NA,NA,NA NA,NA NA NA NA,100,100,100 100,100,100 100 some some,low,some,low Placebo   0, 52.380000 34.000000,NA NA 0 1 1.0 1.0,1.0,1.0 1 1,1,1 1 1 1 1.0 0,1,1 1 1173,Spencer_1998 < 2 months,NA >= 20 yo,24.7 42.10703125,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Atomoxetine,Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  0.69044879,  76.0000000 mg/d,Spencer 1998,NA,RCT RR, 22, 22,  44 outcomes,reverse, 3.0000000000  0.129000000  6.986800e+01,NA NA NA,NA,NA NA,NA,NA 100,100 100 100,100,100 100 some,some,low some,low,Placebo,  0, 52.380000 34.000000,NA NA,0,1 1.0 1.0 1.0,1.0,1 1,1 1 1 1 1 1.0,0,1,1 1 1174,Spencer_1998,< 2 months,NA >= 20 yo,24.7 42.10703125 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2   0,  0,100 100 High Amphetamine,Amphetamine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 0.69044879 NA,NA Kay 2009,NA,RCT,RR,  9, 10   19 outcomes reverse  0.3700000000  0.046000000, 2.954000e+00 NA NA NA NA,NA,NA,NA NA,100 100,100,100 100,100 100 low,low low low low,Placebo   0  53.000000,NA,NA NA 0 1,1.0,1.0,1.0,1.0,1,1,1,1 1 1,1 1.0,0,1,1 1,1175,Kay_2009,< 2 months,NA NA 22.2057971014493 39.0319587628866 NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,  0,  0 100,100,High Amphetamine Amphetamine   0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  0.69044879 NA NA Kay,2009,NA RCT RR   9  10,  19,outcomes,reverse, 1.1110000000  0.081000000  1.528400e+01,NA NA,NA NA,NA NA,NA,NA 100,100,100,100 100 100,100 low,low,low low low Placebo   0, 53.000000,NA NA NA,0,1,1.0,1.0,1.0,1.0 1,1,1,1,1,1 1,1.0,0,1,1 1 1176,Kay_2009 < 2 months,NA,NA,22.2057971014493 39.0319587628866 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,  0   0,100 100,High,Atomoxetine,Atomoxetine   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  0.69044879 NA,NA,Kay,2009 NA,RCT,RR,  8   8,  16 outcomes,reverse  1.0000000000, 0.022000000, 4.512700e+01 NA NA NA NA NA,NA,NA,NA 100,100 100 100 100 100 100 low low,low,low,low Placebo,  0,NA NA NA,NA 0 1,1.0,1.0 1.0 1.0 1 1,1 1 1,1 1,1.0,0,1,1 1 1177 Kay_2009,< 2 months,NA NA,24.7,42.10703125,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,  0   0,100 100,High,Atomoxetine,Atomoxetine   0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability  0.69044879 NA NA Kay,2009 NA,RCT RR   8,  8   16 outcomes,reverse, 1.0000000000  0.022000000, 4.512700e+01 NA,NA NA NA,NA,NA,NA NA 100 100 100 100 100 100 100 low low low,low low,Placebo,  0 NA NA NA NA,0 1 1.0 1.0 1.0 1.0,1 1,1 1,1,1 1,1.0 0,1,1,1 1178 Kay_2009 < 2 months,NA NA 24.7 42.10703125,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100,100 High,Amphetamine,Amphetamine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA ADHD-RS total, 1.38089758,NA,NA Frick,2017 NA RCT G,204 103  307,outcomes,reverse -0.8530000000,-1.100000000,-6.060000e-01  12.3103000, 10.9400000,NA,NA,NA NA,NA,NA 100 100 100 100,100 100 100,low low some low low Placebo,  0  42.339414 36.928990 NA NA 0,1,1.0,1.0,1.0,1.0,1,1 1,1,1 1,1,1.0 0 1 1 1,1179 Frick_2017 < 2 months,NA >= 20 yo,22.2059016393443 39.0276595744681,NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Amphetamine Amphetamine   0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  1.38089758,NA,NA Frick 2017,NA,RCT RR,205 104, 309 outcomes reverse, 0.5650000000, 0.405000000  7.870000e-01 NA NA NA NA,NA NA NA NA 100,100 100 100,100,100,100 low low,low low,low Placebo,  0  42.342395,36.926861 NA,NA 0,1,1.0,1.0 1.0 1.0,1,1 1,1,1 1 1 1.0 0 1,1,1,1180 Frick_2017 < 2 months NA,>= 20 yo 22.2057971014493 39.0319587628866,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100,100,High Amphetamine Amphetamine,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability  1.38089758 NA NA,Frick,2017,NA,RCT,RR 205 104  309 outcomes,reverse, 3.2130000000  0.973000000  1.061000e+01,NA,NA,NA,NA,NA NA,NA NA,100 100 100 100 100,100 100,low low low,low low,Placebo,  0, 42.342395,36.926861 NA,NA 0 1,1.0 1.0 1.0 1.0,1,1 1 1,1,1,1,1.0,0 1 1 1,1181,Frick_2017 < 2 months NA,>= 20 yo,22.2057971014493,39.0319587628866 NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100 High Atomoxetine Atomoxetine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,CAARS-INV:SV  2.30149597,NA NA Michelson,2003 NA RCT,G 124 124  248,outcomes reverse,-0.2410000000 -0.532000000, 4.900000e-02,NA NA,NA NA NA NA  9.3000000  9.3000000,100,100 100 100,100 100,100 low low,low low low Placebo,  0  33.600000,42.100000,NA NA 0,1 1.0 1.0 1.0 1.0,1,1 1 1,1 1 1,1.0 0 1,1,1,1182 Michelson_2003 2-6 months,NA,>= 20 yo,24.7,42.1 NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100,High,Atomoxetine Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA CAARS-S:L, 2.30149597,NA,NA Michelson 2003 NA,RCT,G 124,124, 248,outcomes reverse -0.2610000000,-0.552000000  3.000000e-02 NA NA,NA,NA,NA NA,16.1000000 16.1000000 100 100,100,100,100 100,100 low,low low low,low,Placebo   0, 33.600000 42.100000 NA NA 0,1 1.0,1.0 1.0,1.0,1,1,1 1 1 1,1 1.0 0 1 1 1,1183,Michelson_2003 2-6 months NA >= 20 yo 24.7 42.1 NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High Atomoxetine Atomoxetine,  0,NA Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks) NA WRAADDS, 2.30149597,NA NA Michelson 2003 NA RCT G 124,124, 248 outcomes,reverse -0.2700000000,-0.543000000  3.000000e-03,NA,NA,NA NA NA,NA, 5.7000000  5.7000000,100 100,100 100,100 100,100,low low low low low,Placebo,  0  33.600000,42.100000,NA,NA 0 1,1.0 1.0 1.0 1.0 1,1,1,1,1 1,1 1.0,0 1,1,1 1184 Michelson_2003,2-6 months,NA,>= 20 yo 40.2501872659176,42.1,NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100 High Atomoxetine Atomoxetine   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability  2.30149597,NA NA,Michelson 2003,NA RCT RR,129 127, 256,outcomes reverse  1.4460000000  0.992000000  2.107000e+00,NA,NA,NA NA NA,NA,NA NA,100 100,100,100 100 100,100 low,low,low,low low Placebo,  0, 33.616406,42.107031,NA,NA,0 1 1.0,1.0 1.0,1.0,1 1,1 1,1,1 1 1.0,0,1 1 1,1185 Michelson_2003 2-6 months,NA >= 20 yo,24.7,42.10703125,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Atomoxetine Atomoxetine   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  2.30149597 NA,NA Michelson,2003,NA RCT,RR 129 127  256 outcomes,reverse, 3.9380000000, 1.138000000, 1.362500e+01,NA NA,NA,NA,NA,NA,NA,NA 100 100 100 100,100,100,100,low low,low low low,Placebo,  0  33.616406 42.107031 NA,NA 0 1 1.0,1.0 1.0 1.0,1,1,1,1 1,1 1,1.0 0,1,1,1,1186 Michelson_2003 2-6 months NA >= 20 yo 24.7,42.10703125,NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High Amphetamine,Amphetamine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA Other  0.92059839   25.0000000 mg/d Weisler,2017,NA RCT G 177  86, 263 outcomes,reverse,-0.7010000000,-1.042000000,-3.600000e-01 NA NA,NA NA,NA,NA,11.4700000,11.4700000,100 100,100 100 100 100 100 low low,low low low Placebo,  0, 99.450663,33.288593,NA,NA,0,1 1.0,1.0 1.0,1.0 1,1 1 1,1,1,1 1.0,0,1,1 1 1187,Weisler_2017,< 2 months,NA,>= 20 yo 22.2059016393443 39.0276595744681 NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100 High Amphetamine,Amphetamine,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839   25.0000000,mg/d,Weisler 2017,NA,RCT,RR,184  91  275 outcomes reverse  1.2590000000  0.657000000  2.413000e+00,NA NA,NA NA,NA,NA,NA NA,100 100 100,100 100 100,100,low low,low,low low,Placebo   0  99.451113 33.295636 NA,NA 0 1,1.0 1.0 1.0 1.0,1,1 1 1 1 1 1,1.0 0 1,1 1,1188,Weisler_2017,< 2 months,NA,>= 20 yo 22.2057971014493 39.0319587628866 NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100,High,Amphetamine,Amphetamine   0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability  0.92059839,  25.0000000,mg/d Weisler,2017 NA RCT,RR,184  91, 275 outcomes,reverse 12.4320000000, 0.744000000, 2.076650e+02,NA,NA,NA,NA NA,NA,NA NA 100,100,100 100 100,100,100,low,low low low low Placebo,  0  99.451113,33.295636 NA,NA 0,1 1.0 1.0,1.0,1.0 1,1 1 1 1 1 1,1.0 0 1,1,1,1189,Weisler_2017 < 2 months,NA,>= 20 yo,22.2057971014493 39.0319587628866,NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100 High Methylphenidate,Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,ADHD-RS total  0.92059839,NA NA,Weiss,2020 NA,RCT,G,297, 78, 375 outcomes,reverse,-0.3710000000 -0.622000000 -1.200000e-01, 11.8000000  12.0000000 NA NA NA,NA,NA,NA 100 100 100,100,100,100,100,low low low,low,low Placebo   0  52.724000 36.053600,NA NA 0,1 1.0,1.0,1.0 1.0,1,1 1,1,1,1,1,1.0 0,1,1 1 1190,Weiss_2020,< 2 months,NA >= 20 yo 30.6,40 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100 100 High Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),NA,CAARS-S, 0.92059839,NA,NA,Weiss,2020,NA,RCT,G,297  78, 375 outcomes,reverse -0.2150000000,-0.465000000  3.500000e-02  12.4000000, 13.1000000,NA NA NA NA NA NA 100,100 100,100,100 100 100 low low,low low,low,Placebo,  0  52.724000,36.053600,NA,NA 0 1,1.0,1.0 1.0,1.0 1 1,1 1 1,1,1,1.0,0,1,1 1 1191,Weiss_2020,< 2 months NA >= 20 yo,33.7462897526502 42,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100 High Methylphenidate Methylphenidate,  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  0.92059839 NA,NA,Weiss 2020,NA RCT,RR 297  78  375 outcomes reverse, 0.9630000000, 0.481000000  1.927000e+00 NA NA,NA,NA NA NA NA NA 100,100,100,100 100 100 100 low,low low low low,Placebo,  0, 52.724000,36.053600 NA NA,0 1,1.0 1.0 1.0 1.0,1,1,1 1 1,1,1,1.0,0,1,1 1 1192,Weiss_2020 < 2 months,NA >= 20 yo,28.7959183673469,40 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Methylphenidate Methylphenidate,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 0.92059839,NA NA Weiss 2020 NA,RCT,RR 297  78  375 outcomes,reverse  1.0510000000  0.228000000, 4.848000e+00,NA NA,NA,NA NA,NA NA,NA,100,100 100 100,100,100,100,low low low low low,Placebo   0  52.724000,36.053600 NA,NA 0,1 1.0,1.0,1.0 1.0 1,1 1,1 1,1,1 1.0 0 1,1,1 1193 Weiss_2020 < 2 months NA >= 20 yo,28.7959183673469,40,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100 100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA ADHD-RS total, 2.76179517,   5.0700000 mg/d Iwanami 2020 NA,RCT G 100 100  200 NA reverse -0.3680000000,-0.694000000 -4.100000e-02,NA NA NA NA NA NA 10.7000000,10.7000000,100,100,100 100,  0 100 100 low low high low low,Placebo   0  35.500000 32.450000,NA NA 0,1 1.0 1.0,1.0,1.0,1 1,1 1,1,1 1,1.0 0 1,1 1 1194 Iwanami_2020,2-6 months NA,>= 20 yo 32.45 32.45 NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA Emotional dysregulation Mixed At study endpoint (closest to 12 weeks),NA BRIEF-ASR Emotional control  2.76179517    5.0700000 mg/d Iwanami,2020,NA,RCT,G 100,100, 200,NA,reverse, 0.1170000000,-0.161000000  3.940000e-01,NA,NA,NA NA,NA,NA 13.3000000,13.3000000,100 100,100 100,  0,100 100,low low high,low low,Placebo,  0, 35.500000,32.450000 NA NA,0 1 1.0,1.0,1.0,1.0 1,1,1 1,1 1 1,1.0,0,1,1,1,1195,Iwanami_2020,2-6 months,NA >= 20 yo,32.45,32.45 NA NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA,Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA,Quality of life (patients),Mixed At study endpoint (closest to 12 weeks),NA,AAQoL  2.76179517,   5.0700000,mg/d Iwanami,2020 NA,RCT G 100,100  200,NA reverse,-0.1520000000 -0.431000000, 1.270000e-01,NA,NA NA NA NA,NA 24.3000000,24.3000000 100 100 100 100,  0,100,100 low low,high,low,low Placebo,  0  35.500000,32.450000 NA,NA,0,1 1.0,1.0,1.0,1.0,1 1,1,1 1,1,1 1.0 0 1 1,1,1196 Iwanami_2020 2-6 months,NA,>= 20 yo,32.45,32.45,NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA NA,Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 2.76179517    5.0700000,mg/d Iwanami,2020,NA,RCT RR,101 100, 201 NA reverse  3.1120000000, 1.392000000, 6.955000e+00,NA,NA NA,NA,NA,NA NA NA,100,100 100 100,100 100,100,low low low low low Placebo   0  35.492537 32.443284,NA,NA,0 1,1.0,1.0,1.0 1.0 1,1 1 1 1,1 1 1.0 0,1,1,1 1197 Iwanami_2020 2-6 months NA >= 20 yo 32.4432835820896,32.4432835820896,NA,NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA NA,Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability  2.76179517    5.0700000,mg/d Iwanami,2020 NA RCT RR 101,100, 201,NA,reverse, 6.6010000000  2.025000000, 2.151500e+01 NA NA NA,NA,NA NA NA NA,100 100,100,100 100,100,100 low low,low,low,low Placebo,  0  35.492537 32.443284,NA,NA 0 1 1.0,1.0,1.0,1.0,1 1,1,1 1,1,1 1.0,0,1,1,1 1198,Iwanami_2020,2-6 months,NA,>= 20 yo,32.4432835820896 32.4432835820896 NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA,Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Amphetamine,Amphetamine   0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability, 0.92059839   59.1000000,mg/d,Adler,2021,NA,RCT RR  17  21   38,outcomes,reverse, 0.4070000000, 0.018000000  9.407000e+00,NA,NA NA NA,NA,NA,NA NA,  0   0,  0,  0,  0   0   0,high high,high,high,high Placebo,  0  65.800000 34.000000,NA,NA,0,1,1.0,1.0 1.0 1.0,1 1,1 1 1 1,1 1.0 0 1 1 1,1199,Adler_2021 < 2 months,NA >= 20 yo 22.2057971014493,39.0319587628866,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high high
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100,High,Amphetamine Amphetamine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA ADHD-SRS total, 1.15074799,  30.0000000,mg/d Faraone 2021,NA RCT G,214 106, 320 outcomes reverse -0.1320000000,-0.406000000  1.420000e-01,NA NA NA,NA NA,NA,13.2813629,13.2813629,  0   0,  0   0   0,  0,  0 high,high,high,high high,Placebo   0  45.622500 34.467500 NA,NA 0 1,1.0,1.0,1.0,1.0,1,1 1,1 1 1,1 1.0,0 1 1,1,1200 Faraone_2021 < 2 months,NA,>= 20 yo 22.2059016393443,39.0276595744681 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high high
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100,100,High,Amphetamine,Amphetamine,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability, 1.15074799,  30.0000000,mg/d,Faraone,2021,NA,RCT,RR,214 106, 320 outcomes,reverse, 1.4150000000, 0.806000000, 2.483000e+00 NA NA,NA NA NA NA,NA NA 100 100,100 100 100,100 100,low low,low,low,low,Placebo,  0  45.622500,34.467500,NA NA,0,1 1.0 1.0,1.0 1.0 1 1,1 1,1,1 1 1.0,0 1,1 1 1201,Faraone_2021,< 2 months NA >= 20 yo,22.2057971014493,39.0319587628866,NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Amphetamine Amphetamine,  0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  1.15074799,  30.0000000,mg/d,Faraone 2021,NA RCT RR 214,106  320,outcomes,reverse  1.1560000000, 0.305000000  4.380000e+00 NA NA NA,NA NA NA NA,NA 100,100,100 100,100,100,100,low,low,low,low,low,Placebo,  0  45.622500,34.467500 NA,NA 0 1,1.0 1.0,1.0 1.0 1,1 1,1,1,1 1 1.0 0 1,1,1,1202,Faraone_2021,< 2 months NA,>= 20 yo 22.2057971014493,39.0319587628866,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA CAARS-S:L  0.69044879,NA,NA,Alyagon,2020,NA,RCT G  15, 14,  29,outcomes reverse -0.8570000000 -1.692000000,-2.200000e-02 NA NA,NA,NA NA NA  7.1091490  7.1091490 100,100 100,100,100 100 100 low low some low,low,Sham   0, 82.789655 27.112414,NA NA 0 1,1.0 1.0 1.0 1.0 1 1,1,1 1,1,1 1.0,0 1,1 1,1203 Alyagon_2020 < 2 months,NA,>= 20 yo 27.1124137931034 35.24 NA,NA   4  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1,Ostinelli (2025),27.0733333333333 35.24 NA,NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High,TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation),  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 0.69044879,NA,NA Alyagon,2020 NA RCT RR, 20, 16   36,outcomes,reverse  1.8000000000, 0.677000000, 4.783000e+00 NA NA NA NA NA,NA NA NA,100,100 100 100 100,100 100,low,low,low low low Sham,  0, 83.100000 27.073333,NA NA,0,1,1.0 1.0 1.0,1.0 1,1 1,1 1,1,1,1.0 0,1,1 1 1204,Alyagon_2020 < 2 months NA,>= 20 yo 27.0733333333333 35.22,NA,NA   4, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025),27.0733333333333 35.24 NA NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High,TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation),  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability, 0.69044879,NA,NA,Alyagon 2020,NA,RCT,RR  20, 16   36,outcomes,reverse, 0.8100000000, 0.017000000, 3.871100e+01 NA NA,NA,NA,NA,NA,NA NA 100,100 100 100,100,100 100 low low,low low,low Sham   0, 83.100000 27.073333 NA NA 0,1 1.0,1.0 1.0 1.0,1,1,1,1,1 1,1,1.0 0 1 1 1 1205 Alyagon_2020 < 2 months NA >= 20 yo 27.0733333333333 35.22 NA NA,  4  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1,Ostinelli (2025) 27.0733333333333 35.24,NA,NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100 100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA CAARS-S:L, 1.84119678,NA,NA Anastopoulos 2021 NA RCT,G,111 109  220,outcomes,reverse -0.1930000000 -0.458000000, 7.200000e-02   9.1600000  10.4300000,NA,NA,NA,NA,NA,NA,100,100 100 100 100 100,100 some some,some some,low,WLC   0  65.443182 19.650455 NA,NA,0,1 1.0,1.0 1.0 1.0 1 1,1 1 1,1 1 1.0,0 1 1 1,1206,Anastopoulos_2021,< 2 months,NA,13-19 yo 19.6504545454545,43.1027777777778,NA,NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100 100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At follow-up (closest to 26 weeks) NA,CAARS-S:L  1.84119678 NA NA Anastopoulos,2021 NA RCT G, 95,102  197 outcomes,reverse -0.3380000000 -0.620000000 -5.600000e-02   9.4800000,  9.4800000,NA,NA,NA,NA,NA,NA 100,100,100 100,100,100,100,some,some,some some,low,WLC,  0  65.476650 19.648223,NA NA,0,1,1.0 1.0,1.0 1.0 1,1,1,1,1 1,1,1.0 0 1 1 1 1207 Anastopoulos_2021 < 2 months NA,13-19 yo,19.6482233502538 43.0524590163934 NA NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.84119678,NA,NA Anastopoulos 2021,NA RCT RR,149 131, 280 outcomes,reverse  1.6370000000  1.114000000  2.407000e+00 NA,NA NA NA NA,NA,NA,NA,100,100 100 100,100,100 100 some,some,low,some,low WLC,  0, 65.401786,19.653214 NA NA 0,1,1.0 1.0,1.0,1.0,1,1,1,1 1,1 1 1.0,0,1 1,1,1208,Anastopoulos_2021 < 2 months,NA 13-19 yo,19.6532142857143 43.15,NA NA, 20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100 100,High TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA,CAARS-S:L  1.84119678,NA NA Bleich-Cohen,2021,NA RCT,G, 24  16,  40,outcomes,reverse, 0.1090000000,-0.532000000  7.500000e-01, 13.0200000, 12.4700000 NA NA NA NA,NA,NA 100 100,100,100,100 100,100 some,some low low some Sham   0, 37.520000 35.240000 NA NA 0 1 1.0 1.0 1.0 1.0,1 1 1,1,1 1,1,1.0 0 1,1 1,1209,Bleich-Cohen_2021,< 2 months,NA >= 20 yo 27.1124137931034 35.24 NA NA   4, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025) 27.0733333333333,35.24 NA,NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100 High,TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation),  0 NA Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks) NA,AAQoL, 1.84119678,NA NA Bleich-Cohen 2021 NA RCT,G, 24  16,  40 outcomes reverse -0.2190000000,-0.861000000  4.230000e-01, 15.1100000  18.5700000,NA,NA NA NA NA NA,100 100,100,100,100 100 100,some some,low low,some Sham,  0  37.520000,35.240000,NA,NA 0,1 1.0 1.0,1.0,1.0,1,1,1 1,1 1 1 1.0,0,1,1,1,1210 Bleich-Cohen_2021 < 2 months,NA >= 20 yo 34.9315789473684 35.24 NA NA   4  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025),27.0733333333333 35.24 NA NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation),  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability, 1.84119678 NA,NA Bleich-Cohen 2021 NA RCT,RR  26, 19   45 outcomes,reverse  0.4870000000  0.090000000  2.636000e+00,NA NA,NA,NA NA NA,NA,NA 100,100 100,100 100 100,100,some,some,low some low,Sham,  0, 37.982222 35.220000,NA NA 0 1 1.0,1.0 1.0 1.0 1 1,1 1,1 1,1,1.0,0 1 1,1,1211,Bleich-Cohen_2021 < 2 months,NA,>= 20 yo,27.0733333333333 35.22 NA NA   4  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1,Ostinelli (2025) 27.0733333333333 35.24,NA NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100,100,High,TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation),  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.84119678 NA,NA,Bleich-Cohen 2021,NA,RCT RR, 26, 19,  45 outcomes,reverse, 0.7310000000, 0.113000000  4.735000e+00,NA,NA NA,NA,NA,NA NA,NA,100 100,100,100,100,100 100 some,some low,some,low Sham   0, 37.982222,35.220000 NA NA 0,1 1.0,1.0,1.0 1.0 1 1,1,1,1 1 1,1.0 0 1 1,1,1212,Bleich-Cohen_2021 < 2 months NA,>= 20 yo 27.0733333333333 35.22,NA NA,  4, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025) 27.0733333333333,35.24,NA NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100,High TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA,CAARS-S:L, 1.84119678 NA,NA Bleich-Cohen 2021 NA RCT G  22  16,  38 outcomes,reverse, 0.5760000000,-0.090000000  1.242000e+00  12.7400000, 12.4700000,NA,NA,NA,NA,NA,NA,100 100 100,100 100 100 100 some some low low,some Sham,  0  39.521053,34.931579 NA NA 0 1,1.0,1.0,1.0,1.0,1,1 1,1,1 1 1 1.0 0 1 1 1,1213,Bleich-Cohen_2021 < 2 months NA >= 20 yo 27.1124137931034,35.24 NA NA,  4  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025) 27.0733333333333 35.24 NA,NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation)   0 NA,Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks) NA,AAQoL, 1.84119678,NA NA,Bleich-Cohen 2021,NA,RCT G  22, 16,  38 outcomes reverse -0.5310000000 -1.195000000  1.330000e-01, 16.3000000, 18.5700000,NA NA NA NA,NA NA,100,100,100 100,100,100 100 some some low low,some Sham,  0, 39.521053 34.931579 NA,NA,0 1 1.0,1.0,1.0,1.0 1,1 1,1 1,1,1,1.0,0,1 1 1,1214,Bleich-Cohen_2021,< 2 months NA >= 20 yo,34.9315789473684,35.24 NA,NA   4, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1 Ostinelli (2025) 27.0733333333333 35.24 NA,NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High,TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation)   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 1.84119678 NA NA Bleich-Cohen,2021,NA RCT RR, 28, 19   47,outcomes reverse  0.9050000000, 0.228000000, 3.593000e+00 NA NA,NA NA NA NA NA,NA 100,100 100,100 100,100 100,some,some,low some low Sham,  0, 39.217021,34.938298 NA,NA,0,1 1.0,1.0 1.0 1.0 1,1,1 1,1,1 1 1.0,0 1 1,1,1215,Bleich-Cohen_2021,< 2 months NA >= 20 yo 27.0733333333333 35.22 NA,NA   4  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1,Ostinelli (2025),27.0733333333333,35.24 NA NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100,100,High,TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation),  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability, 1.84119678 NA NA Bleich-Cohen 2021 NA RCT,RR, 28, 19   47 outcomes reverse  1.3570000000, 0.276000000  6.684000e+00,NA,NA NA NA NA NA,NA NA,100,100 100 100 100 100,100 some some,low,some low Sham,  0, 39.217021 34.938298 NA NA 0,1 1.0,1.0,1.0,1.0,1 1,1,1,1 1,1,1.0 0,1 1,1 1216,Bleich-Cohen_2021 < 2 months,NA >= 20 yo,27.0733333333333 35.22 NA,NA   4, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1,Ostinelli (2025),27.0733333333333,35.24 NA,NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High tDCS (transcranial direct current stimulation) tDCS (transcranial direct current stimulation),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA ASRS  0.92059839 NA,NA,Cachoeira,2016,NA RCT G   8,  8   16,NA reverse -0.6350000000,-1.677000000, 4.070000e-01  11.9076782, 12.0490996,NA,NA NA,NA,NA,NA 100 100,100 100,100 100,100 low,low,low,low,low,Sham,  0, 52.800000,32.375000,NA NA,0,1 1.0,1.0 1.0 1.0 1,1,1 1 1 1,1 1.0 0 1 1 1 1217,Cachoeira_2016,< 2 months,NA >= 20 yo 32.375 32.375 NA,NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA,NA,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100,100,High tDCS (transcranial direct current stimulation),tDCS (transcranial direct current stimulation),  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839,NA NA Cachoeira 2016 NA RCT,RR   9   8,  17 outcomes reverse, 2.7000000000  0.125000000  5.823900e+01 NA NA NA NA NA,NA NA,NA 100 100,100,100 100,100 100 low low,low,low low Sham,  0  52.964706 32.294118 NA NA 0,1,1.0 1.0 1.0,1.0,1,1,1 1,1 1 1,1.0,0 1 1,1 1218,Cachoeira_2016 < 2 months NA >= 20 yo 22.085 38.3,NA NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA NA Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100 High tDCS (transcranial direct current stimulation) tDCS (transcranial direct current stimulation),  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.92059839 NA NA,Cachoeira 2016,NA,RCT RR,  9,  8   17,outcomes,reverse, 2.7000000000, 0.125000000  5.823900e+01,NA,NA NA,NA NA,NA,NA NA 100 100,100 100,100,100 100,low low low,low,low,Sham   0, 52.964706 32.294118,NA,NA,0 1,1.0,1.0 1.0 1.0 1,1,1,1 1,1,1,1.0,0 1,1 1,1219,Cachoeira_2016,< 2 months,NA,>= 20 yo,32.2941176470588 38.3 NA,NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857,NA NA Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100,100 High Cognitive training,Cognitive training   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA,CAARS hyperactivity  1.15074799 NA,NA,Dentz 2017,NA,RCT G, 23, 21   44 outcomes reverse, 0.0000000000 -0.598000000  5.980000e-01   3.1400000   4.0800000,NA,NA NA,NA NA NA 100 100 100,100,100,100,100 low,some,some low low Cognitive placebo,  0  61.390909 41.589545 NA,NA 0 1,1.0 1.0,1.0 1.0,1 1,1,1 1 1 1 1.0,0,1 1,1 1220 Dentz_2017 < 2 months NA >= 20 yo 25.7931034482759 41.5895454545455 NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA,Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,  0   0 100,100 High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),100,tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA Kiddie SADS  1.84119678,NA NA Emilsson 2011 NA,RCT,G  17, 17   34,outcomes reverse,-1.0080000000,-1.734000000 -2.820000e-01   7.2300000,  4.0800000,NA NA,NA NA NA NA,100,100 100,100,100 100,100,low some,some some,some TAU,  0 NA NA,NA,NA 0,1,1.0 1.0,1.0 1.0,1,1 1,1,1,1,1,1.0 0,1,1 1 1221 Emilsson_2011,< 2 months NA NA 39.1739024390244 43.1064102564103 NA,NA  20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,  0   0 100,100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT) 100,tau Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA,Other  1.84119678 NA NA,Emilsson 2011,NA,RCT G, 18  17,  35 outcomes,reverse,-0.7440000000,-1.440000000,-4.700000e-02   7.6200000,  8.8000000,NA NA,NA,NA,NA,NA,100,100,100,100 100 100,100,low,some some some some TAU   0,NA NA NA,NA 0,1,1.0,1.0,1.0,1.0 1,1,1,1,1 1,1 1.0,0 1 1 1,1222 Emilsson_2011,< 2 months NA NA,19.6504545454545,43.1027777777778,NA,NA  20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2   0   0 100 100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT) 100,tau,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.84119678,NA,NA,Emilsson 2011,NA RCT RR, 27  27   54 outcomes reverse  1.1670000000, 0.451000000, 3.020000e+00,NA NA,NA,NA,NA,NA NA,NA 100,100,100,100 100,100 100 low some,low,some,low,TAU,  0 NA,NA,NA NA 0,1,1.0 1.0,1.0,1.0 1 1 1 1,1 1 1 1.0 0,1 1 1 1223,Emilsson_2011 < 2 months,NA,NA 19.6532142857143,43.15 NA NA  20  9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100,100,High Mindfulness,Mindfulness   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA,CAARS-S:L, 1.38089758,NA NA Gu,2017 NA RCT G, 28  26,  54 outcomes reverse,-1.2450000000 -1.835000000 -6.550000e-01   8.3500000,  9.1700000,NA,NA,NA,NA NA,NA,100,100 100 100,100,100 100 some some low some,some WLC,  0, 44.488889,20.291852,NA,NA,0,1 1.0 1.0 1.0,1.0 1 1,1 1 1 1,1 1.0 0 1,1 1 1224 Gu_2017 < 2 months,NA >= 20 yo 20.2918518518519,39.3401869158878,NA,NA  13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0 100,100 High,Mindfulness Mindfulness   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 26 weeks),NA CAARS-S:S, 1.38089758,NA,NA Gu,2017,NA RCT,G  28, 26,  54 outcomes,reverse,-1.1440000000 -1.726000000 -5.620000e-01   9.8100000,  8.4400000 NA,NA NA,NA NA,NA 100,100,100,100 100,100,100,some,some low,some,some WLC   0, 44.488889,20.291852,NA,NA,0,1,1.0 1.0 1.0,1.0 1 1,1 1,1 1 1,1.0 0,1,1,1 1225 Gu_2017,< 2 months,NA,>= 20 yo,20.2918518518519 39.337037037037,NA,NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35,NA NA Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1,Homogeneous Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100 High,Mindfulness,Mindfulness   0 NA,Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks) NA ANT alerting error score  1.38089758,NA NA,Gu 2017 NA,RCT,G  28, 26,  54 outcomes reverse -1.2610000000,-1.852000000,-6.700000e-01,  0.0050000,  0.0100000,NA,NA NA NA NA,NA,100,100 100,100,100 100,100,some some,low some some WLC   0  44.488889 20.291852,NA NA,0,1,1.0 1.0 1.0,1.0 1,1,1,1,1,1,1 1.0,0 1 1,1,1226 Gu_2017 < 2 months,NA,>= 20 yo,20.2918518518519,38.6015 NA,NA, 13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA NA,Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100 100 High Mindfulness Mindfulness   0 NA Executive functioning (tests) Mixed,At follow-up (closest to 26 weeks) NA,ANT alerting error score  1.38089758,NA,NA Gu 2017,NA RCT,G, 28  26,  54,outcomes reverse -1.2310000000 -1.820000000,-6.420000e-01,  0.0050000   0.0090000 NA,NA NA NA,NA NA,100 100 100,100,100 100 100,some,some low,some some,WLC,  0  44.488889,20.291852 NA,NA 0,1 1.0,1.0,1.0,1.0 1,1 1,1,1 1,1 1.0 0,1 1 1,1227 Gu_2017,< 2 months,NA,>= 20 yo,20.2918518518519 39.337037037037,NA NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA NA Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous Ostinelli (2025) - Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100 100,High Mindfulness Mindfulness   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  1.38089758 NA NA Gu,2017,NA RCT,RR  30  26   56,outcomes reverse  4.3550000000, 0.219000000, 8.679000e+01,NA,NA NA NA NA,NA NA NA 100 100,100,100 100,100,100 some some low,some low WLC,  0, 44.432143 20.288929 NA,NA 0,1 1.0,1.0,1.0,1.0,1 1,1,1 1,1 1,1.0 0,1,1 1,1228,Gu_2017,< 2 months,NA,>= 20 yo 20.2889285714286 39.35 NA NA, 13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA NA Ostinelli (2025)_Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Mindfulness,Mindfulness,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,CAARS-O:L, 2.76179517 NA,NA,Hepark 2015 NA,RCT G  41, 42,  83 outcomes,reverse -0.8470000000,-1.299000000 -3.950000e-01   7.7000000,  7.5000000,NA NA NA NA NA,NA 100 100 100,100,100,100,100,low,some,some,low some WLC   0, 53.903614,35.842169,NA,NA,0 1,1.0,1.0 1.0,1.0 1,1 1,1 1 1 1 1.0,0 1 1 1,1229,Hepark_2015 2-6 months NA >= 20 yo 35.8421686746988,39.3401869158878,NA NA, 13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA NA Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High Mindfulness Mindfulness   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA CAARS-S:L, 2.76179517,NA NA,Hepark,2015,NA,RCT,G, 41  42   83,outcomes,reverse -0.8090000000 -1.260000000,-3.590000e-01,  7.3000000,  6.9000000 NA NA,NA NA NA NA 100,100 100 100 100,100,100,low some some low,some WLC   0, 53.903614,35.842169 NA,NA 0,1,1.0,1.0,1.0 1.0,1,1 1,1,1 1 1 1.0 0,1 1,1 1230 Hepark_2015 2-6 months NA >= 20 yo,20.2918518518519 39.3401869158878 NA NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35,NA NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100,100 High Mindfulness Mindfulness,  0,NA,Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks),NA,BRIEF-ASR Emotional control  2.76179517,NA NA Hepark,2015,NA RCT G  41, 42   83,outcomes reverse,-0.3510000000,-0.787000000, 8.500000e-02,  4.7000000   4.9000000,NA,NA,NA,NA,NA,NA,100,100,100 100,100 100,100,low,some,some,low some,WLC   0, 53.903614 35.842169 NA NA,0 1 1.0 1.0,1.0,1.0 1 1 1,1,1,1,1,1.0,0 1 1,1 1231,Hepark_2015 2-6 months,NA,>= 20 yo 35.8421686746988,38.6015,NA,NA, 13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35 NA,NA,Ostinelli (2025)_Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100 100,High Mindfulness,Mindfulness   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 2.76179517,NA,NA,Hepark,2015 NA,RCT RR  55  48  103,outcomes,reverse,16.6250000000  0.993000000  2.783170e+02 NA,NA,NA NA NA NA,NA NA 100 100,100,100 100,100,100,low,some low some low WLC,  0  54.543689 35.894175,NA NA,0,1 1.0,1.0 1.0 1.0 1 1 1,1,1 1 1,1.0,0,1 1,1 1232 Hepark_2015 2-6 months NA,>= 20 yo,20.2889285714286,39.35,NA NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35 NA NA Ostinelli (2025)_Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Mindfulness,Mindfulness,100 tau Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA CAARS-INV:SV, 1.84119678,NA NA,Janssen 2018,NA,RCT,G, 52, 55, 107,outcomes reverse -0.4330000000 -0.818000000 -4.700000e-02, 10.2000000,  8.6000000 NA NA,NA NA,NA,NA,100 100 100,100,100 100 100 some,some,low low,low,TAU   0  53.000000,39.340187,NA NA 0,1 1.0 1.0 1.0 1.0 1 1 1,1,1,1 1 1.0,0,1,1 1,1233 Janssen_2018 < 2 months NA,>= 20 yo,35.8421686746988,39.3401869158878,NA,NA  13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA,NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100,100,High,Mindfulness,Mindfulness,100,tau Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At follow-up (closest to 26 weeks) NA CAARS-INV:SV, 1.84119678 NA NA,Janssen 2018 NA,RCT G  52  56, 108,NA,reverse -0.4280000000 -0.811000000 -4.500000e-02   9.7000000   7.4000000,NA,NA NA,NA,NA NA 100,100 100 100 100,100 100,some some low,low low,TAU,  0, 53.000000 39.337037,NA,NA,0 1,1.0 1.0,1.0,1.0,1 1,1,1,1 1 1,1.0 0,1 1,1 1234 Janssen_2018 < 2 months NA >= 20 yo,39.337037037037 39.337037037037,NA,NA  13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA,NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),1 Homogeneous Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High Mindfulness,Mindfulness 100 tau Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA CAARS-S:S, 1.84119678 NA NA Janssen,2018,NA RCT,G  52  55, 107 outcomes reverse,-0.3940000000 -0.779000000,-1.000000e-02,  6.8000000   6.3000000 NA NA,NA,NA NA,NA,100,100,100,100,100 100 100,some some low low low,TAU   0, 53.000000,39.340187,NA,NA,0,1 1.0 1.0 1.0,1.0,1 1 1 1,1,1,1,1.0 0 1 1,1,1235 Janssen_2018,< 2 months,NA,>= 20 yo,20.2918518518519 39.3401869158878,NA NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35 NA,NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100 High,Mindfulness,Mindfulness 100 tau Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 26 weeks),NA,CAARS-S:S, 1.84119678,NA NA Janssen 2018,NA RCT,G  52, 56  108 outcomes reverse,-0.6730000000,-1.063000000 -2.840000e-01,  8.0000000   6.1000000 NA,NA NA NA NA NA 100 100,100 100,100,100 100 some some,low low,low TAU,  0  53.000000 39.337037 NA,NA 0 1 1.0,1.0,1.0 1.0 1 1 1,1,1 1,1,1.0 0 1,1 1 1236 Janssen_2018 < 2 months,NA,>= 20 yo,20.2918518518519 39.337037037037,NA NA, 13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35 NA,NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100 High,Mindfulness Mindfulness 100 tau Executive functioning (tests) Mixed At follow-up (closest to 26 weeks),NA BRIEF-A Executive function  1.84119678 NA NA,Janssen 2018 NA,RCT G  52  56  108 outcomes,reverse,-0.4860000000,-0.870000000 -1.010000e-01  25.7000000  17.6000000,NA,NA NA NA NA,NA,100 100 100,100,100,100 100 some some,low low low,TAU   0  53.000000 39.337037 NA,NA 0 1,1.0,1.0 1.0,1.0 1,1,1 1 1 1,1 1.0 0 1,1,1 1237 Janssen_2018 < 2 months NA,>= 20 yo,20.2918518518519,39.337037037037 NA,NA, 13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA NA Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous,Ostinelli (2025) - Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100,High,Mindfulness Mindfulness 100 tau Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 1.84119678 NA NA Janssen 2018,NA RCT RR  60  60  120 outcomes reverse 19.0000000000  1.131000000  3.192650e+02,NA NA NA,NA NA NA NA NA,100,100 100 100,100,100 100,some,some low,some,low TAU,  0, 53.000000,39.350000,NA,NA,0,1 1.0,1.0 1.0,1.0 1,1,1,1 1,1 1,1.0 0,1 1 1,1238 Janssen_2018,< 2 months NA,>= 20 yo 20.2889285714286 39.35 NA,NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA,NA,Ostinelli (2025)_Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA CAARS-O:S, 2.76179517,NA NA,Konstenius,2010,NA RCT G, 12, 12   24 outcomes,reverse,-0.0350000000,-0.841000000  7.710000e-01 NA,NA NA,NA,NA,NA,13.8000000 13.8000000,100 100,100 100,100,100,100 low,some low some some Active [Placebo + skill training],100  21.000000,37.150000 NA NA 0 1,1.0 1.0 1.0,1.0,1,1,1,1,1 1 1 1.0 0 1,1 1 1239,Konstenius_2010,2-6 months NA >= 20 yo 30.6,40 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA CAARS-S:L  2.76179517,NA,NA Konstenius 2010 NA,RCT,G, 12  12,  24,outcomes,reverse,-0.9460000000 -1.933000000, 4.000000e-02 NA NA NA,NA,NA NA 19.8000000,19.8000000,100,100 100 100,100,100,100,low some low,some some Active [Placebo + skill training],100  21.000000 37.150000,NA NA,0 1 1.0 1.0,1.0 1.0 1,1 1,1,1,1,1 1.0 0 1,1 1 1240,Konstenius_2010,2-6 months,NA,>= 20 yo 33.7462897526502 42 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Methylphenidate Methylphenidate,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  2.76179517,NA,NA,Konstenius,2010 NA,RCT,RR  12, 12,  24,outcomes reverse  2.5000000000  0.597000000, 1.046100e+01,NA NA,NA,NA NA,NA NA,NA,100,100,100 100 100,100,100 low,some,low some low Active [Placebo + skill training],100, 21.000000 37.150000,NA,NA 0 1 1.0,1.0,1.0,1.0,1 1 1,1 1 1 1 1.0,0,1,1,1,1241,Konstenius_2010,2-6 months NA,>= 20 yo 28.7959183673469,40 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Methylphenidate,Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA Other  0.69044879,NA,NA,Kooij 2004 NA RCT G, 25  20   45,outcomes,reverse,-0.2890000000,-0.887000000, 3.090000e-01   0.6500000,  0.5600000,NA,NA NA,NA,NA,NA,100,100,100 100 100 100,100,low low low low,low Placebo,  0  46.700000 39.100000 NA NA,0 1 1.0 1.0 1.0,1.0 1 1,1,1,1,1,1,1.0 0,1,1,1 1242 Kooij_2004,< 2 months,NA,>= 20 yo,33.7462897526502,42 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Methylphenidate,Methylphenidate   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  0.69044879 NA,NA,Kooij 2004 NA RCT,RR, 25, 20,  45 outcomes,reverse  0.8080000000, 0.017000000, 3.901500e+01,NA,NA NA NA NA NA NA NA,100 100,100 100 100 100,100 low,low low,low low Placebo,  0  46.700000,39.100000,NA,NA 0,1,1.0 1.0 1.0 1.0,1,1 1 1,1 1 1 1.0 0,1,1,1,1243 Kooij_2004,< 2 months NA,>= 20 yo,28.7959183673469,40 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100,100 High Methylphenidate,Methylphenidate   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  0.69044879 NA,NA Kooij 2004 NA,RCT,RR  25  20,  45,outcomes reverse, 0.8080000000  0.017000000, 3.901500e+01 NA NA NA,NA,NA,NA,NA,NA 100,100,100 100 100,100 100,low,low,low,low,low,Placebo,  0, 46.700000 39.100000 NA,NA 0 1,1.0,1.0 1.0 1.0 1 1 1,1,1,1,1,1.0,0,1,1 1 1244 Kooij_2004,< 2 months,NA,>= 20 yo 28.7959183673469 40,NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Mindfulness Mindfulness   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA Current ADHD Symptom Scale, 1.84119678,NA NA Mitchell 2017,NA RCT G  11,  9   20,outcomes reverse,-2.4090000000 -3.617000000,-1.201000e+00,  4.2600000,  3.8400000 NA,NA,NA,NA,NA,NA 100 100 100 100 100,100,100 some some some,some some,WLC,  0  59.990000 38.601500,NA NA 0,1,1.0,1.0,1.0,1.0,1 1 1 1 1 1,1,1.0,0,1,1,1,1245 Mitchell_2017,< 2 months,NA,>= 20 yo,35.8421686746988,39.3401869158878 NA NA, 13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA,NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Mindfulness,Mindfulness,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA CASS-L, 1.84119678 NA,NA Mitchell,2017 NA RCT G  11,  9   20,outcomes,reverse,-1.7140000000,-2.783000000 -6.460000e-01   4.8800000   5.0100000 NA,NA,NA,NA,NA,NA 100,100,100,100 100 100,100,some some some some some WLC   0, 59.990000,38.601500 NA,NA 0 1,1.0 1.0,1.0,1.0 1 1 1,1 1,1 1,1.0,0,1 1,1 1246 Mitchell_2017,< 2 months NA >= 20 yo 20.2918518518519 39.3401869158878 NA,NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35 NA,NA Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High,Mindfulness,Mindfulness   0,NA,Emotional dysregulation Mixed At study endpoint (closest to 12 weeks),NA,BRIEF-ASR Emotional control, 1.84119678,NA NA,Mitchell 2017,NA,RCT,G  11,  9   20,outcomes reverse  0.3060000000 -0.604000000  1.216000e+00   2.7900000,  5.0300000 NA,NA,NA NA NA NA 100,100 100,100,100 100 100 some some,some,some,some,WLC   0, 59.990000 38.601500,NA NA,0,1,1.0,1.0 1.0,1.0,1 1,1 1 1,1 1,1.0,0,1 1,1,1247 Mitchell_2017,< 2 months NA >= 20 yo 35.8421686746988 38.6015 NA,NA  13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35,NA NA Ostinelli (2025)_Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Mindfulness,Mindfulness   0,NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) NA,CPT omission  1.84119678,NA,NA Mitchell,2017,NA,RCT G, 11,  9   20 outcomes,reverse,-0.1700000000,-1.076000000  7.360000e-01,  1.2900000   2.2800000 NA,NA,NA,NA NA NA 100,100 100 100 100 100 100 some,some,some,some,some WLC   0  59.990000,38.601500 NA NA,0,1,1.0 1.0,1.0,1.0 1 1,1,1 1 1,1 1.0 0,1 1 1,1248 Mitchell_2017 < 2 months,NA >= 20 yo 20.2918518518519 38.6015 NA NA, 13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA NA Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100,High Mindfulness Mindfulness,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 1.84119678,NA,NA Mitchell,2017 NA RCT,RR, 11  11,  22,outcomes,reverse, 0.2000000000  0.011000000  3.742000e+00,NA,NA,NA NA NA,NA,NA NA 100 100,100 100 100 100 100,some some low,some,low,WLC,  0  60.600000 38.385000,NA,NA 0 1 1.0 1.0 1.0,1.0,1 1 1 1,1 1 1 1.0 0 1,1 1 1249 Mitchell_2017 < 2 months NA >= 20 yo,20.2889285714286 39.35 NA NA  13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA,NA,Ostinelli (2025)_Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2   0   0,100 100 High,Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT),100,tau Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA,ASRS, 2.76179517,NA NA Moritz,2020,NA RCT,G, 13  14,  27,outcomes,reverse,-0.0020000000 -0.772000000, 7.670000e-01,  8.2280000,  7.9340000 NA,NA NA NA NA,NA 100,100,100 100,100 100,100,low,some,some,some low TAU,  0 NA NA NA,NA 0 1 1.0 1.0,1.0 1.0 1 1,1 1,1 1 1,1.0 0,1,1,1,1250 Moritz_2020 2-6 months,NA,NA,35.260736196319,36.9895833333333,NA,NA,  3  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1 Ostinelli (2025) 35.2532407407407,37.004132231405,NA,NA Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2   0   0 100,100 High Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT),100,tau Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability, 2.76179517 NA,NA,Moritz 2020 NA,RCT RR, 16  15,  31,outcomes,reverse  2.8120000000  0.327000000  2.416300e+01,NA NA,NA NA NA,NA,NA,NA 100,100,100,100 100 100 100 low,some low,some,low TAU   0,NA,NA,NA,NA,0 1 1.0,1.0,1.0 1.0 1 1,1,1,1,1,1,1.0 0 1 1 1,1251 Moritz_2020,2-6 months NA NA,35.2532407407407,37.004132231405,NA,NA,  3  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1 Ostinelli (2025),35.2532407407407 37.004132231405 NA,NA Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),100 tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA CAARS-Ob-IN  1.84119678,NA,NA,Nakashima,2021 NA RCT,G, 23  18,  41 outcomes reverse,-0.1070000000 -0.731000000  5.180000e-01, 13.6800000, 14.7800000 NA NA,NA NA,NA NA 100 100,100 100,100,100 100 low some,some some some,TAU   0  87.500000 39.173902 NA NA 0 1,1.0,1.0 1.0,1.0,1 1 1 1 1 1 1 1.0,0 1,1,1 1252,Nakashima_2021 < 2 months NA,>= 20 yo 39.1739024390244 43.1064102564103 NA,NA  20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0 100 100,High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),100,tau Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At follow-up (closest to 26 weeks) NA CAARS-Ob-IN, 1.84119678 NA,NA,Nakashima,2021,NA RCT G, 23, 19,  42 outcomes reverse -0.3180000000,-0.937000000, 3.010000e-01  13.8800000, 16.2600000,NA NA NA,NA NA,NA,100,100 100 100,100,100 100,low some some,some some,TAU,  0, 87.500000,39.158810 NA,NA 0 1,1.0,1.0 1.0 1.0,1,1 1 1 1 1,1,1.0,0 1 1 1 1253 Nakashima_2021 < 2 months NA,>= 20 yo,39.1588095238095,43.0611940298507,NA NA  20  9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),100 tau Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA CAARS-S, 1.84119678,NA,NA Nakashima,2021,NA,RCT G, 23  18   41,outcomes,reverse,-0.3770000000 -1.007000000  2.530000e-01,  9.7700000  11.1600000 NA NA NA NA NA,NA,100,100,100 100 100,100,100 low some,some some,some,TAU   0  87.500000,39.173902 NA,NA,0,1,1.0 1.0 1.0,1.0,1 1 1,1,1,1,1,1.0 0 1 1 1 1254,Nakashima_2021 < 2 months NA,>= 20 yo 19.6504545454545 43.1027777777778,NA NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),100,tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 26 weeks),NA CAARS-S  1.84119678 NA,NA Nakashima,2021 NA RCT,G  23, 19   42,outcomes,reverse -0.6230000000 -1.253000000, 7.000000e-03, 12.3500000  10.9500000,NA NA NA,NA NA NA,100,100,100 100,100,100,100 low,some,some some,some,TAU,  0  87.500000,39.158810,NA,NA 0 1 1.0,1.0 1.0 1.0,1,1 1 1,1 1,1 1.0 0 1 1 1,1255,Nakashima_2021,< 2 months,NA >= 20 yo,19.6482233502538,43.0524590163934,NA,NA, 20  9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),100 tau Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 1.84119678 NA,NA Nakashima,2021 NA,RCT RR  24  24   48,outcomes reverse  0.1670000000, 0.022000000, 1.282000e+00 NA,NA NA,NA NA,NA NA NA,100,100,100 100,100 100,100,low some low some low TAU,  0, 87.500000,39.105000 NA,NA 0 1 1.0,1.0 1.0 1.0 1 1,1 1 1 1 1 1.0 0 1,1,1,1256 Nakashima_2021,< 2 months NA >= 20 yo,19.6532142857143,43.15,NA,NA, 20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100 High,Cognitive training,Cognitive training,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA,ASRS, 2.30149597 NA,NA,NCT02489279,2019,NA,RCT,G  28, 30,  58,outcomes,reverse, 0.2710000000,-0.311000000  8.530000e-01 NA,NA,NA NA NA,NA  4.6700000  4.6700000,100,100 100 100 100,100,100,low,some low low,some Cognitive placebo,  0  58.089655,25.793103,NA,NA 0 1,1.0,1.0,1.0,1.0 1,1 1,1 1,1 1 1.0 0 1 1 1,1257 NCT02489279_2019,2-6 months,NA >= 20 yo 25.7931034482759,41.5895454545455 NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA,Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Cognitive training,Cognitive training   0 NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks),NA CPT reaction time variability  2.30149597 NA NA,NCT02489279,2019 NA,RCT G, 29  30   59 NA reverse,-0.5920000000 -1.115000000 -6.800000e-02 NA NA NA NA,NA,NA,14.8000000,14.8000000 100,100 100 100 100,100,100,low,some,low low,some,Cognitive placebo,  0, 58.323729 25.771186 NA,NA,0 1 1.0 1.0,1.0 1.0,1 1,1 1 1 1 1 1.0 0,1,1,1 1258 NCT02489279_2019,2-6 months,NA >= 20 yo 25.771186440678 25.771186440678 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Ostinelli (2025)_Cognitive training_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive training_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Cognitive training,Cognitive training,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  2.30149597 NA NA,NCT02489279,2019,NA,RCT,RR, 44, 41   85,outcomes,reverse  1.1180000000, 0.542000000, 2.305000e+00,NA,NA,NA NA,NA,NA NA NA,  0   0,  0   0   0   0   0,high high high,high high Cognitive placebo   0, 59.021176 25.705882 NA,NA,0 1 1.0 1.0,1.0,1.0,1 1,1,1 1,1 1,1.0 0 1 1,1,1259 NCT02489279_2019 2-6 months NA >= 20 yo,25.7058823529412,37.3053333333333 NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Ostinelli (2025)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high high
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),NA,CAARS-S:L  0.92059839,NA NA Paz 2017,NA,RCT G,  9  13,  22,outcomes reverse  0.1090000000,-0.762000000  9.800000e-01  13.0200000  10.9969314 NA NA NA,NA NA,NA,100 100 100,100 100,100,100 some some some,low low Sham   0, 36.413636,31.361364,NA NA,0,1 1.0 1.0 1.0 1.0 1,1 1 1,1 1 1 1.0 0,1 1,1,1260 Paz_2017,< 2 months,NA >= 20 yo 27.1124137931034 35.24,NA,NA,  4, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025) 27.0733333333333 35.24 NA NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation)   0,NA,Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),NA,TOVA, 0.92059839,NA,NA,Paz 2017,NA RCT,G,  9, 13,  22,NA,reverse,-0.5010000000,-1.385000000, 3.840000e-01   6.1500000,  4.5790501,NA NA,NA,NA,NA,NA 100,100 100,100 100,100,100,some some,some low low Sham   0, 36.413636 31.361364,NA NA 0 1 1.0,1.0 1.0 1.0 1 1 1,1 1 1 1 1.0,0,1,1 1 1261,Paz_2017,< 2 months NA >= 20 yo,31.3613636363636 31.3613636363636 NA,NA,  4  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025),27.0733333333333 35.24,NA NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation)   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839 NA NA,Paz,2017 NA,RCT,RR  12, 14,  26,outcomes,reverse, 3.5000000000, 0.417000000, 2.938700e+01,NA NA,NA,NA NA NA NA NA 100 100 100 100,100 100,100,some,some low,low low Sham,  0, 36.146154 31.426923,NA,NA,0,1,1.0 1.0 1.0,1.0 1,1,1 1,1 1 1,1.0,0,1,1 1,1262,Paz_2017,< 2 months NA,>= 20 yo 27.0733333333333 35.22,NA NA,  4, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025) 27.0733333333333,35.24 NA,NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100,High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA,Current Symptoms Scale- self report, 2.30149597 NA,NA Pettersson,2014 NA,RCT,G, 27, 18   45 outcomes reverse -0.2240000000,-0.829000000  3.800000e-01, 11.6600000   8.1700000 NA,NA,NA,NA NA NA,100,100 100,100 100 100,100,low some low some,some,WLC   0, 64.390000 37.080000 NA,NA,0,1 1.0 1.0 1.0,1.0 1,1 1 1 1 1 1 1.0,0 1,1,1,1263 Pettersson_2014,2-6 months NA,>= 20 yo,19.6504545454545 43.1027777777778,NA,NA  20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100,100 High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 2.30149597 NA,NA Pettersson,2014 NA RCT,RR  27, 18,  45 outcomes,reverse  0.6670000000  0.151000000  2.943000e+00 NA,NA NA,NA,NA,NA NA,NA,100 100 100 100 100 100,100,low some,low some low WLC   0, 64.390000,37.080000 NA,NA,0,1,1.0 1.0 1.0 1.0 1,1 1 1 1,1,1,1.0,0,1,1 1 1264,Pettersson_2014 2-6 months,NA,>= 20 yo 19.6532142857143 43.15 NA,NA  20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2   0,  0 100 100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,Kiddie SADS, 3.45224396,NA,NA Safren,2004,NA RCT,G, 16, 15,  31 outcomes reverse,-0.6000000000,-1.332000000  1.330000e-01   7.1200000  10.8400000 NA,NA,NA NA,NA NA,100 100,100 100 100 100 100 some some low low low TAU,  0,NA,NA NA NA 0 1 1.0,1.0,1.0,1.0 1,1,1,1,1,1 1 1.0,0,1 1,1 1265 Safren_2004 2-6 months NA,NA,39.1739024390244,43.1064102564103 NA NA  20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,  0,  0,100 100,High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),NA,Current Symptoms Scale- self report  3.45224396,NA NA,Safren 2004 NA RCT G, 16, 15,  31 outcomes reverse,-0.9570000000,-1.714000000 -1.990000e-01,  8.6500000,  9.9200000 NA NA NA NA NA NA,100,100,100 100,100,100 100,some some low,low low TAU,  0 NA,NA,NA,NA 0,1,1.0,1.0 1.0,1.0 1 1 1 1 1 1,1,1.0,0,1,1,1,1266,Safren_2004,2-6 months,NA,NA,19.6504545454545 43.1027777777778 NA,NA, 20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,  0   0,100,100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability  3.45224396 NA NA Safren,2004 NA RCT,RR  16  15,  31,outcomes,reverse  0.9410000000, 0.020000000  4.467400e+01 NA,NA,NA NA NA,NA,NA,NA 100,100,100 100 100,100 100,some,some low,some,low TAU   0 NA,NA NA NA,0,1 1.0 1.0,1.0,1.0,1,1 1 1 1 1 1,1.0,0 1,1 1,1267 Safren_2004,2-6 months,NA,NA,19.6532142857143 43.15,NA,NA  20  9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2   0   0,100,100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability, 3.45224396 NA,NA,Safren 2004 NA RCT RR  16, 15   31,outcomes,reverse, 0.9410000000, 0.020000000  4.467400e+01,NA,NA,NA,NA NA NA NA NA,100 100,100 100 100 100 100,some,some,low,some low TAU,  0,NA,NA,NA,NA,0,1 1.0 1.0 1.0 1.0,1,1 1,1 1,1,1 1.0 0,1,1 1,1268,Safren_2004,2-6 months NA NA,36.9420895522388,43.15,NA,NA  20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,ADHD-RS total  3.45224396 NA,NA,Safren 2010,NA,RCT,G, 41, 37   78,outcomes,reverse,-0.5160000000 -0.971000000,-6.100000e-02   8.4600000   9.7100000 NA NA NA NA NA,NA 100,100,100 100,100,100 100 low,low low,low,low Relaxation therapy,  0  44.200000,43.106410 NA NA,0,1 1.0,1.0,1.0 1.0 1 1,1,1 1,1 1 1.0,0 1 1 1 1269 Safren_2010,2-6 months,NA >= 20 yo 39.1739024390244,43.1064102564103 NA NA, 20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100 100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At follow-up (closest to 26 weeks),NA,ADHD-RS total  3.45224396 NA NA,Safren 2010 NA,RCT G, 37  30,  67 outcomes reverse -0.3050000000,-0.793000000  1.820000e-01,  7.7000000,  9.8100000 NA NA NA,NA,NA,NA 100,100 100 100,100 100 100 low low,low low,low Relaxation therapy,  0, 44.200000,43.061194,NA,NA 0,1,1.0 1.0 1.0,1.0,1,1 1 1 1,1 1,1.0,0 1 1 1,1270,Safren_2010 2-6 months,NA >= 20 yo 39.1588095238095,43.0611940298507,NA,NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At follow-up (closest to 52 weeks),NA ADHD-RS total, 3.45224396,NA,NA,Safren,2010,NA RCT G  38  32   70 NA,reverse -0.3390000000,-0.816000000  1.380000e-01,  8.4900000  10.7200000 NA,NA NA NA NA,NA,100,100 100 100,100 100,100,low,low,low low low,Relaxation therapy,  0, 44.200000,43.077143,NA,NA 0,1,1.0,1.0 1.0,1.0,1 1 1,1 1 1,1 1.0 0,1,1 1,1271 Safren_2010 2-6 months NA >= 20 yo,43.0771428571429,43.0771428571429,NA,NA, 20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks),1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0 100 100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA,Current Symptoms Scale- self report, 3.45224396 NA NA Safren 2010,NA RCT G  38  34   72 outcomes,reverse -0.7750000000 -1.258000000,-2.920000e-01   7.1600000, 11.2100000,NA NA,NA,NA,NA NA,100,100,100,100 100,100,100 low low low low,low Relaxation therapy,  0, 44.200000 43.102778,NA,NA,0 1 1.0 1.0,1.0 1.0 1,1,1 1 1 1 1 1.0 0,1 1 1,1272 Safren_2010 2-6 months NA >= 20 yo,19.6504545454545,43.1027777777778 NA NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100 High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At follow-up (closest to 26 weeks),NA Current Symptoms Scale- self report  3.45224396 NA,NA Safren 2010 NA,RCT G, 34  27,  61 outcomes,reverse -0.3890000000 -0.903000000, 1.250000e-01,  6.0500000, 11.7500000 NA,NA NA,NA,NA,NA 100,100 100 100,100 100 100,low low low,low low Relaxation therapy   0, 44.200000 43.052459,NA,NA,0,1 1.0,1.0 1.0 1.0 1,1,1 1 1,1 1 1.0 0,1,1,1 1273,Safren_2010 2-6 months,NA,>= 20 yo,19.6482233502538,43.0524590163934 NA NA, 20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100,100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 52 weeks) NA Current Symptoms Scale- self report, 3.45224396 NA NA Safren 2010,NA,RCT,G  36  29,  65 outcomes,reverse,-0.2720000000 -0.767000000, 2.230000e-01   9.1400000   9.1800000 NA NA NA,NA,NA,NA 100 100 100 100,100,100 100,low,low low,low low,Relaxation therapy,  0  44.200000,43.058462,NA,NA,0 1,1.0,1.0 1.0 1.0 1 1 1,1,1 1,1,1.0 0 1 1 1,1274 Safren_2010,2-6 months,NA,>= 20 yo,35.8545454545455,43.0584615384615 NA,NA  20  9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks),1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100 High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  3.45224396 NA,NA,Safren 2010 NA RCT,RR  43, 43,  86 outcomes,reverse  0.4000000000, 0.082000000  1.951000e+00,NA,NA NA,NA,NA,NA NA,NA 100,100 100,100 100 100 100,low,low low some low,Relaxation therapy,  0  44.200000 43.150000 NA,NA,0 1 1.0,1.0,1.0 1.0 1,1 1 1 1,1 1,1.0,0 1,1 1,1275 Safren_2010,2-6 months NA >= 20 yo 19.6532142857143,43.15 NA,NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100 High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability  3.45224396,NA NA Safren 2010 NA,RCT RR  43, 43,  86 outcomes reverse  1.0000000000, 0.020000000  4.928400e+01 NA,NA,NA,NA NA,NA NA,NA,100,100,100 100 100 100 100,low low low some low,Relaxation therapy,  0, 44.200000,43.150000,NA,NA 0 1,1.0 1.0 1.0 1.0,1 1,1 1,1 1,1,1.0,0,1,1 1 1276 Safren_2010,2-6 months NA >= 20 yo,36.9420895522388,43.15 NA,NA, 20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA,CAARS-S:L, 3.45224396,NA NA Schoenenberg 2017,NA RCT,G, 38, 38   76 outcomes reverse  0.0150000000 -0.437000000, 4.680000e-01, 31.0503816, 26.0275258 NA,NA NA NA,NA NA   0   0,  0   0   0,  0   0,high,high,high,high,high Sham   0, 40.500000,36.945000,NA,NA 0,1,1.0 1.0,1.0 1.0,1,1 1 1,1,1,1,1.0 0 1,1,1,1277 Schoenenberg_2017,2-6 months NA >= 20 yo,19.6504545454545 43.1027777777778 NA,NA  20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high high
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0 NA,Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks),NA,CPT reaction time  3.45224396 NA NA,Schoenenberg 2017,NA,RCT,G, 38  38   76 NA reverse  0.0970000000 -0.356000000  5.500000e-01,103.7728776,111.2582374,NA,NA,NA NA NA NA   0   0,  0,  0   0,  0   0 high high,high high high,Sham   0  40.500000,36.945000,NA NA 0 1,1.0 1.0,1.0,1.0 1 1,1 1,1 1,1 1.0 0 1,1,1 1278 Schoenenberg_2017,2-6 months,NA >= 20 yo,36.945,36.945,NA NA  20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA ADHD-SRS total, 2.76179517 NA,NA Solanto 2010 NA,RCT G  41  40   81,outcomes reverse -0.5450000000 -0.991000000,-9.800000e-02,  4.2700000   4.7100000 NA NA,NA,NA NA,NA 100,100,100,100 100 100 100 some some,some low,some,Psychological placebo   0  66.061728,41.696790 NA NA 0,1,1.0,1.0,1.0,1.0,1 1,1 1,1,1 1,1.0,0,1 1,1,1279,Solanto_2010 2-6 months,NA,>= 20 yo 39.1739024390244 43.1064102564103,NA,NA  20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability  2.76179517,NA NA Solanto,2010 NA,RCT,RR, 45  43   88,outcomes reverse, 0.4180000000  0.191000000, 9.150000e-01,NA,NA NA NA,NA NA NA NA,100,100,100 100 100,100,100,some,some low some,low Psychological placebo   0, 66.113636 41.689886,NA,NA,0 1 1.0 1.0,1.0 1.0 1 1 1 1,1,1,1,1.0,0,1 1,1 1280,Solanto_2010,2-6 months NA,>= 20 yo 19.6532142857143 43.15,NA NA, 20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Cognitive training Cognitive training,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA ASRS  2.76179517,NA NA Stern 2014 NA RCT G  26  13   39,outcomes reverse -0.0190000000,-0.693000000  6.550000e-01  10.0000000,  8.9200000 NA,NA NA,NA NA,NA 100,100 100 100,100,100,100,low some,some low low,Cognitive placebo,  0  56.666667,37.463333 NA NA 0,1,1.0 1.0 1.0 1.0,1 1,1 1 1 1 1,1.0 0,1 1,1 1281 Stern_2014 2-6 months,NA >= 20 yo,25.7931034482759,41.5895454545455,NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA,Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High Cognitive training Cognitive training   0,NA,Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks) NA,AAQoL, 2.76179517 NA,NA Stern,2014,NA RCT,G  26  13,  39 outcomes reverse  0.3060000000 -0.372000000, 9.840000e-01  16.7900000  14.6400000 NA,NA NA NA,NA NA,100,100 100,100 100 100 100,low some,some low low Cognitive placebo,  0  56.666667,37.463333,NA NA,0,1,1.0 1.0 1.0 1.0 1 1,1 1 1,1 1 1.0,0 1 1,1,1282 Stern_2014 2-6 months NA >= 20 yo,33.0526315789474 37.4633333333333,NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA,Ostinelli (2025)_Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Cognitive training Cognitive training   0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 2.76179517 NA,NA,Stern 2014 NA RCT RR  34  26   60,outcomes,reverse, 0.4710000000  0.230000000, 9.640000e-01,NA NA NA NA NA,NA,NA NA,100,100 100 100 100,100 100 low some,low low,low Cognitive placebo   0, 56.866667,37.305333 NA NA 0 1,1.0 1.0,1.0 1.0 1,1,1,1 1,1,1,1.0 0 1,1,1 1283 Stern_2014,2-6 months,NA,>= 20 yo 25.7058823529412 37.3053333333333 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Ostinelli (2025)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High Cognitive training Cognitive training,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA DSM-IIIR symptom checklist, 1.84119678,NA NA Stevenson,2002,NA,RCT,G, 22, 21   43 NA,reverse -1.6820000000,-2.389000000,-9.750000e-01  26.7000000, 18.0000000,NA NA NA,NA NA NA,100 100,100 100 100,100,100 some some low,some,some WLC   0, 36.441860,35.862791 NA NA 0 1,1.0,1.0,1.0 1.0,1,1 1 1 1,1,1,1.0 0 1,1 1 1284,Stevenson_2002,< 2 months NA >= 20 yo,35.8627906976744 35.8627906976744,NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA,Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Cognitive training Cognitive training   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability, 1.84119678,NA,NA,Stevenson 2002 NA,RCT RR, 23  21,  44,outcomes,reverse, 2.7500000000, 0.118000000, 6.403900e+01,NA NA NA,NA,NA NA,NA NA,100,100 100,100 100 100 100 some some,low,some,low WLC   0  36.386364 35.875000,NA,NA,0,1,1.0,1.0,1.0,1.0 1,1,1 1 1 1 1 1.0 0 1,1 1,1285 Stevenson_2002 < 2 months,NA,>= 20 yo,25.7058823529412,37.3053333333333,NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA Ostinelli (2025)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA BADDS-adults, 2.76179517,NA NA,Virta,2010,NA RCT,G  10  10,  20,outcomes,reverse, 0.0870000000,-0.813000000, 9.870000e-01  18.6000000, 14.2000000 NA NA,NA NA NA,NA 100 100,100 100 100,100 100,some some some,some some No treatment,  0, 65.000000,36.100000,NA NA 0 1 1.0,1.0 1.0,1.0,1,1,1,1 1 1,1 1.0,0 1,1 1 1286,Virta_2010 2-6 months NA,>= 20 yo 19.6504545454545,43.1027777777778 NA NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100,100 High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0 NA,Quality of life (patients),Mixed At study endpoint (closest to 12 weeks) NA,Q-LES-Q, 2.76179517 NA NA Virta 2010,NA RCT,G, 10, 10   20 outcomes,reverse, 0.0900000000,-0.810000000  9.900000e-01  14.5000000, 21.0000000 NA NA NA,NA,NA NA 100,100 100 100,100 100,100 some some,some,some some,No treatment,  0  65.000000 36.100000,NA NA 0 1 1.0 1.0,1.0 1.0,1,1 1,1,1,1 1,1.0 0,1,1,1 1287 Virta_2010 2-6 months NA >= 20 yo,36.1 36.9642105263158,NA,NA, 20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Cognitive training Cognitive training   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA,BADDS-adults  2.76179517,NA NA,Virta,2010 NA RCT,G,  9, 10   19,outcomes,reverse -0.5250000000 -1.469000000, 4.180000e-01, 17.8000000  14.2000000 NA,NA NA,NA NA,NA 100 100 100,100 100 100,100,some,some,some,some some No treatment   0  42.473684,33.052632,NA,NA 0,1 1.0,1.0 1.0 1.0 1 1,1,1 1 1 1,1.0 0,1 1,1 1288 Virta_2010,2-6 months NA,>= 20 yo 25.7931034482759 41.5895454545455 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100 100,High Cognitive training,Cognitive training   0 NA Quality of life (patients) Mixed At study endpoint (closest to 12 weeks),NA,Q-LES-Q, 2.76179517 NA,NA,Virta 2010,NA,RCT,G,  9, 10,  19,outcomes,reverse  0.3150000000 -0.617000000  1.247000e+00, 14.4000000  21.0000000 NA NA,NA,NA,NA,NA 100 100 100,100 100 100 100 some some some some some,No treatment   0, 42.473684 33.052632,NA NA 0 1,1.0 1.0,1.0,1.0,1 1 1,1 1,1,1 1.0,0,1 1,1 1289,Virta_2010,2-6 months NA >= 20 yo 33.0526315789474,37.4633333333333,NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA Ostinelli (2025)_Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Hypnotherapy Hypnotherapy   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA,BADDS-adults, 2.76179517 NA NA,Virta 2010 NA RCT G,  8, 10,  18,NA reverse,-0.4450000000,-1.416000000, 5.250000e-01, 17.7000000, 14.2000000,NA,NA NA,NA NA,NA,100 100 100,100 100 100,100 some some,some,some some,No treatment,  0, 60.000000 34.000000 NA,NA,0 1 1.0,1.0,1.0,1.0,1 1,1 1 1,1 1,1.0,0,1 1 1,1290 Virta_2010 2-6 months,NA >= 20 yo 34 34 NA,NA,  1, 2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients)  1,Ostinelli (2025) 34 34 NA NA Ostinelli (2025)_Hypnotherapy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Hypnotherapy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Hypnotherapy Hypnotherapy,  0,NA Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks),NA Q-LES-Q, 2.76179517 NA NA Virta,2010,NA RCT G,  8, 10   18 NA reverse  0.3090000000 -0.655000000, 1.272000e+00, 13.8000000  21.0000000,NA,NA NA NA NA,NA,100 100,100,100 100 100 100,some,some some some some,No treatment,  0, 60.000000 34.000000 NA,NA,0 1,1.0 1.0,1.0,1.0,1 1,1 1 1 1 1,1.0,0 1 1 1,1291 Virta_2010 2-6 months,NA,>= 20 yo,34 34,NA,NA,  1  2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients)  1,Ostinelli (2025),34 34,NA NA Ostinelli (2025)_Hypnotherapy_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Hypnotherapy_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA ADHD-RS total, 1.38089758 NA,NA,Weisler,2012 NA RCT,G  58, 65, 123,outcomes,reverse -0.4160000000,-0.848000000  1.600000e-02 NA NA,NA NA NA NA,11.7400000,11.7400000 100,100,100,100,100,100,100 low low,low,low low,Placebo,  0, 37.657724,33.305691,NA,NA,0,1 1.0 1.0,1.0,1.0 1,1,1,1 1,1,1 1.0 0 1 1,1 1292,Weisler_2012 < 2 months NA >= 20 yo 30.6 40,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100 High,Methylphenidate Methylphenidate,  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability  1.38089758,NA,NA,Weisler 2012 NA RCT RR  68, 74, 142 outcomes reverse, 1.2860000000  0.618000000, 2.675000e+00 NA,NA,NA,NA NA,NA,NA NA 100,100 100,100,100,100,100 low low,low low low,Placebo,  0, 37.604225 33.304225 NA,NA 0,1 1.0 1.0 1.0 1.0 1,1,1,1 1,1 1,1.0,0 1 1,1,1293,Weisler_2012,< 2 months NA >= 20 yo,28.7959183673469 40,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100 100 High Methylphenidate Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability, 1.38089758,NA NA Weisler,2012,NA,RCT RR, 68  74, 142,outcomes,reverse, 3.2650000000  0.682000000, 1.563100e+01 NA,NA,NA,NA NA NA,NA NA 100,100 100 100 100 100 100,low low low low,low,Placebo   0, 37.604225 33.304225 NA,NA 0 1,1.0 1.0 1.0,1.0 1,1,1 1,1 1 1 1.0 0 1 1 1 1294,Weisler_2012 < 2 months,NA >= 20 yo,28.7959183673469,40 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100 100 High,Atomoxetine Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,ADHD-RS total, 1.38089758,NA,NA Weisler 2012 NA,RCT G  57  65  122 outcomes reverse,-0.2990000000 -0.723000000  1.250000e-01 NA NA,NA,NA NA,NA 11.7400000 11.7400000,100 100 100,100,100,100,100 low low low low,low,Placebo,  0  43.669672,33.960656 NA,NA,0,1,1.0 1.0 1.0 1.0,1,1 1 1,1,1,1 1.0 0,1 1,1 1295 Weisler_2012,< 2 months NA >= 20 yo 24.7,42.1,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Atomoxetine Atomoxetine,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  1.38089758,NA,NA,Weisler,2012,NA,RCT,RR, 74, 74  148 outcomes,reverse, 1.8180000000, 0.938000000, 3.523000e+00,NA NA NA NA,NA NA NA NA,100,100,100,100,100,100 100,low low low low,low,Placebo   0, 43.850000,34.000000 NA NA,0 1 1.0 1.0,1.0 1.0 1,1 1 1 1,1,1,1.0,0,1 1,1,1296,Weisler_2012 < 2 months NA,>= 20 yo 24.7 42.10703125 NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100,100 High Atomoxetine,Atomoxetine   0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability, 1.38089758 NA,NA,Weisler,2012 NA RCT,RR  74  74, 148,outcomes reverse, 4.0000000000, 0.879000000, 1.820900e+01 NA NA,NA NA,NA,NA,NA,NA 100 100 100,100 100,100 100,low low low low,low,Placebo   0, 43.850000 34.000000,NA,NA,0,1 1.0 1.0 1.0 1.0,1 1 1 1,1,1,1 1.0,0 1,1 1,1297 Weisler_2012,< 2 months NA >= 20 yo,24.7 42.10703125,NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High tDCS (transcranial direct current stimulation) tDCS (transcranial direct current stimulation),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,ADHD-RS total, 0.92059839,NA,NA,Leffa 2022,NA,RCT,G  32  32,  64,NA,reverse -0.9450000000 -1.466000000 -4.240000e-01,  5.7900000,  3.9700000 NA NA NA,NA,NA,NA 100,100,100,100 100 100,100,low,low,some some low,Sham   0  46.900000,38.300000 NA,NA,0 1,1.0 1.0,1.0 1.0 1,1 1 1,1 1 1,1.0,0 1,1,1,1298 Leffa_2022 < 2 months NA >= 20 yo,38.3,38.3,NA NA, 19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA NA,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0 100 100 High,tDCS (transcranial direct current stimulation),tDCS (transcranial direct current stimulation),  0 NA,Emotional dysregulation Mixed At study endpoint (closest to 12 weeks),NA BRIEF-ASR Emotional control, 0.92059839 NA,NA,Leffa 2022,NA RCT,G  21  28,  49 NA reverse -0.2060000000,-0.779000000, 3.670000e-01   9.7400000   8.8700000 NA NA NA,NA NA,NA,100,100,100,100,100,100,100,low,low some,some low Sham   0, 45.114286 38.314286 NA NA,0 1,1.0 1.0,1.0,1.0,1 1 1,1 1,1,1 1.0,0 1 1 1,1299 Leffa_2022 < 2 months,NA,>= 20 yo,38.3142857142857,38.3142857142857 NA,NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA,NA Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0 100 100 High tDCS (transcranial direct current stimulation) tDCS (transcranial direct current stimulation),  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 0.92059839,NA NA,Leffa 2022 NA RCT RR  32, 32,  64 outcomes reverse  3.5000000000  0.786000000, 1.557800e+01 NA,NA NA,NA NA,NA,NA,NA,100,100 100,100 100 100 100,low low,low,some,low,Sham,  0  46.900000 38.300000,NA NA 0 1,1.0 1.0,1.0,1.0,1,1 1,1,1,1,1,1.0,0,1 1 1 1300,Leffa_2022,< 2 months,NA >= 20 yo 22.085,38.3,NA NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA,NA Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100 High tDCS (transcranial direct current stimulation),tDCS (transcranial direct current stimulation),  0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability, 0.92059839,NA,NA Leffa 2022,NA,RCT,RR, 32  32,  64,outcomes,reverse, 3.0000000000  0.329000000, 2.733300e+01,NA NA,NA NA,NA NA NA NA 100,100 100 100,100,100,100,low low,low,some low,Sham,  0, 46.900000 38.300000 NA NA,0,1,1.0,1.0 1.0,1.0,1,1,1,1,1,1 1,1.0,0,1,1 1,1301,Leffa_2022 < 2 months,NA >= 20 yo 32.2941176470588 38.3 NA NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA,NA,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Methylphenidate Methylphenidate   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability  3.22209436,NA NA,Levin 2007 NA RCT RR  53, 53  106,outcomes,reverse, 0.9670000000  0.688000000  1.358000e+00 NA,NA,NA,NA NA NA,NA,NA 100,100,100,100 100,100,100 some,some,low,some low Active [Placebo + cbt],100, 17.000000 37.000000,NA NA,0 1,1.0,1.0 1.0,1.0,1,1,1,1 1 1 1 1.0,0 1,1,1 1302,Levin_2007,2-6 months NA,>= 20 yo,28.7959183673469 40 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100 High,Methylphenidate,Methylphenidate,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability  3.22209436 NA,NA,Levin,2007,NA,RCT RR  53, 53, 106,outcomes reverse  0.7500000000, 0.176000000  3.190000e+00 NA NA,NA NA NA NA NA NA,100,100 100 100 100 100 100,some some low,some low,Active [Placebo + cbt] 100, 17.000000,37.000000,NA,NA,0 1 1.0,1.0,1.0 1.0 1 1 1,1 1 1,1 1.0 0 1,1,1,1303,Levin_2007 2-6 months,NA >= 20 yo 28.7959183673469,40 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA,ASRS, 2.76179517 NA NA,Nasri,2022,NA RCT,G  36  31   67,outcomes reverse,-0.4160000000,-0.905000000  7.300000e-02, 12.4000000,  9.5500000 NA NA,NA NA NA NA 100 100 100 100,100 100,100,low low low some,low WLC   0, 62.059701,36.942090 NA NA,0 1,1.0,1.0 1.0 1.0,1,1,1 1 1,1 1,1.0,0 1 1 1 1304 Nasri_2022,2-6 months,NA >= 20 yo,19.6504545454545,43.1027777777778 NA NA  20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100,100 High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 26 weeks) NA ASRS  2.76179517 NA NA Nasri 2022,NA RCT G  36, 31,  67 outcomes,reverse,-0.6590000000 -1.156000000 -1.620000e-01  13.1000000   9.0200000 NA NA NA NA,NA,NA 100 100,100,100,100,100 100,low,low,low,some,low,WLC   0  62.059701 36.942090,NA NA,0 1 1.0,1.0,1.0,1.0,1,1 1 1,1 1,1,1.0 0 1,1,1,1305 Nasri_2022 2-6 months NA,>= 20 yo,19.6482233502538,43.0524590163934,NA NA, 20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0,NA,Emotional dysregulation Mixed At study endpoint (closest to 12 weeks),NA DERS  2.76179517 NA,NA Nasri,2022 NA RCT,G  28  29   57,NA reverse  0.1820000000 -0.343000000  7.070000e-01, 29.0000000, 26.2000000,NA,NA,NA NA,NA,NA 100 100,100,100,100,100,100,low low low some,low WLC   0  61.368421,36.964211 NA NA,0,1 1.0,1.0,1.0 1.0 1 1 1 1,1 1 1,1.0,0,1,1,1 1306,Nasri_2022 2-6 months NA,>= 20 yo 36.9642105263158 36.9642105263158,NA,NA  20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0 NA Emotional dysregulation Mixed At follow-up (closest to 26 weeks) NA DERS  2.76179517 NA NA Nasri 2022 NA RCT,G  26  28,  54,NA reverse,-0.0370000000 -0.576000000, 5.010000e-01, 27.3000000, 30.5000000 NA NA NA NA NA,NA,100 100 100 100,100 100 100 low,low,low some low WLC   0, 61.222222,36.968889 NA NA 0,1,1.0,1.0,1.0 1.0,1 1 1,1,1 1 1,1.0,0,1 1 1,1307,Nasri_2022 2-6 months,NA >= 20 yo,36.9688888888889,36.9688888888889 NA,NA  20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100 High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0,NA,Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks) NA,AAQoL, 2.76179517 NA NA,Nasri 2022 NA RCT G, 28  29,  57,outcomes,reverse -0.3920000000 -0.921000000, 1.370000e-01  11.2000000,  9.3800000 NA NA NA,NA,NA NA 100,100 100 100 100,100,100,low,low low,some,low,WLC   0  61.368421,36.964211,NA NA 0 1,1.0 1.0,1.0,1.0 1 1,1,1 1,1,1 1.0 0,1,1 1,1308,Nasri_2022 2-6 months NA >= 20 yo,36.1,36.9642105263158 NA,NA  20, 9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100 100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0,NA,Quality of life (patients) Mixed At follow-up (closest to 26 weeks),NA AAQoL  2.76179517,NA,NA,Nasri,2022 NA,RCT,G  26  28,  54,NA reverse,-0.4190000000,-0.964000000  1.260000e-01  10.9000000, 11.2000000,NA NA,NA NA NA NA 100,100 100,100,100,100,100,low,low,low some,low,WLC   0  61.222222 36.968889 NA,NA,0,1,1.0 1.0 1.0 1.0,1,1,1 1,1,1 1 1.0,0,1 1,1,1309 Nasri_2022 2-6 months,NA >= 20 yo 36.9688888888889 36.9688888888889,NA,NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability  2.76179517 NA NA,Nasri,2022 NA RCT RR, 36, 31,  67,outcomes,reverse  0.8650000000, 0.018000000, 4.235500e+01 NA NA NA NA NA NA NA NA,100,100 100,100 100 100,100,low low low some low WLC,  0  62.059701 36.942090 NA,NA 0 1,1.0,1.0,1.0,1.0,1 1,1 1,1 1 1 1.0,0 1 1,1,1310 Nasri_2022,2-6 months NA,>= 20 yo,19.6532142857143,43.15 NA,NA  20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability, 2.76179517,NA,NA,Nasri,2022,NA,RCT,RR, 36, 31,  67,outcomes reverse  0.8650000000, 0.018000000  4.235500e+01 NA,NA NA,NA,NA NA,NA NA 100 100,100,100,100 100 100 low,low low,some low WLC   0, 62.059701 36.942090,NA NA 0 1 1.0,1.0,1.0,1.0 1,1,1,1,1 1,1 1.0,0 1 1 1 1311 Nasri_2022,2-6 months NA,>= 20 yo 36.9420895522388 43.15,NA NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100,100 High,Amphetamine Amphetamine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,AISRS, 1.15074799   20.0000000,mg/d,Cutler 2022 NA RCT G  62, 62, 124 outcomes reverse,-0.4970000000,-0.961000000 -3.200000e-02 NA,NA,NA NA NA,NA 10.0500000,10.0500000 100,100 100 100 100 100 100,low low,some,low some,Placebo   0, 59.950000 32.450000 NA NA 0,1 1.0,1.0,1.0 1.0,1 1 1,1 1 1,1,1.0,0,1,1 1,1312,Cutler_2022 < 2 months,NA,>= 20 yo,22.2059016393443 39.0276595744681 NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High,Amphetamine,Amphetamine,  0,NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks),NA,DSST, 1.15074799   20.0000000 mg/d Cutler,2022 NA,RCT,G  62, 62  124 NA,reverse -0.2700000000,-0.671000000, 1.310000e-01,NA,NA,NA,NA,NA NA, 7.2100000  7.2100000,100 100 100 100,100 100,100 low low some low some,Placebo,  0  59.950000 32.450000,NA NA 0,1 1.0,1.0,1.0 1.0 1 1,1,1 1 1 1,1.0 0,1 1 1,1313,Cutler_2022,< 2 months NA >= 20 yo,32.45,32.45,NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,Ostinelli (2025)_Amphetamine_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Amphetamine_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100,100 High,Amphetamine Amphetamine,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.15074799,  20.0000000,mg/kg/d Cutler 2022,NA RCT,RR, 65, 65, 130 outcomes reverse  1.0530000000, 0.622000000, 1.780000e+00,NA,NA,NA,NA,NA NA,NA NA,100,100,100,100,100 100 100,low low,low,low,low Placebo,  0, 59.950000,32.450000,NA,NA,0 1,1.0,1.0 1.0 1.0 1,1,1,1 1 1 1,1.0,0 1,1 1 1314 Cutler_2022 < 2 months,NA,>= 20 yo,22.2057971014493,39.0319587628866 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Amphetamine Amphetamine,  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.15074799   20.0000000 mg/d,Cutler,2022 NA RCT RR  65  65, 130 outcomes reverse, 7.0000000000  0.369000000, 1.328720e+02,NA NA,NA,NA NA NA NA,NA 100 100 100 100 100,100,100 low low,low low low,Placebo   0, 59.950000,32.450000,NA,NA,0,1,1.0,1.0,1.0 1.0 1,1 1 1,1,1,1,1.0,0,1,1 1,1315,Cutler_2022 < 2 months NA >= 20 yo,22.2057971014493,39.0319587628866 NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High,tDCS (transcranial direct current stimulation),tDCS (transcranial direct current stimulation)   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability  0.23014960 NA NA Barham 2022 NA,RCT,RR  11  11   22,outcomes reverse  1.0000000000  0.022000000, 4.640400e+01 NA NA,NA NA NA NA NA NA 100 100,100,100 100 100 100 some low,low low,low,Sham   0, 31.850000,22.085000 NA,NA 0,1,1.0 1.0 1.0,1.0 1 1 1,1,1,1,1,1.0 0 1 1 1,1316,Barham_2022 < 2 months,NA,>= 20 yo 22.085,38.3 NA NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA,NA Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100 High Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA,ASRS  3.22209436,NA,NA Halmoy 2022 NA RCT,G  49, 47   96 outcomes reverse -0.7270000000,-1.142000000,-3.110000e-01   9.0000000   9.3000000 NA,NA NA NA NA NA 100 100 100,100,100 100,100,low,some,low,some,low WLC   0, 56.090625 36.989583,NA,NA,0 1,1.0,1.0,1.0,1.0,1 1 1,1,1,1,1,1.0 0,1 1 1 1317 Halmoy_2022 2-6 months NA >= 20 yo,35.260736196319,36.9895833333333,NA,NA   3  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1,Ostinelli (2025) 35.2532407407407,37.004132231405 NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),  0 NA,Quality of life (patients) Mixed At study endpoint (closest to 12 weeks),NA,AAQoL  3.22209436 NA,NA Halmoy 2022,NA RCT G  49  47   96 NA,reverse  0.3080000000 -0.096000000  7.130000e-01  16.8000000, 17.3000000,NA NA,NA NA NA,NA 100,100,100 100,100 100 100,low,some low,some low WLC   0  56.090625,36.989583,NA NA 0,1,1.0,1.0,1.0 1.0 1,1 1,1 1 1,1 1.0,0 1,1,1 1318,Halmoy_2022 2-6 months NA,>= 20 yo,36.9895833333333,36.9895833333333 NA,NA,  3  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1,Ostinelli (2025) 35.2532407407407,37.004132231405,NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100 100 High,Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT),  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  3.22209436,NA NA,Halmoy 2022 NA RCT,RR  60, 61  121,outcomes,reverse  1.8300000000, 0.651000000, 5.144000e+00 NA NA NA,NA,NA NA NA,NA,100,100 100,100 100 100,100,low some,low,some low,WLC   0  56.173554,37.004132 NA,NA 0,1 1.0,1.0 1.0 1.0 1,1,1 1,1 1 1 1.0,0 1,1,1,1319 Halmoy_2022 2-6 months,NA,>= 20 yo,35.2532407407407,37.004132231405 NA,NA,  3  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1 Ostinelli (2025),35.2532407407407,37.004132231405 NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100 High,Physical training Physical training   0,NA Executive functioning (tests),Mixed,At follow-up (closest to 26 weeks) NA,CPT  5.52359033 NA,NA Kouhbanani 2023,NA,RCT G, 25  27   52 NA reverse -1.9270000000 -2.594000000 -1.259000e+00   0.4700000   0.4900000 NA NA NA,NA NA,NA   0,  0,  0,  0,  0,  0   0 high high high high,high WLC   0,100.000000,35.323077,NA,NA 0,1 1.0 1.0,1.0 1.0 1 1,1 1,1 1,1,1.0,0 1,1 1,1320 Kouhbanani_2023,2-6 months,NA,>= 20 yo 35.3230769230769,35.3230769230769,NA,NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA NA Ostinelli (2025)_Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous,Ostinelli (2025) - Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no high,high
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High,Physical training,Physical training   0,NA,Executive functioning (tests) Mixed At follow-up (closest to 52 weeks),NA,CPT, 5.52359033 NA NA,Kouhbanani,2023 NA RCT,G, 25  27,  52,NA reverse,-1.4530000000 -2.073000000,-8.340000e-01   0.3300000   0.5000000,NA NA,NA,NA,NA NA   0,  0,  0   0,  0   0   0,high,high high,high,high,WLC,  0,100.000000 35.323077,NA NA 0 1,1.0 1.0,1.0 1.0 1 1,1,1,1,1 1,1.0,0,1 1,1,1321,Kouhbanani_2023,2-6 months,NA,>= 20 yo 35.3230769230769,35.3230769230769,NA,NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA,NA,Ostinelli (2025)_Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 52 weeks) 1,Homogeneous,Ostinelli (2025) - Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo 100.00000,no,high high
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High Physical training,Physical training,  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability, 5.52359033 NA,NA,Kouhbanani,2023 NA,RCT RR  30, 30,  60,NA reverse  1.6670000000, 0.437000000, 6.358000e+00 NA,NA NA NA NA NA NA,NA 100,100,100,100 100,100 100,some,some,low,some low,WLC,  0,100.000000,35.320000,NA,NA 0,1,1.0 1.0 1.0 1.0 1 1,1 1 1,1 1 1.0,0,1,1,1 1322,Kouhbanani_2023,2-6 months NA >= 20 yo,35.32 35.32 NA NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769 NA,NA Ostinelli (2025)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High,Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,CAARS-O:L 11.96777906,NA NA Philipsen 2015,NA RCT,G, 95  80, 175 outcomes reverse,-0.1480000000 -0.446000000, 1.510000e-01,  9.1000000   9.8000000,NA NA NA,NA NA NA,100 100,100 100,100,100 100,low low,some,low,low,Placebo   0, 52.408571 35.280000 NA,NA 0,1 1.0 1.0 1.0,1.0,1 1 1,1,1 1,1,1.0 0 1,1 1,1323 Philipsen_2015 7-12 months,NA,>= 20 yo 30.6,40,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100,100 High Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At follow-up (closest to 26 weeks),NA,CAARS-O:L 11.96777906 NA NA Philipsen 2015 NA,RCT G, 85, 62, 147 outcomes reverse -0.3110000000,-0.642000000  1.900000e-02   9.1000000   9.5000000,NA NA NA NA NA NA 100,100 100 100,100,100,100 low,low some low low,Placebo   0  52.291837 35.304762,NA,NA 0 1 1.0,1.0 1.0,1.0 1,1,1 1 1 1,1 1.0,0,1 1,1,1324,Philipsen_2015,7-12 months,NA >= 20 yo 34.7398328690808 35.3047619047619,NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At follow-up (closest to 52 weeks),NA,CAARS-O:L,11.96777906 NA,NA Philipsen 2015,NA RCT G  70, 45  115,NA reverse -0.2360000000,-0.614000000, 1.410000e-01,  8.6000000,  8.1000000,NA NA NA,NA,NA,NA 100,100,100,100 100 100,100,low low,some,low,low Placebo   0  52.191304 35.326087 NA NA,0 1 1.0,1.0,1.0,1.0 1 1 1 1 1,1 1 1.0,0 1,1,1,1325 Philipsen_2015 7-12 months NA,>= 20 yo,35.3260869565217,35.3260869565217 NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100 High Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA,CAARS-S:L 11.96777906 NA,NA Philipsen 2015,NA RCT,G, 91  79  170 outcomes reverse -0.1640000000,-0.467000000, 1.380000e-01   9.6000000,  9.8000000 NA NA,NA,NA,NA,NA,100,100,100,100,100 100,100 low low,some low,low,Placebo   0, 52.433529,35.274706 NA,NA,0,1,1.0 1.0 1.0,1.0,1 1,1 1 1,1,1,1.0 0 1,1,1,1326,Philipsen_2015 7-12 months NA,>= 20 yo,33.7462897526502,42 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Methylphenidate Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 26 weeks),NA,CAARS-S:L 11.96777906 NA NA Philipsen,2015,NA,RCT,G  83  58, 141,outcomes,reverse,-0.1880000000 -0.526000000, 1.490000e-01   9.7000000, 10.5000000,NA,NA,NA,NA,NA NA 100 100 100,100 100 100 100 low,low,some,low low,Placebo   0  52.257447,35.312057,NA NA,0,1,1.0 1.0,1.0 1.0,1 1,1 1,1,1 1 1.0 0 1 1,1 1327 Philipsen_2015 7-12 months,NA >= 20 yo 34.7372549019608,35.3120567375887,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 52 weeks) NA CAARS-S:L 11.96777906 NA NA,Philipsen,2015,NA RCT,G  65  43, 108,NA,reverse,-0.3290000000 -0.719000000  6.000000e-02,  9.5000000, 10.6000000,NA,NA NA,NA,NA,NA,100 100,100,100 100,100 100,low,low some,low,low,Placebo,  0  52.213889 35.321296,NA,NA,0,1,1.0,1.0,1.0 1.0,1,1,1 1 1,1,1,1.0,0 1,1,1,1328 Philipsen_2015 7-12 months,NA >= 20 yo 35.3212962962963,35.3212962962963,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100 High Methylphenidate Methylphenidate,  0 NA,Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks) NA,CAARS impulsivity/emotional lability 11.96777906 NA,NA Philipsen,2015 NA,RCT G, 91  79, 170 outcomes,reverse,-0.1470000000,-0.450000000, 1.560000e-01,  7.5000000,  7.4000000 NA,NA,NA NA NA,NA 100,100 100,100,100,100,100,low,low,some,low low Placebo   0  52.433529,35.274706 NA,NA,0 1 1.0,1.0,1.0 1.0,1,1,1 1 1,1 1,1.0,0,1 1 1 1329,Philipsen_2015,7-12 months NA,>= 20 yo,34.0471698113208,36.9,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100,High,Methylphenidate Methylphenidate,  0 NA Emotional dysregulation,Mixed,At follow-up (closest to 26 weeks),NA,CAARS impulsivity/emotional lability,11.96777906 NA NA,Philipsen 2015,NA,RCT,G  83  58, 141,NA,reverse -0.1800000000,-0.517000000  1.570000e-01   7.6000000   7.9000000,NA,NA,NA NA NA,NA,100 100,100 100 100 100,100,low,low,some,low,low,Placebo   0  52.257447,35.312057 NA NA 0 1 1.0,1.0 1.0,1.0,1 1,1,1,1,1 1,1.0 0,1,1,1,1330,Philipsen_2015 7-12 months NA,>= 20 yo,35.3120567375887,35.3120567375887 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100 High Methylphenidate,Methylphenidate,  0,NA Emotional dysregulation,Mixed,At follow-up (closest to 52 weeks) NA,CAARS impulsivity/emotional lability 11.96777906,NA,NA Philipsen,2015,NA,RCT G  65, 43  108,NA,reverse -0.5080000000,-0.901000000 -1.150000e-01,  6.9000000   7.7000000 NA,NA NA NA NA NA,100,100,100,100,100,100,100 low low,some,low low,Placebo,  0, 52.213889 35.321296,NA,NA 0 1 1.0 1.0 1.0,1.0,1,1,1 1 1,1,1,1.0,0,1 1,1 1331,Philipsen_2015 7-12 months NA,>= 20 yo,35.3212962962963 35.3212962962963,NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100,100,High,Methylphenidate Methylphenidate,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability 11.96777906,NA NA Philipsen 2015 NA RCT RR 110 107  217 outcomes,reverse, 0.3600000000  0.183000000  7.080000e-01,NA NA NA,NA NA,NA NA,NA 100,100 100 100,100 100 100 low,low low,low low,Placebo   0, 52.527189,35.254839 NA,NA,0 1 1.0 1.0,1.0,1.0,1 1 1,1 1 1,1 1.0,0,1,1,1 1332,Philipsen_2015,7-12 months NA,>= 20 yo,28.7959183673469,40 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High,Methylphenidate,Methylphenidate   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability 11.96777906,NA,NA Philipsen,2015,NA,RCT,RR,110 107  217 outcomes,reverse, 0.4860000000, 0.091000000, 2.600000e+00 NA,NA NA,NA,NA,NA NA NA 100 100,100,100 100,100,100,low,low,low,low,low,Placebo,  0  52.527189,35.254839 NA NA 0 1 1.0 1.0,1.0,1.0,1,1,1,1 1,1,1,1.0 0 1 1,1 1333,Philipsen_2015,7-12 months,NA >= 20 yo,28.7959183673469 40 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100 100 High,Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT),100,placebo Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA CAARS-O:L,11.96777906,NA NA Philipsen,2015,NA RCT,G  86, 80, 166,NA reverse, 0.0970000000,-0.209000000  4.020000e-01   8.7000000,  9.8000000 NA NA NA,NA NA,NA 100,100 100,100 100,100,100 low low some low,low Placebo   0, 49.900000 35.262651 NA,NA 0 1,1.0 1.0,1.0 1.0 1 1 1,1 1,1,1 1.0 0 1 1,1,1334,Philipsen_2015 7-12 months,NA,>= 20 yo 35.2626506024096,35.2626506024096,NA,NA,  3  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1 Ostinelli (2025) 35.2532407407407 37.004132231405 NA,NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT) 100 placebo,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At follow-up (closest to 26 weeks),NA CAARS-O:L 11.96777906,NA NA Philipsen 2015,NA RCT G  75, 62  137,NA reverse,-0.1120000000,-0.449000000, 2.260000e-01   8.4000000   9.5000000,NA NA,NA NA NA,NA,100,100 100 100 100,100 100 low low,some,low low,Placebo   0  49.656204,35.283212,NA NA 0 1,1.0 1.0 1.0 1.0,1 1,1,1,1,1,1,1.0,0,1,1,1,1335,Philipsen_2015 7-12 months NA,>= 20 yo 35.2832116788321,35.2832116788321,NA NA   3  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1,Ostinelli (2025) 35.2532407407407 37.004132231405,NA NA Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100,High Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT),100,placebo Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At follow-up (closest to 52 weeks),NA CAARS-O:L,11.96777906 NA,NA,Philipsen,2015,NA,RCT G  59  45, 104 NA reverse,-0.2760000000 -0.668000000  1.160000e-01,  8.4000000   8.1000000 NA,NA,NA NA NA,NA 100,100,100,100 100,100 100 low low some low low,Placebo,  0  49.491346 35.297115 NA,NA,0 1,1.0 1.0 1.0,1.0,1 1 1 1 1,1,1,1.0,0 1 1,1,1336 Philipsen_2015 7-12 months NA >= 20 yo,35.2971153846154 35.2971153846154,NA NA   3  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1,Ostinelli (2025),35.2532407407407,37.004132231405 NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks) 1,Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100 High Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT) 100 placebo Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),NA,CAARS-S:L 11.96777906 NA NA Philipsen,2015,NA,RCT,G, 84  79, 163 outcomes reverse  0.0950000000,-0.213000000  4.030000e-01   9.1000000   9.8000000,NA,NA NA NA NA NA,100 100 100 100 100,100,100,low,low some,low low Placebo   0  49.922699 35.260736,NA,NA,0,1,1.0,1.0 1.0,1.0,1 1 1 1,1,1,1,1.0 0,1,1,1 1337 Philipsen_2015 7-12 months,NA >= 20 yo,35.260736196319,36.9895833333333,NA NA,  3, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1,Ostinelli (2025) 35.2532407407407,37.004132231405,NA,NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100,100,High Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),100 placebo,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 26 weeks) NA CAARS-S:L,11.96777906,NA,NA Philipsen,2015 NA RCT,G  69, 58  127 NA,reverse  0.0100000000,-0.340000000  3.610000e-01   9.1000000, 10.5000000,NA,NA NA NA NA NA 100,100 100,100,100 100,100,low low some,low,low,Placebo   0  49.690551 35.280315 NA,NA,0 1,1.0,1.0,1.0 1.0 1 1,1 1,1 1 1,1.0 0 1 1 1 1338,Philipsen_2015 7-12 months,NA >= 20 yo,35.2803149606299,35.2803149606299,NA NA   3, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1 Ostinelli (2025),35.2532407407407,37.004132231405,NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1,Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100,100 High Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT),100,placebo,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 52 weeks) NA CAARS-S:L 11.96777906,NA NA,Philipsen,2015,NA,RCT G, 56, 43,  99,NA reverse,-0.3580000000,-0.761000000  4.400000e-02,  8.4000000, 10.6000000,NA,NA,NA NA,NA,NA 100,100 100,100,100 100 100,low,low,some,low,low,Placebo,  0, 49.505051 35.295960 NA,NA 0 1,1.0 1.0 1.0,1.0,1,1,1,1,1,1 1,1.0,0 1,1,1,1339,Philipsen_2015,7-12 months,NA >= 20 yo,35.2959595959596 35.2959595959596 NA,NA,  3  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1,Ostinelli (2025) 35.2532407407407,37.004132231405,NA NA Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks),1 Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100,High,Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),100,placebo Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks) NA CAARS impulsivity/emotional lability,11.96777906 NA NA,Philipsen 2015 NA RCT G, 84  79  163,NA reverse  0.1910000000,-0.118000000, 5.000000e-01,  7.2000000,  7.4000000 NA,NA NA,NA,NA NA,100,100,100,100 100,100,100 low low,some low,low Placebo   0, 49.922699 35.260736 NA NA 0 1,1.0,1.0,1.0,1.0,1 1 1 1 1,1 1 1.0 0 1,1,1,1340,Philipsen_2015 7-12 months NA,>= 20 yo 35.260736196319,35.260736196319 NA,NA   3  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1 Ostinelli (2025) 35.2532407407407,37.004132231405,NA,NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100,High,Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT) 100 placebo Emotional dysregulation Mixed At follow-up (closest to 26 weeks) NA,CAARS impulsivity/emotional lability,11.96777906 NA NA,Philipsen,2015,NA,RCT G, 69, 58  127,NA reverse  0.1230000000,-0.228000000, 4.740000e-01,  6.7000000   7.9000000,NA NA NA,NA,NA NA 100 100 100,100,100,100 100 low,low some low low Placebo,  0, 49.690551,35.280315 NA NA 0 1,1.0,1.0 1.0,1.0 1 1 1,1,1 1,1,1.0,0,1 1,1,1341,Philipsen_2015,7-12 months NA >= 20 yo,35.2803149606299,35.2803149606299 NA NA,  3  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1 Ostinelli (2025) 35.2532407407407,37.004132231405,NA,NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100 High Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),100 placebo,Emotional dysregulation Mixed,At follow-up (closest to 52 weeks) NA,CAARS impulsivity/emotional lability 11.96777906 NA NA Philipsen,2015,NA RCT G, 56  43,  99 NA reverse -0.2250000000,-0.626000000, 1.750000e-01   6.5000000   7.7000000,NA NA,NA NA NA,NA 100 100,100 100 100 100 100 low,low,some,low low Placebo   0, 49.505051 35.295960 NA,NA 0 1 1.0,1.0 1.0 1.0,1 1 1 1,1,1 1 1.0 0 1 1,1 1342 Philipsen_2015,7-12 months NA >= 20 yo 35.2959595959596 35.2959595959596,NA NA,  3, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1,Ostinelli (2025) 35.2532407407407 37.004132231405,NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks),1 Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100,100 High Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT) 100 placebo Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability,11.96777906,NA NA,Philipsen 2015 NA,RCT,RR 109,107  216 outcomes,reverse  0.9090000000, 0.566000000, 1.460000e+00,NA,NA,NA,NA NA,NA,NA,NA,100,100,100 100,100 100 100 low low,low low low,Placebo,  0, 50.011574,35.253241 NA,NA,0,1 1.0,1.0 1.0,1.0 1 1 1 1,1 1,1 1.0 0 1 1 1 1343,Philipsen_2015 7-12 months NA,>= 20 yo 35.2532407407407,37.004132231405,NA NA,  3, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1 Ostinelli (2025),35.2532407407407 37.004132231405 NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100,100 High Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),100,placebo Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability 11.96777906 NA NA Philipsen,2015,NA RCT,RR,109 107  216,NA,reverse, 0.7360000000, 0.169000000, 3.212000e+00,NA NA,NA,NA,NA NA NA,NA 100 100,100,100 100 100 100,low low low low,low,Placebo,  0  50.011574,35.253241 NA,NA 0 1 1.0 1.0 1.0,1.0 1 1,1,1,1 1 1 1.0,0,1 1 1,1344,Philipsen_2015 7-12 months,NA,>= 20 yo,35.2532407407407,35.2532407407407 NA NA   3, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1 Ostinelli (2025) 35.2532407407407 37.004132231405,NA,NA Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Goal Management Training (GMT),Goal Management Training (GMT) 100,tau,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  1.84119678 NA NA Hanssen,2023,NA RCT,RR, 41  40,  81,NA reverse,18.5480000000, 1.115000000, 3.084050e+02,NA NA,NA,NA NA NA NA,NA,100,100,100,100 100,100,100,low some low,some low,TAU,  0, 58.034568 31.298765,NA NA 0,1,1.0 1.0 1.0 1.0,1,1 1,1 1,1 1,1.0 0 1,1 1,1345 Hanssen_2023,< 2 months NA,>= 20 yo 31.2987654320988,31.2987654320988,NA,NA,  1, 1 Acceptability: all-cause discontinuation, 1,Ostinelli (2025) 31.2987654320988,31.2987654320988,NA,NA,Ostinelli (2025)_Goal Management Training (GMT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Goal Management Training (GMT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability, 0.46029919 NA,NA Huang 2015,NA,RCT,RR  86  22, 108 outcomes,reverse  1.0230000000, 0.477000000  2.193000e+00 NA NA,NA,NA,NA NA NA,NA 100 100,100 100,100 100,100,low,low,low some low,WLC   0  37.935185,26.623333,NA,NA 0 1 1.0,1.0,1.0,1.0,1 1 1,1,1,1 1,1.0,0,1 1 1,1346,Huang_2015,< 2 months NA,>= 20 yo,19.6532142857143 43.15 NA NA  20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High Viloxazine Viloxazine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA AISRS, 1.38089758 NA NA,Nasser,2022 NA,RCT,G,175,179  354,NA reverse -0.3140000000,-0.582000000 -4.700000e-02,NA NA,NA NA NA NA,12.0411793,12.0411793 100 100 100,100,  0 100 100 low low high,low,low Placebo   0  45.213559,34.757345 NA,NA,0 1,1.0,1.0 1.0,1.0,1,1,1,1 1 1,1,1.0,0 1,1,1,1347,Nasser_2022 < 2 months NA >= 20 yo,34.7573446327684 34.7573446327684,NA,NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA,NA,Ostinelli (2025)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100,High Viloxazine,Viloxazine   0 NA,Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks) NA BRIEF-ASR Emotional control  1.38089758,NA NA Nasser 2022,NA RCT G 175 179  354,NA,reverse, 0.0980000000,-0.118000000, 3.140000e-01 NA NA NA NA,NA,NA, 9.2315708  9.2315708,100,100,100,100   0 100,100 low,low,high,low low,Placebo   0  45.213559 34.757345 NA NA,0,1,1.0,1.0,1.0,1.0,1,1 1,1 1 1,1,1.0,0 1,1 1,1348 Nasser_2022 < 2 months,NA >= 20 yo 34.7573446327684 34.7573446327684 NA,NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA,NA,Ostinelli (2025)_Viloxazine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Viloxazine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Viloxazine,Viloxazine,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability  1.38089758 NA NA Nasser 2022,NA,RCT RR 190,184  374,NA,reverse  1.3870000000, 0.999000000  1.924000e+00,NA,NA,NA,NA,NA NA,NA NA 100,100 100 100 100 100,100,low,low low,low,low Placebo   0  45.180749 34.739572,NA,NA,0 1,1.0 1.0 1.0 1.0,1 1 1,1 1 1 1 1.0,0,1,1 1 1349,Nasser_2022,< 2 months,NA,>= 20 yo,34.7395721925134 34.7395721925134 NA,NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA,Ostinelli (2025)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High,Viloxazine Viloxazine   0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability  1.38089758 NA NA Nasser,2022 NA RCT,RR 190,184  374,NA,reverse  1.8290000000  0.837000000  3.999000e+00 NA,NA,NA NA NA NA,NA NA,100 100,100,100,100 100 100,low low,low low low,Placebo   0, 45.180749,34.739572,NA NA,0,1 1.0 1.0 1.0 1.0,1,1 1,1 1 1,1 1.0,0,1 1,1,1350,Nasser_2022,< 2 months,NA >= 20 yo,34.7395721925134 34.7395721925134,NA NA   6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA NA Ostinelli (2025)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Atomoxetine Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA CAARS-O  1.38089758 NA,NA NCT03324581 2018 NA,RCT G, 50, 59  109,outcomes reverse -0.7500000000 -1.249000000,-2.520000e-01 NA NA,NA NA NA NA 13.5200000,13.5200000,100,100 100 100,  0,100,100 low,low,high,low,low,Placebo,  0, 54.089908,34.829358 NA,NA,0 1 1.0,1.0 1.0,1.0 1 1 1 1 1,1,1,1.0,0 1,1 1,1351 NCT03324581_2018 < 2 months,NA,>= 20 yo,24.7 42.1 NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100 100 High Atomoxetine,Atomoxetine   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability  1.38089758 NA,NA,NCT03324581,2018,NA RCT RR, 80  82, 162 outcomes,reverse, 1.4760000000, 0.983000000, 2.217000e+00 NA,NA,NA,NA,NA NA,NA,NA,100,100 100,100,100,100,100,low,low,low low,low Placebo   0  54.311111,34.846914,NA,NA 0 1,1.0,1.0,1.0 1.0,1,1 1 1,1 1 1 1.0 0,1,1,1,1352,NCT03324581_2018 < 2 months NA,>= 20 yo,24.7 42.10703125 NA NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100,100,High,Atomoxetine Atomoxetine   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability  1.38089758,NA NA,NCT03324581 2018,NA RCT RR  80, 82, 162,outcomes reverse, 1.6110000000  0.657000000  3.947000e+00,NA NA NA NA,NA,NA NA,NA 100,100,100 100,100 100 100 low,low,low,low low Placebo   0  54.311111,34.846914 NA NA 0 1 1.0 1.0 1.0 1.0 1 1 1 1,1 1,1,1.0 0 1,1 1 1353 NCT03324581_2018,< 2 months NA,>= 20 yo 24.7,42.10703125,NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100 100 High,TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation)   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA CAARS-S:L  0.92059839,NA NA NCT03663179 2020,NA RCT,G  14  13,  27,outcomes reverse, 0.1880000000,-0.617000000, 9.920000e-01 NA NA,NA NA,NA NA, 7.6000000, 7.6000000,  0   0   0,  0,  0   0,  0,high high high,high,high Sham   0, 33.340741,34.392593,NA NA 0,1,1.0 1.0 1.0 1.0,1 1,1 1 1,1 1,1.0 0 1,1 1 1354 NCT03663179_2020,< 2 months,NA,>= 20 yo,27.1124137931034 35.24,NA NA,  4, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1,Ostinelli (2025) 27.0733333333333,35.24,NA,NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high high
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation),  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  0.92059839 NA NA NCT03663179,2020,NA,RCT RR, 18, 14   32 outcomes,reverse  3.1110000000, 0.390000000  2.482900e+01,NA NA NA NA,NA NA,NA,NA   0   0   0   0,  0,  0,  0 high high,high high high Sham   0, 33.556250,34.256250,NA,NA,0,1 1.0,1.0 1.0,1.0,1 1,1,1 1 1,1 1.0,0 1,1,1,1355 NCT03663179_2020,< 2 months,NA,>= 20 yo,27.0733333333333 35.22,NA,NA,  4, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1,Ostinelli (2025),27.0733333333333,35.24,NA,NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high,high
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100 High,TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation)   0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 0.92059839 NA,NA NCT03663179 2020,NA,RCT RR  18, 14   32 outcomes reverse, 0.7890000000, 0.017000000, 3.751100e+01 NA,NA NA,NA NA,NA,NA NA   0,  0,  0   0,  0   0,  0,high,high high,high high,Sham   0  33.556250 34.256250,NA,NA,0 1,1.0 1.0,1.0,1.0,1 1,1 1 1,1,1 1.0,0,1,1 1,1356 NCT03663179_2020,< 2 months,NA >= 20 yo 27.0733333333333 35.22,NA NA,  4, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1,Ostinelli (2025),27.0733333333333,35.24,NA,NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high high
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT) 100 tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 26 weeks),NA Adult Barkley CSS,NA,NA NA,Dittner 2018 NA RCT,G, 27, 19,  46 outcomes reverse -1.1620000000,-1.804000000,-5.210000e-01, 10.6000000   7.8000000,NA,NA NA,NA NA,NA   0   0,  0   0,  0   0   0 high high,high high,high,TAU   0, 28.671739,35.865217,NA,NA 0,1,1.0 1.0,1.0 1.0,1 1 1,1,1,1 1 1.0,0 1 1,1 1357 Dittner_2018,NA,NA >= 20 yo,19.6482233502538,43.0524590163934 NA NA  20, 9 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no,high high
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT) 100,tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 52 weeks),NA,Adult Barkley CSS NA NA NA Dittner,2018 NA,RCT,G  27  17   44 outcomes reverse -0.9790000000 -1.627000000 -3.300000e-01   8.8000000,  7.5000000 NA,NA,NA,NA,NA NA,  0   0   0   0   0,  0   0,high,high,high high high TAU,  0, 28.156818,35.854545,NA NA 0 1 1.0 1.0 1.0 1.0,1 1,1 1 1,1 1 1.0,0 1 1 1,1358 Dittner_2018,NA NA,>= 20 yo,35.8545454545455,43.0584615384615 NA NA, 20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo 100.00000 no,high,high
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100,100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT) 100,tau Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability NA,NA NA,Dittner,2018,NA RCT,RR, 30  30,  60,outcomes reverse  1.0000000000  0.151000000  6.643000e+00,NA,NA,NA NA,NA,NA,NA,NA,100,100,100,  0,100 100 100 low,high low,low,low TAU,  0, 30.350000 35.900000 NA,NA,0,1,1.0 1.0,1.0 1.0 1,1,1 1 1,1 1,1.0 0 1 1 1,1359 Dittner_2018 NA,NA,>= 20 yo 19.6532142857143,43.15,NA,NA  20  9,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,21:SNAP-IV-short-Total  1.05868815,  48.3000000,mg/d Abikoff 2009 NA RCT G  19, 19,  38,outcomes reverse -0.6790000000 -1.342000000,-1.600000e-02,  0.5500000   0.6300000,NA,NA NA NA,NA NA 100,100 100,100 100,100,100,some some,low some some Placebo   0, 21.100000,10.050000,NA NA,0,1 1.0 1.0,1.0 1.0 1,1 0 1 1,1,1,1.0 1 1 1,1,1360,Abikoff_2009,< 2 months,NA,6-12 yo 8.60731707317073,10.9714285714286,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100,High Methylphenidate Methylphenidate   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability  1.05868815,  48.3000000,mg/d Abikoff,2009 NA RCT,RR  19, 19   38 outcomes,reverse, 1.0000000000, 0.021000000, 4.797200e+01,NA,NA,NA,NA NA NA NA NA 100 100 100 100 100,100,100 some,some low some some Placebo   0, 21.100000,10.050000 NA NA,0 1,1.0 1.0,1.0,1.0 1 1,0 1,1,1,1 1.0,1 1 1 1 1361,Abikoff_2009,< 2 months,NA 6-12 yo,7.9578947368421 14.7 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Methylphenidate,Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 1.05868815   48.3000000 mg/d Abikoff 2009 NA,RCT,RR, 19, 19   38 outcomes,reverse  1.0000000000  0.021000000  4.797200e+01,NA NA NA,NA,NA NA NA NA,100,100 100,100,100,100,100,some,some low,some some Placebo   0  21.100000,10.050000 NA,NA 0,1,1.0,1.0,1.0,1.0 1,1 0 1 1 1 1,1.0,1,1 1,1 1362 Abikoff_2009,< 2 months,NA,6-12 yo,7.9578947368421 14.7 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Adults (2018) Cortese - Adults 2018,10.1016/S2215-0366(18)30269-4 100   0,100 100 High,Atomoxetine,Atomoxetine,  0,NA,CGI Clinician-rated At follow-up (closest to 26 weeks),NA,CGI-I  5.52359033   85.2000000 mg/d,Adler 2008a,NA RCT,G,271,139, 410 NA,reverse,-0.0940000000 -0.298000000  1.110000e-01   1.1000000   1.0000000,NA,NA NA NA NA,NA 100 100,100,100 100 100,100 low,some some,some low,Placebo,  0  41.459024,36.727073,NA NA,0 1,1.0 1.0,1.0 1.0 1 1,0 1,1,1 1 1.0,1 1,1 1 1363 Adler_2008a,2-6 months,NA >= 20 yo 36.7270731707317,36.7270731707317,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Cortese - Adults (2018)_Atomoxetine_CGI_Clinician-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Cortese - Adults (2018) - Atomoxetine_CGI_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Atomoxetine Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA 24:Other, 1.38089758   44.2000000 mg/kg/d,Arnold 2006 NA,RCT G, 16  16,  32,outcomes,reverse,-0.5060000000 -1.222000000, 2.090000e-01,  6.2000000,  6.5000000,NA NA NA NA NA,NA,100,100,100,100,100,100 100,some,low low,low,some,Placebo   0  25.000000  9.260000 NA NA 0 1 1.0,1.0,1.0,1.0,1,1 0 1,1,1,1,1.0 1,1,1,1 1364 Arnold_2006,< 2 months,NA,6-12 yo 9.26,11.2017964071856,NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High Atomoxetine,Atomoxetine   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability  1.38089758,  44.2000000 mg/kg/d Arnold,2006,NA RCT,RR, 16, 16,  32 outcomes,reverse  0.5000000000, 0.050000000, 4.978000e+00 NA NA NA,NA,NA,NA,NA NA,100 100 100,100,100,100,100,some low low low,some Placebo   0, 25.000000, 9.260000,NA,NA 0 1,1.0,1.0 1.0 1.0,1 1,0 1 1 1,1,1.0,1,1 1,1 1365,Arnold_2006 < 2 months NA 6-12 yo,8.65154639175258,12.2493548387097 NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Adults (2018) Cortese - Adults 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Modafinil Modafinil,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,17:Other  2.07134638, 255.0000000,mg/d,Arnold 2014,NA RCT G  71, 72  143 outcomes,reverse  0.2550000000 -0.075000000, 5.860000e-01, 10.5326872, 12.7279221,NA,NA NA NA,NA NA 100,100,100,100,100,100 100,some,low low low some Placebo,  0  38.559441,39.841259 NA,NA,0,1 1.0,1.0 1.0,1.0,1,1,0 1 1 1,1,1.0,1,1,1,1 1366,Arnold_2014,2-6 months NA >= 20 yo 38.1070422535211,39.8412587412587 NA,NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA,NA Cortese - Adults (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Adults (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 757 Cortese - Adults (2018),Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100 High,Modafinil Modafinil,  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 2.07134638, 255.0000000,mg/d,Arnold,2014 NA,RCT,RR, 73  74  147 outcomes,reverse  1.3220000000  0.855000000, 2.046000e+00,NA,NA,NA,NA NA NA NA,NA,100 100 100 100,100,100,100 some low low,low,some,Placebo   0  38.557823,39.841497 NA NA,0 1 1.0 1.0 1.0 1.0,1 1,0,1,1,1,1,1.0 1 1,1 1,1367,Arnold_2014 2-6 months NA,>= 20 yo 38.1034013605442,39.8414965986395,NA NA,  8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA NA,Cortese - Adults (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Adults (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 757,Cortese - Adults (2018),Cortese - Adults 2018,10.1016/S2215-0366(18)30269-4,100   0 100,100 High,Modafinil Modafinil   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  2.07134638  255.0000000,mg/d,Arnold,2014 NA RCT,RR, 73  74  147,outcomes,reverse, 3.2100000000, 1.360000000, 7.578000e+00 NA NA,NA NA NA,NA NA,NA 100 100,100,100 100,100,100,some low,low low,some,Placebo   0  38.557823,39.841497,NA NA,0,1 1.0,1.0,1.0 1.0,1,1,0,1 1 1,1 1.0,1 1,1 1 1368,Arnold_2014 2-6 months NA,>= 20 yo,38.1034013605442,39.8414965986395 NA,NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA,NA Cortese - Adults (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Adults (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 757 Cortese - Adults (2018) Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100,High,Modafinil Modafinil,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,17:Other, 2.07134638, 340.0000000,mg/d Arnold 2014,NA,RCT,G, 70  72, 142,outcomes,reverse  0.0000000000 -0.330000000  3.300000e-01  12.5499004, 12.7279221,NA,NA NA NA,NA,NA 100 100,100,100 100,100 100,some,low,low low,some Placebo,  0, 44.535211 38.107042 NA,NA,0 1 1.0 1.0,1.0 1.0 1,1 0 1 1,1,1 1.0,1,1,1 1 1369 Arnold_2014 2-6 months,NA,>= 20 yo 38.1070422535211 39.8412587412587 NA,NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA NA,Cortese - Adults (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Adults (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 757,Cortese - Adults (2018),Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100 High,Modafinil Modafinil,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability, 2.07134638, 340.0000000 mg/d,Arnold 2014 NA,RCT,RR, 73, 74, 147 outcomes,reverse, 1.5870000000, 1.052000000, 2.394000e+00,NA NA,NA,NA NA NA NA NA,100 100,100,100,100 100 100 some low low low,some,Placebo   0, 44.517007,38.103401 NA NA,0 1,1.0 1.0,1.0,1.0 1 1 0,1 1,1 1 1.0,1 1,1 1,1370,Arnold_2014,2-6 months,NA >= 20 yo,38.1034013605442,39.8414965986395,NA,NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA,NA Cortese - Adults (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Adults (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 757 Cortese - Adults (2018) Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Modafinil Modafinil,  0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,Tolerability, 2.07134638, 340.0000000,mg/d,Arnold 2014,NA,RCT,RR  73  74  147,outcomes,reverse  3.2100000000  1.360000000, 7.578000e+00 NA,NA,NA NA,NA NA NA NA,100 100,100 100,100,100,100 some,low low low some Placebo,  0, 44.517007,38.103401,NA,NA 0,1,1.0 1.0 1.0 1.0,1 1 0,1,1,1,1,1.0,1 1,1 1,1371,Arnold_2014 2-6 months,NA >= 20 yo 38.1034013605442,39.8414965986395 NA NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA NA,Cortese - Adults (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Adults (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 757 Cortese - Adults (2018),Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4 100   0 100,100,High,Modafinil,Modafinil,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA 17:Other  2.07134638  425.0000000,mg/d Arnold 2014,NA RCT,G, 72  72  144 outcomes,reverse, 0.1560000000,-0.172000000, 4.850000e-01  12.7279221, 12.7279221 NA NA NA NA NA NA 100,100 100 100 100,100 100 some low low,low some Placebo   0, 46.000000,39.100000 NA NA 0 1,1.0,1.0,1.0 1.0,1 1 0 1,1,1,1,1.0,1 1 1,1,1372 Arnold_2014,2-6 months NA >= 20 yo,38.1070422535211,39.8412587412587,NA,NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA NA,Cortese - Adults (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Adults (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 757,Cortese - Adults (2018),Cortese - Adults 2018,10.1016/S2215-0366(18)30269-4 100   0 100 100 High,Modafinil Modafinil,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 2.07134638  425.0000000 mg/d,Arnold,2014,NA RCT RR, 74, 74  148 outcomes,reverse, 1.5220000000  1.004000000, 2.306000e+00 NA,NA,NA NA,NA NA,NA NA,100,100 100,100 100,100,100 some low low,low,some Placebo   0  46.000000,39.100000,NA NA,0,1 1.0 1.0,1.0 1.0,1 1 0 1 1 1,1,1.0 1 1,1,1,1373,Arnold_2014,2-6 months NA >= 20 yo,38.1034013605442,39.8414965986395 NA,NA,  8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA,NA Cortese - Adults (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Adults (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 757 Cortese - Adults (2018) Cortese - Adults 2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100,High Modafinil Modafinil   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability, 2.07134638, 425.0000000 mg/d Arnold,2014,NA,RCT RR, 74, 74, 148 outcomes,reverse, 3.6670000000, 1.578000000, 8.521000e+00,NA NA NA,NA,NA,NA,NA NA 100 100,100,100 100,100 100,some,low,low,low some Placebo,  0  46.000000,39.100000,NA,NA 0,1,1.0 1.0 1.0 1.0 1,1 0 1,1,1 1,1.0,1 1,1,1 1374 Arnold_2014,2-6 months NA >= 20 yo 38.1034013605442 39.8414965986395,NA NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA,NA Cortese - Adults (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Adults (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 757 Cortese - Adults (2018) Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High Modafinil,Modafinil,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,17:Other  2.07134638, 510.0000000 mg/d Arnold,2014 NA,RCT,G  41, 72  113,outcomes reverse  0.2510000000 -0.136000000  6.370000e-01, 10.2449988, 12.7279221 NA NA NA NA,NA,NA 100 100 100 100,100 100 100,some low low,low some,Placebo,  0  42.283186,38.962832 NA NA,0,1,1.0,1.0,1.0 1.0,1,1 0,1,1,1 1,1.0,1,1,1,1,1375 Arnold_2014 2-6 months,NA >= 20 yo 38.1070422535211,39.8412587412587 NA,NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA,NA,Cortese - Adults (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Adults (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 757 Cortese - Adults (2018) Cortese - Adults 2018 10.1016/S2215-0366(18)30269-4 100   0 100,100,High,Modafinil,Modafinil,  0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability  2.07134638, 510.0000000 mg/d Arnold,2014 NA RCT RR, 44  74, 118 outcomes reverse, 1.5360000000  0.970000000  2.430000e+00 NA,NA,NA NA NA NA,NA,NA,100,100 100 100 100 100,100,some low,low low some Placebo   0  42.152542,38.972881,NA,NA 0 1 1.0 1.0,1.0,1.0,1 1 0 1 1 1,1,1.0,1 1 1,1,1376 Arnold_2014,2-6 months,NA,>= 20 yo,38.1034013605442,39.8414965986395,NA,NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA NA Cortese - Adults (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Adults (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 757 Cortese - Adults (2018),Cortese - Adults 2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Modafinil,Modafinil   0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability, 2.07134638  510.0000000,mg/d Arnold,2014,NA,RCT RR  44  74, 118 outcomes reverse  2.5230000000, 0.963000000, 6.610000e+00 NA,NA,NA,NA NA NA,NA NA 100 100,100 100 100,100 100 some low low low,some,Placebo,  0, 42.152542,38.972881 NA NA,0 1,1.0,1.0 1.0 1.0 1 1,0 1 1,1 1 1.0 1 1,1 1,1377,Arnold_2014 2-6 months NA,>= 20 yo,38.1034013605442,39.8414965986395 NA NA   8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA,NA,Cortese - Adults (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Adults (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100 100,High Atomoxetine,Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 16:SNAP-IV-Short-Hyper-Impuls, 1.84119678    1.2000000,mg/kg/d Bangs,2008 NA,RCT,G 153  68  221,outcomes,reverse -0.3200000000,-0.632000000,-8.000000e-03 NA NA NA NA,NA NA  8.4000000, 8.4000000,100 100,100 100,100 100,100 low low,some low low,Placebo,  0   6.638462  9.561538 NA,NA,0 1 1.0,1.0 1.0,1.0 1,1 0,1,1,1,1,1.0,1,1,1,1,1378 Bangs_2008,< 2 months,NA,6-12 yo,8.65157894736842,12.2493333333333 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100,100 High Atomoxetine,Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA 24:Other  1.84119678    1.2000000 mg/kg/d Bangs,2008,NA RCT,G 150  67, 217,outcomes reverse -0.4040000000,-0.706000000,-1.010000e-01,NA NA NA NA,NA NA, 3.9000000, 3.9000000 100 100 100,100 100 100,100,low low some,low,low,Placebo,  0,  6.632719  9.561751 NA NA,0 1,1.0,1.0,1.0 1.0,1 1 0,1 1,1,1 1.0,1 1 1,1,1379,Bangs_2008,< 2 months,NA 6-12 yo,9.26 11.2017964071856 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100 High,Atomoxetine,Atomoxetine,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability  1.84119678    1.2000000,mg/kg/d,Bangs,2008 NA RCT,RR 156, 70  226 outcomes,reverse, 2.1540000000, 0.857000000, 5.412000e+00 NA NA NA,NA NA NA NA NA,100 100,100 100,100 100 100 low low,some,low low,Placebo   0,  6.627434, 9.561947,NA,NA 0,1 1.0,1.0,1.0,1.0,1 1,0 1 1 1 1 1.0,1,1 1 1,1380,Bangs_2008 < 2 months NA 6-12 yo,8.65154639175258 12.2493548387097 NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Atomoxetine Atomoxetine   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 1.84119678    1.2000000 mg/kg/d,Bangs 2008,NA,RCT RR 156  70  226,outcomes reverse, 5.8790000000  0.336000000, 1.029390e+02 NA NA NA,NA NA NA NA NA 100,100,100 100 100,100,100 low,low,some,low,low,Placebo,  0,  6.627434  9.561947,NA,NA 0 1,1.0 1.0 1.0,1.0 1,1 0 1,1 1 1,1.0 1 1 1 1,1381 Bangs_2008,< 2 months NA,6-12 yo 8.65154639175258,12.2493548387097,NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100,100 High Amphetamine,Amphetamine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA 1:ADHD-RS Total, 0.92059839   30.0000000 mg/d Biederman 2007b,NA,RCT,G  69, 72, 141 outcomes,reverse -1.1960000000,-1.556000000 -8.360000e-01, 13.0200000, 12.6400000 NA NA NA NA,NA,NA,100,100 100,100 100 100,100 low,low,some,low,low Placebo,  0, 28.553191  9.204255 NA,NA 0,1 1.0,1.0,1.0,1.0 1,1 0 1,1,1 1 1.0,1,1 1,1,1382,Biederman_2007b < 2 months,NA,6-12 yo,9.04758620689655 14.6347014925373,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Amphetamine,Amphetamine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA 13:CPRS-R:S, 0.92059839   30.0000000,mg/d Biederman,2007b,NA RCT,G  69, 72, 141 outcomes,reverse,-0.5820000000 -0.942000000 -2.220000e-01 NA NA,NA,NA,NA,NA  9.3338095, 9.3338095 100 100,100,100 100,100 100 low,low some low low,Placebo   0  28.553191, 9.204255 NA NA,0,1,1.0 1.0 1.0,1.0,1 1,0,1,1,1 1 1.0 1,1,1,1 1383,Biederman_2007b,< 2 months,NA,6-12 yo,9.05 9.20425531914894,NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100,100,High Amphetamine Amphetamine   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability  0.92059839   30.0000000 mg/d Biederman 2007b,NA,RCT,RR  71  72, 143 outcomes reverse  0.8450000000, 0.463000000, 1.542000e+00 NA,NA NA NA,NA NA,NA NA,100 100 100 100 100,100 100 low,low some,low low,Placebo,  0, 28.517483, 9.201399 NA NA,0,1,1.0 1.0,1.0,1.0 1 1,0,1 1 1 1 1.0 1,1,1,1,1384,Biederman_2007b,< 2 months NA,6-12 yo 8.22105263157895 14.6335365853659 NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100,100,High,Amphetamine Amphetamine,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  0.92059839,  30.0000000,mg/d,Biederman,2007b,NA RCT,RR, 71  72  143 outcomes,reverse, 6.0850000000, 0.751000000, 4.926500e+01,NA NA NA,NA NA,NA,NA,NA 100,100,100 100 100,100,100,low,low some,low,low,Placebo,  0, 28.517483  9.201399 NA,NA 0 1 1.0,1.0,1.0,1.0,1 1 0 1 1,1,1,1.0 1 1,1 1,1385,Biederman_2007b,< 2 months,NA,6-12 yo,8.22105263157895 14.6335365853659,NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100,100,High Amphetamine,Amphetamine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total, 0.92059839   50.0000000,mg/d Biederman 2007b,NA,RCT G, 71, 72  143,outcomes,reverse -1.2450000000 -1.605000000,-8.850000e-01  14.4900000  12.6400000 NA NA NA,NA NA,NA,100,100 100,100,100 100,100,low low some,low,low Placebo   0, 34.475524  9.151748 NA,NA 0,1,1.0,1.0,1.0,1.0,1,1 0,1 1,1,1,1.0,1 1 1 1 1386 Biederman_2007b < 2 months NA 6-12 yo,9.04758620689655 14.6347014925373,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100,High Amphetamine Amphetamine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA,13:CPRS-R:S, 0.92059839   50.0000000 mg/d Biederman 2007b,NA RCT,G, 68, 72, 140 outcomes reverse -1.2890000000,-1.711000000 -8.660000e-01,NA NA NA,NA NA,NA  9.3338095  9.3338095,100 100,100,100 100 100,100,low low some,low,low Placebo   0, 34.400000, 9.157143 NA NA,0,1,1.0,1.0,1.0 1.0 1,1 0 1,1 1 1 1.0,1,1,1 1 1387,Biederman_2007b < 2 months,NA 6-12 yo,9.05 9.20425531914894 NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100 100,High Amphetamine,Amphetamine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  0.92059839,  50.0000000 mg/d,Biederman 2007b NA RCT,RR  74, 72  146 outcomes,reverse, 0.7570000000  0.408000000  1.405000e+00 NA NA,NA NA,NA,NA,NA NA 100,100 100,100,100,100 100,low,low,some low low Placebo   0  34.547945, 9.146575,NA,NA,0,1 1.0,1.0,1.0,1.0,1 1,0,1 1,1,1 1.0,1,1,1 1 1388,Biederman_2007b < 2 months,NA 6-12 yo 8.22105263157895,14.6335365853659 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100,100 High,Amphetamine,Amphetamine,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.92059839   50.0000000,mg/d Biederman 2007b,NA RCT,RR, 74, 72  146 outcomes,reverse, 3.8920000000, 0.446000000  3.398900e+01,NA NA,NA,NA,NA,NA NA,NA,100 100 100,100,100 100,100,low,low,some,low,low,Placebo,  0, 34.547945  9.146575,NA,NA,0,1 1.0 1.0 1.0,1.0,1,1,0 1 1,1,1,1.0,1 1 1 1 1389 Biederman_2007b < 2 months,NA 6-12 yo,8.22105263157895,14.6335365853659,NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100 100 High Amphetamine Amphetamine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total, 0.92059839,  70.0000000 mg/d,Biederman,2007b NA,RCT G  73, 72, 145,outcomes,reverse -1.3760000000,-1.740000000,-1.013000e+00  14.4100000  12.6400000,NA,NA,NA,NA NA,NA,100,100 100 100,100 100,100,low,low some,low,low Placebo   0, 29.993103  9.047586,NA,NA 0 1 1.0 1.0,1.0 1.0,1 1 0 1,1 1 1 1.0 1,1,1,1,1390,Biederman_2007b,< 2 months NA 6-12 yo,9.04758620689655,14.6347014925373,NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100 High,Amphetamine Amphetamine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA 13:CPRS-R:S  0.92059839,  70.0000000 mg/d Biederman 2007b NA RCT G, 72, 72  144,outcomes reverse,-1.3530000000,-1.774000000,-9.320000e-01 NA NA,NA NA NA NA, 9.3338095, 9.3338095 100,100,100 100 100 100 100 low,low,some low low,Placebo,  0  30.000000  9.050000,NA NA 0 1,1.0,1.0,1.0 1.0 1,1,0 1,1,1,1,1.0 1 1,1,1 1391 Biederman_2007b < 2 months,NA,6-12 yo 9.05,9.20425531914894 NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Amphetamine,Amphetamine   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  0.92059839,  70.0000000,mg/d Biederman 2007b NA,RCT RR  73  72  145 outcomes,reverse  0.7120000000  0.378000000, 1.344000e+00,NA NA,NA NA NA,NA NA NA 100 100 100,100 100 100,100 low low,some,low low Placebo   0, 29.993103  9.047586,NA,NA,0,1 1.0 1.0 1.0 1.0 1 1 0 1,1,1 1,1.0 1,1,1 1,1392,Biederman_2007b < 2 months,NA 6-12 yo 8.22105263157895,14.6335365853659,NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100,High,Amphetamine,Amphetamine,  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability, 0.92059839,  70.0000000,mg/d,Biederman,2007b,NA RCT,RR  73, 72  145,outcomes reverse  9.8630000000, 1.296000000  7.507400e+01 NA NA,NA,NA NA,NA,NA,NA 100 100,100 100 100,100,100 low,low,some low low,Placebo,  0  29.993103, 9.047586,NA NA 0,1,1.0,1.0 1.0 1.0,1 1,0,1,1 1,1 1.0 1,1,1 1,1393,Biederman_2007b,< 2 months NA 6-12 yo 8.22105263157895 14.6335365853659,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Amphetamine Amphetamine,  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability  0.69044879 NA NA Biederman 2002 NA RCT,RR,129,210, 339,outcomes reverse  0.4400000000, 0.227000000, 8.540000e-01 NA NA,NA,NA NA,NA NA NA,100 100 100 100 100,100 100,some,some low some,some,Placebo,  0, 25.121239, 8.561947 NA,NA 0,1 1.0,1.0 1.0,1.0,1,1,0 1 1,1,1 1.0 1,1,1 1 1394,Biederman_2002,< 2 months,NA 6-12 yo,8.22105263157895 14.6335365853659 NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Amphetamine,Amphetamine   0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability, 0.69044879 NA,NA Biederman,2002,NA,RCT,RR 129 210  339,outcomes reverse, 0.1250000000  0.007000000  2.198000e+00,NA,NA,NA NA,NA,NA NA NA 100,100 100 100 100,100 100,some,some low,some some,Placebo   0, 25.121239  8.561947 NA NA,0,1,1.0,1.0,1.0,1.0,1,1 0 1 1 1 1 1.0,1 1 1,1,1395,Biederman_2002,< 2 months NA,6-12 yo 8.22105263157895 14.6335365853659,NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Amphetamine,Amphetamine,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 0.69044879,NA,NA,Biederman,2002 NA,RCT,RR 121,210, 331 outcomes reverse  0.7510000000, 0.436000000  1.291000e+00 NA,NA,NA,NA NA NA,NA,NA,100,100,100,100,100,100 100 some,some,low some,some Placebo,  0, 24.358308  8.526888 NA NA,0,1 1.0,1.0 1.0,1.0,1,1,0 1 1,1 1,1.0 1 1,1 1 1396 Biederman_2002 < 2 months,NA 6-12 yo 8.22105263157895,14.6335365853659,NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100,100 High Amphetamine Amphetamine   0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.69044879 NA,NA Biederman,2002 NA RCT,RR,121,210, 331 outcomes,reverse, 1.1570000000, 0.333000000  4.019000e+00,NA NA NA,NA,NA NA NA NA,100 100 100 100,100 100 100 some some,low some,some Placebo   0, 24.358308  8.526888,NA NA 0 1 1.0 1.0,1.0,1.0,1 1,0 1 1,1,1,1.0,1 1,1,1,1397,Biederman_2002,< 2 months,NA,6-12 yo 8.22105263157895 14.6335365853659 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100 High Amphetamine,Amphetamine   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability  0.69044879,NA,NA,Biederman,2002,NA,RCT,RR 124 210, 334 outcomes,reverse  0.5490000000  0.298000000, 1.013000e+00 NA NA,NA,NA,NA NA,NA NA 100,100 100 100,100 100 100 some,some,low some,some Placebo   0  24.464072  8.674251 NA NA,0 1 1.0,1.0 1.0 1.0,1 1 0 1,1,1 1 1.0 1,1,1 1 1398,Biederman_2002 < 2 months NA 6-12 yo 8.22105263157895,14.6335365853659 NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100,High Amphetamine Amphetamine,  0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 0.69044879,NA,NA Biederman 2002,NA,RCT RR,124 210  334,outcomes,reverse, 1.4110000000, 0.440000000, 4.528000e+00 NA,NA NA,NA,NA NA,NA,NA 100,100 100 100,100 100 100,some,some low,some,some,Placebo,  0, 24.464072  8.674251 NA,NA,0,1 1.0,1.0 1.0 1.0,1,1,0,1 1,1,1,1.0 1 1 1 1 1399 Biederman_2002 < 2 months,NA,6-12 yo 8.22105263157895,14.6335365853659 NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100,100 High Modafinil Modafinil,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total, 2.07134638  368.5000000,mg/d,Biederman,2005,NA RCT G 163  81  244,outcomes reverse -0.4490000000,-0.719000000,-1.790000e-01  14.5000000  12.1000000,NA,NA NA,NA,NA NA 100 100 100 100,  0,100 100,low some high,some,some Placebo   0, 29.340164 10.300410 NA NA 0,1 1.0 1.0 1.0,1.0,1 1 0,1,1,1 1,1.0 1 1,1,1,1400 Biederman_2005 2-6 months NA 6-12 yo,8.85049504950495,10.3004098360656 NA,NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100,100 High Modafinil,Modafinil   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA 13:CPRS-R:S  2.07134638  368.5000000 mg/d,Biederman,2005 NA RCT G 163  81, 244,outcomes,reverse -0.4390000000 -0.732000000,-1.460000e-01,NA NA,NA NA NA,NA, 9.9000000  9.9000000 100 100 100,100   0,100,100,low some,high,some some Placebo,  0  29.340164 10.300410 NA,NA,0,1 1.0,1.0 1.0,1.0,1 1,0,1,1 1 1,1.0 1 1 1,1 1401 Biederman_2005 2-6 months NA,6-12 yo 8.85049504950495,10.3004098360656,NA,NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA,NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Modafinil Modafinil,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability  2.07134638  368.5000000,mg/d,Biederman 2005 NA,RCT,RR,164  84  248 outcomes,reverse, 0.6730000000  0.523000000, 8.660000e-01,NA NA NA,NA,NA,NA NA NA,100 100,100,100,  0 100,100 low,some,high,some,some Placebo,  0  29.306452 10.298387,NA NA,0 1,1.0 1.0,1.0 1.0 1 1 0,1 1 1 1,1.0,1 1,1,1 1402,Biederman_2005,2-6 months NA 6-12 yo 7.875 10.2983870967742,NA,NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA NA,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Modafinil,Modafinil,  0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 2.07134638, 368.5000000 mg/d,Biederman,2005,NA,RCT RR 164, 84, 248 outcomes,reverse  0.8540000000  0.209000000  3.486000e+00,NA NA,NA NA NA,NA,NA NA,100,100 100 100   0 100 100 low some,high some some Placebo,  0, 29.306452 10.298387,NA NA,0 1,1.0 1.0 1.0 1.0 1,1 0 1 1 1,1 1.0 1,1,1,1 1403,Biederman_2005,2-6 months,NA 6-12 yo,7.875 10.2983870967742,NA NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA,NA,Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Modafinil Modafinil   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total  0.92059839  300.0000000,mg/d Biederman,2006b NA RCT,G, 50  51, 101 outcomes reverse -0.5740000000,-1.004000000 -1.430000e-01,NA NA NA,NA NA,NA,12.1404283,12.1404283,100,100 100,100 100 100,100 some,some low,some some Placebo   0  29.455446, 8.850495 NA NA,0,1,1.0 1.0 1.0 1.0 1,1,0,1 1 1 1 1.0,1 1,1 1 1404,Biederman_2006b < 2 months,NA,6-12 yo,8.85049504950495 10.3004098360656,NA NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100,High,Modafinil,Modafinil,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,24:Other, 0.92059839, 300.0000000 mg/d Biederman,2006b NA RCT G, 50  51  101,outcomes reverse,-0.2710000000,-0.683000000  1.410000e-01 NA NA NA,NA NA,NA,12.1404283 12.1404283 100 100 100,100 100 100,100,some some,low,some some,Placebo   0, 29.455446  8.850495 NA NA 0 1,1.0 1.0,1.0 1.0,1,1 0 1,1,1,1,1.0 1,1 1,1,1405,Biederman_2006b,< 2 months NA,6-12 yo 8.85049504950495 10.3004098360656,NA,NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA,NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Modafinil Modafinil,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks) NA,5:ADHD-RS Total, 0.92059839, 300.0000000 mg/d Biederman,2006b NA RCT G, 50  51, 101,outcomes reverse,-0.4410000000,-0.851000000,-3.200000e-02,NA,NA NA NA,NA NA 13.5687140 13.5687140,100,100 100 100 100,100 100,some some low,some,some Placebo   0  29.455446  8.850495,NA,NA 0 1 1.0,1.0 1.0,1.0 1 1 0 1,1 1,1 1.0 1,1 1,1 1406,Biederman_2006b < 2 months NA 6-12 yo,8.85049504950495 9.96229508196721 NA,NA   8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100,100,High Modafinil,Modafinil,  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  0.92059839, 300.0000000 mg/d Biederman,2006b,NA,RCT RR  50  51, 101,outcomes reverse, 2.0400000000, 0.540000000  7.712000e+00,NA,NA,NA,NA NA,NA NA NA 100,100,100,100 100,100 100 some,some low,some some,Placebo,  0, 29.455446, 8.850495 NA NA,0 1,1.0,1.0,1.0 1.0 1,1,0 1,1 1,1,1.0,1,1 1 1 1407 Biederman_2006b < 2 months NA 6-12 yo,7.875 10.2983870967742 NA NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA NA,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100 High Modafinil Modafinil,  0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability  0.92059839  300.0000000 mg/d Biederman 2006b NA RCT,RR  50, 51, 101,outcomes,reverse  5.0980000000  0.251000000, 1.036010e+02,NA,NA NA NA NA NA NA,NA 100 100,100 100 100,100 100 some some,low some,some Placebo   0, 29.455446  8.850495,NA,NA 0 1 1.0 1.0 1.0,1.0,1,1,0,1,1 1 1,1.0 1,1 1,1,1408,Biederman_2006b < 2 months,NA,6-12 yo,7.875,10.2983870967742 NA NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA,NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Modafinil Modafinil   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA 1:ADHD-RS Total  0.92059839, 300.0000000,mg/d,Biederman,2006b,NA RCT,G  49  51  100,outcomes reverse,-0.3780000000,-0.797000000  4.100000e-02 NA,NA NA NA NA NA 12.1404283 12.1404283 100,100 100,100,100,100 100 some some low some,some,Placebo,  0  22.550000, 8.851000 NA,NA 0 1,1.0 1.0,1.0 1.0,1 1 0 1,1 1 1,1.0,1,1 1,1 1409 Biederman_2006b,< 2 months NA 6-12 yo,8.85049504950495,10.3004098360656,NA NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Modafinil Modafinil,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA,24:Other, 0.92059839, 300.0000000 mg/d Biederman,2006b,NA,RCT G  49, 51, 100 outcomes reverse -0.0310000000 -0.434000000, 3.720000e-01 NA NA,NA NA NA NA 12.1404283 12.1404283,100 100,100 100 100,100,100,some,some low,some some Placebo,  0  22.550000, 8.851000 NA,NA,0,1 1.0 1.0,1.0 1.0 1,1 0,1,1 1,1 1.0,1 1 1,1,1410 Biederman_2006b,< 2 months NA,6-12 yo 8.85049504950495 10.3004098360656 NA,NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100,High Modafinil Modafinil   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),NA,5:ADHD-RS Total, 0.92059839  300.0000000 mg/d,Biederman 2006b NA RCT,G, 49, 51, 100,outcomes,reverse -0.4720000000,-0.886000000 -5.800000e-02 NA,NA,NA NA NA NA,13.5687140,13.5687140,100 100 100,100,100,100,100,some,some,low,some some,Placebo,  0  22.550000, 8.851000,NA NA,0 1 1.0 1.0,1.0,1.0 1,1 0,1 1 1,1 1.0,1,1 1 1,1411 Biederman_2006b,< 2 months NA,6-12 yo 8.85049504950495,9.96229508196721,NA NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA,NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100 High,Modafinil Modafinil   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability, 0.92059839, 300.0000000 mg/d,Biederman 2006b,NA,RCT,RR  49  51, 100 outcomes,reverse, 1.3880000000, 0.327000000, 5.885000e+00,NA NA NA NA NA NA,NA NA 100 100,100,100 100 100,100,some,some low,some,some,Placebo   0  22.550000  8.851000 NA NA,0 1,1.0,1.0,1.0,1.0 1 1,0 1,1 1 1,1.0,1,1 1 1,1412,Biederman_2006b < 2 months,NA,6-12 yo,7.875 10.2983870967742 NA NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA,NA Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Modafinil,Modafinil   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.92059839, 300.0000000 mg/d,Biederman,2006b,NA RCT RR, 49, 51, 100,outcomes reverse, 5.2000000000, 0.256000000, 1.056470e+02,NA NA NA NA,NA,NA NA NA 100 100 100,100,100 100,100 some some low,some some Placebo   0, 22.550000, 8.851000,NA NA,0 1 1.0,1.0 1.0 1.0 1 1 0,1 1,1,1,1.0,1,1 1,1 1413,Biederman_2006b,< 2 months NA,6-12 yo,7.875 10.2983870967742,NA NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100 High,Modafinil Modafinil,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total  0.92059839, 300.0000000,mg/d,Biederman,2006b NA,RCT G, 47  51   98 outcomes reverse -0.3840000000 -0.808000000, 4.000000e-02 NA,NA NA,NA NA,NA 12.1404283 12.1404283 100 100 100 100 100,100 100 some,some,low,some some Placebo,  0  23.081633, 9.043878 NA,NA 0,1,1.0,1.0 1.0 1.0,1 1,0 1 1 1 1,1.0 1 1 1,1 1414 Biederman_2006b,< 2 months,NA,6-12 yo,8.85049504950495 10.3004098360656,NA NA   8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA,NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100 100 High,Modafinil,Modafinil,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,24:Other, 0.92059839  300.0000000,mg/d,Biederman,2006b NA,RCT,G  47  51   98,outcomes,reverse,-0.3560000000 -0.781000000  6.800000e-02 NA NA NA NA,NA NA 12.1404283 12.1404283,100 100 100 100 100 100 100 some,some low some some Placebo   0  23.081633, 9.043878,NA NA,0,1 1.0,1.0,1.0,1.0 1,1 0 1 1,1,1,1.0 1,1 1 1 1415 Biederman_2006b,< 2 months NA,6-12 yo,8.85049504950495,10.3004098360656 NA NA   8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High,Modafinil,Modafinil,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),NA,5:ADHD-RS Total, 0.92059839, 300.0000000,mg/d,Biederman,2006b,NA,RCT,G, 47, 51,  98,outcomes,reverse,-0.3080000000,-0.717000000, 1.010000e-01 NA NA NA,NA,NA,NA,13.5687140,13.5687140,100 100 100,100,100 100 100 some some low,some some Placebo,  0  23.081633  9.043878,NA,NA,0 1,1.0,1.0 1.0 1.0,1,1 0 1 1,1 1,1.0 1,1 1 1,1416 Biederman_2006b < 2 months NA 6-12 yo 8.85049504950495,9.96229508196721 NA NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA,NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Modafinil,Modafinil,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  0.92059839, 300.0000000,mg/d,Biederman 2006b,NA,RCT,RR  48  51   99,outcomes,reverse  2.8330000000  0.798000000, 1.005900e+01 NA,NA NA NA,NA,NA NA,NA 100,100,100 100 100,100 100,some,some,low,some,some,Placebo   0  23.060606  9.045455,NA NA 0 1 1.0,1.0,1.0 1.0,1,1,0,1 1 1 1 1.0 1,1,1,1,1417,Biederman_2006b < 2 months,NA 6-12 yo 7.875,10.2983870967742,NA NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA NA Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Modafinil,Modafinil,  0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability  0.92059839  300.0000000,mg/d Biederman 2006b,NA RCT RR  48, 51,  99,outcomes reverse  9.5510000000, 0.528000000, 1.728140e+02 NA NA NA NA NA,NA NA,NA 100,100 100 100,100,100,100 some,some low,some,some,Placebo   0  23.060606  9.045455,NA,NA 0,1,1.0 1.0,1.0,1.0 1,1 0 1,1 1,1,1.0 1,1 1 1,1418,Biederman_2006b,< 2 months NA,6-12 yo 7.875,10.2983870967742 NA,NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA,NA,Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100 High,Modafinil Modafinil   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total  0.92059839, 400.0000000 mg/d,Biederman 2006b NA,RCT G, 50, 51  101,outcomes reverse -0.5040000000,-0.929000000 -7.900000e-02 NA,NA NA NA,NA,NA 12.1404283 12.1404283 100 100,100,100 100 100 100 some some low some some Placebo   0, 25.495050  9.692079 NA NA,0 1 1.0 1.0,1.0,1.0 1,1 0 1 1,1 1 1.0 1,1,1,1 1419,Biederman_2006b < 2 months NA 6-12 yo,8.85049504950495 10.3004098360656,NA NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100 100,High Modafinil Modafinil,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA 24:Other  0.92059839  400.0000000,mg/d Biederman 2006b,NA,RCT G  50, 51  101,outcomes,reverse -0.3390000000,-0.755000000  7.700000e-02 NA NA NA,NA,NA,NA,12.1404283,12.1404283 100,100 100,100 100 100 100 some some,low some,some Placebo,  0  25.495050  9.692079 NA NA,0 1,1.0,1.0,1.0,1.0,1 1 0,1 1,1 1,1.0,1,1,1 1,1420 Biederman_2006b,< 2 months NA 6-12 yo 8.85049504950495,10.3004098360656 NA,NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100,100 High,Modafinil,Modafinil,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks) NA,5:ADHD-RS Total, 0.92059839  400.0000000,mg/d,Biederman,2006b,NA,RCT G  50, 51  101,outcomes reverse,-0.3150000000,-0.717000000  8.800000e-02,NA,NA NA,NA,NA,NA,13.5687140,13.5687140,100,100,100,100,100 100,100 some some,low some,some,Placebo,  0, 25.495050, 9.692079 NA,NA 0 1 1.0 1.0,1.0,1.0 1,1 0 1,1,1 1 1.0,1 1,1,1,1421,Biederman_2006b < 2 months NA 6-12 yo 8.85049504950495 9.96229508196721,NA,NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA,NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High,Modafinil,Modafinil   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 0.92059839, 400.0000000,mg/d,Biederman 2006b NA,RCT RR  50, 51  101 outcomes reverse  1.3600000000, 0.321000000  5.770000e+00 NA NA NA NA,NA NA,NA,NA,100,100 100,100 100,100,100 some some,low some some Placebo   0  25.495050, 9.692079,NA NA 0 1,1.0 1.0 1.0,1.0 1,1,0,1 1 1,1 1.0,1,1 1,1,1422,Biederman_2006b < 2 months,NA 6-12 yo 7.875,10.2983870967742 NA NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA,NA,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Modafinil Modafinil,  0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability  0.92059839, 400.0000000 mg/d Biederman 2006b,NA,RCT,RR, 50  51  101 outcomes reverse, 3.0590000000, 0.128000000, 7.335000e+01 NA NA,NA NA,NA,NA,NA NA 100,100,100,100 100 100,100 some some low some some Placebo   0  25.495050, 9.692079 NA NA,0,1 1.0,1.0 1.0 1.0 1,1 0,1 1 1,1,1.0,1,1 1 1,1423 Biederman_2006b < 2 months NA,6-12 yo 7.875 10.2983870967742 NA,NA,  8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA 1:ADHD-RS Total, 1.84119678,NA NA Biederman,2008 NA RCT,G, 84  78, 162,outcomes reverse -0.5850000000 -0.963000000,-2.080000e-01 NA,NA,NA NA,NA,NA 12.5411004 12.5411004 100,100,100,100,100,100 100,low low some,low low Placebo   0  24.251852,10.600000,NA NA 0 1,1.0,1.0 1.0 1.0 1 1 0 1 1,1 1,1.0 1 1,1 1 1424 Biederman_2008,< 2 months NA 6-12 yo,8.99719626168224 14.5496794871795,NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability, 1.84119678,NA,NA,Biederman 2008,NA RCT RR  87, 86  173,outcomes reverse, 0.8690000000  0.582000000  1.296000e+00 NA NA NA NA NA NA NA,NA 100,100,100,100,100 100 100 low,low,some low low Placebo,  0  24.292486,10.600000 NA NA 0 1,1.0 1.0,1.0,1.0,1,1,0,1,1 1,1 1.0,1 1 1,1 1425 Biederman_2008 < 2 months NA,6-12 yo,8.23931034482759 12.6640449438202 NA NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability  1.84119678 NA NA Biederman,2008 NA RCT,RR  87, 86, 173,outcomes reverse, 8.8970000000, 1.152000000, 6.872000e+01,NA NA,NA,NA NA NA,NA NA 100 100,100 100,100 100 100,low,low,some,low low Placebo,  0  24.292486 10.600000,NA NA,0 1 1.0 1.0 1.0,1.0 1 1 0,1 1,1 1,1.0,1 1 1,1 1426,Biederman_2008,< 2 months NA 6-12 yo 9,12.6640449438202,NA NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total, 1.84119678,NA NA,Biederman 2008,NA,RCT G  82  78, 160 outcomes reverse -0.5990000000,-0.980000000,-2.180000e-01 NA NA,NA,NA,NA,NA,12.5411004,12.5411004,100 100,100 100 100 100 100 low low,some low low,Placebo   0, 22.627500 10.702500,NA NA 0,1,1.0,1.0,1.0,1.0,1,1 0 1,1 1 1,1.0 1,1,1,1 1427,Biederman_2008 < 2 months NA,6-12 yo,8.99719626168224 14.5496794871795 NA NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100,100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability  1.84119678 NA,NA Biederman,2008,NA RCT,RR, 86, 86  172,outcomes reverse  0.9390000000, 0.637000000  1.385000e+00 NA,NA NA NA,NA,NA,NA NA 100 100,100,100 100 100 100,low low some,low,low,Placebo   0  22.700000 10.700000,NA,NA,0 1 1.0,1.0 1.0 1.0 1,1 0 1 1 1 1 1.0,1,1,1 1,1428,Biederman_2008 < 2 months,NA 6-12 yo,8.23931034482759,12.6640449438202 NA NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability  1.84119678,NA,NA Biederman 2008,NA RCT,RR, 86  86, 172,outcomes reverse 13.0000000000, 1.739000000, 9.720500e+01,NA,NA NA,NA,NA,NA NA,NA 100 100 100,100,100,100,100 low low some low low,Placebo,  0, 22.700000 10.700000,NA,NA 0 1,1.0,1.0 1.0,1.0,1 1,0,1 1 1 1,1.0,1 1,1,1,1429,Biederman_2008 < 2 months,NA 6-12 yo,9,12.6640449438202 NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total, 1.84119678,NA,NA,Biederman,2008,NA,RCT,G, 81, 78  159 outcomes reverse -0.7940000000 -1.193000000 -3.950000e-01,NA NA,NA,NA NA,NA,12.5411004,12.5411004,100,100 100,100,100,100 100 low,low some,low low,Placebo   0  29.726415,10.345283 NA NA 0,1,1.0,1.0,1.0,1.0 1,1,0,1 1 1 1 1.0 1,1 1 1,1430 Biederman_2008 < 2 months,NA,6-12 yo 8.99719626168224,14.5496794871795,NA NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100,100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability  1.84119678 NA,NA,Biederman 2008,NA RCT RR, 86, 86, 172 outcomes,reverse  1.1210000000, 0.781000000  1.610000e+00,NA NA NA,NA,NA,NA NA NA 100,100,100 100,100,100 100 low,low some low low,Placebo   0  29.650000,10.350000 NA NA,0 1 1.0 1.0 1.0,1.0 1,1 0,1,1 1 1,1.0,1 1 1,1,1431 Biederman_2008 < 2 months,NA,6-12 yo 8.23931034482759,12.6640449438202 NA,NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100 High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability  1.84119678 NA NA Biederman 2008,NA,RCT,RR, 86, 86  172 outcomes reverse,20.0000000000  2.745000000, 1.457270e+02,NA,NA NA,NA,NA,NA,NA NA,100,100,100 100,100,100 100 low,low,some,low,low Placebo,  0  29.650000 10.350000 NA,NA,0,1 1.0,1.0 1.0,1.0,1 1 0 1,1 1 1,1.0 1,1,1,1 1432 Biederman_2008,< 2 months,NA,6-12 yo,9,12.6640449438202 NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4   0,  0 100,100,High Methylphenidate Methylphenidate,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 0.92059839,NA NA,Buitelaar,1996,NA,RCT,RR, 21, 21   42 outcomes reverse  5.0000000000  0.254000000, 9.827200e+01,NA,NA NA,NA,NA NA NA NA,100 100,100,100 100 100,100 some,some low some some Placebo,  0 NA NA,NA,NA 0 1 1.0,1.0 1.0 1.0 1 1 0,1 1,1 1,1.0,1,1 1,1 1433 Buitelaar_1996 < 2 months,NA,NA 7.9578947368421 14.7 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4   0   0,100 100 High,Methylphenidate Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.92059839,NA,NA Buitelaar,1996,NA RCT RR, 21  21   42 outcomes,reverse, 5.0000000000, 0.254000000  9.827200e+01,NA NA,NA NA NA,NA NA,NA,100,100,100,100,100 100 100,some some low some some Placebo,  0 NA,NA,NA,NA,0,1 1.0,1.0,1.0,1.0 1 1 0 1,1,1,1,1.0,1,1,1 1,1434,Buitelaar_1996 < 2 months NA NA 7.9578947368421,14.7 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100 High Bupropion Bupropion   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839,NA,NA,Casat 1989 NA,RCT RR  20, 10   30 NA reverse, 0.5000000000  0.035000000  7.190000e+00 NA NA,NA,NA,NA,NA,NA NA,100 100,100,100 100,100,100 some some,low,some,some Placebo   0,NA,11.500000 NA,NA,0,1 1.0 1.0 1.0,1.0 1 1,0,1 1 1,1 1.0,1 1 1 1,1435,Casat_1989,< 2 months,NA 6-12 yo,11.5,11.5,NA,NA, 10, 7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25,NA NA,Cortese - Children (2018)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High,Bupropion Bupropion   0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  0.92059839 NA,NA Casat,1989 NA RCT RR, 20  10   30 NA reverse, 1.5710000000  0.070000000, 3.545800e+01,NA,NA,NA,NA,NA,NA NA NA,100 100,100 100,100 100 100,some some,low,some,some,Placebo   0 NA,11.500000,NA,NA,0,1,1.0 1.0,1.0,1.0 1 1 0,1 1 1 1 1.0,1,1,1,1 1436 Casat_1989,< 2 months,NA,6-12 yo 11.5 11.5,NA NA, 10  7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25,NA NA Cortese - Children (2018)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100,High Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA 24:Other, 1.15074799 NA,NA,Childress 2009 NA,RCT,G, 60, 63, 123,outcomes,reverse -0.8040000000,-1.173000000,-4.350000e-01  14.1800000, 13.0300000,NA,NA NA NA,NA NA 100 100,100 100 100,100,100 low some,low some some Placebo,  0, 35.068293  8.607317 NA,NA,0,1 1.0 1.0 1.0,1.0,1 1,0 1,1 1 1 1.0,1,1,1 1 1437 Childress_2009,< 2 months,NA 6-12 yo 8.60731707317073 10.9714285714286 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100 High Methylphenidate Methylphenidate,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA 24:Other  1.15074799 NA NA,Childress 2009 NA,RCT,G, 61, 63, 124 outcomes reverse -0.8900000000,-1.261000000,-5.190000e-01  13.1200000, 13.0100000,NA NA,NA,NA,NA NA 100 100,100,100 100,100,100 low some,low some,some Placebo   0  35.079032  8.604839 NA,NA,0 1,1.0 1.0 1.0,1.0 1 1 0,1,1,1 1 1.0 1 1 1 1,1438,Childress_2009 < 2 months NA,6-12 yo 8.60483870967742 9.97113402061856 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High Methylphenidate,Methylphenidate   0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  1.15074799 NA NA Childress 2009 NA RCT RR  66, 65  131,outcomes reverse  1.2310000000, 0.519000000  2.922000e+00,NA,NA,NA,NA,NA,NA,NA,NA,100,100 100,100 100,100 100,low some,low some,some Placebo   0, 35.109924, 8.597710,NA NA 0 1,1.0,1.0 1.0 1.0 1 1,0 1 1 1,1,1.0 1,1,1 1,1439 Childress_2009,< 2 months,NA,6-12 yo 7.9578947368421 14.7,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High Methylphenidate Methylphenidate   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability  1.15074799,NA,NA Childress,2009 NA RCT RR, 66  65, 131,outcomes,reverse, 2.9550000000, 0.123000000, 7.124200e+01,NA NA,NA NA,NA NA,NA NA 100,100,100 100 100 100,100,low some low,some,some,Placebo   0, 35.109924, 8.597710,NA,NA 0 1,1.0,1.0 1.0 1.0,1 1 0,1,1,1,1 1.0 1 1,1 1 1440 Childress_2009 < 2 months NA,6-12 yo,7.9578947368421,14.7 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100 High Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,24:Other  1.15074799 NA,NA Childress 2009,NA,RCT G  58  63  121,outcomes reverse -1.0680000000,-1.451000000 -6.850000e-01  13.9700000  13.0300000 NA,NA NA NA NA,NA,100,100 100,100,100 100 100 low,some,low,some,some,Placebo   0, 36.148760  8.804132 NA,NA,0 1 1.0,1.0 1.0,1.0 1 1,0,1,1 1 1,1.0,1 1 1,1 1441,Childress_2009 < 2 months,NA 6-12 yo,8.60731707317073 10.9714285714286 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100 100 High,Methylphenidate Methylphenidate,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks),NA 24:Other  1.15074799,NA,NA Childress 2009 NA,RCT,G, 59, 63, 122,outcomes reverse,-0.8990000000,-1.273000000 -5.250000e-01, 13.3100000, 13.0100000 NA,NA NA NA NA NA,100,100 100 100 100 100,100 low some low,some,some Placebo   0  36.169672, 8.803279 NA NA 0 1 1.0,1.0 1.0 1.0 1 1,0,1,1,1 1,1.0,1,1,1 1,1442,Childress_2009 < 2 months NA,6-12 yo,8.60483870967742 9.97113402061856 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100,100,High,Methylphenidate Methylphenidate   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  1.15074799 NA NA Childress 2009 NA,RCT,RR, 62, 65  127 outcomes reverse  1.0480000000, 0.419000000  2.621000e+00,NA NA,NA,NA NA,NA NA NA 100,100,100 100,100 100,100,low some,low some some Placebo   0, 36.192126  8.802362,NA,NA,0 1 1.0,1.0 1.0,1.0,1 1,0 1 1 1,1,1.0 1,1,1 1 1443,Childress_2009,< 2 months,NA 6-12 yo 7.9578947368421,14.7 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100,High Methylphenidate Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability, 1.15074799 NA NA,Childress 2009 NA,RCT RR  62, 65  127,outcomes,reverse  3.1430000000, 0.130000000  7.572200e+01 NA,NA NA NA,NA NA,NA,NA,100 100 100,100 100 100,100,low,some,low,some,some Placebo   0  36.192126  8.802362 NA NA,0 1,1.0,1.0,1.0,1.0,1 1 0 1 1,1,1,1.0,1,1,1 1 1444,Childress_2009 < 2 months NA,6-12 yo,7.9578947368421,14.7 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Amphetamine,Amphetamine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total, 1.61104718,  53.8000000 mg/d,Coghill,2013 NA RCT,G, 98 104, 202,outcomes reverse,-1.6090000000 -2.018000000,-1.199000e+00,NA NA,NA NA,NA,NA,11.5237841,11.5237841 100 100,100,100,  0,100 100 low,low high low low,Placebo   0, 19.386139 10.951485,NA NA,0,1 1.0,1.0 1.0 1.0 1,1,0,1,1,1 1,1.0,1 1 1,1 1445 Coghill_2013 < 2 months,NA,6-12 yo,9.04758620689655 14.6347014925373 NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100 High,Amphetamine,Amphetamine,  0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.61104718,  53.8000000,mg/d Coghill 2013 NA RCT,RR,113,111  224 outcomes reverse, 0.4770000000  0.345000000  6.580000e-01,NA NA,NA,NA,NA,NA,NA NA,100 100,100 100   0,100 100 low,low high low low Placebo,  0, 19.469196,10.949554,NA NA 0,1,1.0 1.0 1.0,1.0 1 1 0,1,1 1 1 1.0 1,1 1 1 1446 Coghill_2013,< 2 months NA 6-12 yo 8.22105263157895 14.6335365853659 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Amphetamine,Amphetamine   0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability, 1.61104718,  53.8000000 mg/d Coghill 2013 NA,RCT,RR 113,111, 224 outcomes reverse  1.2280000000  0.339000000  4.454000e+00 NA,NA,NA NA,NA NA,NA NA,100 100 100,100,  0,100 100 low,low,high low,low Placebo,  0  19.469196,10.949554 NA NA,0,1,1.0 1.0 1.0,1.0 1 1 0,1,1 1,1 1.0 1,1 1 1 1447 Coghill_2013 < 2 months NA,6-12 yo 8.22105263157895,14.6335365853659,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100,High,Methylphenidate Methylphenidate,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 1.61104718   45.4000000 mg/d Coghill,2013 NA,RCT,G 103,104  207 outcomes,reverse -1.1130000000,-1.470000000,-7.570000e-01,NA NA,NA NA,NA,NA,11.5237841,11.5237841,100,100 100 100,  0 100 100,low,low high low low,Placebo   0  18.096135 10.950242,NA,NA,0 1 1.0 1.0,1.0 1.0 1,1 0,1,1 1 1 1.0 1 1,1 1,1448,Coghill_2013,< 2 months,NA 6-12 yo,9.745,14.7,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Methylphenidate Methylphenidate,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability, 1.61104718   45.4000000,mg/d,Coghill,2013 NA,RCT RR,112 111  223 outcomes,reverse, 0.5540000000  0.411000000  7.460000e-01 NA NA,NA NA,NA,NA NA,NA,100 100 100,100,  0 100,100,low,low high,low,low Placebo   0, 18.103587 10.949776,NA NA 0,1,1.0,1.0,1.0 1.0 1,1,0 1 1 1,1 1.0,1 1,1,1,1449,Coghill_2013,< 2 months NA 6-12 yo,7.9578947368421,14.7,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High Methylphenidate,Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability, 1.61104718,  45.4000000,mg/d Coghill 2013,NA,RCT,RR,112,111, 223 outcomes reverse, 0.4960000000  0.093000000  2.651000e+00,NA,NA,NA NA,NA NA NA NA 100 100,100 100,  0 100 100,low low high,low low,Placebo,  0, 18.103587,10.949776,NA,NA,0 1,1.0,1.0 1.0 1.0,1,1,0 1,1 1,1,1.0,1,1,1,1 1450,Coghill_2013 < 2 months NA,6-12 yo 7.9578947368421 14.7,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total  2.07134638,NA,NA Connor 2010 NA RCT,G,130, 75  205,outcomes reverse,-0.7480000000 -1.123000000 -3.720000e-01 NA,NA,NA NA,NA NA 12.6500000 12.6500000,100,100,100 100 100,100 100 low low,low low low,Placebo,  0, 31.280488, 9.363415,NA,NA 0,1 1.0,1.0 1.0,1.0,1 1 0,1,1,1 1 1.0 1 1,1,1 1451 Connor_2010 2-6 months NA,6-12 yo,8.99719626168224,14.5496794871795,NA,NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 2.07134638,NA NA,Connor 2010 NA,RCT RR 138  79  217 outcomes,reverse  0.5360000000  0.350000000  8.180000e-01 NA,NA NA NA,NA NA,NA,NA 100 100,100,100,100,100,100 low,low,low,low low Placebo   0  31.303687  9.363594,NA,NA,0,1,1.0 1.0,1.0,1.0 1,1 0 1 1 1 1,1.0,1 1 1 1,1452 Connor_2010,2-6 months NA,6-12 yo,8.23931034482759 12.6640449438202,NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability, 2.07134638,NA NA Connor,2010 NA RCT,RR 138, 79  217,outcomes,reverse  8.0140000000, 1.074000000  5.980400e+01 NA,NA NA NA,NA NA,NA NA 100 100,100,100,100 100,100,low,low,low low,low,Placebo   0  31.303687  9.363594 NA NA,0,1,1.0,1.0,1.0,1.0,1,1 0,1,1 1 1 1.0 1,1,1 1 1453,Connor_2010,2-6 months NA 6-12 yo,9,12.6640449438202,NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100 100,High Methylphenidate,Methylphenidate,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 0.69044879    0.3000000,mg/kg/d Cook 1993 NA,RCT RR, 15, 15,  30 outcomes reverse, 1.0000000000, 0.021000000  4.738000e+01,NA,NA,NA,NA NA,NA,NA NA 100 100 100 100 100,100 100,low some,some,some some,Placebo   0   0.000000, 8.700000 NA NA,0 1 1.0 1.0 1.0,1.0,1 1,0,1,1,1,1,1.0,1 1 1,1,1454 Cook_1993 < 2 months,NA 6-12 yo,7.9578947368421,14.7,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100 100,High,Methylphenidate,Methylphenidate,  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.69044879,   0.3000000,mg/kg/d,Cook,1993 NA RCT,RR  15, 15   30,outcomes,reverse  1.0000000000, 0.021000000, 4.738000e+01,NA,NA,NA NA,NA,NA NA NA 100 100,100,100,100 100,100,low,some some some some Placebo   0   0.000000, 8.700000,NA,NA,0 1,1.0,1.0 1.0,1.0,1 1,0,1,1 1 1 1.0 1 1 1,1 1455,Cook_1993 < 2 months,NA,6-12 yo 7.9578947368421,14.7,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100,High Atomoxetine,Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA 13:CPRS-R:S, 1.84119678    1.1000000,mg/kg/d Dell'Agnello 2009 NA,RCT G,103  32  135 outcomes,reverse -0.7160000000,-1.121000000,-3.100000e-01 NA,NA,NA,NA NA,NA  3.9000000, 3.9000000,100 100 100,100,100,100,100,some,some low some,some Placebo,  0,  7.340000, 9.771111,NA NA 0,1,1.0 1.0 1.0 1.0 1 1,0,1,1 1,1 1.0,1,1,1 1,1456 Dell'Agnello_2009,< 2 months NA 6-12 yo,9.26 11.2017964071856,NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100 100,High,Atomoxetine,Atomoxetine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),NA,13:CTRS-R:S, 1.84119678    1.1000000,mg/kg/d Dell'Agnello 2009,NA RCT,G, 58  18,  76 outcomes,reverse -0.2260000000,-0.758000000, 3.060000e-01 NA,NA,NA NA,NA,NA, 3.3000000  3.3000000,100 100 100,100,100,100 100 some some low some some,Placebo,  0   7.339474  9.771053,NA NA 0 1,1.0,1.0 1.0,1.0 1,1 0,1 1 1,1,1.0,1 1 1,1 1457 Dell'Agnello_2009,< 2 months NA 6-12 yo,9.77105263157895 12.2504651162791,NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100,High Atomoxetine,Atomoxetine   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability  1.84119678,   1.1000000,mg/kg/d Dell'Agnello,2009 NA,RCT RR 107, 32  139,outcomes reverse  3.3610000000, 0.191000000, 5.920200e+01,NA NA,NA NA NA NA NA NA 100 100,100,100 100 100,100 some,some,low some,some Placebo,  0,  7.321583  9.769065,NA,NA,0 1,1.0,1.0 1.0,1.0,1,1 0,1 1 1 1,1.0 1 1,1,1,1458,Dell'Agnello_2009 < 2 months NA 6-12 yo 8.65154639175258 12.2493548387097,NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100 High,Atomoxetine,Atomoxetine   0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  1.84119678,   1.1000000 mg/kg/d,Dell'Agnello 2009 NA RCT,RR 107  32, 139 outcomes,reverse, 2.1390000000  0.113000000  4.035500e+01 NA NA,NA NA NA,NA,NA NA 100,100 100 100 100,100,100 some,some low,some some Placebo,  0,  7.321583, 9.769065,NA,NA,0,1 1.0,1.0 1.0,1.0 1,1 0,1,1 1 1 1.0,1 1,1 1,1459,Dell'Agnello_2009,< 2 months NA 6-12 yo 8.65154639175258,12.2493548387097,NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100 100 High,Atomoxetine,Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,16:SNAP-IV-Short-Hyper-Impuls  2.07134638,   1.2000000,mg/kg/d,Dittman 2011 NA RCT,G, 61, 59  120,outcomes reverse,-0.7350000000 -1.106000000 -3.630000e-01, 10.9343495  11.5217186,NA NA,NA NA,NA NA,100,100 100,100 100,100,100,low,low some low,low,Placebo,  0  15.804167,10.947500,NA,NA,0 1 1.0 1.0 1.0 1.0,1 1,0,1,1 1,1 1.0,1,1,1,1 1460 Dittman_2011 2-6 months NA 6-12 yo 8.65157894736842 12.2493333333333,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100,100 High,Atomoxetine,Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA 24:Other, 2.07134638    1.2000000 mg/kg/d Dittman 2011 NA RCT G  61  59  120 outcomes reverse -0.5130000000 -0.878000000 -1.480000e-01   0.7810250,  0.7681146,NA,NA,NA NA,NA,NA,100 100 100,100,100 100 100,low,low,some,low low Placebo   0  15.804167,10.947500 NA,NA 0 1 1.0,1.0,1.0 1.0,1 1,0 1,1 1 1 1.0 1 1 1 1 1461 Dittman_2011 2-6 months NA 6-12 yo,9.26,11.2017964071856 NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Atomoxetine,Atomoxetine,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 2.07134638,   1.2000000 mg/kg/d,Dittman 2011,NA RCT,RR, 61, 59  120 outcomes reverse  0.5720000000, 0.318000000, 1.026000e+00,NA NA NA,NA NA NA NA,NA 100 100,100,100 100,100,100 low,low some,low,low Placebo   0, 15.804167,10.947500,NA NA,0 1,1.0 1.0,1.0 1.0 1 1,0 1 1,1,1,1.0,1 1,1,1,1462 Dittman_2011 2-6 months,NA,6-12 yo,8.65154639175258 12.2493548387097 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100,High Atomoxetine Atomoxetine   0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability, 2.07134638,   1.2000000,mg/kg/d Dittman 2011 NA,RCT RR, 61, 59  120 outcomes reverse  1.9340000000  0.180000000, 2.076900e+01 NA NA NA,NA NA,NA NA NA,100,100,100,100 100,100 100,low low,some,low low,Placebo,  0  15.804167 10.947500,NA,NA 0,1,1.0 1.0 1.0 1.0,1,1,0,1 1,1 1,1.0 1 1 1,1,1463 Dittman_2011,2-6 months NA 6-12 yo 8.65154639175258 12.2493548387097,NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100 100,High Atomoxetine,Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,16:SNAP-IV-Short-Hyper-Impuls, 2.07134638,   1.2000000 mg/kg/d Dittman 2011 NA RCT,G  60  59  119,outcomes,reverse -0.5750000000 -0.944000000 -2.070000e-01, 11.6189500, 11.5217186,NA,NA,NA NA,NA NA 100 100 100 100 100 100,100 low low some low,low,Placebo,  0  16.784874,11.100000,NA NA 0 1,1.0 1.0,1.0,1.0 1 1 0,1 1 1,1,1.0 1,1,1,1,1464 Dittman_2011 2-6 months,NA 6-12 yo,8.65157894736842,12.2493333333333,NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High Atomoxetine,Atomoxetine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA 24:Other  2.07134638,   1.2000000 mg/kg/d,Dittman 2011 NA RCT G, 50  59, 109 outcomes reverse -0.4020000000 -0.784000000,-2.000000e-02   0.7071068,  0.7681146,NA NA NA,NA,NA,NA 100 100,100,100,100 100,100 low,low some low low Placebo   0, 16.948624,11.100000,NA NA,0,1,1.0,1.0,1.0,1.0,1 1,0,1,1,1,1 1.0 1,1 1,1,1465,Dittman_2011,2-6 months NA,6-12 yo 9.26 11.2017964071856 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100,100,High Atomoxetine Atomoxetine   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 2.07134638    1.2000000 mg/kg/d,Dittman 2011 NA RCT,RR, 60  59, 119 outcomes,reverse, 0.7150000000  0.419000000  1.220000e+00,NA,NA,NA,NA,NA,NA NA,NA 100 100,100 100,100,100 100,low,low some low,low,Placebo   0, 16.784874,11.100000,NA,NA 0 1 1.0,1.0 1.0 1.0 1,1,0,1 1 1 1,1.0 1 1 1,1,1466 Dittman_2011,2-6 months NA,6-12 yo 8.65154639175258 12.2493548387097 NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100,High Atomoxetine Atomoxetine   0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability, 2.07134638    1.2000000,mg/kg/d,Dittman 2011,NA,RCT RR, 60  59, 119,outcomes reverse, 5.9000000000  0.732000000  4.752400e+01 NA,NA,NA NA,NA NA,NA NA,100,100 100 100 100 100,100 low,low some,low,low,Placebo,  0, 16.784874 11.100000,NA,NA 0,1 1.0 1.0 1.0,1.0,1 1 0,1 1,1,1 1.0 1,1 1,1,1467,Dittman_2011,2-6 months,NA 6-12 yo,8.65154639175258 12.2493548387097 NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,24:Other, 0.92059839 NA,NA,Dopfner 2003 NA,RCT G, 43, 42   85 outcomes,reverse -0.9430000000,-1.395000000 -4.920000e-01   0.7000000   0.6200000 NA,NA NA NA,NA NA,100,100 100 100 100 100 100 low,low,low low low,Placebo,  0  11.776471  9.800000,NA,NA 0 1 1.0 1.0 1.0 1.0 1,1 0,1 1,1 1 1.0,1 1,1 1,1468,Dopfner_2003 < 2 months NA 6-12 yo,8.60731707317073,10.9714285714286,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks),NA,24:Other, 0.92059839,NA NA Dopfner 2003,NA,RCT,G, 43, 42   85,outcomes,reverse -1.1940000000 -1.659000000,-7.290000e-01   0.6200000,  0.6900000 NA NA NA,NA NA,NA 100 100 100 100,100,100 100,low low,low low,low Placebo   0  11.776471, 9.800000,NA NA 0,1 1.0 1.0,1.0 1.0,1 1,0,1,1,1,1,1.0 1,1,1 1,1469 Dopfner_2003,< 2 months,NA 6-12 yo 8.60483870967742 9.97113402061856 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100 100,High,Methylphenidate Methylphenidate,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 0.92059839 NA NA,Dopfner,2003 NA,RCT,RR, 43, 42   85 outcomes reverse  0.9770000000  0.209000000, 4.569000e+00 NA,NA,NA NA NA,NA NA NA 100,100 100 100,100,100,100 low low low,low low,Placebo,  0  11.776471  9.800000 NA NA,0 1 1.0 1.0 1.0 1.0 1,1 0 1,1 1 1,1.0 1 1 1 1,1470,Dopfner_2003,< 2 months,NA 6-12 yo 7.9578947368421,14.7,NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100,100 High Methylphenidate,Methylphenidate   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.92059839 NA,NA Dopfner,2003,NA,RCT,RR, 43, 42   85,outcomes,reverse  4.8860000000  0.242000000, 9.884800e+01,NA NA NA NA,NA NA,NA,NA,100 100 100 100 100,100 100 low,low low low low Placebo   0, 11.776471, 9.800000 NA,NA 0,1 1.0 1.0 1.0,1.0,1 1 0 1,1 1,1,1.0,1,1 1,1 1471 Dopfner_2003,< 2 months NA 6-12 yo,7.9578947368421,14.7 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100 100,High Methylphenidate Methylphenidate   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.61104718,NA,NA,Findling,2008 NA,RCT,RR, 94, 88, 182 outcomes,reverse, 0.4770000000, 0.336000000  6.760000e-01 NA,NA,NA NA NA NA NA,NA,100 100,100,100,100,100 100 some some some,some some Placebo,  0  30.180220  8.654945 NA NA,0 1,1.0 1.0,1.0 1.0,1,1,0,1 1,1,1 1.0 1,1 1 1 1472,Findling_2008,< 2 months,NA 6-12 yo 7.9578947368421,14.7,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100,High Methylphenidate,Methylphenidate   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability  1.61104718,NA NA,Findling,2008,NA RCT RR, 94, 88, 182,outcomes reverse, 1.8720000000, 0.173000000  2.028700e+01,NA,NA,NA NA NA NA NA,NA 100 100 100,100,100 100 100,some some some,some some Placebo,  0  30.180220  8.654945,NA NA 0 1,1.0,1.0 1.0 1.0 1 1,0 1 1,1,1 1.0 1 1 1 1 1473,Findling_2008,< 2 months,NA,6-12 yo 7.9578947368421 14.7,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100 100,High Amphetamine Amphetamine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total, 0.92059839   30.0000000 mg/d,Findling,2011,NA RCT G  78, 77  155 outcomes reverse,-0.4180000000,-0.737000000,-9.900000e-02  13.0300000, 12.6800000,NA NA NA,NA,NA NA,100 100,100,100 100,100,100 low low some low low,Placebo   0, 27.976774,14.550323 NA NA,0,1 1.0,1.0 1.0,1.0 1,1,0,1 1,1,1 1.0 1,1,1,1,1474,Findling_2011,< 2 months NA 13-19 yo 9.04758620689655 14.6347014925373,NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Amphetamine Amphetamine   0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  0.92059839,  30.0000000 mg/d,Findling,2011 NA,RCT,RR  78  79, 157 outcomes,reverse  1.5190000000, 0.727000000, 3.173000e+00,NA NA NA,NA NA NA,NA,NA 100 100 100 100,100 100 100,low low,some,low,low Placebo,  0, 28.022930 14.549682 NA,NA,0,1 1.0 1.0 1.0 1.0 1,1,0 1 1,1 1,1.0,1,1 1,1,1475 Findling_2011 < 2 months,NA,13-19 yo 8.22105263157895 14.6335365853659,NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Amphetamine Amphetamine   0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability  0.92059839   30.0000000,mg/d Findling 2011 NA,RCT RR  78, 79, 157,outcomes reverse, 3.0380000000  0.323000000, 2.858300e+01 NA,NA NA,NA,NA,NA NA NA,100 100 100 100,100,100,100,low,low,some low,low Placebo,  0, 28.022930,14.549682 NA NA,0 1 1.0 1.0 1.0 1.0 1 1,0,1 1 1,1 1.0 1,1 1 1,1476 Findling_2011,< 2 months,NA 13-19 yo,8.22105263157895,14.6335365853659 NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100,100,High,Amphetamine Amphetamine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total, 0.92059839   50.0000000,mg/d Findling 2011,NA RCT G  76, 77, 153,outcomes reverse,-0.7560000000,-1.086000000,-4.270000e-01, 10.3400000  12.6800000 NA,NA NA,NA NA,NA 100,100,100,100 100 100,100,low,low some low,low,Placebo,  0  25.986928,14.599346 NA NA 0,1,1.0,1.0,1.0,1.0 1,1 0 1,1 1,1,1.0 1,1 1,1,1477 Findling_2011,< 2 months,NA,13-19 yo,9.04758620689655,14.6347014925373 NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100,100 High Amphetamine,Amphetamine   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839,  50.0000000 mg/d Findling 2011,NA,RCT,RR, 79, 79  158 outcomes,reverse  1.3000000000, 0.606000000  2.789000e+00,NA NA,NA,NA,NA NA,NA NA,100,100,100 100 100,100 100,low low some low,low Placebo,  0, 25.950000 14.600000 NA,NA,0 1 1.0,1.0 1.0,1.0,1 1 0 1 1 1,1 1.0,1 1,1,1,1478 Findling_2011 < 2 months NA 13-19 yo,8.22105263157895,14.6335365853659,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Amphetamine Amphetamine   0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability  0.92059839,  50.0000000 mg/d,Findling 2011,NA,RCT RR, 79, 79, 158,outcomes,reverse, 3.0000000000, 0.319000000, 2.822500e+01 NA,NA NA,NA NA NA,NA NA,100 100 100 100,100,100,100,low,low,some low low,Placebo,  0, 25.950000 14.600000 NA,NA 0,1 1.0,1.0 1.0 1.0 1 1 0 1,1,1 1,1.0 1 1 1 1,1479,Findling_2011 < 2 months NA 13-19 yo 8.22105263157895,14.6335365853659 NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High Amphetamine,Amphetamine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total  0.92059839   70.0000000 mg/d,Findling,2011 NA,RCT,G, 78, 77, 155,outcomes,reverse -0.7670000000 -1.095000000 -4.400000e-01   9.4000000, 12.6800000 NA,NA,NA,NA,NA,NA 100 100 100,100 100 100 100,low low,some,low,low,Placebo,  0  37.638710 14.449677 NA NA,0,1,1.0 1.0 1.0,1.0 1,1 0 1,1 1 1,1.0,1,1,1,1,1480 Findling_2011,< 2 months NA 13-19 yo,9.04758620689655,14.6347014925373 NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100,100 High Amphetamine,Amphetamine,  0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability  0.92059839   70.0000000,mg/d,Findling,2011 NA RCT,RR  78, 79, 157 outcomes reverse  1.1140000000, 0.502000000  2.472000e+00,NA NA,NA NA,NA,NA NA NA,100,100 100 100,100,100 100 low,low some low low,Placebo   0  37.561783,14.450318 NA NA 0 1 1.0,1.0 1.0,1.0,1 1,0 1,1 1,1 1.0 1,1,1 1,1481,Findling_2011 < 2 months,NA 13-19 yo,8.22105263157895 14.6335365853659,NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100,High,Amphetamine Amphetamine,  0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability  0.92059839   70.0000000,mg/d Findling 2011,NA RCT,RR  78  79  157,outcomes reverse, 4.0510000000, 0.463000000  3.544200e+01,NA,NA NA,NA,NA,NA NA,NA,100 100 100 100,100,100,100,low,low,some,low low,Placebo   0, 37.561783 14.450318 NA,NA 0 1 1.0 1.0 1.0,1.0 1,1,0 1 1,1 1 1.0,1 1,1,1 1482 Findling_2011,< 2 months NA,13-19 yo 8.22105263157895 14.6335365853659,NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Atomoxetine,Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total  0.92059839,NA,NA Gau,2007 NA,RCT,G  72, 34  106,outcomes reverse,-0.9370000000 -1.366000000,-5.080000e-01  10.1000000, 11.9000000 NA,NA NA,NA,NA NA 100,100 100,100,100 100,100 low low,some low,low,Placebo   0, 11.303774, 9.228302 NA,NA 0,1,1.0,1.0 1.0,1.0 1 1,0,1 1,1 1,1.0,1,1,1 1,1483 Gau_2007,< 2 months,NA,6-12 yo 8.65157894736842 12.2493333333333 NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Atomoxetine,Atomoxetine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 1.38089758 NA NA Geller 2007 NA,RCT G, 55  58, 113,outcomes,reverse,-0.8030000000 -1.215000000 -3.900000e-01,NA,NA,NA NA NA NA, 8.4535081, 8.4535081 100 100 100 100,100,100,100,low low low low low Placebo,  0, 35.179646 11.994690,NA NA 0,1 1.0 1.0 1.0 1.0,1,1,0 1 1,1 1,1.0,1 1 1 1,1484,Geller_2007 < 2 months NA 6-12 yo,8.65157894736842,12.2493333333333,NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100,100,High Methylphenidate Methylphenidate   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability, 0.69044879   40.7000000,mg/d Greenhill,2002 NA,RCT,RR 158 163, 321,outcomes,reverse, 0.6260000000, 0.357000000  1.098000e+00,NA,NA NA NA,NA NA,NA NA 100 100 100 100 100 100 100 some some,low some,some,Placebo   0  18.015576  9.000000 NA NA 0 1 1.0 1.0,1.0 1.0,1 1 0 1,1,1,1,1.0 1,1 1,1 1485,Greenhill_2002 < 2 months,NA 6-12 yo 7.9578947368421,14.7,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Methylphenidate,Methylphenidate   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability  0.69044879   40.7000000,mg/d,Greenhill 2002 NA RCT,RR 158,163, 321 outcomes reverse  5.1570000000, 0.250000000, 1.065820e+02,NA,NA,NA,NA NA NA,NA,NA 100,100,100 100 100,100 100 some some low,some some,Placebo,  0  18.015576, 9.000000,NA NA 0,1 1.0,1.0 1.0 1.0 1,1 0 1 1,1 1,1.0 1 1,1,1 1486,Greenhill_2002,< 2 months NA 6-12 yo,7.9578947368421,14.7,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High,Modafinil Modafinil   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total  2.07134638  361.4000000 mg/d,Greenhill 2006a,NA RCT,G,128, 66  194,outcomes,reverse,-0.5660000000,-0.869000000,-2.630000e-01, 14.0000000  13.2000000 NA NA,NA,NA,NA,NA 100,100 100 100   0 100,100 some some,high some some,Placebo   0, 27.000000  9.900000 NA NA,0,1 1.0,1.0 1.0,1.0 1,1 0,1,1 1 1 1.0,1 1 1 1,1487 Greenhill_2006a 2-6 months NA 6-12 yo,8.85049504950495 10.3004098360656,NA NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100 100 High Modafinil,Modafinil   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,13:CPRS-R:S  2.07134638, 361.4000000 mg/d,Greenhill,2006a,NA RCT,G,128  66  194,outcomes reverse,-0.4580000000 -0.759000000 -1.560000e-01, 11.9000000, 10.8000000 NA,NA NA NA,NA NA,100 100 100,100,  0,100 100 some,some,high,some,some Placebo   0  27.000000  9.900000,NA,NA,0,1,1.0,1.0,1.0,1.0 1 1,0,1 1 1 1,1.0,1 1 1,1,1488 Greenhill_2006a 2-6 months,NA 6-12 yo 8.85049504950495,10.3004098360656,NA,NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA,NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100,100,High Modafinil,Modafinil   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA 1:ACTeRS-2, 2.07134638  361.4000000,mg/d Greenhill,2006a NA RCT,G,128  66, 194,outcomes reverse,-0.5170000000,-0.819000000,-2.140000e-01, 13.6000000, 12.7000000,NA NA,NA,NA,NA NA 100 100,100 100,  0,100 100 some some,high some,some,Placebo   0, 27.000000  9.900000,NA NA,0 1,1.0 1.0,1.0 1.0,1 1,0,1 1 1,1 1.0 1,1 1 1 1489 Greenhill_2006a 2-6 months NA,6-12 yo 8.85049504950495,9.96229508196721,NA NA,  8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA,NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Modafinil,Modafinil,  0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 2.07134638  361.4000000,mg/d Greenhill,2006a NA,RCT,RR,133  67, 200 outcomes reverse  0.6390000000  0.419000000  9.750000e-01 NA,NA,NA NA,NA,NA NA NA 100 100,100,100,  0,100,100,some,some high,some,some Placebo,  0  27.000000  9.900000 NA NA,0 1,1.0 1.0 1.0,1.0,1 1,0 1,1,1,1 1.0 1,1,1,1 1490,Greenhill_2006a 2-6 months,NA,6-12 yo 7.875,10.2983870967742 NA NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA,NA,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100,High,Modafinil Modafinil,  0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability, 2.07134638, 361.4000000,mg/d Greenhill,2006a NA RCT,RR 133  67  200,outcomes,reverse  0.7560000000, 0.221000000  2.587000e+00 NA,NA NA,NA NA NA NA NA,100,100 100,100,  0,100 100,some,some,high,some,some Placebo,  0, 27.000000  9.900000 NA NA,0,1 1.0,1.0,1.0,1.0,1,1 0,1 1 1,1,1.0,1,1 1,1,1491,Greenhill_2006a,2-6 months,NA 6-12 yo 7.875 10.2983870967742,NA,NA,  8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100 100 High Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA,24:Other  1.61104718,  24.0000000,mg/d,Greenhill,2006b NA RCT,G, 52, 45   97,outcomes,reverse -0.8610000000,-1.280000000,-4.410000e-01  13.6500000, 11.7200000 NA NA,NA,NA NA NA 100 100 100,100 100,100 100,some,some low,some,some,Placebo   0, 36.164948  9.971134,NA NA,0 1,1.0,1.0 1.0,1.0,1 1 0,1,1 1 1,1.0 1,1,1,1 1492 Greenhill_2006b,< 2 months,NA,6-12 yo 8.60731707317073 10.9714285714286,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100 High,Methylphenidate Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),NA 24:Other  1.61104718,  24.0000000 mg/d,Greenhill,2006b NA,RCT G  52  45,  97 outcomes,reverse,-0.8220000000,-1.240000000,-4.050000e-01  12.4200000  15.6200000 NA,NA NA NA NA,NA 100,100 100,100,100,100 100 some some,low,some some,Placebo,  0  36.164948  9.971134,NA NA 0,1,1.0 1.0 1.0 1.0 1 1 0 1 1,1 1,1.0 1,1,1,1 1493 Greenhill_2006b < 2 months,NA 6-12 yo 8.60483870967742 9.97113402061856 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100 High,Methylphenidate,Methylphenidate   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  1.61104718,  24.0000000 mg/d,Greenhill,2006b NA,RCT RR, 53, 50  103 outcomes reverse, 0.3630000000  0.139000000, 9.440000e-01 NA,NA NA,NA,NA,NA NA,NA,100 100 100 100,100 100 100,some,some low,some,some Placebo   0  35.917476, 9.988350,NA,NA 0,1,1.0,1.0,1.0,1.0,1 1,0,1,1,1,1 1.0 1 1 1,1,1494 Greenhill_2006b < 2 months,NA 6-12 yo 7.9578947368421,14.7,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100,High,Methylphenidate,Methylphenidate,  0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability, 1.61104718,  24.0000000 mg/d Greenhill 2006b,NA RCT,RR, 53, 50, 103 outcomes,reverse  0.3150000000, 0.013000000, 7.552000e+00,NA NA,NA,NA NA,NA,NA,NA,100 100 100 100 100 100 100,some,some,low,some,some Placebo,  0, 35.917476, 9.988350,NA,NA,0,1 1.0,1.0,1.0 1.0,1 1,0,1 1 1,1 1.0,1 1,1 1,1495 Greenhill_2006b,< 2 months NA,6-12 yo,7.9578947368421,14.7,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,  0   0,100 100 High Methylphenidate,Methylphenidate   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability, 0.46029919 NA NA Grizenko 2012 NA RCT,RR 237 258, 495,outcomes reverse  0.3630000000, 0.015000000  8.861000e+00 NA,NA,NA,NA NA NA,NA,NA,100,100,100,100,100 100 100 low,low low low low Placebo   0 NA NA,NA,NA 0 1 1.0,1.0 1.0 1.0 1,1 0 1,1 1,1 1.0,1,1,1,1 1496 Grizenko_2012,< 2 months NA NA,7.9578947368421,14.7 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,  0,  0,100 100 High Methylphenidate,Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability, 0.46029919,NA,NA Grizenko,2012,NA,RCT RR 237 258, 495 outcomes reverse  1.0880000000  0.022000000  5.462700e+01,NA,NA,NA NA NA,NA NA NA,100 100 100 100,100 100 100 low low low low low,Placebo,  0,NA,NA,NA,NA 0,1 1.0 1.0,1.0 1.0 1 1 0,1 1 1 1 1.0,1,1,1,1 1497,Grizenko_2012 < 2 months,NA NA,7.9578947368421,14.7,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100 100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA 4:ADHD-SRS Total  1.84119678 NA NA Jain,2011,NA,RCT G  78  76  154 outcomes,reverse,-0.4180000000,-0.807000000 -2.800000e-02,NA NA,NA NA NA NA  9.4100000, 9.4100000,100 100,100 100 100,100 100,some low low low,low Placebo   0, 30.536364  9.400000 NA,NA,0 1 1.0 1.0 1.0 1.0,1,1,0 1,1,1,1,1.0,1,1,1 1,1498,Jain_2011,< 2 months,NA,6-12 yo 8.99719626168224,14.5496794871795 NA,NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability, 1.84119678 NA,NA Jain 2011,NA,RCT,RR  80  78, 158,outcomes,reverse  0.8430000000  0.591000000, 1.204000e+00 NA NA NA,NA NA,NA,NA,NA,100,100,100 100 100,100 100,some low,low,low,low Placebo   0, 30.536709  9.400000 NA,NA 0 1,1.0 1.0,1.0,1.0 1,1 0 1 1,1 1 1.0 1,1,1 1,1499 Jain_2011,< 2 months NA,6-12 yo 8.23931034482759,12.6640449438202,NA NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.84119678,NA NA Jain 2011,NA,RCT RR  80, 78  158,outcomes reverse 14.6250000000, 1.979000000, 1.080730e+02 NA NA NA NA NA NA,NA NA 100 100,100 100 100 100,100 some,low,low,low,low,Placebo   0  30.536709  9.400000 NA NA 0 1 1.0 1.0,1.0 1.0 1 1,0,1,1,1 1,1.0,1,1,1,1,1500 Jain_2011 < 2 months,NA 6-12 yo 9,12.6640449438202 NA NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total, 1.84119678 NA NA,Jain,2011,NA RCT,G  74, 76, 150,outcomes,reverse,-0.4020000000 -0.797000000 -8.000000e-03,NA,NA NA NA NA,NA  9.4100000, 9.4100000 100 100 100,100,100 100,100 some,low low low,low,Placebo   0  26.666667  9.498667 NA NA 0,1,1.0 1.0,1.0 1.0 1,1 0,1 1,1 1,1.0,1 1 1 1 1501,Jain_2011,< 2 months NA 6-12 yo 8.99719626168224,14.5496794871795 NA NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  1.84119678,NA NA,Jain,2011,NA RCT RR  78  78, 156 outcomes,reverse, 0.6490000000  0.432000000, 9.740000e-01 NA,NA NA,NA,NA NA,NA NA 100 100 100 100 100 100,100 some low low low,low,Placebo   0, 26.600000  9.500000 NA NA,0,1 1.0 1.0 1.0,1.0,1 1 0,1 1 1,1 1.0 1,1,1,1 1502,Jain_2011,< 2 months,NA,6-12 yo 8.23931034482759 12.6640449438202,NA,NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 1.84119678 NA,NA,Jain,2011,NA,RCT RR, 78  78, 156 outcomes reverse  5.0000000000, 0.598000000  4.182100e+01 NA NA,NA,NA NA NA NA NA,100 100 100,100,100,100 100,some low,low,low low Placebo,  0, 26.600000, 9.500000,NA NA,0,1 1.0,1.0 1.0 1.0,1 1 0 1 1,1,1 1.0,1 1 1 1 1503,Jain_2011,< 2 months NA,6-12 yo,9 12.6640449438202 NA,NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100 High Modafinil,Modafinil,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total  1.38089758,NA NA Kahbazi,2009,NA,RCT G, 23  23   46,outcomes reverse,-1.1430000000,-2.142000000 -1.440000e-01,NA NA,NA,NA NA,NA  6.1500000, 6.1500000 100,100,100 100,100 100,100,low low low,low some,Placebo   0  23.915000  9.065000 NA NA 0 1 1.0 1.0 1.0 1.0,1,1,0 1 1,1 1 1.0,1 1,1,1,1504,Kahbazi_2009,< 2 months,NA,6-12 yo,8.85049504950495,10.3004098360656 NA NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100 100 High,Modafinil Modafinil,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) NA,5:ADHD-RS Total, 1.38089758 NA NA Kahbazi 2009,NA,RCT,G, 23, 23   46,outcomes reverse,-1.2820000000,-2.374000000,-1.910000e-01,NA,NA,NA,NA NA,NA, 5.0400000, 5.0400000 100,100 100 100,100,100 100,low,low low,low,some,Placebo,  0  23.915000, 9.065000 NA,NA,0 1,1.0,1.0,1.0 1.0 1,1,0,1,1 1,1,1.0,1 1 1,1,1505 Kahbazi_2009 < 2 months NA,6-12 yo,8.85049504950495 9.96229508196721 NA,NA   8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA,NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100 High Modafinil,Modafinil,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  1.38089758 NA NA Kahbazi 2009,NA,RCT RR  23  23,  46 outcomes reverse  0.5000000000  0.049000000  5.138000e+00,NA NA,NA NA NA,NA,NA,NA 100,100 100 100,100 100,100,low,low low,low,some,Placebo   0  23.915000, 9.065000 NA NA 0,1,1.0,1.0 1.0 1.0 1,1,0 1 1 1,1,1.0,1 1 1,1,1506 Kahbazi_2009 < 2 months,NA 6-12 yo 7.875 10.2983870967742,NA,NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA NA Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100,High,Modafinil Modafinil   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,Tolerability  1.38089758 NA NA,Kahbazi,2009 NA,RCT RR  23, 23,  46,outcomes reverse, 1.0000000000  0.021000000, 4.837000e+01,NA NA,NA,NA NA,NA,NA NA,100,100,100,100 100 100,100 low,low low,low,some,Placebo,  0, 23.915000  9.065000 NA,NA 0,1 1.0,1.0 1.0 1.0,1 1 0 1 1,1,1 1.0,1 1 1 1 1507 Kahbazi_2009,< 2 months NA,6-12 yo 7.875 10.2983870967742 NA,NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA,NA,Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100 100,High,Atomoxetine Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 0.92059839 NA NA Kelsey,2004,NA,RCT,G,126  60, 186,outcomes,reverse -0.3510000000,-0.662000000 -4.100000e-02, 19.0824527, 16.2665301,NA,NA NA,NA NA NA,100,100 100,100,100,100,100,low,low some low low,Placebo,  0, 29.429032  9.467742 NA,NA,0 1 1.0,1.0 1.0,1.0,1,1 0 1,1 1,1 1.0 1 1 1,1,1508 Kelsey_2004,< 2 months,NA,6-12 yo,8.65157894736842,12.2493333333333,NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100 100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total, 1.38089758,NA,NA,Kollins 2011 NA,RCT G 121, 57, 178 outcomes reverse -0.7740000000 -1.187000000 -3.610000e-01,NA NA NA NA,NA NA,13.1200000,13.1200000,100,100,100 100 100,100 100,low low low low,low Placebo   0, 30.345506,12.664045 NA NA 0,1,1.0 1.0,1.0,1.0 1 1,0 1 1 1 1 1.0 1 1,1 1 1509,Kollins_2011,< 2 months NA,6-12 yo 8.99719626168224 14.5496794871795 NA NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability  1.38089758 NA,NA,Kollins 2011 NA RCT,RR 121, 57  178 outcomes reverse  1.0990000000, 0.295000000, 4.096000e+00,NA NA NA,NA NA,NA,NA,NA,100,100 100,100,100,100,100 low low low low,low Placebo   0  30.345506,12.664045 NA NA 0 1 1.0,1.0,1.0 1.0,1 1,0,1 1,1 1,1.0,1,1,1,1 1510,Kollins_2011,< 2 months,NA,6-12 yo 8.23931034482759 12.6640449438202 NA,NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability  1.38089758,NA NA Kollins,2011,NA,RCT RR,121  57, 178,outcomes reverse  1.8840000000, 0.215000000, 1.648000e+01 NA NA NA,NA NA NA NA NA,100 100 100 100,100,100,100 low,low,low,low,low,Placebo,  0, 30.345506,12.664045,NA NA 0,1 1.0,1.0 1.0 1.0,1 1 0 1,1 1,1,1.0 1 1 1 1,1511,Kollins_2011,< 2 months NA,6-12 yo,9 12.6640449438202,NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100,100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 3.68239356    0.2500000 mg/d,Kurlan,2002 NA RCT RR  34, 32,  66 outcomes reverse  0.5380000000  0.174000000  1.664000e+00,NA,NA,NA,NA,NA,NA,NA,NA 100 100,100,100,100 100,100 low,low,low low,low,Placebo   0  12.090909, 9.700000,NA NA 0,1 1.0,1.0,1.0,1.0 1,1 0 1 1,1 1 1.0 1 1 1 1 1512,Kurlan_2002,2-6 months NA 6-12 yo,8.23931034482759 12.6640449438202,NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100 High Methylphenidate,Methylphenidate   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  3.68239356,  25.7000000 mg/d Kurlan 2002 NA,RCT,RR  37  32   69 outcomes,reverse, 0.4940000000  0.159000000  1.536000e+00 NA,NA,NA NA NA NA NA,NA 100,100 100 100 100 100 100 low low,low,low,low Placebo,  0,  8.463768,10.236232,NA NA 0,1,1.0 1.0,1.0,1.0 1 1 0,1 1,1 1 1.0,1,1,1 1,1513,Kurlan_2002,2-6 months NA,6-12 yo,7.9578947368421 14.7 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100,100 High Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total  1.84119678 NA,NA,Lin 2014,NA,RCT G, 26  63   89 outcomes,reverse -0.6330000000,-1.260000000 -6.000000e-03,NA,NA,NA,NA NA NA 12.0646260 12.0646260 100 100 100 100 100,100,100 low some low some low,Placebo   0  30.025843,10.961798 NA NA,0,1,1.0 1.0,1.0 1.0,1,1 0,1 1,1 1,1.0,1 1 1 1 1514 Lin_2014,< 2 months NA,6-12 yo,9.745,14.7 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100 High Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) NA,24:Other  1.84119678,NA NA,Lin,2014 NA,RCT G  24, 60   84 outcomes reverse -0.3880000000,-0.973000000, 1.970000e-01,NA,NA,NA NA,NA,NA 12.8869985,12.8869985,100,100,100 100,100 100 100,low,some,low some,low Placebo,  0  30.071429,10.971429 NA,NA 0 1 1.0,1.0 1.0,1.0 1 1 0,1 1,1,1 1.0,1 1,1,1,1515,Lin_2014 < 2 months NA 6-12 yo,8.60731707317073 10.9714285714286,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Methylphenidate Methylphenidate,  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.84119678 NA NA,Lin,2014 NA RCT,RR, 36  78  114 outcomes,reverse, 1.0110000000, 0.452000000  2.263000e+00,NA,NA,NA,NA,NA NA,NA NA 100,100,100 100 100 100 100 low,some,low,some low,Placebo   0, 29.857895 10.926316 NA NA 0,1,1.0 1.0 1.0 1.0,1,1 0 1,1,1 1 1.0 1 1 1 1 1516 Lin_2014,< 2 months,NA 6-12 yo 7.9578947368421 14.7,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Methylphenidate Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.84119678,NA,NA,Lin 2014 NA,RCT,RR, 36, 78  114,outcomes reverse  2.1670000000  0.459000000  1.021600e+01,NA NA,NA,NA NA,NA,NA NA 100,100,100,100,100 100,100,low,some,low some low,Placebo,  0, 29.857895 10.926316,NA,NA 0,1 1.0,1.0,1.0 1.0,1 1,0,1 1,1,1,1.0 1,1,1 1,1517 Lin_2014,< 2 months NA,6-12 yo,7.9578947368421 14.7,NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Atomoxetine Atomoxetine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total  0.92059839 NA NA Martenyi 2010,NA RCT G  72  33, 105 outcomes reverse,-0.4480000000 -1.070000000  1.750000e-01,NA,NA NA,NA NA NA  6.7916012, 6.7916012,100 100,100 100,100,100,100 low,low,low,low low Placebo,  0, 14.291429  9.805714 NA NA 0,1,1.0 1.0 1.0 1.0 1 1 0 1 1 1,1 1.0,1 1,1,1 1518 Martenyi_2010,< 2 months NA 6-12 yo,8.65157894736842,12.2493333333333 NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total, 0.92059839    2.2000000 mg/d McCracken,2016,NA RCT,G  68  69  137,outcomes reverse -1.0200000000,-1.377000000,-6.630000e-01,  6.5969690,  8.3066239,NA NA,NA,NA NA NA 100 100,100,100,100,100 100 some some low some,some Placebo   0  33.548175,10.100000 NA NA 0 1 1.0 1.0 1.0,1.0,1 1 0 1,1 1,1,1.0,1 1,1 1,1519 McCracken_2016,< 2 months NA,6-12 yo 8.99719626168224,14.5496794871795 NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability  0.92059839    2.2000000,mg/d,McCracken,2016,NA RCT,RR  71, 70, 141 outcomes reverse, 2.9580000000, 0.315000000  2.775400e+01 NA,NA,NA NA NA NA NA,NA,100,100,100,100 100,100,100,some some low,some,some Placebo   0, 33.551773,10.100000 NA,NA,0,1 1.0 1.0,1.0,1.0,1 1,0,1,1 1 1 1.0,1,1,1 1 1520 McCracken_2016,< 2 months,NA,6-12 yo 8.23931034482759 12.6640449438202 NA NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability  0.92059839    2.2000000,mg/d McCracken,2016 NA RCT,RR, 71  70  141,outcomes,reverse, 0.9860000000  0.020000000, 4.901900e+01 NA NA NA,NA,NA NA,NA,NA,100 100 100,100 100,100,100,some,some low some some Placebo   0  33.551773,10.100000,NA,NA 0,1 1.0,1.0,1.0,1.0,1 1,0,1 1,1,1,1.0 1,1,1,1,1521 McCracken_2016,< 2 months,NA 6-12 yo,9 12.6640449438202 NA,NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total  0.92059839    2.4000000,mg/d McCracken,2016 NA,RCT,G  70  69, 139 outcomes reverse,-1.0160000000 -1.371000000 -6.610000e-01,  6.6932802,  8.3066239,NA,NA NA NA NA NA 100,100 100 100 100 100 100,some some,low,some,some,Placebo   0, 30.177698  9.999281,NA,NA,0 1 1.0 1.0 1.0 1.0 1,1 0,1 1,1 1 1.0,1 1 1,1,1522 McCracken_2016 < 2 months,NA 6-12 yo 8.99719626168224 14.5496794871795,NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability  0.92059839,   2.4000000 mg/d,McCracken 2016 NA RCT RR, 71, 70  141,outcomes,reverse, 0.9860000000, 0.063000000, 1.545400e+01,NA NA NA NA,NA NA,NA NA,100 100 100,100,100,100,100,some,some,low,some,some,Placebo   0  30.178014  9.999291 NA,NA,0 1 1.0 1.0,1.0,1.0,1 1 0,1,1,1 1 1.0 1,1 1 1 1523 McCracken_2016 < 2 months NA,6-12 yo,8.23931034482759,12.6640449438202 NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 0.92059839,   2.4000000,mg/d McCracken,2016,NA,RCT RR  71, 70  141,outcomes reverse, 0.9860000000, 0.020000000, 4.901900e+01,NA,NA,NA NA,NA NA NA,NA,100 100,100,100,100 100 100,some,some,low,some,some,Placebo   0  30.178014  9.999291 NA,NA,0 1,1.0,1.0 1.0 1.0,1 1,0 1,1,1 1,1.0 1,1,1 1 1524,McCracken_2016,< 2 months NA,6-12 yo,9 12.6640449438202 NA NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Atomoxetine Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total  1.84119678,NA,NA Michelson 2001 NA RCT G  43, 83  126 outcomes reverse,-0.1390000000,-0.540000000  2.630000e-01 NA NA,NA NA,NA NA 10.9000000 10.9000000,100,100 100,100 100 100,100,low low,low,low low,Placebo   0  28.911032 11.036508,NA NA,0,1 1.0,1.0,1.0,1.0 1,1 0,1 1 1 1 1.0 1 1,1 1,1525,Michelson_2001 < 2 months NA,6-12 yo,8.65157894736842 12.2493333333333 NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100,100,High,Atomoxetine Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA 13:CPRS-R:S  1.84119678 NA,NA,Michelson 2001 NA RCT G  43, 83, 126 outcomes,reverse,-0.6200000000,-1.024000000 -2.150000e-01,NA NA,NA NA NA,NA  8.5000000, 8.5000000,100 100,100,100 100 100,100,low,low low low,low Placebo   0, 28.911032 11.036508,NA NA 0,1,1.0 1.0,1.0 1.0,1,1,0,1,1,1,1,1.0 1 1 1 1,1526 Michelson_2001,< 2 months,NA,6-12 yo,9.26 11.2017964071856 NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100,100 High Atomoxetine,Atomoxetine   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 1.84119678,NA,NA Michelson 2001 NA RCT RR, 44  84  128 outcomes,reverse  1.5910000000  0.747000000, 3.388000e+00 NA,NA NA,NA,NA,NA NA,NA 100 100 100 100 100,100 100,low,low low low,low Placebo   0  28.913438,11.037500 NA,NA 0,1,1.0,1.0 1.0 1.0,1,1 0,1,1 1 1 1.0 1,1 1 1 1527 Michelson_2001,< 2 months,NA 6-12 yo 8.65154639175258,12.2493548387097,NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100 High,Atomoxetine Atomoxetine,  0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability, 1.84119678,NA NA,Michelson,2001 NA RCT,RR, 44  84, 128 outcomes reverse  5.6670000000, 0.236000000, 1.362850e+02,NA,NA,NA NA NA,NA NA NA 100 100,100 100 100,100,100 low low,low low low Placebo,  0  28.913438 11.037500,NA,NA 0 1 1.0,1.0,1.0 1.0 1,1,0 1,1,1,1 1.0 1 1 1,1 1528,Michelson_2001 < 2 months NA 6-12 yo 8.65154639175258,12.2493548387097,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100,High Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA 4:ADHD-SRS Total, 1.84119678,NA,NA,Michelson,2001,NA,RCT,G, 84, 83  167 outcomes,reverse,-0.4350000000 -0.781000000 -8.900000e-02,NA NA,NA,NA NA,NA,10.9000000,10.9000000 100,100 100 100,100,100,100,low,low low,low low Placebo   0  28.580000 11.201796,NA,NA 0 1 1.0,1.0,1.0,1.0 1,1,0 1 1 1,1,1.0 1,1 1 1,1529,Michelson_2001,< 2 months NA 6-12 yo,8.65157894736842,12.2493333333333,NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100 High Atomoxetine,Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA,13:CPRS-R:S  1.84119678,NA NA,Michelson,2001,NA,RCT,G  84  83  167,outcomes,reverse -0.7340000000,-1.068000000,-4.000000e-01 NA NA NA,NA NA,NA  8.5000000, 8.5000000 100,100,100,100,100,100,100,low low low low low,Placebo   0, 28.580000,11.201796 NA,NA,0,1 1.0,1.0 1.0 1.0,1,1 0 1 1 1 1 1.0,1,1,1 1,1530,Michelson_2001 < 2 months,NA,6-12 yo,9.26,11.2017964071856,NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100,100 High,Atomoxetine Atomoxetine   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 1.84119678 NA NA Michelson 2001,NA,RCT,RR, 84, 84, 168 outcomes reverse, 1.2500000000, 0.623000000, 2.508000e+00 NA NA NA NA NA NA NA NA 100,100 100 100,100 100,100,low low low,low,low,Placebo   0  28.580000 11.200000 NA NA 0,1,1.0,1.0 1.0 1.0 1 1,0,1 1,1,1 1.0,1,1,1,1,1531,Michelson_2001 < 2 months NA 6-12 yo 8.65154639175258,12.2493548387097,NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100,High Atomoxetine,Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability, 1.84119678,NA NA,Michelson,2001,NA RCT,RR, 84  84, 168 outcomes,reverse, 5.0000000000, 0.244000000, 1.026040e+02 NA,NA NA,NA,NA NA NA,NA,100,100,100 100,100,100 100 low,low low,low,low,Placebo   0, 28.580000,11.200000,NA NA,0,1 1.0,1.0 1.0 1.0,1,1,0 1,1 1 1,1.0,1,1 1,1,1532,Michelson_2001 < 2 months NA,6-12 yo 8.65154639175258 12.2493548387097 NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100,100 High Atomoxetine,Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total  0.92059839 NA NA,Michelson,2002 NA,RCT G, 84, 83  167 outcomes reverse,-0.6260000000 -0.938000000,-3.140000e-01  11.1814847, 11.2058333 NA NA,NA,NA NA NA,100,100 100,100,100,100 100,low low,low,low low,Placebo   0  29.400000 10.298802,NA NA,0,1 1.0,1.0 1.0,1.0,1 1,0,1,1 1 1 1.0 1,1,1,1 1533 Michelson_2002 < 2 months,NA 6-12 yo,8.65157894736842,12.2493333333333,NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100,High,Atomoxetine,Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,6:ADHD-SRS-Hyp-Imp  2.76179517,NA,NA,Montoya,2009,NA,RCT,G  99  50  149,outcomes,reverse -0.6730000000,-1.023000000 -3.230000e-01  12.7000000, 12.3000000 NA NA NA,NA NA NA 100,100 100 100 100 100 100 low low low low,low,Placebo,  0  20.530201 10.300000 NA NA,0,1,1.0,1.0 1.0,1.0 1 1 0 1,1 1,1,1.0 1 1 1 1,1534 Montoya_2009 2-6 months NA 6-12 yo 8.65157894736842,12.2493333333333 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High Atomoxetine,Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA NA, 2.76179517,NA NA Montoya,2009,NA,RCT G, 99, 50, 149,outcomes,reverse,-0.7560000000,-1.108000000,-4.040000e-01   8.5000000   7.0000000,NA NA,NA NA NA NA,100,100,100 100,100,100 100,low,low,low low low Placebo,  0, 20.530201 10.300000,NA NA 0,1 1.0 1.0,1.0 1.0 1,1,0 1 1 1,1,1.0,1,1,1,1 1535,Montoya_2009,2-6 months,NA,6-12 yo 9.26 11.2017964071856 NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High Atomoxetine,Atomoxetine   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability, 2.76179517 NA NA Montoya,2009 NA,RCT RR 100, 51, 151,outcomes reverse, 1.0200000000  0.266000000  3.912000e+00 NA NA,NA,NA NA,NA,NA NA,100 100,100 100,100,100 100,low low,low,low,low,Placebo,  0  20.527152 10.300000 NA,NA 0 1,1.0 1.0,1.0 1.0 1 1,0 1 1 1,1,1.0 1 1 1,1,1536 Montoya_2009 2-6 months NA,6-12 yo,8.65154639175258 12.2493548387097,NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High Atomoxetine,Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,Tolerability, 2.76179517 NA NA,Montoya 2009,NA,RCT,RR 100, 51, 151,outcomes,reverse, 0.5150000000, 0.010000000, 2.557800e+01 NA,NA NA,NA NA,NA,NA,NA,100 100 100,100,100 100,100 low,low low low low,Placebo,  0  20.527152,10.300000,NA,NA,0 1 1.0 1.0,1.0,1.0,1,1,0,1,1 1 1 1.0 1,1 1 1 1537,Montoya_2009,2-6 months,NA 6-12 yo,8.65154639175258 12.2493548387097 NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 0.92059839,NA NA NCT01069523,NA NA,RCT,RR, 16  13   29 outcomes reverse, 1.4220000000, 0.530000000, 3.814000e+00,NA,NA NA,NA,NA,NA NA NA,100 100 100 100 100 100 100 low,some low,low,low Placebo,  0  44.896552, 8.239310,NA NA 0,1,1.0 1.0 1.0 1.0,1 1 0,1,1 1 1,1.0,1 1,1 1,1538,NCT01069523_NA,< 2 months NA,6-12 yo,8.23931034482759,12.6640449438202,NA NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Amphetamine Amphetamine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total, 1.38089758 NA NA NCT01552902,NA NA RCT G,175, 93, 268 outcomes,reverse -0.8860000000 -1.330000000 -4.420000e-01 NA,NA,NA,NA,NA,NA, 9.9329603  9.9329603,100,100,100,100 100 100,100 some,some low,some,low,Placebo,  0  35.570896,14.634701,NA,NA,0,1,1.0 1.0,1.0 1.0 1 1,0,1 1 1,1,1.0,1 1,1 1 1539,NCT01552902_NA < 2 months,NA,13-19 yo 9.04758620689655,14.6347014925373 NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High,Amphetamine,Amphetamine   0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability  1.38089758,NA NA NCT01552902,NA,NA RCT,RR,218 110  328,outcomes reverse, 1.4360000000  0.797000000  2.588000e+00 NA,NA NA NA,NA,NA,NA NA,100 100,100 100,100 100 100 some some low,some,low,Placebo   0, 35.652439 14.633537,NA NA 0 1,1.0,1.0 1.0,1.0 1 1,0 1,1,1 1 1.0 1,1,1 1,1540 NCT01552902_NA,< 2 months NA,13-19 yo 8.22105263157895,14.6335365853659 NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100 High,Amphetamine Amphetamine,  0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability, 1.38089758 NA,NA NCT01552902,NA,NA RCT,RR 218 110, 328 outcomes,reverse  7.5690000000, 1.013000000  5.655700e+01 NA NA NA NA,NA NA,NA,NA,100 100,100 100 100 100 100 some,some low,some,low Placebo   0, 35.652439 14.633537 NA NA,0 1 1.0 1.0,1.0,1.0 1 1,0 1 1,1 1,1.0,1,1 1,1 1541,NCT01552902_NA < 2 months,NA 13-19 yo 8.22105263157895 14.6335365853659,NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High Methylphenidate Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA 4:ADHD-SRS Total  1.38089758 NA,NA NCT01552902,NA NA,RCT G 181  93  274,outcomes,reverse,-0.5430000000 -0.963000000 -1.240000e-01,NA NA,NA,NA NA NA, 9.9329603  9.9329603,100 100 100 100,100 100,100,some some,low,some,low,Placebo   0  31.660584,14.700000 NA,NA,0,1,1.0 1.0 1.0,1.0,1 1 0,1 1,1,1,1.0 1 1 1 1 1542 NCT01552902_NA,< 2 months,NA 13-19 yo,9.745 14.7,NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100,High Methylphenidate,Methylphenidate,  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.38089758,NA NA NCT01552902,NA NA RCT RR,219 110, 329 outcomes,reverse, 1.2750000000, 0.700000000  2.322000e+00,NA,NA NA,NA,NA,NA,NA NA,100 100 100,100,100 100,100 some,some low some low Placebo,  0  31.665653,14.700000 NA,NA,0,1 1.0,1.0,1.0,1.0 1,1,0 1 1 1,1 1.0,1,1 1,1 1543 NCT01552902_NA < 2 months NA 13-19 yo 7.9578947368421,14.7,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100,100,High Methylphenidate Methylphenidate,  0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability  1.38089758 NA,NA,NCT01552902 NA,NA RCT RR 219 110, 329 outcomes reverse, 7.0320000000  0.937000000  5.278600e+01,NA,NA NA NA,NA,NA NA,NA,100,100,100 100 100,100 100 some,some low some low Placebo,  0  31.665653 14.700000 NA NA 0,1,1.0,1.0,1.0,1.0,1 1 0,1,1 1,1 1.0,1,1,1,1 1544,NCT01552902_NA,< 2 months NA,13-19 yo,7.9578947368421,14.7,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100 100 High,Atomoxetine Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total  1.38089758,   1.4500000,mg/kg/d,Newcorn 2008 NA RCT G,222  74  296 outcomes reverse -0.5020000000 -0.802000000 -2.020000e-01 NA NA,NA,NA NA,NA 11.5000000,11.5000000 100 100 100 100,100,100 100 low,low,low,low low,Placebo,  0  23.000000,10.250000,NA NA,0,1 1.0,1.0,1.0,1.0,1,1 0 1 1 1,1,1.0,1,1,1 1 1545 Newcorn_2008,< 2 months,NA 6-12 yo 8.65157894736842,12.2493333333333,NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High,Atomoxetine Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,13:CPRS-R:S  1.38089758,   1.4500000,mg/kg/d,Newcorn 2008 NA,RCT G 208  66, 274 outcomes reverse,-0.5740000000,-0.865000000 -2.830000e-01 NA,NA,NA,NA,NA,NA, 8.4000000  8.4000000,100,100,100 100,100 100 100 low,low low low low,Placebo,  0  22.963504 10.251825 NA,NA 0,1,1.0 1.0,1.0 1.0,1 1,0,1,1 1 1 1.0 1,1,1 1,1546 Newcorn_2008,< 2 months NA,6-12 yo 9.26 11.2017964071856,NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Atomoxetine,Atomoxetine,  0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.38089758,   1.4500000 mg/kg/d,Newcorn,2008,NA RCT RR,222  74  296,outcomes reverse  0.7060000000  0.422000000  1.179000e+00,NA NA NA NA NA,NA NA,NA,100,100,100 100 100,100,100,low,low low low low,Placebo   0  23.000000,10.250000 NA,NA,0 1 1.0 1.0,1.0,1.0 1,1 0 1 1 1,1 1.0,1,1,1 1 1547 Newcorn_2008 < 2 months NA 6-12 yo 8.65154639175258 12.2493548387097 NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High,Atomoxetine,Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability  1.38089758,   1.4500000 mg/kg/d,Newcorn 2008 NA RCT RR,222  74  296 outcomes reverse  0.8330000000  0.165000000  4.205000e+00,NA NA NA,NA NA NA NA NA,100 100,100 100,100,100 100 low,low,low,low,low,Placebo   0  23.000000 10.250000,NA NA,0,1 1.0,1.0,1.0,1.0 1 1,0,1 1 1,1,1.0 1 1 1 1,1548 Newcorn_2008 < 2 months NA,6-12 yo,8.65154639175258 12.2493548387097,NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Methylphenidate,Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total  1.38089758   39.9000000 mg/kg/d,Newcorn 2008,NA,RCT G 220  74, 294 outcomes,reverse -0.6570000000,-0.963000000,-3.510000e-01 NA NA,NA,NA,NA NA 11.5000000,11.5000000 100,100 100,100,100,100 100,low low low,low,low,Placebo   0  28.244898 10.174830 NA,NA,0 1 1.0,1.0,1.0 1.0,1 1,0,1 1 1,1 1.0,1,1,1,1 1549,Newcorn_2008 < 2 months NA 6-12 yo,9.745 14.7 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Methylphenidate Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA 13:CPRS-R:S  1.38089758,  39.9000000,mg/kg/d Newcorn 2008 NA RCT,G,195, 66  261,outcomes reverse -0.8460000000 -1.149000000 -5.430000e-01,NA,NA,NA NA NA,NA  8.4000000, 8.4000000,100,100,100 100,100 100,100,low low,low,low,low,Placebo   0, 28.241379,10.174713 NA NA,0,1,1.0,1.0,1.0,1.0,1 1,0 1,1 1 1,1.0,1,1 1 1,1550 Newcorn_2008,< 2 months,NA 6-12 yo,8.60731707317073,10.9714285714286,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100 100 High,Methylphenidate,Methylphenidate   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability, 1.38089758   39.9000000 mg/kg/d Newcorn,2008,NA RCT RR,220, 74  294 outcomes reverse, 0.7910000000, 0.479000000  1.308000e+00,NA NA,NA,NA,NA NA NA NA,100,100 100,100 100,100 100,low low,low low low,Placebo,  0, 28.244898 10.174830 NA NA 0,1,1.0 1.0 1.0 1.0,1,1 0 1,1,1 1,1.0 1 1,1 1,1551 Newcorn_2008 < 2 months NA,6-12 yo,7.9578947368421 14.7,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100 High,Methylphenidate,Methylphenidate   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability, 1.38089758   39.9000000,mg/kg/d,Newcorn,2008 NA RCT,RR,220, 74  294,outcomes reverse, 0.8410000000  0.167000000  4.243000e+00 NA NA NA NA,NA NA,NA,NA,100,100,100 100,100,100,100,low,low low,low low,Placebo   0, 28.244898 10.174830,NA,NA,0,1,1.0,1.0,1.0,1.0,1 1 0 1 1,1 1 1.0,1 1,1,1 1552 Newcorn_2008,< 2 months,NA 6-12 yo 7.9578947368421,14.7 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100,100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 1.84119678    2.9000000 mg/d Newcorn,2013 NA,RCT,G,104,110  214,outcomes reverse,-0.6730000000 -1.030000000 -3.160000e-01 NA,NA,NA,NA,NA,NA,12.9300000 12.9300000   0   0 100,  0,  0 100,  0 some,high,high,high,low,Placebo,  0  28.279439  8.997196,NA NA,0 1,1.0,1.0 1.0,1.0 1 1,0 1 1,1 1 1.0 1,1,1,1,1553,Newcorn_2013 < 2 months,NA 6-12 yo,8.99719626168224 14.5496794871795 NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100 100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 1.84119678    2.9000000,mg/d,Newcorn,2013 NA,RCT RR,113 113  226 outcomes,reverse  0.9190000000, 0.625000000, 1.351000e+00,NA,NA,NA,NA NA,NA,NA NA,  0,  0 100   0   0 100   0 some high high,high low Placebo,  0, 28.400000  9.000000,NA NA,0 1 1.0 1.0,1.0,1.0,1 1,0,1,1 1,1 1.0 1 1 1,1 1554,Newcorn_2013,< 2 months NA,6-12 yo,8.23931034482759 12.6640449438202 NA,NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100 100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability, 1.84119678    2.9000000,mg/d,Newcorn 2013,NA,RCT,RR 113,113  226,outcomes reverse  8.0000000000, 1.017000000, 6.292100e+01,NA NA,NA NA,NA NA NA,NA   0   0 100   0   0 100,  0,some high high high,low,Placebo   0  28.400000, 9.000000 NA,NA,0 1,1.0,1.0,1.0 1.0 1 1 0 1,1,1 1 1.0 1 1 1,1,1555 Newcorn_2013,< 2 months,NA,6-12 yo 9,12.6640449438202,NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100 100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total  1.84119678    3.0000000,mg/d,Newcorn 2013,NA,RCT G,111,110  221 outcomes,reverse -0.6860000000,-1.037000000 -3.350000e-01 NA,NA NA,NA,NA,NA 12.9300000,12.9300000,  0,  0 100   0   0 100,  0 some high,high high low Placebo   0  27.866968, 9.100905 NA NA 0,1,1.0,1.0 1.0,1.0 1,1,0 1,1 1,1 1.0 1,1,1,1 1556 Newcorn_2013,< 2 months,NA 6-12 yo,8.99719626168224,14.5496794871795,NA NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 1.84119678    3.0000000 mg/d,Newcorn 2013 NA RCT,RR,114 113  227 outcomes reverse  0.6970000000, 0.454000000  1.069000e+00 NA,NA,NA,NA,NA,NA NA NA   0,  0 100,  0   0 100   0,some high,high,high low,Placebo,  0, 27.866520, 9.100881,NA,NA 0,1,1.0 1.0 1.0,1.0 1 1 0 1,1 1 1 1.0,1 1 1,1,1557,Newcorn_2013 < 2 months NA 6-12 yo,8.23931034482759,12.6640449438202 NA NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 1.84119678    3.0000000 mg/d Newcorn 2013,NA RCT RR 114,113  227,outcomes,reverse  7.9300000000  1.008000000, 6.237400e+01,NA NA NA,NA,NA,NA,NA,NA,  0,  0 100,  0,  0 100   0 some high,high high,low,Placebo   0, 27.866520  9.100881 NA,NA 0 1 1.0,1.0,1.0 1.0,1,1 0,1 1,1,1 1.0 1 1 1 1,1558 Newcorn_2013 < 2 months NA 6-12 yo,9 12.6640449438202,NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100,100,High,Methylphenidate Methylphenidate,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  3.68239356   30.2000000,mgTDS Palumbo,2008 NA RCT,RR, 29  30   59 outcomes,reverse, 0.5690000000  0.335000000  9.670000e-01,NA NA,NA,NA,NA NA NA,NA,100,100,100,100   0,100 100,low some,high some,low,Placebo   0  20.301695, 9.196610,NA NA 0 1,1.0,1.0,1.0,1.0,1 1 0,1,1 1 1 1.0,1 1,1,1,1559 Palumbo_2008 2-6 months,NA,6-12 yo 7.9578947368421,14.7,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High,Methylphenidate,Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 3.68239356,  30.2000000 mgTDS,Palumbo,2008 NA,RCT RR  29  30,  59 outcomes reverse, 3.1000000000, 0.131000000  7.314200e+01,NA,NA NA NA NA,NA NA NA,100,100,100,100   0,100 100 low some,high,some low,Placebo,  0  20.301695, 9.196610 NA NA,0,1 1.0 1.0,1.0 1.0 1 1,0 1,1 1,1,1.0,1,1 1 1,1560,Palumbo_2008 2-6 months,NA,6-12 yo 7.9578947368421 14.7 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100,100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability  3.68239356    0.2400000,mgTDS,Palumbo 2008 NA,RCT,RR, 31, 30,  61 outcomes,reverse  0.2420000000, 0.104000000, 5.610000e-01,NA,NA,NA NA,NA,NA,NA NA,100 100 100 100,  0 100 100,low,some high some,low Placebo,  0, 18.014754  9.203279 NA NA,0,1,1.0,1.0 1.0 1.0 1 1 0,1,1 1 1 1.0,1,1,1 1,1561 Palumbo_2008 2-6 months,NA 6-12 yo 8.23931034482759 12.6640449438202,NA,NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability, 3.68239356,   0.2400000,mgTDS Palumbo 2008 NA,RCT RR, 31  30,  61 outcomes reverse  2.9060000000  0.123000000, 6.865700e+01,NA NA NA,NA,NA NA NA NA,100,100,100 100,  0,100,100 low some,high some,low Placebo   0, 18.014754  9.203279 NA,NA,0 1,1.0,1.0 1.0,1.0 1,1,0 1 1 1 1,1.0 1 1,1 1,1562,Palumbo_2008,2-6 months NA,6-12 yo,9 12.6640449438202 NA NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High Methylphenidate,Methylphenidate   0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability  0.69044879,  25.2000000,mg/d,Plizka,2000 NA,RCT,RR, 20  18,  38 outcomes reverse  0.4500000000, 0.044000000, 4.554000e+00,NA,NA,NA,NA NA NA,NA,NA 100,100,100 100 100,100 100,low low low,low low Placebo,  0  15.500000  7.957895,NA NA,0,1,1.0,1.0 1.0,1.0 1,1,0 1,1 1,1,1.0,1 1 1 1,1563 Plizka_2000 < 2 months,NA 6-12 yo 7.9578947368421,14.7 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100 100 High,Methylphenidate,Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability, 0.69044879   25.2000000 mg/d,Plizka,2000 NA RCT RR  20  18   38 outcomes,reverse, 2.7140000000  0.117000000, 6.270200e+01,NA NA NA,NA,NA,NA NA NA 100,100 100 100 100,100 100 low low low,low,low,Placebo   0  15.500000, 7.957895,NA NA 0 1 1.0 1.0,1.0,1.0 1 1 0,1,1 1,1,1.0 1,1 1 1 1564 Plizka_2000 < 2 months,NA,6-12 yo,7.9578947368421,14.7,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High,Amphetamine,Amphetamine   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 0.69044879   12.5000000,mg/d Plizka 2000 NA,RCT RR  20, 18,  38,outcomes,reverse  0.9000000000, 0.141000000, 5.745000e+00,NA,NA NA NA,NA NA,NA,NA 100,100 100,100 100 100,100,low,low low low low,Placebo   0  15.500000, 8.221053,NA,NA 0 1 1.0 1.0,1.0 1.0,1 1,0 1,1,1 1 1.0,1 1 1,1,1565 Plizka_2000,< 2 months,NA 6-12 yo 8.22105263157895 14.6335365853659 NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100 100,High,Amphetamine,Amphetamine,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability  0.69044879   12.5000000,mg/d,Plizka,2000 NA RCT,RR, 20, 18   38 outcomes,reverse, 4.5240000000  0.232000000, 8.837800e+01,NA NA NA,NA NA NA,NA,NA 100,100 100,100,100 100,100 low low low low,low Placebo   0, 15.500000  8.221053 NA NA 0 1 1.0 1.0 1.0,1.0 1,1 0,1 1 1,1,1.0,1 1 1 1 1566 Plizka_2000 < 2 months NA,6-12 yo 8.22105263157895,14.6335365853659,NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100 100 High,Modafinil Modafinil   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability, 1.38089758  264.0000000,mg/d Rugino,2003,NA RCT,RR, 13, 11,  24,outcomes,reverse  4.2860000000, 0.227000000  8.081200e+01 NA NA,NA NA,NA NA NA NA,100,100 100,100 100,100 100 low,some low,some,some,Placebo   0, 36.400000, 7.875000 NA,NA 0 1 1.0,1.0 1.0,1.0 1,1,0,1 1,1,1,1.0,1,1,1,1,1567,Rugino_2003 < 2 months NA,6-12 yo 7.875,10.2983870967742 NA NA   8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA NA,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100,100 High Modafinil Modafinil   0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability  1.38089758  264.0000000,mg/d,Rugino,2003 NA RCT RR  13, 11   24 outcomes,reverse  2.5710000000, 0.115000000, 5.744400e+01,NA,NA NA,NA NA NA NA NA 100,100,100,100 100,100 100,low some,low some some Placebo,  0  36.400000, 7.875000,NA,NA,0,1 1.0 1.0 1.0 1.0,1,1,0 1 1 1,1 1.0 1,1,1 1 1568 Rugino_2003 < 2 months,NA,6-12 yo 7.875,10.2983870967742,NA NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total  2.07134638,NA,NA,Sallee,2009 NA,RCT,G, 57  63  120 outcomes reverse,-0.4120000000,-0.775000000 -4.800000e-02  12.7800000  15.0200000 NA,NA NA,NA,NA,NA,100 100 100,100,100 100 100 some,low low,low,low,Placebo,  0  32.793255,10.087500 NA NA,0,1 1.0 1.0 1.0 1.0,1,1 0 1,1 1 1,1.0 1 1 1 1,1569 Sallee_2009 2-6 months NA 6-12 yo 8.99719626168224 14.5496794871795,NA,NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100 100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  2.07134638 NA NA,Sallee,2009 NA,RCT,RR, 62  66  128,outcomes,reverse, 0.7240000000  0.435000000  1.205000e+00,NA,NA,NA,NA NA NA NA,NA,100,100 100 100 100 100 100,some,low,low low,low Placebo,  0  32.812500 10.073438 NA,NA,0,1 1.0,1.0,1.0 1.0,1,1,0 1,1 1 1,1.0 1,1 1 1,1570,Sallee_2009,2-6 months NA,6-12 yo 8.23931034482759 12.6640449438202,NA,NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability  2.07134638,NA,NA,Sallee,2009,NA,RCT RR, 62  66, 128 outcomes reverse, 0.4260000000  0.086000000, 2.115000e+00,NA,NA NA,NA,NA NA,NA NA 100,100 100 100 100,100,100 some low low,low low Placebo   0, 32.812500,10.073438 NA,NA 0 1 1.0,1.0,1.0 1.0 1 1 0 1 1 1,1,1.0 1 1,1 1 1571 Sallee_2009,2-6 months NA 6-12 yo 9,12.6640449438202 NA NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100 100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total, 2.07134638 NA NA Sallee,2009,NA,RCT G, 63  63  126 outcomes reverse -0.3550000000 -0.708000000 -2.000000e-03, 14.0800000  15.0200000,NA,NA NA,NA NA,NA,100 100,100,100 100 100 100 some,low,low,low,low Placebo,  0  30.524476,10.700000 NA NA 0 1 1.0 1.0,1.0,1.0 1,1 0,1 1 1 1,1.0,1 1,1,1,1572 Sallee_2009 2-6 months NA,6-12 yo 8.99719626168224 14.5496794871795 NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability, 2.07134638 NA,NA Sallee 2009,NA,RCT,RR, 65, 66  131 outcomes reverse, 0.7310000000, 0.444000000, 1.205000e+00 NA NA,NA NA,NA NA,NA,NA 100,100 100,100 100,100,100,some low low,low,low,Placebo   0  30.534351 10.700763,NA NA 0 1,1.0 1.0 1.0,1.0 1,1 0 1 1,1,1,1.0,1 1 1 1 1573,Sallee_2009,2-6 months NA 6-12 yo,8.23931034482759 12.6640449438202,NA NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 2.07134638 NA,NA,Sallee,2009,NA,RCT RR, 65  66, 131 outcomes reverse, 0.4060000000  0.082000000, 2.019000e+00 NA NA,NA NA NA NA,NA NA 100,100,100 100 100 100 100 some,low,low low low Placebo,  0, 30.534351 10.700763,NA,NA,0 1 1.0 1.0 1.0 1.0 1,1 0,1 1,1 1 1.0,1 1 1,1 1574 Sallee_2009 2-6 months NA,6-12 yo 9,12.6640449438202,NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total, 2.07134638,NA,NA Sallee,2009 NA RCT,G  60, 63, 123,outcomes reverse -0.5320000000,-0.893000000 -1.710000e-01, 12.4600000, 15.0200000,NA,NA NA,NA,NA NA 100,100,100,100 100,100 100 some low low,low,low,Placebo,  0, 29.055091 10.946341,NA,NA,0 1,1.0 1.0,1.0,1.0 1,1 0,1,1 1 1,1.0 1,1 1 1,1575 Sallee_2009,2-6 months NA,6-12 yo 8.99719626168224,14.5496794871795 NA,NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100 100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  2.07134638 NA,NA Sallee 2009 NA RCT,RR  65, 66, 131 outcomes,reverse  1.0970000000, 0.719000000  1.673000e+00,NA,NA,NA NA,NA NA NA NA 100 100,100 100,100,100,100,some low low low,low,Placebo   0  29.007634,10.948855 NA NA,0,1,1.0,1.0 1.0 1.0,1,1 0,1,1 1,1,1.0 1,1,1,1,1576,Sallee_2009,2-6 months NA 6-12 yo,8.23931034482759,12.6640449438202,NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability  2.07134638,NA NA Sallee,2009,NA RCT,RR, 65, 66  131,outcomes reverse, 1.2180000000  0.391000000, 3.796000e+00 NA,NA NA NA NA NA,NA,NA,100,100,100,100 100,100,100,some low low,low,low Placebo,  0, 29.007634,10.948855,NA,NA,0,1 1.0 1.0 1.0,1.0,1 1,0 1,1 1 1,1.0 1 1 1 1 1577,Sallee_2009,2-6 months NA,6-12 yo,9,12.6640449438202 NA NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total, 2.07134638 NA NA,Sallee,2009 NA,RCT G, 63, 63  126,outcomes reverse,-0.5590000000,-0.916000000,-2.010000e-01, 11.0100000, 15.0200000,NA,NA NA,NA,NA NA 100,100,100 100 100,100,100,some,low,low,low,low,Placebo,  0  25.139860 10.650000 NA NA 0,1 1.0,1.0,1.0,1.0 1 1,0,1 1,1 1,1.0,1 1 1,1,1578,Sallee_2009 2-6 months,NA 6-12 yo,8.99719626168224,14.5496794871795 NA,NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100 100,High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 2.07134638 NA NA Sallee 2009 NA RCT RR  66, 66, 132 outcomes,reverse  1.0400000000  0.676000000  1.599000e+00 NA,NA,NA NA,NA NA,NA,NA,100,100 100 100 100,100 100,some low low,low low,Placebo,  0, 25.139860,10.650000,NA,NA,0,1,1.0,1.0,1.0,1.0 1 1 0 1 1 1,1,1.0 1 1 1 1,1579,Sallee_2009 2-6 months NA,6-12 yo 8.23931034482759 12.6640449438202 NA NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 2.07134638 NA NA,Sallee 2009,NA,RCT,RR, 66, 66, 132 outcomes reverse, 1.8000000000, 0.637000000, 5.086000e+00,NA NA NA,NA NA,NA,NA NA 100,100,100,100,100,100 100 some low low low,low Placebo,  0, 25.139860 10.650000,NA NA 0,1,1.0 1.0 1.0 1.0 1,1 0 1,1 1,1,1.0,1,1,1,1,1580,Sallee_2009 2-6 months,NA 6-12 yo 9 12.6640449438202 NA,NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA 24:Other, 1.84119678,   1.0000000,mg/d Schahill 2001 NA,RCT,G  17, 17   34 NA reverse,-0.2260000000 -0.911000000  4.580000e-01   6.7000000,  5.3000000 NA,NA NA,NA NA,NA,100 100 100,100,100,100,100 some some,some,some,some Placebo,  0,NA,10.600000 NA,NA 0,1,1.0 1.0,1.0 1.0,1,1 0 1,1,1 1,1.0,1,1,1 1,1581 Schahill_2001 < 2 months NA 6-12 yo 10.6,10.6 NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100 100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) NA,5:ADHD-RS Total, 1.84119678,   1.0000000,mg/d Schahill 2001,NA RCT,G, 17  17,  34,NA reverse,-0.6350000000,-1.335000000, 6.500000e-02, 13.6000000, 11.2000000 NA NA,NA,NA NA NA 100 100,100,100,100 100,100 some some,some some some,Placebo   0 NA,10.600000 NA,NA 0,1,1.0,1.0,1.0,1.0,1,1 0 1 1,1,1 1.0 1,1 1 1,1582,Schahill_2001,< 2 months NA 6-12 yo 10.6 10.6,NA,NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100,100,High Methylphenidate Methylphenidate   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  3.68239356,NA,NA Schrantee 2016,NA,RCT,RR, 25, 25   50 outcomes,reverse, 5.0000000000, 0.252000000  9.916100e+01,NA,NA,NA NA NA,NA NA NA,100,100,100,100,100 100 100 low low,low,low,low Placebo   0,  0.000000 11.350000,NA NA,0,1,1.0,1.0,1.0 1.0,1 1 0,1 1 1 1 1.0,1 1,1 1,1583,Schrantee_2016,2-6 months,NA,6-12 yo,7.9578947368421,14.7 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Methylphenidate,Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability, 3.68239356 NA NA,Schrantee,2016 NA RCT RR, 25  25,  50 outcomes reverse, 3.0000000000, 0.128000000, 7.029600e+01,NA,NA,NA,NA,NA,NA,NA,NA,100 100,100 100,100,100 100,low,low low,low low Placebo   0   0.000000,11.350000,NA,NA,0,1 1.0 1.0,1.0,1.0 1,1 0 1 1 1 1,1.0,1 1 1 1 1584,Schrantee_2016,2-6 months,NA,6-12 yo,7.9578947368421,14.7 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4   0,  0 100,100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 1.38089758,NA NA,Singer 1995 NA,RCT,RR  37, 37   74 outcomes,reverse  0.1430000000, 0.008000000  2.672000e+00,NA NA NA,NA NA NA,NA NA,100,100 100,100,100,100,100,some low,low,low,some Placebo,  0,NA NA,NA NA 0 1,1.0 1.0 1.0,1.0 1,1,0 1,1 1,1 1.0,1,1,1,1,1585,Singer_1995,< 2 months,NA NA 8.23931034482759 12.6640449438202 NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Atomoxetine Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA 4:ADHD-SRS Total  2.07134638 NA NA Spencer 2002,NA,RCT G, 63  60  123 outcomes reverse,-0.5820000000,-0.944000000 -2.190000e-01  14.3000000  14.4000000 NA NA,NA,NA,NA,NA 100 100 100,100,100 100 100,low,low some low low,Placebo,  0  19.860976  9.878293 NA,NA,0 1 1.0 1.0 1.0,1.0 1,1,0,1,1,1,1,1.0,1 1 1,1,1586,Spencer_2002,2-6 months NA,6-12 yo 8.65157894736842 12.2493333333333 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Atomoxetine Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA 13:CPRS-R:S, 2.07134638,NA,NA,Spencer,2002 NA RCT,G, 61, 60, 121 outcomes reverse -0.6710000000,-1.062000000,-2.790000e-01 NA,NA NA,NA NA NA  9.6000000  9.6000000,100,100 100 100,100,100 100,low low,some low,low,Placebo,  0  19.853719, 9.879421 NA NA,0,1 1.0 1.0,1.0,1.0 1,1 0,1,1,1,1,1.0 1 1,1,1,1587,Spencer_2002 2-6 months,NA,6-12 yo,9.26 11.2017964071856 NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Atomoxetine,Atomoxetine   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability, 2.07134638 NA NA Spencer 2002,NA,RCT,RR, 64, 62, 126 outcomes,reverse, 0.6270000000, 0.320000000, 1.229000e+00 NA,NA NA,NA,NA NA NA NA 100,100,100,100 100,100,100,low low some,low,low Placebo   0  19.857143, 9.878889 NA,NA 0 1 1.0 1.0 1.0 1.0 1,1,0 1,1,1,1,1.0,1 1,1,1 1588,Spencer_2002,2-6 months,NA 6-12 yo 8.65154639175258 12.2493548387097,NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100 High,Atomoxetine Atomoxetine   0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability  2.07134638,NA NA,Spencer 2002,NA,RCT RR, 64  62  126 outcomes,reverse, 1.9380000000, 0.180000000, 2.082800e+01 NA NA NA NA NA NA NA NA,100 100,100 100,100,100,100 low low some low,low Placebo   0  19.857143  9.878889 NA,NA,0,1 1.0,1.0 1.0,1.0 1 1,0 1,1,1 1,1.0 1 1 1 1 1589,Spencer_2002 2-6 months NA,6-12 yo,8.65154639175258,12.2493548387097,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High,Methylphenidate Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total  2.07134638,NA NA Spencer 2002,NA,RCT,G  17, 60,  77,outcomes,reverse,-1.1810000000,-1.755000000,-6.070000e-01  13.7000000  14.4000000 NA NA,NA NA,NA,NA,100,100,100,100,100 100,100,low low,some low low,Placebo   0  17.567532, 9.901429,NA,NA,0,1 1.0,1.0 1.0,1.0,1,1 0 1 1 1 1,1.0,1,1,1 1 1590 Spencer_2002,2-6 months NA 6-12 yo 9.745 14.7 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Methylphenidate Methylphenidate,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,13:CPRS-R:S  2.07134638,NA,NA,Spencer 2002 NA RCT,G, 17  60   77,outcomes reverse,-0.8990000000,-1.549000000,-2.490000e-01,NA,NA,NA,NA NA,NA, 9.6000000  9.6000000 100,100 100,100,100 100,100 low low,some,low low,Placebo   0  17.567532, 9.901429,NA NA,0 1 1.0,1.0,1.0 1.0,1,1,0,1 1 1,1 1.0,1 1 1 1 1591,Spencer_2002,2-6 months,NA,6-12 yo,8.60731707317073 10.9714285714286 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100,High Methylphenidate Methylphenidate   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  2.07134638,NA,NA Spencer 2002 NA,RCT RR  18, 62,  80,outcomes reverse, 0.2030000000, 0.029000000  1.420000e+00,NA,NA NA NA NA NA,NA NA 100,100,100,100 100,100,100,low,low some,low low Placebo,  0, 17.532500, 9.900500 NA NA,0,1,1.0 1.0,1.0 1.0 1,1 0,1 1 1,1,1.0,1 1 1 1,1592 Spencer_2002,2-6 months NA 6-12 yo 7.9578947368421 14.7 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Methylphenidate Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  2.07134638 NA NA,Spencer,2002 NA,RCT RR, 18  62   80 outcomes,reverse  1.1050000000, 0.047000000, 2.603200e+01,NA NA NA NA NA,NA,NA NA 100,100,100,100,100 100 100,low,low,some,low low Placebo   0, 17.532500, 9.900500 NA NA,0 1,1.0 1.0,1.0,1.0 1,1 0,1 1 1 1 1.0,1 1,1 1 1593 Spencer_2002 2-6 months,NA 6-12 yo,7.9578947368421 14.7,NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Atomoxetine,Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total  2.07134638,NA,NA,Spencer,2002 NA RCT G  64  60, 124,outcomes,reverse -0.4180000000,-0.775000000 -6.100000e-02  14.6000000, 14.4000000 NA,NA NA NA,NA NA 100,100,100,100 100,100,100 low,low some,low,low Placebo   0, 23.683871, 9.759032 NA,NA,0,1,1.0,1.0,1.0 1.0 1 1,0 1 1 1 1,1.0 1 1,1,1 1594,Spencer_2002 2-6 months NA 6-12 yo 8.65157894736842,12.2493333333333,NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100 High,Atomoxetine,Atomoxetine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA,13:CPRS-R:S  2.07134638,NA NA,Spencer,2002 NA RCT G, 64  60, 124 outcomes reverse  2.4480000000, 1.979000000, 2.916000e+00,  9.8000000   9.6000000 NA NA NA,NA,NA NA 100 100,100 100,100 100 100 low,low,some,low,low Placebo   0  23.683871  9.759032,NA NA 0,1 1.0,1.0 1.0 1.0 1 1 0 1,1,1,1 1.0 1 1,1 1,1595,Spencer_2002 2-6 months,NA 6-12 yo 9.26 11.2017964071856,NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100 High,Atomoxetine Atomoxetine,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 2.07134638 NA,NA Spencer 2002 NA,RCT RR, 65  62  127,outcomes reverse, 0.8980000000  0.499000000  1.615000e+00 NA,NA NA NA,NA NA NA NA 100 100,100 100 100,100,100,low low some,low,low,Placebo   0  23.648031  9.760630,NA,NA,0 1 1.0,1.0 1.0,1.0,1,1 0 1 1,1 1,1.0,1 1 1 1,1596 Spencer_2002 2-6 months,NA,6-12 yo 8.65154639175258,12.2493548387097 NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Atomoxetine,Atomoxetine   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability  2.07134638 NA NA,Spencer,2002,NA,RCT,RR  65  62, 127 outcomes,reverse  3.8150000000  0.438000000  3.320000e+01 NA NA NA NA,NA,NA NA,NA 100 100 100,100 100 100,100,low low some,low,low Placebo   0  23.648031  9.760630 NA NA 0,1 1.0 1.0,1.0 1.0 1,1,0,1 1 1,1,1.0 1,1 1 1,1597,Spencer_2002 2-6 months,NA,6-12 yo,8.65154639175258,12.2493548387097,NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100,100 High,Methylphenidate,Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total  2.07134638,NA,NA,Spencer,2002 NA RCT,G  20, 60,  80 outcomes reverse -0.7260000000 -1.248000000 -2.040000e-01, 13.5000000  14.4000000,NA,NA NA,NA,NA,NA 100,100 100,100,100,100,100,low,low,some,low low Placebo   0, 15.800000  9.745000,NA,NA 0,1 1.0,1.0 1.0 1.0,1,1 0 1 1 1 1 1.0,1 1,1 1 1598,Spencer_2002 2-6 months NA,6-12 yo,9.745 14.7,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Methylphenidate Methylphenidate,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability, 2.07134638,NA,NA Spencer,2002,NA,RCT RR  20  62,  82,outcomes reverse, 1.6410000000, 0.873000000  3.086000e+00,NA NA NA NA,NA NA,NA,NA,100,100 100 100 100 100 100,low,low some low low Placebo,  0  15.887805, 9.750000 NA NA 0 1 1.0,1.0 1.0 1.0,1,1 0 1,1,1 1,1.0 1,1,1,1,1599 Spencer_2002,2-6 months,NA 6-12 yo,7.9578947368421,14.7 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100,High Methylphenidate Methylphenidate,  0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability  2.07134638 NA,NA,Spencer 2002,NA RCT RR, 20  62,  82 outcomes,reverse  6.2000000000  0.593000000  6.481200e+01,NA NA NA,NA,NA,NA,NA,NA 100,100,100 100,100 100,100,low,low some,low,low,Placebo   0, 15.887805  9.750000,NA NA,0 1 1.0 1.0 1.0,1.0 1,1 0 1 1,1 1 1.0 1,1,1 1 1600,Spencer_2002 2-6 months,NA,6-12 yo,7.9578947368421,14.7,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100 High,Amphetamine Amphetamine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total, 0.92059839 NA,NA,Spencer 2006b,NA,RCT,G  54, 52  106 outcomes,reverse,-0.4490000000 -0.836000000,-6.100000e-02, 11.8000000, 13.4000000 NA NA,NA,NA NA,NA,100 100,100,100 100 100 100 some,low,low,low,low Placebo   0  35.858491 14.449057,NA,NA 0 1 1.0,1.0,1.0,1.0 1,1 0 1 1 1 1,1.0,1 1,1,1,1601 Spencer_2006b < 2 months NA,13-19 yo,9.04758620689655,14.6347014925373,NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100,High,Amphetamine Amphetamine,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 0.92059839 NA NA Spencer,2006b NA RCT,RR, 56  54, 110,outcomes reverse, 1.6880000000, 0.524000000, 5.438000e+00,NA NA NA NA,NA,NA,NA,NA,100 100,100,100 100,100,100 some,low low low,low,Placebo,  0, 35.856364 14.449091 NA NA,0,1 1.0,1.0,1.0 1.0,1 1,0,1 1,1 1,1.0,1 1 1 1 1602,Spencer_2006b < 2 months NA,13-19 yo 8.22105263157895,14.6335365853659,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100,100 High,Amphetamine Amphetamine   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability, 0.92059839,NA NA,Spencer 2006b,NA RCT,RR  56, 54  110,outcomes,reverse  2.8950000000, 0.120000000, 6.954600e+01,NA NA NA NA NA NA,NA,NA 100,100 100 100,100 100,100 some low,low low,low Placebo,  0  35.856364,14.449091 NA,NA,0,1 1.0 1.0 1.0,1.0 1,1,0 1,1 1 1 1.0,1,1 1,1 1603,Spencer_2006b,< 2 months NA 13-19 yo 8.22105263157895,14.6335365853659,NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High Amphetamine,Amphetamine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total  0.92059839,NA,NA,Spencer 2006b NA,RCT,G, 53, 52, 105,outcomes reverse,-1.0310000000 -1.441000000 -6.220000e-01, 10.3000000, 13.4000000,NA,NA,NA NA,NA NA 100 100 100,100,100 100 100 some,low,low low low,Placebo   0  31.438095,14.348571,NA NA,0,1 1.0 1.0,1.0,1.0 1 1 0,1,1,1 1 1.0,1 1 1,1,1604,Spencer_2006b < 2 months NA,13-19 yo 9.04758620689655,14.6347014925373,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100,100 High,Amphetamine Amphetamine,  0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability  0.92059839,NA NA,Spencer,2006b,NA RCT RR  56, 54  110 outcomes reverse  1.2050000000, 0.342000000, 4.252000e+00 NA,NA NA NA,NA,NA,NA,NA 100,100,100 100,100,100 100,some low low low low,Placebo,  0, 31.427273,14.347273 NA NA,0,1,1.0,1.0 1.0 1.0 1,1 0 1 1 1 1 1.0,1 1 1,1 1605,Spencer_2006b,< 2 months NA 13-19 yo,8.22105263157895 14.6335365853659,NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Amphetamine,Amphetamine   0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 0.92059839 NA,NA,Spencer 2006b,NA RCT RR  56  54  110 outcomes reverse, 2.8950000000  0.120000000  6.954600e+01 NA,NA,NA NA,NA NA,NA,NA 100 100 100,100,100 100,100,some low,low low,low,Placebo,  0  31.427273,14.347273 NA,NA 0,1,1.0 1.0 1.0,1.0 1,1 0 1 1,1 1 1.0 1 1,1,1,1606 Spencer_2006b,< 2 months NA,13-19 yo 8.22105263157895,14.6335365853659,NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Atomoxetine,Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total  2.30149597 NA mg/kg/d,Svanborg 2009,NA RCT G, 49, 50,  99 outcomes reverse -1.1960000000,-1.740000000 -6.530000e-01 NA,NA NA NA,NA,NA 10.6066017,10.6066017 100 100,100 100 100,100 100,some some,low some low Placebo,  0  59.989899,11.448485 NA NA 0,1,1.0,1.0 1.0,1.0 1 1,0,1,1,1,1,1.0 1,1 1 1 1607 Svanborg_2009 2-6 months NA 6-12 yo,8.65157894736842 12.2493333333333 NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100,High Atomoxetine Atomoxetine,  0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 2.30149597,NA,mg/kg/d,Svanborg,2009,NA,RCT,RR, 49, 50   99 outcomes,reverse  1.0200000000, 0.021000000, 5.041400e+01 NA NA,NA,NA,NA NA NA NA,100 100,100,100,100,100 100,some,some,low,some,low Placebo   0, 59.989899 11.448485,NA,NA,0,1 1.0,1.0,1.0 1.0 1,1 0 1,1,1 1 1.0,1 1,1 1,1608 Svanborg_2009 2-6 months,NA 6-12 yo,8.65154639175258,12.2493548387097 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100,High,Atomoxetine,Atomoxetine,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability, 2.30149597,NA mg/kg/d Svanborg 2009,NA RCT,RR  49  50   99,outcomes reverse  1.0200000000  0.021000000  5.041400e+01,NA,NA,NA NA NA,NA,NA,NA,100 100,100 100,100,100,100,some,some,low,some,low,Placebo,  0, 59.989899 11.448485 NA NA 0,1,1.0 1.0 1.0,1.0,1 1 0,1 1,1 1 1.0 1,1 1 1 1609 Svanborg_2009 2-6 months NA 6-12 yo 8.65154639175258 12.2493548387097 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Modafinil,Modafinil   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA 6:ADHD-SRS-Hyp-Imp  1.61104718 NA NA Swanson 2006,NA,RCT,G,120, 63  183,outcomes reverse,-0.4150000000,-0.724000000,-1.070000e-01, 13.8000000, 14.8000000 NA NA NA,NA NA,NA 100,100 100 100,  0 100 100 some some high,some,some Placebo   0, 24.967213  9.962295 NA NA,0 1,1.0,1.0,1.0,1.0,1,1 0,1 1,1 1,1.0,1 1,1,1 1610,Swanson_2006 < 2 months,NA,6-12 yo,8.85049504950495 10.3004098360656,NA NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA,NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100,100,High Modafinil,Modafinil,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA,NA  1.61104718,NA NA,Swanson 2006 NA RCT G,120  63, 183 outcomes reverse -0.6620000000 -0.975000000 -3.490000e-01   7.4000000, 12.2000000 NA,NA NA,NA,NA,NA 100 100 100,100,  0 100 100,some,some,high,some,some Placebo   0, 24.967213  9.962295 NA NA,0 1 1.0,1.0 1.0 1.0,1 1,0 1 1 1 1 1.0 1,1,1,1,1611,Swanson_2006 < 2 months NA,6-12 yo,8.85049504950495,10.3004098360656 NA,NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High,Modafinil Modafinil,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA 5:ADHD-RS Total, 1.61104718 NA NA,Swanson 2006,NA RCT G 120, 63  183 outcomes reverse,-0.5910000000 -0.903000000 -2.800000e-01  13.1000000  12.7000000 NA,NA NA NA NA,NA 100,100,100 100,  0 100,100 some some,high some,some,Placebo,  0  24.967213, 9.962295 NA NA,0 1 1.0,1.0,1.0 1.0 1 1,0 1 1 1 1 1.0,1,1 1,1,1612,Swanson_2006 < 2 months,NA,6-12 yo,8.85049504950495,9.96229508196721 NA,NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100 100,High Modafinil,Modafinil   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.61104718,NA,NA Swanson,2006 NA RCT,RR,126, 64, 190,outcomes,reverse  0.9740000000  0.658000000, 1.440000e+00 NA NA,NA,NA NA,NA,NA,NA,100 100,100,100   0 100 100 some some high,some,some Placebo   0, 24.989474  9.965263 NA,NA,0,1 1.0,1.0,1.0 1.0,1,1,0 1,1 1 1,1.0 1,1,1,1 1613 Swanson_2006,< 2 months,NA,6-12 yo 7.875,10.2983870967742 NA NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA NA,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100 100,High,Modafinil Modafinil   0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability  1.61104718,NA NA,Swanson,2006,NA,RCT,RR,126  64, 190,outcomes reverse 12.7950000000  0.770000000  2.127100e+02 NA NA,NA NA,NA,NA,NA,NA,100,100 100 100   0 100 100,some,some high,some,some,Placebo   0  24.989474, 9.965263 NA NA,0,1 1.0 1.0,1.0,1.0 1,1,0,1,1 1,1 1.0,1 1 1,1 1614 Swanson_2006 < 2 months,NA,6-12 yo,7.875 10.2983870967742 NA,NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Atomoxetine Atomoxetine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total, 1.84119678,   0.5000000,mg/kg/d Takahashi 2009 NA,RCT G, 62, 61  123,outcomes reverse -0.1310000000,-0.486000000  2.240000e-01  11.4000000  11.4000000,NA NA,NA,NA NA NA 100,100,100,100,100,100,100,low,low low low low Placebo,  0  16.100000 10.502927 NA NA 0,1 1.0 1.0,1.0,1.0 1,1,0,1 1 1 1,1.0,1 1,1,1 1615,Takahashi_2009,< 2 months,NA 6-12 yo 8.65157894736842,12.2493333333333,NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100,High,Atomoxetine,Atomoxetine   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.84119678    0.5000000,mg/kg/d Takahashi,2009,NA,RCT RR, 62  62  124,outcomes reverse  2.0000000000, 0.186000000  2.149100e+01,NA,NA,NA,NA NA NA NA NA 100,100,100,100 100,100 100,low low low,low low Placebo   0, 16.100000,10.505000,NA,NA,0 1,1.0 1.0,1.0,1.0 1 1,0 1 1 1 1,1.0 1,1,1,1,1616,Takahashi_2009 < 2 months NA 6-12 yo 8.65154639175258 12.2493548387097 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100,100,High,Atomoxetine,Atomoxetine,  0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability, 1.84119678,   0.5000000 mg/kg/d,Takahashi,2009,NA,RCT,RR  62, 62, 124 outcomes reverse  1.0000000000  0.020000000  4.961700e+01,NA NA,NA NA NA NA NA NA,100 100 100 100,100 100,100,low low low,low low Placebo,  0  16.100000 10.505000,NA,NA,0 1,1.0 1.0 1.0 1.0,1 1 0,1 1,1 1 1.0,1 1 1,1 1617 Takahashi_2009,< 2 months,NA,6-12 yo,8.65154639175258 12.2493548387097,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High Atomoxetine,Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total  1.84119678,   1.2000000 mg/kg/d Takahashi 2009,NA RCT G, 58  61  119 outcomes reverse -0.1550000000 -0.517000000, 2.060000e-01  10.3000000, 11.4000000,NA,NA NA,NA,NA NA,100,100,100 100,100 100,100,low,low low,low,low Placebo   0, 14.735294 10.682017 NA,NA 0,1 1.0 1.0,1.0 1.0 1,1,0,1,1 1 1 1.0 1,1,1 1,1618,Takahashi_2009 < 2 months NA,6-12 yo,8.65157894736842,12.2493333333333,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100 100,High,Atomoxetine Atomoxetine   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability  1.84119678    1.2000000,mg/kg/d Takahashi,2009 NA RCT RR, 60, 62  122 outcomes reverse, 3.1000000000, 0.332000000, 2.897900e+01 NA NA NA,NA,NA,NA NA,NA,100 100,100,100,100 100 100 low,low low,low,low Placebo,  0, 14.722951 10.681311,NA,NA,0 1 1.0,1.0 1.0,1.0,1,1 0,1,1,1,1,1.0,1,1 1,1 1619 Takahashi_2009 < 2 months,NA,6-12 yo 8.65154639175258 12.2493548387097,NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100 High Atomoxetine,Atomoxetine,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability, 1.84119678,   1.2000000,mg/kg/d,Takahashi,2009,NA RCT RR, 60  62, 122 outcomes,reverse, 3.0980000000  0.129000000  7.459400e+01 NA NA NA,NA,NA NA,NA,NA,100 100 100,100 100 100,100,low,low low low low Placebo,  0, 14.722951 10.681311,NA NA 0,1,1.0,1.0 1.0 1.0,1 1 0 1,1,1,1,1.0,1,1 1 1 1620 Takahashi_2009,< 2 months,NA 6-12 yo 8.65154639175258 12.2493548387097,NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100 100 High Methylphenidate,Methylphenidate,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 0.69044879,NA,NA Taylor,1987 NA RCT,RR, 39  39,  78,outcomes,reverse, 0.3330000000, 0.014000000, 7.939000e+00,NA,NA NA NA,NA,NA NA NA,100 100,100,100,100,100,100 low low,low,some,low,Placebo   0   0.000000  8.500000,NA,NA,0,1 1.0 1.0,1.0,1.0 1 1,0,1 1 1 1,1.0,1,1,1 1 1621,Taylor_1987 < 2 months,NA,6-12 yo,7.9578947368421 14.7 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Methylphenidate Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability  0.69044879 NA NA,Taylor,1987 NA RCT RR  39  39   78,outcomes,reverse  0.3330000000, 0.014000000, 7.939000e+00,NA,NA NA,NA NA NA NA NA,100,100 100,100,100,100,100,low,low,low,some,low Placebo,  0,  0.000000, 8.500000,NA,NA,0,1 1.0 1.0 1.0,1.0 1 1,0,1 1,1,1 1.0 1 1 1 1,1622 Taylor_1987 < 2 months NA 6-12 yo 7.9578947368421,14.7 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High Methylphenidate,Methylphenidate,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks),NA 13:CTRS-R:S, 1.61104718 NA,mg/d,van der Meere,1999,NA,RCT,G, 24  24,  48 outcomes,reverse,-0.3800000000,-0.956000000  1.970000e-01   4.4090815,  5.3888774,NA NA NA,NA,NA,NA,100 100 100,100,100,100 100 some,some some,some some,Placebo,  0 NA, 8.800000 NA NA 0 1 1.0 1.0,1.0,1.0,1 1,0 1 1 1 1,1.0,1 1,1 1,1623,van der Meere_1999,< 2 months,NA,6-12 yo,8.60483870967742,9.97113402061856 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100,High,Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total  1.84119678 NA,NA,Wehmeier,2012,NA RCT G, 63  62, 125,outcomes reverse -0.6440000000,-1.044000000,-2.450000e-01,NA,NA NA NA NA NA,10.8900000,10.8900000 100,100 100 100 100,100,100,low low,some low,low Placebo   0  22.424000, 9.000800,NA NA 0 1,1.0,1.0 1.0 1.0,1 1 0,1,1 1,1,1.0 1 1 1 1 1624 Wehmeier_2012,< 2 months,NA,6-12 yo 8.65157894736842 12.2493333333333 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High Atomoxetine Atomoxetine   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 1.84119678 NA,NA Wehmeier,2012,NA RCT,RR, 64  64, 128,outcomes reverse, 0.8180000000, 0.364000000, 1.839000e+00,NA,NA NA,NA,NA,NA NA,NA 100,100 100 100 100 100,100 low low some low low,Placebo   0  22.400000, 9.000000 NA,NA,0 1,1.0,1.0 1.0 1.0 1 1,0,1,1,1,1 1.0,1 1 1,1 1625 Wehmeier_2012 < 2 months,NA 6-12 yo 8.65154639175258,12.2493548387097,NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100,100 High,Atomoxetine,Atomoxetine   0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 1.84119678 NA,NA Wehmeier,2012 NA RCT,RR, 64, 64, 128,outcomes reverse, 0.6670000000, 0.115000000  3.857000e+00,NA,NA NA,NA NA NA,NA NA,100,100,100 100,100 100,100,low,low,some low low Placebo,  0, 22.400000, 9.000000 NA,NA,0,1,1.0 1.0,1.0,1.0 1 1 0 1,1,1,1 1.0,1 1,1,1 1626 Wehmeier_2012,< 2 months NA,6-12 yo,8.65154639175258,12.2493548387097,NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100,High Atomoxetine Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total, 0.69044879,NA,NA,Weiss,2005 NA,RCT G,100  51  151 outcomes,reverse -0.2980000000 -0.638000000, 4.200000e-02, 25.5000000, 18.4248853 NA,NA,NA,NA,NA NA,100,100,100 100,100 100,100,low low low low,low Placebo,  0, 19.590066, 9.933245 NA NA 0,1,1.0,1.0,1.0,1.0,1 1,0,1 1,1 1,1.0,1,1 1,1 1627,Weiss_2005 < 2 months,NA 6-12 yo 8.65157894736842 12.2493333333333,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100,100,High Atomoxetine,Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA 1:ADHD-RS Total, 3.68239356,NA NA,Wietecha,2013 NA,RCT G  62, 58, 120,outcomes,reverse,-0.4040000000 -0.910000000  1.020000e-01 NA NA NA NA,NA,NA,10.7500000,10.7500000,100,100,100,100,100 100,100,low,some,low some,low,Placebo   0  36.296667,12.249333,NA NA,0 1 1.0 1.0 1.0 1.0,1,1 0,1 1 1 1,1.0 1,1 1,1,1628 Wietecha_2013,2-6 months NA 6-12 yo 8.65157894736842,12.2493333333333 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100 100 High,Atomoxetine Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA 5:ADHD-RS Total  3.68239356,NA,NA,Wietecha 2013 NA RCT G  21  22   43,outcomes,reverse -0.7470000000,-1.424000000,-7.100000e-02,NA,NA NA,NA NA NA 10.8300000 10.8300000,100,100,100,100 100,100 100 low some low,some low,Placebo   0, 36.132558,12.250465 NA,NA 0,1 1.0,1.0,1.0,1.0 1 1,0,1 1 1 1 1.0,1 1,1 1,1629,Wietecha_2013 2-6 months NA 6-12 yo,9.77105263157895 12.2504651162791 NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100 100 High,Atomoxetine Atomoxetine,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability  3.68239356,NA NA,Wietecha 2013 NA RCT,RR, 64, 60, 124 outcomes reverse  2.1090000000, 0.992000000  4.487000e+00 NA,NA,NA NA,NA,NA NA,NA,100 100 100,100 100,100,100 low some low some low,Placebo   0  36.293548,12.249355 NA,NA 0,1 1.0 1.0 1.0 1.0 1 1,0 1 1 1 1 1.0 1 1 1 1,1630,Wietecha_2013,2-6 months,NA 6-12 yo 8.65154639175258,12.2493548387097 NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Atomoxetine Atomoxetine,  0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  3.68239356 NA NA Wietecha,2013,NA RCT RR  64, 60, 124,outcomes,reverse, 5.6250000000  0.697000000, 4.536400e+01,NA NA NA NA,NA NA,NA,NA,100 100,100 100 100,100 100,low,some,low,some,low,Placebo,  0, 36.293548 12.249355,NA,NA,0,1,1.0,1.0 1.0,1.0 1,1 0 1,1,1 1 1.0,1 1,1 1 1631,Wietecha_2013 2-6 months NA 6-12 yo 8.65154639175258,12.2493548387097 NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100 High Methylphenidate,Methylphenidate,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA 18:SNAP-IV-Long Total  0.92059839   36.5000000 mg/d,Wigal,2004,NA RCT,G  43  41   84 outcomes reverse -0.5700000000 -1.050000000,-9.000000e-02 NA NA NA NA NA,NA  0.5122499  0.5122499,100 100 100 100,100,100,100,some some,some some some,Placebo   0  11.632143, 9.804762 NA NA,0,1,1.0 1.0 1.0 1.0,1,1 0 1 1,1,1,1.0,1 1 1 1,1632 Wigal_2004,< 2 months NA 6-12 yo,8.60731707317073,10.9714285714286,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100 High Methylphenidate,Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),NA 21:SNAP-IV-short Total, 0.92059839   36.5000000,mg/d,Wigal 2004,NA RCT G, 42, 41,  83,outcomes reverse,-0.9540000000 -1.411000000,-4.970000e-01   0.6600000   0.7700000,NA NA,NA,NA,NA,NA 100,100 100,100,100,100,100 some some,some,some some Placebo,  0  11.690361, 9.802410 NA NA 0,1 1.0 1.0 1.0 1.0 1 1,0 1 1 1 1,1.0 1,1,1,1 1633,Wigal_2004 < 2 months NA 6-12 yo,8.60483870967742,9.97113402061856,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100 100 High Methylphenidate Methylphenidate,  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  0.92059839,  36.5000000,mg/d,Wigal,2004,NA RCT,RR, 44, 42   86 outcomes,reverse  0.3180000000, 0.068000000  1.489000e+00 NA NA,NA NA,NA NA NA,NA,100 100,100 100,100 100,100 some some,some,some some Placebo   0  11.634884  9.804651 NA NA,0 1 1.0 1.0 1.0,1.0 1,1,0,1 1,1 1 1.0,1,1 1 1,1634 Wigal_2004,< 2 months NA,6-12 yo,7.9578947368421 14.7 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100 100 High,Methylphenidate Methylphenidate   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability  0.92059839   36.5000000,mg/d Wigal,2004,NA,RCT,RR, 44  42,  86,outcomes reverse, 0.1910000000, 0.009000000, 3.867000e+00 NA,NA,NA,NA,NA NA NA NA 100,100 100,100,100 100 100,some,some,some,some some,Placebo,  0  11.634884  9.804651,NA,NA 0 1 1.0,1.0,1.0 1.0,1 1,0 1,1 1,1 1.0,1 1,1,1 1635,Wigal_2004 < 2 months,NA 6-12 yo,7.9578947368421,14.7 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100,High Methylphenidate,Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA 18:SNAP-IV-Long Total  0.92059839   64.2800000 mg/d Wigal 2004,NA,RCT,G, 46, 41   87,outcomes,reverse -0.2860000000,-0.736000000, 1.640000e-01,NA,NA,NA,NA,NA NA  0.5122499, 0.5122499,100 100,100,100,100,100,100,some some,some,some,some,Placebo,  0  14.743678, 9.705747,NA,NA,0,1 1.0,1.0 1.0 1.0 1,1 0,1,1 1,1 1.0,1,1 1,1,1636 Wigal_2004 < 2 months NA 6-12 yo 8.60731707317073 10.9714285714286,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100,100,High Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks) NA,21:SNAP-IV-short Total, 0.92059839,  64.2800000,mg/d Wigal 2004 NA,RCT G, 41  41   82 outcomes,reverse -0.4170000000,-0.857000000  2.400000e-02   0.8900000   0.7700000,NA NA NA NA,NA NA,100,100 100,100,100,100,100 some,some,some,some,some,Placebo   0, 14.850000  9.700000,NA NA 0,1,1.0 1.0,1.0 1.0 1,1 0 1,1,1,1 1.0 1 1 1,1 1637,Wigal_2004 < 2 months,NA,6-12 yo,8.60483870967742 9.97113402061856,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100,High Methylphenidate,Methylphenidate   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839   64.2800000 mg/d,Wigal,2004 NA,RCT,RR, 46  42   88,outcomes,reverse  0.9130000000, 0.319000000, 2.613000e+00 NA,NA NA,NA,NA NA NA NA 100 100,100,100 100 100 100,some some,some,some some Placebo   0  14.765909  9.704545 NA,NA 0 1,1.0,1.0,1.0,1.0,1 1,0,1 1,1,1,1.0,1,1 1,1,1638 Wigal_2004 < 2 months,NA,6-12 yo 7.9578947368421 14.7 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100 100,High Methylphenidate Methylphenidate,  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability, 0.92059839,  64.2800000,mg/d,Wigal 2004,NA,RCT,RR, 46, 42   88 outcomes reverse, 0.9130000000, 0.135000000  6.196000e+00 NA,NA NA NA,NA NA,NA,NA 100 100 100,100 100,100 100 some,some some,some some Placebo   0, 14.765909  9.704545,NA,NA,0 1 1.0,1.0 1.0,1.0,1,1 0 1 1,1 1 1.0,1 1 1,1,1639 Wigal_2004,< 2 months NA,6-12 yo 7.9578947368421,14.7 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total, 0.23014960 NA NA,Wigal,2015 NA RCT,G, 48, 46,  94 outcomes reverse -0.5410000000 -1.006000000,-7.700000e-02 NA,NA NA,NA,NA NA,10.3000000 10.3000000,100 100 100 100,100 100,100,some some low,some low,Placebo   0  37.527660,10.695745,NA,NA,0 1,1.0,1.0 1.0 1.0 1 1 0 1,1 1 1 1.0 1,1,1,1 1640 Wigal_2015 < 2 months,NA 6-12 yo,9.745,14.7 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100 High,Methylphenidate Methylphenidate   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 0.23014960,NA,NA Wigal,2015,NA RCT RR, 49  47,  96 outcomes,reverse, 0.9590000000  0.062000000, 1.489600e+01,NA,NA NA NA,NA NA NA NA 100 100,100 100 100,100,100 some,some low some,low Placebo   0  37.527083,10.695833 NA,NA 0,1 1.0 1.0,1.0 1.0,1,1,0,1,1 1 1,1.0,1 1 1,1 1641 Wigal_2015 < 2 months,NA 6-12 yo,7.9578947368421 14.7 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100 100,High Methylphenidate,Methylphenidate,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  0.23014960,NA NA Wigal,2015 NA,RCT,RR, 49, 47   96 outcomes,reverse  0.9600000000, 0.019000000  4.742000e+01,NA NA NA NA NA NA,NA,NA,100 100 100 100 100 100 100,some some,low some,low,Placebo   0, 37.527083 10.695833 NA,NA,0 1 1.0,1.0,1.0 1.0,1,1,0 1,1 1 1 1.0,1 1 1 1,1642,Wigal_2015 < 2 months NA 6-12 yo 7.9578947368421 14.7,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Methylphenidate,Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 0.23014960 NA NA Wigal 2015 NA RCT,G, 40, 46   86,outcomes,reverse -0.4210000000,-0.899000000  5.800000e-02 NA,NA NA NA,NA,NA,10.3000000,10.3000000 100 100,100 100,100 100,100,some,some,low,some,low,Placebo   0  34.153488,10.574419 NA NA,0,1,1.0 1.0 1.0,1.0 1 1 0,1,1,1,1,1.0,1,1,1 1 1643,Wigal_2015,< 2 months NA 6-12 yo,9.745 14.7 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High Methylphenidate,Methylphenidate,  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability  0.23014960,NA,NA Wigal,2015 NA RCT RR  44, 47,  91,outcomes reverse  4.2730000000, 0.497000000  3.676900e+01 NA NA NA NA,NA,NA,NA,NA,100,100,100 100 100 100 100 some some low some low Placebo,  0, 34.072527 10.561538 NA NA,0 1 1.0 1.0 1.0 1.0 1,1 0 1 1,1,1 1.0,1,1,1,1,1644,Wigal_2015,< 2 months,NA 6-12 yo,7.9578947368421 14.7,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100 High,Methylphenidate Methylphenidate   0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability, 0.23014960 NA NA Wigal 2015 NA RCT,RR, 44, 47,  91 outcomes,reverse, 3.2000000000, 0.134000000  7.654000e+01,NA NA,NA NA,NA,NA NA NA,100,100 100,100,100,100,100,some some,low some low Placebo   0, 34.072527 10.561538,NA NA 0 1 1.0 1.0 1.0,1.0,1 1 0 1,1,1,1,1.0 1,1 1 1,1645,Wigal_2015,< 2 months,NA 6-12 yo 7.9578947368421,14.7,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Methylphenidate,Methylphenidate,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total  0.23014960,NA,NA Wigal 2015 NA,RCT,G, 44  46   90,outcomes reverse,-0.7460000000,-1.244000000,-2.480000e-01 NA NA,NA NA NA NA,10.3000000,10.3000000,100 100 100 100 100,100 100 some,some,low,some,low Placebo,  0, 33.706667 10.997778,NA,NA,0 1 1.0 1.0 1.0 1.0,1 1,0,1,1 1,1,1.0 1 1,1 1 1646,Wigal_2015,< 2 months,NA,6-12 yo,9.745,14.7 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High,Methylphenidate Methylphenidate,  0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 0.23014960 NA,NA,Wigal 2015 NA,RCT,RR  45, 47   92 outcomes reverse  1.0440000000, 0.067000000  1.620000e+01,NA,NA NA,NA,NA NA NA,NA,100 100 100 100 100,100,100 some some,low some low,Placebo   0  33.705435,10.997826,NA,NA,0,1 1.0 1.0,1.0,1.0 1 1 0 1,1,1,1 1.0,1 1 1 1,1647,Wigal_2015 < 2 months,NA,6-12 yo,7.9578947368421 14.7 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100 100,High Methylphenidate Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 0.23014960 NA NA Wigal,2015 NA RCT RR  45  47   92,outcomes reverse, 1.0430000000, 0.021000000, 5.149900e+01,NA NA NA NA NA,NA,NA,NA 100 100 100,100,100,100 100 some some low,some,low,Placebo,  0  33.705435 10.997826 NA,NA 0,1 1.0,1.0,1.0,1.0,1 1,0 1 1 1 1 1.0 1,1,1,1 1648 Wigal_2015,< 2 months,NA,6-12 yo,7.9578947368421,14.7,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100,100 High,Methylphenidate,Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total  0.23014960,NA,NA Wigal 2015,NA,RCT G  43  46,  89,outcomes reverse -0.7720000000 -1.276000000 -2.670000e-01,NA,NA NA,NA,NA,NA 10.3000000,10.3000000 100,100,100,100,100 100 100,some,some,low,some low,Placebo   0  31.610112,11.044944 NA,NA 0,1,1.0,1.0 1.0,1.0 1,1 0,1,1,1,1 1.0 1,1,1 1 1649 Wigal_2015 < 2 months,NA,6-12 yo,9.745 14.7,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High Methylphenidate,Methylphenidate   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability  0.23014960,NA NA,Wigal 2015,NA,RCT,RR  45  47   92 outcomes reverse  2.0890000000, 0.196000000  2.224300e+01,NA,NA NA NA,NA NA,NA,NA,100 100,100,100,100 100,100,some some,low,some low,Placebo   0  31.553261,11.046739 NA,NA,0 1,1.0 1.0,1.0 1.0 1,1 0,1 1 1 1 1.0,1,1 1,1,1650,Wigal_2015,< 2 months NA 6-12 yo 7.9578947368421 14.7 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Methylphenidate,Methylphenidate   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.23014960 NA NA Wigal,2015,NA,RCT,RR, 45, 47,  92,outcomes reverse, 5.2170000000  0.257000000, 1.057750e+02,NA NA NA NA,NA,NA,NA NA,100 100,100 100,100,100 100,some some,low,some,low Placebo   0, 31.553261,11.046739 NA NA,0 1,1.0 1.0,1.0,1.0,1 1 0 1 1,1,1,1.0,1 1,1,1,1651 Wigal_2015 < 2 months NA,6-12 yo,7.9578947368421 14.7 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Adults (2018) Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100,High Bupropion,Bupropion   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total, 1.38089758  724.0000000 mg/d Wilens,2001,NA,RCT G, 21  19   40,outcomes reverse,-0.3960000000 -1.031000000  2.390000e-01, 11.0000000, 11.8000000 NA,NA NA NA NA,NA,100,100,100 100 100,100 100,some some,low some,some Placebo,  0  44.900000,38.235000 NA NA,0,1,1.0 1.0 1.0,1.0,1,1 0,1 1,1 1,1.0,1 1,1,1,1652,Wilens_2001 < 2 months NA >= 20 yo,38.235,40.25 NA,NA, 10  7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25,NA NA Cortese - Adults (2018)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Adults (2018) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100 100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total, 0.92059839 NA NA,Wilens,2015 NA RCT,G 157 155, 312,outcomes,reverse -0.3910000000,-0.687000000 -9.400000e-02,NA NA,NA NA NA,NA 12.4498996,12.4498996,100 100,100 100 100 100,100,some some some,some low,Placebo,  0, 35.254423,14.549679,NA NA 0,1,1.0 1.0,1.0 1.0 1,1,0 1 1 1 1,1.0 1,1 1,1,1653 Wilens_2015 < 2 months NA 13-19 yo,8.99719626168224 14.5496794871795 NA,NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Adults (2018),Cortese - Adults,2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100 High Bupropion Bupropion   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total, 1.84119678, 398.0000000 mg/d Wilens 2005a,NA RCT,G, 81, 81  162,outcomes,reverse -0.3830000000,-0.740000000 -2.500000e-02,NA NA NA NA,NA NA 11.1000000,11.1000000 100,100 100,100 100,100 100 some,some,some,some,low Placebo,  0  40.500000,40.250000 NA NA 0 1 1.0 1.0,1.0,1.0 1,1 0,1,1 1 1 1.0,1,1 1 1 1654 Wilens_2005a < 2 months,NA >= 20 yo 38.235 40.25 NA,NA, 10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25 NA,NA Cortese - Adults (2018)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Adults (2018) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100 100 High Atomoxetine Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA 4:ADHD-SRS Total  1.84119678,NA,NA Wilens,2011 NA,RCT,G  49, 46,  95 outcomes,reverse,-0.6870000000,-1.184000000 -1.900000e-01,NA NA NA,NA NA,NA 12.2081940,12.2081940,100 100,100,100 100,100 100 some,low,low low some Placebo,  0, 34.873684  8.651579 NA NA 0,1 1.0 1.0,1.0 1.0 1,1,0,1 1,1,1,1.0,1,1,1,1,1655 Wilens_2011,< 2 months,NA,6-12 yo,8.65157894736842 12.2493333333333,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100 100 High Atomoxetine,Atomoxetine,  0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability, 1.84119678 NA NA Wilens,2011 NA RCT,RR  50  47   97,outcomes reverse, 1.3160000000  0.449000000  3.861000e+00 NA NA,NA NA,NA NA NA NA 100,100,100,100 100 100 100 some low low low some,Placebo   0, 34.876289, 8.651546 NA NA 0,1,1.0 1.0,1.0 1.0,1,1 0,1 1,1,1 1.0,1,1,1 1 1656 Wilens_2011,< 2 months,NA 6-12 yo 8.65154639175258 12.2493548387097 NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Atomoxetine Atomoxetine   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 1.84119678 NA NA Wilens,2011,NA,RCT,RR  50, 47,  97,outcomes reverse  1.8800000000  0.176000000  2.005500e+01,NA,NA NA NA NA NA,NA NA 100 100 100 100 100 100 100,some,low,low low,some,Placebo,  0, 34.876289  8.651546 NA NA,0 1 1.0,1.0 1.0 1.0,1 1,0,1,1,1 1 1.0 1 1,1 1 1657 Wilens_2011,< 2 months NA,6-12 yo 8.65154639175258,12.2493548387097,NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 575 Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355,100,  0 100 100,Low,Carnitine,NA 100 stimulant,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA,NA,NA,NA Abbasi,2011 NA RCT,RR, 20, 20   40 outcomes,reverse  1.0000000000  0.067096465  1.490391e+01,NA NA,NA,NA NA NA,NA NA 100,100,100,100,100,100 100,some,low low low,some,Active (any credible active intervention),100  30.000000, 8.600000,NA NA,1,1 1.0 0.0 1.0,1.0,1,1,0 1,1 1,1,0.5,1,1 1,1 1658,Abbasi_2011,NA NA,6-12 yo 8.4,9.5,NA NA   4  1,Acceptability: all-cause discontinuation, 1 Catala-Lopez (2017),8.4 9.5 NA,NA,Catala-Lopez (2017)_Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 575 Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355,100   0 100,100,Low,Parent-mediated behavioral interventions,NA,  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,NA,NA,NA NA,Abikoff 2015 NA RCT,RR 130  34  164,outcomes reverse, 3.1384615385, 0.422729292  2.330082e+01,NA,NA,NA,NA,NA,NA,NA NA,100,100,100 100,100 100,100 some,some,low,some some Waiting list   0, 56.200000, 4.000000 NA,NA,1,1 1.0 0.0,1.0 1.0,1,1 0 1,1 1,1 0.5 1 1,1,1 1659,Abikoff_2015 NA,NA,< 6 yo 3.6,12.5,NA NA, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Mixed,Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious low low
 575,Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355,100   0,100,100 Low,Zinc,NA,100,stimulant,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA NA,NA,NA NA Akhondzadeh 2004,NA,RCT,RR, 22, 22   44 outcomes,reverse, 1.0000000000, 0.154316076  6.480206e+00 NA NA,NA NA,NA NA NA NA,100,100,100,100 100,100,100 some some,some,some some,Active (any credible active intervention) 100  40.900000  7.900000,NA NA,1,1 1.0 0.0 1.0 1.0 1 1,0 1,1 1,1 0.5,1,1,1 1 1660,Akhondzadeh_2004,NA,NA 6-12 yo,7.9 9.6 NA,NA   6, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Talebi (2021) | Catala-Lopez (2017) 7.14 9.92,NA NA Catala-Lopez (2017)_Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 575 Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0 100 100 Low Risperidone,NA 100 stimulant+bt,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA NA,NA,NA,NA,Aman,2014,NA RCT RR, 84, 84, 168,outcomes reverse  1.5333333333  0.862043122  2.727371e+00 NA,NA,NA,NA NA,NA NA NA 100,100,100,100,100,100 100,low some,low low some,Active (any credible active intervention) 100  23.200000  8.900000 NA NA 1 1,1.0,0.0,1.0 1.0,1,1 0 1 1 1,1,0.5 1,1,1 1 1661,Aman_2014 NA NA 6-12 yo,8.1,8.9 NA NA   2, 1,Acceptability: all-cause discontinuation, 1 Catala-Lopez (2017),8.1 8.9,NA,NA,Catala-Lopez (2017)_Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100,  0,100 100 Low Risperidone NA 100,stimulant,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA NA NA,NA Armenteros 2007 NA,RCT RR, 12, 13   25 outcomes reverse, 1.0833333333  0.075895602, 1.546349e+01 NA NA,NA NA,NA NA,NA NA,  0,  0 100 100,100,  0 100 low,low,some low high Active (any credible active intervention),100, 12.000000  8.100000,NA,NA,1 1 1.0,0.0,1.0 1.0 1 1,0,1 1,1 1 0.5 1,1 1 1,1662,Armenteros_2007 NA,NA,6-12 yo,8.1,8.9 NA,NA,  2  1 Acceptability: all-cause discontinuation, 1 Catala-Lopez (2017) 8.1 8.9 NA,NA Catala-Lopez (2017)_Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
 575 Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355 100,  0,100 100,Low Carnitine NA,  0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA NA,NA,NA NA,Arnold 2007,NA,RCT RR, 58  60  118,outcomes reverse, 0.7881773399, 0.458815786, 1.353972e+00 NA NA,NA,NA,NA NA NA,NA,100,100,100 100 100,100 100,some,some,some some,some,Placebo   0, 26.000000, 8.400000 NA NA,1 1,1.0 0.0,1.0 1.0 1,1,0 1,1,1 1 0.5 1 1,1 1 1663 Arnold_2007 NA NA 6-12 yo,8.4,9.5,NA,NA   4  1 Acceptability: all-cause discontinuation, 1,Catala-Lopez (2017),8.4 9.5 NA,NA,Catala-Lopez (2017)_Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 575 Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100,  0 100 100 Low Zinc,NA   0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA NA NA NA,Arnold 2011 NA,RCT,RR  28, 24   52,outcomes,reverse  0.8571428571  0.130451199  5.631944e+00,NA,NA,NA,NA,NA NA,NA,NA,100 100,100 100 100 100,100 some,some,some,some,some Placebo   0, 17.300000  9.600000,NA NA,1,1,1.0,0.0 1.0,1.0,1,1 0 1,1 1,1 0.5,1,1,1,1,1664 Arnold_2011 NA NA 6-12 yo,7.9 9.6,NA NA   6  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Talebi (2021) | Catala-Lopez (2017),7.14 9.92,NA NA Catala-Lopez (2017)_Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0,100,100 Low Zinc NA   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,NA NA,NA,NA,Arnold 2011,NA RCT RR  28, 24   52 outcomes reverse  0.8571428571, 0.056596501, 1.298126e+01,NA,NA NA,NA,NA,NA,NA,NA 100,100 100,100,100,100,100,some some some some some Placebo,  0  17.300000, 9.600000,NA NA,1 1,1.0 0.0 1.0 1.0 1 1,0,1,1,1 1,0.5 1,1,1,1,1665,Arnold_2011,NA NA,6-12 yo,9.6,9.6,NA,NA,  6, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Talebi (2021) | Catala-Lopez (2017) 7.14 9.92,NA,NA,Catala-Lopez (2017)_Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0 100 100 Low Neurofeedback,NA   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,NA NA,NA,NA Arnold 2013 NA,RCT RR  26  13   39 outcomes,reverse  0.3333333333, 0.063334434  1.754355e+00 NA NA NA NA NA,NA NA NA 100 100,100 100,100 100,100 some some,low,some some,Placebo   0  20.500000  8.900000 NA,NA,1,1 1.0,0.0,1.0,1.0 1,1 0 1 1,1 1,0.5,1 1,1 1 1666 Arnold_2013 NA,NA,6-12 yo,8.6,12.4 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100   0,100 100,Low,Neurofeedback NA   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA NA NA NA,NA Bakhshayesh 2011 NA,RCT,RR  18  17   35 outcomes,reverse  0.4722222222, 0.047008528, 4.743689e+00 NA,NA,NA NA NA NA NA,NA   0,  0 100,100,100 100,  0 some,low,some high,some Control,  0  25.700000, 9.300000 NA,NA 1,1,1.0,0.0 1.0,1.0,1,1,0 1 1,1 1,0.5 1 1 1 1 1667 Bakhshayesh_2011 NA,NA,6-12 yo,8.6,12.4 NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355 100   0 100,100 Low Polyunsaturated fatty acids NA 100 stimulant+bt,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,NA,NA NA NA Barragn,2014,NA RCT RR  30  30,  60 outcomes,reverse  0.1666666667  0.021335412, 1.301956e+00 NA,NA NA,NA,NA NA NA,NA,  0,  0 100   0   0   0   0,some high high,high high,Active (any credible active intervention),100, 33.300000, 8.300000,NA,NA 1 1 1.0 0.0 1.0,1.0 1,1 0,1 1 1,1 0.5,1 1,1,1,1668 Barragn_2014,NA NA,6-12 yo 8.3,13.7,NA NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA,NA,Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high,high
 575,Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355 100,  0 100,100,Low,Desipramine,NA   0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA,NA NA NA,Biederman,1989,NA,RCT,RR  37, 36   73,outcomes,reverse  1.1675675676  0.390779688  3.488446e+00,NA NA NA,NA NA NA NA,NA,100,100 100,100,100 100,100 some,low some low,some Placebo   0,  6.500000,11.500000 NA NA 1,1 1.0 0.0,1.0 1.0,1 1,0,1,1 1 1 0.5,1,1,1,1 1669 Biederman_1989 NA NA 6-12 yo,11,11.5,NA NA   4, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Otasowie (2014) | Catala-Lopez (2017) 11 11.5 NA,NA Catala-Lopez (2017)_Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 575 Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355 100   0,100,100,Low,Desipramine,NA,  0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,NA,NA,NA,NA,Biederman 1989 NA,RCT,RR, 37  36   73 outcomes,reverse  2.9210526316, 0.122886973  6.943412e+01 NA NA,NA,NA,NA,NA,NA,NA,100,100 100 100,100 100,100 some,low some,low some Placebo,  0   6.500000 11.500000 NA,NA,1,1 1.0 0.0 1.0,1.0 1,1,0 1,1,1 1 0.5 1 1 1,1,1670,Biederman_1989,NA NA,6-12 yo 11,11.5 NA NA   4, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Otasowie (2014) | Catala-Lopez (2017) 11,11.5 NA,NA,Catala-Lopez (2017)_Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 575,Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0,100,100,Low Cognitive training NA   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA NA,NA NA Bigorra 2015 NA,RCT,RR  36  30   66,outcomes,reverse  7.5405405405, 0.422227534  1.346661e+02,NA,NA,NA,NA,NA,NA,NA,NA,100,100 100,100 100,100,100,some low low low,some Placebo   0, 54.500000  8.900000,NA NA,1 1 1.0,0.0,1.0,1.0 1 1,0 1 1 1,1,0.5,1 1,1,1,1671,Bigorra_2015,NA NA,6-12 yo,6.6,10.4 NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA,Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 575 Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355 100,  0 100,100,Low Zinc NA   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA NA,NA NA NA Bilici 2004 NA RCT RR,202,198, 400 outcomes,reverse  1.0488118812, 0.867787205  1.267599e+00,NA,NA NA,NA,NA NA,NA NA 100,100,100,100,100,100,100 some,some,some,some some Placebo   0  18.000000  9.600000,NA NA,1,1,1.0,0.0,1.0,1.0,1 1 0 1,1 1 1 0.5,1,1,1,1 1672,Bilici_2004 NA NA,6-12 yo,7.9,9.6 NA,NA   6  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Talebi (2021) | Catala-Lopez (2017),7.14,9.92,NA NA Catala-Lopez (2017)_Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 575 Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355,100   0,100,100,Low Zinc,NA   0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,NA,NA NA,NA Bilici 2004,NA,RCT,RR 202 202, 404 outcomes reverse, 1.4705882353, 0.819716708, 2.638265e+00,NA NA,NA,NA,NA,NA NA NA 100 100 100 100 100 100 100 some,some,some some,some,Placebo   0  18.000000, 9.600000,NA,NA,1,1 1.0,0.0,1.0 1.0 1 1 0 1 1,1 1,0.5,1 1 1 1,1673,Bilici_2004 NA,NA,6-12 yo,9.6,9.6,NA,NA   6  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Talebi (2021) | Catala-Lopez (2017) 7.14 9.92 NA NA,Catala-Lopez (2017)_Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 575,Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355 100   0,100,100,Low,Parent-mediated behavioral interventions,NA,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,NA,NA NA,NA Bor,2002,NA RCT RR  55  32   87,outcomes reverse, 2.2109090909  0.913837430, 5.349003e+00 NA,NA,NA,NA NA,NA,NA NA 100 100,100,100,100 100 100 some some,some,low,some Waiting list,  0, 32.000000, 3.600000 NA,NA 1,1,1.0,0.0,1.0 1.0,1 1,0,1,1 1 1 0.5,1,1,1 1,1674 Bor_2002 NA,NA,< 6 yo 3.6,12.5,NA,NA, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious low low
 575,Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355,100,  0 100,100,Low,Polyunsaturated fatty acids NA,  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA NA,NA,NA,NA,Bos,2015 NA,RCT,RR  20, 20,  40,outcomes reverse  0.3333333333, 0.014385324  7.723921e+00,NA,NA,NA NA,NA NA NA NA 100,100,100 100 100 100,100 some,some some,some,some,Placebo,  0,  0.000000 10.300000 NA NA,1 1,1.0,0.0,1.0,1.0 1,1 0,1 1 1,1 0.5 1,1,1,1,1675,Bos_2015 NA,NA 6-12 yo 8.3,13.7 NA NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA NA Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 575 Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355 100,  0 100 100,Low Bupropion,NA   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA NA NA NA NA Casat 1987 NA RCT RR  20  10,  30 outcomes,reverse, 0.5000000000, 0.034770484, 7.190006e+00,NA,NA,NA,NA,NA NA NA NA   0   0,100,100,  0   0 100 some,some high,some,high,Placebo   0, 20.000000  8.700000,NA NA,1,1 1.0 0.0,1.0 1.0 1,1,0 1,1 1 1,0.5,1 1,1,1,1676 Casat_1987 NA,NA 6-12 yo,8.5 8.7 NA,NA  10  7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25 NA NA,Catala-Lopez (2017)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high,high
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355,100   0 100 100,Low,Bupropion,NA   0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA NA,NA NA,NA Casat 1987,NA RCT,RR, 20, 10,  30,outcomes reverse  1.5714285714  0.069642424, 3.545810e+01,NA NA NA NA NA,NA,NA NA,  0   0,100,100   0,  0,100 some,some high some high Placebo   0, 20.000000, 8.700000,NA NA 1,1,1.0,0.0 1.0,1.0 1,1,0 1,1 1,1 0.5,1 1,1,1,1677 Casat_1987,NA,NA 6-12 yo,8.5,8.7,NA NA  10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25,NA NA Catala-Lopez (2017)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
 575,Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355 100,  0 100,100 Low Cognitive training,NA,  0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA,NA NA NA,Chacko 2014,NA RCT RR, 44  41   85,outcomes reverse, 1.0871212121  0.398331639, 2.966956e+00,NA NA,NA NA,NA NA,NA NA 100,100,100,100,100,100,100,some low some,low,some Placebo,  0, 22.400000  8.400000 NA NA,1 1 1.0,0.0 1.0,1.0,1,1 0,1 1,1,1 0.5,1,1,1,1,1678,Chacko_2014 NA,NA,6-12 yo,6.6 10.4,NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA,Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355 100   0 100 100 Low Bupropion NA   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA,NA,NA,NA Conners,1996 NA RCT RR, 72, 37  109,outcomes reverse, 2.0555555556  0.459615944, 9.193129e+00 NA,NA NA,NA NA,NA,NA,NA,  0   0,100,100,  0,  0,100,some some high,some high Placebo   0, 10.000000  8.500000,NA,NA 1,1 1.0,0.0 1.0 1.0 1 1 0,1,1 1,1,0.5,1 1,1,1 1679 Conners_1996 NA,NA 6-12 yo 8.5 8.7 NA NA, 10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25 NA NA,Catala-Lopez (2017)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
 575,Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355 100   0,100 100,Low,Bupropion,NA,  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,NA NA NA,NA Conners,1996 NA RCT,RR, 72, 37, 109 outcomes,reverse, 4.6849315068  0.258989993  8.474684e+01 NA,NA NA,NA,NA NA NA NA,  0   0 100,100   0   0 100 some some,high some,high Placebo   0  10.000000  8.500000 NA NA 1,1,1.0 0.0,1.0,1.0 1 1,0,1 1,1,1 0.5 1,1 1,1,1680 Conners_1996,NA NA 6-12 yo,8.5 8.7 NA NA, 10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25,NA NA Catala-Lopez (2017)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0,100,100,Low Neurofeedback NA 100 stimulant,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA,NA NA NA Duric 2012,NA RCT RR  44, 44,  88,outcomes reverse  0.7333333333, 0.380435291, 1.413585e+00,NA NA NA,NA NA,NA,NA,NA,  0   0 100   0 100 100,  0,some high some,high,some,Active (any credible active intervention),100, 20.900000 11.200000 NA,NA,1 1,1.0,0.0 1.0 1.0,1,1,0,1 1 1,1,0.5,1 1,1,1 1681 Duric_2012 NA,NA,6-12 yo,8.6 12.4,NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0,100,100,Low,Diet (restricted/elimination),NA,  0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,NA NA,NA NA,Egger,1992 NA,RCT RR, 20  20   40,outcomes,reverse, 2.0000000000  0.196731882, 2.033224e+01,NA,NA NA NA NA,NA,NA,NA   0   0 100,100   0   0 100,some some,high,some,high,Placebo,  0  10.000000  9.300000 NA NA,1 1,1.0,0.0 1.0 1.0,1 1 0 1,1 1,1 0.5,1 1 1 1,1682 Egger_1992 NA,NA 6-12 yo 6.2 9.3,NA,NA,  8  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Sonuga-Barke (2014) | Catala-Lopez (2017),4.5,9.5,NA,NA,Catala-Lopez (2017)_Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high high
 575 Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100   0 100,100,Low,Multimodal behavioral interventions,NA,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA NA NA NA NA,Fabiano 2010 NA RCT RR, 33, 30,  63,outcomes reverse  0.1302521008  0.007004357, 2.422151e+00,NA NA NA NA,NA,NA,NA NA   0   0,100,  0 100,100   0,some,high,low,high,some,Control,  0, 14.000000  8.200000,NA NA 1 1 1.0 0.0 1.0 1.0,1,1 0,1 1 1,1 0.5,1,1,1 1,1683 Fabiano_2010 NA NA,6-12 yo 8.2 9.9 NA NA,  5, 1 Acceptability: all-cause discontinuation, 1,Catala-Lopez (2017) 8.2,9.9 NA NA,Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 575 Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0 100 100 Low,Parent-mediated behavioral interventions NA   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA NA,NA,NA Fabiano,2012 NA,RCT RR  28  27,  55,outcomes,reverse, 1.2053571429, 0.361662002, 4.017248e+00,NA NA NA NA NA,NA,NA NA   0   0 100,100 100 100   0,some some,low,high some,Waiting list   0, 12.700000, 8.500000 NA,NA 1,1 1.0,0.0 1.0,1.0,1 1,0,1 1 1 1,0.5 1 1,1,1,1684,Fabiano_2012 NA NA 6-12 yo,3.6,12.5,NA NA  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Mixed,Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious low high
 575,Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0,100,100,Low Parent-mediated behavioral interventions NA   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA NA NA,NA Ferrin,2014 NA RCT,RR, 44  37,  81 outcomes reverse  1.6818181818, 0.158748568  1.781756e+01 NA,NA NA,NA NA NA,NA,NA 100,100,100,100,100,100 100,low low low,low,some Control (parent counseling with support),  0  19.800000,10.600000,NA,NA,1,1,1.0,0.0 1.0,1.0 1 1,0,1 1 1 1 0.5,1,1 1,1 1685 Ferrin_2014,NA NA,6-12 yo,3.6,12.5 NA,NA, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15 108.21 Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 serious,low low
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0,100,100,Low Parent-mediated behavioral interventions NA,  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA,NA,NA,NA,Ferrin,2016,NA RCT,RR, 35  34   69 outcomes reverse  0.7285714286  0.175999888, 3.016004e+00,NA,NA,NA,NA NA,NA NA NA   0,  0,100,100,100 100,  0 low,some,low,high,some,Control (usual care)   0  18.900000 10.700000,NA NA 1,1 1.0 0.0,1.0,1.0,1 1,0 1 1 1,1,0.5 1 1 1,1,1686 Ferrin_2016 NA,NA 6-12 yo,3.6,12.5,NA NA  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious low,high
 575,Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355,100   0 100,100 Low,Parent-mediated behavioral interventions,NA 100 stimulant,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA NA NA NA NA Firestone,1986 NA RCT RR, 22, 30   52 outcomes reverse  1.1363636364, 0.602967863, 2.141611e+00,NA,NA,NA NA NA,NA,NA,NA   0   0 100,100   0   0 100 some,low,high low,high Active (any credible active intervention) 100,NA, 7.000000,NA NA,1 1,1.0,0.0,1.0 1.0 1,1,0 1 1,1,1,0.5 1,1,1 1 1687,Firestone_1986,NA,NA,6-12 yo,3.6,12.5,NA,NA  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious high high
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355 100,  0 100,100 Low Diet (restricted/elimination) NA,100,stimulant,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA NA NA NA Ghanizadeh 2015,NA RCT RR, 53  53, 106,outcomes,reverse, 0.9090909091  0.422152689  1.957695e+00,NA NA,NA NA NA,NA,NA NA,100 100,100 100 100,100,100,some some,some,some,some,Active (any credible active intervention),100,NA, 8.400000 NA,NA 1 1 1.0 0.0 1.0 1.0,1,1 0,1,1,1 1 0.5 1 1,1 1,1688 Ghanizadeh_2015 NA NA,6-12 yo,6.2,9.3,NA,NA   8  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5 NA NA Catala-Lopez (2017)_Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 575,Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355 100,  0 100 100,Low,Cognitive training NA   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA NA NA,NA Green,2012 NA RCT,RR, 15, 15,  30,outcomes reverse, 3.0000000000, 0.350490848, 2.567827e+01,NA,NA NA NA,NA,NA,NA,NA   0,  0,100 100,  0   0 100,some some,high some high,Placebo   0, 34.600000  9.700000 NA,NA,1 1 1.0,0.0,1.0 1.0 1,1 0,1 1 1 1 0.5 1 1 1,1 1689 Green_2012 NA NA,6-12 yo 6.6,10.4 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA,Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
 575,Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355 100,  0 100 100 Low,Parent-mediated behavioral interventions,NA   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA,NA,NA NA Hiscock,2015 NA RCT,RR,122,122, 244 outcomes,reverse  0.6666666667, 0.373015709, 1.191490e+00,NA,NA NA,NA,NA,NA,NA NA 100,100,100,  0 100 100 100,low high low low,some Control (usual care),  0, 14.800000 10.100000 NA NA,1,1 1.0,0.0,1.0 1.0 1,1,0 1 1 1 1 0.5 1,1 1 1,1690 Hiscock_2015,NA,NA,6-12 yo,3.6 12.5,NA NA, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Mixed,Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious low low
 575 Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355,100,  0 100,100,Low,Cognitive training,NA   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,NA,NA NA NA Hovik 2013,NA RCT,RR, 38  37,  75,outcomes,reverse  1.6228070175  0.417390898, 6.309439e+00,NA NA NA,NA,NA,NA,NA NA,  0   0,100   0 100 100   0,some high low,high some Control   0  26.900000 10.400000,NA,NA 1,1,1.0 0.0 1.0 1.0,1 1,0 1 1 1 1,0.5,1,1,1 1 1691 Hovik_2013,NA NA,6-12 yo,6.6 10.4 NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 575,Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0 100,100 Low Homeopathy NA,  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA NA NA NA,Jacobs,2005 NA RCT RR  22, 21   43 outcomes reverse  0.4772727273, 0.097467378, 2.337082e+00,NA,NA NA,NA,NA,NA,NA NA,100,100,100 100,100 100 100,low low some low some,Placebo   0  23.300000  9.300000 NA NA 1,1,1.0 0.0 1.0,1.0,1 1 0 1 1,1,1,0.5,1,1,1,1 1692,Jacobs_2005,NA,NA 6-12 yo 9.3,9.3,NA,NA   3  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  2,Heirs (2007) | Catala-Lopez (2017) 8.5 9.3,NA,NA Catala-Lopez (2017)_Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 575 Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355 100,  0,100,100 Low,Polyunsaturated fatty acids,NA   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,NA,NA,NA NA,Johnson 2009 NA RCT,RR, 37, 38,  75 outcomes reverse  2.0540540541, 0.194451659  2.169762e+01 NA NA,NA,NA NA,NA,NA NA,100 100 100,100,100 100,100,some low,some some,some Placebo   0  14.700000 12.000000 NA NA 1,1,1.0 0.0,1.0 1.0,1,1 0,1,1 1 1 0.5 1,1,1 1 1693 Johnson_2009,NA,NA,6-12 yo 8.3,13.7 NA NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA,NA,Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100,  0,100 100,Low,Cognitive training NA   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA NA NA NA Klingberg,2005,NA RCT RR  27, 26,  53 outcomes reverse, 3.3703703704  0.770061336, 1.475129e+01,NA,NA,NA NA,NA,NA NA,NA 100,100,100 100,100,100 100,low low,some,low some,Control   0, 18.000000  9.800000,NA,NA 1 1,1.0 0.0,1.0,1.0 1 1 0 1 1,1,1,0.5,1 1,1 1 1694,Klingberg_2005,NA NA 6-12 yo,6.6 10.4 NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 575,Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355 100,  0,100 100 Low,Neurofeedback NA 100 stimulant,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA NA,NA NA NA Li 2013,NA,RCT,RR, 32, 32   64 outcomes reverse, 0.3333333333  0.036585472  3.037028e+00,NA NA,NA NA,NA,NA NA,NA,100,100,100 100 100 100,100 low low low low some,Active (any credible active intervention) 100  15.600000,10.600000,NA,NA,1 1 1.0,0.0 1.0 1.0,1,1 0,1 1,1 1,0.5 1 1,1,1,1695,Li_2013,NA,NA,6-12 yo 8.6 12.4 NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 575 Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0 100,100,Low,Multimodal behavioral interventions,NA,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA NA NA,NA NA,MTA Cooperative,1999,NA,RCT RR 144,146, 290 outcomes reverse, 0.5069444444, 0.129249949, 1.988339e+00,NA NA NA,NA,NA,NA,NA,NA,  0,  0,100,  0,100 100   0,low high low high,low Standard care   0  20.000000  8.500000,NA,NA,1,1,1.0,0.0 1.0,1.0 1 1,0,1 1 1 1,0.5,1,1 1,1 1696,MTA Cooperative_1999 NA,NA,6-12 yo 8.2 9.9,NA NA,  5  1,Acceptability: all-cause discontinuation, 1,Catala-Lopez (2017) 8.2 9.9 NA NA,Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
 575,Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355,100   0 100,100 Low,Polyunsaturated fatty acids,NA,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA NA,NA NA NA,Manor,2012,NA RCT,RR 137, 63  200 outcomes reverse, 0.9197080292  0.084962836  9.955681e+00,NA NA NA NA NA NA,NA NA,  0,  0 100 100 100   0,100 some,some low,some high,Placebo   0, 33.500000, 9.200000 NA,NA,1,1 1.0 0.0 1.0 1.0,1,1 0,1,1,1,1 0.5 1,1 1 1,1697,Manor_2012,NA,NA 6-12 yo 8.3,13.7,NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA,NA,Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
 575 Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0 100 100 Low Polyunsaturated fatty acids,NA   0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,NA,NA NA NA,Matsudaira 2015 NA,RCT,RR, 38, 38,  76 outcomes,reverse  7.0000000000, 0.373869893, 1.310616e+02,NA,NA NA,NA NA,NA NA,NA,  0   0,100,100,  0   0,100 some some high some,high,Placebo   0,  0.000000 13.700000 NA NA 1,1,1.0 0.0,1.0 1.0 1 1,0 1 1,1,1,0.5,1 1 1 1 1698 Matsudaira_2015 NA NA 13-19 yo 8.3 13.7,NA NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high,high
 575 Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355 100,  0,100,100,Low,Homeopathy NA   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA,NA NA,NA,Oberai,2013,NA RCT RR, 30  31,  61,outcomes,reverse  0.7515151515  0.351495584  1.606777e+00,NA NA NA NA NA,NA NA,NA   0   0,100,  0,100   0 100,low high some some,high,Placebo   0  20.400000  9.300000,NA NA 1 1 1.0 0.0 1.0,1.0 1 1 0,1,1 1 1,0.5 1,1,1,1 1699 Oberai_2013 NA NA 6-12 yo 9.3 9.3,NA NA,  3, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  2,Heirs (2007) | Catala-Lopez (2017),8.5,9.3,NA,NA Catala-Lopez (2017)_Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
 575,Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0 100 100,Low Methylphenidate + Alpha-2 agonists (guanfacine / clonidine) NA,  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA NA NA NA,Palumbo 2008,NA RCT RR, 32  30,  62 outcomes,reverse  0.3750000000  0.195517429  7.192453e-01 NA,NA,NA,NA NA NA NA NA,100,100 100,100 100 100 100,low low,some,low some Placebo   0, 19.600000, 9.500000 NA NA,1,1,1.0 0.0 1.0 1.0 1,1 0 1,1,1 1 0.5 1 1 1,1,1700 Palumbo_2008,NA NA,6-12 yo,9.5,10.2 NA NA   2, 2 Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 1 Catala-Lopez (2017),9.5,10.2,NA,NA,Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100,  0 100 100,Low,Methylphenidate + Alpha-2 agonists (guanfacine / clonidine) NA,  0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,NA NA,NA NA Palumbo 2008,NA,RCT,RR  32  30   62,outcomes reverse  2.8181818182, 0.119224233, 6.661522e+01,NA NA,NA,NA,NA NA,NA NA 100 100,100 100,100 100,100 low low,some,low,some,Placebo   0, 19.600000, 9.500000 NA NA,1 1 1.0,0.0,1.0,1.0,1,1,0 1 1 1,1,0.5 1,1,1,1,1701 Palumbo_2008,NA,NA,6-12 yo,9.5,10.2,NA NA   2  2 Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  1,Catala-Lopez (2017),9.5 10.2 NA NA,Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 575,Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355,100   0 100,100 Low Diet (restricted/elimination) NA,  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,NA NA,NA NA,Pelsser 2009,NA RCT,RR, 15  12   27 outcomes reverse  1.6000000000, 0.164101731, 1.560008e+01,NA NA,NA,NA NA,NA NA NA,  0,  0 100,  0 100,100,  0 some,high low high,some,Waiting list,  0, 18.500000  6.200000,NA,NA 1,1 1.0 0.0 1.0 1.0 1 1 0 1 1 1,1 0.5 1 1 1 1,1702 Pelsser_2009 NA NA 6-12 yo 6.2,9.3,NA NA   8, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5 NA NA Catala-Lopez (2017)_Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0,100,100,Low,Diet (restricted/elimination) NA   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA NA,NA,NA,NA,Pelsser 2009 NA RCT RR  15  12   27,outcomes reverse  2.4375000000  0.108084503, 5.497001e+01,NA NA,NA NA NA NA NA NA   0   0,100,  0,100 100   0 some high low high some Waiting list,  0, 18.500000  6.200000,NA NA,1 1,1.0,0.0 1.0,1.0,1 1,0 1 1,1 1,0.5 1,1 1 1 1703,Pelsser_2009 NA NA 6-12 yo 6.2 6.9 NA NA,  8, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5 NA NA Catala-Lopez (2017)_Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355,100,  0 100 100,Low Diet (restricted/elimination) NA   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA NA NA NA Pelsser,2011,NA,RCT RR  50, 50  100 outcomes,reverse, 1.1250000000  0.472283459  2.679800e+00 NA NA,NA NA,NA,NA NA,NA,100 100 100,100 100 100 100 low some low some,some,Control   0, 14.000000, 6.900000,NA,NA,1,1,1.0 0.0 1.0,1.0,1,1 0,1,1,1,1 0.5,1,1 1,1,1704 Pelsser_2011 NA,NA,6-12 yo 6.2 9.3 NA NA,  8, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Sonuga-Barke (2014) | Catala-Lopez (2017),4.5 9.5,NA NA Catala-Lopez (2017)_Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 575 Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355,100   0,100 100,Low,Diet (restricted/elimination),NA   0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA NA NA,NA NA Pelsser 2011 NA RCT,RR  50  50  100 outcomes reverse  3.0000000000, 0.125133458, 7.192321e+01,NA NA NA,NA NA NA NA,NA 100,100,100 100,100,100,100 low,some,low,some some,Control,  0, 14.000000  6.900000 NA NA,1,1 1.0 0.0 1.0 1.0,1,1 0 1,1,1 1,0.5 1,1,1,1,1705,Pelsser_2011,NA NA,6-12 yo 6.2 6.9 NA,NA,  8  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5,NA NA Catala-Lopez (2017)_Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 575 Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355 100   0,100,100 Low Neurofeedback NA,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,NA,NA,NA,NA,Perreau-Linck 2010,NA,RCT,RR   5,  4    9,outcomes,reverse  0.8000000000, 0.069719235  9.179676e+00 NA NA,NA,NA NA,NA NA NA 100 100 100   0 100 100,100 some,high,low,some,some,Placebo,  0, 11.100000,10.300000 NA NA,1 1,1.0,0.0,1.0 1.0 1,1 0,1 1,1 1,0.5,1,1,1 1 1706,Perreau-Linck_2010 NA NA,6-12 yo,8.6 12.4 NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 575,Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355,100   0,100,100,Low,Multimodal behavioral interventions,NA,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,NA,NA NA NA,Pfiffner 2014,NA RCT RR, 74  51, 125,outcomes reverse  0.2297297297, 0.024582101, 2.146918e+00 NA,NA,NA,NA,NA NA NA,NA   0,  0,100   0,100,100   0,some high,low high low,Control (usual care),  0, 41.600000  8.600000 NA NA,1 1 1.0 0.0 1.0,1.0 1 1,0,1 1 1,1,0.5 1,1 1,1 1707,Pfiffner_2014 NA NA,6-12 yo 8.2 9.9 NA,NA,  5  1,Acceptability: all-cause discontinuation  1 Catala-Lopez (2017) 8.2,9.9,NA NA Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 575 Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0 100 100 Low,Parent-mediated behavioral interventions,NA,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA,NA NA NA Pfiffner 2014,NA RCT RR  74, 51, 125,outcomes,reverse, 0.0990476190, 0.005225745  1.877327e+00,NA NA NA,NA,NA NA NA,NA,  0   0 100,  0,100 100   0,some high low high,low,Control (usual care),  0  41.600000  8.600000 NA,NA 1,1 1.0 0.0 1.0,1.0,1,1 0,1 1,1 1,0.5 1 1 1,1 1708,Pfiffner_2014,NA,NA 6-12 yo 3.6 12.5 NA NA, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15 108.21 Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious,low,high
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355 100,  0 100,100 Low,Parent-mediated behavioral interventions NA   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA NA NA NA NA Pisterman 1992 NA,RCT RR, 28, 29   57,outcomes,reverse, 0.7397959184  0.265852758, 2.058651e+00,NA NA NA,NA NA,NA,NA,NA   0,  0   0,100   0,  0,100 high,some,high some,high,Waiting list   0, 15.800000  4.100000,NA,NA 1,1 1.0 0.0,1.0 1.0,1 1,0,1 1,1 1,0.5 1,1,1 1,1709,Pisterman_1992,NA,NA,< 6 yo 3.6,12.5,NA NA, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15 108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious,high high
 575 Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355,100,  0 100,100 Low,Polyunsaturated fatty acids,NA   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,NA,NA,NA NA,Raz,2009 NA,RCT RR, 39, 39   78 outcomes,reverse  3.0000000000, 0.125952829  7.145532e+01,NA NA NA NA NA NA NA,NA   0   0,100,100,  0,  0 100,some,some,high,low high,Placebo,  0, 39.700000,10.500000 NA,NA,1 1 1.0,0.0 1.0,1.0,1 1 0 1,1,1 1 0.5,1 1,1 1,1710 Raz_2009 NA NA,6-12 yo,8.3 13.7,NA NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA,NA Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
 575,Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355 100,  0,100 100,Low,Desipramine NA   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA,NA NA NA,Spencer 2002c 2002,NA,RCT,RR  21  20   41 outcomes,reverse  0.1909090909  0.009726873, 3.746968e+00,NA NA,NA NA,NA,NA,NA NA 100,100 100 100 100 100 100 low some some some some,Placebo   0  17.100000,11.000000,NA NA,1,1,1.0 0.0,1.0 1.0 1,1,0 1,1,1 1,0.5 1 1,1 1,1711 Spencer 2002c_2002 NA NA 6-12 yo 11,11.5,NA,NA   4, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Otasowie (2014) | Catala-Lopez (2017) 11,11.5 NA NA,Catala-Lopez (2017)_Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 575 Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0,100,100 Low Desipramine NA,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA NA NA,NA NA,Spencer 2002c,2002 NA RCT,RR, 21, 20,  41 outcomes reverse  0.1909090909  0.009726873, 3.746968e+00 NA NA NA,NA,NA NA,NA NA 100,100,100,100,100,100,100 low some some,some,some Placebo   0, 17.100000,11.000000 NA,NA,1,1 1.0 0.0,1.0,1.0,1,1,0 1 1,1 1,0.5 1,1 1,1 1712 Spencer 2002c_2002 NA,NA 6-12 yo 11 11.5 NA,NA   4, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Otasowie (2014) | Catala-Lopez (2017),11,11.5,NA NA Catala-Lopez (2017)_Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355 100   0,100,100 Low,Parent-mediated behavioral interventions,NA   0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA NA,NA NA Steeger 2016,NA RCT RR  26  26   52,outcomes,reverse, 3.0000000000  0.127807565, 7.041837e+01 NA NA NA NA NA NA,NA NA 100 100 100,100,100,100,100 some some,some some some,Placebo,  0  31.000000,12.500000 NA NA,1,1 1.0 0.0,1.0,1.0 1,1 0 1,1 1 1,0.5 1 1,1 1 1713,Steeger_2016 NA,NA 6-12 yo,3.6 12.5,NA NA  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious,low low
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355 100,  0,100 100 Low,Neurofeedback NA,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,NA,NA NA NA,Steiner 2011 NA RCT,RR, 13, 13   26 outcomes,reverse, 1.5000000000, 0.298151645, 7.546495e+00 NA,NA NA,NA NA NA NA,NA,100,100,100 100 100,100,100 some some low,some,some Control,  0  47.800000 12.400000 NA,NA,1 1 1.0 0.0,1.0 1.0 1 1,0 1 1 1 1 0.5,1 1 1 1 1714,Steiner_2011,NA NA,6-12 yo 8.6 12.4 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 575 Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355,100,  0 100,100,Low,Neurofeedback NA   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,NA,NA,NA,NA,Steiner 2011,NA,RCT RR, 13  15,  28,outcomes reverse, 8.0000000000  0.451299980  1.418125e+02 NA NA,NA,NA,NA,NA NA NA 100,100,100,100,100,100,100 some,some,low some,some,Waiting list,  0, 47.800000 12.400000 NA NA 1,1,1.0 0.0 1.0,1.0,1 1 0,1,1 1 1 0.5 1,1 1 1,1715,Steiner_2011 NA NA 6-12 yo 8.6,12.4,NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0 100,100,Low,Cognitive training,NA,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA NA,NA,NA NA,Steiner,2014 NA RCT RR, 34  36,  70,outcomes reverse  2.1176470588, 0.414337234, 1.082314e+01,NA NA NA,NA NA,NA,NA,NA,  0   0,100 100 100,100   0 some,some low high some,Control,  0  32.700000, 8.600000 NA,NA 1,1 1.0 0.0,1.0 1.0 1 1,0,1 1,1 1,0.5,1,1 1,1,1716 Steiner_2014 NA NA,6-12 yo,6.6 10.4 NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
 575,Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0 100 100 Low,Neurofeedback NA,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,NA NA NA NA Steiner,2014,NA,RCT,RR, 34  36,  70,outcomes,reverse  0.2114285714  0.010516026, 4.250849e+00,NA,NA NA NA NA NA,NA NA   0   0,100 100,100 100   0 some some low high,some,Control   0  32.700000  8.600000,NA,NA 1 1,1.0 0.0 1.0 1.0,1,1 0,1 1,1,1,0.5,1 1,1,1 1717 Steiner_2014 NA NA,6-12 yo 8.6,12.4 NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA,Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 575,Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355,100,  0 100 100 Low Methylphenidate + Alpha-2 agonists (guanfacine / clonidine) NA   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,NA NA NA NA TSSG 2002 NA RCT RR  33, 32,  65,outcomes reverse, 0.5541125541  0.179330722, 1.712148e+00,NA,NA NA NA,NA NA,NA,NA,100 100,100,100,100 100 100,low,low,low,low,low Placebo,  0  14.700000,10.200000,NA NA 1,1,1.0,0.0,1.0,1.0 1 1 0 1,1 1 1,0.5,1 1,1,1 1718,TSSG_2002 NA NA 6-12 yo 9.5,10.2 NA,NA   2  2 Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 1,Catala-Lopez (2017),9.5,10.2 NA,NA Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 575 Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355 100,  0 100 100,Low Methylphenidate + Alpha-2 agonists (guanfacine / clonidine) NA,  0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA NA NA NA,NA,TSSG 2002,NA RCT,RR  33  32   65 outcomes reverse, 2.9117647059, 0.122970612, 6.894634e+01 NA,NA NA,NA,NA,NA,NA NA 100 100,100 100 100,100,100 low low low low,low,Placebo   0  14.700000 10.200000,NA,NA 1,1 1.0 0.0,1.0 1.0,1,1,0 1,1,1,1 0.5,1 1,1,1,1719,TSSG_2002 NA,NA,6-12 yo,9.5 10.2 NA,NA   2  2,Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  1 Catala-Lopez (2017),9.5,10.2 NA,NA Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 575 Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355,100   0,100,100,Low Cognitive training,NA   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA NA NA,NA Tamm 2013 NA RCT RR  54, 51, 105,outcomes,reverse  1.7000000000  0.610539306  4.733520e+00,NA,NA NA NA NA NA,NA,NA   0   0 100,  0,100,100   0,some,high,some high,some Waiting list,  0, 32.400000  9.300000 NA,NA 1 1,1.0,0.0,1.0 1.0,1 1 0,1,1,1,1 0.5,1,1,1 1 1720 Tamm_2013,NA,NA,6-12 yo,6.6,10.4 NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
 575,Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355,100,  0 100 100 Low,Parent-mediated behavioral interventions,NA,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA NA NA,NA NA Thompson 2009 NA,RCT,RR, 21  20,  41,outcomes reverse, 0.3809523810, 0.185051658  7.842389e-01 NA,NA NA,NA,NA NA NA NA,100,100,100,100,100,100,100 some,some,low low,some,Control,  0, 27.000000, 4.200000,NA,NA,1 1,1.0 0.0 1.0,1.0,1,1 0,1 1 1 1,0.5,1 1,1 1 1721,Thompson_2009,NA NA < 6 yo 3.6,12.5 NA,NA  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21 Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Mixed,Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious low low
 575 Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355 100   0 100,100,Low Carnitine NA   0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA,NA,NA,NA Torrioli 2008 NA,RCT RR, 30  33,  63 outcomes reverse  0.8250000000  0.200827259, 3.389107e+00 NA NA NA NA NA,NA,NA NA,  0   0 100,100,  0,  0 100 some,some high some,high,Placebo   0   0.000000, 9.200000 NA,NA 1,1 1.0 0.0,1.0 1.0 1,1,0,1 1 1 1 0.5 1,1,1 1 1722 Torrioli_2008,NA,NA,6-12 yo,8.4,9.5,NA NA,  4, 1 Acceptability: all-cause discontinuation, 1 Catala-Lopez (2017),8.4 9.5,NA,NA,Catala-Lopez (2017)_Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high,high
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355 100   0 100,100 Low,Polyunsaturated fatty acids,NA   0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA NA,NA NA NA Vaisman 2008,NA,RCT RR  29, 26   55,outcomes,reverse, 4.5000000000, 0.225950350, 8.962146e+01 NA NA NA,NA NA NA NA NA,100 100,100 100 100,100,100 some some,low some some,Placebo,  0  45.800000  9.300000,NA NA,1 1 1.0,0.0 1.0 1.0,1 1 0,1,1,1 1,0.5 1 1 1,1 1723,Vaisman_2008,NA,NA,6-12 yo,8.3 13.7 NA,NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA NA Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 575 Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0 100,100,Low Multimodal behavioral interventions,NA 100,non-stimulant Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,NA NA,NA NA,Waxmonsky 2010,NA,RCT,RR, 29  27,  56 outcomes,reverse  2.3275862069, 0.492153878  1.100806e+01,NA NA,NA,NA NA NA,NA NA,  0,  0,100,  0,100,  0,  0 some high,some high,high,Active (any credible active intervention) 100  19.600000  8.600000,NA,NA,1 1 1.0,0.0,1.0,1.0 1 1 0 1,1 1 1 0.5 1 1,1 1 1724 Waxmonsky_2010,NA NA,6-12 yo,8.2 9.9 NA,NA,  5, 1,Acceptability: all-cause discontinuation, 1 Catala-Lopez (2017) 8.2 9.9 NA,NA,Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Catala-Lopez (2017) - Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
 575,Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355 100   0 100,100 Low,Zinc NA,100,stimulant Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA NA NA NA NA Zamora 2011,NA RCT,RR  20  20,  40,outcomes reverse  0.3333333333  0.037807004, 2.938903e+00 NA NA NA NA NA,NA,NA NA   0   0   0 100   0   0,100 high,some,high some high Active (any credible active intervention) 100, 27.500000, 9.600000,NA NA,1 1 1.0 0.0 1.0,1.0,1 1,0 1 1,1 1 0.5 1 1,1,1 1725 Zamora_2011 NA NA 6-12 yo 7.9,9.6 NA,NA   6  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Talebi (2021) | Catala-Lopez (2017) 7.14,9.92,NA,NA Catala-Lopez (2017)_Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high,high
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100,  0,100 100,Low,Cognitive training NA   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA,NA NA,NA,van Dongen-Boomsma 2014 NA RCT,RR, 27  24,  51 outcomes,reverse  0.2962962963, 0.032983234  2.661701e+00 NA,NA,NA NA NA NA,NA NA 100 100 100 100 100 100,100 some low,some,low some Placebo   0  27.700000  6.600000 NA,NA 1,1,1.0,0.0,1.0 1.0,1 1,0,1,1 1,1,0.5 1 1,1,1,1726,van Dongen-Boomsma_2014 NA,NA,6-12 yo 6.6,10.4 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA,Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 575,Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0 100 100 Low,Carnitine,NA   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA NA,NA,NA NA,van Oudheusden,2002 NA RCT RR, 13, 13,  26,outcomes,reverse, 1.0000000000  0.069734044, 1.434020e+01 NA NA,NA,NA,NA,NA,NA,NA 100 100,100,100,100 100 100,some,some,some,some,some Placebo,  0,  0.000000  9.500000 NA,NA,1 1 1.0,0.0,1.0 1.0,1 1,0 1 1,1 1 0.5,1 1 1 1,1727 van Oudheusden_2002 NA NA 6-12 yo 8.4,9.5,NA NA   4, 1 Acceptability: all-cause discontinuation  1 Catala-Lopez (2017),8.4,9.5 NA,NA,Catala-Lopez (2017)_Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 575,Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355 100,  0 100 100 Low,Parent-mediated behavioral interventions NA,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA NA NA NA,NA,van den Hoofdakker 2007,NA RCT RR  48  48   96,outcomes reverse, 7.0000000000, 0.895091374, 5.474301e+01 NA NA NA NA NA,NA NA NA,  0   0,100,100,100,100   0,some some some high some Control,  0  19.100000, 7.400000,NA,NA 1 1,1.0,0.0,1.0 1.0 1,1,0 1 1 1,1 0.5 1,1 1 1 1728,van den Hoofdakker_2007,NA NA 6-12 yo 3.6,12.5,NA,NA, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15 108.21 Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious low high
 575 Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355,100,  0,100,100 Low,Multimodal behavioral interventions,NA,100 stimulant,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA NA,NA NA van der Oord,2007 NA,RCT,RR, 27  23   50,outcomes,reverse, 1.2777777778, 0.233297223  6.998438e+00,NA NA,NA,NA NA,NA NA NA,  0   0,100,  0 100 100   0,some high some,high,some Active (any credible active intervention),100, 12.000000  9.900000,NA,NA,1,1,1.0,0.0 1.0,1.0,1,1 0,1 1 1 1,0.5 1,1,1 1 1729 van der Oord_2007,NA NA 6-12 yo,8.2 9.9 NA NA   5  1,Acceptability: all-cause discontinuation  1 Catala-Lopez (2017),8.2 9.9,NA NA Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Catala-Lopez (2017) - Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
